
<html lang="en"     class="pb-page"  data-request-id="3ea98a47-2eaf-496d-af6f-867131bc146f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-21;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b00055;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy" /></meta><meta name="dc.Creator" content="Ying-Qing  Wang" /></meta><meta name="dc.Creator" content="Ping-Yuan  Wang" /></meta><meta name="dc.Creator" content="Yu-Ting  Wang" /></meta><meta name="dc.Creator" content="Guang-Fu  Yang" /></meta><meta name="dc.Creator" content="Ao  Zhang" /></meta><meta name="dc.Creator" content="Ze-Hong  Miao" /></meta><meta name="dc.Description" content="Poly(ADP-ribose)polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills ca..." /></meta><meta name="Description" content="Poly(ADP-ribose)polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills ca..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 27, 2016" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00055" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00055" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00055" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00055" /></link>
        
    
    

<title>An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00055" /></meta><meta property="og:title" content="An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0016.jpeg" /></meta><meta property="og:description" content="Poly(ADP-ribose)polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills cancer cells by targeting homologous recombination repair defects. Since 2010, important advances have been achieved in PARP-1 inhibitors. Specifically, the approval of olaparib in 2014 for the treatment of ovarian cancer with BRCA mutations validated PARP-1 as an anticancer target and established its clinical importance in cancer therapy. Here, we provide an update on PARP-1 inhibitors, focusing on breakthroughs in their clinical applications and investigations into relevant mechanisms of action, biomarkers, and drug resistance. We also provide an update on the design strategies and the structural types of PARP-1 inhibitors. Opportunities and challenges in PARP-1 inhibitors for cancer therapy will be discussed based on the above advances." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00055"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00055">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00055&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00055&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00055&amp;href=/doi/10.1021/acs.jmedchem.6b00055" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 9575-9598</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.6b00376" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ying-Qing++Wang">Ying-Qing Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ping-Yuan++Wang">Ping-Yuan Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu-Ting++Wang">Yu-Ting Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guang-Fu++Yang">Guang-Fu Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ao++Zhang">Ao Zhang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ze-Hong++Miao">Ze-Hong Miao</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">CAS Key Laboratory of Receptor Research, and Synthetic Organic & Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Lu, Building 3, Room 426, Pudong, Shanghai 201203, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, China</span></div><div class="corresp-info"><strong>*</strong>For Z.H.M.: phone, +86-21-50806820; fax, 86-21-50806820; E-mail, <a href="/cdn-cgi/l/email-protection#ec968481858d83ac9f858181c28d8fc28f82"><span class="__cf_email__" data-cfemail="ec968481858d83ac9f858181c28d8fc28f82">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For A.Z.: phone, +86-21-50806035; fax, 86-21-50806035; E-mail, <a href="/cdn-cgi/l/email-protection#c3a2acb9aba2ada483b0aaaeaeeda2a0eda0ad"><span class="__cf_email__" data-cfemail="4e2f2134262f20290e3d272323602f2d602d20">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00055&amp;href=/doi/10.1021%2Facs.jmedchem.6b00055" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 9575–9598</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 14, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 January 2016</li><li><span class="item_label"><b>Published</b> online</span>27 July 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 November 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00055</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9575%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYing-Qing%2BWang%252C%2BPing-Yuan%2BWang%252C%2BYu-Ting%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D21%26contentID%3Dacs.jmedchem.6b00055%26title%3DAn%2BUpdate%2Bon%2BPoly%2528ADP-ribose%2529polymerase-1%2B%2528PARP-1%2529%2BInhibitors%253A%2BOpportunities%2Band%2BChallenges%2Bin%2BCancer%2BTherapy%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9598%26publicationDate%3DNovember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00055"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5197</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">88</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00055" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ying-Qing&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Ping-Yuan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yu-Ting&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Guang-Fu&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Ao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Ze-Hong&quot;,&quot;last_name&quot;:&quot;Miao&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;9575-9598&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00055&quot;},&quot;abstract&quot;:&quot;Poly(ADP-ribose)polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills cancer cells by targeting homologous recombination repair defects. Since 2010, important advances have been achieved in PARP-1 inhibitors. Specifically, the approval of olaparib in 2014 for the treatment of ovarian cancer with BRCA mutations validated PARP-1 as an anticancer target and established its clinical importance in cancer therapy. Here, we provide an update on PARP-1 inhibitors, focusing on breakthroughs in their clinical applications and investigations into relevant mechanisms of action, biomarkers, and drug resistance. We also provide an update on the design strategies and the structural types of PARP-1 inhibitors. Opportunities and challenges in PARP-1 inhibitors for cancer therapy will be discussed based on the above advances.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00055&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00055" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00055&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00055" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00055&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00055" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00055&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00055&amp;href=/doi/10.1021/acs.jmedchem.6b00055" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00055" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00055" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00055%26sid%3Dliteratum%253Aachs%26pmid%3D27416328%26genre%3Darticle%26aulast%3DWang%26date%3D2016%26atitle%3DAn%2BUpdate%2Bon%2BPoly%2528ADP-ribose%2529polymerase-1%2B%2528PARP-1%2529%2BInhibitors%253A%2BOpportunities%2Band%2BChallenges%2Bin%2BCancer%2BTherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D21%26spage%3D9575%26epage%3D9598%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292519" title="Cancer therapy">Cancer therapy</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/jmcmar.2016.59.issue-21/20161110/jmcmar.2016.59.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Poly(ADP-ribose)polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills cancer cells by targeting homologous recombination repair defects. Since 2010, important advances have been achieved in PARP-1 inhibitors. Specifically, the approval of olaparib in 2014 for the treatment of ovarian cancer with BRCA mutations validated PARP-1 as an anticancer target and established its clinical importance in cancer therapy. Here, we provide an update on PARP-1 inhibitors, focusing on breakthroughs in their clinical applications and investigations into relevant mechanisms of action, biomarkers, and drug resistance. We also provide an update on the design strategies and the structural types of PARP-1 inhibitors. Opportunities and challenges in PARP-1 inhibitors for cancer therapy will be discussed based on the above advances.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71626" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71626" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Poly(ADP-ribose)polymerases (PARPs) are a family of enzymes that catalyze the transfer of ADP-ribose from nicotinamide adenine dinucleotide (NAD<sup>+</sup>) onto acceptor proteins. Among this family, which consists of at least 17 members, PARP-1 is the most widely investigated. It functions primarily as a DNA repair factor, especially in base excision repair (BER).<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6">(1-6)</a> In 2010, Ferraris and colleagues systematically reviewed the catalytic function of PARP-1, the rationale for targeting PARP-1 as a therapeutic approach, the pharmacophore of its inhibitors, and the progress in related drug discovery.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Since then, important advances and breakthroughs have been achieved in the field of PARP-1 inhibitors, including (a) the failure of iniparib<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> (<b>1</b>, BSI-201, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) in its clinical trials and the successful approval of olaparib<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> (<b>2</b>, also known as AZD2281 and LYNPARZA; <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), (b) the clinical development of several new inhibitors, (c) the emergence of new anticancer mechanisms, (d) the identification of new biomarkers, (e) the exploration of drug resistance mechanisms, and (f) the establishment of new design strategies and structural types of PARP inhibitors, such as those with high selectivity. All these advances are dramatically reshaping R&D and clinical applications in the context of PARP-1 inhibitors. Therefore, now is the time to combine all the latest developments to provide a solid foundation for studies of PARP-targeted cancer therapy and to propose future directions.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of some PARP-1 inhibitors that are currently being or have been (gray structures) evaluated clinically for cancer therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The clinical development of PARP-1 inhibitors was not smooth but was ultimately successful. Compound <b>1</b> was the first PARP-1 inhibitor tested in phase III clinical trials for triple-negative breast cancer (TNBC) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Unfortunately, the expanded phase III clinical trial of this compound was announced to be unsuccessful in 2011.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Phase II trials for nonsmall cell lung cancer (NSCLC) also showed no improved objective response.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The subsequent investigations for the causes of these failures proved that <b>1</b> was not a true PARP-1 inhibitor due to its poor PARP-1 inhibition (IC<sub>50</sub>: approximately 100 μM)<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and its inability to selectively kill homologous recombination repair (HRR)-deficient cells.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Later in the same year, AstraZeneca announced that it would discontinue its planned phase III clinical trials of the PARP-1 inhibitor <b>2</b> because of its poor effectiveness in a phase II study on ovarian cancer.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> However, a positive result was obtained from a subsequent retrospective analysis of the data from this phase II clinical trial. When patients were reassigned by BRCA status, the median progression-free survival (PFS) of the patients with BRCA mutations was significantly longer in the <b>2</b> treatment group than in the placebo group (11.2 months vs 4.3 months); however, the difference between the groups of wild-type BRCA patients was lower (7.4 months vs 5.5 months).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This result demonstrated both that patients with BRCA mutations might benefit from treatment with <b>2</b> and indicated that the monotherapy of <b>2</b> was an effective targeted therapy for platinum-sensitive recurrent ovarian cancer with BRCA mutations. This result led to a restarting of the phase III clinical trials of <b>2</b> in 2013. Together with some additional results,<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> this study led directly to the approval of <b>2</b> for the treatment of advanced ovarian cancer in patients with BRCA mutations by the European Union<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and by the U.S. Food and Drug Administration (FDA)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> in December 2014. The approval of <b>2</b> marked the successful establishment of PARP-1 inhibition as a clinically efficacious therapeutic strategy for cancer and thus reactivated the field of PARP-1 inhibition for cancer therapy. Moreover, in January 2016, the FDA further granted the Breakthrough Therapy designation (BTD) for <b>2</b> to treat patients with metastatic castration-resistant prostate cancer carrying BRCA1/2 or ataxia telangiectasia mutated (ATM) mutations.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 PARP-1 Inhibitors in Clinical Evaluation for Cancer Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35070" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35070" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To our knowledge, 13 PARP-1 inhibitors are currently being or have been tested in the clinic for cancer therapy. Among them, three (<b>1</b>, <b>9</b>,<a onclick="showRef(event, 'ref20 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref23">(20, 23)</a> and <b>10</b><a onclick="showRef(event, 'ref21 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref24">(21, 24)</a>) were discontinued and nine are active in various clinical trials including <b>2</b>, rucaparib (<b>3</b>),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> niraparib (<b>4</b>),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> veliparib (<b>5</b>),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> talazoparib (<b>6</b>),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> E7449 (<b>7</b>),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> E7016 (<b>8</b>),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> BGB-290 (<b>12</b>,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> chemical structure not disclosed), and ABT-767 (<b>13</b>,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> chemical structure not disclosed) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). The current clinical status of one inhibitor (<b>11</b>,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> AZD2461) is unknown (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Almost all of these inhibitors except <b>1</b> (not a true PARP-1 inhibitor, as described above) show potent but nonselective inhibition on PARP-1 and PARP-2 enzymatic activity, with IC<sub>50</sub>s in the nM range; however, some IC<sub>50</sub> values are not available. Their chemical structures (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) contain an amide pharmacophore that mimics NAD<sup>+</sup>, one of critical substrates of PARPs, suggesting that these inhibitors could inhibit PARP-1 in a competitive manner with NAD<sup>+</sup>. Although one phase I clinical trial of <b>11</b> has been completed (NCT01247168), no results or any information about its further clinical development are available. Compounds <b>1</b>, <b>9</b>, and <b>10</b> were eliminated for clinical evaluation due to poor therapeutic effectiveness<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> (<b>1</b>, phase III), poor pharmacokinetic features, or severe toxicity (<b>9</b>, phase I/II;<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><b>10</b>, phase Ib<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>). Among the nine PARP-1 inhibitors currently in active clinical trials, five are undergoing phase III trials, including <b>2</b>–<b>6</b>, while the other four are still in early phase clinical trials, i.e., <b>7</b><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> in phase Ib/I, <b>8</b><a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> in phase II, <b>12</b><a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> in phase Ib, and <b>13</b><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> in phase I (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Most of these clinical trials are designed to primarily test the compounds as monotherapies against breast, ovarian, or pancreatic cancers harboring BRCA defects. In addition, or in conjunction with these efforts, the effects of these compounds in combination with several conventional chemotherapeutic drugs are also being determined against other solid tumors, including NSCLC and glioblastoma (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Currently, no reports about these ongoing clinical trials are available.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. PARP-1 Inhibitors That Have Been (Gray) or Are Being Clinically Evaluated for Cancer Therapy<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref8 ref20 ref21 ref22 ref25 ref26 ref27 ref28 ref30 ref32 ref58'); return false;" href="javascript:void(0);" class="ref ref8 ref20 ref21 ref22 ref25 ref26 ref27 ref28 ref30 ref32 ref58">()</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0019.gif" alt="" id="GRAPHIC-d7e496-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">The listed clinical trials are for the highest stage of corresponding inhibitors. Gray represents the PARP-1 inhibitors that currently have unknown or terminated clinical trial status. NA*: The IC<sub>50</sub> values for PARP-1 and/or PARP-2 are not available. Compound <b>8</b> was reported to inhibit PARP activity by 84% at 3 μM.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></p></div></div><div></div></div><div class="NLM_p">Among all the PARP-1 inhibitors mentioned above, <b>2</b> has been clinically evaluated most extensively and its results can be considered to represent the recent advances in the clinical development of PARP-1 inhibitors either as a single agent or as part of a combination therapy. Therefore, we here discuss the clinical trials of <b>2</b> in hopes of further understanding the status of the clinical development of PARP-1 inhibitors.</div><div class="NLM_p">Five phase I clinical trials of <b>2</b> monotherapy have been reported,<a onclick="showRef(event, 'ref33 ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref36 ref37">(-33-37)</a> of which one compared the bioavailability of its two different oral formulations (capsule and tablet).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The results with the capsule formulation revealed a maximum tolerated dose (MTD) of 400 mg BID.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> To reach this dose, 16 capsules (50 mg/capsule) each day were required which might compromise patient compliance. Therefore, the tablet formulation was developed and showed at least 2-fold improvement in bioavailability.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The tablet formulation was used in later studies, especially in phase III clinical trials. Compound <b>2</b> is absorbed rapidly and reaches its peak plasma concentrations 1–3 h after single dosing. It has a terminal half-life (<i>t</i><sub>1/2</sub>) of approximately 10 h, an average apparent distribution volume (<i>V</i><sub>d</sub>) of 40.3 L, and an average plasma clearance rate (CL) of 4.6 L/h/kg. Its PARP-1 inhibition can be monitored by the formation of phosphorylated histone H2AX (γH2AX) foci in plucked eyebrow-hair follicles and poly(ADP-ribose) (PAR) reduction in tumor tissues and peripheral blood mononuclear cells (PBMCs).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The primary toxicities of <b>2</b> are related to gastrointestinal reactions and myelosuppression. Very favorably, <b>2</b> did not show interethnic differences in its safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles.<a onclick="showRef(event, 'ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref36">(33-36)</a> In addition, phase I studies revealed preliminary therapeutic activity as a monotherapy in cancers harboring BRCA1 or BRCA2 mutations.<a onclick="showRef(event, 'ref33 ref34 ref37'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref37">(33, 34, 37)</a></div><div class="NLM_p">Compound <b>2</b> was subsequently tested in the phase II clinical trials. There are eight phase II monotherapy studies that have been reported for ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, or Ewing sarcoma (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref38 ref39 ref40 ref41 ref42">(13-16, 38-42)</a> In patients with Ewing sarcoma, no significant responses or durable disease control was observed.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> All other tested cancers showed different degrees of therapeutic responses, and BRCA-mutated ovarian cancer showed the best responses. Compound <b>2</b> was tested in a proof-of-concept and a nonrandomized phase II trial, respectively,<a onclick="showRef(event, 'ref15 ref38'); return false;" href="javascript:void(0);" class="ref ref15 ref38">(15, 38)</a> and both studies indicated that <b>2</b> was promising in BRCA-mutated ovarian cancer. Two randomized phase II studies further strengthened the evidence of the effectiveness of <b>2</b> to treat platinum-sensitive relapsed high-grade serous ovarian cancer (HGS-OvCa).<a onclick="showRef(event, 'ref13 ref14 ref39'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref39">(13, 14, 39)</a> Unexpectedly, however, patients with breast cancer, even those carrying BRCA mutations, showed much weaker responses to <b>2</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Pancreatic and prostate cancers with BRCA mutations were also found to improve from <b>2</b> monotherapy.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Moreover, in a recent phase II study in patients with prostate cancer, four of five patients with ATM aberrations showed responses to <b>2</b>.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Together with other supporting evidence, this result led to the FDA classification of <b>2</b> as a BTD for prostate cancer.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Therapeutic Responses of Different Cancers to <b>2</b> as Monotherapy (400 mg BID) in Phase II Clinical Studies<a class="ref internalNav" href="#t2fn2" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">tumor types</th><th class="colsep0 rowsep0" align="center">NCT no.</th><th class="colsep0 rowsep0" align="center">patients with BRCA mutations</th><th class="colsep0 rowsep0" align="center">CR (%)</th><th class="colsep0 rowsep0" align="center">PR (%)</th><th class="colsep0 rowsep0" align="center">SD (%)</th><th class="colsep0 rowsep0" align="center">ORR (%)</th><th class="colsep0 rowsep0" align="center" char=".">PFS (months)</th><th class="colsep0 rowsep0" align="center">CBR</th><th class="colsep0 rowsep0" align="center">DOR (months)</th><th class="colsep0 rowsep0" align="center">median OS (months)</th><th class="colsep0 rowsep0" align="center">refs</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ovarian cancer</td><td class="colsep0 rowsep0" align="left">00494442</td><td class="colsep0 rowsep0" align="center">33</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">27</td><td class="colsep0 rowsep0" align="center">36</td><td class="colsep0 rowsep0" align="center">33</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="center">52</td><td class="colsep0 rowsep0" align="center">9.7</td><td class="colsep0 rowsep0" align="center">–<a class="ref internalNav" href="#t2fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">38</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">00679783</td><td class="colsep0 rowsep0" align="center">17</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">41</td><td class="colsep0 rowsep0" align="center">29</td><td class="colsep0 rowsep0" align="center">41</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="center">76</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">00628251</td><td class="colsep0 rowsep0" align="center">32</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">59</td><td class="colsep0 rowsep0" align="center">31</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">6.8</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">39</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">00753545</td><td class="colsep0 rowsep0" align="center">74</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="char" char=".">11.2</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">13,14</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">01078662</td><td class="colsep0 rowsep0" align="center">193</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">28</td><td class="colsep0 rowsep0" align="center">40</td><td class="colsep0 rowsep0" align="center">31</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">16.6</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">00679783</td><td class="colsep0 rowsep0" align="center">8</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">63</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="center">63</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">01078662</td><td class="colsep0 rowsep0" align="center">62</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center">47</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">11.0</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">00494234</td><td class="colsep0 rowsep0" align="center">27</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">37</td><td class="colsep0 rowsep0" align="center">44</td><td class="colsep0 rowsep0" align="center">41</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">4.8</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">40</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pancreatic cancer</td><td class="colsep0 rowsep0" align="left">01078662</td><td class="colsep0 rowsep0" align="center">23</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">17</td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="center">21</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">9.8</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="left">01078662</td><td class="colsep0 rowsep0" align="center">8</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">50</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="center">50</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">18.4</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">01682772</td><td class="colsep0 rowsep0" align="center">16 (DNA-repair defects)</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">88</td><td class="colsep0 rowsep0" align="char" char=".">9.8</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">13.8</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">41</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ewing sarcoma</td><td class="colsep0 rowsep0" align="left">01583543</td><td class="colsep0 rowsep0" align="center">12 (no BRCA test)</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">33</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">42</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn2"><div class="footnote" id="t2fn2"><sup>a</sup><p class="last">Abbreviations: CBR, clinical benefit rate; CR, complete response; DOR, duration of response; PR, partial response; SD, stable disease.</p></div><div class="footnote" id="t2fn1"><sup>b</sup><p class="last">NA, no data available.</p></div></div></div><div class="NLM_p last">There have been 15 clinical trials reported for combinational uses of <b>2</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b00055/suppl_file/jm6b00055_si_001.pdf" class="ext-link">Table 1</a>), including 12 phase I trials and three phase II trials. The anticancer drugs that are used in combination with <b>2</b> primarily include DNA-damaged agents, microtubule inhibitors, angiogenesis inhibitors, and kinase inhibitors. The results from six phase I studies on DNA-damaging agents revealed that <b>2</b> improved the therapeutic responses of patients with different cancers to carboplatin, cisplatin, and the topoisomerase II inhibitor pegylated liposomal doxorubicin (PLD), although the toxicities of these drugs were also increased.<a onclick="showRef(event, 'ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45">(43-45)</a> The combination of <b>2</b> with cisplatin plus gemcitabine, the alkylating agent dacarbazine, or the topoisomerase I (Top1) inhibitor topotecan could not be tolerated due to increased toxicities<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a> or showed no significant clinical advantage over the single-agent therapy.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> In contrast, both phase I and II trials indicated that <b>2</b> was synergistic with paclitaxel or paclitaxel plus carboplatin in TNBC, ovarian, and gastric cancers.<a onclick="showRef(event, 'ref49 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51 ref52">(49-52)</a> In particular, the combination of <b>2</b> and paclitaxel caused a high objective response rate (ORR) of 34.6% in a subpopulation of gastric cancer patients with low expression of ATM (ATM<sub>low</sub>).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> This result encouraged further investigation of this combination in phase III trials for gastric cancer (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In addition, <b>2</b> in combination with protein kinase inhibitors also showed promising results. Compound <b>2</b> in combination with the angiogenesis inhibitor bevacizumab was well tolerated in a phase I study.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Both phase I and II clinical trials revealed that the combination of <b>2</b> and the vascular endothelial growth factor receptor (VEGFR) inhibitor cediranib improved the therapeutic efficacy in patients with ovarian cancers regardless of BRCA status (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b00055/suppl_file/jm6b00055_si_001.pdf" class="ext-link">Table 1</a>).<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54, 55)</a> The pan-phosphatidylinositol 3-kinase (PI3K) inhibitor 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine (BKM120) and the epidermal growth factor receptor (EGFR) inhibitor gefitinib were also found to offer additional clinical benefit with the use of <b>2</b>.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56, 57)</a> All these clinical explorations help to expand the clinical uses of <b>2</b> itself, and the results are also valuable for the clinical development of other PARP-1 inhibitors.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">3 Anticancer Mechanisms of PARP-1 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08164" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08164" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The anticancer mechanism of PARP-1 inhibitors as monotherapy has not been fully understood yet. Initially, PARP-1 inhibitors were believed to inhibit the enzymatic activity of PARP-1 and to impair BER-mediated DNA single-strand break (SSB) repair. Due to replication fork collision, the accumulated SSBs are converted to DNA double-strand breaks (DSBs), which are primarily repaired via the HRR pathway to allow cell survival. Therefore, in HRR-deficient cancers, including BRCA1- or BRCA2- deficient cancers, PARP-1 inhibition results in cell death via a synthetic lethality mechanism and elicits anticancer effects.<a onclick="showRef(event, 'ref1 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref3">(1, 3)</a> However, this mechanism can not fully explain why the capacity of the inhibitors to inhibit PARP-1 catalytic activity is poorly correlated with their cell killing in HRR-deficient cells. Moreover, PARP-1 inhibitors delay SSB repair and induce cytotoxicity to a greater extent than PARP-1 depletion. Additionally, PARP-1 itself is essential to the cytotoxic effects of PARP-1 inhibitors.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Therefore, some new mechanisms of action by which PARP-1 inhibitors elicit cell killing and anticancer effects have been proposed. The current evidence shows that there are three possible mechanisms for the effects of these inhibitors, as follows.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">3.1 Interactions between DNA, PARP-1 and its inhibitors</h3><div class="NLM_p">Interactions between DNA, PARP-1, and its inhibitors lead to the inhibition of PARP-1 catalytic activity and trapping of the DNA–PARP-1 complexes. These mechanisms are likely to be the most basic anticancer mechanisms of PARP-1 inhibitors, although there are related events that remain to be clarified.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> The mechanism related to the inhibition of PARP-1 catalytic activity was mentioned above. Therefore, here we focus on the trapping of DNA–PARP-1 complexes.</div><div class="NLM_p">Noncovalent DNA–PARP complexes exist normally in intact cells. PARP-1 inhibitors bind to the NAD<sup>+</sup>-binding pocket of PARP-1 (and/or PARP-2), induce anallosteric conformational change in PARP-1 (and/or PARP-2), and stabilize the reversible association of PARP-1/2 with DNA. This process is referred to as the trapping of DNA–PARP-1/2 complexes.<a onclick="showRef(event, 'ref60 ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref60 ref62 ref63 ref64">(60, 62-64)</a> DNA–PARP trapping leads to persistent DNA–PARP complexes at SSBs, and during S phase, trapped DNA can undergo lethal DSBs in HRR-deficient cells, causing cell death. This effect has been proposed as a mechanism by which PARP-1 inhibitors exert anticancer activity.<a onclick="showRef(event, 'ref60 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref62">(60, 62)</a> Systematic comparisons<a onclick="showRef(event, 'ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref62 ref63 ref64">(62-64)</a> reveal that the DNA–PARP trapping capacity of PARP-1 inhibitors has a much higher correlation with their cytotoxicity than their ability to inhibit PARP-1 catalytic activity. However, a recent study with <b>2</b>, <b>4</b>, <b>5</b>, and <b>6</b> indicates that DNA–PARP trapping by PARP-1 inhibitors is not an allosteric effect but is correlated with catalytic inhibition linearly in biochemical systems and nonlinearly in cells. The levels of DSBs (as reflected by γH2AX) are more significantly correlated with cell death than are levels of trapping. Moreover, PARP inhibitors with different trapping capacity can elicit comparable in vivo efficacy at MTDs.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p">In many ways, PARP-1 inhibitors act similar to Top1 inhibitors at trapped DNA–enzyme complexes, although there are also differences.<a onclick="showRef(event, 'ref60 ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref60 ref62 ref63 ref64">(60, 62-64)</a> Importantly, the trapping of both DNA–PARP complexes and DNA–Top1 complexes elicits cell-killing effects primarily through the conversion of unrepaired SSBs into lethal DSBs. The cytotoxicity of Top1 inhibitors does not require HRR deficiency, although deficient HRR can sensitize cells to these compounds. In most cases, however, the cytotoxicity of PARP-1 inhibitors requires HRR deficiency, either due to mutations in BRCA1/2 or due to other effects. This difference does not appear to be fully explained by the described DNA–enzyme trapping mechanism. PARP-1 plays roles in multiple types of DNA repair, including BER, HRR, nonhomologous end-joining (NHEJ), alternative NHEJ (Alt-NHEJ) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), and nucleotide excision repair (NER). Detectable SSBs were not found to increase in BRCA2-deficient cells treated with PARP-1 inhibitors.<a onclick="showRef(event, 'ref5 ref61 ref66'); return false;" href="javascript:void(0);" class="ref ref5 ref61 ref66">(5, 61, 66)</a> Therefore, further investigations into the DNA–PARP trapping are still needed, especially with respect to the relationship of this effect with the cytotoxicity of PARP-1 inhibitors and their therapeutic implications.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Simplified schematic representation of the repair pathways for SSBs and DSBs and the forms of synthetic lethality caused by PARP-1 inhibitors. The cyan rectangles represent different repair pathways. In the text, red represents the target (PARP-1) or the most important HRR defects (BRCA1/2); blue, green, orange, and purple represent the potential biomarkers, i.e., HRR factors and their downstream-regulated factors, factors that regulate HRR factors, the target PARP-1 and its related factors, and other molecules, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.2 Synthetic Lethality</h3><div class="NLM_p last">Synthetic lethality is likely to be the direct mechanism of cell killing by PARP-1 inhibitor monotherapy. There are three known forms of synthetic lethality (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). In addition to classical synthetic lethality between BER inhibition by PARP-1 inhibitors and HRR defects (e.g., BRCA1/2 loss-of function mutations), synthetic lethality was recently shown to occur between Alt-NHEJ inhibition (via PARP-1 inhibition) and HRR defects.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Alt-NHEJ, also known as microhomology-mediated end-joining (MMEJ), is an error-prone DSB repair mode requiring PARP-1 and DNA polymerase θ (Pol θ, also known as Pol Q in mice) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67, 68)</a> PARP-1 stimulates HRR by PARylating BRCA1-associated RING domain protein 1 (BARD1) to promote the recruitment of BRCA1 to damage sites. In HRR-proficient cells, DSBs are repaired predominantly by HRR. In contrast, HRR-deficient cancers are dependent on Alt-NHEJ,<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67, 68)</a> and Alt-NHEJ inhibition by PARP-1 inhibitors induces cancer cell killing in this context. A third form of synthetic lethality may occur between NHEJ activation by PARP-1 inhibitors and HRR defects. PARP-1 suppresses the error-prone NHEJ repair pathway by PARylating Ku70/Ku80 and the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs). PARP-1 inhibitors might remove this suppression and enhance NHEJ activity. In HRR-deficient cells, active NHEJ causes increased chromosomal rearrangements and mutations, leading to cell death.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> At present, however, it is unclear to what degree these three forms of synthetic lethality contribute to the anticancer activity of PARP-1 inhibitors.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.3 Possible Anticancer Mechanisms of PARP-1 Inhibitors That Are Unrelated to DNA Repair</h3><div class="NLM_p">Although most studies on the anticancer mechanisms of PARP-1 inhibitors have focused on their DNA repair inhibition, some unrelated anticancer mechanisms are emerging. PARPs have extensive target substrates, specifically, 291 proteins have been experimentally identified to be PARylated with PAR antibodies and 746 PAR-modified proteins have been predicted in silico.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The poly(ADP-ribose)ylation (PARylation) of target proteins inhibits their interactions with other binding partners (proteins and nucleic acids), serves as interaction scaffolds to recruit other related proteins, and/or triggers their ubiquitination and subsequent degradation.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> In addition to its function in DNA repair, PARP-1 has been consistently reported to be involved in various biological processes, including chromatin remodeling, transcriptional regulation, hypoxic response, angiogenesis, epithelial-mesenchymal transition (EMT), and cancer metastasis.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Most of these processes are related to tumorigenesis and progression, possibly explaining the anticancer mechanisms of PARP-1 inhibitors that are unrelated to DNA repair.</div><div class="NLM_p">PARP-1 functions in chromatin remodeling, possibly by PARylating histones, the chromatin remodeling factors that facilitates chromatin transcription (FACT), imitation SWItch (ISWI), and the lysine-specific histone demethylases (KDM)5B and KDM4D.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Among other functions, such chromatin remodeling facilitates the access of transcription factors to DNA and the loading of RNA polymerase II machinery on related promoters.<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69, 70)</a> PARP-1 also functions as a transcriptional coregulator by PARylating several transcription factors to activate or repress related gene transcription. Such PARylated transcription factions include circadian locomotor output cycles kaput (CLOCK), hypoxia-inducible factor (HIF), nuclear factor kappa B (NF-κB), nuclear factor of activated T-cells (NFAT), Snail, Smad, Sp1, and Sox2. Importantly, most of these transcription factors are implicated in carcinogenesis.<a onclick="showRef(event, 'ref5 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref5 ref69 ref70">(5, 69, 70)</a> Of these transcription factors, it is notable that HIF plays a central role in regulating hypoxic response and angiogenesis in cancer. HIF is a heterodimer of HIF-α and HIF-β. The PARP-1-driven PARylation enhances the stability and accumulation of HIF-1α and HIF-2α as well as the transcriptional activity of the HIF coactivator p300. In this way, PARP-1 modulates the transcription of many genes, including <i>VEGF</i>. The protein product of the <i>VEGF</i> gene, VEGF, is the most potent angiogenesis stimulator. Therefore, the PARP-1–HIF–VEGF pathway promotes cancer angiogenesis.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> In addition, PARylation of the transcription factor Snail-1 by PARP-1 increases the former’s stability, promotes the expression of vimentin, a well-known marker of EMT, and stimulates cancer progression to metastasis.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> In fact, many other transcription factors, such as Smad3 and Smad4, are also similarly regulated by PARP-1 and are involved in EMT. Therefore, PARP-1 can stimulate tumorigenesis and malignant progression by regulating chromatin remodeling and gene transcription. It is worth noting that these functions of PARP-1 may be gene-specific, cell type-specific, and/or cell state-specific.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70, 71)</a></div><div class="NLM_p">PARP-1 inhibitors have been revealed to suppress the PARP-1-mediated processes described above. VEGF-induced angiogenesis was repressed by PARP-1 inhibitors.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Treatment with the PARP inhibitor <b>14</b><a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> (PJ-34, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) or <b>2</b> was reported to increase the degradation of Snail-1, downregulated vimentin levels, disrupted EMT, and thus impaired the metastatic capacity of melanoma cells. Different PARP-1 inhibitors have also been shown to counteract the Smad3- and Smad4-mediated EMT phenotype and thus prevent the metastasis of melanoma cells.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Therefore, the anticancer and/or antimetastatic activities of PARP-1 inhibitors likely result from these activities of PARP-1 that are unrelated to DNA repair. In conditions of functional HRR machinery, PARP-1 inhibitors have been consistently shown to elicit therapeutic effects both in clinical trials and in vitro.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of <b>14</b> and <b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">4 Non-BRCA Mutation Biomarkers</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28127" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28127" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Currently, BRCA mutations are the most reliable, feasible biomarkers used to select patients for cancer therapy with PARP-1 inhibitors. Actually, a molecular companion diagnostic test, BRACAnalysis CDx, which detects the presence of BRCA mutations in blood samples, was approved.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> However, BRCA status is not the only relevant biomarker and is not sufficient to predict the therapeutic effects of PARP-1 inhibitors.<a onclick="showRef(event, 'ref14 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref14 ref74 ref75">(14, 74, 75)</a> Here, we define non-BRCA biomarkers of PARP-1 inhibitor sensitivity, which likely predict therapeutic responses to PARP-1 inhibitor monotherapy in the absence of loss-of-function BRCA mutations. We have classified potential non-BRCA biomarkers according to their relationships to the HRR pathway and PARP-1 as follows (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">4.1 HRR factors and Their Downstream Factors</h3><div class="NLM_p">Increasing evidence shows that in addition to BRCA mutations, other HRR defects could also serve as potential biomarkers to predict the therapeutic responses to PARP-1 inhibitors (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). These defects include aberrations of the Meiotic recombination 11 (MRE11)–RAD50–Nijmegen breakage syndrome 1 (NBS1) complex (MRN), ATM, and their related proteins and Fanconi anemia (FA) proteins and epigenetic inactivation of BRCA1.</div><div class="NLM_p">MRN induces HRR by activating ATM.<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76, 77)</a> The disruption of MRE11 was shown to impair HRR.<a onclick="showRef(event, 'ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref78 ref79">(78, 79)</a> The knockdown of MRE11 or NBS1 sensitized cancer cells to the PARP-1 inhibitor <b>15</b><a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> (KU0058948, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Similarly, MRE11-deficient cancers showed higher sensitivity to <b>5</b>.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> MRE11 mutations were found in 30.7% of tested endometrial cancer samples<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> and approximately 12% of tested colorectal cancer cell lines.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div><div class="NLM_p">ATM can phosphorylate the histone variant H2AX to form γH2AX and trigger cell cycle checkpoints (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81, 82)</a> The loss of function on this pathway, including ATM, checkpoint kinase (CHK)1, CHK2, and the cyclin B1/cyclin-dependent kinase (CDK)1 complex, was found to cause synthetic lethality with PARP-1 inhibitors.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> ATM deletions made breast cancer cells sensitive to <b>2</b>.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The levels of ATM protein were negatively correlated to the sensitivity of gastric cancer cells to <b>2</b>.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> ATM-deficient lymphoma cells were also highly sensitive to <b>2</b>.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86, 87)</a> However, data from 109 patient-derived chronic lymphocytic leukemia samples revealed an inconsistent result.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Nevertheless, <b>2</b> has recently been granted BTD status by the FDA for prostate cancer-harboring ATM aberrations.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p">In most cases of sporadic breast or ovarian cancer, BRCA1 is not mutated but is often decreased or absent. The epigenetic inactivation of BRCA1 via promoter hypermethylation was found to be significantly associated with lymphovessel invasion, low BRCA1 mRNA expression, loss of BRCA1 protein expression, and shorter OS in TNBC and ovarian cancer.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89, 90)</a> Unexpectedly, however, no impact of BRCA1 promoter methylation status on PFS and OS was found in HGS-OvCa or breast cancer patients treated with PARP-1 inhibitors.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91, 92)</a></div><div class="NLM_p last">In addition, defects of FA proteins, including FANCA, FANCC,<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> FANCD2,<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> and FANCM<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> have been reported to contribute to PARP-1 inhibitor sensitivity. Patient-derived FANCA<sup>–/–</sup> and FANCC<sup>–/–</sup> head and neck squamous cell carcinomas (HNSCC) cells are highly sensitive to both PARP-1 inhibitors <b>2</b> and <b>14</b>, and gene complementation can reverse such sensitivity.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> FANCD2 reduction results in the increased sensitivity of NSCLC cells to both PARP inhibitors <b>5</b> and <b>6</b>.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Similarly, FA lymphoblasts with FANCM mutations are hypersensitive to <b>15</b><a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">4.2 Factors Regulating HRR Factors</h3><div class="NLM_p">These factors themselves are not components of the HRR pathway but can alter HRR activity by regulating the levels or activities of HRR factors (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). The following factors show their potential as biomarkers of PARP-1 inhibitor sensitivity.</div><div class="NLM_p">CDK12 orchestrates the transcription of DDR genes, such as <i>BRCA1</i>, <i>ATR</i>, and <i>FANCD2</i> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Disabling its catalytic activity lowered BRCA1 levels in ovarian cancer cells and sensitized the cells to PARP-1 inhibitors.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Moreover, CDK12 has a high mutation rate in HGS-OvCa and the majority of CDK12 mutations are mutually exclusive with mutations in either BRCA1 or BRCA2.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><div class="NLM_p">Inositol polyphosphate 4-phosphatase type II (INPP4B) inhibits the PI3K/protein kinase B (AKT) pathway. INPP4B loss caused significantly increased sensitivity to PARP-1 inhibitors<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> and reduced the protein stability of BRCA1, ATM, and ATR.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Its loss is found in 40% or more of ovarian cancers as well as in other tumors.<a onclick="showRef(event, 'ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref98 ref99">(98, 99)</a> However, phosphatase and tensin homologue (PTEN), another tumor suppressor in the same pathway, was recently confirmed not to be such a biomarker.<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100, 101)</a></div><div class="NLM_p">Protein phosphatase 2 regulatory subunit B, alpha (PPP2R2A) negatively regulates γH2AX, ATM, CHK1, and CHK2.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> PPP2R2A loss dramatically increases ATM phosphorylation and the activity of CHK2, BRCA1, and RAD51. Blocking PPP2R2A was found to impair HRR and to sensitize tumor cells to PARP-1 inhibitors.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> PPP2R2A downregulation is found in various types of cancers, including NSCLC,<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> breast cancer,<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> and prostate cancer.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div><div class="NLM_p">EMSY binds to BRCA2 in partnership with HP1β. EMSY amplification could mimic BRCA2 deficiency<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> and was associated with cellular sensitivity to <b>3</b>.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The <i>EMSY</i> gene is amplified almost exclusively in sporadic breast cancer (13%) and HSG-OvCa (17%).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> In contrast, HP1β, a partner protein of EMSY, was shown to promote BRCA1 function<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> and HP1β-knockdown cells were hypersensitive to the PARP inhibitor <b>5</b>.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></div><div class="NLM_p last">The last one is Aurora A that controls mitotic entry. It inhibits RAD51 recruitment to DSBs, impairs RAD51 foci formation, and represses HRR.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Aurora A overexpression was found to sensitize BRCA-proficient cells to the PARP-1 inhibitor <b>15</b>.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Its overexpression is observed in various tumors, including breast, ovarian, and pancreatic cancers.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">4.3 The Target PARP-1 Related Factors</h3><div class="NLM_p">PARP-1 cannot serve as a general biomarker to predict PARP-1 inhibitor sensitivity although PARP-1 is the primary target of PARP-1 inhibitors.<a onclick="showRef(event, 'ref60 ref81 ref88 ref110'); return false;" href="javascript:void(0);" class="ref ref60 ref81 ref88 ref110">(60, 81, 88, 110)</a> In contrast, other factors related to PARP-1, such as fused erythroblast transformation specific (ETS) genes and forkhead box O (FOXO)3A, display potential as biomarkers.</div><div class="NLM_p">Fusions of ETS genes such as <i>FLI-1</i>, <i>ERG</i>, and <i>ETV-1</i> are common driving events in Ewing sarcoma and prostate cancer.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Gene fusions of <i>EWS–FLI1</i> and <i>EWS–ERG</i> are seen in ∼90% and ∼10% of Ewing sarcomas, respectively. <i>ERG</i> and <i>ETV1</i> are fused to the <i>TMPRSS2</i> gene in 50% and 5% prostate cancers, respectively.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a><i>EWS–FLI1</i> was found to drive PARP-1 expression,<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> while <i>TMPRSS2–ERG</i> was shown to interact with PARP-1.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Recently, <i>EWS–FLI1</i>-driven SLFN11 expression has been demonstrated to be a determinant of Ewing sarcoma sensitivity to PARP inhibitor <b>4</b>.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> However, clinical trials in patients with either Ewing sarcoma<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> or prostate cancer<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> failed to confirm the results.</div><div class="NLM_p last">Additionally, FOXO3A promotes p21/p27 transcription.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> PARP-1 may reduce FOXO3A levels in two ways. One possibility is a downregulation of the PH domain and leucine rich repeat protein phosphatase (PHLPP)1, leading to an increase in AKT-mediated FOXO3A phosphorylation and, thereby, FOXO3A degradation. The other possibility is the PARylation of kappa B kinase (IKK)γ inhibitors, inducing its degradation, attenuating its inhibition on NF-κB, and thereby repressing FOXO3A expression (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> PARP-1 inhibitors inhibit PARP-1 and enhance the levels of FOXO3A via either of these ways.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> In gastric cancer, the expression status of PARP-1 and FOXO3A was observed to be significantly associated with OS and relapse-free survival. Patients with PARP-1<sup>–</sup>/FOXO3A<sup>+</sup> have more favorable prognoses than those with PARP-1<sup>+</sup>/FOXO3A<sup>–</sup>.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">4.4 Other Biomarkers</h3><div class="NLM_p">Other potential biomarkers of PARP-1 inhibitor sensitivity include those that are difficult to classify, such as 53BP1, REV7, and CDK5. Both 53BP1 and REV7 inhibit HRR. The loss of either protein restores HRR and renders resistance to PARP-1 inhibitors in BRCA1-deficient cells.<a onclick="showRef(event, 'ref117 ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref117 ref118 ref119">(117-119)</a> REV7 was shown to be downstream of 53BP1 in coordinating the DSB repair pathway choice in BRCA1-deficient cells.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Moreover, the loss of these proteins has been found in subsets of breast cancers.<a onclick="showRef(event, 'ref117 ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref117 ref118 ref119">(117-119)</a></div><div class="NLM_p">CDK5 was discovered to be a determinant of PARP-1 inhibitor sensitivity in a synthetic lethal siRNA screen.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Silencing CDK5 was confirmed to result in synthetic lethality with PARP-1 inhibitors.<a onclick="showRef(event, 'ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref121 ref122">(121, 122)</a> The genomic loss of the <i>CDK5</i> gene is observed in approximately 5.5% of breast cancers, and the differential expression of CDK5 is also detected in hepatocellular carcinoma.<a onclick="showRef(event, 'ref123 ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref123 ref124 ref125">(123-125)</a></div><div class="NLM_p last">Together, all non-BRCA-mutation candidate predictive biomarkers of PARP-1 inhibitor sensitivity, including those mentioned above, require additional evidence, especially clinical data.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">5 Resistance to PARP-1 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08271" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08271" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Currently, PARP-1 inhibitors are primarily used to treat HRR-deficient cancers as monotherapies or HRR-proficient cancers as part of a combination therapy. Cancer cells are able to develop resistance to PARP-1 inhibitors. The possible resistance mechanisms include the following: (a) restoration of HRR function in HRR-deficient cancer cells, (b) decreased expression of the target enzyme PARP-1, (c) increased drug efflux, and (d) others.<a onclick="showRef(event, 'ref126 ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref126 ref127 ref128">(126-128)</a> However, most of these mechanisms have not been examined in the clinic and require further validation. Nevertheless, these known resistance mechanisms might provide valuable information for the clinical development of PARP-1 inhibitors for cancer therapy.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">5.1 Restoration of HRR Function</h3><div class="NLM_p">Mutations in BRCA1 or BRCA2 confer HRR defects to cancer cells, which generally make the cells sensitive to PARP-1 inhibitors. Secondary mutations in the mutated BRCA allele are the most extensively recognized resistance mechanism.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Such secondary mutations can restore the wild-type BRCA protein coding sequence or encode a new form of BRCA that regains the lost critical C-terminal region. Both types of secondary mutations can produce a recovery of the function of BRCA and HRR and thus result in resistance to PARP inhibitors either alone or in combination.<a onclick="showRef(event, 'ref126 ref128'); return false;" href="javascript:void(0);" class="ref ref126 ref128">(126, 128)</a> BRCA secondary mutations have been observed in patients with BRCA-mutated breast or ovarian cancer that was initially sensitive but subsequently resistant to PARP inhibitors, emphasizing the clinical importance of these mutations in cancer therapy. Cancer cells with secondary BRCA mutations may arise from the selective killing properties of PARP-1 inhibitors. Specifically, the inhibitors kill BRCA- and HRR-deficient cells but spare BRCA- and HRR-proficient cells in a large cell population.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Notably, cells that are resistant to PARP-1 inhibitors are occasionally also cross-resistant to other anticancer drugs, such as platinum-based drugs. In contrast, cancers that are resistant to such chemotherapies might be resistant or sensitive to PARP inhibitors.<a onclick="showRef(event, 'ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref126 ref127">(126, 127)</a> Factors other than BRCA secondary mutations that result in this type of drug resistance remain to be identified.</div><div class="NLM_p last">In addition, the loss of 53BP1 or REV7 enhances HRR but represses NHEJ. In addition, the loss of either of these proteins may lead to a partially ATM-dependent HRR.<a onclick="showRef(event, 'ref119 ref126'); return false;" href="javascript:void(0);" class="ref ref119 ref126">(119, 126)</a> The loss of Ku70/80, DNA-PKcs, or Artemis also impairs NHEJ repair.<a onclick="showRef(event, 'ref61 ref66'); return false;" href="javascript:void(0);" class="ref ref61 ref66">(61, 66)</a> The downregulation of the microRNAs miR-9 and miR-182 upregulates BRCA1 expression.<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(130, 131)</a> Rad51 activity increases due to loss of miR-9 and Aurora-1 or the activation of PTEN.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Overexpression of the transcription factor HOXA9 in AML cells<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> and the phosphorylation of the ribosomal protein S6 in BRCA1-deficient cancer cells<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> inhibits DDR and/or restores defective HRR. All these results have been shown to restore or stimulate HRR and thus lead to resistance to PARP-1 inhibitors in specific conditions.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">5.2 Decrease in the Target Enzyme PARP-1</h3><div class="NLM_p">The target enzyme PARP-1 is required for the anticancer activity of its inhibitors. The loss of PARP-1 led to higher than 100-fold resistance to <b>2</b> or <b>6</b>.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Persistent treatments with temozolomide or <b>5</b> resulted in decreased PARP-1 protein levels and resistance to PARP-1 inhibitors in resistant HCT116 cells.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The microRNA miR-210 inhibits the expression of PARP-1. The level of miR-210 has been found to differ in different developmental stages of breast cancer, suggesting that these different stages may exhibit different levels of PARP-1 and have differential sensitivity/resistance to PARP-1 inhibitors.<a onclick="showRef(event, 'ref66 ref134'); return false;" href="javascript:void(0);" class="ref ref66 ref134">(66, 134)</a> It should be noted that such differential sensitivity/resistance might result from cancer progression itself not from the effects of PARP-1 inhibitors themselves.</div><div class="NLM_p last">PARP-1 inhibitor resistance due to decreased PARP-1 expression is likely to be correlated with a reduction in its catalytic activity and DNA trapping capacity. PARP-1 has been identified as a mediator of the toxicity of <b>2</b>,<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> and the anticancer effects of this compound require 90% inhibition of PARP-1 enzymatic activity.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Cancer cells with decreased endogenous PARylation show increased resistance to PARP-1 inhibitors.<a onclick="showRef(event, 'ref66 ref78'); return false;" href="javascript:void(0);" class="ref ref66 ref78">(66, 78)</a> These data suggest the importance of PARP-1 catalytic activity to PARP-1 inhibitor resistance. However, AML patient-derived bone marrow cells with PARP-1 overexpression were unexpectedly found to be resistant to <b>2</b>.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> In addition, other lines of evidence reveal that the DNA trapping capacity of PARP-1 inhibitors is highly correlated with their cell killing ability, as discussed above. However, little is known about the relationships between their DNA–PARP-1 complex trapping capacity and drug resistance.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">5.3 Increase in Drug Efflux</h3><div class="NLM_p last">Many mechanisms exist that can reduce PARP-1 inhibitor levels in cancer cell. Among these mechanisms, increased drug efflux from cancer cells due to the overexpression of drug transporters, especially P-glycoprotein (P-gp), has been considered as a possible mechanism of PARP-1 inhibitor resistance.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> P-gp can be inhibited by PAR, and PARP-1 inhibitors could therefore enhance its drug efflux function due to alleviation of the PAR-mediated inhibition.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Until now, of the PARP-1 inhibitors at late-stage clinical trials, only <b>2</b> has been reported as a possible substrate of P-gp.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Therefore, P-gp-overexpressing cancer cells are significantly resistant to <b>2</b> but not to other tested PARP-1 inhibitors.<a onclick="showRef(event, 'ref66 ref136 ref137 ref138'); return false;" href="javascript:void(0);" class="ref ref66 ref136 ref137 ref138">(66, 136-138)</a> It should be noted that <b>2</b> did not persistently induce P-gp expression in human cancer cells, although it did have this effect in a mouse tumor model.<a onclick="showRef(event, 'ref136 ref139'); return false;" href="javascript:void(0);" class="ref ref136 ref139">(136, 139)</a> Moreover, the relationships between P-gp overexpression and PARP-1 inhibitor sensitivity/resistance in the clinical setting have not been established. These data indicate that with respect to PARP-1 inhibitor resistance, the clinical value of P-gp overexpression in cancer cells requires further evaluation.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">5.4 Other Resistant Factors</h3><div class="NLM_p last">Other factors may also contribute to PARP-1 inhibitor resistance. One possibility is that high levels of the transcription factor NF-κB confer drug resistance to <b>2</b>.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> NF-κB levels have been found to increase in <b>2</b>-resistant cells, and these cells were sensitive to the NF-κB inhibitor (<i>E</i>)-3-tosylacrylonitrile (BAY 11-7082) and the proteasome inhibitor bortezomib. Bortezomib inhibits the degradation of IκBα and thus enhances its suppression of NF-κB signaling. Moreover, silencing p65, a core component of NF-κB signaling, reverses <b>2</b> resistance.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">6 Design Strategies and Structural Types of PARP Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Because of the essential role of PARP-1 in DNA repair, tremendous medicinal chemistry efforts have been devoted to the design of PARP-1 inhibitors with high potency, many of which have been or are being tested in various clinical trials. Recently, an increasing amount of medicinal chemistry efforts are focused on the development of novel PARP-1 inhibitors with diverse structural scaffolds to achieve higher potency, better selectivity, and optimal safety profiles.</div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">6.1 Binding Modes of PARP-1 Inhibitors in Nicotinamide Binding Sites</h3><div class="NLM_p">The binding mode of NAD<sup>+</sup> in the PARP-1 catalytic domain was first described by Ruf and co-workers.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> As shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, the NAD<sup>+</sup> binding domain of PARP-1, also known as the donor site, is divided into three subdomains, including: (a) the nicotinamide-ribose binding domain (NI site), (b) the phosphate binding domain (PH site), and (c) the adenine-ribose binding domain (AD site) (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Most of currently reported PARP inhibitors were designed to mimic the nicotinamide structure and bind competitively with NAD<sup>+</sup> at the NI site of the PARP-1 catalytic domain. Nicotinamide and its 3-aminobenzoamide analogues were the earliest PARP-1 inhibitors<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> but generally showed low inhibitory potency and off-target side effects. Subsequent medicinal chemistry artwork that restricted the rotation of the amide side chain of the 3-aminobenzoamide template led to bicyclic lactam amides (e.g., <b>2</b>,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a><b>3</b>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and <b>6</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a>) or pseudobicyclic amides (e.g., <b>4</b><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and <b>5</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>). These second-generation PARP-1 inhibitors exhibited much higher PARP-1 potency and selectivity. In both types of inhibitors, the amido function forms a critical H-bond network with the Gly and Ser residues. The π–π stacking formed between the ring-A (green) and the Tyr residue is also essential. In addition, a long chain (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B) or a short chain (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B) is generally required to connect the NI binding and AD binding units. This chain is also important for the potency and physicochemical properties of the inhibitors. As some of the medicinal chemistry of these inhibitors was reviewed in 2010,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> we here provide the latest update on the design, optimization, PARP-1/2 selectivity, and further pharmacological profiling of these compounds.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding modes of PARP-1 inhibitors in nicotinamide binding sites. (A) NAD<sup>+</sup> binding domain and subdomains of PARP-1/2 proteins. (B) Binding mode of PARP-1 inhibitors bearing a lactam bicyclic pharmacophore or a pseudobicyclic pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">6.2 PARP-1/2 Nonselective Inhibitors</h3><div class="NLM_p">Most of current PARP-1 inhibitors have poor selectivity over PARP-2 due to the high homology of these proteins in the catalytic domain. Structurally, PARP-1/2 nonselective inhibitors can be divided into two subclasses based on the embedded bicyclic or pseudobicyclic lactam pharmacophore.</div><div id="sec6_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">6.2.1 PARP Inhibitors Bearing a Bicyclic Lactam Pharmacophore</h4><div class="NLM_p">Phthalazinones belong to the earliest PARP inhibitors and were first reported by Banasik and Ueda in 1992.<a onclick="showRef(event, 'ref142 ref143'); return false;" href="javascript:void(0);" class="ref ref142 ref143">(142, 143)</a> Although the early compounds showed low potency, subsequent structural modification on this framework yielded numerous potent PARP inhibitors, including the first-in-class PARP inhibitor <b>2</b>.</div><div class="NLM_p">Although <b>2</b> is used in the clinic, not all patients bearing BRCA mutants respond to treatment.<a onclick="showRef(event, 'ref38 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref40">(38, 40)</a> In 2008, Jonkers and co-workers reported that tumors failed to respond to long-term treatment with <b>2</b> primarily due to P-gp overexpression.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> To address this issue, AstraZeneca developed a backup compound <b>11</b><a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>) that was structurally similar to <b>2</b> but was a poor substrate of P-gp. A long-term treatment with <b>11</b> showed that eight of the nine mice with <i>K14cre</i>; <i>Brca1</i><sup><i>F/F</i></sup>; <i>p53</i><sup><i>F/F</i></sup> (KB1P) tumor xenografts were not refractory within 300 days. More encouragingly, six of seven KB1P tumor-bearing mice that received 100 days of consecutive <b>2</b> treatment acquired drug resistance, whereas compound <b>11</b> was well tolerated and the median relapse-free survival was increased from 64 to 132 days.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Subsequently, this compound entered clinical trials to treat solid tumors and the phase I study (NCT01247168) was recently completed.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. New PARP-1 inhibitors bearing a phthalazinone scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To discover small molecules that could block centrosome clustering for cancer therapeuty, Johannes and cowokers screened the NAD<sup>+</sup> mimics of phthalazinone and quinaolinone compounds in their home library. Compound <b>17</b><a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> was the most potent compound in their screen, with IC<sub>50</sub> value 1 nM (PARP-1), and it showed very potent centrosome declustering activity in HeLa cells (EC<sub>50</sub> < 18 nM). Further optimization of compound <b>17</b> for improved declustering potency and PK profiles resulted in compound <b>18</b>,<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> with IC<sub>50</sub> value 1 nM (PARP-1) and EC<sub>50</sub> = 53 nM (declustering). Compound <b>18</b>, which is a PARP-1, -2, -6 multiple inhibitor with high potency of declustering and with excellent rat oral bioavailability, was suitable for further srudy.</div><div class="NLM_p">Because phthalazinone analogues, including <b>2</b>, generally have poor aqueous solubility and low bioavailability, efforts were also conducted to directly modify this framework. In 2010, Pescatore and co-workers<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> designed a class of new PARP-1 inhibitors bearing a pyrrolo[1,2-<i>a</i>]pyrazine-1(2<i>H</i>)-one scaffold. Among these, compound <b>19</b><a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> was identified as exhibiting high PARP-1 inhibitory potency (IC<sub>50</sub> = 1.8 nM). However, this compound failed to show any cytotoxicity against BRCA1-deficient cells at a concentration of 20 μM. It was found that substituents on the pyrrole fragment and simultaneous introduction of a piperazine or piperidine moiety as the side chain improved potency. The dichloro-substituted analogue <b>20</b><a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> exhibited an IC<sub>50</sub> of 2.1 nM against PARP-1 and a cellular potency (CC<sub>50</sub>) of 53 nM against BRCA1-deficient cells. Similarly, the [6,5]-spirobicyclic compound <b>22</b><a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> showed similarly high potency both against the PARP-1 enzyme and BRCA1-deficient cells. In contrast, other spirobicyclic congeners<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> (<b>21</b>, <b>23</b>) have much reduced cellular potency. Unfortunately, compounds <b>20</b> and <b>22</b> displayed high plasma clearance in rats (<b>20</b>, CL > 200 mL/min/kg; <b>22</b>, CL = 130 mL/min/kg), preventing the analysis of these compounds in further studies.</div><div class="NLM_p">Replacing the pyrrole motif in compounds <b>20</b> and <b>22</b> with a dimethylpyridazin-3(2<i>H</i>)-one skeleton led to compounds <b>24</b><a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> and <b>25</b><a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Both of the compounds retained high potency against PARP-1 enzyme, but their effects varied significantly in a cellular assay. Compound <b>24</b> retained enzymatic and cellular potencies that were nearly as high as those of the parent compound <b>22</b> but still suffered from high plasma clearance (CL = 57 mL/min/kg). Further introducing a <i>para</i>-fluoro benzyl group into the side chain afforded compound <b>26</b>,<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> which retained high PARP inhibitory potency (3.6 nM). This compound showed much improved cellular activity against BRCA1-deficient cells, with a CC<sub>50</sub> value of 9.1 nM. Unfortunately, the metabolic instability and high intrinsic clearance of the parent compound were not improved.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PARP-1 inhibitors bearing the pyrrolo[1,2-<i>a</i>]pyrazinone or dimethylpyridazin-3-one scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Zhu and co-workers<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> at Abbott reported another example of modifying the phthalazinone template and generated a series of tetrahydropyridopyridazinone analogues. It was proposed that replacement of the phenyl moiety in the phthalazinone scaffold with a piperidine ring would provide an additional water-mediated H-bond between the piperidine NH and Glu988 in the NI site of PARP-1. In this way, the water solubility of the new inhibitors would be enhanced. Although the initial compound <b>27</b><a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> showed only a moderate potency (<i>K</i><sub>i</sub> = 118 nM), the subsequent addition of an <i>N</i>-pyridinyl piperazine side chain through the benzoic linker generated the highly potent PARP-1 inhibitor <b>28</b>.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> This compound exhibited a potency of 1 nM both against PARP-1 enzyme and BRCA1-deficient cells (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). In murine B16F10 syngeneic melanoma xenografts, which were relatively resistant to most chemotherapeutics, a low dose of compound <b>28</b> (1.25 mg/kg) in combination with temozolomide (50 mg/kg) showed significant antitumor efficacy and no body weight loss.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PARP-1 inhibitors by modification of the phthalazinone scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, Zheng and Wang<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> reported that replacement of the pendant fluorobenzyl linker in <b>2</b> with a thienyl moiety has no effect on PARP-1 inhibitory potency. Interestingly, the introduction of another thienyl moiety in the side chain generated compound <b>29</b>,<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> which is highly potent, possessing an IC<sub>50</sub> value of 10.8 nM. Docking studies revealed that the thienyl moiety in the side chain formed a new π–π interaction with Arg 217.</div><div class="NLM_p">Compound <b>8</b> (GPI 2116, <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) was a tetracyclic PARP-1 inhibitor developed by Eisai (formerly MGI Pharma).<a onclick="showRef(event, 'ref59 ref150'); return false;" href="javascript:void(0);" class="ref ref59 ref150">(59, 150)</a> This compound has a <i>K</i><sub>i</sub> value of 50 nM against PARP-1 and showed significantly enhanced chemosensitivity in a p388 leukemia model in B6D2F1 mice when used in combination with cisplatin.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Systematic in vitro and in vivo tests indicated that treatment with a combination of <b>8</b>, temozolomide, and irradiation results in a longer life span compared to temozolomide or irradiation alone. A phase I trial was subsequently conducted, and for patients with advanced solid tumors, the MTD of <b>8</b> was established as 4 mg/kg (po, days 1–7) in combination with temozolomide at 150 mg/kg (po, days 1–5) for a 28-day dosing cycle.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> A phase II study of <b>8</b> in combination with temozolomide is ongoing in patients with wild-type BRAF stage 4 or unresectable stage 3 melanoma (NCT01605162). In 2014, the same company reported a phase I study of the PARP inhibitor <b>7</b> (E7449), which has IC<sub>50</sub> values of 1.0 nM against PARP-1 and 1.1 nM against PARP-2 (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The MTD of <b>7</b> was 600 mg/kg once daily when used as a single agent in advanced solid tumor patients. The partial response was 7.1% (<i>n</i> = 2, both with ovarian cancer), and 46.4% of patients had durable stable disease (≥23 weeks). The PK profile indicated that <b>7</b> was rapidly absorbed at a single dose, with a <i>T</i><sub>max</sub> of 1.5 h and an elimination half-life of 8 h. Significant inhibition of PARP was observed at all doses, ranging from 50 to 600 mg. This compound is now undergoing both phase I and phase II studies as a single agent or as part of a combination with a cytotoxic agent for advanced solid tumors or B-cell malignancies (NCT01618136). In addition, Li and co-workers recently reported more analogues by replacement of the isoindoline moiety in the side chain with various aryl or heteroaryl groups; however, none of these compounds were more potent than <b>7</b>.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. PARP-1 inhibitors by modification of the tetracyclic isoquinolones scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A scaffold-combining strategy was reported by BioMarin Pharma, eventually leading to the discovery of <b>6</b>,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> the most potent clinical PARP-1 inhibitor. The initial effort to combine the benzimidazole <b>30</b> and phthalazinone <b>16</b> cores yields a tricyclic phthalazinone derivate <b>31</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> that has high potency against PARP-1, with an IC<sub>50</sub> of 6.1 nM (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>). Subsequent structural optimization by replacing one phenyl ring with a triazole moiety to improve aqueous solubility and introducing two fluoro atoms to enhance cellular potency affords the final compound <b>6</b>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Discovery of the highly potent clinical PARP-1 inhibitor <b>6</b> and its cocrystal structure with the catalytic domain of PARP-1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PJT">4PJT</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The stereochemistry is found to play an essential role, and the isomer <b>6</b> (BMN673) was found to be 240- and 340-fold more potent than its enantiomer <b>32</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> (BMN674) in PARP-1 enzymatic and cellular assays, respectively. The X-ray cocrystal structure of PARP-1 catalytic domain with <b>6</b><a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> shows that the fused tricyclic core not only retains all the key interactions as that the phthalazinone core in <b>2</b> but also provides for more additional direct or indirect interactions, including H-bonds and π–π stackings. Compound <b>6</b> is a highly potent PARP-1 inhibitor, with an IC<sub>50</sub> value of 0.57 nM, and significantly inhibited H<sub>2</sub>O<sub>2</sub>-elicited PAR synthesis in vitro (IC<sub>50</sub> = 2.5 nM). In addition, <b>6</b> was exhibited at least 18-fold selectivity in killing tumor cells carrying BRCA gene or PTEN gene defects.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Recent studies further revealed that the high potency of <b>6</b> may be partially relevant to its high PARP-trapping capacity at the SSB sites. Furthermore, <b>6</b> has good oral bioavailability (>40% in rats), optimal plasma exposure, and a long half-life (<i>t</i><sub>1/2</sub>, approximately 40 h). At an oral dose of 0.33 mg/kg once daily for 28 days, <b>6</b> significantly inhibited the growth of BRCA-1 mutant MX-1 tumor xenografts in mice. In these experiments, four of six mice achieved a complete response. On the basis of the promising preclinical results, compound <b>6</b> is being investigated in a number of clinical trials either alone<a onclick="showRef(event, 'ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref155 ref156">(155, 156)</a> or in combination (NCT02049593, NCT02358200, NCT02116777, and NCT02317874).</div><div class="NLM_p">3,4-Dihydroquinolin-2(1<i>H</i>)-one and its derivatives are also reported as pharmacophores of PARP-1 inhibitors to interact with the catalytic domain, similar to phthalazinones. Fusing a thiopyrano ring to this scaffold provided compound <b>33</b><a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> with an IC<sub>50</sub> value of 42 nM against PARP-1 and a cellular potency of 220 nM (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). PK studies on this compound showed that it had a relatively long intravenous half-life (<i>t</i><sub>1/2</sub> = 3.45 h), AUC concentration (2908 h·ng/mL), and acceptable clearance (3.4 L/h/kg) at 10 mg/kg in rat. Good metabolic stability (<i>t</i><sub>1/2</sub> = 52.6 min) was also detected in human liver microsomes. Meanwhile, compound <b>33</b> has a high brain/plasma ratio of 0.64–0.72 over 4 h.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. PARP-1 inhibitors bearing a dihydroquinolin-2(1<i>H</i>)-one core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Starting from 3,4-dihydroquinolin-2(1<i>H</i>)-one <b>34</b>,<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Gangloff and co-workers conducted a structural modification to afford compound <b>35</b>,<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> showing (a) an IC<sub>50</sub> value of 76 nM for PARP-1 inhibition and (b) optimal cellular activity, with a chemopotentiation factor of approximately 4300. Compound <b>35</b> significantly inhibited PAR synthesis in a SW-620 tumor xenograft model. However, this compound suffered from unacceptable hERG inhibition (>97% at 10 μM). Fusing a pyrrole or thiophene moiety to the dihydroquinolin-2(1<i>H</i>)-one template leads to diverse tricyclic derivatives, among which compound <b>36</b><a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> has an IC<sub>50</sub> value of 44 nM. Further modification from a six- to a seven-membered lactam leads to a decrease of PARP-1 inhibition potency for <b>37</b>;<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> however, the thiophene-fused compound <b>38</b><a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> retains similar potency as that of <b>36</b> (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). Unfortunately, both <b>36</b> and <b>38</b> fail to exhibit significant antiproliferative effects in BRCA mutant cells.</div><div class="NLM_p">Through a scaffold hopping strategy, Zhang and co-workers use a tetrahydroisoquinolin-1-one skeleton that is commonly seen in dopamine receptor ligands to mimic the phthalazinone scaffold of <b>2</b> to interact with the PARP-1 catalytic domain.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> First, they introduce a bicyclic amino side chain to this tricyclic scaffold through an acetamido moiety as the linker. However, most compounds derived from <b>40</b><a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> only show marginal PARP-1 potency. Further modifications on both the side chain and the linker lead to significantly improved potency. The representative compound <b>41</b><a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> bears a flexible linker, whereas compound <b>42</b><a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> has a bulky linker. These two compounds showed PARP-1 IC<sub>50</sub> values of 19 and 0.31 nM, respectively. In addition to excellent enzymatic potency, compound <b>42</b> displayed a CC<sub>50</sub> value of 96 nM against BRCA2-deficient V-C8 cells. Interestingly, further modification on the tricyclic core generated compound <b>43</b>,<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> bearing both tetrahydrocyclopenta[<i>ij</i>]isoquinolin-7(1<i>H</i>)-one and phthalazinone frameworks. This compound showed equally high potency against both PARP-1 and the BRCA2-deficient V-C8 cell (IC<sub>50</sub> = 3.46 nM, CC<sub>50</sub> = 4.53 nM). Even higher potency was observed in BRCA1-deficient MDA-MB-436 cells (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). Mechanic studies revealed that the new PARP-1 inhibitor <b>43</b> significantly inhibited H<sub>2</sub>O<sub>2</sub>-triggered PARylation in SKOV3 cells, induced cellular accumulation of DNA double-strand breaks, and impaired cell-cycle progression in BRCA2-deficient cells.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. PARP-1 inhibitors bearing a tetrahydroisoquinolin-1-one core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, Giannini and co-workers<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> identified a class of new PARP-1 inhibitors bearing a quinazolinone pharmacophore through a virtual screening approach. Representative compound <b>44</b><a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> shows high PARP-1 potency (IC<sub>50</sub> = 9.8 nM), but the cellular potency is moderate (EC<sub>50</sub> = 256 nM). Tumor growth inhibition was 47% at 200 mg/kg in BRCA1-deleted and BRCA2-mutated MX1 human breast carcinoma xenografts. Recently, quinazolinedione analogues were reported as PARP-1 inhibitors. Compound <b>45</b><a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> has a flexible linker and shows an IC<sub>50</sub> value of 120 nM against PARP-1, with a nearly equal potency against PARP-2 (70 nM). Further modification on this scaffold affords compound <b>46</b>,<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> which shows much improved PARP-1 potency, with an IC<sub>50</sub> of 9.51 nM. However, this compound does not show noticeable potency in a cellular assay (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>).<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> In the meantime, a more potent PARP inhibitor <b>47</b><a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> is developed by the same group showing an IC<sub>50</sub> value of 1.29 nM against PARP-1, almost 8-fold less potency against PARP-2 (11.3 nM). Mechanic studies reveal that compound <b>47</b> raises the level of DNA damage, induces G2/M arrest and cell death, and exerts a chemosensitizing effect on BRCA proficient cancer cells. The MX-1 xenograft tumor model shows that compound <b>47</b> (25 mg/kg) in combination with TMZ (50 mg/kg) could remarkably inhibit the growth of tumor without aggravating side effects.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. PARP-1 inhibitors bearing a quinazolinone or quinazolinedione core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">6.2.2 PARP-1 Inhibitors Bearing a pseudobicyclic Lactam as the Pharmacophore</h4><div class="NLM_p">On the basis of the promising results of the clinical PARP-1 inhibitor <b>5</b>, which bears a pseudobicyclic lactam pharmacophore, more efforts to optimize this scaffold were recently conducted. Imidazo[4,5-<i>c</i>]-pyridine carboxamide <b>48</b><a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> was found to have an IC<sub>50</sub> value of 528 nM (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>). Further studies showed that the combination of compound <b>48</b> (25 mg/kg) with cisplatin (2 mg/kg) had similar antitumor efficacy as a combination of compound <b>5</b> (25 mg/kg) and cisplatin (2 mg/kg) in a A549 mouse model.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. PARP-1 inhibitors bearing a pseudobicyclic lactam core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Recently, dihydrobenzofuran carboxamides were reported to show PARP-1 activity as well. Representative compound <b>49</b><a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> has an IC<sub>50</sub> value of 114 nM (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>) but only showed marginal activity in BRCA2-deficient DT40 cells. 7-Azaindole-1-carboxamides are an additional series of PARP-1 inhibitors bearing a pseudobicyclic lactam. Among these compounds, <b>50</b><a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> is the most potent, with an IC<sub>50</sub> of 70 nM (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>). Compared to <b>2</b>, compound <b>50</b> shows higher sensitivity against resistant, P-gp-overexpressing cells. At a dose of 100 mg/kg, <b>50</b> showed similar antitumor growth inhibition of the MX-1 human breast carcinoma xenografts as <b>2</b> at a dose of 167 mg/kg and no death or significant body weight loss were observed.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">6.3 Efforts on the Development of Selective PARP-1 or PARP-2 Inhibitors</h3><div class="NLM_p">In 2006, Hattori and co-workers<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> identified a series of quinazolinone analogues that showed moderate PARP-1 selectivity over PARP-2, ranging from 9- to 39-fold selectivity. The representative compound <b>51</b><a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> has IC<sub>50</sub> values of 13 and 500 nM for PARP-1 and PARP-2, respectively. The cocrystallization structure of the methyl analogue <b>52</b><a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> with the PARP-1 catalytic domain indicated that the PARP-1/2 selectivity is likely due to an insertion of the side chain’s pyridinyl motif into the pocket containing amino acids Asn 767, Asp 770, Asp 796, Asn 868, and Ala 880. In this way, the pyridinyl motif forms van de Waals interactions in the AD site. Interestingly, further modification leads to the quinoxaline derivative <b>53</b><a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> that shows reversed PARP-1/2 selectivity. This compound has an IC<sub>50</sub> value of 8 nM against PARP-2 and is more than 10-fold more potent than against PARP-1. Compounds bearing an isoquinolindione core also preferably interact with PARP-1. The representative compound <b>54</b><a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> shows an IC<sub>50</sub> value of 45 nM and more than 80-fold PARP-1/2 selectivity (<a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>).</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Selective PARP-1 or PARP-2 inhibitors bearing a quinazolinone or isoquinolinone core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Many efforts<a onclick="showRef(event, 'ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref169 ref170">(169, 170)</a> were also devoted to the structural modification of isoquinolinones as selective PARP-2 inhibitors. This class of compounds is generally less potent than other reported PARP-2 inhibitors. The most potent compound is <b>55</b>,<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> bearing a benzamido moiety but only showing moderate PARP-2 potency (1.5 μM). However, this compound was still nearly 10-fold more potent against PARP-2 than against PARP-1.</div><div class="NLM_p">Recently, Papeo and co-workers<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> reported a high throughput screening and subsequent structural optimization effort that led to a series of isoindole-4-carboxamides that showed moderate PARP-1/2 selectivity. The representative compounds <b>56</b><a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> and <b>57</b><a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> showed IC<sub>50</sub> values of less than 100 nM and were slightly selective against PARP-1 over PARP-2. The cocrystal structure showed that the pseudo seven-membered lactam ring in these compounds formed an H-bonding network and π–π stacking in the PARP-1 catalytic domain. On the basis of this analysis, further structural modification focusing on the side chain yields compound <b>58</b>,<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> which shows a PARP-1 <i>K</i><sub>D</sub> value of 30 nM and is >87-fold selective over PARP-2 (<a class="ref internalNav" href="#fig15" aria-label="Figure 15">Figure 15</a>A). This compound also shows high inhibitory potency against PARylation. However, high clearance (230 mL/min/kg) and poor oral bioavailability are also observed.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Selective PARP-1 inhibitors bearing anisoindolinone core and cocrystal structure of <b>60</b> with PARP-1 (left) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A00">5A00</a>) and PARP-2 (right) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZY">4ZZY</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further optimization of the side chain, especially the introduction of a difluoro-substituted cyclohexyl moiety, significantly improved the PK parameters. Among these compounds, compounds <b>59</b><a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> and <b>60</b><a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> both retain high PARP-1 potency and selectivity and show significantly reduced plasma exposure and a much elevated bioavailability (<a class="ref internalNav" href="#fig15" aria-label="Figure 15">Figure 15</a>A).</div><div class="NLM_p">At an oral dose of 150 mg/kg once daily, compound <b>60</b> alone elicits significant tumor growth inhibition in BRCA1-mutated MDA-MB-436 human tumor xenograft models. When used as part of a combination, compound <b>60</b> (100 mg/kg) combined with temozolomide (50 mg/kg) also results in high antitumor growth inhibition, with three out of six mice showing complete tumor regression.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></div><div class="NLM_p last">From the cocrystal structures with the catalytic domains of both hPARP-1 and hPARP-2 (<a class="ref internalNav" href="#fig15" aria-label="Figure 15">Figure 15</a>B,C), both <b>59</b> and <b>60</b> form the same H-bonding networks with the Gly (Gly 863 for PARP-1, Gly 429 for PARP-2) and Ser (Ser 904 for PARP-1, Ser 470 for PARP-2) moieties as well as π–π stacking with Tyr (Tyr 907 for PARP-1, Tyr 473 for PARP-2) in the NI sites of PARP-1 and PARP-2.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Meanwhile, the 4,4-difluorocyclohexylpiperidinyl moiety is found to insert deep within the AD site and allow the 4,4-difluorocyclohexyl ring, in combination with the slightly dissimilar orientation of the α-helix in the two proteins, to induce a larger pocket in PARP-1 that is able to better accommodate the 4,4-difluorocyclohexyl moiety.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">7 Opportunities and Challenges in PARP-1 Inhibitors for Cancer Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since 2010, many important advances in the field of PARP-1 inhibitors for cancer therapy have been achieved. As described above, the most important of these advances is the approval of <b>2</b> as the first in-class PARP-1 inhibitor to be used to treat ovarian cancer harboring BRCA1/2 mutations. This breakthrough has reignited great interest in PARP-1 inhibitors. From basic research to development and to clinical applications, such successes have paved a new avenue for more extensive, deeper investigations of PARP-1 inhibitors. Simultaneously, various challenges are also emerging.</div><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">7.1 Exploiting DDR Defects</h3><div class="NLM_p last">There are at least 450 reported DDR genes, 40% of which encode enzymes, which is higher than the proportion of tumorigenic enzyme-encoding genes (25–30%).<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Germline defects in 58 DDR genes are related to cancer predisposition. Somatic mutations or alterations of DDR genes can also contribute to tumorigenesis and tumor progression.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> PARP-1 inhibitors that inhibit BER, block the recently recognized Alt-NHEJ pathway, and/or derepress NHEJ exert synthetic lethality with HRR defects (e.g., BRCA loss-of-function mutations), causing selective anticancer activity (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Abnormal alterations of more than 20 DDR-related genes have been determined to be potential determinants of PARP-1 inhibitor sensitivity (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), and more will certainly be identified. These facts reveal that among the numerous DDR genes, there are abundant opportunities (a) to exploit potential defects in the DDR pathway to induce synthetic lethality via PARP-1 inhibition, (b) to discover more predictive biomarkers of PARP-1 inhibitor sensitivity/resistance, and (c) to identify and validate druggable targets whose inhibitors might elicit synthetic lethality when combined with PARP-1 inhibitors. Making the best of these opportunities is likely to further expand the clinical uses of PARP-1 inhibitors, allow their therapeutic application in more precise patient populations, and produce higher efficacy and/or lower toxicity. However, there are also major challenges that remain, including our limited knowledge regarding the functions of many DDR genes, possible interactions between them and, particularly, their relationships to PARP-1 and its inhibition.</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">7.2 Discovering and Validating Biomarkers of PARP-1 Inhibitor Sensitivity</h3><div class="NLM_p last">Correctly identifying patients with PARP-1 inhibitor-responsive cancers is critical for successful cancer therapy, particularly with single-agent PARP-1 inhibitors. It is important to select patients according to specific biomarkers rather than the tissue types of their cancers.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> At present, despite their limited prediction ability, BRCA1/2 mutations are essentially the only two biomarkers of PARP-1 inhibitor sensitivity that can be used as the basis of selection for patients. Nevertheless, more than 20 non-BRCA potential biomarkers of the PARP-1 inhibitor sensitivity have been reported and many more will certainly be identified. These studies provide important clues for the discovery of new biomarkers; however, most biomarkers are derived from basic research and lack critical validation in clinical trials. In addition to continuously searching for potential biomarkers of PARP-1 inhibitor sensitivity, therefore, more efforts are needed to evaluate the predictive power of the reported candidate biomarkers in the clinic or in clinical trials. Systematically analyzing the frequencies of biomarker aberrations in cancer patients is also helpful for patient selection. Considering the limited prediction value of any single biomarker, such as loss of BRCA1 or BRCA2, combinations of two or more candidate biomarkers should be tested to further enhance their ability to predict PARP-1 inhibitor responsiveness.</div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">7.3 Understanding and Overcoming PARP-1 Inhibitor Resistance</h3><div class="NLM_p last">The clinical use of PARP-1 inhibitors to treat cancers has a short history, and there is only a limited understanding regarding the characteristics and mechanisms of cancer resistance to PARP-1 inhibitors. Most of the current knowledge of PARP-1 inhibitor resistance comes from preclinical studies, especially in vitro studies. However, clinical resistance to PARP-1 inhibitors will be inevitable, just as is the case for other anticancer drugs. Moreover, PARP-1 inhibitors are likely to be used to treat cancers that harbor different genetic defects. Therefore, the following issues regarding the clinical resistance to PARP-1 inhibitors need to be further explored, including: (a) drug resistance in cancers with different genetic defects, (b) tumor resistance to different PARP-1 inhibitors, (c) potential biomarkers of PARP-1 inhibitor resistance in different contexts, (d) overcoming PARP-1 inhibitor resistance, and (e) clinical therapeutic regimens that prevent and/or delay the emergence of inhibitor resistance. However, some issues will be difficult to address by using PARP-1 inhibitors alone, such as so-called secondary mutations in BRCA1/2, which are believed to restore HRR function. Such secondary mutations likely exist in very few cancer cells that are insensitive to PARP-1 inhibitors but can expand to become the predominant cell population after BRCA mutant cells that are sensitive to PARP-1 inhibitors are killed.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Therefore, secondary mutations are not likely to be remutations in mutated BRCA1/2 alleles within PARP-1 inhibitor-sensitive populations. Rather, such BRCA1/2 mutations are likely to be inherent in a subset of cancer cells that are insensitive to PARP-1 inhibitors. To prevent and/or delay the occurrence of tumor drug resistance in the clinic, combinations of PARP-1 inhibitors and other proper anticancer agents will be necessary, even in treating cancers that are apparently sensitive to PARP-1 inhibitors.</div></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">7.4 Enhancing the Selectivity of PARP-1 Inhibitors</h3><div class="NLM_p last">All PARP-1 inhibitors that are currently in the late-stage of clinical trials also inhibit its closest isoform, PARP-2, sometimes with higher potency (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). These compounds can inhibit other members of the PARP family as well. For example, both <b>2</b> and <b>5</b> inhibit PARP-3 and PARP-4 and <b>3</b> also inhibits PARP-5a.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> An intensive study was performed with 185 small-molecule inhibitors regarding their ability to bind to the catalytic domains of 13 human PARP family members, including PARP-1 to PARP-5. The data showed that many inhibitors, including <b>2</b>, <b>3</b>, and <b>5</b>, can bind to several PARP family members and inhibit their enzymatic activity.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> In addition, some inhibitors (e.g.,<b>7</b>) can inhibit other signaling pathways (e.g., Wnt signaling).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Therefore, the inhibitors that are under clinical evaluation are not selective PARP-1 inhibitors and might cause additional, possibly harmful effects. It has been revealed that only the loss of both PARP-1 and PARP-2 can cause embryonic lethality in mice,<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> suggesting that inhibiting both PARP-1 and PARP-2 likely causes more severe toxicity than selectively inhibiting either protein. In this regard, developing high selectivity PARP-1 inhibitors might be worthwhile, although their anticancer activity possibly decreases due to the overlapping functions of PARP-1 and PARP-2 in DNA repair. Until now, one selective PARP-1 inhibitor (<b>60</b>) has been reported that inhibited PARP-1 80-fold more potently than PARP-2 and totally repressed the growth of MDA-MB-436 tumor xenografts.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> These results indicated that development of selective PARP-1 inhibitors might be a promising approach.</div></div><div id="sec7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">7.5 Persistently Exploring Rational Combination Therapy to Expand the Patient Population</h3><div class="NLM_p">Current evidence shows that PARP-1 inhibitors alone might be clinically effective only in cancers that harbor defective HRR, as described above and as demonstrated by the effects of <b>2</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Relatively low incidence of HRR deficiencies limits the anticancer uses of PARP-1 inhibitors. The combination of PARP-1 inhibitors with other anticancer drugs has been revealed to not only improve their therapeutic efficacy but also to extend their treatments to HRR-proficient cancers. In this way, the patient population that can benefit from PARP-1 inhibitors can be expanded. Examples of such combinations with <b>2</b> are shown in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b00055/suppl_file/jm6b00055_si_001.pdf" class="ext-link">Table 1</a>. Moreover, combination therapy is a classical therapeutic mode for the majority of cancers and anticancer drugs. Therefore, exploring the combination therapy of PARP-1 inhibitors becomes necessary for their clinical development.</div><div class="NLM_p">In exploring their combination therapy in clinical trials, the greatest challenge might be that the ideal combination regimens cannot be effectively determined based on the known mechanisms of action of candidate anticancer drugs. For instance, the anticancer potentiation of PARP-1 inhibitors is primarily correlated with their inhibition of SSB repair, which amplifies the DNA-damaging effects of anticancer drugs.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Some chemotherapies, including platinum drugs (carboplatin and cisplatin), Top I inhibitors (topotecan), and alkylating agents (dacarbazine and temozolomide), all elicit SSBs that are repaired in part by PARP-1-mediated BER. When combined with most of these drugs, however, PARP-1 inhibitors did not give rise to the expected clinical benefits, as shown by the examples of combination therapies with <b>2</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b00055/suppl_file/jm6b00055_si_001.pdf" class="ext-link">Table 1</a>). In sharp contrast, the PARP-1 inhibitor <b>2</b> significantly improved clinical benefits when used with a microtubule inhibitor (paclitaxel) or an angiogenesis inhibitor (cediranib), although these drugs are not classically DNA-damaging agents. Recently, paclitaxel has been shown to disrupt intracellular trafficking of DNA repair proteins, including ATM, on interphase microtubules. This effect could further increase the accumulation of DNA damage due to the inhibition of SSB repair by <b>2</b>.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> This effect is a possible cause of the improved efficacy of the <b>2</b> plus paclitaxel combination observed in gastric cancer with low levels of ATM.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Angiogenesis inhibitors normally cause hypoxia, which leads to defects in DNA repair by interfering with the expression of DNA repair factors.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Low BRCA1 expression might be an effective response predictor for the EGFR inhibitor treatment in NSCLC,<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> and <b>2</b> can attenuate and/or prevent BRCA1 expression.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> From the viewpoint of mechanistic synergism, <b>2</b> should achieve better therapeutic effects in combination with DNA-damaging agents than with other anticancer drugs. However, more promising effects were seen in combinations containing paclitaxel or cediranib even though both of these drugs only caused weak interferences with DNA repair (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b00055/suppl_file/jm6b00055_si_001.pdf" class="ext-link">Table 1</a>). One possible reason for this result is that patients could not tolerate the enhanced toxicity of the combination of <b>2</b> and DNA-damaging agents due to severe DNA damage.</div><div class="NLM_p last">The examples mentioned above reveal that balancing enhanced therapeutic effects with increased toxicities in order to achieve maximal clinical benefit is the predominant issue in designing rational combination regimens with PARP-1 inhibitors. Drugs that mildly interfere with DNA repair might be more useful as PARP-1 inhibitor combination partners. On the other hand, tumor drug resistance is another important issue that should be taken into account in designing combination therapy. Drugs that can overcome and/or delay tumor resistance to PARP-1 inhibitors (or drugs with resistance mechanisms that can be overcome and/or delayed by PARP-1 inhibitors) are potential combination partners for PARP-1 inhibitors. Such drugs deserve persistent exploration as possible combination partners with PARP-1 inhibitors, and the molecular mechanisms of these combinations should be thoroughly studied.</div></div><div id="sec7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">7.6 Developing Next-Generation PARP Inhibitors for Cancer Therapy</h3><div class="NLM_p last">The PARP-1 inhibitors that are currently approved or are in late-stage clinical trials have the following common features: (a) their PARP-1 inhibition is not selective, (b) they can induce tumor drug resistance against which there is no effective strategy, and (c) they are used in combination therapies that are plagued by uncertainties concerning the selection of the proper partner, principally with respect to therapeutic effects, toxicity, and drug resistance. Such uncertainties increase the complexity and unpredictability of these combination therapies. Therefore, the development of next-generation PARP inhibitors for cancer therapy is becoming necessary. Next-generation PARP inhibitors might include inhibitors that (a) can highly selectively inhibit PARP-1 or other members of the PARP family, (b) can overcome tumor resistance to present PARP inhibitors, and (c) might concurrently inhibit PARP and other validated anticancer targets, the inhibitors of which have been proven to be clinically effective in combination with existing PARP-1 inhibitors. Fortunately, the first selective PARP-1 inhibitors have been designed based on available structural knowledge and design strategies. This result, together with further clinical trials, will fuel more efforts in the pursuit of more selective and safer PARP-1 inhibitors. Meanwhile, efforts to discover additional types of PARP-1 inhibitors are also urgently needed given that resistance against PARP-1 inhibitors that are used extensively in the clinic will unavoidably occur. The use of additional types of inhibitors might simplify combination therapies with existing PARP inhibitors and other anticancer drugs, reducing uncertainty and enhancing reliability.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00055">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00055" class="ext-link">10.1021/acs.jmedchem.6b00055</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Olaparib (<b>2</b>) in completed combinatorial studies (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00055/suppl_file/jm6b00055_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00055/suppl_file/jm6b00055_si_001.pdf">jm6b00055_si_001.pdf (236.1 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00055" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ao Zhang</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, and Synthetic Organic & Medicinal
Chemistry Laboratory, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Lu, Building 3, Room 426, Pudong, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#97f6f8edfff6f9f0d7e4fefafab9f6f4b9f4f9"><span class="__cf_email__" data-cfemail="60010f1a08010e072013090d0d4e01034e030e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ze-Hong Miao</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b8c2d0d5d1d9d7f8cbd1d5d596d9db96dbd6"><span class="__cf_email__" data-cfemail="fc869491959d93bc8f959191d29d9fd29f92">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying-Qing Wang</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ping-Yuan Wang</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, and Synthetic Organic & Medicinal
Chemistry Laboratory, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Lu, Building 3, Room 426, Pudong, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">Key
Laboratory of Pesticide & Chemical Biology, Ministry of Education,
College of Chemistry, Central China Normal
University, Wuhan 430079, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu-Ting Wang</span> - <span class="hlFld-Affiliation affiliation">Division
of Antitumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guang-Fu Yang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Pesticide & Chemical Biology, Ministry of Education,
College of Chemistry, Central China Normal
University, Wuhan 430079, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.-Q.W. and P.-Y.W. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01185" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01185" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Ying-Qing Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=BIO-d7e3165-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ying-Qing Wang</b> received her Ph.D. in Pharmacology from Jilin University in 2010. After her postdoctoral work in the field of preclinical drug development and cancer research, she joined the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, in 2013, where she has been associate professor of Tumor Pharmacology since 2013.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Ping-Yuan Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=BIO-d7e3170-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ping-Yuan Wang</b> received his B.S. in chemistry from Central China Normal University in 2010 and then became a graduate student under the supervision of Professor Guang-Fu Yang at the Central China Normal University. In 2011, he joined Professor Ao Zhang’s group at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, as a joint graduate student. His doctoral thesis focuses on the design and synthesis of novel PARP-1 inhibitors as anticancer treatments.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Yu-Ting Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=BIO-d7e3175-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yu-Ting Wang</b> received her Bachelor of Science degree in Pharmaceutical Science from Sun Yat-sen University in 2013 and then became a graduate student under the supervision of Professor Ze-Hong Miao at Shanghai Institute of Materia Medica, Chinese Academy of Sciences.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Guang-Fu Yang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=BIO-d7e3180-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Guang-Fu Yang</b> obtained his Bachelor of Science degree in Chemistry at Central China Normal University (CCNU) in 1992 and his Doctor of Philosophy in Pesticide Science from Nankai University in 1997. He has worked at CCNU since 1997 and became a full Professor in 2001. He was the Dean of College of Chemistry, CCNU, from 2002 to 2014. Since 2003, he has also been the director of the Key Laboratory of Pesticide & Chemical Biology of the Ministry of Education. In 2014, he was promoted to the Assistant President of CCNU. In 2009, he was awarded the Distinguished Young Investigator Award from National Nature Science Foundation of China. His research interests include rational design and syntheses of biologically active small molecules and their chemical biology.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Ao Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=BIO-d7e3185-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ao Zhang</b> received his doctorate in Organic Chemistry in 2000 and performed postdoctoral research in Medicinal Chemistry during 2001–2004 at Georgetown University Medical Center and Harvard Medical School McLean Hospital. In 2004, he was promoted to Research Investigator and Instructor of Harvard Medical School. In 2006, he received the Hundred Talent Project award from the Chinese Academy of Sciences and became the Professor of Medicinal Chemistry at the Shanghai Institute of Materia Medica (SIMM). In 2011, he was awarded the Distinguished Young Investigator Award from the Chinese Natural Science Foundation. He has coauthored more than 100 original articles and reviews. His research interests include the design and synthesis of novel small molecules as structural and functional probes for the diagnosis and treatment of brain disorders and cancers.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Ze-Hong Miao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=BIO-d7e3190-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ze-Hong Miao</b> received his Ph.D. degree from the Shanghai Institute of Materia Medica (SIMM) in 2003. He was trained as a visiting fellow at the National Cancer Institute of the National Institutes of Health in the United States from 2004 to 2006. He has been a professor in pharmacology at SIMM since 2007. His research interests are focused on cellular and molecular mechanisms of anticancer compounds, including PARP inhibitors. Several lead compounds for PARP inhibitors were identified in his group as well as in his collaborators’ groups. In addition, a great deal of work has been performed on the structure–activity relationship and structural optimization of these inhibitors. Currently, the preclinical studies on two PARP-1 inhibitors, simmiparib and mefuparib hydrochloride, have been completed.</p></figure></div><div class="ack" id="ACK-d7e3195-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76887" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76887" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Basic Research Program of China (2012CB932502 for Z.H.M. and 2015CB910603 for A.Z.), the National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program” of China (2016ZX09101009 for Z.H.M.), the National Natural Science Foundation of China (81573450 and 81321092 for Z.H.M. and 81430080 for A.Z.), the Chinese Academy of Sciences (XDA12020104 and Hundred Talents Project for Z.H.M.), the Institutes for Drug Discovery and Development of the Chinese Academy of Sciences (CASIMM0120152003 and CASIMM0120153005 for Z.H.M.), the Science and Technology Commission of Shanghai Municipality (16JC1406300 to Z.H.M., 14431905300 for A.Z.), and the State Key Laboratory of Drug Research (SIMM1601ZZ-03 for Z.H.M.).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i41" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i41"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i42" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i42"> Abbreviations Used</h2><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">adenine-ribose</p></td></tr><tr><td class="NLM_term">Alt-NHEJ</td><td class="NLM_def"><p class="first last">alternative nonhomologous end-joining</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">ATM</td><td class="NLM_def"><p class="first last">ataxia telangiectasia mutated</p></td></tr><tr><td class="NLM_term">ATR</td><td class="NLM_def"><p class="first last">ataxia telangiectasia and Rad3 related</p></td></tr><tr><td class="NLM_term">BARD1</td><td class="NLM_def"><p class="first last">BRCA1-associated RING domain protein 1</p></td></tr><tr><td class="NLM_term">BER</td><td class="NLM_def"><p class="first last">base excision repair</p></td></tr><tr><td class="NLM_term">BTD</td><td class="NLM_def"><p class="first last">breakthrough therapy designation</p></td></tr><tr><td class="NLM_term">Cdc25</td><td class="NLM_def"><p class="first last">cell division cycle 25</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance rate</p></td></tr><tr><td class="NLM_term">CLOCK</td><td class="NLM_def"><p class="first last">circadian locomotor output cycles kaput</p></td></tr><tr><td class="NLM_term">DDR</td><td class="NLM_def"><p class="first last">DNA damage response</p></td></tr><tr><td class="NLM_term">DNA-PKcs</td><td class="NLM_def"><p class="first last">catalytic subunit of the DNA-dependent protein kinase</p></td></tr><tr><td class="NLM_term">DSB</td><td class="NLM_def"><p class="first last">double-strand breaks</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial–mesenchymal transition</p></td></tr><tr><td class="NLM_term">ETS</td><td class="NLM_def"><p class="first last">erthroblast transformation specific</p></td></tr><tr><td class="NLM_term">FA</td><td class="NLM_def"><p class="first last">Fanconi anemia</p></td></tr><tr><td class="NLM_term">FACT</td><td class="NLM_def"><p class="first last">facilitates chromatin transcription</p></td></tr><tr><td class="NLM_term">FOXO</td><td class="NLM_def"><p class="first last">Forkhead box O</p></td></tr><tr><td class="NLM_term">HGS-OvCa</td><td class="NLM_def"><p class="first last">high-grade serous ovarian cancer</p></td></tr><tr><td class="NLM_term">HIF</td><td class="NLM_def"><p class="first last">hypoxia-inducible factor</p></td></tr><tr><td class="NLM_term">HNSCC</td><td class="NLM_def"><p class="first last">head and neck squamous cell carcinomas</p></td></tr><tr><td class="NLM_term">HP1</td><td class="NLM_def"><p class="first last">heterochromatin protein 1</p></td></tr><tr><td class="NLM_term">HRR</td><td class="NLM_def"><p class="first last">homologous recombination repair</p></td></tr><tr><td class="NLM_term">IKK</td><td class="NLM_def"><p class="first last">inhibitor of κ B kinase</p></td></tr><tr><td class="NLM_term">INPP4B</td><td class="NLM_def"><p class="first last">inositol polyphosphate 4-phosphatase type II</p></td></tr><tr><td class="NLM_term">ISWI</td><td class="NLM_def"><p class="first last">imitation switch</p></td></tr><tr><td class="NLM_term">KDM</td><td class="NLM_def"><p class="first last">lysine-specific histone demethylase</p></td></tr><tr><td class="NLM_term">MMEJ</td><td class="NLM_def"><p class="first last">microhomology-mediated end-joining</p></td></tr><tr><td class="NLM_term">MRE11</td><td class="NLM_def"><p class="first last">meiotic recombination 11</p></td></tr><tr><td class="NLM_term">MRN</td><td class="NLM_def"><p class="first last">MRE11–RAD50–NBS1 complex</p></td></tr><tr><td class="NLM_term">NBS1</td><td class="NLM_def"><p class="first last">Nijmegen breakage syndrome 1</p></td></tr><tr><td class="NLM_term">NER</td><td class="NLM_def"><p class="first last">nucleotide excision repair</p></td></tr><tr><td class="NLM_term">NFAT</td><td class="NLM_def"><p class="first last">nuclear factor of activated T-cells</p></td></tr><tr><td class="NLM_term">NHEJ</td><td class="NLM_def"><p class="first last">nonhomologous end-joining</p></td></tr><tr><td class="NLM_term">NI</td><td class="NLM_def"><p class="first last">nicotinamide-ribose</p></td></tr><tr><td class="NLM_term">ORR</td><td class="NLM_def"><p class="first last">objective response rate</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">overall survival</p></td></tr><tr><td class="NLM_term">PAR</td><td class="NLM_def"><p class="first last">poly(ADP-ribose)</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">PARylation</td><td class="NLM_def"><p class="first last">poly(ADP-ribose)ylation</p></td></tr><tr><td class="NLM_term">PBMCs</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cells</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression-free survival</p></td></tr><tr><td class="NLM_term">PHLPP</td><td class="NLM_def"><p class="first last">PH domain and leucine rich repeat protein phosphatase</p></td></tr><tr><td class="NLM_term">PI(3,4)P2</td><td class="NLM_def"><p class="first last">phosphatidylinositol (3,4) bisphosphate</p></td></tr><tr><td class="NLM_term">PIKK</td><td class="NLM_def"><p class="first last">PI3K-related kinase</p></td></tr><tr><td class="NLM_term">PLD</td><td class="NLM_def"><p class="first last">pegylated liposomal doxorubicin</p></td></tr><tr><td class="NLM_term">Pol θ</td><td class="NLM_def"><p class="first last">polymerase θ</p></td></tr><tr><td class="NLM_term">PP2A</td><td class="NLM_def"><p class="first last">protein phosphatase 2A</p></td></tr><tr><td class="NLM_term">PPP2R2A</td><td class="NLM_def"><p class="first last">PP2A regulatory subunit B, alpha</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homologue</p></td></tr><tr><td class="NLM_term">γH2AX</td><td class="NLM_def"><p class="first last">phosphorylated histone H2AX</p></td></tr><tr><td class="NLM_term">RPA-32</td><td class="NLM_def"><p class="first last">replication protein A-32</p></td></tr><tr><td class="NLM_term">SSB</td><td class="NLM_def"><p class="first last">single-strand break</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">Top1</td><td class="NLM_def"><p class="first last">topoisomerase I</p></td></tr><tr><td class="NLM_term">Vd</td><td class="NLM_def"><p class="first last">distribution volume</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57378" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57378" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 178 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Ferraris, D. V.</span><span> </span><span class="NLM_article-title">Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4561</span><span class="NLM_x">–</span> <span class="NLM_lpage">4584</span><span class="refDoi"> DOI: 10.1021/jm100012m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100012m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4561-4584&author=D.+V.+Ferraris&title=Evolution+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29+inhibitors.+From+concept+to+clinic&doi=10.1021%2Fjm100012m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic</span></div><div class="casAuthors">Ferraris, Dana V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4561-4584</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1) has been an actively pursued drug discovery target for almost 3 decades.  Often referred to as the "guardian angel of DNA", this abundant nuclear enzyme has been the focus of over 20 medicinal chem. programs in a wide range of therapeutic areas encompassing stroke, cardiac ischemia, cancer, inflammation, and diabetes.  Despite the great therapeutic potential for this target and the tremendous academic and industrial efforts dedicated to it, only recently have PARP-1 inhibitors made headway in clin. trials.  Recent results from several PARP-1 inhibitors in phase II clin. trials for cancer therapy have attracted the attention of national media.  Of the several potential therapeutic indications for PARP-1 inhibitors, the two major areas that hold the most promise are ischemia and cancer.  This review is structured to provide the readers with a brief summary of the rationale for PARP-1 as a therapeutic target, to explain the PARP-1 inhibitor pharmacophore, and to provide an update on the progress of the PARP-1 drug discovery programs.  This Perspective will offer a historical account of the crit. PARP-1 publications that instilled the interest of the biopharmaceutical industry in the late 1980s and early 1990s.  Furthermore, I will discuss why PARP- 1 received so much attention in the late 1990s and early 2000s followed by the slight decline in the medicinal chem. efforts today.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPhFTTs4raarVg90H21EOLACvtfcHk0ljc8w0tHGskHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D&md5=6c093238562c908d45dfcd2f3055457d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm100012m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100012m%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26atitle%3DEvolution%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%2520inhibitors.%2520From%2520concept%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4561%26epage%3D4584%26doi%3D10.1021%2Fjm100012m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M. Y.</span><span> </span><span class="NLM_article-title">Emerging cancer therapeutic opportunities target DNA-repair systems</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">338</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span><span class="refDoi"> DOI: 10.1016/j.tips.2006.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.tips.2006.04.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=338-344&author=J.+Dingauthor=Z.+H.+Miaoauthor=L.+H.+Mengauthor=M.+Y.+Geng&title=Emerging+cancer+therapeutic+opportunities+target+DNA-repair+systems&doi=10.1016%2Fj.tips.2006.04.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2006.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2006.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26aulast%3DMeng%26aufirst%3DL.%2BH.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26atitle%3DEmerging%2520cancer%2520therapeutic%2520opportunities%2520target%2520DNA-repair%2520systems%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D338%26epage%3D344%26doi%3D10.1016%2Fj.tips.2006.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">He, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z. H.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1172</span><span class="NLM_x">–</span> <span class="NLM_lpage">1180</span><span class="refDoi"> DOI: 10.1038/aps.2010.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Faps.2010.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20676117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSntr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=1172-1180&author=J.+X.+Heauthor=C.+H.+Yangauthor=Z.+H.+Miao&title=Poly%28ADP-ribose%29+polymerase+inhibitors+as+promising+cancer+therapeutics&doi=10.1038%2Faps.2010.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics</span></div><div class="casAuthors">He, Jin-xue; Yang, Chun-hao; Miao, Ze-hong</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1172-1180</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The year of 2005 was a watershed in the history of poly(ADP-ribose) polymerase (PARP) inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition.  The findings made PARP inhibition one of the most promising new therapeutic approaches to cancers, esp. to those with specific defects.  With AZD2281 and BSI-201 entering phase III clin. trials, the final application of PARP inhibitors in clinic would come true soon.  This current paper will review the major advances in targeting PARP for cancer therapy and discuss the existing questions, the answers to which may influence the future of PARP inhibitors as cancer therapeutics.  Acta Pharmacologica Sinica (2010) 31: 1172-1180; doi: 10.1038/aps.2010.103; published online 2 Aug 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzohhmJ-aZLVg90H21EOLACvtfcHk0lg1w4FAUPtpqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSntr3P&md5=618e92fd637cf51f1979928527df9ae7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Faps.2010.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2010.103%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%2BX.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%2520as%2520promising%2520cancer%2520therapeutics%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2010%26volume%3D31%26spage%3D1172%26epage%3D1180%26doi%3D10.1038%2Faps.2010.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Vyas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, P.</span><span> </span><span class="NLM_article-title">New PARP targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span><span class="refDoi"> DOI: 10.1038/nrc3748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnrc3748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24898058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlKqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=502-509&author=S.+Vyasauthor=P.+Chang&title=New+PARP+targets+for+cancer+therapy&doi=10.1038%2Fnrc3748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">New PARP targets for cancer therapy</span></div><div class="casAuthors">Vyas, Sejal; Chang, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-509</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARPs) modify target proteins post-translationally with poly(ADP-ribose) (PAR) or mono(ADP-ribose) (MAR) using NAD+ as substrate.  The best-studied PARPs generate PAR modifications and include PARP1 and the tankyrase PARP5A, both of which are targets for cancer therapy with inhibitors in either clin. trials or preclin. development.  There are 15 addnl. PARPs, most of which modify proteins with MAR, and their biol. is less well understood.  Recent data identify potentially cancer-relevant functions for these PARPs, which indicates that we need to understand more about these PARPs to effectively target them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouf6CtI5GhsrVg90H21EOLACvtfcHk0lg1w4FAUPtpqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlKqsb0%253D&md5=24a3b64d2d0518e13c9540ee012e29ca</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc3748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3748%26sid%3Dliteratum%253Aachs%26aulast%3DVyas%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DP.%26atitle%3DNew%2520PARP%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D502%26epage%3D509%26doi%3D10.1038%2Fnrc3748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Morales, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattah, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bey, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boothman, D. A.</span><span> </span><span class="NLM_article-title">Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases</span> <span class="citation_source-journal">Crit. Rev. Eukaryotic Gene Expression</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.1615/CritRevEukaryotGeneExpr.2013006875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1615%2FCritRevEukaryotGeneExpr.2013006875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24579667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2cvpsVSrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=15-28&author=J.+Moralesauthor=L.+Liauthor=F.+J.+Fattahauthor=Y.+Dongauthor=E.+A.+Beyauthor=M.+Patelauthor=J.+Gaoauthor=D.+A.+Boothman&title=Review+of+poly+%28ADP-ribose%29+polymerase+%28PARP%29+mechanisms+of+action+and+rationale+for+targeting+in+cancer+and+other+diseases&doi=10.1615%2FCritRevEukaryotGeneExpr.2013006875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases</span></div><div class="casAuthors">Morales Julio; Li Longshan; Fattah Farjana J; Dong Ying; Patel Malina; Gao Jinming; Boothman David A; Bey Erik A</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in eukaryotic gene expression</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-28</span>
        ISSN:<span class="NLM_cas:issn">1045-4403</span>.
    </div><div class="casAbstract">Poly (ADP-ribose) polymerases (PARPs) are a family of related enzymes that share the ability to catalyze the transfer of ADP-ribose to target proteins.  PARPs play an important role in various cellular processes, including modulation of chromatin structure, transcription, replication, recombination, and DNA repair.  The role of PARP proteins in DNA repair is of particular interest, in view of the finding that certain tumors defective in homologous recombination mechanisms, may rely on PARP-mediated DNA repair for survival, and are sensitive to its inhibition.  PARP inhibitors may also increase tumor sensitivity to DNA-damaging agents.  Clinical trials of PARP inhibitors are investigating the utility of these approaches in cancer.  The hyperactivation of PARP has also been shown to result in a specific programmed cell death pathway involving NAD+/ATP depletion, mu-calpain activation, loss of mitochondrial membrane potential, and the release of apoptosis inducing factor.  Hyperactivation of the PARP pathway may be exploited to selectively kill cancer cells.  Other PARP forms, including tankyrase 1 (PARP 5a), which plays an important role in enhancing telomere elongation by telomerase, have been found to be potential targets in cancer therapy.  The PARP pathway and its inhibition thus offers a number of opportunities for therapeutic intervention in both cancer and other disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQO6ujQ1G1GLwaK-_ZudimnfW6udTcc2ebICGpBbXsfZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvpsVSrsw%253D%253D&md5=3590812f36c4075309ad19923d2e2852</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1615%2FCritRevEukaryotGeneExpr.2013006875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevEukaryotGeneExpr.2013006875%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DFattah%26aufirst%3DF.%2BJ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DBey%26aufirst%3DE.%2BA.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DBoothman%26aufirst%3DD.%2BA.%26atitle%3DReview%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520mechanisms%2520of%2520action%2520and%2520rationale%2520for%2520targeting%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DCrit.%2520Rev.%2520Eukaryotic%2520Gene%2520Expression%26date%3D2014%26volume%3D24%26spage%3D15%26epage%3D28%26doi%3D10.1615%2FCritRevEukaryotGeneExpr.2013006875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Benafif, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M.</span><span> </span><span class="NLM_article-title">An update on PARP inhibitors for the treatment of cancer</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.2147/OTT.S30793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.2147%2FOTT.S30793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25750544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1WntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=519-528&author=S.+Benafifauthor=M.+Hall&title=An+update+on+PARP+inhibitors+for+the+treatment+of+cancer&doi=10.2147%2FOTT.S30793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">An update on PARP inhibitors for the treatment of cancer</span></div><div class="casAuthors">Benafif, Sarah; Hall, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519-528</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The development of poly (ADP [ADP]) ribose polymerase (PARP) inhibitors (PARPi) has progressed greatly over the last few years and has shown encouraging results in the BRCA1/2 mutation-related cancers.  This article attempts to summarize the rationale and theory behind PARPi, the clin. trials already reported, as well as ongoing studies designed to det. the role of PARPi in patients with and without germline mutations of BRCA genes.  Future plans for PARPi both as monotherapy and in combination with std. cytotoxics, other biol. agents, and as radiosensitizers are also covered.  The widening scope of PARPi adds another important targeted agent to the growing list of mol. inhibitors; future and ongoing trials will identify the most effective role for PARPi, including for patients other than BRCA germline mutation carriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG5uVLd7Fi37Vg90H21EOLACvtfcHk0liDTsu4Gu82hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1WntLg%253D&md5=3256f24adfac3e4f006314db8fd3ab48</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2147%2FOTT.S30793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S30793%26sid%3Dliteratum%253Aachs%26aulast%3DBenafif%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DM.%26atitle%3DAn%2520update%2520on%2520PARP%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2015%26volume%3D8%26spage%3D519%26epage%3D528%26doi%3D10.2147%2FOTT.S30793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">O’Shaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippen, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocha, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C.</span><span> </span><span class="NLM_article-title">Iniparib plus chemotherapy in metastatic triple-negative breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span><span class="refDoi"> DOI: 10.1056/NEJMoa1011418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1056%2FNEJMoa1011418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21208101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=205-214&author=J.+O%E2%80%99Shaughnessyauthor=C.+Osborneauthor=J.+E.+Pippenauthor=M.+Yoffeauthor=D.+Pattauthor=C.+Rochaauthor=I.+C.+Kooauthor=B.+M.+Shermanauthor=C.+Bradley&title=Iniparib+plus+chemotherapy+in+metastatic+triple-negative+breast+cancer&doi=10.1056%2FNEJMoa1011418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Iniparib plus chemotherapy in metastatic triple-negative breast cancer</span></div><div class="casAuthors">O'Shaughnessy, Joyce; Osborne, Cynthia; Pippen, John E.; Yoffe, Mark; Patt, Debra; Rocha, Christine; Koo, Ingrid Chou; Sherman, Barry M.; Bradley, Charles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-214</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(ADP-ribose) polymerase (PARP) inhibition.  We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small mol. with PARP-inhibitory activity, in patients with metastatic triple-neg. breast cancer.  A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equiv. to an area under the concn.-time curve of 2) on days 1 and 8 - with or without iniparib (at a dose of 5.6 mg per kg of body wt.) on days 1, 4, 8, and 11 - every 21 days.  Primary end points were the rate of clin. benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 mo) and safety.  Addnl. end points included the rate of objective response, progression-free survival, and overall survival.  The addn. of iniparib to gemcitabine and carboplatin improved the rate of clin. benefit from 34 to 56% and the rate of overall response from 32 to 52%.  The addn. of iniparib also prolonged the median progression-free survival from 3.6 mo to 5.9 mo (hazard ratio for progression, 0.59) and the median overall survival from 7.7 mo to 12.3 mo (hazard ratio for death, 0.57).  The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level.  No significant difference was seen between the 2 groups in the rate of adverse events.  The addn. of iniparib to chemotherapy improved the clin. benefit and survival of patients with metastatic triple-neg. breast cancer without, significantly increased toxic effects.  On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7tn6oRjsja7Vg90H21EOLACvtfcHk0ljtNQKjcc0P_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGis7c%253D&md5=d50866c03ab6a61f780f14e13fdbae28</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1011418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1011418%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DPippen%26aufirst%3DJ.%2BE.%26aulast%3DYoffe%26aufirst%3DM.%26aulast%3DPatt%26aufirst%3DD.%26aulast%3DRocha%26aufirst%3DC.%26aulast%3DKoo%26aufirst%3DI.%2BC.%26aulast%3DSherman%26aufirst%3DB.%2BM.%26aulast%3DBradley%26aufirst%3DC.%26atitle%3DIniparib%2520plus%2520chemotherapy%2520in%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D205%26epage%3D214%26doi%3D10.1056%2FNEJMoa1011418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span> </span><span class="NLM_article-title">4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4- fluorobenzyl]-2 H-phthalazin- 1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">–</span> <span class="NLM_lpage">6591</span><span class="refDoi"> DOI: 10.1021/jm8001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.+L.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+M.+Smithauthor=N.+M.+Martin&title=4-%5B3-%284-cyclopropanecarbonylpiperazine-1-carbonyl%29-4-+fluorobenzyl%5D-2+H-phthalazin-+1-one%3A+a+novel+bioavailable+inhibitor+of+poly+%28ADP-ribose%29+polymerase-1&doi=10.1021%2Fjm8001263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26atitle%3D4-%255B3-%25284-cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-%2520fluorobenzyl%255D-2%2520H-phthalazin-%25201-one%253A%2520a%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591%26doi%3D10.1021%2Fjm8001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">O’Shaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartzberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danso, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellerstedt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specht, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yardley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charpentier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Ribas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span> </span><span class="NLM_article-title">Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">3840</span><span class="NLM_x">–</span> <span class="NLM_lpage">3847</span><span class="refDoi"> DOI: 10.1200/JCO.2014.55.2984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2014.55.2984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25349301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslCnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=3840-3847&author=J.+O%E2%80%99Shaughnessyauthor=L.+Schwartzbergauthor=M.+A.+Dansoauthor=K.+D.+Millerauthor=H.+S.+Rugoauthor=M.+Neubauerauthor=N.+Robertauthor=B.+Hellerstedtauthor=M.+Salehauthor=P.+Richardsauthor=J.+M.+Spechtauthor=D.+A.+Yardleyauthor=R.+W.+Carlsonauthor=R.+S.+Finnauthor=E.+Charpentierauthor=I.+Garcia-Ribasauthor=E.+P.+Winer&title=Phase+III+study+of+iniparib+plus+gemcitabine+and+carboplatin+versus+gemcitabine+and+carboplatin+in+patients+with+metastatic+triple-negative+breast+cancer&doi=10.1200%2FJCO.2014.55.2984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer</span></div><div class="casAuthors">O'Shaughnessy, Joyce; Schwartzberg, Lee; Danso, Michael A.; Miller, Kathy D.; Rugo, Hope S.; Neubauer, Marcus; Robert, Nicholas; Hellerstedt, Beth; Saleh, Mansoor; Richards, Paul; Specht, Jennifer M.; Yardley, Denise A.; Carlson, Robert W.; Finn, Richard S.; Charpentier, Eric; Garcia-Ribas, Ignacio; Winer, Eric P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3840-3847</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: There is a lack of treatments providing survival benefit for patients with metastatic triple-neg. breast cancer (mTNBC), with no std. of care.  A randomized phase II trial showed significant benefit for gemcitabine, carboplatin, and iniparib (GCI) over gemcitabine and carboplatin (GC) in clin. benefit rate, response rate, progression-free survival (PFS), and overall survival (OS).  Here, we formally compare the efficacy of these regimens in a phase III trial.  Patients and Methods: Patients with stage IV/locally recurrent TNBC who had received no more than two previous chemotherapy regimens for mTNBC were randomly allocated to gemcitabine 1,000 mg/m2 and carboplatin area under the curve 2 (days 1 and 8) alone or GC plus iniparib 5.6 mg/kg (days 1, 4, 8, and 11) every 3 wk.  Random assignment was stratified by the no. of prior chemotherapies.  The coprimary end points were OS and PFS.  Patients receiving GC could cross over to iniparib on progression.  Results: Five hundred nineteen patients were randomly assigned (261 GCI; 258 GC).  In the primary anal., no statistically significant difference was obsd. for OS (hazard ratio [HR] = 0.88; 95% CI, 0.69 to 1.12; P = .28) nor PFS (HR = 0.79; 95% CI, 0.65 to 0.98; P = .027).  An exploratory anal. showed that patients in the second-/third-line had improved OS (HR = 0.65; 95% CI, 0.46 to 0.91) and PFS (HR = 0.68; 95% CI, 0.50 to 0.92) with GCI.  The safety profile for GCI was similar to GC.  Conclusion: The trial did not meet the prespecified criteria for the coprimary end points of PFS and OS in the ITT population.  The potential benefit with iniparib obsd. in second-/third-line subgroup warrants further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAG23pXvdehrVg90H21EOLACvtfcHk0liT9nCiazXyBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslCnsQ%253D%253D&md5=04c056c1d2e0d61729d3c9917c7ce08e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.55.2984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.55.2984%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DSchwartzberg%26aufirst%3DL.%26aulast%3DDanso%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DNeubauer%26aufirst%3DM.%26aulast%3DRobert%26aufirst%3DN.%26aulast%3DHellerstedt%26aufirst%3DB.%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DRichards%26aufirst%3DP.%26aulast%3DSpecht%26aufirst%3DJ.%2BM.%26aulast%3DYardley%26aufirst%3DD.%2BA.%26aulast%3DCarlson%26aufirst%3DR.%2BW.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DCharpentier%26aufirst%3DE.%26aulast%3DGarcia-Ribas%26aufirst%3DI.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26atitle%3DPhase%2520III%2520study%2520of%2520iniparib%2520plus%2520gemcitabine%2520and%2520carboplatin%2520versus%2520gemcitabine%2520and%2520carboplatin%2520in%2520patients%2520with%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D3840%26epage%3D3847%26doi%3D10.1200%2FJCO.2014.55.2984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Novello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlesi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazieres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcereny, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Ribas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scagliotti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2156</span><span class="NLM_x">–</span> <span class="NLM_lpage">2162</span><span class="refDoi"> DOI: 10.1093/annonc/mdu384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fannonc%2Fmdu384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25139550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FjtlaisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=2156-2162&author=S.+Novelloauthor=B.+Besseauthor=E.+Felipauthor=F.+Barlesiauthor=J.+Mazieresauthor=G.+Zalcmanauthor=J.+von+Pawelauthor=M.+Reckauthor=F.+Cappuzzoauthor=D.+Ferryauthor=E.+Carcerenyauthor=A.+Santoroauthor=I.+Garcia-Ribasauthor=G.+Scagliottiauthor=J.+C.+Soria&title=A+phase+II+randomized+study+evaluating+the+addition+of+iniparib+to+gemcitabine+plus+cisplatin+as+first-line+therapy+for+metastatic+non-small-cell+lung+cancer&doi=10.1093%2Fannonc%2Fmdu384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer</span></div><div class="casAuthors">Novello S; Scagliotti G; Besse B; Soria J-C; Felip E; Barlesi F; Mazieres J; Zalcman G; von Pawel J; Reck M; Cappuzzo F; Ferry D; Carcereny E; Santoro A; Garcia-Ribas I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2156-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Iniparib is a novel anticancer agent initially considered a poly (ADP-ribose) polymerase (PARP) inhibitor, but subsequently shown to act via non-selective protein modification through cysteine adducts.  This randomized phase II study investigated the addition of iniparib to gemcitabine-cisplatin in metastatic non-small-cell lung cancer (NSCLC) patients.  PATIENTS AND METHODS:  Patients with histologically confirmed stage IV NSCLC were randomized 2 : 1 to receive gemcitabine (1250 mg/m(2), days 1/8) and cisplatin (75 mg/m(2), day 1) with [gemcitabine/cisplatin/iniparib (GCI)] or without [gemcitabine/cisplatin (GC)] iniparib (5.6 mg/kg, days 1/4/8/11) every 3 weeks for six cycles.  The primary end point was the overall response rate (ORR).  Secondary objectives included progression-free survival (PFS), overall survival (OS), and safety.  The study was not designed for formal efficacy comparison, the control arm being to benchmark results against the literature.  RESULTS:  One hundred and nineteen patients were randomized (39 GC and 80 GCI).  More GCI patients were male (80% GCI and 67% GC) and had PS 0 (61% GCI and 49% GC).  The ORR was 25.6% [95% confidence interval (CI) 13.0%-42.1%] with GC versus 20.0% (95% CI 11.9%-30.4%) with GCI, which did not allow rejection of the null hypothesis (ORR with GCI ≤20%; P = 0.545).  Median PFS was 4.3 (95% CI 2.8-5.6) months with GC and 5.7 (95% CI 4.6-6.6) months with GCI (hazard ratio 0.89, 95% CI 0.56-1.40).  Median OS was 8.5 (95% CI 5.5 to not reached) months with GC, and 12.0 (95% CI 8.9-17.1) months with GCI (hazard ratio 0.78, 95% CI 0.48-1.27).  More GCI patients received second-line treatment (51% GC and 68% GCI).  Toxicity was similar in the two arms.  Grade 3-4 toxicities included asthenia (28% GC and 8% GCI), nausea (3% GC and 14% GCI), and decreased appetite (10% in each).  CONCLUSIONS:  Addition of iniparib to GC did not improve ORR over GC alone.  The GCI safety profile was comparable to GC alone.  Imbalances in PS and gender distribution may have impacted study results regarding PFS and OS.  TRIAL REGISTRATION:  ClinicalTrial.gov Identifier NCT01086254.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJ5_69URqBZmgRQsDqrjW_fW6udTcc2eazNlGBllbVVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FjtlaisQ%253D%253D&md5=076aa5b16ee2dfb8ba124168a9c3c64d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu384%26sid%3Dliteratum%253Aachs%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DZalcman%26aufirst%3DG.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DFerry%26aufirst%3DD.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DGarcia-Ribas%26aufirst%3DI.%26aulast%3DScagliotti%26aufirst%3DG.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DA%2520phase%2520II%2520randomized%2520study%2520evaluating%2520the%2520addition%2520of%2520iniparib%2520to%2520gemcitabine%2520plus%2520cisplatin%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520non-small-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D2156%26epage%3D2162%26doi%3D10.1093%2Fannonc%2Fmdu384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Mendeleyev, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsten, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buki, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kun, E.</span><span> </span><span class="NLM_article-title">Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span><span class="refDoi"> DOI: 10.1016/0006-2952(95)00189-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2F0006-2952%2895%2900189-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1995&pages=705-714&author=J.+Mendeleyevauthor=E.+Kirstenauthor=A.+Hakamauthor=K.+G.+Bukiauthor=E.+Kun&title=Potential+chemotherapeutic+activity+of+4-iodo-3-nitrobenzamide.+Metabolic+reduction+to+the+3-nitroso+derivative+and+induction+of+cell+death+in+tumor+cells+in+culture&doi=10.1016%2F0006-2952%2895%2900189-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2895%2900189-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252895%252900189-7%26sid%3Dliteratum%253Aachs%26aulast%3DMendeleyev%26aufirst%3DJ.%26aulast%3DKirsten%26aufirst%3DE.%26aulast%3DHakam%26aufirst%3DA.%26aulast%3DBuki%26aufirst%3DK.%2BG.%26aulast%3DKun%26aufirst%3DE.%26atitle%3DPotential%2520chemotherapeutic%2520activity%2520of%25204-iodo-3-nitrobenzamide.%2520Metabolic%2520reduction%2520to%2520the%25203-nitroso%2520derivative%2520and%2520induction%2520of%2520cell%2520death%2520in%2520tumor%2520cells%2520in%2520culture%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D50%26spage%3D705%26epage%3D714%26doi%3D10.1016%2F0006-2952%2895%2900189-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Patel, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lorenzo, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatten, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1662</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-11-2890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22291137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVynu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1655-1662&author=A.+G.+Patelauthor=S.+B.+De+Lorenzoauthor=K.+S.+Flattenauthor=G.+G.+Poirierauthor=S.+H.+Kaufmann&title=Failure+of+iniparib+to+inhibit+poly%28ADP-Ribose%29+polymerase+in+vitro&doi=10.1158%2F1078-0432.CCR-11-2890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro</span></div><div class="casAuthors">Patel, Anand G.; De Lorenzo, Silvana B.; Flatten, Karen S.; Poirier, Guy G.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1655-1662</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Poly(ADP-ribose) polymerase (PARP) inhibitors are undergoing extensive clin. testing for their single-agent activity in homologous recombination (HR)-deficient tumors and ability to enhance the action of certain DNA-damaging agents.  Compared with other PARP inhibitors in development, iniparib (4-iodo-3-nitrobenzamide) is notable for its simple structure and the reported ability of its intracellular metabolite 4-iodo-3-nitrosobenzamide to covalently inhibit PARP1 under cell-free conditions.  The present preclin. studies were conducted to compare the actions iniparib with the more extensively characterized PARP inhibitors olaparib and veliparib.  Exptl. Design: The abilities of iniparib, olaparib, and veliparib to (i) selectively induce apoptosis or inhibit colony formation in HR-deficient cell lines, (ii) selectively sensitize HR-proficient cells to topoisomerase I poisons, and (iii) inhibit formation of poly(ADP-ribose) polymer (pADPr) in intact cells were compared.  RESULTS: Consistent with earlier reports, olaparib and veliparib selectively induced apoptosis and inhibited colony formation in cells lacking BRCA2 or ATM.  Moreover, like earlier generation PARP inhibitors, olaparib and veliparib sensitized cells to the topoisomerase I poisons camptothecin and topotecan.  Finally, olaparib and veliparib inhibited formation of pADPr in intact cells.  In contrast, iniparib exhibited little or no ability to selectively kill HR-deficient cells, sensitize cells to topoisomerase I poisons, or inhibit pADPr formation in situ.  In further expts., iniparib also failed to sensitize cells to cisplatin, gemcitabine, or paclitaxel.  CONCLUSIONS: While iniparib kills normal and neoplastic cells at high (>40 μmol/L) concns., its effects are unlikely to reflect PARP inhibition and should not be used to guide decisions about other PARP inhibitors.  Clin Cancer Res; 18(6); 1655-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6PlliVCr5ErVg90H21EOLACvtfcHk0ljynd-m1tHjGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVynu7k%253D&md5=82cb650b8bb7114cfc6afdc68fc5c3d9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2890%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DA.%2BG.%26aulast%3DDe%2BLorenzo%26aufirst%3DS.%2BB.%26aulast%3DFlatten%26aufirst%3DK.%2BS.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DFailure%2520of%2520iniparib%2520to%2520inhibit%2520poly%2528ADP-Ribose%2529%2520polymerase%2520in%2520vitro%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1655%26epage%3D1662%26doi%3D10.1158%2F1078-0432.CCR-11-2890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira-Frommer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span> </span><span class="NLM_article-title">Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">1382</span><span class="NLM_x">–</span> <span class="NLM_lpage">1392</span><span class="refDoi"> DOI: 10.1056/NEJMoa1105535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1056%2FNEJMoa1105535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22452356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=1382-1392&author=J.+Ledermannauthor=P.+Harterauthor=C.+Gourleyauthor=M.+Friedlanderauthor=I.+Vergoteauthor=G.+Rustinauthor=C.+Scottauthor=W.+Meierauthor=R.+Shapira-Frommerauthor=T.+Safraauthor=D.+Mateiauthor=E.+Macphersonauthor=C.+Watkinsauthor=J.+Carmichaelauthor=U.+Matulonis&title=Olaparib+maintenance+therapy+in+platinum-sensitive+relapsed+ovarian+cancer&doi=10.1056%2FNEJMoa1105535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer</span></div><div class="casAuthors">Ledermann, Jonathan; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; MacPherson, Euan; Watkins, Claire; Carmichael, James; Matulonis, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1382-1392</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Olaparib (AZD2281) is an oral poly(ADP [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations.  METHODS We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen.  Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo.  The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines.  RESULTS Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group.  Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 mo vs. 4.8 mo from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001).  Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression.  Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2.  An interim anal. of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P = 0.75).  CONCLUSIONS Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer.  Interim anal. showed no overall survival benefit.  The toxicity profile of olaparib in this population was consistent with that in previous studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroGMJNLsHGObVg90H21EOLACvtfcHk0liQ-0O1k3Qprw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOrsLw%253D&md5=1612aa24cd17a29f03599a7c2acf5f0f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105535%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DHarter%26aufirst%3DP.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DScott%26aufirst%3DC.%26aulast%3DMeier%26aufirst%3DW.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DMatulonis%26aufirst%3DU.%26atitle%3DOlaparib%2520maintenance%2520therapy%2520in%2520platinum-sensitive%2520relapsed%2520ovarian%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D1382%26epage%3D1392%26doi%3D10.1056%2FNEJMoa1105535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira-Frommer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span> </span><span class="NLM_article-title">Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">861</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70228-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS1470-2045%2814%2970228-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24882434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWrsrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=852-861&author=J.+Ledermannauthor=P.+Harterauthor=C.+Gourleyauthor=M.+Friedlanderauthor=I.+Vergoteauthor=G.+Rustinauthor=C.+L.+Scottauthor=W.+Meierauthor=R.+Shapira-Frommerauthor=T.+Safraauthor=D.+Mateiauthor=A.+Fieldingauthor=S.+Spencerauthor=B.+Doughertyauthor=M.+Orrauthor=D.+Hodgsonauthor=J.+C.+Barrettauthor=U.+Matulonis&title=Olaparib+maintenance+therapy+in+patients+with+platinum-sensitive+relapsed+serous+ovarian+cancer%3A+a+preplanned+retrospective+analysis+of+outcomes+by+BRCA+status+in+a+randomised+phase+2+trial&doi=10.1016%2FS1470-2045%2814%2970228-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial</span></div><div class="casAuthors">Ledermann, Jonathan; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare L.; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; Fielding, Anitra; Spencer, Stuart; Dougherty, Brian; Orr, Maria; Hodgson, Darren; Barrett, J. Carl; Matulonis, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-861</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Maintenance monotherapy with the PARP inhibitor olaparib significantly prolonged progression-free survival (PFS) vs. placebo in patients with platinum-sensitive recurrent serous ovarian cancer.  We aimed to explore the hypothesis that olaparib is most likely to benefit patients with a BRCA mutation.We present data from the second interim anal. of overall survival and a retrospective, preplanned anal. of data by BRCA mutation status from our randomised, double-blind, phase 2 study that assessed maintenance treatment with olaparib 400 mg twice daily (capsules) vs. placebo in patients with platinum-sensitive recurrent serous ovarian cancer who had received two or more platinum-based regimens and who had a partial or complete response to their most recent platinum-based regimen.  Randomisation was by an interactive voice response system, stratified by time to progression on penultimate platinum-based regimen, response to the most recent platinum-based regimen before randomisation, and ethnic descent.  The primary endpoint was PFS, analyzed for the overall population and by BRCA status.  This study is registered with ClinicalTrials.gov, no. NCT00753545.Between Aug 28, 2008, and Feb 9, 2010, 136 patients were assigned to olaparib and 129 to placebo.  BRCA status was known for 131 (96%) patients in the olaparib group vs. 123 (95%) in the placebo group, of whom 74 (56%) vs. 62 (50%) had a deleterious or suspected deleterious germline or tumor BRCA mutation.  Of patients with a BRCA mutation, median PFS was significantly longer in the olaparib group than in the placebo group (11·2 mo [95% CI 8·3-not calculable] vs 4·3 mo [3·0-5·4]; HR 0·18 [0·10-0·31]; p<0·0001); similar findings were noted for patients with wild-type BRCA, although the difference between groups was lower (7·4 mo [5·5-10·3] vs 5·5 mo [3·7-5·6]; HR 0·54 [0·34-0·85]; p=0·0075).  At the second interim anal. of overall survival (58% maturity), overall survival did not significantly differ between the groups (HR 0·88 [95% CI 0·64-1·21]; p=0·44); similar findings were noted for patients with mutated BRCA (HR 0·73 [0·45-1·17]; p=0·19) and wild-type BRCA (HR 0·99 [0·63-1·55]; p=0·96).  The most common grade 3 or worse adverse events in the olaparib group were fatigue (in ten [7%] patients in the olaparib group vs four [3%] in the placebo group) and anemia (seven [5%] vs one [<1%]).  Serious adverse events were reported in 25 (18%) patients who received olaparib and 11 (9%) who received placebo.  Tolerability was similar in patients with mutated BRCA and the overall population.These results support the hypothesis that patients with platinum-sensitive recurrent serous ovarian cancer with a BRCA mutation have the greatest likelihood of benefiting from olaparib treatment.AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozZjZdcu1e4rVg90H21EOLACvtfcHk0liQ-0O1k3Qprw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWrsrrK&md5=bfc15e933746672148dd7237e3f67f01</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970228-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970228-1%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DHarter%26aufirst%3DP.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DScott%26aufirst%3DC.%2BL.%26aulast%3DMeier%26aufirst%3DW.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DFielding%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DOrr%26aufirst%3DM.%26aulast%3DHodgson%26aufirst%3DD.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DMatulonis%26aufirst%3DU.%26atitle%3DOlaparib%2520maintenance%2520therapy%2520in%2520patients%2520with%2520platinum-sensitive%2520relapsed%2520serous%2520ovarian%2520cancer%253A%2520a%2520preplanned%2520retrospective%2520analysis%2520of%2520outcomes%2520by%2520BRCA%2520status%2520in%2520a%2520randomised%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D852%26epage%3D861%26doi%3D10.1016%2FS1470-2045%2814%2970228-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Gelmon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischkowitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenerton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robidoux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonkin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirte, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntsman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemons, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilks, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yerushalmi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, A.</span><span> </span><span class="NLM_article-title">Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">861</span><span class="refDoi"> DOI: 10.1016/S1470-2045(11)70214-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS1470-2045%2811%2970214-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21862407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSqs7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=852-861&author=K.+A.+Gelmonauthor=M.+Tischkowitzauthor=H.+Mackayauthor=K.+Swenertonauthor=A.+Robidouxauthor=K.+Tonkinauthor=H.+Hirteauthor=D.+Huntsmanauthor=M.+Clemonsauthor=B.+Gilksauthor=R.+Yerushalmiauthor=E.+Macphersonauthor=J.+Carmichaelauthor=A.+Oza&title=Olaparib+in+patients+with+recurrent+high-grade+serous+or+poorly+differentiated+ovarian+carcinoma+or+triple-negative+breast+cancer%3A+a+phase+2%2C+multicentre%2C+open-label%2C+non-randomised+study&doi=10.1016%2FS1470-2045%2811%2970214-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study</span></div><div class="casAuthors">Gelmon, Karen A.; Tischkowitz, Marc; MacKay, Helen; Swenerton, Kenneth; Robidoux, Andre; Tonkin, Katia; Hirte, Hal; Huntsman, David; Clemons, Mark; Gilks, Blake; Yerushalmi, Rinat; MacPherson, Euan; Carmichael, James; Oza, Amit</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">852-861</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Olaparib (AZD2281) is a small-mol., potent oral poly(ADP-ribose) polymerase (PARP) inhibitor.  We aimed to assess the safety and tolerability of this drug in patients without BRCA1 or BRCA2 mutations with advanced triple-neg. breast cancer or high-grade serous and/or undifferentiated ovarian cancer.  Methods: In this phase 2, multicenter open-label, non-randomized study, women with advanced high-grade serous and/or undifferentiated ovarian carcinoma or triple-neg. breast cancer were enrolled and received olaparib 400 mg twice a day.  Patients were stratified according to whether they had a BRCA1 or BRCA2 mutation or not.  The primary endpoint was objective response rate by Response Evaluation Criteria In Solid Tumors (RECIST).  All patients who received treatment were included in the anal. of toxic effects, and patients who had measurable lesions at baseline were included in the primary efficacy anal.  This trial is registered at ClinicalTrials.gov, no. NCT00679783.  Findings: 91 patients were enrolled (65 with ovarian cancer and 26 breast cancer) and 90 were treated between July 8, 2008, and Sept 24, 2009.  In the ovarian cancer cohorts, 64 patients received treatment. 63 patients had target lesions and therefore were evaluable for objective response as per RECIST.  In these patients, confirmed objective responses were seen in seven (41%; 95% CI 22-64) of 17 patients with BRCA1 or BRCA2 mutations and 11 (24%; 14-38) of 46 without mutations.  No confirmed objective responses were reported in patients with breast cancer.  The most common adverse events were fatigue (45 [70%] of patients with ovarian cancer, 13 [50%] of patients with breast cancer), nausea (42 [66%] and 16 [62%]), vomiting (25 [39%] and nine [35%]), and decreased appetite (23 [36%] and seven [27%]).  Interpretation: Our study suggests that olaparib is a promising treatment for women with ovarian cancer and further assessment of the drug in clin. trials is needed.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRwn4h9db66rVg90H21EOLACvtfcHk0lhAc-of2xTXTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSqs7%252FE&md5=6b05f51741618757c4ef7a9b74d8041a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970214-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970214-5%26sid%3Dliteratum%253Aachs%26aulast%3DGelmon%26aufirst%3DK.%2BA.%26aulast%3DTischkowitz%26aufirst%3DM.%26aulast%3DMackay%26aufirst%3DH.%26aulast%3DSwenerton%26aufirst%3DK.%26aulast%3DRobidoux%26aufirst%3DA.%26aulast%3DTonkin%26aufirst%3DK.%26aulast%3DHirte%26aufirst%3DH.%26aulast%3DHuntsman%26aufirst%3DD.%26aulast%3DClemons%26aufirst%3DM.%26aulast%3DGilks%26aufirst%3DB.%26aulast%3DYerushalmi%26aufirst%3DR.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DOza%26aufirst%3DA.%26atitle%3DOlaparib%2520in%2520patients%2520with%2520recurrent%2520high-grade%2520serous%2520or%2520poorly%2520differentiated%2520ovarian%2520carcinoma%2520or%2520triple-negative%2520breast%2520cancer%253A%2520a%2520phase%25202%252C%2520multicentre%252C%2520open-label%252C%2520non-randomised%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D852%26epage%3D861%26doi%3D10.1016%2FS1470-2045%2811%2970214-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Kaufman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira-Frommer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmutzler, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audeh, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balmana, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemmer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosengarten, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domchek, S. M.</span><span> </span><span class="NLM_article-title">Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1200/JCO.2014.56.2728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2014.56.2728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25366685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVWrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=244-250&author=B.+Kaufmanauthor=R.+Shapira-Frommerauthor=R.+K.+Schmutzlerauthor=M.+W.+Audehauthor=M.+Friedlanderauthor=J.+Balmanaauthor=G.+Mitchellauthor=G.+Friedauthor=S.+M.+Stemmerauthor=A.+Hubertauthor=O.+Rosengartenauthor=M.+Steinerauthor=N.+Lomanauthor=K.+Bowenauthor=A.+Fieldingauthor=S.+M.+Domchek&title=Olaparib+monotherapy+in+patients+with+advanced+cancer+and+a+germline+BRCA1%2F2+mutation&doi=10.1200%2FJCO.2014.56.2728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation</span></div><div class="casAuthors">Kaufman, Bella; Shapira-Frommer, Ronnie; Schmutzler, Rita K.; Audeh, M. William; Friedlander, Michael; Balmana, Judith; Mitchell, Gillian; Fried, Georgeta; Stemmer, Salomon M.; Hubert, Ayala; Rosengarten, Ora; Steiner, Mariana; Loman, Niklas; Bowen, Karin; Fielding, Anitra; Domchek, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-250</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) -assocd. breast and ovarian cancers.  We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-assocd. cancers.  This multicenter phase II study enrolled individuals with a germline BRCA1/2 mutation and recurrent cancer.  Eligibility included ovarian cancer resistant to prior platinum; breast cancer with ≥ three chemotherapy regimens for metastatic disease; pancreatic cancer with prior gemcitabine treatment; or prostate cancer with progression on hormonal and one systemic therapy.  Olaparib was administered at 400 mg twice per day.  The primary efficacy end point was tumor response rate.  A total of 298 patients received treatment and were evaluable.  The tumor response rate was 26.2% (78 of 298; 95% CI, 21.3 to 31.6) overall and 31.1% (60 of 193; 95% CI, 24.6 to 38.1), 12.9% (eight of 62; 95% CI, 5.7 to 23.9), 21.7% (five of 23; 95% CI, 7.5 to 43.7), and 50.0% (four of eight; 95% CI, 15.7 to 84.3) in ovarian, breast, pancreatic, and prostate cancers, resp.  Stable disease ≥ 8 wk was obsd. in 42% of patients (95% CI, 36.0 to 47.4), including 40% (95% CI, 33.4 to 47.7), 47% (95% CI, 34.0 to 59.9), 35% (95% CI, 16.4 to 57.3), and 25% (95% CI, 3.2 to 65.1) of those with ovarian, breast, pancreatic, or prostate cancer, resp.  The most common adverse events (AEs) were fatigue, nausea, and vomiting.  Grade ≥ 3 AEs were reported for 54% of patients; anemia was the most common (17%).  Responses to olaparib were obsd. across different tumor types assocd. with germline BRCA1/2 mutations.  Olaparib warrants further investigation in confirmatory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooKvduc8Sx3bVg90H21EOLACvtfcHk0lieDXA_3GDc8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVWrsLY%253D&md5=8ba52a3fa98d1137e6c134245ea42b87</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.56.2728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.56.2728%26sid%3Dliteratum%253Aachs%26aulast%3DKaufman%26aufirst%3DB.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DBalmana%26aufirst%3DJ.%26aulast%3DMitchell%26aufirst%3DG.%26aulast%3DFried%26aufirst%3DG.%26aulast%3DStemmer%26aufirst%3DS.%2BM.%26aulast%3DHubert%26aufirst%3DA.%26aulast%3DRosengarten%26aufirst%3DO.%26aulast%3DSteiner%26aufirst%3DM.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DBowen%26aufirst%3DK.%26aulast%3DFielding%26aufirst%3DA.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26atitle%3DOlaparib%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520cancer%2520and%2520a%2520germline%2520BRCA1%252F2%2520mutation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D244%26epage%3D250%26doi%3D10.1200%2FJCO.2014.56.2728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span>Lynparza Approved in the European Union As First-in-Class Treatment for Advanced BRCA-Mutated Ovarian Cancer; <span class="NLM_publisher-name">AstraZeneca Global</span>, 18 Dec<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span><a href="http://astrazeneca.com" class="extLink">http://astrazeneca.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lynparza+Approved+in+the+European+Union+As+First-in-Class+Treatment+for+Advanced+BRCA-Mutated+Ovarian+Cancer%3B+AstraZeneca+Global%2C+18+Dec+2014%3B+http%3A%2F%2Fastrazeneca.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DLynparza%2520Approved%2520in%2520the%2520European%2520Union%2520As%2520First-in-Class%2520Treatment%2520for%2520Advanced%2520BRCA-Mutated%2520Ovarian%2520Cancer%26pub%3DAstraZeneca%2520Global%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span>LYNPARZA Approved by the US Food and Drug Administration for the Treatment of Advanced Ovarian Cancer in Patients with Germline BRCA Mutations; <span class="NLM_publisher-name">AstraZeneca Global</span>, 19 Dec<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span><a href="http://astrazeneca.com" class="extLink">http://astrazeneca.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LYNPARZA+Approved+by+the+US+Food+and+Drug+Administration+for+the+Treatment+of+Advanced+Ovarian+Cancer+in+Patients+with+Germline+BRCA+Mutations%3B+AstraZeneca+Global%2C+19+Dec+2014%3B+http%3A%2F%2Fastrazeneca.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DLYNPARZA%2520Approved%2520by%2520the%2520US%2520Food%2520and%2520Drug%2520Administration%2520for%2520the%2520Treatment%2520of%2520Advanced%2520Ovarian%2520Cancer%2520in%2520Patients%2520with%2520Germline%2520BRCA%2520Mutations%26pub%3DAstraZeneca%2520Global%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span>Lynparza (Olaparib) Granted Breakthrough Therapy Designation by US FDA for Treatment of BRCA1/2 or ATM Gene Mutated Metastatic Castration Resistant Prostate Cancer; <span class="NLM_publisher-name">AstraZeneca</span>, 28 Jan<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://astrazeneca.com" class="extLink">http://astrazeneca.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lynparza+%28Olaparib%29+Granted+Breakthrough+Therapy+Designation+by+US+FDA+for+Treatment+of+BRCA1%2F2+or+ATM+Gene+Mutated+Metastatic+Castration+Resistant+Prostate+Cancer%3B+AstraZeneca%2C+28+Jan+2016%3B+http%3A%2F%2Fastrazeneca.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DLynparza%2520%2528Olaparib%2529%2520Granted%2520Breakthrough%2520Therapy%2520Designation%2520by%2520US%2520FDA%2520for%2520Treatment%2520of%2520BRCA1%252F2%2520or%2520ATM%2520Gene%2520Mutated%2520Metastatic%2520Castration%2520Resistant%2520Prostate%2520Cancer%26pub%3DAstraZeneca%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Miknyoczki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worrell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deibold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parchment, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span> </span><span class="NLM_article-title">The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to Temozolomide and irinotecan but does not potentiate myelotoxicity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2290</span><span class="NLM_x">–</span> <span class="NLM_lpage">2302</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.MCT-07-0062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=17699724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2290-2302&author=S.+Miknyoczkiauthor=H.+Changauthor=J.+Grobelnyauthor=S.+Pritchardauthor=C.+Worrellauthor=N.+McGannauthor=M.+Atorauthor=J.+Hustenauthor=J.+Deiboldauthor=R.+Hudkinsauthor=A.+Zulliauthor=R.+Parchmentauthor=B.+Ruggeri&title=The+selective+poly%28ADP-ribose%29+polymerase-1%282%29+inhibitor%2C+CEP-8983%2C+increases+the+sensitivity+of+chemoresistant+tumor+cells+to+Temozolomide+and+irinotecan+but+does+not+potentiate+myelotoxicity&doi=10.1158%2F1535-7163.MCT-07-0062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity</span></div><div class="casAuthors">Miknyoczki, Sheila; Chang, Hong; Grobelny, Jennifer; Pritchard, Sonya; Worrell, Candace; McGann, Natalie; Ator, Mark; Husten, Jean; Deibold, James; Hudkins, Robert; Zulli, Allison; Parchment, Ralph; Ruggeri, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2290-2302</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The effect of the potent and selective poly(ADP-ribose) (PAR) polymerase-1 [and PAR polymerase-2] inhibitor CEP-8983 on the ability to sensitize chemoresistant glioblastoma (RG2), rhabdomyosarcoma (RH18), neuroblastoma (NB1691), and colon carcinoma (HT29) tumor cells to temozolomide- and camptothecin-induced cytotoxicity, DNA damage, and G2-M arrest and on the potentiation of chemotherapy-induced myelotoxicity was evaluated using in vitro assays.  In addn., the effect of the prodrug CEP-9722 in combination with temozolomide and/or irinotecan on PAR accumulation and tumor growth was also detd. using glioblastoma and/or colon carcinoma xenografts relative to chemotherapy alone.  CEP-8983 sensitized carcinoma cells to the growth-inhibitory effects of temozolomide and/or SN38 increased the fraction of and/or lengthened duration of time tumor cells accumulated in chemotherapy-induced G2-M arrest and sensitized tumor cells to chemotherapy-induced DNA damage and apoptosis.  A granulocyte-macrophage colony-forming unit colony formation assay showed that coincubation of CEP-8983 with temozolomide or topotecan did not potentiate chemotherapy-assocd. myelotoxicity.  CEP-9722 (136 mg/kg) administered with temozolomide (68 mg/kg for 5 days) or irinotecan (10 mg/kg for 5 days) inhibited significantly the growth of RG2 tumors (60%) or HT29 tumors (80%) compared with temozolomide or irinotecan monotherapy, resp.  In addn., CEP-9722 showed "stand alone" antitumor efficacy in these preclin. xenografts.  In vivo biochem. efficacy studies showed that CEP-9722 attenuated PAR accumulation in glioma xenografts in a dose- and time-related manner.  These data indicate that CEP-8983 and its prodrug are effective chemosensitizing agents when administered in combination with select chemotherapeutic agents against chemoresistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr870nJ_ojOQbVg90H21EOLACvtfcHk0lgx9PianyIoag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltbc%253D&md5=eef1600ec2ce56e71ca6045dca135bf4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0062%26sid%3Dliteratum%253Aachs%26aulast%3DMiknyoczki%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DGrobelny%26aufirst%3DJ.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWorrell%26aufirst%3DC.%26aulast%3DMcGann%26aufirst%3DN.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DDeibold%26aufirst%3DJ.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DZulli%26aufirst%3DA.%26aulast%3DParchment%26aufirst%3DR.%26aulast%3DRuggeri%26aufirst%3DB.%26atitle%3DThe%2520selective%2520poly%2528ADP-ribose%2529%2520polymerase-1%25282%2529%2520inhibitor%252C%2520CEP-8983%252C%2520increases%2520the%2520sensitivity%2520of%2520chemoresistant%2520tumor%2520cells%2520to%2520Temozolomide%2520and%2520irinotecan%2520but%2520does%2520not%2520potentiate%2520myelotoxicity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2290%26epage%3D2302%26doi%3D10.1158%2F1535-7163.MCT-07-0062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Lechaftois, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margaill, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchand-Leroux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachelot-Loza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerouet, D.</span><span> </span><span class="NLM_article-title">Another ″string to the bow″ of PJ34, a potent poly(ADP-Ribose)polymerase inhibitor: an antiplatelet effect through P2Y12 antagonism?</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e110776</span><span class="refDoi"> DOI: 10.1371/journal.pone.0110776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1371%2Fjournal.pone.0110776" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e110776&author=M.+Lechaftoisauthor=E.+Dreanoauthor=B.+Palmierauthor=I.+Margaillauthor=C.+Marchand-Lerouxauthor=C.+Bachelot-Lozaauthor=D.+Lerouet&title=Another+%E2%80%B3string+to+the+bow%E2%80%B3+of+PJ34%2C+a+potent+poly%28ADP-Ribose%29polymerase+inhibitor%3A+an+antiplatelet+effect+through+P2Y12+antagonism%3F&doi=10.1371%2Fjournal.pone.0110776"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0110776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0110776%26sid%3Dliteratum%253Aachs%26aulast%3DLechaftois%26aufirst%3DM.%26aulast%3DDreano%26aufirst%3DE.%26aulast%3DPalmier%26aufirst%3DB.%26aulast%3DMargaill%26aufirst%3DI.%26aulast%3DMarchand-Leroux%26aufirst%3DC.%26aulast%3DBachelot-Loza%26aufirst%3DC.%26aulast%3DLerouet%26aufirst%3DD.%26atitle%3DAnother%2520%25E2%2580%25B3string%2520to%2520the%2520bow%25E2%2580%25B3%2520of%2520PJ34%252C%2520a%2520potent%2520poly%2528ADP-Ribose%2529polymerase%2520inhibitor%253A%2520an%2520antiplatelet%2520effect%2520through%2520P2Y12%2520antagonism%253F%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De110776%26doi%3D10.1371%2Fjournal.pone.0110776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Menear, K. A.; Hummersone, M. G.; Gomez, S.; Javaid, M. H.; Martin, N. M. B.; Kerrigan, F.</span><span> </span><span class="NLM_article-title">Phthalazinone derivatives</span>. WO 2009093032,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+A.+Menear&author=M.+G.+Hummersone&author=S.+Gomez&author=M.+H.+Javaid&author=N.+M.+B.+Martin&author=F.+Kerrigan&title=Phthalazinone+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26atitle%3DPhthalazinone%2520derivatives%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Awada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aftimos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenel, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahleda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gombos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourbouloux, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1097%2FCAD.0000000000000336" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=342-348&author=A.+Awadaauthor=M.+Camponeauthor=A.+Vargaauthor=P.+Aftimosauthor=J.+S.+Frenelauthor=R.+Bahledaauthor=A.+Gombosauthor=E.+Bourboulouxauthor=J.+C.+Soria&title=An+open-label%2C+dose-escalation+study+to+evaluate+the+safety+and+pharmacokinetics+of+CEP-9722+%28a+PARP-1+and+PARP-2+inhibitor%29+in+combination+with+gemcitabine+and+cisplatin+in+patients+with+advanced+solid+tumors&doi=10.1097%2FCAD.0000000000000336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000336%26sid%3Dliteratum%253Aachs%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DAftimos%26aufirst%3DP.%26aulast%3DFrenel%26aufirst%3DJ.%2BS.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DGombos%26aufirst%3DA.%26aulast%3DBourbouloux%26aufirst%3DE.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DAn%2520open-label%252C%2520dose-escalation%2520study%2520to%2520evaluate%2520the%2520safety%2520and%2520pharmacokinetics%2520of%2520CEP-9722%2520%2528a%2520PARP-1%2520and%2520PARP-2%2520inhibitor%2529%2520in%2520combination%2520with%2520gemcitabine%2520and%2520cisplatin%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2016%26volume%3D27%26spage%3D342%26epage%3D348%26doi%3D10.1097%2FCAD.0000000000000336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Bedikian, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwu, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homsi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudewicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernillet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwu, P.</span><span> </span><span class="NLM_article-title">A phase IB trial of intravenous INO-1001 plus oral Temozolomide in subjects with unresectable stage-III or IV melanoma</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span><span class="refDoi"> DOI: 10.1080/07357900802709159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1080%2F07357900802709159" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=756-763&author=A.+Y.+Bedikianauthor=N.+E.+Papadopoulosauthor=K.+B.+Kimauthor=W.+J.+Hwuauthor=J.+Homsiauthor=M.+R.+Glassauthor=S.+Cainauthor=P.+Rudewiczauthor=L.+Vernilletauthor=P.+Hwu&title=A+phase+IB+trial+of+intravenous+INO-1001+plus+oral+Temozolomide+in+subjects+with+unresectable+stage-III+or+IV+melanoma&doi=10.1080%2F07357900802709159"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F07357900802709159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07357900802709159%26sid%3Dliteratum%253Aachs%26aulast%3DBedikian%26aufirst%3DA.%2BY.%26aulast%3DPapadopoulos%26aufirst%3DN.%2BE.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DHomsi%26aufirst%3DJ.%26aulast%3DGlass%26aufirst%3DM.%2BR.%26aulast%3DCain%26aufirst%3DS.%26aulast%3DRudewicz%26aufirst%3DP.%26aulast%3DVernillet%26aufirst%3DL.%26aulast%3DHwu%26aufirst%3DP.%26atitle%3DA%2520phase%2520IB%2520trial%2520of%2520intravenous%2520INO-1001%2520plus%2520oral%2520Temozolomide%2520in%2520subjects%2520with%2520unresectable%2520stage-III%2520or%2520IV%2520melanoma%26jtitle%3DCancer%2520Invest.%26date%3D2009%26volume%3D27%26spage%3D756%26epage%3D763%26doi%3D10.1080%2F07357900802709159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">945</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.MCT-06-0552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=17363489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=945-956&author=H.+D.+Thomasauthor=C.+R.+Calabreseauthor=M.+A.+Bateyauthor=S.+Cananauthor=Z.+Hostomskyauthor=S.+Kyleauthor=K.+A.+Maegleyauthor=D.+R.+Newellauthor=D.+Skalitzkyauthor=L.+Z.+Wangauthor=S.+E.+Webberauthor=N.+J.+Curtin&title=Preclinical+selection+of+a+novel+poly%28ADP-ribose%29+polymerase+inhibitor+for+clinical+trial&doi=10.1158%2F1535-7163.MCT-06-0552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span></div><div class="casAuthors">Thomas, Huw D.; Calabrese, Christopher R.; Batey, Michael A.; Canan, Stacie; Hostomsky, Zdenek; Kyle, Suzanne; Maegley, Karen A.; Newell, David R.; Skalitzky, Donald; Wang, Lan-Zhen; Webber, Stephen E.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks.  Inhibition of PARP-1 enhances the efficacy of DNA alkylating agents, topoisomerase I poisons, and ionizing radiation.  Our aim was to identify a PARP inhibitor for clin. trial from a panel of 42 potent PARP inhibitors (Ki, 1.4-15.1 nmol/L) based on the quinazolinone, benzimidazole, tricyclic benzimidazole, tricyclic indole, and tricyclic indole-1-one core structures.  We evaluated chemosensitization of temozolomide and topotecan using LoVo and SW620 human colorectal cells; in vitro radiosensitization was measured using LoVo cells, and the enhancement of antitumor activity of temozolomide was evaluated in mice bearing SW620 xenografts.  Excellent chemopotentiation and radiopotentiation were obsd. in vitro, with 17 of the compds. causing a greater temozolomide and topotecan sensitization than the benchmark inhibitor AG14361 and 10 compds. were more potent radiosensitizers than AG14361.  In tumor-bearing mice, none of the compds. were toxic when given alone, and the antitumor activity of the PARP inhibitor-temozolomide combinations was unrelated to toxicity.  Compds. that were more potent chemosensitizers in vivo than AG14361 were also more potent in vitro, validating in vitro assays as a prescreen.  These studies have identified a compd., AG14447, as a PARP inhibitor with outstanding in vivo chemosensitization potency at tolerable doses, which is at least 10 times more potent than the initial lead, AG14361.  The phosphate salt of AG14447 (AG014699), which has improved aq. soly., has been selected for clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-3D2oL2giLVg90H21EOLACvtfcHk0lgTkWPqsOGRDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D&md5=b451bf2c1fc836cc5a800c2799e5d211</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0552%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCanan%26aufirst%3DS.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPreclinical%2520selection%2520of%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520for%2520clinical%2520trial%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D945%26epage%3D956%26doi%3D10.1158%2F1535-7163.MCT-06-0552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcoxen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span> </span><span class="NLM_article-title">Niraparib: A Poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3302</span><span class="NLM_x">–</span> <span class="NLM_lpage">3314</span><span class="refDoi"> DOI: 10.1021/jm5018237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5018237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFams7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3302-3314&author=P.+Jonesauthor=K.+Wilcoxenauthor=M.+Rowleyauthor=C.+Toniatti&title=Niraparib%3A+A+Poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+for+the+treatment+of+tumors+with+defective+homologous+recombination&doi=10.1021%2Fjm5018237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination</span></div><div class="casAuthors">Jones, Philip; Wilcoxen, Keith; Rowley, Michael; Toniatti, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3302-3314</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repair following damage by endogenous or exogenous processes.  It has become clear over the past decade that inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells.  We describe the rationale for this approach and the design and discovery of niraparib, a potent PARP-1/2 inhibitor with good cell based activity, selectivity for cancer over normal cells, and oral bioavailability.  Niraparib was characterized in a no. of preclin. models before moving to phase I clin. trials, where it showed excellent human pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had promising activity in cancer patients.  It is currently being tested in phase 3 clin. trials as maintenance therapy in ovarian cancer and as a treatment for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsaJDnhFDPhbVg90H21EOLACvtfcHk0lhFnU_ykkfpGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFams7s%253D&md5=ffb7cb2503acde0a1e3452448d98693f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm5018237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5018237%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26atitle%3DNiraparib%253A%2520A%2520Poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520tumors%2520with%2520defective%2520homologous%2520recombination%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3302%26epage%3D3314%26doi%3D10.1021%2Fjm5018237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery of the poly (ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1 H-benzimidazole-4- carboxamide (ABT-888) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">523</span><span class="refDoi"> DOI: 10.1021/jm801171j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly+%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1+H-benzimidazole-4-+carboxamide+%28ABT-888%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm801171j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1%2520H-benzimidazole-4-%2520carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523%26doi%3D10.1021%2Fjm801171j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span> </span><span class="NLM_article-title">Discovery and characterization of (8S, 9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1, 2, 4-triazol-5-yl)-2, 7, 8, 9-tetrahydro-3H-pyrido [4, 3, 2-de] phthalazin-3-one (BMN 673, talazoparib), a novel, highly potent, and orally efficacious poly (ADP-ribose) polymerase-1/2 inhibitor as an anticancer agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">357</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01498</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01498" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=335-357&author=B.+Wangauthor=D.+Chuauthor=Y.+Fengauthor=Y.+Shenauthor=M.+Aoyagi-Scharberauthor=L.+E.+Post&title=Discovery+and+characterization+of+%288S%2C+9R%29-5-fluoro-8-%284-fluorophenyl%29-9-%281-methyl-1H-1%2C+2%2C+4-triazol-5-yl%29-2%2C+7%2C+8%2C+9-tetrahydro-3H-pyrido+%5B4%2C+3%2C+2-de%5D+phthalazin-3-one+%28BMN+673%2C+talazoparib%29%2C+a+novel%2C+highly+potent%2C+and+orally+efficacious+poly+%28ADP-ribose%29+polymerase-1%2F2+inhibitor+as+an+anticancer+agent&doi=10.1021%2Facs.jmedchem.5b01498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent</span></div><div class="casAuthors">Wang, Bing; Chu, Daniel; Feng, Ying; Shen, Yuqiao; Aoyagi-Scharber, Mika; Post, Leonard E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">335-357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors discovered and developed a novel series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors.  Lead optimization led to the identification of (I) (talazoparib; BMN 673; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one).  The novel stereospecific dual chiral-center-embedded structure of this compd. has enabled extensive and unique binding interactions with PARP1/2 proteins. I demonstrates excellent potency, inhibiting PARP1 and PARP2 enzyme activity with Ki = 1.2 and 0.87 nM, resp.  It inhibits PARP-mediated PARylation in a whole-cell assay with an EC50 of 2.51 nM and prevents proliferation of cancer cells carrying mutant BRCA1/2, with EC50 = 0.3 nM (MX-1) and 5 nM (Capan-1), resp. I is orally available, displaying favorable pharmacokinetic (PK) properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following oral administration as a single-agent or in combination with chemotherapy agents such as temozolomide and cisplatin. I has completed phase 1 clin. trial and is currently being studied in phase 2 and 3 clin. trials for the treatment of locally advanced and/or metastatic breast cancer with germline BRCA1/2 deleterious mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBpTb90_rQhLVg90H21EOLACvtfcHk0lhFnU_ykkfpGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN&md5=443bfeb7aeda6c6522d41ab52793931a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01498%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DPost%26aufirst%3DL.%2BE.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520%25288S%252C%25209R%2529-5-fluoro-8-%25284-fluorophenyl%2529-9-%25281-methyl-1H-1%252C%25202%252C%25204-triazol-5-yl%2529-2%252C%25207%252C%25208%252C%25209-tetrahydro-3H-pyrido%2520%255B4%252C%25203%252C%25202-de%255D%2520phthalazin-3-one%2520%2528BMN%2520673%252C%2520talazoparib%2529%252C%2520a%2520novel%252C%2520highly%2520potent%252C%2520and%2520orally%2520efficacious%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%252F2%2520inhibitor%2520as%2520an%2520anticancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D335%26epage%3D357%26doi%3D10.1021%2Facs.jmedchem.5b01498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Plummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dua, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cresti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prathapan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de las Heras, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarker, D.</span><span> </span><span class="NLM_article-title">Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">e19531</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=e19531&issue=15+suppl&author=R.+Plummerauthor=D.+Duaauthor=N.+Crestiauthor=A.+Suderauthor=Y.+Drewauthor=V.+Prathapanauthor=P.+Stephensauthor=J.+K.+Thorntonauthor=B.+de+las+Herasauthor=B.+Inkauthor=L.+Leeauthor=M.+Matijevicauthor=S.+McGrathauthor=D.+Sarker&title=Phase+1+study+of+the+PARP+inhibitor+E7449+as+a+single+agent+in+patients+with+advanced+solid+tumors+or+B-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DDua%26aufirst%3DD.%26aulast%3DCresti%26aufirst%3DN.%26aulast%3DSuder%26aufirst%3DA.%26aulast%3DDrew%26aufirst%3DY.%26aulast%3DPrathapan%26aufirst%3DV.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DThornton%26aufirst%3DJ.%2BK.%26aulast%3Dde%2Blas%2BHeras%26aufirst%3DB.%26aulast%3DInk%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DMatijevic%26aufirst%3DM.%26aulast%3DMcGrath%26aufirst%3DS.%26aulast%3DSarker%26aufirst%3DD.%26atitle%3DPhase%25201%2520study%2520of%2520the%2520PARP%2520inhibitor%2520E7449%2520as%2520a%2520single%2520agent%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%2520or%2520B-cell%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15%2520suppl%26spage%3De19531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">McGonigle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolber-Simonds, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackermann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twine, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shie, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moniz, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomoto, K.</span><span> </span><span class="NLM_article-title">E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">41307</span><span class="NLM_x">–</span> <span class="NLM_lpage">41323</span><span class="refDoi"> DOI: 10.18632/oncotarget.5846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.5846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26513298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC28zmsFajsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=41307-41323&author=S.+McGonigleauthor=Z.+Chenauthor=J.+Wuauthor=P.+Changauthor=D.+Kolber-Simondsauthor=K.+Ackermannauthor=N.+C.+Twineauthor=J.+L.+Shieauthor=J.+T.+Miuauthor=K.+C.+Huangauthor=G.+A.+Monizauthor=K.+Nomoto&title=E7449%3A+A+dual+inhibitor+of+PARP1%2F2+and+tankyrase1%2F2+inhibits+growth+of+DNA+repair+deficient+tumors+and+antagonizes+Wnt+signaling&doi=10.18632%2Foncotarget.5846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling</span></div><div class="casAuthors">McGonigle Sharon; Chen Zhihong; Wu Jiayi; Kolber-Simonds Donna; Ackermann Karen; Twine Natalie C; Shie Jue-Lon; Miu Jingzang Tao; Huang Kuan-Chun; Nomoto Kenichi; Chang Paul; Chang Paul; Miu Jingzang Tao; Moniz George A; Moniz George A</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">41307-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have demonstrated clinical proof of concept for cancer treatment.  Here, we describe the development of the novel PARP inhibitor E7449, a potent PARP1/2 inhibitor that also inhibits PARP5a/5b, otherwise known as tankyrase1 and 2 (TNKS1 and 2), important regulators of canonical Wnt/β-catenin signaling.  E7449 inhibits PARP enzymatic activity and additionally traps PARP1 onto damaged DNA; a mechanism previously shown to augment cytotoxicity.  Cells deficient in DNA repair pathways beyond homologous recombination were sensitive to E7449 treatment.  Chemotherapy was potentiated by E7449 and single agent had significant antitumor activity in BRCA-deficient xenografts.  Additionally, E7449 inhibited Wnt/β-catenin signaling in colon cancer cell lines, likely through TNKS inhibition.  Consistent with this possibility, E7449 stabilized axin and TNKS proteins resulting in β-catenin de-stabilization and significantly altered expression of Wnt target genes.  Notably, hair growth mediated by Wnt signaling was inhibited by E7449.  A pharmacodynamic effect of E7449 on Wnt target genes was observed in tumors, although E7449 lacked single agent antitumor activity in vivo, a finding typical for selective TNKS inhibitors.  E7449 antitumor activity was increased through combination with MEK inhibition.  Particularly noteworthy was the lack of toxicity, most significantly the lack of intestinal toxicity reported for other TNKS inhibitors.  E7449 represents a novel dual PARP1/2 and TNKS1/2 inhibitor which has the advantage of targeting Wnt/β-catenin signaling addicted tumors.  E7449 is currently in early clinical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScNmr1n8UDWbrIbt-tGZmxfW6udTcc2eZhZ_eRoSVLR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zmsFajsA%253D%253D&md5=8e0ce94993305253e4b5d76355583498</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5846%26sid%3Dliteratum%253Aachs%26aulast%3DMcGonigle%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DP.%26aulast%3DKolber-Simonds%26aufirst%3DD.%26aulast%3DAckermann%26aufirst%3DK.%26aulast%3DTwine%26aufirst%3DN.%2BC.%26aulast%3DShie%26aufirst%3DJ.%2BL.%26aulast%3DMiu%26aufirst%3DJ.%2BT.%26aulast%3DHuang%26aufirst%3DK.%2BC.%26aulast%3DMoniz%26aufirst%3DG.%2BA.%26aulast%3DNomoto%26aufirst%3DK.%26atitle%3DE7449%253A%2520A%2520dual%2520inhibitor%2520of%2520PARP1%252F2%2520and%2520tankyrase1%252F2%2520inhibits%2520growth%2520of%2520DNA%2520repair%2520deficient%2520tumors%2520and%2520antagonizes%2520Wnt%2520signaling%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D41307%26epage%3D41323%26doi%3D10.18632%2Foncotarget.5846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span>BGB-290: PARP1 and PARP2 Inhibitor with Unique Properties; <span class="NLM_publisher-name">BeiGene</span>: <span class="NLM_publisher-loc">Beijing</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.beigene.com/pipeline/clinical-candidates/bgb-290/" class="extLink">http://www.beigene.com/pipeline/clinical-candidates/bgb-290/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BGB-290%3A+PARP1+and+PARP2+Inhibitor+with+Unique+Properties%3B+BeiGene%3A+Beijing%2C+2016%3B+http%3A%2F%2Fwww.beigene.com%2Fpipeline%2Fclinical-candidates%2Fbgb-290%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DBGB-290%253A%2520PARP1%2520and%2520PARP2%2520Inhibitor%2520with%2520Unique%2520Properties%26pub%3DBeiGene%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">de Jonge, M. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Herpen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koornstra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jager, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Den Hollander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serpenti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">452P A study of ABT-767 in advanced solid tumors with BRCA 1 and BRCA 2 mutations and high grade serous ovarian, fallopian tube, or primary peritoneal cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">suppl 4</span><span class="NLM_x">) </span> <span class="NLM_fpage">iv150</span><span class="refDoi"> DOI: 10.1093/annonc/mdu331.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fannonc%2Fmdu331.12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=iv150&issue=suppl+4&author=M.+J.+A.+de+Jongeauthor=C.+van+Herpenauthor=J.+Gietemaauthor=S.+Shepherdauthor=R.+Koornstraauthor=A.+Jagerauthor=M.+Den+Hollanderauthor=M.+Dunbarauthor=R.+Hetmanauthor=C.+Serpentiauthor=H.+Xiongauthor=M.+Zhuauthor=V.+L.+Giranda&title=452P+A+study+of+ABT-767+in+advanced+solid+tumors+with+BRCA+1+and+BRCA+2+mutations+and+high+grade+serous+ovarian%2C+fallopian+tube%2C+or+primary+peritoneal+cancer&doi=10.1093%2Fannonc%2Fmdu331.12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu331.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu331.12%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BJ.%2BA.%26aulast%3Dvan%2BHerpen%26aufirst%3DC.%26aulast%3DGietema%26aufirst%3DJ.%26aulast%3DShepherd%26aufirst%3DS.%26aulast%3DKoornstra%26aufirst%3DR.%26aulast%3DJager%26aufirst%3DA.%26aulast%3DDen%2BHollander%26aufirst%3DM.%26aulast%3DDunbar%26aufirst%3DM.%26aulast%3DHetman%26aufirst%3DR.%26aulast%3DSerpenti%26aufirst%3DC.%26aulast%3DXiong%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3D452P%2520A%2520study%2520of%2520ABT-767%2520in%2520advanced%2520solid%2520tumors%2520with%2520BRCA%25201%2520and%2520BRCA%25202%2520mutations%2520and%2520high%2520grade%2520serous%2520ovarian%252C%2520fallopian%2520tube%252C%2520or%2520primary%2520peritoneal%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26issue%3Dsuppl%25204%26spage%3Div150%26doi%3D10.1093%2Fannonc%2Fmdu331.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Fong, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mergui-Roelvink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.1056/NEJMoa0900212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1056%2FNEJMoa0900212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=19553641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=123-134&author=P.+C.+Fongauthor=D.+S.+Bossauthor=T.+A.+Yapauthor=A.+Tuttauthor=P.+Wuauthor=M.+Mergui-Roelvinkauthor=P.+Mortimerauthor=H.+Swaislandauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=A.+Ashworthauthor=J.+Carmichaelauthor=S.+B.+Kayeauthor=J.+H.+Schellensauthor=J.+S.+de+Bono&title=Inhibition+of+poly%28ADP-Ribose%29+polymerase+in+tumors+from+BRCA+mutation+carriers&doi=10.1056%2FNEJMoa0900212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</span></div><div class="casAuthors">Fong, Peter C.; Boss, David S.; Yap, Timothy A.; Tutt, Andrew; Wu, Peijun; Mergui-Roelvink, Marja; Mortimer, Peter; Swaisland, Helen; Lau, Alan; O'Connor, Mark J.; Ashworth, Alan; Carmichael, James; Kaye, Stan B.; Schellens, Jan H. M.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The inhibition of poly(ADP-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation.  We conducted a clin. evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor.  This was a phase 1 trial that included the anal. of pharmacokinetic and pharmacodynamic characteristics of olaparib.  Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation.  We enrolled and treated 60 patients; 22 were carriers of a BRCA1 or BRCA2 mutation and 1 had a strong family history of BRCA-assocd. cancer but declined to undergo mutational testing.  The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 wk to 600 mg twice daily continuously.  Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily (grade 3 mood alteration and fatigue) and two of five patients receiving 600 mg twice daily (grade 4 thrombocytopenia and grade 3 somnolence).  This led us to enroll another cohort, consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olaparib at a dose of 200 mg twice daily.  Other adverse effects included mild gastrointestinal symptoms.  There was no obvious increase in adverse effects seen in the mutation carriers.  Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic studies confirmed PARP inhibition in surrogate samples (of peripheral-blood mononuclear cells and plucked eyebrow-hair follicles) and tumor tissue.  Objective antitumor activity was reported only in mutation carriers, all of whom had ovarian, breast, or prostate cancer and had received multiple treatment regimens.  Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer assocd. with the BRCA1 or BRCA2 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCT49Hz0HbW7Vg90H21EOLACvtfcHk0lgT0yeHIur36Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D&md5=aec7dcffe3d3cf614362a4f38bbb369a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0900212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0900212%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DMergui-Roelvink%26aufirst%3DM.%26aulast%3DMortimer%26aufirst%3DP.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520poly%2528ADP-Ribose%2529%2520polymerase%2520in%2520tumors%2520from%2520BRCA%2520mutation%2520carriers%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D123%26epage%3D134%26doi%3D10.1056%2FNEJMoa0900212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nokihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahina, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T. A.</span><span> </span><span class="NLM_article-title">A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">504</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span><span class="refDoi"> DOI: 10.1111/j.1349-7006.2011.02179.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1111%2Fj.1349-7006.2011.02179.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22145984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1eru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2012&pages=504-509&author=N.+Yamamotoauthor=H.+Nokiharaauthor=Y.+Yamadaauthor=Y.+Gotoauthor=M.+Taniokaauthor=T.+Shibataauthor=K.+Yamadaauthor=H.+Asahinaauthor=T.+Kawataauthor=X.+Shiauthor=T.+A.+Tamura&title=A+phase+I%2C+dose-finding+and+pharmacokinetic+study+of+olaparib+%28AZD2281%29+in+Japanese+patients+with+advanced+solid+tumors&doi=10.1111%2Fj.1349-7006.2011.02179.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors</span></div><div class="casAuthors">Yamamoto, Noboru; Nokihara, Hiroshi; Yamada, Yasuhide; Goto, Yasushi; Tanioka, Maki; Shibata, Takashi; Yamada, Kazuhiko; Asahina, Hajime; Kawata, Toshio; Shi, Xiaojin; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">504-509</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Olaparib (AZD2281) is an orally active Poly(ADP-ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers with BRCA1/2 mutations in Western (USA and European) studies.  This Phase I dose-finding study evaluated the tolerability, pharmacokinetics, PARP inhibitory activity, and antitumor activity of olaparib in Japanese patients with solid tumors.  Olaparib was administered as a single-dose on day 1, followed by twice-daily dosing for 28 days from 48 h after a single dose.  Doses were escalated from 100 mg b.i.d. in successive cohorts, up to a max. of 400 mg b.i.d.  The present study enrolled 12 patients (n = 3, 3, and 6 in 100, 200 and 400-mg b.i.d. levels, resp.).  The most common adverse events were nausea, increased blood creatinine, decreased hematocrit, leukopenia and lymphopenia; dose-limiting toxicities were not obsd. up to and including the 400-mg b.i.d. dose level.  Following twice-daily dosing, olaparib showed no marked increase in exposure at steady state over that expected from the single-dose pharmacokinetics.  PARP-1 inhibition was obsd. from the 100-mg b.i.d. dose level in peripheral blood mononuclear cells from 6 h post-dose on day 1 during the multiple-dosing period.  A patient with metastatic breast cancer (100 mg b.i.d.) had a partial response for 13 mo and four patients (two each in the 200 and 400-mg b.i.d. levels) had stable disease >8 wk.  Olaparib was well tolerated up to the 400-mg b.i.d. dose in Japanese patients with solid tumors.  Preliminary evidence of antitumor activity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfnA3Dxz9hnbVg90H21EOLACvtfcHk0ljMOYJkKjLnDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1eru7k%253D&md5=56706a86e4388164e010ea363bd1524c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2011.02179.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2011.02179.x%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DTanioka%26aufirst%3DM.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DAsahina%26aufirst%3DH.%26aulast%3DKawata%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTamura%26aufirst%3DT.%2BA.%26atitle%3DA%2520phase%2520I%252C%2520dose-finding%2520and%2520pharmacokinetic%2520study%2520of%2520olaparib%2520%2528AZD2281%2529%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Sci.%26date%3D2012%26volume%3D103%26spage%3D504%26epage%3D509%26doi%3D10.1111%2Fj.1349-7006.2011.02179.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Molife, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forster, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pwint, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">2599</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2599&issue=15+suppl&author=L.+R.+Molifeauthor=M.+D.+Forsterauthor=M.+Krebsauthor=T.+Pwintauthor=M.+R.+Middletonauthor=S.+B.+Kayeauthor=P.+McCormackauthor=H.+Swaislandauthor=J.+Carmichaelauthor=M.+Ranson&title=A+phase+I+study+to+determine+the+comparative+bioavailability+of+two+different+oral+formulations+of+the+PARP+inhibitor%2C+olaparib+%28AZD2281%29%2C+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DForster%26aufirst%3DM.%2BD.%26aulast%3DKrebs%26aufirst%3DM.%26aulast%3DPwint%26aufirst%3DT.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DMcCormack%26aufirst%3DP.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DA%2520phase%2520I%2520study%2520to%2520determine%2520the%2520comparative%2520bioavailability%2520of%2520two%2520different%2520oral%2520formulations%2520of%2520the%2520PARP%2520inhibitor%252C%2520olaparib%2520%2528AZD2281%2529%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D15%2520suppl%26spage%3D2599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Bundred, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardovskis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaskiewicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eglitis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paramonov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavallin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, J. M.</span><span> </span><span class="NLM_article-title">Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">958</span><span class="refDoi"> DOI: 10.1007/s10637-012-9922-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1007%2Fs10637-012-9922-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=949-958&author=N.+Bundredauthor=J.+Gardovskisauthor=J.+Jaskiewiczauthor=J.+Eglitisauthor=V.+Paramonovauthor=P.+McCormackauthor=H.+Swaislandauthor=M.+Cavallinauthor=T.+Parryauthor=J.+Carmichaelauthor=J.+M.+Dixon&title=Evaluation+of+the+pharmacodynamics+and+pharmacokinetics+of+the+PARP+inhibitor+olaparib%3A+a+Phase+I+multicentre+trial+in+patients+scheduled+for+elective+breast+cancer+surgery&doi=10.1007%2Fs10637-012-9922-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9922-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9922-7%26sid%3Dliteratum%253Aachs%26aulast%3DBundred%26aufirst%3DN.%26aulast%3DGardovskis%26aufirst%3DJ.%26aulast%3DJaskiewicz%26aufirst%3DJ.%26aulast%3DEglitis%26aufirst%3DJ.%26aulast%3DParamonov%26aufirst%3DV.%26aulast%3DMcCormack%26aufirst%3DP.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DCavallin%26aufirst%3DM.%26aulast%3DParry%26aufirst%3DT.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DDixon%26aufirst%3DJ.%2BM.%26atitle%3DEvaluation%2520of%2520the%2520pharmacodynamics%2520and%2520pharmacokinetics%2520of%2520the%2520PARP%2520inhibitor%2520olaparib%253A%2520a%2520Phase%2520I%2520multicentre%2520trial%2520in%2520patients%2520scheduled%2520for%2520elective%2520breast%2520cancer%2520surgery%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D949%26epage%3D958%26doi%3D10.1007%2Fs10637-012-9922-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Fong, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carden, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mergui-Roelvink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Greve, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messiou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">A’Hern, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span> </span><span class="NLM_article-title">Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2512</span><span class="NLM_x">–</span> <span class="NLM_lpage">2519</span><span class="refDoi"> DOI: 10.1200/JCO.2009.26.9589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2009.26.9589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20406929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVyjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2512-2519&author=P.+C.+Fongauthor=T.+A.+Yapauthor=D.+S.+Bossauthor=C.+P.+Cardenauthor=M.+Mergui-Roelvinkauthor=C.+Gourleyauthor=J.+De+Greveauthor=J.+Lubinskiauthor=S.+Shanleyauthor=C.+Messiouauthor=R.+A%E2%80%99Hernauthor=A.+Tuttauthor=A.+Ashworthauthor=J.+Stoneauthor=J.+Carmichaelauthor=J.+H.+Schellensauthor=J.+S.+de+Bonoauthor=S.+B.+Kaye&title=Poly%28ADP%29-ribose+polymerase+inhibition%3A+frequent+durable+responses+in+BRCA+carrier+ovarian+cancer+correlating+with+platinum-free+interval&doi=10.1200%2FJCO.2009.26.9589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval</span></div><div class="casAuthors">Fong, Peter C.; Yap, Timothy A.; Boss, David S.; Carden, Craig P.; Mergui-Roelvink, Maria; Gourley, Charlie; De Greve, Jacques; Lubinski, Jan; Shanley, Susan; Messiou, Christina; A'Hern, Roger; Tutt, Andrew; Ashworth, Alan; Stone, John; Carmichael, James; Schellens, Jan H. M.; de Bono, Johann S.; Kaye, Stan B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2512-2519</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair.  Platinum-based chemotherapy responses correlate with HR DNA repair capacity.  Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers.  Patients and Methods: Patients with BRCA1/2-mutated ovarian cancer were treated with olaparib within a dose-escalation and single-stage expansion of a phase I trial.  Antitumor activity was subsequently correlated with platinum sensitivity.  Results: Fifty patients were treated: 48 had germline BRCA1/2 mutations; one had a BRCA2 germline sequence change of unknown significance, and another had a strong family history of BRCA1/2-assocd. cancers who declined mutation testing.  Of the 50 patients, 13 had platinum-sensitive disease, 24 had platinum-resistant disease, and 13 had platinum-refractory disease (according to platinum-free interval).  Twenty (40%; 95% CI, 26% to 55%) achieved Response Evaluation Criteria in Solid Tumors (RECIST) complete or partial responses and/or tumor marker (CA125) responses, and three (6.0%) maintained RECIST disease stabilization for more than 4 mo, giving an overall clin. benefit rate of 46% (95% CI, 32% to 61 %).  Median response duration was 28 wk.  There was a significant assocn. between the clin. benefit rate and platinum-free interval across the platinum-sensitive, resistant, and refractory subgroups (69%, 45%, and 23%, resp.).  Post hoc analyses indicated assocns. between platinum sensitivity and extent of olaparib response (radiol. change, P = .001; CA125 change, P = .002).  Conclusion: Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is assocd. with platinum sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvj9Ym5yY27Vg90H21EOLACvtfcHk0lhjpgsuPm3EdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVyjtr4%253D&md5=4198806c2b9d41e7068d26049fd0cd3f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.26.9589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.26.9589%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DCarden%26aufirst%3DC.%2BP.%26aulast%3DMergui-Roelvink%26aufirst%3DM.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DDe%2BGreve%26aufirst%3DJ.%26aulast%3DLubinski%26aufirst%3DJ.%26aulast%3DShanley%26aufirst%3DS.%26aulast%3DMessiou%26aufirst%3DC.%26aulast%3DA%25E2%2580%2599Hern%26aufirst%3DR.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DPoly%2528ADP%2529-ribose%2520polymerase%2520inhibition%253A%2520frequent%2520durable%2520responses%2520in%2520BRCA%2520carrier%2520ovarian%2520cancer%2520correlating%2520with%2520platinum-free%2520interval%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D2512%26epage%3D2519%26doi%3D10.1200%2FJCO.2009.26.9589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Audeh, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penson, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell-McGuinn, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitzel, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oaknin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmutzler, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span> </span><span class="NLM_article-title">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">251</span><span class="refDoi"> DOI: 10.1016/S0140-6736(10)60893-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS0140-6736%2810%2960893-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20609468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=245-251&author=M.+W.+Audehauthor=J.+Carmichaelauthor=R.+T.+Pensonauthor=M.+Friedlanderauthor=B.+Powellauthor=K.+M.+Bell-McGuinnauthor=C.+Scottauthor=J.+N.+Weitzelauthor=A.+Oakninauthor=N.+Lomanauthor=K.+Luauthor=R.+K.+Schmutzlerauthor=U.+Matulonisauthor=M.+Wickensauthor=A.+Tutt&title=Oral+poly%28ADP-ribose%29+polymerase+inhibitor+olaparib+in+patients+with+BRCA1+or+BRCA2+mutations+and+recurrent+ovarian+cancer%3A+a+proof-of-concept+trial&doi=10.1016%2FS0140-6736%2810%2960893-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span></div><div class="casAuthors">Audeh, M. William; Carmichael, James; Penson, Richard T.; Friedlander, Michael; Powell, Bethan; Bell-McGuinn, Katherine M.; Scott, Clare; Weitzel, Jeffrey N.; Oaknin, Ana; Loman, Niklas; Lu, Karen; Schmutzler, Rita K.; Matulonis, Ursula; Wickens, Mark; Tutt, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9737</span>),
    <span class="NLM_cas:pages">245-251</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells.  We aimed to assess the efficacy and safety of olaparib for treatment of advanced ovarian cancer in patients with BRCA1 or BRCA2 mutations.  In this international, multicentre, phase 2 study, we enrolled two sequential cohorts of women (aged ≥18 years) with confirmed genetic BRCA1 or BRCA2 mutations, and recurrent, measurable disease.  The study was undertaken in 12 centers in Australia, Germany, Spain, Sweden, and the USA.  The first cohort (n=33) was given continuous oral olaparib at the max. tolerated dose of 400 mg twice daily, and the second cohort (n=24) was given continuous oral olaparib at 100 mg twice daily.  The primary efficacy endpoint was objective response rate (ORR).  This study is registered with ClinicalTrials.gov, no. NCT00494442.  Patients had been given a median of three (range 1-16) previous chemotherapy regimens.  ORR was 11 (33%) of 33 patients (95% CI 20-51) in the cohort assigned to olaparib 400 mg twice daily, and three (13%) of 24 (4-31) in the cohort assigned to 100 mg twice daily.  In patients given olaparib 400 mg twice daily, the most frequent causally related adverse events were nausea (grade 1 or 2, 14 [42%]; grade 3 or 4, 2 [6%]), fatigue (grade 1 or 2, 10 [30%]; grade 3 or 4, one [3%]), and anemia (grade 1 or 2, 5 [15%]; grade 3 or 4, 1 [3%]).  The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea (grade 1 or 2, 7 [29%]; grade 3 or 4, 2 [8%]) and fatigue (grade 1 or 2, 9 [38%]; none grade 3 or 4).  Findings from this phase 2 study provide pos. proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfC3epcFKsLrVg90H21EOLACvtfcHk0lhjpgsuPm3EdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D&md5=e74985d2c7ae53462d48277fbc36bb6a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960893-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960893-8%26sid%3Dliteratum%253Aachs%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DPenson%26aufirst%3DR.%2BT.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DScott%26aufirst%3DC.%26aulast%3DWeitzel%26aufirst%3DJ.%2BN.%26aulast%3DOaknin%26aufirst%3DA.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DMatulonis%26aufirst%3DU.%26aulast%3DWickens%26aufirst%3DM.%26aulast%3DTutt%26aufirst%3DA.%26atitle%3DOral%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520olaparib%2520in%2520patients%2520with%2520BRCA1%2520or%2520BRCA2%2520mutations%2520and%2520recurrent%2520ovarian%2520cancer%253A%2520a%2520proof-of-concept%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D245%26epage%3D251%26doi%3D10.1016%2FS0140-6736%2810%2960893-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlan, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amnon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell-McGuinn, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, B.</span><span> </span><span class="NLM_article-title">Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">372</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span><span class="refDoi"> DOI: 10.1200/JCO.2011.36.9215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2011.36.9215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22203755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=372-379&author=S.+B.+Kayeauthor=J.+Lubinskiauthor=U.+Matulonisauthor=J.+E.+Angauthor=C.+Gourleyauthor=B.+Y.+Karlanauthor=A.+Amnonauthor=K.+M.+Bell-McGuinnauthor=L.+M.+Chenauthor=M.+Friedlanderauthor=T.+Safraauthor=I.+Vergoteauthor=M.+Wickensauthor=E.+S.+Loweauthor=J.+Carmichaelauthor=B.+Kaufman&title=Phase+II%2C+open-label%2C+randomized%2C+multicenter+study+comparing+the+efficacy+and+safety+of+olaparib%2C+a+poly+%28ADP-ribose%29+polymerase+inhibitor%2C+and+pegylated+liposomal+doxorubicin+in+patients+with+BRCA1+or+BRCA2+mutations+and+recurrent+ovarian+cancer&doi=10.1200%2FJCO.2011.36.9215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II, open-label, randomized, multicenter study comparing the efficacy of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 and BRCA2 mutations and recurrent ovarian cancer</span></div><div class="casAuthors">Kaye, Stan B.; Lubinski, Jan; Matulonis, Ursula; Ang, Joo Ern; Gourley, Charlie; Karlan, Beth V.; Amnon, Amit; Bell-McGuinn, Katherine M.; Chen, Lee-May; Friedlander, Michael; Safra, Tamar; Vergote, Ignace; Wickens, Mark; Lowe, Elizabeth S.; Carmichael, James; Kaufman, Bella</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">372-379</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or BRCA2-deficient cells, has shown promising clin. efficacy in nonrandomized phase II trials in patients with ovarian cancer with BRCA1 or BRCA2 deficiency.  We assessed the comparative efficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population.  Patients and Methods In this multicenter, open-label, randomized, phase II study, patients with ovarian cancer that recurred within 12 mo of prior platinum therapy and with confirmed germline BRCA1 or BRCA2 mutations were enrolled.  Patients were assigned in a 1:1:1 ratio to olaparib 200 mg twice per day or 400 mg twice per day continuously or PLD 50 mg/m2 i.v. every 28 days.  The primary efficacy end point was Response Evaluation Criteria in Solid Tumors (RECIST) -assessed progression-free survival (PFS).  Secondary end points included objective response rate (ORR) and safety.  Results Ninety-seven patients were randomly assigned.  Median PFS was 6.5 mo (95% CI, 5.5 to 10.1 mo), 8.8 mo (95% CI, 5.4 to 9.2 mo), and 7.1 mo (95% CI, 3.7 to 10.7 mo) for the olaparib 200 mg, olaparib 400 mg, and PLD groups, resp.  There was no statistically significant difference in PFS (hazard ratio, 0.88; 95% CI, 0.51 to 1.56; P = .66) for combined olaparib doses vs. PLD.  RECIST-assessed ORRs were 25%, 31 %, and 18% for olaparib 200 mg, olaparib 400 mg, and PLD, resp.; differences were not statistically significant.  Tolerability of both treatments was as expected based on previous trials.  Conclusion The efficacy of olaparib was consistent with previous studies.  However, the efficacy of PLD was greater than expected.  Olaparib 400 mg twice per day is a suitable dose to explore in further studies in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMk-rXAQhaM7Vg90H21EOLACvtfcHk0lh6-hn0WtT4Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKgsr8%253D&md5=4f32a5c28cb1e568687f2d58c19ef885</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.36.9215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.36.9215%26sid%3Dliteratum%253Aachs%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DLubinski%26aufirst%3DJ.%26aulast%3DMatulonis%26aufirst%3DU.%26aulast%3DAng%26aufirst%3DJ.%2BE.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DKarlan%26aufirst%3DB.%2BY.%26aulast%3DAmnon%26aufirst%3DA.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DChen%26aufirst%3DL.%2BM.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DWickens%26aufirst%3DM.%26aulast%3DLowe%26aufirst%3DE.%2BS.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DB.%26atitle%3DPhase%2520II%252C%2520open-label%252C%2520randomized%252C%2520multicenter%2520study%2520comparing%2520the%2520efficacy%2520and%2520safety%2520of%2520olaparib%252C%2520a%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitor%252C%2520and%2520pegylated%2520liposomal%2520doxorubicin%2520in%2520patients%2520with%2520BRCA1%2520or%2520BRCA2%2520mutations%2520and%2520recurrent%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D372%26epage%3D379%26doi%3D10.1200%2FJCO.2011.36.9215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garber, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domchek, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audeh, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitzel, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arun, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmutzler, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span> </span><span class="NLM_article-title">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.1016/S0140-6736(10)60892-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS0140-6736%2810%2960892-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20609467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1KktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=235-244&author=A.+Tuttauthor=M.+Robsonauthor=J.+E.+Garberauthor=S.+M.+Domchekauthor=M.+W.+Audehauthor=J.+N.+Weitzelauthor=M.+Friedlanderauthor=B.+Arunauthor=N.+Lomanauthor=R.+K.+Schmutzlerauthor=A.+Wardleyauthor=G.+Mitchellauthor=H.+Earlauthor=M.+Wickensauthor=J.+Carmichael&title=Oral+poly%28ADP-ribose%29+polymerase+inhibitor+olaparib+in+patients+with+BRCA1+or+BRCA2+mutations+and+advanced+breast+cancer%3A+a+proof-of-concept+trial&doi=10.1016%2FS0140-6736%2810%2960892-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial</span></div><div class="casAuthors">Tutt, Andrew; Robson, Mark; Garber, Judy E.; Domchek, Susan M.; Audeh, M. William; Weitzel, Jeffrey N.; Friedlander, Michael; Arun, Banu; Loman, Niklas; Schmutzler, Rita K.; Wardley, Andrew; Mitchell, Gillian; Earl, Helena; Wickens, Mark; Carmichael, James</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9737</span>),
    <span class="NLM_cas:pages">235-244</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced synthetic lethality in BRCA-deficient cells.  A max. tolerated dose and initial signal of efficacy in BRCA-deficient ovarian cancers have been reported.  We therefore assessed the efficacy, safety, and tolerability of olaparib alone in women with BRCA1 or BRCA2 mutations and advanced breast cancer.  Women (aged ≥18 years) with confirmed BRCA1 or BRCA2 mutations and recurrent, advanced breast cancer were assigned to two sequential cohorts in a phase 2 study undertaken in 16 centers in Australia, Germany, Spain, Sweden, the UK, and the USA.  The first cohort (n=27) was given continuous oral olaparib at the max. tolerated dose (400 mg twice daily), and the second (n=27) was given a lower dose (100 mg twice daily).  The primary efficacy endpoint was objective response rate (ORR).  This study is registered with ClinicalTrials.gov, no. NCT00494234.  Patients had been given a median of three previous chemotherapy regimens (range 1-5 in cohort 1, and 2-4 in cohort 2).  ORR was 11 (41%) of 27 patients (95% CI 25-59) in the cohort assigned to 400 mg twice daily, and 6 (22%) of 27 (11-41) in the cohort assigned to 100 mg twice daily.  Toxicities were mainly at low grades.  The most frequent causally related adverse events in the cohort given 400 mg twice daily were fatigue (grade 1 or 2, 11 [41%]; grade 3 or 4, 4 [15%]), nausea (grade 1 or 2, 11 [41%]; grade 3 or 4, 4 [15%]), vomiting (grade 1 or 2, 3 [11%]; grade 3 or 4, 3 [11%]), and anemia (grade 1 or 2, 1 [4%]; grade 3 or 4, 3 [11%]).  The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea (grade 1 or 2, 11 [41%]; none grade 3 or 4) and fatigue (grade 1 or 2, 7 [26%]; grade 3 or 4, 1 [4%]).  The results of this study provide pos. proof of concept for PARP inhibition in BRCA-deficient breast cancers and shows a favorable therapeutic index for a novel targeted treatment strategy in patients with tumors that have genetic loss of function of BRCA1-assocd. or BRCA2-assocd. DNA repair.  Toxicity in women with BRCA1 and BRCA2 mutations was similar to that reported previously in those without such mutations.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonjJjcPScaZbVg90H21EOLACvtfcHk0lh6-hn0WtT4Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1KktLc%253D&md5=a797f2aef3dd530bc74e57f2050fa7d7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960892-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960892-6%26sid%3Dliteratum%253Aachs%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DGarber%26aufirst%3DJ.%2BE.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DWeitzel%26aufirst%3DJ.%2BN.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DArun%26aufirst%3DB.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DWardley%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DG.%26aulast%3DEarl%26aufirst%3DH.%26aulast%3DWickens%26aufirst%3DM.%26aulast%3DCarmichael%26aufirst%3DJ.%26atitle%3DOral%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520olaparib%2520in%2520patients%2520with%2520BRCA1%2520or%2520BRCA2%2520mutations%2520and%2520advanced%2520breast%2520cancer%253A%2520a%2520proof-of-concept%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D235%26epage%3D244%26doi%3D10.1016%2FS0140-6736%2810%2960892-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Mateo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mossop, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Lopez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nava Rodrigues, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunariu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boysen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figueiredo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulding, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seed, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralph, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protheroe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGovern, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zafeiriou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraldeschi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riisnaes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebbs, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">A’Hern, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunju, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eeles, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">DNA-repair defects and olaparib in metastatic prostate cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">1697</span><span class="NLM_x">–</span> <span class="NLM_lpage">1708</span><span class="refDoi"> DOI: 10.1056/NEJMoa1506859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1056%2FNEJMoa1506859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26510020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVemuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1697-1708&author=J.+Mateoauthor=S.+Carreiraauthor=S.+Sandhuauthor=S.+Mirandaauthor=H.+Mossopauthor=R.+Perez-Lopezauthor=D.+Nava+Rodriguesauthor=D.+Robinsonauthor=A.+Omlinauthor=N.+Tunariuauthor=G.+Boysenauthor=N.+Portaauthor=P.+Flohrauthor=A.+Gillmanauthor=I.+Figueiredoauthor=C.+Pauldingauthor=G.+Seedauthor=S.+Jainauthor=C.+Ralphauthor=A.+Protheroeauthor=S.+Hussainauthor=R.+Jonesauthor=T.+Elliottauthor=U.+McGovernauthor=D.+Bianchiniauthor=J.+Goodallauthor=Z.+Zafeiriouauthor=C.+T.+Williamsonauthor=R.+Ferraldeschiauthor=R.+Riisnaesauthor=B.+Ebbsauthor=G.+Fowlerauthor=D.+Rodaauthor=W.+Yuanauthor=Y.+M.+Wuauthor=X.+Caoauthor=R.+Broughauthor=H.+Pembertonauthor=R.+A%E2%80%99Hernauthor=A.+Swainauthor=L.+P.+Kunjuauthor=R.+Eelesauthor=G.+Attardauthor=C.+J.+Lordauthor=A.+Ashworthauthor=M.+A.+Rubinauthor=K.+E.+Knudsenauthor=F.+Y.+Fengauthor=A.+M.+Chinnaiyanauthor=E.+Hallauthor=J.+S.+de+Bono&title=DNA-repair+defects+and+olaparib+in+metastatic+prostate+cancer&doi=10.1056%2FNEJMoa1506859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-repair defects and olaparib in metastatic prostate cancer</span></div><div class="casAuthors">Mateo, J.; Carreira, S.; Sandhu, S.; Miranda, S.; Mossop, H.; Perez-Lopez, R.; Rodrigues, D. Nava; Robinson, D.; Omlin, A.; Tunariu, N.; Boysen, G.; Porta, N.; Flohr, P.; Gillman, A.; Figueiredo, I.; Paulding, C.; Seed, G.; Jain, S.; Ralph, C.; Protheroe, A.; Hussain, S.; Jones, R.; Elliott, T.; McGovern, U.; Bianchini, D.; Goodall, J.; Zafeiriou, Z.; Williamson, C. T.; Ferraldeschi, R.; Riisnaes, R.; Ebbs, B.; Fowler, G.; Roda, D.; Yuan, W.; Wu, Y.-M.; Cao, X.; Brough, R.; Pemberton, H.; A'Hern, R.; Swain, A.; Kunju, L. P.; Eeles, R.; Attard, G.; Lord, C. J.; Ashworth, A.; Rubin, M. A.; Knudsen, K. E.; Feng, F. Y.; Chinnaiyan, A. M.; Hall, E.; de Bono, J. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1697-1708</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Prostate cancer is a heterogeneous disease, but current treatments are not based on mol. stratification.  We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(ADP [ADP]-ribose) polymerase (PARP) inhibition with olaparib.  We conducted a phase 2 trial in which patients with metastatic, castration-resistant prostate cancer were treated with olaparib tablets at a dose of 400 mg twice a day.  The primary end point was the response rate, defined either as an objective response according to Response Evaluation Criteria in Solid Tumors, version 1.1, or as a redn. of at least 50% in the prostate-specific antigen level or a confirmed redn. in the circulating tumor-cell count from 5 or more cells per 7.5 mL of blood to less than 5 cells per 7.5 mL.  Targeted next-generation sequencing, exome and transcriptome anal., and digital polymerase-chain-reaction testing were performed on samples from mandated tumor biopsies.  Overall, 50 patients were enrolled; all had received prior treatment with docetaxel, 49 (98%) had received abiraterone or enzalutamide, and 29 (58%) had received cabazitaxel.  Sixteen of 49 patients who could be evaluated had a response (33%; 95% confidence interval, 20 to 48), with 12 patients receiving the study treatment for more than 6 mo.  Next-generation sequencing identified homozygous deletions, deleterious mutations, or both in DNA-repair genes - including BRCA1/2, ATM, Fanconi's anemia genes, and CHEK2 - in 16 of 49 patients who could be evaluated (33%).  Of these 16 patients, 14 (88%) had a response to olaparib, including all 7 patients with BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations) and 4 of 5 with ATM aberrations.  The specificity of the biomarker suite was 94%.  Anemia (in 10 of the 50 patients [20%]) and fatigue (in 6 [12%]) were the most common grade 3 or 4 adverse events, findings that are consistent with previous studies of olaparib.  Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to std. treatments and who had defects in DNA-repair genes led to a high response rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6UTScmDZ6SLVg90H21EOLACvtfcHk0lg1s10bzl2kag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVemuro%253D&md5=8a54b17a8d5b7dd8d35afae907c00fe8</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1506859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1506859%26sid%3Dliteratum%253Aachs%26aulast%3DMateo%26aufirst%3DJ.%26aulast%3DCarreira%26aufirst%3DS.%26aulast%3DSandhu%26aufirst%3DS.%26aulast%3DMiranda%26aufirst%3DS.%26aulast%3DMossop%26aufirst%3DH.%26aulast%3DPerez-Lopez%26aufirst%3DR.%26aulast%3DNava%2BRodrigues%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DOmlin%26aufirst%3DA.%26aulast%3DTunariu%26aufirst%3DN.%26aulast%3DBoysen%26aufirst%3DG.%26aulast%3DPorta%26aufirst%3DN.%26aulast%3DFlohr%26aufirst%3DP.%26aulast%3DGillman%26aufirst%3DA.%26aulast%3DFigueiredo%26aufirst%3DI.%26aulast%3DPaulding%26aufirst%3DC.%26aulast%3DSeed%26aufirst%3DG.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DRalph%26aufirst%3DC.%26aulast%3DProtheroe%26aufirst%3DA.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DElliott%26aufirst%3DT.%26aulast%3DMcGovern%26aufirst%3DU.%26aulast%3DBianchini%26aufirst%3DD.%26aulast%3DGoodall%26aufirst%3DJ.%26aulast%3DZafeiriou%26aufirst%3DZ.%26aulast%3DWilliamson%26aufirst%3DC.%2BT.%26aulast%3DFerraldeschi%26aufirst%3DR.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DEbbs%26aufirst%3DB.%26aulast%3DFowler%26aufirst%3DG.%26aulast%3DRoda%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DY.%2BM.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DPemberton%26aufirst%3DH.%26aulast%3DA%25E2%2580%2599Hern%26aufirst%3DR.%26aulast%3DSwain%26aufirst%3DA.%26aulast%3DKunju%26aufirst%3DL.%2BP.%26aulast%3DEeles%26aufirst%3DR.%26aulast%3DAttard%26aufirst%3DG.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DKnudsen%26aufirst%3DK.%2BE.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26aulast%3DHall%26aufirst%3DE.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DDNA-repair%2520defects%2520and%2520olaparib%2520in%2520metastatic%2520prostate%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1697%26epage%3D1708%26doi%3D10.1056%2FNEJMoa1506859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Choy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmon, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Adamo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamand, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="refDoi"> DOI: 10.1186/1471-2407-14-813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2F1471-2407-14-813" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=813&author=E.+Choyauthor=J.+E.+Butrynskiauthor=D.+C.+Harmonauthor=J.+A.+Morganauthor=S.+Georgeauthor=A.+J.+Wagnerauthor=D.+D%E2%80%99Adamoauthor=G.+M.+Coteauthor=Y.+Flamandauthor=C.+H.+Benesauthor=D.+A.+Haberauthor=J.+M.+Baselgaauthor=G.+D.+Demetri&title=Phase+II+study+of+olaparib+in+patients+with+refractory+Ewing+sarcoma+following+failure+of+standard+chemotherapy&doi=10.1186%2F1471-2407-14-813"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-14-813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-14-813%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DE.%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DHarmon%26aufirst%3DD.%2BC.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%26aulast%3DCote%26aufirst%3DG.%2BM.%26aulast%3DFlamand%26aufirst%3DY.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DBaselga%26aufirst%3DJ.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DPhase%2520II%2520study%2520of%2520olaparib%2520in%2520patients%2520with%2520refractory%2520Ewing%2520sarcoma%2520following%2520failure%2520of%2520standard%2520chemotherapy%26jtitle%3DBMC%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D813%26doi%3D10.1186%2F1471-2407-14-813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hays, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annunziata, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noonan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minasian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zujewski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sissung, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azad, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, E. C.</span><span> </span><span class="NLM_article-title">Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">dju089</span><span class="refDoi"> DOI: 10.1093/jnci/dju089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fjnci%2Fdju089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24842883" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=dju089&author=J.+M.+Leeauthor=J.+L.+Haysauthor=C.+M.+Annunziataauthor=A.+M.+Noonanauthor=L.+Minasianauthor=J.+A.+Zujewskiauthor=M.+Yuauthor=N.+Gordonauthor=J.+Jiauthor=T.+M.+Sissungauthor=W.+D.+Figgauthor=N.+Azadauthor=B.+J.+Woodauthor=J.+Doroshowauthor=E.+C.+Kohn&title=Phase+I%2FIb+study+of+olaparib+and+carboplatin+in+BRCA1+or+BRCA2+mutation-associated+breast+or+ovarian+cancer+with+biomarker+analyses&doi=10.1093%2Fjnci%2Fdju089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdju089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdju089%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DHays%26aufirst%3DJ.%2BL.%26aulast%3DAnnunziata%26aufirst%3DC.%2BM.%26aulast%3DNoonan%26aufirst%3DA.%2BM.%26aulast%3DMinasian%26aufirst%3DL.%26aulast%3DZujewski%26aufirst%3DJ.%2BA.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DN.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DSissung%26aufirst%3DT.%2BM.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DAzad%26aufirst%3DN.%26aulast%3DWood%26aufirst%3DB.%2BJ.%26aulast%3DDoroshow%26aufirst%3DJ.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26atitle%3DPhase%2520I%252FIb%2520study%2520of%2520olaparib%2520and%2520carboplatin%2520in%2520BRCA1%2520or%2520BRCA2%2520mutation-associated%2520breast%2520or%2520ovarian%2520cancer%2520with%2520biomarker%2520analyses%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2014%26volume%3D106%26spage%3Ddju089%26doi%3D10.1093%2Fjnci%2Fdju089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Balmaña, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakoff, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graña, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frewer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garber, J. E.</span><span> </span><span class="NLM_article-title">Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1656</span><span class="NLM_x">–</span> <span class="NLM_lpage">1663</span><span class="refDoi"> DOI: 10.1093/annonc/mdu187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fannonc%2Fmdu187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24827126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2cjislyjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1656-1663&author=J.+Balma%C3%B1aauthor=N.+M.+Tungauthor=S.+J.+Isakoffauthor=B.+Gra%C3%B1aauthor=P.+D.+Ryanauthor=C.+Sauraauthor=E.+S.+Loweauthor=P.+Frewerauthor=E.+Winerauthor=J.+Baselgaauthor=J.+E.+Garber&title=Phase+I+trial+of+olaparib+in+combination+with+cisplatin+for+the+treatment+of+patients+with+advanced+breast%2C+ovarian+and+other+solid+tumors&doi=10.1093%2Fannonc%2Fmdu187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors</span></div><div class="casAuthors">Balmana J; Grana B; Saura C; Tung N M; Isakoff S J; Ryan P D; Lowe E S; Frewer P; Winer E; Garber J E; Baselga J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1656-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  To establish the maximum tolerated dose, determine safety/tolerability and evaluate the pharmacokinetics and preliminary efficacy of olaparib in combination with cisplatin in patients with advanced solid tumors.  PATIENTS AND METHODS:  Patients aged ≥ 18 years with advanced solid tumors, who had progressed on standard treatment, were assigned to a treatment cohort and received oral olaparib [50-200 mg twice daily (bid); 21-day cycle] continuously or intermittently (days 1-5 or 1-10) in combination with cisplatin (60-75 mg/m(2) intravenously) on day 1 of each cycle.  RESULTS:  Dose-limiting toxicities (DLTs) of grade 3 neutropenia (cisplatin 75 mg/m(2) with continuous olaparib 100 mg bid or 200 mg bid; n = 1 each) and grade 3 lipase elevation (cisplatin 75 mg/m(2) with olaparib 100 mg bid days 1-10 or 50 mg bid days 1-5; n = 1 each) were reported.  Olaparib and cisplatin doses were subsequently reduced to 50 mg bid days 1-5 and 60 mg/m(2), respectively; no DLTs were reported for patients receiving this regimen.  The most frequent grade ≥ 3 adverse events were neutropenia (16.7%), anemia (9.3%) and leucopenia (9.3%).  Thirty patients (55.6%) received colony-stimulating factors for hematologic support.  The overall objective response rate was 41% for patients with measurable disease, and 43% and 71% among patients with a BRCA1/2 mutation who had ovarian and breast cancer, respectively.  CONCLUSIONS:  Olaparib in combination with cisplatin 75 mg/m(2) was not considered tolerable; intermittent olaparib (50 mg bid, days 1-5) with cisplatin 60 mg/m(2) improved tolerability.  Promising antitumor activity in patients with germline BRCA1/2 mutations was observed and warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsk4Vjqyl9wRpyrDyM_m9cfW6udTcc2eZghyDsvmo1krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjislyjug%253D%253D&md5=10beab5b7a4eec0000a7a8e687f88d3e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu187%26sid%3Dliteratum%253Aachs%26aulast%3DBalma%25C3%25B1a%26aufirst%3DJ.%26aulast%3DTung%26aufirst%3DN.%2BM.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DGra%25C3%25B1a%26aufirst%3DB.%26aulast%3DRyan%26aufirst%3DP.%2BD.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DLowe%26aufirst%3DE.%2BS.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DWiner%26aufirst%3DE.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DGarber%26aufirst%3DJ.%2BE.%26atitle%3DPhase%2520I%2520trial%2520of%2520olaparib%2520in%2520combination%2520with%2520cisplatin%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520advanced%2520breast%252C%2520ovarian%2520and%2520other%2520solid%2520tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D1656%26epage%3D1663%26doi%3D10.1093%2Fannonc%2Fmdu187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Del Conte, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sessa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Moos, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viganò, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Digena, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locatelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallerani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasolo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tessari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cathomas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span> </span><span class="NLM_article-title">Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span><span class="refDoi"> DOI: 10.1038/bjc.2014.345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fbjc.2014.345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25025963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyhsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=651-659&author=G.+Del+Conteauthor=C.+Sessaauthor=R.+von+Moosauthor=L.+Vigan%C3%B2author=T.+Digenaauthor=A.+Locatelliauthor=E.+Galleraniauthor=A.+Fasoloauthor=A.+Tessariauthor=R.+Cathomasauthor=L.+Gianni&title=Phase+I+study+of+olaparib+in+combination+with+liposomal+doxorubicin+in+patients+with+advanced+solid+tumours&doi=10.1038%2Fbjc.2014.345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours</span></div><div class="casAuthors">Del Conte, G.; Sessa, C.; von Moos, R.; Vigano, L.; Digena, T.; Locatelli, A.; Gallerani, E.; Fasolo, A.; Tessari, A.; Cathomas, R.; Gianni, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">651-659</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Olaparib, an oral PARP inhibitor, has shown antitumor activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer.  This study evaluated olaparib capsules in combination with liposomal doxorubicin (PLD) in patients with advanced solid tumors (NCT00819221).  Methods: Patients received 28-day cycles of olaparib, continuously (days 1-28) or intermittently (days 1-7), plus PLD (40 mg m-2, day 1); seven olaparib dose cohorts (50-400 mg bid) were explored to det. the recommended dose.  Assessments included safety, pharmacokinetics, pharmacodynamics and preliminary efficacy (objective response rate (ORR)).  Results: Of 44 patients treated (ovarian, n=28; breast, n=13; other/unknown, n=3), two experienced dose-limiting toxicities (grade 3 stomatitis and fatal pneumonia/pneumonitis (200 mg per 28-day cycle); grade 4 thrombocytopenia (400 mg per 7-day cycle)).  The max. tolerated dose was not reached using continuous olaparib 400 mg bid plus PLD.  Grade ≥3 and serious AEs were reported for 27 (61%) and 12 (27%) patients, resp.  No major pharmacokinetic interference was obsd. between olaparib and PLD.  The ORR was 33% (n=14 out of 42; complete response, n=3).  A total of 13 responders had ovarian cancer: 10 were platinum-sensitive, 11 had a gBRCA mutation.  Conclusions: Continuous/intermittent olaparib (up to 400 mg bid) combined with PLD (40 mg m-2) was generally tolerated and showed evidence of antitumor activity in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-rSh3-J1BVbVg90H21EOLACvtfcHk0lgTnKg9QTAxTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyhsbzP&md5=02f946362148381e15a25e527a4117f5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2014.345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2014.345%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BConte%26aufirst%3DG.%26aulast%3DSessa%26aufirst%3DC.%26aulast%3Dvon%2BMoos%26aufirst%3DR.%26aulast%3DVigan%25C3%25B2%26aufirst%3DL.%26aulast%3DDigena%26aufirst%3DT.%26aulast%3DLocatelli%26aufirst%3DA.%26aulast%3DGallerani%26aufirst%3DE.%26aulast%3DFasolo%26aufirst%3DA.%26aulast%3DTessari%26aufirst%3DA.%26aulast%3DCathomas%26aufirst%3DR.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DPhase%2520I%2520study%2520of%2520olaparib%2520in%2520combination%2520with%2520liposomal%2520doxorubicin%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2014%26volume%3D111%26spage%3D651%26epage%3D659%26doi%3D10.1038%2Fbjc.2014.345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Rajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kummar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannargudi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span> </span><span class="NLM_article-title">A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2344</span><span class="NLM_x">–</span> <span class="NLM_lpage">2351</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-11-2425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22371451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFOnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2344-2351&author=A.+Rajanauthor=C.+A.+Carterauthor=R.+J.+Kellyauthor=M.+Gutierrezauthor=S.+Kummarauthor=E.+Szaboauthor=M.+A.+Yanceyauthor=J.+Jiauthor=B.+Mannargudiauthor=S.+Wooauthor=S.+Spencerauthor=W.+D.+Figgauthor=G.+Giaccone&title=A+phase+I+combination+study+of+olaparib+with+cisplatin+and+gemcitabine+in+adults+with+solid+tumors&doi=10.1158%2F1078-0432.CCR-11-2425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors</span></div><div class="casAuthors">Rajan, Arun; Carter, Corey A.; Kelly, Ronan J.; Gutierrez, Martin; Kummar, Shivaani; Szabo, Eva; Yancey, Mary Ann; Ji, Jiuping; Mannargudi, Baskar; Woo, Sukyung; Spencer, Shawn; Figg, William Douglas; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2344-2351</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To det. the safety and tolerability of olaparib with cisplatin and gemcitabine, establish the max. tolerated dose (MTD), and evaluate the pharmacodynamic and pharmacokinetic profile of the combination.  Exptl. Design: We conducted a phase I study of olaparib with cisplatin and gemcitabine in patients with advanced solid tumors.  Treatment at dose level 1 (DL1) consisted of olaparib 100 mg orally every 12 h on days 1 to 4, gemcitabine 500 mg/m2 on days 3 and 10, and cisplatin 60 mg/m2 on day 3.  PAR levels were measured in peripheral blood mononuclear cells (PBMC).  RESULTS: Dose-limiting toxicities (DLT) in two of three patients at DL1 included thrombocytopenia and febrile neutropenia.  The protocol was amended to enroll patients treated with ≤2 prior severely myelosuppressive chemotherapy regimens and treated with olaparib 100 mg once daily on days 1 to 4 (DL-1).  No DLTs were seen in six patients at DL-1.  Because of persistent thrombocytopenia and neutropenia following a return to DL1, patients received 100 mg olaparib every 12 h on day 1 only.  No hematol. DLTs were obsd.; nonhematol. DLTs included gastrointestinal bleed, syncope, and hypoxia.  Of 21 patients evaluable for response, two had partial response.  Olaparib inhibited PARP in PBMCs and tumor tissue, although PAR levels were less effectively inhibited when olaparib was used for a short duration.  CONCLUSIONS: Olaparib in combination with cisplatin and gemcitabine is assocd. with myelosuppression even at relatively low doses.  Modified schedules of olaparib in chemotherapy naive patients will have to be explored with std. doses of chemotherapy.  Clin Cancer Res; 18(8); 2344-51.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI7TqGiAg307Vg90H21EOLACvtfcHk0lgTnKg9QTAxTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFOnu7o%253D&md5=c1b311dfb8abb03ba06b7d5b5a9739b6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2425%26sid%3Dliteratum%253Aachs%26aulast%3DRajan%26aufirst%3DA.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DKelly%26aufirst%3DR.%2BJ.%26aulast%3DGutierrez%26aufirst%3DM.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DYancey%26aufirst%3DM.%2BA.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DMannargudi%26aufirst%3DB.%26aulast%3DWoo%26aufirst%3DS.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DA%2520phase%2520I%2520combination%2520study%2520of%2520olaparib%2520with%2520cisplatin%2520and%2520gemcitabine%2520in%2520adults%2520with%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2344%26epage%3D2351%26doi%3D10.1158%2F1078-0432.CCR-11-2425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Samol, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassidy, J.</span><span> </span><span class="NLM_article-title">Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span><span class="refDoi"> DOI: 10.1007/s10637-011-9682-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1007%2Fs10637-011-9682-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21590367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVyksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1493-1500&author=J.+Samolauthor=M.+Ransonauthor=E.+Scottauthor=E.+Macphersonauthor=J.+Carmichaelauthor=A.+Thomasauthor=J.+Cassidy&title=Safety+and+tolerability+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor%2C+olaparib+%28AZD2281%29+in+combination+with+topotecan+for+the+treatment+of+patients+with+advanced+solid+tumors%3A+a+phase+I+study&doi=10.1007%2Fs10637-011-9682-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study</span></div><div class="casAuthors">Samol, Jens; Ranson, Malcolm; Scott, Edwina; MacPherson, Euan; Carmichael, James; Thomas, Anne; Cassidy, James</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1493-1500</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: The aim of this phase I study was to det. the safety and tolerability and to establish the max. tolerated dose (MTD) of orally administered olaparib (AZD2281) in combination with topotecan in patients with advanced solid tumors.  Patients and methods: Patients aged ≥18 years with histol. or cytol. diagnosed advanced solid tumors for whom no suitable effective therapy exists were included.  Patients in four cohorts received topotecan (0.5 mg/m2/day × 3 days or 1.0 mg/m2/day × 3 days) i.v. in combination with oral olaparib 50, 100 or 200 mg bid for six cycles.  The primary objectives were to det. the safety and tolerability and to establish the MTD of olaparib in combination with topotecan.  Results: Twenty-one patients were enrolled and 19 received treatment.  Dose-limiting toxicities were neutropenia and thrombocytopenia.  The MTD was established as topotecan 1.0 mg/m2/day × 3 days plus olaparib 100 mg bid.  The most common adverse events (AEs) included fatigue and gastrointestinal events.  There was an olaparib and topotecan dose-related increase in neutropenia which was dose limiting.  Conclusions: Further development of olaparib and topotecan in combination was not explored due to dose-limiting hematol. AEs and the resulting sub-therapeutic MTD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpxE-e7YyctbVg90H21EOLACvtfcHk0li3CoewQSPe0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVyksrg%253D&md5=4c51e093fa061c437d15e29add6f7fb0</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs10637-011-9682-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-011-9682-9%26sid%3Dliteratum%253Aachs%26aulast%3DSamol%26aufirst%3DJ.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DE.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DCassidy%26aufirst%3DJ.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%252C%2520olaparib%2520%2528AZD2281%2529%2520in%2520combination%2520with%2520topotecan%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520advanced%2520solid%2520tumors%253A%2520a%2520phase%2520I%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D1493%26epage%3D1500%26doi%3D10.1007%2Fs10637-011-9682-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Khan, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greystoke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGown, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorncroft, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margison, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Califano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span> </span><span class="NLM_article-title">A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">750</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span><span class="refDoi"> DOI: 10.1038/bjc.2011.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fbjc.2011.8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21326243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXis1eit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2011&pages=750-755&author=O.+A.+Khanauthor=M.+Goreauthor=P.+Loriganauthor=J.+Stoneauthor=A.+Greystokeauthor=W.+Burkeauthor=J.+Carmichaelauthor=A.+J.+Watsonauthor=G.+McGownauthor=M.+Thorncroftauthor=G.+P.+Margisonauthor=R.+Califanoauthor=J.+Larkinauthor=S.+Wellmanauthor=M.+R.+Middleton&title=A+phase+I+study+of+the+safety+and+tolerability+of+olaparib+%28AZD2281%2C+KU0059436%29+and+dacarbazine+in+patients+with+advanced+solid+tumours&doi=10.1038%2Fbjc.2011.8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours</span></div><div class="casAuthors">Khan, O. A.; Gore, M.; Lorigan, P.; Stone, J.; Greystoke, A.; Burke, W.; Carmichael, J.; Watson, A. J.; McGown, G.; Thorncroft, M.; Margison, G. P.; Califano, R.; Larkin, J.; Wellman, S.; Middleton, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">750-755</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Poly ADP-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the base excision repair pathway (BER).  The PARP inhibition can be directly cytotoxic to tumor cells and augments the anti-tumor effects of DNA-damaging agents.  This study evaluated the optimally tolerated dose of olaparib (4-(3--4-fluorophenyl) methyl-1(2H)-one; AZD2281, KU0059436), a potent PARP inhibitor, with dacarbazine and assessed safety, toxicity, clin. pharmacokinetics and efficacy of combination treatment.  Patients and methods: Patients with advanced cancer received olaparib (20-200 mg PO) on days 1-7 with dacarbazine (600-800 mg m-2 IV) on day 1 (cycle 2, day 2) of a 21-day cycle.  An expansion cohort of chemonaive melanoma patients was treated at an optimally tolerated dose.  The BER enzyme, methylpurine-DNA glycosylase and its substrate 7-methylguanine were quantified in peripheral blood mononuclear cells.  Results: The optimal combination to proceed to phase II was defined as 100 mg bd olaparib with 600 mg m-2 dacarbazine.  Dose-limiting toxicities were neutropaenia and thrombocytopaenia.  There were two partial responses, both in patients with melanoma.  Conclusion: This study defined a tolerable dose of olaparib in combination with dacarbazine, but there were no responses in chemonaive melanoma patients, demonstrating no clin. advantage over single-agent dacarbazine at these doses.  British Journal of Cancer (2011) 104, 750-755; doi:10.1038/bjc.2011.8 www.bjcancer.com. Published online 15 Feb. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVFcr3GWBYlrVg90H21EOLACvtfcHk0li3CoewQSPe0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXis1eit7Y%253D&md5=0fb6c9543b41feafac4821e5c55c5d30</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.8%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DO.%2BA.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DGreystoke%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DW.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DA.%2BJ.%26aulast%3DMcGown%26aufirst%3DG.%26aulast%3DThorncroft%26aufirst%3DM.%26aulast%3DMargison%26aufirst%3DG.%2BP.%26aulast%3DCalifano%26aufirst%3DR.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DWellman%26aufirst%3DS.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520the%2520safety%2520and%2520tolerability%2520of%2520olaparib%2520%2528AZD2281%252C%2520KU0059436%2529%2520and%2520dacarbazine%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D104%26spage%3D750%26epage%3D755%26doi%3D10.1038%2Fbjc.2011.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Dent, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemons, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildiers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span> </span><span class="NLM_article-title">Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">R88</span><span class="refDoi"> DOI: 10.1186/bcr3484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2Fbcr3484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24063698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=R88&author=R.+A.+Dentauthor=G.+J.+Lindemanauthor=M.+Clemonsauthor=H.+Wildiersauthor=A.+Chanauthor=N.+J.+McCarthyauthor=C.+F.+Singerauthor=E.+S.+Loweauthor=C.+L.+Watkinsauthor=J.+Carmichael&title=Phase+I+trial+of+the+oral+PARP+inhibitor+olaparib+in+combination+with+paclitaxel+for+first-+or+second-line+treatment+of+patients+with+metastatic+triple-negative+breast+cancer&doi=10.1186%2Fbcr3484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer</span></div><div class="casAuthors">Dent, Rebecca A.; Lindeman, Geoffrey J.; Clemons, Mark; Wildiers, Hans; Chan, Arlene; McCarthy, Nicole J.; Singer, Christian F.; Lowe, Elizabeth S.; Watkins, Claire L.; Carmichael, James</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">R88/1-R88/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-neg. breast cancer (mTNBC).  Methods: Eligible patients who had received ≤1 prior cytotoxic regimen for mTNBC were treated with olaparib 200 mg bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle.  Dose modifications in a large proportion of patients due to neutropenia resulted in enrollment of a second cohort of patients who, if they experienced grade ≥2 neutropenia in cycle 1, received granulocyte-colony stimulating factor, which was continued prophylactically in subsequent cycles.  All patients had measurable disease; tumor responses were evaluated according to RECIST (version 1.0).  Results: Nineteen patients (cohort 1, n = 9; cohort 2, n = 10) received treatment; 15 had received prior taxane chemotherapy.  The most frequent adverse events were diarrhea (n = 12, 63%), nausea (n = 11, 58%) and neutropenia (n = 11, 58%).  Seven neutropenia events were reported in cohort 1 (four grade ≥3) and four in cohort 2 (two grade ≥3, including one event of febrile neutropenia).  The median (range) dose intensity of paclitaxel was 57% (26 to 100%) in cohort 1 and 73% (29 to 100%) in cohort 2.  Seven patients (37%) had a confirmed partial response; one patient remains on olaparib monotherapy without progression.  Conclusions: The combination of olaparib and weekly paclitaxel was complicated by a significant clin. interaction, with higher-than-expected rates of neutropenia despite secondary prophylaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFe81cPlJPr7Vg90H21EOLACvtfcHk0lj0bsL1NZHgGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb8%253D&md5=1da261cd68c4d2cd5b8eb222dc61db9c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1186%2Fbcr3484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr3484%26sid%3Dliteratum%253Aachs%26aulast%3DDent%26aufirst%3DR.%2BA.%26aulast%3DLindeman%26aufirst%3DG.%2BJ.%26aulast%3DClemons%26aufirst%3DM.%26aulast%3DWildiers%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DMcCarthy%26aufirst%3DN.%2BJ.%26aulast%3DSinger%26aufirst%3DC.%2BF.%26aulast%3DLowe%26aufirst%3DE.%2BS.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DCarmichael%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520oral%2520PARP%2520inhibitor%2520olaparib%2520in%2520combination%2520with%2520paclitaxel%2520for%2520first-%2520or%2520second-line%2520treatment%2520of%2520patients%2520with%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2013%26volume%3D15%26spage%3DR88%26doi%3D10.1186%2Fbcr3484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Rivkin, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iriarte, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiseman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, J.</span><span> </span><span class="NLM_article-title">Phase Ib/II with expansion of patients at the MTD study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">5527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=5527&issue=15+suppl&author=S.+E.+Rivkinauthor=D.+Iriarteauthor=H.+Sloanauthor=C.+Wisemanauthor=J.+Moon&title=Phase+Ib%2FII+with+expansion+of+patients+at+the+MTD+study+of+olaparib+plus+weekly+%28metronomic%29+carboplatin+and+paclitaxel+in+relapsed+ovarian+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRivkin%26aufirst%3DS.%2BE.%26aulast%3DIriarte%26aufirst%3DD.%26aulast%3DSloan%26aufirst%3DH.%26aulast%3DWiseman%26aufirst%3DC.%26aulast%3DMoon%26aufirst%3DJ.%26atitle%3DPhase%2520Ib%252FII%2520with%2520expansion%2520of%2520patients%2520at%2520the%2520MTD%2520study%2520of%2520olaparib%2520plus%2520weekly%2520%2528metronomic%2529%2520carboplatin%2520and%2520paclitaxel%2520in%2520relapsed%2520ovarian%2520cancer%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15%2520suppl%26spage%3D5527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Oza, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cibula, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benzaquen, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathijssen, R. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonke, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spacek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vuylsteke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirte, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plante, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmalfeldt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowbottom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchakov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span> </span><span class="NLM_article-title">Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">5001</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=5001&issue=15+suppl&author=A.+M.+Ozaauthor=D.+Cibulaauthor=A.+O.+Benzaquenauthor=C.+J.+Pooleauthor=R.+H.+J.+Mathijssenauthor=G.+S.+Sonkeauthor=N.+Colomboauthor=J.+Spacekauthor=P.+Vuylstekeauthor=H.+W.+Hirteauthor=S.+Mahnerauthor=M.+Planteauthor=B.+Schmalfeldtauthor=H.+Mackayauthor=J.+Rowbottomauthor=I.+Tchakovauthor=M.+Friedlander&title=Olaparib+plus+paclitaxel+plus+carboplatin+%28P%2FC%29+followed+by+olaparib+maintenance+treatment+in+patients+%28pts%29+with+platinum-sensitive+recurrent+serous+ovarian+cancer+%28PSR+SOC%29%3A+A+randomized%2C+open-label+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOza%26aufirst%3DA.%2BM.%26aulast%3DCibula%26aufirst%3DD.%26aulast%3DBenzaquen%26aufirst%3DA.%2BO.%26aulast%3DPoole%26aufirst%3DC.%2BJ.%26aulast%3DMathijssen%26aufirst%3DR.%2BH.%2BJ.%26aulast%3DSonke%26aufirst%3DG.%2BS.%26aulast%3DColombo%26aufirst%3DN.%26aulast%3DSpacek%26aufirst%3DJ.%26aulast%3DVuylsteke%26aufirst%3DP.%26aulast%3DHirte%26aufirst%3DH.%2BW.%26aulast%3DMahner%26aufirst%3DS.%26aulast%3DPlante%26aufirst%3DM.%26aulast%3DSchmalfeldt%26aufirst%3DB.%26aulast%3DMackay%26aufirst%3DH.%26aulast%3DRowbottom%26aufirst%3DJ.%26aulast%3DTchakov%26aufirst%3DI.%26aulast%3DFriedlander%26aufirst%3DM.%26atitle%3DOlaparib%2520plus%2520paclitaxel%2520plus%2520carboplatin%2520%2528P%252FC%2529%2520followed%2520by%2520olaparib%2520maintenance%2520treatment%2520in%2520patients%2520%2528pts%2529%2520with%2520platinum-sensitive%2520recurrent%2520serous%2520ovarian%2520cancer%2520%2528PSR%2520SOC%2529%253A%2520A%2520randomized%252C%2520open-label%2520phase%2520II%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26issue%3D15%2520suppl%26spage%3D5001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zang, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowbottom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. H.</span><span> </span><span class="NLM_article-title">Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">3858</span><span class="NLM_x">–</span> <span class="NLM_lpage">3865</span><span class="refDoi"> DOI: 10.1200/JCO.2014.60.0320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2014.60.0320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26282658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVylsbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3858-3865&author=Y.+J.+Bangauthor=S.+A.+Imauthor=K.+W.+Leeauthor=J.+Y.+Choauthor=E.+K.+Songauthor=K.+H.+Leeauthor=Y.+H.+Kimauthor=J.+O.+Parkauthor=H.+G.+Chunauthor=D.+Y.+Zangauthor=A.+Fieldingauthor=J.+Rowbottomauthor=D.+Hodgsonauthor=M.+J.+O%E2%80%99Connorauthor=X.+Yinauthor=W.+H.+Kim&title=Randomized%2C+double-blind+phase+II+trial+with+prospective+classification+by+ATM+protein+level+to+evaluate+the+efficacy+and+tolerability+of+olaparib+plus+paclitaxel+in+patients+with+recurrent+or+metastatic+gastric+cancer&doi=10.1200%2FJCO.2014.60.0320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, double-blind phase II trial with prospective classification by ATM Protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer</span></div><div class="casAuthors">Bang, Yung-Jue; Im, Seock-Ah; Lee, Keun-Wook; Cho, Jae Yong; Song, Eun-Kee; Lee, Kyung Hee; Kim, Yeul Hong; Park, Joon Oh; Chun, Hoo Geun; Zang, Dae Young; Fielding, Anitra; Rowbottom, Jacqui; Hodgson, Darren; O'Connor, Mark J.; Yin, Xiaolu; Kim, Woo Ho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3858-3865</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Gastric cancer cell lines, particularly those with low levels of ataxia telangiectasia mutated (ATM), a key activator of DNA damage response, are sensitive to the poly (ADP-ribose) polymerase inhibitor olaparib.  We compared the efficacy of olaparib plus paclitaxel (olaparib/paclitaxel) with paclitaxel alone in patients with recurrent or metastatic gastric cancer and assessed whether low ATM expression is predictive of improved clin. outcome for olaparib/paclitaxel.  Patients and Methods In this phase II, double-blind study (Study 39;NCT01063517), patients were randomly assigned to oral olaparib 100 mg twice per day (tablets) plus paclitaxel (80 mg/m2 per day i.v. on days 1, 8, and 15 of every 28-day cycle) or placebo plus paclitaxel (placebo/paclitaxel), followed by maintenance monotherapy with olaparib (200 mg twice per day) or placebo.  The study population was enriched to 50% for patients with low or undetectable ATM levels (ATMlow).  Primary end point was progression-free survival (PFS).  Results One hundred twenty-three of 124 randomly assigned patients received treatment (olaparib/paclitaxel, n = 61; placebo/paclitaxel, n = 62).  The screening prevalence of ATMlow patients was 14%.  Olaparib/paclitaxel did not lead to a significant improvement in PFS vs. placebo/paclitaxel (overall population: hazard ratio [HR], 0.80; median PFS, 3.91 v 3.55 mo, resp.; ATMlow population: HR, 0.74; median PFS, 5.29 v 3.68 mo, resp.).  However, olaparib/paclitaxel significantly improved overall survival (OS) vs. placebo/paclitaxel in both the overall population (HR, 0.56; 80% CI, 0.41 to 0.75; P =.005; median OS, 13.1 v 8.3 mo, resp.) and the ATMlow population (HR, 0.35; 80% CI, 0.22 to 0.56; P =.002; median OS, not reached v 8.2 mo, resp.).  Olaparib/paclitaxel was generally well tolerated, with no unexpected safety findings.  Conclusion Olaparib/paclitaxel is active in the treatment of patients with metastatic gastric cancer, with a greater OS benefit in ATMlow patients.  A phase III trial in this setting is under way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZFw6yUXmfdbVg90H21EOLACvtfcHk0lj0bsL1NZHgGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVylsbbI&md5=366f633d5c7e010d6037289029879c7b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.60.0320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.60.0320%26sid%3Dliteratum%253Aachs%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DCho%26aufirst%3DJ.%2BY.%26aulast%3DSong%26aufirst%3DE.%2BK.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DChun%26aufirst%3DH.%2BG.%26aulast%3DZang%26aufirst%3DD.%2BY.%26aulast%3DFielding%26aufirst%3DA.%26aulast%3DRowbottom%26aufirst%3DJ.%26aulast%3DHodgson%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DW.%2BH.%26atitle%3DRandomized%252C%2520double-blind%2520phase%2520II%2520trial%2520with%2520prospective%2520classification%2520by%2520ATM%2520protein%2520level%2520to%2520evaluate%2520the%2520efficacy%2520and%2520tolerability%2520of%2520olaparib%2520plus%2520paclitaxel%2520in%2520patients%2520with%2520recurrent%2520or%2520metastatic%2520gastric%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D3858%26epage%3D3865%26doi%3D10.1200%2FJCO.2014.60.0320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Dean, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pwint, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodege-Kunwar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">468</span><span class="NLM_x">–</span> <span class="NLM_lpage">474</span><span class="refDoi"> DOI: 10.1038/bjc.2011.555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fbjc.2011.555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22223088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslGgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=468-474&author=E.+Deanauthor=M.+R.+Middletonauthor=T.+Pwintauthor=H.+Swaislandauthor=J.+Carmichaelauthor=P.+Goodege-Kunwarauthor=M.+Ranson&title=Phase+I+study+to+assess+the+safety+and+tolerability+of+olaparib+in+combination+with+bevacizumab+in+patients+with+advanced+solid+tumours&doi=10.1038%2Fbjc.2011.555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours</span></div><div class="casAuthors">Dean, E.; Middleton, M. R.; Pwint, T.; Swaisland, H.; Carmichael, J.; Goodege-Kunwar, P.; Ranson, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">468-474</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Olaparib (AZD2281) is a potent oral poly(ADP-ribose) polymerase inhibitor with anti-tumor activity and acceptable toxicity as monotherapy in patients with BRCA-deficient cancers.  The vascular endothelial growth factor receptor inhibitor bevacizumab has been incorporated into std. of care with chemotherapy in various tumors.  This phase I study established the safety, tolerability and clin. pharmacokinetics of olaparib alone and in combination with bevacizumab.  Methods: Patients with advanced solid tumors received increasing doses of continuous oral olaparib (100, 200 and 400 mg b.i.d. capsule formulation) in combination with bevacizumab (10 mg kg-1 i.v. q2w).  Results: In all, 12 patients enrolled and received treatment.  The most common adverse events (AEs) related to olaparib were grade 1/2 nausea and fatigue.  No haematol. parameters were reported as AEs.  No serious AEs related to olaparib or dose-limiting toxicities (DLTs) were reported.  Three patients discontinued due to AEs, two patients discontinued both olaparib and bevacizumab and one patient discontinued olaparib.  Five patients received combination treatment for over 6 mo.  There was no evidence that bevacizumab affected olaparib.  Conclusion: The combination of olaparib 400 mg b.i.d. with bevacizumab 10 mg kg-1 q2w was generally well tolerated with no DLTs.  This combination could be considered for future clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-ENSDqg38vLVg90H21EOLACvtfcHk0ligithLghMLDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslGgu7c%253D&md5=fdfa3b274b116623c067c1fbe52f8cc8</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.555%26sid%3Dliteratum%253Aachs%26aulast%3DDean%26aufirst%3DE.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DPwint%26aufirst%3DT.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DGoodege-Kunwar%26aufirst%3DP.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DPhase%2520I%2520study%2520to%2520assess%2520the%2520safety%2520and%2520tolerability%2520of%2520olaparib%2520in%2520combination%2520with%2520bevacizumab%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D106%26spage%3D468%26epage%3D474%26doi%3D10.1038%2Fbjc.2011.555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Liu, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buss, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyburski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U. A.</span><span> </span><span class="NLM_article-title">A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2972</span><span class="NLM_x">–</span> <span class="NLM_lpage">2978</span><span class="refDoi"> DOI: 10.1016/j.ejca.2013.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.ejca.2013.05.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=2972-2978&author=J.+F.+Liuauthor=S.+M.+Tolaneyauthor=M.+Birrerauthor=G.+F.+Flemingauthor=M.+K.+Bussauthor=S.+E.+Dahlbergauthor=H.+Leeauthor=C.+Whalenauthor=K.+Tyburskiauthor=E.+Winerauthor=P.+Ivyauthor=U.+A.+Matulonis&title=A+Phase+1+trial+of+the+poly%28ADP-ribose%29+polymerase+inhibitor+olaparib+%28AZD2281%29+in+combination+with+the+anti-angiogenic+cediranib+%28AZD2171%29+in+recurrent+epithelial+ovarian+or+triple-negative+breast+cancer&doi=10.1016%2Fj.ejca.2013.05.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2013.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2013.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DBirrer%26aufirst%3DM.%26aulast%3DFleming%26aufirst%3DG.%2BF.%26aulast%3DBuss%26aufirst%3DM.%2BK.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DWhalen%26aufirst%3DC.%26aulast%3DTyburski%26aufirst%3DK.%26aulast%3DWiner%26aufirst%3DE.%26aulast%3DIvy%26aufirst%3DP.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26atitle%3DA%2520Phase%25201%2520trial%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520olaparib%2520%2528AZD2281%2529%2520in%2520combination%2520with%2520the%2520anti-angiogenic%2520cediranib%2520%2528AZD2171%2529%2520in%2520recurrent%2520epithelial%2520ovarian%2520or%2520triple-negative%2520breast%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3D2972%26epage%3D2978%26doi%3D10.1016%2Fj.ejca.2013.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Liu, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckanovich, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buss, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nattam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurteau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obermayer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U. A.</span><span> </span><span class="NLM_article-title">Combination of cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1207</span><span class="NLM_x">–</span> <span class="NLM_lpage">1214</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70391-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS1470-2045%2814%2970391-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25218906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KltbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1207-1214&author=J.+F.+Liuauthor=W.+T.+Barryauthor=M.+Birrerauthor=J.+M.+Leeauthor=R.+J.+Buckanovichauthor=G.+F.+Flemingauthor=B.+Rimelauthor=M.+K.+Bussauthor=S.+Nattamauthor=J.+Hurteauauthor=W.+Luoauthor=P.+Quyauthor=C.+Whalenauthor=L.+Obermayerauthor=H.+Leeauthor=E.+P.+Winerauthor=E.+C.+Kohnauthor=S.+P.+Ivyauthor=U.+A.+Matulonis&title=Combination+of+cediranib+and+olaparib+versus+olaparib+alone+for+women+with+recurrent+platinum-sensitive+ovarian+cancer%3A+a+randomised+phase+2+study&doi=10.1016%2FS1470-2045%2814%2970391-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study</span></div><div class="casAuthors">Liu, Joyce F.; Barry, William T.; Birrer, Michael; Lee, Jung-Min; Buckanovich, Ronald J.; Fleming, Gini F.; Rimel, B. J.; Buss, Mary K.; Nattam, Sreenivasa; Hurteau, Jean; Luo, Weixiu; Quy, Philippa; Whalen, Christin; Obermayer, Lisa; Lee, Hang; Winer, Eric P.; Kohn, Elise C.; Ivy, S. Percy; Matulonis, Ursula A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1207-1214</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3.  Both oral agents have antitumor activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial.  We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer.  In our randomized, open-label, phase 2 study, we recruited women (aged ≥18 years) who had measurable platinum-sensitive, relapsed, high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer, or those with deleterious germline BRCA1/2 mutations from nine participating US academic medical centers.  We randomly allocated participants (1:1) according to permuted blocks, stratified by germline BRCA status and previous anti-angiogenic therapy, to receive olaparib capsules 400 mg twice daily or the combination at the recommended phase 2 dose of cediranib 30 mg daily and olaparib capsules 200 mg twice daily.  The primary endpoint was progression-free survival analyzed in the intention-to-treat population.  The phase 2 trial is no longer accruing patients.  An interim anal. was conducted in Nov., 2013, after 50% of expected events had occurred and efficacy results were unmasked.  The primary anal. was performed on March 31, 2014, after 47 events (66% of those expected).  The trial is registered with ClinicalTrials.gov, no. NCT01116648.  Between Oct 26, 2011, and June 3, 2013, we randomly allocated 46 women to receive olaparib alone and 44 to receive the combination of olaparib and cediranib.  Median PFS was 17·7 mo (95% CI 14·7-not reached) for the women treated with cediranib plus olaparib compared with 9·0 mo (95% CI 5·7-16·5) for those treated with olaparib monotherapy (hazard ratio 0·42, 95% CI 0·23-0·76; p=0·005).  Grade 3 and 4 adverse events were more common with combination therapy than with monotherapy, including fatigue (12 patients in the cediranib plus olaparib group vs five patients in the olaparib monotherapy group), diarrhea (ten vs none), and hypertension (18 vs none).  Cediranib plus olaparib seems to improve PFS in women with recurrent platinum-sensitive high-grade serous or endometrioid ovarian cancer, and warrants study in a phase 3 trial.  The side-effect profile suggests such investigations should include assessments of quality of life and patient-reported outcomes to understand the effects of a continuing oral regimen with that of intermittent chemotherapy.  American Recovery and Reinvestment Act grant from the National Institutes of Health (NIH) (3 U01 CA062490-16S2); Intramural Program of the Center for Cancer Research; and the Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBLud-6qAoe7Vg90H21EOLACvtfcHk0ligithLghMLDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KltbfP&md5=4ee05408050567ae01591fe319beaebd</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970391-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970391-2%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DBarry%26aufirst%3DW.%2BT.%26aulast%3DBirrer%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DBuckanovich%26aufirst%3DR.%2BJ.%26aulast%3DFleming%26aufirst%3DG.%2BF.%26aulast%3DRimel%26aufirst%3DB.%26aulast%3DBuss%26aufirst%3DM.%2BK.%26aulast%3DNattam%26aufirst%3DS.%26aulast%3DHurteau%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DQuy%26aufirst%3DP.%26aulast%3DWhalen%26aufirst%3DC.%26aulast%3DObermayer%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26atitle%3DCombination%2520of%2520cediranib%2520and%2520olaparib%2520versus%2520olaparib%2520alone%2520for%2520women%2520with%2520recurrent%2520platinum-sensitive%2520ovarian%2520cancer%253A%2520a%2520randomised%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1207%26epage%3D1214%26doi%3D10.1016%2FS1470-2045%2814%2970391-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Matulonis, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulf, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birrer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westin, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell-McGuinn, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasonde, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aghajanian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span> </span><span class="NLM_article-title">Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">2510</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=2510&issue=15+suppl&author=U.+Matulonisauthor=G.+M.+Wulfauthor=M.+J.+Birrerauthor=S.+N.+Westinauthor=P.+Quyauthor=K.+M.+Bell-McGuinnauthor=B.+Lasondeauthor=C.+Whalenauthor=C.+Aghajanianauthor=D.+B.+Solitauthor=G.+B.+Millsauthor=L.+Cantleyauthor=E.+P.+Winer&title=Phase+I+study+of+oral+BKM120+and+oral+olaparib+for+high-grade+serous+ovarian+cancer+%28HGSC%29+or+triple-negative+breast+cancer+%28TNBC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatulonis%26aufirst%3DU.%26aulast%3DWulf%26aufirst%3DG.%2BM.%26aulast%3DBirrer%26aufirst%3DM.%2BJ.%26aulast%3DWestin%26aufirst%3DS.%2BN.%26aulast%3DQuy%26aufirst%3DP.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DLasonde%26aufirst%3DB.%26aulast%3DWhalen%26aufirst%3DC.%26aulast%3DAghajanian%26aufirst%3DC.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DCantley%26aufirst%3DL.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26atitle%3DPhase%2520I%2520study%2520of%2520oral%2520BKM120%2520and%2520oral%2520olaparib%2520for%2520high-grade%2520serous%2520ovarian%2520cancer%2520%2528HGSC%2529%2520or%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15%2520suppl%26spage%3D2510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Campelo, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcereny, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina-Vila, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cajal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez-Ronco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span> </span><span class="NLM_article-title">Phase Ib study to evaluate the efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) patients</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">8079</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8079&issue=15+suppl&author=R.+G.+Campeloauthor=E.+Felipauthor=B.+Massutiauthor=M.+Majemauthor=E.+Carcerenyauthor=R.+Palmeroauthor=M.+A.+Molina-Vilaauthor=R.+Cajalauthor=M.+Sanchez-Roncoauthor=R.+Rosell&title=Phase+Ib+study+to+evaluate+the+efficacy+and+tolerability+of+olaparib+%28AZD2281%29+plus+gefitinib+in+patients+%28P%29+with+epidermal+growth+factor+receptor+%28EGFR%29+mutation+positive+advanced+non-small+cell+lung+cancer+%28NSCLC%29+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampelo%26aufirst%3DR.%2BG.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DMolina-Vila%26aufirst%3DM.%2BA.%26aulast%3DCajal%26aufirst%3DR.%26aulast%3DSanchez-Ronco%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DPhase%2520Ib%2520study%2520to%2520evaluate%2520the%2520efficacy%2520and%2520tolerability%2520of%2520olaparib%2520%2528AZD2281%2529%2520plus%2520gefitinib%2520in%2520patients%2520%2528P%2529%2520with%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520mutation%2520positive%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15%2520suppl%26spage%3D8079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Tang, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, We. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span> </span><span class="NLM_article-title">BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1653</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-1653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1538-7445.AM2015-1653" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1653&author=Z.+Y.+Tangauthor=Y.+Liuauthor=Q.+Zhenauthor=B.+Renauthor=H.+X.+Wangauthor=Z.+Y.+Shiauthor=We.+F.+Gongauthor=Y.+Liuauthor=X.+Wangauthor=Y.+J.+Gaoauthor=F.+L.+Yuauthor=Y.+Y.+Wuauthor=B.+Jiangauthor=X.+B.+Sunauthor=M.+Weiauthor=C.+Y.+Zhouauthor=L.+S.+Luoauthor=Z.+X.+Liauthor=J.+Y.+Yuauthor=J.+Zhaoauthor=J.+Wangauthor=L.+Wang&title=BGB-290%3A+A+highly+potent+and+specific+PARP1%2F2+inhibitor+potentiates+anti-tumor+activity+of+chemotherapeutics+in+patient+biopsy+derived+SCLC+models&doi=10.1158%2F1538-7445.AM2015-1653"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-1653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-1653%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.%2BY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhen%26aufirst%3DQ.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%2BX.%26aulast%3DShi%26aufirst%3DZ.%2BY.%26aulast%3DGong%26aufirst%3DWe.%2BF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DY.%2BJ.%26aulast%3DYu%26aufirst%3DF.%2BL.%26aulast%3DWu%26aufirst%3DY.%2BY.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DX.%2BB.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DC.%2BY.%26aulast%3DLuo%26aufirst%3DL.%2BS.%26aulast%3DLi%26aufirst%3DZ.%2BX.%26aulast%3DYu%26aufirst%3DJ.%2BY.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DBGB-290%253A%2520A%2520highly%2520potent%2520and%2520specific%2520PARP1%252F2%2520inhibitor%2520potentiates%2520anti-tumor%2520activity%2520of%2520chemotherapeutics%2520in%2520patient%2520biopsy%2520derived%2520SCLC%2520models%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D1653%26doi%3D10.1158%2F1538-7445.AM2015-1653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Russo, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgan, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slusher, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tofilon, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camphausen, K.</span><span> </span><span class="NLM_article-title">In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">607</span><span class="NLM_x">–</span> <span class="NLM_lpage">612</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-08-2079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=19147766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFeqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=607-612&author=A.+L.+Russoauthor=H.+C.+Kwonauthor=W.+E.+Burganauthor=D.+Carterauthor=K.+Beamauthor=X.+Weizhengauthor=J.+Zhangauthor=B.+S.+Slusherauthor=A.+Chakravartiauthor=P.+J.+Tofilonauthor=K.+Camphausen&title=In+vitro+and+in+vivo+radiosensitization+of+glioblastoma+cells+by+the+poly+%28ADP-ribose%29+polymerase+inhibitor+E7016&doi=10.1158%2F1078-0432.CCR-08-2079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016</span></div><div class="casAuthors">Russo, Andrea L.; Kwon, Hyuk-Chan; Burgan, William E.; Carter, Donna; Beam, Katie; Weizheng, Xu; Zhang, Jie; Slusher, Barbara S.; Chakravarti, Arnab; Tofilon, Philip J.; Camphausen, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">607-612</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Poly (ADP-ribose) polymerase (PARP) inhibitors are undergoing clin. evaluation for cancer therapy.  Because PARP inhibition has been shown to enhance tumor cell sensitivity to radiation, we investigated the in vitro and in vivo effects of the novel PARP inhibitor E7016.  Exptl. Design: The effect of E7016 on the in vitro radiosensitivity of tumor cell lines was evaluated using clonogenic survival.  DNA damage and repair were measured using γH2AX foci and neutral comet assay.  Mitotic catastrophe was detd. by immunostaining. Tumor growth delay was evaluated in mice for the effect of E7016 on in vivo (U251) tumor radiosensitivity.  Results: Cell lines exposed to E7016 preirradn. yielded an increase in radiosensitivity with dose enhancement factors at a surviving fraction of 0.1 from 1.4 to 1.7.  To assess DNA double-strand breaks repair, γH2AX measured at 24 h postirradn. had significantly more foci per cell in the E7016/irradn. group vs. irradn. alone.  Neutral comet assay further suggested unrepaired double-strand breaks with significantly greater DNA damage at 6 h postirradn. in the combination group vs. irradn. alone.  Mitotic catastrophe staining revealed a significantly greater no. of cells staining pos. at 24 h postirradn. in the combination group.  In vivo, mice treated with E7016/irradn./temozolomide had an addnl. growth delay of six days compared with the combination of temozolomide and irradn.  Conclusions: These results indicate that E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair.  Moreover, enhanced growth delay with the addn. of E7016 to temozolomide and radiotherapy in a glioma mouse model suggests a potential role for this drug in the treatment of glioblastoma multiforme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwKbKGkXjVd7Vg90H21EOLACvtfcHk0ljqX5zwRMchtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFeqsg%253D%253D&md5=6b7d2b4cc62ff752d8402788fae07d71</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2079%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DA.%2BL.%26aulast%3DKwon%26aufirst%3DH.%2BC.%26aulast%3DBurgan%26aufirst%3DW.%2BE.%26aulast%3DCarter%26aufirst%3DD.%26aulast%3DBeam%26aufirst%3DK.%26aulast%3DWeizheng%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DChakravarti%26aufirst%3DA.%26aulast%3DTofilon%26aufirst%3DP.%2BJ.%26aulast%3DCamphausen%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520radiosensitization%2520of%2520glioblastoma%2520cells%2520by%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520E7016%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D607%26epage%3D612%26doi%3D10.1158%2F1078-0432.CCR-08-2079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span> </span><span class="NLM_article-title">Trapping poly(ADP-Ribose) polymerase</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span><span class="refDoi"> DOI: 10.1124/jpet.114.222448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1124%2Fjpet.114.222448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25758918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=446-457&author=Y.+Shenauthor=M.+Aoyagi-Scharberauthor=B.+Wang&title=Trapping+poly%28ADP-Ribose%29+polymerase&doi=10.1124%2Fjpet.114.222448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Shen, Yuqiao; Aoyagi-Scharber, Mika; Wang, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">446-457</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the sites of DNA damage.  The PARP enzyme-inhibitor complex "locks" onto damaged DNA and prevents DNA repair, replication, and transcription, leading to cell death.  Several clin.-stage PARP inhibitors, including veliparib, rucaparib, olaparib, niraparib, and talazoparib, have been evaluated for their PARP-trapping activity.  Although they display similar capacity to inhibit PARP catalytic activity, their relative abilities to trap PARP differ by several orders of magnitude, with the ability to trap PARP closely correlating with each drug's ability to kill cancer cells.  In this article, we review the available data on mol. interactions between these clin.-stage PARP inhibitors and PARP proteins, and discuss how their biol. differences might be explained by the trapping mechanism.  We also discuss how to use the PARP-trapping mechanism to guide the development of PARP inhibitors as a new class of cancer therapy, both for single-agent and combination treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf7H8kc8UmXLVg90H21EOLACvtfcHk0li5dQx0nKQ72g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D&md5=36ceb95db0a63ab9ce002906df555482</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.222448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.222448%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DTrapping%2520poly%2528ADP-Ribose%2529%2520polymerase%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D446%26epage%3D457%26doi%3D10.1124%2Fjpet.114.222448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Scott, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swisher, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">Poly (ADP-ribose) polymerase inhibitors: recent advances and future development</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1397</span><span class="NLM_x">–</span> <span class="NLM_lpage">1406</span><span class="refDoi"> DOI: 10.1200/JCO.2014.58.8848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2014.58.8848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25779564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVaqtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1397-1406&author=C.+L.+Scottauthor=E.+M.+Swisherauthor=S.+H.+Kaufmann&title=Poly+%28ADP-ribose%29+polymerase+inhibitors%3A+recent+advances+and+future+development&doi=10.1200%2FJCO.2014.58.8848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Poly (ADP-Ribose) polymerase inhibitors: recent advances and future development</span></div><div class="casAuthors">Scott, Clare L.; Swisher, Elizabeth M.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1397-1406</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, esp. relapsed platinum-sensitive high-grade serous disease.  Consistent with preclin. studies, ovarian cancers and a no. of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive.  However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors.  We provide an update on PARP inhibitor clin. development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowf5pO-7WPjrVg90H21EOLACvtfcHk0li5dQx0nKQ72g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVaqtL%252FM&md5=a9a1668a322c4a2e099a1fd9891a15da</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.58.8848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.58.8848%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DC.%2BL.%26aulast%3DSwisher%26aufirst%3DE.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DPoly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitors%253A%2520recent%2520advances%2520and%2520future%2520development%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1397%26epage%3D1406%26doi%3D10.1200%2FJCO.2014.58.8848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Trapping of PARP1 and PARP-2 by clinical PARP inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5588</span><span class="NLM_x">–</span> <span class="NLM_lpage">5599</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-2753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-12-2753" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=5588-5599&author=J.+Muraiauthor=S.+Y.+Huangauthor=B.+B.+Dasauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+H.+Doroshowauthor=J.+Jiauthor=S.+Takedaauthor=Y.+Pommier&title=Trapping+of+PARP1+and+PARP-2+by+clinical+PARP+inhibitors&doi=10.1158%2F0008-5472.CAN-12-2753"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-2753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-2753%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DDas%26aufirst%3DB.%2BB.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DTrapping%2520of%2520PARP1%2520and%2520PARP-2%2520by%2520clinical%2520PARP%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D5588%26epage%3D5599%26doi%3D10.1158%2F0008-5472.CAN-12-2753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.MCT-13-0803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24356813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=433-443&author=J.+Muraiauthor=S.+Y.+Huangauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+Jiauthor=S.+Takedaauthor=J.+Morrisauthor=B.+Teicherauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Stereospecific+PARP+trapping+by+BMN+673+and+comparison+with+olaparib+and+rucaparib&doi=10.1158%2F1535-7163.MCT-13-0803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-Yin N.; Renaud, Amelie; Zhang, Yiping; Ji, Jiuping; Takeda, Shunichi; Morris, Joel; Teicher, Beverly; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks.  We recently reported that several PARP inhibitors have an addnl. cytotoxic mechanism by trapping PARP-DNA complexes, and that both olaparib and niraparib act as PARP poisons at pharmacol. concns.  Therefore, we have proposed that PARP inhibitors should be evaluated based both on catalytic PARP inhibition and PARP-DNA trapping.  Here, we evaluated the novel PARP inhibitor, BMN 673, and compared its effects on PARP1 and PARP2 with two other clin. PARP inhibitors, olaparib and rucaparib, using biochem. and cellular assays in genetically modified chicken DT40 and human cancer cell lines.  Although BMN 673, olaparib, and rucaparib are comparable at inhibiting PARP catalytic activity, BMN 673 is ∼100-fold more potent at trapping PARP-DNA complexes and more cytotoxic as single agent than olaparib, whereas olaparib and rucaparib show similar potencies in trapping PARP-DNA complexes.  The high level of resistance of PARP1/2 knockout cells to BMN 673 demonstrates the selectivity of BMN 673 for PARP1/2.  Moreover, we show that BMN 673 acts by stereospecific binding to PARP1 as its enantiomer, LT674, is several orders of magnitude less efficient.  BMN 673 is also approx. 100-fold more cytotoxic than olaparib and rucaparib in combination with the DNA alkylating agents Me methane sulfonate (MMS) and temozolomide.  Our study demonstrates that BMN 673 is the most potent clin. PARP inhibitor tested to date with the highest efficiency at trapping PARP-DNA complexes.  Mol Cancer Ther; 13(2); 433-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8p5YTwAneh7Vg90H21EOLACvtfcHk0li5dQx0nKQ72g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D&md5=513c544d1cb5c2203e7696af76201afd</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0803%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DStereospecific%2520PARP%2520trapping%2520by%2520BMN%2520673%2520and%2520comparison%2520with%2520olaparib%2520and%2520rucaparib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D433%26epage%3D443%26doi%3D10.1158%2F1535-7163.MCT-13-0803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or Temozolomide based on PARP trapping versus catalytic inhibition</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">408</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span><span class="refDoi"> DOI: 10.1124/jpet.113.210146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1124%2Fjpet.113.210146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24650937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2crlslWjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2014&pages=408-416&author=J.+Muraiauthor=Y.+Zhangauthor=J.+Morrisauthor=J.+Jiauthor=S.+Takedaauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Rationale+for+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitors+in+combination+therapy+with+camptothecins+or+Temozolomide+based+on+PARP+trapping+versus+catalytic+inhibition&doi=10.1124%2Fjpet.113.210146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition</span></div><div class="casAuthors">Murai Junko; Zhang Yiping; Morris Joel; Ji Jiuping; Takeda Shunichi; Doroshow James H; Pommier Yves</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">408-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We recently showed that poly(ADP-ribose) polymerase (PARP) inhibitors exert their cytotoxicity primarily by trapping PARP-DNA complexes in addition to their NAD(+)-competitive catalytic inhibitory mechanism.  PARP trapping is drug-specific, with olaparib exhibiting a greater ability than veliparib, whereas both compounds are potent catalytic PARP inhibitors.  Here, we evaluated the combination of olaparib or veliparib with therapeutically relevant DNA-targeted drugs, including the topoisomerase I inhibitor camptothecin, the alkylating agent temozolomide, the cross-linking agent cisplatin, and the topoisomerase II inhibitor etoposide at the cellular and molecular levels.  We determined PARP-DNA trapping and catalytic PARP inhibition in genetically modified chicken lymphoma DT40, human prostate DU145, and glioblastoma SF295 cancer cells.  For camptothecin, both PARP inhibitors showed highly synergistic effects due to catalytic PARP inhibition, indicating the value of combining either veliparib or olaparib with topoisomerase I inhibitors.  On the other hand, for temozolomide, PARP trapping was critical in addition to catalytic inhibition, consistent with the fact that olaparib was more effective than veliparib in combination with temozolomide.  For cisplatin and etoposide, olaparib only showed no or a weak combination effect, which is consistent with the lack of involvement of PARP in the repair of cisplatin- and etoposide-induced lesions.  Hence, we conclude that catalytic PARP inhibitors are highly effective in combination with camptothecins, whereas PARP inhibitors capable of PARP trapping are more effective with temozolomide.  Our study provides insights in combination treatment rationales for different PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxMGPopCndgkbxh97K6Vt6fW6udTcc2eZGoUC-2IyGirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crlslWjtQ%253D%253D&md5=c3614636b019d2543975a5d677535c18</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.210146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.210146%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DRationale%2520for%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitors%2520in%2520combination%2520therapy%2520with%2520camptothecins%2520or%2520Temozolomide%2520based%2520on%2520PARP%2520trapping%2520versus%2520catalytic%2520inhibition%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D349%26spage%3D408%26epage%3D416%26doi%3D10.1124%2Fjpet.113.210146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Hopkins, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiGiammarino, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panchal, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilsbacher, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolarik, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maag, D.</span><span> </span><span class="NLM_article-title">Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1477</span><span class="refDoi"> DOI: 10.1158/1541-7786.MCR-15-0191-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1541-7786.MCR-15-0191-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26217019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVajsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=1465-1477&author=T.+A.+Hopkinsauthor=Y.+Shiauthor=L.+E.+Rodriguezauthor=L.+R.+Solomonauthor=C.+K.+Donawhoauthor=E.+L.+DiGiammarinoauthor=S.+C.+Panchalauthor=J.+L.+Wilsbacherauthor=W.+Gaoauthor=A.+M.+Olsonauthor=D.+F.+Stolarikauthor=D.+J.+Osterlingauthor=E.+F.+Johnsonauthor=D.+Maag&title=Mechanistic+dissection+of+PARP1+trapping+and+the+impact+on+in+vivo+tolerability+and+efficacy+of+PARP+inhibitors&doi=10.1158%2F1541-7786.MCR-15-0191-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors</span></div><div class="casAuthors">Hopkins, Todd A.; Shi, Yan; Rodriguez, Luis E.; Solomon, Larry R.; Donawho, Cherrie K.; DiGiammarino, Enrico L.; Panchal, Sanjay C.; Wilsbacher, Julie L.; Gao, Wenqing; Olson, Amanda M.; Stolarik, DeAnne F.; Osterling, Donald J.; Johnson, Eric F.; Maag, David</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1465-1477</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerases (PARP1, -2, and -3) play important roles in DNA damage repair.  As such, a no. of PARP inhibitors are undergoing clin. development as anticancer therapies, particularly in tumors with DNA repair deficits and in combination with DNA-damaging agents.  Preclin. evidence indicates that PARP inhibitors potentiate the cytotoxicity of DNA alkylating agents.  It has been proposed that a major mechanism underlying this activity is the allosteric trapping of PARP1 at DNA single-strand breaks during base excision repair; however, direct evidence of allostery has not been reported.  Here the data reveal that veliparib, olaparib, niraparib, and talazoparib (BMN-673) potentiate the cytotoxicity of alkylating agents.  Consistent with this, all four drugs possess PARP1 trapping activity.  Using biochem. and cellular approaches, we directly probe the trapping mechanism for an allosteric component.  These studies indicate that trapping is due to catalytic inhibition and not allostery.  The potency of PARP inhibitors with respect to trapping and catalytic inhibition is linearly correlated in biochem. systems but is nonlinear in cells.  High-content imaging of γH2Ax levels suggests that this is attributable to differential potentiation of DNA damage in cells.  Trapping potency is inversely correlated with tolerability when PARP inhibitors are combined with temozolomide in mouse xenograft studies.  As a result, PARP inhibitors with dramatically different trapping potencies elicit comparable in vivo efficacy at max. tolerated doses.  Finally, the impact of trapping on tolerability and efficacy is likely to be context specific.  Implications: Understanding the context-specific relationships of trapping and catalytic inhibition with both tolerability and efficacy will aid in detg. the suitability of a PARP inhibitor for inclusion in a particular clin. regimen.  Mol Cancer Res; 13(11); 1465-77. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ITvwLl2ImbVg90H21EOLACvtfcHk0lixwXhiGZtJvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVajsbbK&md5=3a7f11c925a3d51a6a87ca5f01ff5e5c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-15-0191-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-15-0191-T%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DT.%2BA.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DRodriguez%26aufirst%3DL.%2BE.%26aulast%3DSolomon%26aufirst%3DL.%2BR.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DDiGiammarino%26aufirst%3DE.%2BL.%26aulast%3DPanchal%26aufirst%3DS.%2BC.%26aulast%3DWilsbacher%26aufirst%3DJ.%2BL.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DStolarik%26aufirst%3DD.%2BF.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMaag%26aufirst%3DD.%26atitle%3DMechanistic%2520dissection%2520of%2520PARP1%2520trapping%2520and%2520the%2520impact%2520on%2520in%2520vivo%2520tolerability%2520and%2520efficacy%2520of%2520PARP%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2015%26volume%3D13%26spage%3D1465%26epage%3D1477%26doi%3D10.1158%2F1541-7786.MCR-15-0191-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Montoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouliot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, G. M.</span><span> </span><span class="NLM_article-title">Resistance to PARP-inhibitors in cancer therapy</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="refDoi"> DOI: 10.3389/fphar.2013.00018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.3389%2Ffphar.2013.00018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23450678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC3svitlKjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=18&author=A.+Montoniauthor=M.+Robuauthor=E.+Pouliotauthor=G.+M.+Shah&title=Resistance+to+PARP-inhibitors+in+cancer+therapy&doi=10.3389%2Ffphar.2013.00018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to PARP-Inhibitors in Cancer Therapy</span></div><div class="casAuthors">Montoni Alicia; Robu Mihaela; Pouliot Emilie; Shah Girish M</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) family of proteins have shown promising results in preclinical studies and clinical trials as a monotherapy or in combination therapy for some cancers.  Thus, usage of PARP-inhibitors (PARPi) in cancer therapy is bound to increase with time, but resistance of cancer cells to PARPi is also beginning to be observed.  Here we review different known and potential mechanisms by which: (i) PARPi kill cancer cells; and (ii) cancer cells develop resistance to PARPi.  Understanding the lethality caused by PARPi and the countermeasures deployed by cancers cells to survive PARPi will help us rationalize the use of this new class of drugs in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR47jIB3kLCzdK0qsdY6Nc1fW6udTcc2eZdJL793rTgo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svitlKjug%253D%253D&md5=b76a0ac9d0cbb311bc2429f231fb2d14</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2013.00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2013.00018%26sid%3Dliteratum%253Aachs%26aulast%3DMontoni%26aufirst%3DA.%26aulast%3DRobu%26aufirst%3DM.%26aulast%3DPouliot%26aufirst%3DE.%26aulast%3DShah%26aufirst%3DG.%2BM.%26atitle%3DResistance%2520to%2520PARP-inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DFront.%2520Pharmacol.%26date%3D2013%26volume%3D4%26spage%3D18%26doi%3D10.3389%2Ffphar.2013.00018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Ceccaldi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amunugama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Primack, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petalcorin, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstantinopoulos, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elledge, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusufzai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, A. D.</span><span> </span><span class="NLM_article-title">Homologous-recombination-deficient tumours are dependent on Polθ -mediated repair</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">518</span><span class="NLM_x">, </span> <span class="NLM_fpage">258</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1038/nature14184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnature14184" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=518&publication_year=2015&pages=258-262&author=R.+Ceccaldiauthor=J.+C.+Liuauthor=R.+Amunugamaauthor=I.+Hajduauthor=B.+Primackauthor=M.+I.+Petalcorinauthor=K.+W.+O%E2%80%99Connorauthor=P.+A.+Konstantinopoulosauthor=S.+J.+Elledgeauthor=S.+J.+Boultonauthor=T.+Yusufzaiauthor=A.+D.+D%E2%80%99Andrea&title=Homologous-recombination-deficient+tumours+are+dependent+on+Pol%CE%B8+-mediated+repair&doi=10.1038%2Fnature14184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnature14184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14184%26sid%3Dliteratum%253Aachs%26aulast%3DCeccaldi%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%2BC.%26aulast%3DAmunugama%26aufirst%3DR.%26aulast%3DHajdu%26aufirst%3DI.%26aulast%3DPrimack%26aufirst%3DB.%26aulast%3DPetalcorin%26aufirst%3DM.%2BI.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DK.%2BW.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26aulast%3DBoulton%26aufirst%3DS.%2BJ.%26aulast%3DYusufzai%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26atitle%3DHomologous-recombination-deficient%2520tumours%2520are%2520dependent%2520on%2520Pol%25CE%25B8%2520-mediated%2520repair%26jtitle%3DNature%26date%3D2015%26volume%3D518%26spage%3D258%26epage%3D262%26doi%3D10.1038%2Fnature14184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Mateos-Gomez, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazzerini-Denchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sfeir, A.</span><span> </span><span class="NLM_article-title">Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">518</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span><span class="refDoi"> DOI: 10.1038/nature14157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnature14157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25642960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=518&publication_year=2015&pages=254-257&author=P.+A.+Mateos-Gomezauthor=F.+Gongauthor=N.+Nairauthor=K.+M.+Millerauthor=E.+Lazzerini-Denchiauthor=A.+Sfeir&title=Mammalian+polymerase+%CE%B8+promotes+alternative+NHEJ+and+suppresses+recombination&doi=10.1038%2Fnature14157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination</span></div><div class="casAuthors">Mateos-Gomez, Pedro A.; Gong, Fade; Nair, Nidhi; Miller, Kyle M.; Lazzerini-Denchi, Eros; Sfeir, Agnel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">518</span>
        (<span class="NLM_cas:issue">7538</span>),
    <span class="NLM_cas:pages">254-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The alternative non-homologous end-joining (NHEJ) machinery facilitates several genomic rearrangements, some of which can lead to cellular transformation.  This error-prone repair pathway is triggered upon telomere de-protection to promote the formation of deleterious chromosome end-to-end fusions.  Using next-generation sequencing technol., here we show that repair by alternative NHEJ yields non-TTAGGG nucleotide insertions at fusion breakpoints of dysfunctional telomeres.  Investigating the enzymic activity responsible for the random insertions enabled us to identify polymerase theta (Polθ; encoded by Polq in mice) as a crucial alternative NHEJ factor in mammalian cells.  Polq inhibition suppresses alternative NHEJ at dysfunctional telomeres, and hinders chromosomal translocations at non-telomeric loci.  In addn., we found that loss of Polq in mice results in increased rates of homol.-directed repair, evident by recombination of dysfunctional telomeres and accumulation of RAD51 at double-stranded breaks.  Lastly, we show that depletion of Polθ has a synergistic effect on cell survival in the absence of BRCA genes, suggesting that the inhibition of this mutagenic polymerase represents a valid therapeutic avenue for tumors carrying mutations in homol.-directed repair genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjmeOnljJKrVg90H21EOLACvtfcHk0lixwXhiGZtJvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGisbs%253D&md5=253d05f40b619712fbe7be371a7e64ea</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnature14157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14157%26sid%3Dliteratum%253Aachs%26aulast%3DMateos-Gomez%26aufirst%3DP.%2BA.%26aulast%3DGong%26aufirst%3DF.%26aulast%3DNair%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26aulast%3DLazzerini-Denchi%26aufirst%3DE.%26aulast%3DSfeir%26aufirst%3DA.%26atitle%3DMammalian%2520polymerase%2520%25CE%25B8%2520promotes%2520alternative%2520NHEJ%2520and%2520suppresses%2520recombination%26jtitle%3DNature%26date%3D2015%26volume%3D518%26spage%3D254%26epage%3D257%26doi%3D10.1038%2Fnature14157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Rodriguez, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majuelos-Melguizo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martí Martín-Consuegra, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz de Almodovar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López-Rivas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javier Oliver, F.</span><span> </span><span class="NLM_article-title">Deciphering the insights of poly(ADP-ribosylation) in tumor progression</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">697</span><span class="refDoi"> DOI: 10.1002/med.21339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1002%2Fmed.21339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25604534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWgs7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=678-697&author=M.+I.+Rodriguezauthor=J.+Majuelos-Melguizoauthor=J.+M.+Mart%C3%AD+Mart%C3%ADn-Consuegraauthor=M.+Ruiz+de+Almodovarauthor=A.+L%C3%B3pez-Rivasauthor=F.+Javier+Oliver&title=Deciphering+the+insights+of+poly%28ADP-ribosylation%29+in+tumor+progression&doi=10.1002%2Fmed.21339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Deciphering the Insights of Poly(ADP-Ribosylation) in Tumor Progression</span></div><div class="casAuthors">Rodriguez, Maria Isabel; Majuelos-Melguizo, Jara; Marti Martin-Consuegra, Juan Manuel; Ruiz de Almodovar, Mariano; Lopez-Rivas, Abelardo; Javier Oliver, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">678-697</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Poly (ADP-ribose) polymerase (PARP) inhibitors are particularly efficient against tumors with defects in the homologous recombination repair pathway.  Nonetheless poly(ADP-ribosylation) (PARylation) modulates prometastasic activities and adaptation of tumor to a hostile microenvironment.  Modulation of metastasis-promoting traits is possible through the alteration of key transcription factors involved in the regulation of the hypoxic response, the recruitment of new vessels (or angiogenesis), and the stimulation of epithelial to mesenchymal transition (EMT).  In this review, we summarized some of the findings that focalize on PARP-1's action on tumor aggressiveness, suggesting new therapeutic opportunities against an assembly of tumors not necessarily bearing DNA repair defects.  Metastasis accounts for the vast majority of mortality derived from solid cancer.  PARP-1 is an active player in tumor adaptation to metastasis and PARP inhibitors, recognized as promising therapeutic agents against homologous recombination deficient tumors, has novel properties responsible for the antimetastatic actions in different tumor settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8fqnWODbvJbVg90H21EOLACvtfcHk0lgpmGBMFl_q3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWgs7nI&md5=58436604c3b03d5741f15fd65d1bd541</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fmed.21339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21339%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DM.%2BI.%26aulast%3DMajuelos-Melguizo%26aufirst%3DJ.%26aulast%3DMart%25C3%25AD%2BMart%25C3%25ADn-Consuegra%26aufirst%3DJ.%2BM.%26aulast%3DRuiz%2Bde%2BAlmodovar%26aufirst%3DM.%26aulast%3DL%25C3%25B3pez-Rivas%26aufirst%3DA.%26aulast%3DJavier%2BOliver%26aufirst%3DF.%26atitle%3DDeciphering%2520the%2520insights%2520of%2520poly%2528ADP-ribosylation%2529%2520in%2520tumor%2520progression%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2015%26volume%3D35%26spage%3D678%26epage%3D697%26doi%3D10.1002%2Fmed.21339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Ryu, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, W. L.</span><span> </span><span class="NLM_article-title">New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2453</span><span class="NLM_x">–</span> <span class="NLM_lpage">2481</span><span class="refDoi"> DOI: 10.1021/cr5004248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr5004248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1yrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=2453-2481&author=K.+W.+Ryuauthor=D.+S.+Kimauthor=W.+L.+Kraus&title=New+facets+in+the+regulation+of+gene+expression+by+ADP-ribosylation+and+poly%28ADP-ribose%29+polymerases&doi=10.1021%2Fcr5004248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases</span></div><div class="casAuthors">Ryu, Keun Woo; Kim, Dae-Seok; Kraus, W. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2453-2481</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the role of poly(ADP-ribose) polymerases (PARPs) and ADP-ribosylation in gene regulation, with a particular emphasis on the role of PARPs in RNA biol.  Topics include: the PARP family; NAD+ metab. and PARP-1; PARP-1 in gene regulation including chromatin modulation, transcription regulation, and non-coding RNA regulation; and PARP-1 in ribosome biogenesis, stress response, circadian rhythm, and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF0xfFz6hkG7Vg90H21EOLACvtfcHk0lgpmGBMFl_q3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1yrsg%253D%253D&md5=496f79e7a373d08dd7c116fe9d74eb1a</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fcr5004248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr5004248%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DK.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DNew%2520facets%2520in%2520the%2520regulation%2520of%2520gene%2520expression%2520by%2520ADP-ribosylation%2520and%2520poly%2528ADP-ribose%2529%2520polymerases%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26spage%3D2453%26epage%3D2481%26doi%3D10.1021%2Fcr5004248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Rodríguez, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peralta-Leal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Valle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Vargas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Flores, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majuelos-Melguizo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Herreros, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodríguez-Manzaneque, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Moral, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Almodóvar, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, F. J.</span><span> </span><span class="NLM_article-title">PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation</span> <span class="citation_source-journal">PLoS Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1003531</span><span class="refDoi"> DOI: 10.1371/journal.pgen.1003531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1371%2Fjournal.pgen.1003531" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=e1003531&author=M.+I.+Rodr%C3%ADguezauthor=A.+Peralta-Lealauthor=F.+O%E2%80%99Valleauthor=J.+M.+Rodriguez-Vargasauthor=A.+Gonzalez-Floresauthor=J.+Majuelos-Melguizoauthor=L.+L%C3%B3pezauthor=S.+Serranoauthor=A.+G.+de+Herrerosauthor=J.+C.+Rodr%C3%ADguez-Manzanequeauthor=R.+Fern%C3%A1ndezauthor=R.+G.+Del+Moralauthor=J.+M.+de+Almod%C3%B3varauthor=F.+J.+Oliver&title=PARP-1+regulates+metastatic+melanoma+through+modulation+of+vimentin-induced+malignant+transformation&doi=10.1371%2Fjournal.pgen.1003531"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1003531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1003531%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DM.%2BI.%26aulast%3DPeralta-Leal%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Valle%26aufirst%3DF.%26aulast%3DRodriguez-Vargas%26aufirst%3DJ.%2BM.%26aulast%3DGonzalez-Flores%26aufirst%3DA.%26aulast%3DMajuelos-Melguizo%26aufirst%3DJ.%26aulast%3DL%25C3%25B3pez%26aufirst%3DL.%26aulast%3DSerrano%26aufirst%3DS.%26aulast%3Dde%2BHerreros%26aufirst%3DA.%2BG.%26aulast%3DRodr%25C3%25ADguez-Manzaneque%26aufirst%3DJ.%2BC.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DR.%26aulast%3DDel%2BMoral%26aufirst%3DR.%2BG.%26aulast%3Dde%2BAlmod%25C3%25B3var%26aufirst%3DJ.%2BM.%26aulast%3DOliver%26aufirst%3DF.%2BJ.%26atitle%3DPARP-1%2520regulates%2520metastatic%2520melanoma%2520through%2520modulation%2520of%2520vimentin-induced%2520malignant%2520transformation%26jtitle%3DPLoS%2520Genet.%26date%3D2013%26volume%3D9%26spage%3De1003531%26doi%3D10.1371%2Fjournal.pgen.1003531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Kraus, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hottiger, M. O.</span><span> </span><span class="NLM_article-title">PARP-1 and gene regulation: progress and puzzles</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1109</span><span class="NLM_x">–</span> <span class="NLM_lpage">1123</span><span class="refDoi"> DOI: 10.1016/j.mam.2013.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.mam.2013.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23357755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisVygsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=1109-1123&author=W.+L.+Krausauthor=M.+O.+Hottiger&title=PARP-1+and+gene+regulation%3A+progress+and+puzzles&doi=10.1016%2Fj.mam.2013.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-1 and gene regulation: Progress and puzzles</span></div><div class="casAuthors">Kraus, W. Lee; Hottiger, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1109-1123</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1), also referred to as ADP-ribosyltransferase Diphtheria toxin-like 1 (ARTD1), is an abundant nuclear protein that plays key roles in a variety of nuclear processes, including the regulation of transcription.  PARP-1 possesses an intrinsic enzymic activity that catalyzes the transfer of ADP-ribose (ADPR) units from NAD (NAD+) onto target gene regulatory proteins, thereby modulating their activities.  Although great strides have been made in the past decade in deciphering the seemingly opposing and varied roles of PARP-1 in gene regulation, many puzzles remain.  In this review, the authors discuss the current state of understanding in this area, esp. how PARP-1 interfaces with various components of gene regulatory pathways (e.g., the basal transcription machinery, DNA-binding transcription factors, coregulators, chromatin remodeling, histone modifications, and DNA methylation).  In addn., the authors discuss some gene-specific, cell type-specific, and cell state-specific effects of PARP-1 on gene regulation, which might contribute to its biol. functions.  Finally, the authors review some of the recent progress targeting PARPs using chem. inhibitors, some of which may alter PARP-1-dependent gene regulatory programs to promote therapeutic outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCLrQy2hgJJ7Vg90H21EOLACvtfcHk0lgpmGBMFl_q3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisVygsL8%253D&md5=96d89c9df4cd49011e55d3a9e6407747</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2013.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2013.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DW.%2BL.%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26atitle%3DPARP-1%2520and%2520gene%2520regulation%253A%2520progress%2520and%2520puzzles%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26spage%3D1109%26epage%3D1123%26doi%3D10.1016%2Fj.mam.2013.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Gunderson, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, K. N.</span><span> </span><span class="NLM_article-title">BRACAnalysis CDx as a companion diagnostic tool for Lynparza</span> <span class="citation_source-journal">Expert Rev. Mol. Diagn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">–</span> <span class="NLM_lpage">1116</span><span class="refDoi"> DOI: 10.1586/14737159.2015.1078238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1586%2F14737159.2015.1078238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26292709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCms7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=1111-1116&author=C.+C.+Gundersonauthor=K.+N.+Moore&title=BRACAnalysis+CDx+as+a+companion+diagnostic+tool+for+Lynparza&doi=10.1586%2F14737159.2015.1078238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">BRACAnalysis CDx as a companion diagnostic tool for Lynparza</span></div><div class="casAuthors">Gunderson, Camille C.; Moore, Kathleen N.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Molecular Diagnostics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1111-1116</span>CODEN:
                <span class="NLM_cas:coden">ERMDCW</span>;
        ISSN:<span class="NLM_cas:issn">1473-7159</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Lynparza and its companion diagnostic test, BRACAnal. were approved by the US FDA in Dec. 2014 for recurrent ovarian cancer in women with a germline BRCA mutation.  Women with a deleterious BRCA mutation are predisposed to ovarian cancer due to deficient homologous recombination repair.  Inhibition of the PARP enzyme forces use of an alternate error-prone pathway for repair; PARP trapping is another mechanism utilized that blocks cellular replication by trapping inactivated PARP onto single-stranded DNA breaks.  Although many companion diagnostic kits are already in use in oncol., BRACAnaylsis is unique in several ways including comprehensive BRCA gene germline profiling, availability to all women with ovarian cancer and implications for family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRE8_moU7kr7Vg90H21EOLACvtfcHk0ljLzRKFTjIrMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCms7vO&md5=a83b033abe4fc9f9e10e56989869abae</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1586%2F14737159.2015.1078238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737159.2015.1078238%26sid%3Dliteratum%253Aachs%26aulast%3DGunderson%26aufirst%3DC.%2BC.%26aulast%3DMoore%26aufirst%3DK.%2BN.%26atitle%3DBRACAnalysis%2520CDx%2520as%2520a%2520companion%2520diagnostic%2520tool%2520for%2520Lynparza%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Diagn.%26date%3D2015%26volume%3D15%26spage%3D1111%26epage%3D1116%26doi%3D10.1586%2F14737159.2015.1078238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">The Cancer Genome Atlas Research Network</span>. <span> </span><span class="NLM_article-title">Integrated genomic analyses of ovarian carcinoma</span>.  <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">474</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span>.<span class="refDoi"> DOI: 10.1038/nature10166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnature10166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21720365" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=474&publication_year=2011&pages=609-615&author=The+Cancer+Genome+Atlas+Research+Network&title=Integrated+genomic+analyses+of+ovarian+carcinoma&doi=10.1038%2Fnature10166"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnature10166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10166%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DIntegrated%2520genomic%2520analyses%2520of%2520ovarian%2520carcinoma%26jtitle%3DNature%26date%3D2011%26volume%3D474%26spage%3D609%26epage%3D615%26doi%3D10.1038%2Fnature10166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Ihnen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">zu Eulenburg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolarova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manivong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalukya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winterhoff, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velculescu, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Udar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänicke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konecny, G. E.</span><span> </span><span class="NLM_article-title">Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1002</span><span class="NLM_x">–</span> <span class="NLM_lpage">1015</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.MCT-12-0813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23729402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1002-1015&author=M.+Ihnenauthor=C.+zu+Eulenburgauthor=T.+Kolarovaauthor=J.+Qiauthor=K.+Manivongauthor=M.+Chalukyaauthor=J.+Deringauthor=L.+Andersonauthor=C.+Gintherauthor=A.+Meuterauthor=B.+Winterhoffauthor=S.+Jonesauthor=V.+E.+Velculescuauthor=N.+Venkatesanauthor=H.+M.+Rongauthor=S.+Dandekarauthor=N.+Udarauthor=F.+J%C3%A4nickeauthor=G.+Losauthor=D.+J.+Slamonauthor=G.+E.+Konecny&title=Therapeutic+potential+of+the+poly%28ADP-ribose%29+polymerase+inhibitor+rucaparib+for+the+treatment+of+sporadic+human+ovarian+cancer&doi=10.1158%2F1535-7163.MCT-12-0813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer</span></div><div class="casAuthors">Ihnen, Maike; zu Eulenburg, Christine; Kolarova, Teodora; Qi, Jing Wei; Manivong, Kanthinh; Chalukya, Meenal; Dering, Judy; Anderson, Lee; Ginther, Charles; Meuter, Alexandra; Winterhoff, Boris; Jones, Sian; Velculescu, Victor E.; Venkatesan, Natarajan; Rong, Hong-Mei; Dandekar, Sugandha; Udar, Nitin; Jaenicke, Fritz; Los, Gerrit; Slamon, Dennis J.; Konecny, Gottfried E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1002-1015</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer.  We studied the growth inhibitory effects of rucaparib in a panel of 39 ovarian cancer cell lines that were each characterized for mutation and methylation status of BRCA1/2, baseline gene expression signatures, copy no. variations of selected genes, PTEN status, and sensitivity to platinum-based chemotherapy.  To study interactions with chemotherapy, we used multiple drug effect analyses and assessed apoptosis, DNA fragmentation, and γH2AX formation.  Concn.-dependent antiproliferative effects of rucaparib were seen in 26 of 39 (67%) cell lines and were not restricted to cell lines with BRCA1/2 mutations.  Low expression of other genes involved in homologous repair (e.g., BCCIP, BRCC3, ATM, RAD51L1), amplification of AURKA or EMSY, and response to platinum-based chemotherapy was assocd. with sensitivity to rucaparib.  Drug interactions with rucaparib were synergistic for topotecan, synergistic, or additive for carboplatin, doxorubicin or paclitaxel, and additive for gemcitabine.  Synergy was most pronounced when rucaparib was combined with topotecan, which resulted in enhanced apoptosis, DNA fragmentation, and γH2AX formation.  Importantly, rucaparib potentiated chemotherapy independent of its activity as a single agent.  PARP inhibition may be a useful therapeutic strategy for a wider range of ovarian cancers bearing deficiencies in the homologous recombination pathway other than just BRCA1/2 mutations.  These results support further clin. evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe7ZBqJCdQobVg90H21EOLACvtfcHk0ljLzRKFTjIrMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOltLw%253D&md5=4eaf35f1dd521263a63ee6cb5a8c8ad6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0813%26sid%3Dliteratum%253Aachs%26aulast%3DIhnen%26aufirst%3DM.%26aulast%3Dzu%2BEulenburg%26aufirst%3DC.%26aulast%3DKolarova%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DManivong%26aufirst%3DK.%26aulast%3DChalukya%26aufirst%3DM.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DMeuter%26aufirst%3DA.%26aulast%3DWinterhoff%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DVenkatesan%26aufirst%3DN.%26aulast%3DRong%26aufirst%3DH.%2BM.%26aulast%3DDandekar%26aufirst%3DS.%26aulast%3DUdar%26aufirst%3DN.%26aulast%3DJ%25C3%25A4nicke%26aufirst%3DF.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26atitle%3DTherapeutic%2520potential%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520rucaparib%2520for%2520the%2520treatment%2520of%2520sporadic%2520human%2520ovarian%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1002%26epage%3D1015%26doi%3D10.1158%2F1535-7163.MCT-12-0813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Hartlerode, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D. O.</span><span> </span><span class="NLM_article-title">Recruitment and activation of the ATM kinase in the absence of DNA-damage sensors</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">736</span><span class="NLM_x">–</span> <span class="NLM_lpage">743</span><span class="refDoi"> DOI: 10.1038/nsmb.3072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnsmb.3072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26280532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSnt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=736-743&author=A.+J.+Hartlerodeauthor=M.+J.+Morganauthor=Y.+Wuauthor=J.+Buisauthor=D.+O.+Ferguson&title=Recruitment+and+activation+of+the+ATM+kinase+in+the+absence+of+DNA-damage+sensors&doi=10.1038%2Fnsmb.3072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Recruitment and activation of the ATM kinase in the absence of DNA-damage sensors</span></div><div class="casAuthors">Hartlerode, Andrea J.; Morgan, Mary J.; Wu, Yipin; Buis, Jeffrey; Ferguson, David O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">736-743</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Two kinases, ATM and DNA-PKcs, control rapid responses to DNA double-strand breaks (DSBs).  The paradigm for ATM control is recruitment and activation by the Mre11-Rad50-NBS1 (MRN) sensor complex, whereas DNA-PKcs requires the sensor Ku (Ku70-Ku80).  Using mouse cells contg. targeted mutant alleles of Mre11 (Mre11a) and/or Ku70 (Xrcc6), together with pharmacol. kinase inhibition, we demonstrate that ATM can be activated by DSBs in the absence of MRN.  When MRN is deficient, DNA-PKcs efficiently substitutes for ATM in facilitating local chromatin responses.  In the absence of both MRN and Ku, ATM is recruited to chromatin, where it phosphorylates H2AX and triggers the G2-M cell-cycle checkpoint, but the DNA-repair functions of MRN are not restored.  These results suggest that, in contrast to straightforward recruitment and activation by MRN, a complex interplay between sensors has a substantial role in ATM control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8KcjWkVKNabVg90H21EOLACvtfcHk0lgOA1KBU_aOxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSnt7%252FP&md5=bafce12c6277489b19437f07684ebc71</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3072%26sid%3Dliteratum%253Aachs%26aulast%3DHartlerode%26aufirst%3DA.%2BJ.%26aulast%3DMorgan%26aufirst%3DM.%2BJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBuis%26aufirst%3DJ.%26aulast%3DFerguson%26aufirst%3DD.%2BO.%26atitle%3DRecruitment%2520and%2520activation%2520of%2520the%2520ATM%2520kinase%2520in%2520the%2520absence%2520of%2520DNA-damage%2520sensors%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D736%26epage%3D743%26doi%3D10.1038%2Fnsmb.3072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Stracker, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrini, J. H.</span><span> </span><span class="NLM_article-title">The MRE11 complex: starting from the ends</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1038/nrm3047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnrm3047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21252998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlSgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=90-103&author=T.+H.+Strackerauthor=J.+H.+Petrini&title=The+MRE11+complex%3A+starting+from+the+ends&doi=10.1038%2Fnrm3047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">The MRE11 complex: Starting from the ends</span></div><div class="casAuthors">Stracker, Travis H.; Petrini, John H. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The maintenance of genome stability depends on the DNA damage response (DDR), which is a functional network comprising signal transduction, cell cycle regulation and DNA repair.  The metab. of DNA double-strand breaks governed by the DDR is important for preventing genomic alterations and sporadic cancers, and hereditary defects in this response cause debilitating human pathologies, including developmental defects and cancer.  The MRE11 complex, composed of the meiotic recombination 11 (MRE11), RAD50 and Nijmegen breakage syndrome 1 (NBS1; also known as nibrin) proteins is central to the DDR, and recent insights into its structure and function were gained from in vitro structural anal. and studies of animal models in which the DDR response is deficient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosXAZgukwJ-7Vg90H21EOLACvtfcHk0lgOA1KBU_aOxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlSgsA%253D%253D&md5=bbdf62041cb087a33f1c3d023282a11b</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnrm3047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3047%26sid%3Dliteratum%253Aachs%26aulast%3DStracker%26aufirst%3DT.%2BH.%26aulast%3DPetrini%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520MRE11%2520complex%253A%2520starting%2520from%2520the%2520ends%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2011%26volume%3D12%26spage%3D90%26epage%3D103%26doi%3D10.1038%2Fnrm3047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Oplustilova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolanin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistrik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korinkova, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simkova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouchal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenobel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartkova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span> </span><span class="NLM_article-title">Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3837</span><span class="NLM_x">–</span> <span class="NLM_lpage">3850</span><span class="refDoi"> DOI: 10.4161/cc.22026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.4161%2Fcc.22026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=3837-3850&author=L.+Oplustilovaauthor=K.+Wolaninauthor=M.+Mistrikauthor=G.+Korinkovaauthor=D.+Simkovaauthor=J.+Bouchalauthor=R.+Lenobelauthor=J.+Bartkovaauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=J.+Lukasauthor=J.+Bartek&title=Evaluation+of+candidate+biomarkers+to+predict+cancer+cell+sensitivity+or+resistance+to+PARP-1+inhibitor+treatment&doi=10.4161%2Fcc.22026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.4161%2Fcc.22026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.22026%26sid%3Dliteratum%253Aachs%26aulast%3DOplustilova%26aufirst%3DL.%26aulast%3DWolanin%26aufirst%3DK.%26aulast%3DMistrik%26aufirst%3DM.%26aulast%3DKorinkova%26aufirst%3DG.%26aulast%3DSimkova%26aufirst%3DD.%26aulast%3DBouchal%26aufirst%3DJ.%26aulast%3DLenobel%26aufirst%3DR.%26aulast%3DBartkova%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DLukas%26aufirst%3DJ.%26aulast%3DBartek%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520candidate%2520biomarkers%2520to%2520predict%2520cancer%2520cell%2520sensitivity%2520or%2520resistance%2520to%2520PARP-1%2520inhibitor%2520treatment%26jtitle%3DCell%2520Cycle%26date%3D2012%26volume%3D11%26spage%3D3837%26epage%3D3850%26doi%3D10.4161%2Fcc.22026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Koppensteiner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samartzis, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noske, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Teichman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dedes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwerder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imesch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikenberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stucki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dedes, K. J.</span><span> </span><span class="NLM_article-title">Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e100041</span><span class="refDoi"> DOI: 10.1371/journal.pone.0100041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1371%2Fjournal.pone.0100041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e100041&author=R.+Koppensteinerauthor=E.+P.+Samartzisauthor=A.+Noskeauthor=A.+von+Teichmanauthor=I.+Dedesauthor=M.+Gwerderauthor=P.+Imeschauthor=K.+Ikenbergauthor=H.+Mochauthor=D.+Finkauthor=M.+Stuckiauthor=K.+J.+Dedes&title=Effect+of+MRE11+loss+on+PARP-inhibitor+sensitivity+in+endometrial+cancer+in+vitro&doi=10.1371%2Fjournal.pone.0100041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0100041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0100041%26sid%3Dliteratum%253Aachs%26aulast%3DKoppensteiner%26aufirst%3DR.%26aulast%3DSamartzis%26aufirst%3DE.%2BP.%26aulast%3DNoske%26aufirst%3DA.%26aulast%3Dvon%2BTeichman%26aufirst%3DA.%26aulast%3DDedes%26aufirst%3DI.%26aulast%3DGwerder%26aufirst%3DM.%26aulast%3DImesch%26aufirst%3DP.%26aulast%3DIkenberg%26aufirst%3DK.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DD.%26aulast%3DStucki%26aufirst%3DM.%26aulast%3DDedes%26aufirst%3DK.%2BJ.%26atitle%3DEffect%2520of%2520MRE11%2520loss%2520on%2520PARP-inhibitor%2520sensitivity%2520in%2520endometrial%2520cancer%2520in%2520vitro%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De100041%26doi%3D10.1371%2Fjournal.pone.0100041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Vilar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartnik, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenzel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raskin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iniesta, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennert, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, S. B.</span><span> </span><span class="NLM_article-title">MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">2632</span><span class="NLM_x">–</span> <span class="NLM_lpage">2642</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-10-1120" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2632-2642&author=E.+Vilarauthor=C.+M.+Bartnikauthor=S.+L.+Stenzelauthor=L.+Raskinauthor=J.+Ahnauthor=V.+Morenoauthor=B.+Mukherjeeauthor=M.+D.+Iniestaauthor=M.+A.+Morganauthor=G.+Rennertauthor=S.+B.+Gruber&title=MRE11+deficiency+increases+sensitivity+to+poly%28ADP-ribose%29+polymerase+inhibition+in+microsatellite+unstable+colorectal+cancers&doi=10.1158%2F0008-5472.CAN-10-1120"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1120%26sid%3Dliteratum%253Aachs%26aulast%3DVilar%26aufirst%3DE.%26aulast%3DBartnik%26aufirst%3DC.%2BM.%26aulast%3DStenzel%26aufirst%3DS.%2BL.%26aulast%3DRaskin%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DJ.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DMukherjee%26aufirst%3DB.%26aulast%3DIniesta%26aufirst%3DM.%2BD.%26aulast%3DMorgan%26aufirst%3DM.%2BA.%26aulast%3DRennert%26aufirst%3DG.%26aulast%3DGruber%26aufirst%3DS.%2BB.%26atitle%3DMRE11%2520deficiency%2520increases%2520sensitivity%2520to%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibition%2520in%2520microsatellite%2520unstable%2520colorectal%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2632%26epage%3D2642%26doi%3D10.1158%2F0008-5472.CAN-10-1120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Faraoni, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Compagnone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavorgna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelini, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cencioni, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piras, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panetta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venditti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo-Coco, F.</span><span> </span><span class="NLM_article-title">BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Basis Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1852</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span><span class="refDoi"> DOI: 10.1016/j.bbadis.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bbadis.2014.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25483710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyksbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1852&publication_year=2015&pages=462-472&author=I.+Faraoniauthor=M.+Compagnoneauthor=S.+Lavorgnaauthor=D.+F.+Angeliniauthor=M.+T.+Cencioniauthor=E.+Pirasauthor=P.+Panettaauthor=T.+Ottoneauthor=S.+Dolciauthor=A.+Vendittiauthor=G.+Grazianiauthor=F.+Lo-Coco&title=BRCA1%2C+PARP1+and+gammaH2AX+in+acute+myeloid+leukemia%3A+Role+as+biomarkers+of+response+to+the+PARP+inhibitor+olaparib&doi=10.1016%2Fj.bbadis.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib</span></div><div class="casAuthors">Faraoni, Isabella; Compagnone, Mirco; Lavorgna, Serena; Angelini, Daniela Francesca; Cencioni, Maria Teresa; Piras, Eleonora; Panetta, Paola; Ottone, Tiziana; Dolci, Susanna; Venditti, Adriano; Graziani, Grazia; Lo-Coco, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1852</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">462-472</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase (PARP) inhibitor currently under investigation in patients with solid tumors.  To study the clin. potential of olaparib as a single-agent for the treatment of acute myeloid leukemia (AML) patients, we analyzed the in vitro sensitivity of AML cell lines and primary blasts.  Clin. achievable concns. of olaparib were able to induce cell death in the majority of primary AML case samples (88%) and tested cell lines.  At these concns., olaparib preferentially killed leukemic blasts sparing normal lymphocytes derived from the same patient and did not substantially affect the viability of normal bone marrow and CD34-enriched peripheral blood cells obtained from healthy donors.  Most primary AML analyzed were characterized by low BRCA1 mRNA level and undetectable protein expression that likely contributed to explain their sensitivity to olaparib.  Noteworthy, while PARP1 over-expression was detected in blasts not responsive to olaparib, phosphorylation of the histone H2AFX (γH2AX) was assocd. with drug sensitivity.  As to genetic features of tested cases the highest sensitivity was shown by a patient carrying a 11q23 deletion.  The high sensitivity of AML blasts and the identification of biomarkers potentially able to predict response and/or resistance may foster further investigation of olaparib monotherapy for AML patients unfit to conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUBo2_k6iHarVg90H21EOLACvtfcHk0lifFbU-8444eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyksbvK&md5=2d7a28d00a293fa716fbb960c78b9638</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DFaraoni%26aufirst%3DI.%26aulast%3DCompagnone%26aufirst%3DM.%26aulast%3DLavorgna%26aufirst%3DS.%26aulast%3DAngelini%26aufirst%3DD.%2BF.%26aulast%3DCencioni%26aufirst%3DM.%2BT.%26aulast%3DPiras%26aufirst%3DE.%26aulast%3DPanetta%26aufirst%3DP.%26aulast%3DOttone%26aufirst%3DT.%26aulast%3DDolci%26aufirst%3DS.%26aulast%3DVenditti%26aufirst%3DA.%26aulast%3DGraziani%26aufirst%3DG.%26aulast%3DLo-Coco%26aufirst%3DF.%26atitle%3DBRCA1%252C%2520PARP1%2520and%2520gammaH2AX%2520in%2520acute%2520myeloid%2520leukemia%253A%2520Role%2520as%2520biomarkers%2520of%2520response%2520to%2520the%2520PARP%2520inhibitor%2520olaparib%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2015%26volume%3D1852%26spage%3D462%26epage%3D472%26doi%3D10.1016%2Fj.bbadis.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Weber, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span> </span><span class="NLM_article-title">ATM and ATR as therapeutic targets in cancer</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">124</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.pharmthera.2014.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25512053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtV2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2015&pages=124-138&author=A.+M.+Weberauthor=A.+J.+Ryan&title=ATM+and+ATR+as+therapeutic+targets+in+cancer&doi=10.1016%2Fj.pharmthera.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">ATM and ATR as therapeutic targets in cancer</span></div><div class="casAuthors">Weber, Anika Maria; Ryan, Anderson Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">124-138</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  In order to maintain genomic stability, cells have developed sophisticated signalling pathways to enable DNA damage or DNA replication stress to be resolved.  Key mediators of this DNA damage response (DDR) are the ATM and ATR kinases, which induce cell cycle arrest and facilitate DNA repair via their downstream targets.  Inhibiting the DDR has become an attractive therapeutic concept in cancer therapy, since (i) resistance to genotoxic therapies has been assocd. with increased DDR signalling, and (ii) many cancers have defects in certain components of the DDR rendering them highly dependent on the remaining DDR pathways for survival.  ATM and ATR act as the apical regulators of the response to DNA double strand breaks and replication stress, resp., with overlapping but non-redundant activities.  Highly selective small mol. inhibitors of ATM and ATR are currently in preclin. and clin. development, resp.  Preclin. data have provided a strong rationale for clin. testing of these compds. both in combination with radio- or chemotherapy, and in synthetic lethal approaches to treat tumors with deficiencies in certain DDR components.  Whole genome sequencing studies have reported that mutations in DDR genes occur with a high frequency in many common tumor types, suggesting that a synthetic lethal approach with ATM or ATR inhibitors could have widespread utility, providing that appropriate biomarkers are developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXNTHNVGQUGbVg90H21EOLACvtfcHk0lifFbU-8444eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtV2msA%253D%253D&md5=204198bfeef4fc9cdf3d0e8968334363</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DA.%2BM.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26atitle%3DATM%2520and%2520ATR%2520as%2520therapeutic%2520targets%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D149%26spage%3D124%26epage%3D138%26doi%3D10.1016%2Fj.pharmthera.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Hoglund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stromvall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forshell, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, J. A.</span><span> </span><span class="NLM_article-title">Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">3598</span><span class="NLM_x">–</span> <span class="NLM_lpage">3607</span><span class="refDoi"> DOI: 10.4161/cc.10.20.17887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.4161%2Fcc.10.20.17887" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=3598-3607&author=A.+Hoglundauthor=K.+Stromvallauthor=Y.+Liauthor=L.+P.+Forshellauthor=J.+A.+Nilsson&title=Chk2+deficiency+in+Myc+overexpressing+lymphoma+cells+elicits+a+synergistic+lethal+response+in+combination+with+PARP+inhibition&doi=10.4161%2Fcc.10.20.17887"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.4161%2Fcc.10.20.17887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.10.20.17887%26sid%3Dliteratum%253Aachs%26aulast%3DHoglund%26aufirst%3DA.%26aulast%3DStromvall%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DForshell%26aufirst%3DL.%2BP.%26aulast%3DNilsson%26aufirst%3DJ.%2BA.%26atitle%3DChk2%2520deficiency%2520in%2520Myc%2520overexpressing%2520lymphoma%2520cells%2520elicits%2520a%2520synergistic%2520lethal%2520response%2520in%2520combination%2520with%2520PARP%2520inhibition%26jtitle%3DCell%2520Cycle%26date%3D2011%26volume%3D10%26spage%3D3598%26epage%3D3607%26doi%3D10.4161%2Fcc.10.20.17887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Gilardini Montani, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodosmo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stagni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteonofrio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentileschi, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barila, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soddu, S.</span><span> </span><span class="NLM_article-title">ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition</span> <span class="citation_source-journal">J. Exp. Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="refDoi"> DOI: 10.1186/1756-9966-32-95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2F1756-9966-32-95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24252502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2c7os1Glsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=95&author=M.+S.+Gilardini+Montaniauthor=A.+Prodosmoauthor=V.+Stagniauthor=D.+Merliauthor=L.+Monteonofrioauthor=V.+Gattiauthor=M.+P.+Gentileschiauthor=D.+Barilaauthor=S.+Soddu&title=ATM-depletion+in+breast+cancer+cells+confers+sensitivity+to+PARP+inhibition&doi=10.1186%2F1756-9966-32-95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition</span></div><div class="casAuthors">Gilardini Montani Maria Saveria; Prodosmo Andrea; Stagni Venturina; Merli Dania; Monteonofrio Laura; Gatti Veronica; Gentileschi Maria Pia; Barila Daniela; Soddu Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mutations in the DNA damage response (DDR) factors, breast cancer 1 (BRCA1) and BRCA2, sensitize tumor cells to poly(ADP-ribose) polymerase (PARP) inhibitors.  The ataxia telangiectasia mutated (ATM) kinase is a key DDR protein whose heterozygous germline mutation is a moderate-risk factor for developing breast cancer.  In this study, we examined whether ATM inactivation in breast cancer cell lines confers sensitivity to PARP inhibitors.  METHODS:  Wild-type BRCA1/2 breast cancer cells (i.e., MCF-7 and ZR-75-1 lines) were genetically manipulated to downregulate ATM expression then assayed for cytostaticity/cytotoxicity upon treatment with PARP inhibitors, olaparib and iniparib.  RESULTS:  When ATM-depleted cells and their relative controls were treated with olaparib (a competitive PARP-1/2 inhibitor) and iniparib (a molecule originally described as a covalent PARP-1 inhibitor) a different response to the two compounds was observed.  ATM-depletion sensitized both MCF-7 and ZR-75-1 cells to olaparib-treatment, as assessed by short and long survival assays and cell cycle profiles.  In contrast, iniparib induced only a mild, ATM-dependent cytostatic effect in MCF-7 cells whereas ZR-75-1 cells were sensitive to this drug, independently of ATM inactivation.  These latest results might be explained by recent observations indicating that iniparib acts with mechanisms other than PARP inhibition.  CONCLUSIONS:  These data indicate that ATM-depletion can sensitize breast cancer cells to PARP inhibition, suggesting a potential in the treatment of breast cancers low in ATM protein expression/activity, such as those arising in mutant ATM heterozygous carriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRve4U0u-sYhbmQt-ICR3qNfW6udTcc2ebudbAFBtk3F7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7os1Glsw%253D%253D&md5=00fee550e2b9a4d7ad30171b228f235a</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1186%2F1756-9966-32-95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-9966-32-95%26sid%3Dliteratum%253Aachs%26aulast%3DGilardini%2BMontani%26aufirst%3DM.%2BS.%26aulast%3DProdosmo%26aufirst%3DA.%26aulast%3DStagni%26aufirst%3DV.%26aulast%3DMerli%26aufirst%3DD.%26aulast%3DMonteonofrio%26aufirst%3DL.%26aulast%3DGatti%26aufirst%3DV.%26aulast%3DGentileschi%26aufirst%3DM.%2BP.%26aulast%3DBarila%26aufirst%3DD.%26aulast%3DSoddu%26aufirst%3DS.%26atitle%3DATM-depletion%2520in%2520breast%2520cancer%2520cells%2520confers%2520sensitivity%2520to%2520PARP%2520inhibition%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D32%26spage%3D95%26doi%3D10.1186%2F1756-9966-32-95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Kubota, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elegbede, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lees-Miller, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebb, D. G.</span><span> </span><span class="NLM_article-title">Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2137</span><span class="refDoi"> DOI: 10.4161/cc.29212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.4161%2Fcc.29212" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2129-2137&author=E.+Kubotaauthor=C.+T.+Williamsonauthor=R.+Yeauthor=A.+Elegbedeauthor=L.+Petersonauthor=S.+P.+Lees-Millerauthor=D.+G.+Bebb&title=Low+ATM+protein+expression+and+depletion+of+p53+correlates+with+olaparib+sensitivity+in+gastric+cancer+cell+lines&doi=10.4161%2Fcc.29212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.4161%2Fcc.29212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.29212%26sid%3Dliteratum%253Aachs%26aulast%3DKubota%26aufirst%3DE.%26aulast%3DWilliamson%26aufirst%3DC.%2BT.%26aulast%3DYe%26aufirst%3DR.%26aulast%3DElegbede%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DL.%26aulast%3DLees-Miller%26aufirst%3DS.%2BP.%26aulast%3DBebb%26aufirst%3DD.%2BG.%26atitle%3DLow%2520ATM%2520protein%2520expression%2520and%2520depletion%2520of%2520p53%2520correlates%2520with%2520olaparib%2520sensitivity%2520in%2520gastric%2520cancer%2520cell%2520lines%26jtitle%3DCell%2520Cycle%26date%3D2014%26volume%3D13%26spage%3D2129%26epage%3D2137%26doi%3D10.4161%2Fcc.29212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Weston, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldreive, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skowronska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oscier, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudzki, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearns, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stankovic, T.</span><span> </span><span class="NLM_article-title">The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">4578</span><span class="NLM_x">–</span> <span class="NLM_lpage">4587</span><span class="refDoi"> DOI: 10.1182/blood-2010-01-265769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1182%2Fblood-2010-01-265769" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=4578-4587&author=V.+J.+Westonauthor=C.+E.+Oldreiveauthor=A.+Skowronskaauthor=D.+G.+Oscierauthor=G.+Prattauthor=M.+J.+Dyerauthor=G.+Smithauthor=J.+E.+Powellauthor=Z.+Rudzkiauthor=P.+Kearnsauthor=P.+A.+Mossauthor=A.+M.+Taylorauthor=T.+Stankovic&title=The+PARP+inhibitor+olaparib+induces+significant+killing+of+ATM-deficient+lymphoid+tumor+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2010-01-265769"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-01-265769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-01-265769%26sid%3Dliteratum%253Aachs%26aulast%3DWeston%26aufirst%3DV.%2BJ.%26aulast%3DOldreive%26aufirst%3DC.%2BE.%26aulast%3DSkowronska%26aufirst%3DA.%26aulast%3DOscier%26aufirst%3DD.%2BG.%26aulast%3DPratt%26aufirst%3DG.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DPowell%26aufirst%3DJ.%2BE.%26aulast%3DRudzki%26aufirst%3DZ.%26aulast%3DKearns%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DP.%2BA.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DStankovic%26aufirst%3DT.%26atitle%3DThe%2520PARP%2520inhibitor%2520olaparib%2520induces%2520significant%2520killing%2520of%2520ATM-deficient%2520lymphoid%2520tumor%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D4578%26epage%3D4587%26doi%3D10.1182%2Fblood-2010-01-265769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Williamson, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzik, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turhan, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamò, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebb, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lees-Miller, S. P.</span><span> </span><span class="NLM_article-title">ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">357</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.MCT-09-0872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20124459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslektb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=347-357&author=C.+T.+Williamsonauthor=H.+Muzikauthor=A.+G.+Turhanauthor=A.+Zam%C3%B2author=M.+J.+O%E2%80%99Connorauthor=D.+G.+Bebbauthor=S.+P.+Lees-Miller&title=ATM+deficiency+sensitizes+mantle+cell+lymphoma+cells+to+poly%28ADP-ribose%29+polymerase-1+inhibitors&doi=10.1158%2F1535-7163.MCT-09-0872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors</span></div><div class="casAuthors">Williamson, Chris T.; Muzik, Huong; Turhan, Ali G.; Zamo, Alberto; O'Connor, Mark J.; Bebb, D. Gwyn; Lees-Miller, Susan P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase-1 (PARP-1) inhibition is toxic to cells with mutations in the breast and ovarian cancer susceptibility genes BRCA1 or BRCA2, a concept termed synthetic lethality.  However, whether this approach is applicable to other human cancers with defects in other DNA repair genes has yet to be detd.  The ataxia telangiectasia mutated (ATM) gene is altered in several human cancers including mantle cell lymphoma (MCL).  Here, the authors characterize a panel of MCL cell lines for ATM status and function and investigate the potential for synthetic lethality in MCL in the presence of small-mol. inhibitors of PARP-1.  The authors show that Granta-519 and UPN2 cells have low levels of ATM protein, are defective in DNA damage-induced ATM-dependent signaling, are radiation sensitive, and have cell cycle checkpoint defects: all characteristics of defective ATM function.  Significantly, Granta-519 and UPN2 cells were more sensitive to PARP-1 inhibition than were the ATM-proficient MCL cell lines examd.  Furthermore, the PARP-1 inhibitor olaparib (known previously as AZD2281/KU-0059436) significantly decreased tumor growth and increased overall survival in mice bearing s.c. xenografts of ATM-deficient Granta-519 cells while producing only a modest effect on overall survival of mice bearing xenografts of the ATM-proficient cell line, Z138.  Thus, PARP inhibitors have therapeutic potential in the treatment of MCL, and the concept of synthetic lethality extends to human cancers with ATM alterations.  Mol Cancer Ther; 9(2); 347-57.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQmQjsqIbdVrVg90H21EOLACvtfcHk0liT-5UENlyuEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslektb8%253D&md5=6243397aa39febdd9bd613b413a1f9ad</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0872%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DC.%2BT.%26aulast%3DMuzik%26aufirst%3DH.%26aulast%3DTurhan%26aufirst%3DA.%2BG.%26aulast%3DZam%25C3%25B2%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DBebb%26aufirst%3DD.%2BG.%26aulast%3DLees-Miller%26aufirst%3DS.%2BP.%26atitle%3DATM%2520deficiency%2520sensitizes%2520mantle%2520cell%2520lymphoma%2520cells%2520to%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D347%26epage%3D357%26doi%3D10.1158%2F1535-7163.MCT-09-0872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Herriott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudhope, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junge, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhouse, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allinson, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willmore, E.</span><span> </span><span class="NLM_article-title">PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">43978</span><span class="NLM_x">–</span> <span class="NLM_lpage">43991</span><span class="refDoi"> DOI: 10.18632/oncotarget.6287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.6287" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=43978-43991&author=A.+Herriottauthor=S.+J.+Tudhopeauthor=G.+Jungeauthor=N.+Rodriguesauthor=M.+J.+Pattersonauthor=L.+Woodhouseauthor=J.+Lunecauthor=J.+E.+Hunterauthor=E.+A.+Mulliganauthor=M.+Coleauthor=L.+M.+Allinsonauthor=J.+P.+Wallisauthor=S.+Marshallauthor=E.+Wangauthor=N.+J.+Curtinauthor=E.+Willmore&title=PARP1+expression%2C+activity+and+ex+vivo+sensitivity+to+the+PARP+inhibitor%2C+talazoparib+%28BMN+673%29%2C+in+chronic+lymphocytic+leukaemia&doi=10.18632%2Foncotarget.6287"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6287%26sid%3Dliteratum%253Aachs%26aulast%3DHerriott%26aufirst%3DA.%26aulast%3DTudhope%26aufirst%3DS.%2BJ.%26aulast%3DJunge%26aufirst%3DG.%26aulast%3DRodrigues%26aufirst%3DN.%26aulast%3DPatterson%26aufirst%3DM.%2BJ.%26aulast%3DWoodhouse%26aufirst%3DL.%26aulast%3DLunec%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DJ.%2BE.%26aulast%3DMulligan%26aufirst%3DE.%2BA.%26aulast%3DCole%26aufirst%3DM.%26aulast%3DAllinson%26aufirst%3DL.%2BM.%26aulast%3DWallis%26aufirst%3DJ.%2BP.%26aulast%3DMarshall%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DWillmore%26aufirst%3DE.%26atitle%3DPARP1%2520expression%252C%2520activity%2520and%2520ex%2520vivo%2520sensitivity%2520to%2520the%2520PARP%2520inhibitor%252C%2520talazoparib%2520%2528BMN%2520673%2529%252C%2520in%2520chronic%2520lymphocytic%2520leukaemia%26jtitle%3DOncotarget%26date%3D2015%26volume%3D22%26spage%3D43978%26epage%3D43991%26doi%3D10.18632%2Foncotarget.6287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Wang, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, X. P.</span><span> </span><span class="NLM_article-title">Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression</span> <span class="citation_source-journal">J. Obstet. Gynaecol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">554</span><span class="refDoi"> DOI: 10.1111/j.1447-0756.2012.01979.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1111%2Fj.1447-0756.2012.01979.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23006047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisVCisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=549-554&author=Y.+Q.+Wangauthor=Q.+Yanauthor=J.+R.+Zhangauthor=S.+D.+Liauthor=Y.+X.+Yangauthor=X.+P.+Wan&title=Epigenetic+inactivation+of+BRCA1+through+promoter+hypermethylation+in+ovarian+cancer+progression&doi=10.1111%2Fj.1447-0756.2012.01979.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression</span></div><div class="casAuthors">Wang, Yan-Qiu; Yan, Qin; Zhang, Jia-Rong; Li, Shuang-Di; Yang, Yi-Xia; Wan, Xiao-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Obstetrics and Gynaecology Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">549-554, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOGRFD</span>;
        ISSN:<span class="NLM_cas:issn">1447-0756</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim: The BRCA1 promoter is hypermethylated in ovarian cancer patients.  We postulated that this hypermethylation might be involved in ovarian cancer progression.  Methods: To confirm our hypothesis, tissue and serum samples were collected from ovarian carcinoma patients and categorized according to tumor stage.  Healthy or benign ovarian disease tissue samples and corresponding serum samples were used as controls.  Breast and ovarian cancer susceptibility gene 1 (BRCA1) promoter methylation levels were detected by real-time polymerase chain reaction (PCR).  Real-time PCR was also used to evaluate BRCA1 gene expression and Western blot was performed to assay the expression of BRCA1 protein.  Results: BRCA1 showed hypomethylation in 30 normal ovarian and 30 benign ovarian tumors, but showed hypermethylation or methylation in ovarian cancer patients.  There was also a significant difference in the BRCA1 promoter methylation levels between different ovarian cancer stages.  Compared to stage I and the control groups, there were higher BRCA1 promoter methylation frequencies in stage II and III ovarian cancers.  BRCA1 methylation correlated with the loss of BRCA1 expression.  BRCA1 promoter in stage I tumors showed hypomethylated.  Conclusion: Promoter hypermethylation may act as a biomarker for sporadic ovarian cancer progression, but is unlikely to be helpful in the early diagnosis of ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5RYjc-u-FWbVg90H21EOLACvtfcHk0lhvC75qZr30qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisVCisrY%253D&md5=ad27a54a34e8de0e62358226edc36815</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1111%2Fj.1447-0756.2012.01979.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1447-0756.2012.01979.x%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BQ.%26aulast%3DYan%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DS.%2BD.%26aulast%3DYang%26aufirst%3DY.%2BX.%26aulast%3DWan%26aufirst%3DX.%2BP.%26atitle%3DEpigenetic%2520inactivation%2520of%2520BRCA1%2520through%2520promoter%2520hypermethylation%2520in%2520ovarian%2520cancer%2520progression%26jtitle%3DJ.%2520Obstet.%2520Gynaecol.%2520Res.%26date%3D2013%26volume%3D39%26spage%3D549%26epage%3D554%26doi%3D10.1111%2Fj.1447-0756.2012.01979.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Yamashita, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokunaga, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hisamatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taketani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyoshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maehara, Y.</span><span> </span><span class="NLM_article-title">Epigenetic inactivation of BRCA1 through promoter hypermethylation and its clinical importance in triple-negative breast cancer</span> <span class="citation_source-journal">Clin. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span><span class="refDoi"> DOI: 10.1016/j.clbc.2015.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.clbc.2015.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26195437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2is7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=498-504&author=N.+Yamashitaauthor=E.+Tokunagaauthor=H.+Kitaoauthor=M.+Hitchinsauthor=Y.+Inoueauthor=K.+Tanakaauthor=Y.+Hisamatsuauthor=K.+Taketaniauthor=S.+Akiyoshiauthor=S.+Okadaauthor=Y.+Odaauthor=H.+Saekiauthor=E.+Okiauthor=Y.+Maehara&title=Epigenetic+inactivation+of+BRCA1+through+promoter+hypermethylation+and+its+clinical+importance+in+triple-negative+breast+cancer&doi=10.1016%2Fj.clbc.2015.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Yamashita, Nami; Tokunaga, Eriko; Kitao, Hiroyuki; Hitchins, Megan; Inoue, Yuka; Tanaka, Kimihiro; Hisamatsu, Yuichi; Taketani, Kenji; Akiyoshi, Sayuri; Okada, Satoko; Oda, Yoshinao; Saeki, Hiroshi; Oki, Eiji; Maehara, Yoshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">498-504</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) has many similarities with basal-like breast cancer.  Addnl., TNBCs are assocd. with Breast cancer susceptibility gene I (BRCA1) functional loss, which leads to impaired homologous recombination-mediated DNA repair.  Although somatic mutations in BRCA1 rarely occur in sporadic breast cancer, lower than normal rates of expression of BRCA1 is reported to be an important factor that contributes to tumorigenesis in sporadic tumors.  The epigenetic inactivation of BRCA1 expression might thus play an important role in sporadic breast cancer cases.  Breast cancer specimens were obtained from 69 TNBC and 161 non-TNBC patients who underwent surgery without neoadjuvant systemic therapy.  BRCA1 promoter methylation status was investigated using combined bisulfite and restriction anal.  BRCA1 mRNA expression was evaluated using quant. reverse transcriptase polymerase chain reaction and BRCA1 protein expression was assessed using immunohistochem.  BRCA1 promoter methylation was found in 11 tumors and all of these were in TNBC cases (P < .0001).  BRCA1 promoter methylation was significantly assocd. with lymphovessel invasion (P = .02), high nuclear grade (P = .05), low BRCA1 mRNA expression (P < .0001), and loss of BRCA1 protein expression (P = .0015).  BRCA1 promoter methylation was significantly assocd. with shorter overall survival (P = .038).BRCA1 promotor methylation was found only in TNBC cases and the methylated cases account for 16% of TNBC.  BRCA1 promoter methylation was significantly assocd. with reduced BRCA1 expression, aggressive phenotype, and poor prognosis.  BRCA1 promoter methylation is an important mechanism that leads to functional loss of BRCA1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreIh-usNCN-bVg90H21EOLACvtfcHk0lhvC75qZr30qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2is7%252FP&md5=1e4e736cf744ff5d1b2ed1e06fffc26f</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2015.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2015.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DN.%26aulast%3DTokunaga%26aufirst%3DE.%26aulast%3DKitao%26aufirst%3DH.%26aulast%3DHitchins%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DHisamatsu%26aufirst%3DY.%26aulast%3DTaketani%26aufirst%3DK.%26aulast%3DAkiyoshi%26aufirst%3DS.%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DOda%26aufirst%3DY.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DOki%26aufirst%3DE.%26aulast%3DMaehara%26aufirst%3DY.%26atitle%3DEpigenetic%2520inactivation%2520of%2520BRCA1%2520through%2520promoter%2520hypermethylation%2520and%2520its%2520clinical%2520importance%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D498%26epage%3D504%26doi%3D10.1016%2Fj.clbc.2015.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Ruscito, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasconcelos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellhaus, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwachula, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeillinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti-Panici, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cacsire-Tong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darb-Esfahani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambrechts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sehouli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braicu, E. I.</span><span> </span><span class="NLM_article-title">BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2090</span><span class="NLM_x">–</span> <span class="NLM_lpage">2098</span><span class="refDoi"> DOI: 10.1016/j.ejca.2014.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.ejca.2014.05.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=2090-2098&author=I.+Ruscitoauthor=D.+Dimitrovaauthor=I.+Vasconcelosauthor=K.+Gellhausauthor=T.+Schwachulaauthor=F.+Bellatiauthor=R.+Zeillingerauthor=P.+Benedetti-Paniciauthor=I.+Vergoteauthor=S.+Mahnerauthor=D.+Cacsire-Tongauthor=N.+Concinauthor=S.+Darb-Esfahaniauthor=S.+Lambrechtsauthor=J.+Sehouliauthor=S.+Olekauthor=E.+I.+Braicu&title=BRCA1+gene+promoter+methylation+status+in+high-grade+serous+ovarian+cancer+patients%2D%2Da+study+of+the+tumour+Bank+ovarian+cancer+%28TOC%29+and+ovarian+cancer+diagnosis+consortium+%28OVCAD%29&doi=10.1016%2Fj.ejca.2014.05.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2014.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2014.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DRuscito%26aufirst%3DI.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DVasconcelos%26aufirst%3DI.%26aulast%3DGellhaus%26aufirst%3DK.%26aulast%3DSchwachula%26aufirst%3DT.%26aulast%3DBellati%26aufirst%3DF.%26aulast%3DZeillinger%26aufirst%3DR.%26aulast%3DBenedetti-Panici%26aufirst%3DP.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DMahner%26aufirst%3DS.%26aulast%3DCacsire-Tong%26aufirst%3DD.%26aulast%3DConcin%26aufirst%3DN.%26aulast%3DDarb-Esfahani%26aufirst%3DS.%26aulast%3DLambrechts%26aufirst%3DS.%26aulast%3DSehouli%26aufirst%3DJ.%26aulast%3DOlek%26aufirst%3DS.%26aulast%3DBraicu%26aufirst%3DE.%2BI.%26atitle%3DBRCA1%2520gene%2520promoter%2520methylation%2520status%2520in%2520high-grade%2520serous%2520ovarian%2520cancer%2520patients--a%2520study%2520of%2520the%2520tumour%2520Bank%2520ovarian%2520cancer%2520%2528TOC%2529%2520and%2520ovarian%2520cancer%2520diagnosis%2520consortium%2520%2528OVCAD%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2014%26volume%3D50%26spage%3D2090%26epage%3D2098%26doi%3D10.1016%2Fj.ejca.2014.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Jacot, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thezenas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viglianti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laberenne, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Crapez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibeau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleuse, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romieu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamy, P. J.</span><span> </span><span class="NLM_article-title">BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="refDoi"> DOI: 10.1186/1471-2407-13-523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2F1471-2407-13-523" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=523&author=W.+Jacotauthor=S.+Thezenasauthor=R.+Senalauthor=C.+Vigliantiauthor=A.+C.+Laberenneauthor=E.+Lopez-Crapezauthor=F.+Bibeauauthor=J.+P.+Bleuseauthor=G.+Romieuauthor=P.+J.+Lamy&title=BRCA1+promoter+hypermethylation%2C+53BP1+protein+expression+and+PARP-1+activity+as+biomarkers+of+DNA+repair+deficit+in+breast+cancer&doi=10.1186%2F1471-2407-13-523"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-523%26sid%3Dliteratum%253Aachs%26aulast%3DJacot%26aufirst%3DW.%26aulast%3DThezenas%26aufirst%3DS.%26aulast%3DSenal%26aufirst%3DR.%26aulast%3DViglianti%26aufirst%3DC.%26aulast%3DLaberenne%26aufirst%3DA.%2BC.%26aulast%3DLopez-Crapez%26aufirst%3DE.%26aulast%3DBibeau%26aufirst%3DF.%26aulast%3DBleuse%26aufirst%3DJ.%2BP.%26aulast%3DRomieu%26aufirst%3DG.%26aulast%3DLamy%26aufirst%3DP.%2BJ.%26atitle%3DBRCA1%2520promoter%2520hypermethylation%252C%252053BP1%2520protein%2520expression%2520and%2520PARP-1%2520activity%2520as%2520biomarkers%2520of%2520DNA%2520repair%2520deficit%2520in%2520breast%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D523%26doi%3D10.1186%2F1471-2407-13-523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Lombardi, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoskins, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foglesong, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wikenheiser-Brokamp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmüller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanenberg, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreassen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeble, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hays, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S. I.</span><span> </span><span class="NLM_article-title">Acquisition of relative interstrand crosslinker resistance and PARP inhibitor sensitivity in fanconi anemia head and neck cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1962</span><span class="NLM_x">–</span> <span class="NLM_lpage">1972</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-14-2616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25609062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsl2gtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1962-1972&author=A.+J.+Lombardiauthor=E.+E.+Hoskinsauthor=G.+D.+Foglesongauthor=K.+A.+Wikenheiser-Brokampauthor=L.+Wiesm%C3%BCllerauthor=H.+Hanenbergauthor=P.+R.+Andreassenauthor=A.+J.+Jacobsauthor=S.+B.+Olsonauthor=W.+W.+Keebleauthor=L.+E.+Haysauthor=S.+I.+Wells&title=Acquisition+of+relative+interstrand+crosslinker+resistance+and+PARP+inhibitor+sensitivity+in+fanconi+anemia+head+and+neck+cancers&doi=10.1158%2F1078-0432.CCR-14-2616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers</span></div><div class="casAuthors">Lombardi, Anne J.; Hoskins, Elizabeth E.; Foglesong, Grant D.; Wikenheiser-Brokamp, Kathryn A.; Wiesmueller, Lisa; Hanenberg, Helmut; Andreassen, Paul R.; Jacobs, Allison J.; Olson, Susan B.; Keeble, Winifred W.; Hays, Laura E.; Wells, Susanne I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1962-1972</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Fanconi anemia is an inherited disorder assocd. with a constitutional defect in the Fanconi anemia DNA repair machinery that is essential for resoln. of DNA interstrand crosslinks.  Individuals with Fanconi anemia are predisposed to formation of head and neck squamous cell carcinomas (HNSCC) at a young age.  Prognosis is poor, partly due to patient intolerance of chemotherapy and radiation requiring dose redn., which may lead to early recurrence of disease.  Exptl. Design: Using HNSCC cell lines derived from the tumors of patients with Fanconi anemia, and murine HNSCC cell lines derived from the tumors of wild-type and Fancc-/- mice, we sought to define Fanconi anemia-dependent chemosensitivity and DNA repair characteristics.  We utilized DNA repair reporter assays to explore the preference of Fanconi anemia HNSCC cells for non-homologous end joining (NHEJ).  Results: Surprisingly, interstrand crosslinker (ICL) sensitivity was not necessarily Fanconi anemia-dependent in human or murine cell systems.  Our results suggest that the increased Ku-dependent NHEJ that is expected in Fanconi anemia cells did not mediate relative ICL resistance.  ICL exposure resulted in increased DNA damage sensing and repair by PARP in Fanconi anemia-deficient cells.  Moreover, human and murine Fanconi anemia HNSCC cells were sensitive to PARP inhibition, and sensitivity of human cells was attenuated by Fanconi anemia gene complementation.  Conclusions: The obsd. reliance upon PARP-mediated mechanisms reveals a means by which Fanconi anemia HNSCCs can acquire relative resistance to the ICL-based chemotherapy that is a foundation of HNSCC treatment, as well as a potential target for overcoming chemoresistance in the chemosensitive individual.  Clin Cancer Res; 21(8); 1962-72. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcw9nBMGFl9rVg90H21EOLACvtfcHk0lgUw-wx1XvH6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsl2gtbo%253D&md5=b0b40c1229cf1808b30551418a5ba770</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2616%26sid%3Dliteratum%253Aachs%26aulast%3DLombardi%26aufirst%3DA.%2BJ.%26aulast%3DHoskins%26aufirst%3DE.%2BE.%26aulast%3DFoglesong%26aufirst%3DG.%2BD.%26aulast%3DWikenheiser-Brokamp%26aufirst%3DK.%2BA.%26aulast%3DWiesm%25C3%25BCller%26aufirst%3DL.%26aulast%3DHanenberg%26aufirst%3DH.%26aulast%3DAndreassen%26aufirst%3DP.%2BR.%26aulast%3DJacobs%26aufirst%3DA.%2BJ.%26aulast%3DOlson%26aufirst%3DS.%2BB.%26aulast%3DKeeble%26aufirst%3DW.%2BW.%26aulast%3DHays%26aufirst%3DL.%2BE.%26aulast%3DWells%26aufirst%3DS.%2BI.%26atitle%3DAcquisition%2520of%2520relative%2520interstrand%2520crosslinker%2520resistance%2520and%2520PARP%2520inhibitor%2520sensitivity%2520in%2520fanconi%2520anemia%2520head%2520and%2520neck%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1962%26epage%3D1972%26doi%3D10.1158%2F1078-0432.CCR-14-2616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Duan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguila, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalvala, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterson, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalona-Calero, M. A.</span><span> </span><span class="NLM_article-title">Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">368</span><span class="refDoi"> DOI: 10.3389/fonc.2014.00368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.3389%2Ffonc.2014.00368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25566506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2MvksFaitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=368&author=W.+Duanauthor=L.+Gaoauthor=B.+Aguilaauthor=A.+Kalvalaauthor=G.+A.+Ottersonauthor=M.+A.+Villalona-Calero&title=Fanconi+anemia+repair+pathway+dysfunction%2C+a+potential+therapeutic+target+in+lung+cancer&doi=10.3389%2Ffonc.2014.00368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer</span></div><div class="casAuthors">Duan Wenrui; Otterson Gregory A; Gao Li; Aguila Brittany; Kalvala Arjun; Villalona-Calero Miguel A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">368</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Fanconi anemia (FA) pathway is a major mechanism of homologous recombination DNA repair.  The functional readout of the pathway is activation through mono-ubiquitination of FANCD2 leading to nuclear foci of repair.  We have recently developed an FA triple-staining immunofluorescence based method (FATSI) to evaluate FANCD2 foci formation in formalin fixed paraffin-embedded (FFPE) tumor samples.  DNA-repair deficiencies have been considered of interest in lung cancer prevention, given the persistence of damage produced by cigarette smoke in this setting, as well as in treatment, given potential increased efficacy of DNA-damaging drugs.  We screened 139 non-small cell lung cancer (NSCLC) FFPE tumors for FANCD2 foci formation by FATSI analysis.  Among 104 evaluable tumors, 23 (22%) were FANCD2 foci negative, thus repair deficient.  To evaluate and compare novel-targeted agents in the background of FA deficiency, we utilized RNAi technology to render several lung cancer cell lines FANCD2 deficient.  Successful FANCD2 knockdown was confirmed by reduction in the FANCD2 protein.  Subsequently, we treated the FA defective H1299D2-down and A549D2-down NSCLC cells and their FA competent counterparts (empty vector controls) with the PARP inhibitors veliparib (ABT-888) (5 μM) and BMN673 (0.5 μM), as well as the CHK1 inhibitor Arry-575 at a dose of 0.5 μM.  We also treated the FA defective small cell lung cancer cell lines H719D2-down and H792D2-down and their controls with the BCL-2/XL inhibitor ABT-263 at a dose of 2 μM.  The treated cells were harvested at 24, 48, and 72 h post treatment.  MTT cell viability analysis showed that each agent was more cytotoxic to the FANCD2 knock-down cells.  In all tests, the FA defective lung cancer cells had less viable cells as comparing to controls 72 h post treatment.  Both MTT and clonogenic analyses comparing the two PARP inhibitors, showed that BMN673 was more potent compared to veliparib.  Given that FA pathway plays essential roles in response to DNA damage, our results suggest that a subset of lung cancer patients are likely to be more susceptible to DNA cross-link based therapy, or to treatments in which additional repair mechanisms are targeted.  These subjects can be identified through FATSI analysis.  Clinical trials to evaluate this therapeutic concept are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3SpAGegTY3HthwrmtH4OBfW6udTcc2eazIIVquYL2V7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvksFaitw%253D%253D&md5=e96d223c4459e2749129c71cd8d4ceb1</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2014.00368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2014.00368%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DAguila%26aufirst%3DB.%26aulast%3DKalvala%26aufirst%3DA.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DVillalona-Calero%26aufirst%3DM.%2BA.%26atitle%3DFanconi%2520anemia%2520repair%2520pathway%2520dysfunction%252C%2520a%2520potential%2520therapeutic%2520target%2520in%2520lung%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2014%26volume%3D4%26spage%3D368%26doi%3D10.3389%2Ffonc.2014.00368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Stoepker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faramarz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooimans, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Mil, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balk, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velleuer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ameziane, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Te Riele, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Winter, J. P.</span><span> </span><span class="NLM_article-title">DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity</span> <span class="citation_source-journal">DNA Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1016/j.dnarep.2014.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.dnarep.2014.12.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=54-64&author=C.+Stoepkerauthor=A.+Faramarzauthor=M.+A.+Rooimansauthor=S.+E.+van+Milauthor=J.+A.+Balkauthor=E.+Velleuerauthor=N.+Amezianeauthor=H.+Te+Rieleauthor=J.+P.+de+Winter&title=DNA+helicases+FANCM+and+DDX11+are+determinants+of+PARP+inhibitor+sensitivity&doi=10.1016%2Fj.dnarep.2014.12.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.dnarep.2014.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dnarep.2014.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DStoepker%26aufirst%3DC.%26aulast%3DFaramarz%26aufirst%3DA.%26aulast%3DRooimans%26aufirst%3DM.%2BA.%26aulast%3Dvan%2BMil%26aufirst%3DS.%2BE.%26aulast%3DBalk%26aufirst%3DJ.%2BA.%26aulast%3DVelleuer%26aufirst%3DE.%26aulast%3DAmeziane%26aufirst%3DN.%26aulast%3DTe%2BRiele%26aufirst%3DH.%26aulast%3Dde%2BWinter%26aufirst%3DJ.%2BP.%26atitle%3DDNA%2520helicases%2520FANCM%2520and%2520DDX11%2520are%2520determinants%2520of%2520PARP%2520inhibitor%2520sensitivity%26jtitle%3DDNA%2520Repair%26date%3D2015%26volume%3D26%26spage%3D54%26epage%3D64%26doi%3D10.1016%2Fj.dnarep.2014.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Bajrami, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankum, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehman, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafiq, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarewa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assiotis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenwick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natrajan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-2541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-13-2541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24240700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=287-297&author=I.+Bajramiauthor=J.+R.+Frankumauthor=A.+Kondeauthor=R.+E.+Millerauthor=F.+L.+Rehmanauthor=R.+Broughauthor=J.+Campbellauthor=D.+Simsauthor=R.+Rafiqauthor=S.+Hooperauthor=L.+N.+Chenauthor=I.+Kozarewaauthor=I.+Assiotisauthor=K.+Fenwickauthor=R.+Natrajanauthor=C.+J.+Lordauthor=A.+Ashworth&title=Genome-wide+profiling+of+genetic+synthetic+lethality+identifies+CDK12+as+a+novel+determinant+of+PARP1%2F2+inhibitor+sensitivity&doi=10.1158%2F0008-5472.CAN-13-2541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity</span></div><div class="casAuthors">Bajrami, Ilirjana; Frankum, Jessica R.; Konde, Asha; Miller, Rowan E.; Rehman, Farah L.; Brough, Rachel; Campbell, James; Sims, David; Rafiq, Rumana; Hooper, Sean; Chen, Lina; Kozarewa, Iwanka; Assiotis, Ioannis; Fenwick, Kerry; Natrajan, Rachael; Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">287-297</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of PARP1/2, such as olaparib, have been proposed to serve as a synthetic lethal therapy for cancers that harbor BRCA1 or BRCA2 mutations.  Indeed, in clin. trials, PARP1/2 inhibitors elicit sustained antitumor responses in patients with germline BRCA gene mutations.  In hypothesizing that addnl. genetic determinants might direct use of these drugs, we conducted a genome-wide synthetic lethal screen for candidate olaparib sensitivity genes.  In support of this hypothesis, the set of identified genes included known determinants of olaparib sensitivity, such as BRCA1, RAD51, and Fanconi's anemia susceptibility genes.  In addn., the set included genes implicated in established networks of DNA repair, DNA cohesion, and chromatin remodeling, none of which were known previously to confer sensitivity to PARP1/2 inhibition.  Notably, integration of the list of candidate sensitivity genes with data from tumor DNA sequencing studies identified CDK12 deficiency as a clin. relevant biomarker of PARP1/2 inhibitor sensitivity.  In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1.  As one of only nine genes known to be significantly mutated in HGS-OVCa, CDK12 has properties that should confirm interest in its use as a biomarker, particularly in ongoing clin. trials of PARP1/2 inhibitors and other agents that trigger replication fork arrest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNCJR_Nh_WjbVg90H21EOLACvtfcHk0lhxbnu4DacsJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjuw%253D%253D&md5=9e07aa538aed0fb3a5ac6be21659d051</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-2541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-2541%26sid%3Dliteratum%253Aachs%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DFrankum%26aufirst%3DJ.%2BR.%26aulast%3DKonde%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DR.%2BE.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DSims%26aufirst%3DD.%26aulast%3DRafiq%26aufirst%3DR.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DL.%2BN.%26aulast%3DKozarewa%26aufirst%3DI.%26aulast%3DAssiotis%26aufirst%3DI.%26aulast%3DFenwick%26aufirst%3DK.%26aulast%3DNatrajan%26aufirst%3DR.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DGenome-wide%2520profiling%2520of%2520genetic%2520synthetic%2520lethality%2520identifies%2520CDK12%2520as%2520a%2520novel%2520determinant%2520of%2520PARP1%252F2%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D287%26epage%3D297%26doi%3D10.1158%2F0008-5472.CAN-13-2541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Joshi, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntoon, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnitz, L. M.</span><span> </span><span class="NLM_article-title">Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">9247</span><span class="NLM_x">–</span> <span class="NLM_lpage">9253</span><span class="refDoi"> DOI: 10.1074/jbc.M114.551143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1074%2Fjbc.M114.551143" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=9247-9253&author=P.+M.+Joshiauthor=S.+L.+Sutorauthor=C.+J.+Huntoonauthor=L.+M.+Karnitz&title=Ovarian+cancer-associated+mutations+disable+catalytic+activity+of+CDK12%2C+a+kinase+that+promotes+homologous+recombination+repair+and+resistance+to+cisplatin+and+poly%28ADP-ribose%29+polymerase+inhibitors&doi=10.1074%2Fjbc.M114.551143"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.551143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.551143%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DP.%2BM.%26aulast%3DSutor%26aufirst%3DS.%2BL.%26aulast%3DHuntoon%26aufirst%3DC.%2BJ.%26aulast%3DKarnitz%26aufirst%3DL.%2BM.%26atitle%3DOvarian%2520cancer-associated%2520mutations%2520disable%2520catalytic%2520activity%2520of%2520CDK12%252C%2520a%2520kinase%2520that%2520promotes%2520homologous%2520recombination%2520repair%2520and%2520resistance%2520to%2520cisplatin%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D9247%26epage%3D9253%26doi%3D10.1074%2Fjbc.M114.551143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Ip, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulogiannis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viciano, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kofuji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spanswick, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhauser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewinner, C. A.</span><span> </span><span class="NLM_article-title">Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">10548</span><span class="NLM_x">–</span> <span class="NLM_lpage">10562</span><span class="refDoi"> DOI: 10.18632/oncotarget.3307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.3307" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10548-10562&author=L.+R.+Ipauthor=G.+Poulogiannisauthor=F.+C.+Vicianoauthor=J.+Sasakiauthor=S.+Kofujiauthor=V.+J.+Spanswickauthor=D.+Hochhauserauthor=J.+A.+Hartleyauthor=T.+Sasakiauthor=C.+A.+Gewinner&title=Loss+of+INPP4B+causes+a+DNA+repair+defect+through+loss+of+BRCA1%2C+ATM+and+ATR+and+can+be+targeted+with+PARP+inhibitor+treatment&doi=10.18632%2Foncotarget.3307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3307%26sid%3Dliteratum%253Aachs%26aulast%3DIp%26aufirst%3DL.%2BR.%26aulast%3DPoulogiannis%26aufirst%3DG.%26aulast%3DViciano%26aufirst%3DF.%2BC.%26aulast%3DSasaki%26aufirst%3DJ.%26aulast%3DKofuji%26aufirst%3DS.%26aulast%3DSpanswick%26aufirst%3DV.%2BJ.%26aulast%3DHochhauser%26aufirst%3DD.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DGewinner%26aufirst%3DC.%2BA.%26atitle%3DLoss%2520of%2520INPP4B%2520causes%2520a%2520DNA%2520repair%2520defect%2520through%2520loss%2520of%2520BRCA1%252C%2520ATM%2520and%2520ATR%2520and%2520can%2520be%2520targeted%2520with%2520PARP%2520inhibitor%2520treatment%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D10548%26epage%3D10562%26doi%3D10.18632%2Foncotarget.3307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Salmena, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fans, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narod, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotsopoulos, J.</span><span> </span><span class="NLM_article-title">Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer</span> <span class="citation_source-journal">Eur. J. Gynaecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26189250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FkslajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=260-267&author=L.+Salmenaauthor=P.+Shawauthor=I.+Fansauthor=+McLaughlinauthor=B.+Rosenauthor=H.+Rischauthor=C.+Mitchellauthor=P.+Sunauthor=S.+A.+Narodauthor=J.+Kotsopoulos&title=Prognostic+value+of+INPP4B+protein+immunohistochemistry+in+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer</span></div><div class="casAuthors">Salmena L; Shaw P; Fans I; McLaughlin; Rosen B; Risch H; Mitchell C; Sun P; Narod S A; Kotsopoulos J</div><div class="citationInfo"><span class="NLM_cas:title">European journal of gynaecological oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">260-7</span>
        ISSN:<span class="NLM_cas:issn">0392-2936</span>.
    </div><div class="casAbstract">PURPOSE OF INVESTIGATION:  Ovarian cancer is associated with poor prognosis and altered protein expression patterns may be useful for identifying patients likely to have poor disease outcomes.  The impact of altered INPP4B protein expression on prognosis is unclear.  The aim of this study was to evaluate the implication of INPP4B expression changes in a large series of ovarian cancer tissue samples.  MATERIALS AND METHODS:  Tissue microarrays were constructed from 599 epithelial ovarian tumors and stained with antibodies for INPP4B, p53, and PTEN.  Proportional hazard models were used to estimate survival hazard ratios (HRs) associated with altered protein expression.  RESULTS:  Seventy-nine percent of the ovarian cancers demonstrated loss of INPP4B, whereas 53% showed aberrant p53 expression (i.e., complete loss of p53 or over-expression of p53) and 8% showed loss of PTEN.  INPP4B was frequently lost in serous and endometrioid cancer subtypes, aberrant p53 expression was most common among serous subtype, and loss of PTEN was most common among endometrioid tumors (p for all three proteins across histologic subtypes ≤ 0.0001).  INPP4B loss or aberrant p53 expression were both associated with increased mortality (HR = 1.84; 95% CI 1.27 - 2.68 and HR = 3.10; 95% CI 2.33 - 4.11, respectively); however, in multivariate models, only the relationship with p53 achieved statistical significance (HR = 1.20; 95% CI 0.82 - 1.76 for INPP4B and HR = 1.73; 95% CI 1.28 - 2.34 for p53).  Conclusion: The INPP4B protein is frequently lost in serous and endometrioid subtypes of ovarian cancer.  A possible prognostic role of INPP4B for endometrioid ovarian tumors requires further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTH_GNAkXtkK-IHSmpohpd0fW6udTcc2eYLrIBuZ_25GLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FkslajsQ%253D%253D&md5=be6ee65120d07c350f3c7748f4183191</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalmena%26aufirst%3DL.%26aulast%3DShaw%26aufirst%3DP.%26aulast%3DFans%26aufirst%3DI.%26aulast%3DMcLaughlin%26aulast%3DRosen%26aufirst%3DB.%26aulast%3DRisch%26aufirst%3DH.%26aulast%3DMitchell%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DNarod%26aufirst%3DS.%2BA.%26aulast%3DKotsopoulos%26aufirst%3DJ.%26atitle%3DPrognostic%2520value%2520of%2520INPP4B%2520protein%2520immunohistochemistry%2520in%2520ovarian%2520cancer%26jtitle%3DEur.%2520J.%2520Gynaecol.%2520Oncol.%26date%3D2015%26volume%3D36%26spage%3D260%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Fraser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luoto, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coackley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshua, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bismar, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, R. G.</span><span> </span><span class="NLM_article-title">PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1027</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-11-2189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22114138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGhu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1015-1027&author=M.+Fraserauthor=H.+Zhaoauthor=K.+R.+Luotoauthor=C.+Lundinauthor=C.+Coackleyauthor=N.+Chanauthor=A.+M.+Joshuaauthor=T.+A.+Bismarauthor=A.+Evansauthor=T.+Helledayauthor=R.+G.+Bristow&title=PTEN+deletion+in+prostate+cancer+cells+does+not+associate+with+loss+of+RAD51+function%3A+implications+for+radiotherapy+and+chemotherapy&doi=10.1158%2F1078-0432.CCR-11-2189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy</span></div><div class="casAuthors">Fraser, Michael; Zhao, Helen; Luoto, Kaisa R.; Lundin, Cecilia; Coackley, Carla; Chan, Norman; Joshua, Anthony M.; Bismar, Tarek A.; Evans, Andrew; Helleday, Thomas; Bristow, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1015-1027</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE:PTEN deletions in prostate cancer are assocd. with tumor aggression and poor outcome.  Recent studies have implicated PTEN as a determinant of homologous recombination (HR) through defective RAD51 function.  Similar to BRCA1/2-defective tumor cells, PTEN-null prostate and other cancer cells have been reported to be sensitive to PARP inhibitors (PARPi).  To date, no direct comparison between PTEN and RAD51 expression in primary prostate tumors has been reported.  Exptl. Design: Prostate cancer cell lines and xenografts with known PTEN status (22RV1-PTEN+/+, DU145-PTEN+/-, PC3-PTEN-/-) and H1299 and HCT116 cancer cells were used to evaluate how PTEN loss affects RAD51 expression and PARPi sensitivity.  Primary prostate cancers with known PTEN status were analyzed for RAD51 expression.  RESULTS:PTEN status is not assocd. with reduced RAD51 mRNA or protein expression in primary prostate cancers.  Decreased PTEN expression did not reduce RAD51 expression or clonogenic survival following PARPi among prostate cancer cells that vary in TP53 and PTEN.  PARPi sensitivity instead assocd. with a defect in MRE11 expression.  PTEN-deficient cells had only mild PARPi sensitivity and no loss of HR or RAD51 recruitment.  Clonogenic cell survival following a series of DNA damaging agents was variable: PTEN-deficient cells were sensitive to ionizing radiation, mitomycin-C, UV, H2O2, and Me methanesulfonate but not to cisplatin, camptothecin, or paclitaxel.  CONCLUSIONS: These data suggest that the relationship between PTEN status and survival following DNA damage is indirect and complex.  It is unlikely that PTEN status will be a direct biomarker for HR status or PARPi response in prostate cancer clin. trials.  Clin Cancer Res; 18(4); 1015-27.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdSEknO1ii17Vg90H21EOLACvtfcHk0li4FeAB_EwAGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGhu78%253D&md5=4587c3be1a7b7930edab02d67d45ac54</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2189%26sid%3Dliteratum%253Aachs%26aulast%3DFraser%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLuoto%26aufirst%3DK.%2BR.%26aulast%3DLundin%26aufirst%3DC.%26aulast%3DCoackley%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DN.%26aulast%3DJoshua%26aufirst%3DA.%2BM.%26aulast%3DBismar%26aufirst%3DT.%2BA.%26aulast%3DEvans%26aufirst%3DA.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DBristow%26aufirst%3DR.%2BG.%26atitle%3DPTEN%2520deletion%2520in%2520prostate%2520cancer%2520cells%2520does%2520not%2520associate%2520with%2520loss%2520of%2520RAD51%2520function%253A%2520implications%2520for%2520radiotherapy%2520and%2520chemotherapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1015%26epage%3D1027%26doi%3D10.1158%2F1078-0432.CCR-11-2189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Hunt, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horikoshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, T. K.</span><span> </span><span class="NLM_article-title">Does PTEN loss impair DNA double-strand break repair by homologous recombination?</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">920</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-11-3131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22179663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGgsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=920-922&author=C.+R.+Huntauthor=A.+Guptaauthor=N.+Horikoshiauthor=T.+K.+Pandita&title=Does+PTEN+loss+impair+DNA+double-strand+break+repair+by+homologous+recombination%3F&doi=10.1158%2F1078-0432.CCR-11-3131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Does PTEN Loss Impair DNA Double-Strand Break Repair by Homologous Recombination?</span></div><div class="casAuthors">Hunt, Clayton R.; Gupta, Arun; Horikoshi, Nobuo; Pandita, Tej K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">920-922</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The tumor suppressor PTEN is frequently lost in cancer cells, resulting in altered radiation and drug sensitivity.  However, the role of PTEN in DNA repair is controversial.  Detailed studies in prostate cancer cells now indicate PTEN does not regulate RAD51 expression or homologous recombination and is not a biomarker for PARP inhibitor sensitivity.  Clin Cancer Res; 18(4); 920-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaJF1ZTOF0wrVg90H21EOLACvtfcHk0li4FeAB_EwAGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGgsrc%253D&md5=376c7ca945c950f2c2ae55bf30b0882b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3131%26sid%3Dliteratum%253Aachs%26aulast%3DHunt%26aufirst%3DC.%2BR.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHorikoshi%26aufirst%3DN.%26aulast%3DPandita%26aufirst%3DT.%2BK.%26atitle%3DDoes%2520PTEN%2520loss%2520impair%2520DNA%2520double-strand%2520break%2520repair%2520by%2520homologous%2520recombination%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D920%26epage%3D922%26doi%3D10.1158%2F1078-0432.CCR-11-3131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Freeman, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteiro, A. N.</span><span> </span><span class="NLM_article-title">Phosphatases in the cellular response to DNA damage</span> <span class="citation_source-journal">Cell Commun. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="refDoi"> DOI: 10.1186/1478-811X-8-27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2F1478-811X-8-27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20860841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC3cfosFOitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=27&author=A.+K.+Freemanauthor=A.+N.+Monteiro&title=Phosphatases+in+the+cellular+response+to+DNA+damage&doi=10.1186%2F1478-811X-8-27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatases in the cellular response to DNA damage</span></div><div class="casAuthors">Freeman Alyson K; Monteiro Alvaro Na</div><div class="citationInfo"><span class="NLM_cas:title">Cell communication and signaling : CCS</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract"> In the last fifteen years, rapid progress has been made in delineating the cellular response to DNA damage.  The DNA damage response network is composed of a large number of proteins with different functions that detect and signal the presence of DNA damage in order to coordinate DNA repair with a variety of cellular processes, notably cell cycle progression.  This signal, which radiates from the chromatin template, is driven primarily by phosphorylation events, mainly on serine and threonine residues.  While we have accumulated detailed information about kinases and their substrates our understanding of the role of phosphatases in the DNA damage response is still preliminary.  Identifying the phosphatases and their regulation will be instrumental to obtain a complete picture of the dynamics of the DNA damage response.  Here we give an overview of the DNA damage response in mammalian cells and then review the data on the role of different phosphatases and discuss their biological relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhDrrK_lAT3jQLBVDQn4bCfW6udTcc2eZTv8pAAJO61rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfosFOitA%253D%253D&md5=66d2062f064ff876f379964fc2028283</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1186%2F1478-811X-8-27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1478-811X-8-27%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DA.%2BK.%26aulast%3DMonteiro%26aufirst%3DA.%2BN.%26atitle%3DPhosphatases%2520in%2520the%2520cellular%2520response%2520to%2520DNA%2520damage%26jtitle%3DCell%2520Commun.%2520Signaling%26date%3D2010%26volume%3D8%26spage%3D27%26doi%3D10.1186%2F1478-811X-8-27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Kalev, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simicek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sablina, A.</span><span> </span><span class="NLM_article-title">Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">6414</span><span class="NLM_x">–</span> <span class="NLM_lpage">6424</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-1667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-12-1667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23087057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyns7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=6414-6424&author=P.+Kalevauthor=M.+Simicekauthor=I.+Vazquezauthor=S.+Munckauthor=L.+Chenauthor=T.+Soinauthor=N.+Dandaauthor=W.+Chenauthor=A.+Sablina&title=Loss+of+PPP2R2A+inhibits+homologous+recombination+DNA+repair+and+predicts+tumor+sensitivity+to+PARP+inhibition&doi=10.1158%2F0008-5472.CAN-12-1667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition</span></div><div class="casAuthors">Kalev, Peter; Simicek, Michal; Vazquez, Iria; Munck, Sebastian; Chen, Liping; Soin, Thomas; Danda, Natasha; Chen, Wen; Sablina, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6414-6424</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings suggest that downregulation of a PP2A family phosphatase in tumors may predict therapeutic responses to a promising new class of anticancer agents currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3mqXzgrVh4LVg90H21EOLACvtfcHk0ljO7t1qg2_8mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyns7rK&md5=b93954d366c436b42e61d924466bc717</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-1667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-1667%26sid%3Dliteratum%253Aachs%26aulast%3DKalev%26aufirst%3DP.%26aulast%3DSimicek%26aufirst%3DM.%26aulast%3DVazquez%26aufirst%3DI.%26aulast%3DMunck%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSoin%26aufirst%3DT.%26aulast%3DDanda%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSablina%26aufirst%3DA.%26atitle%3DLoss%2520of%2520PPP2R2A%2520inhibits%2520homologous%2520recombination%2520DNA%2520repair%2520and%2520predicts%2520tumor%2520sensitivity%2520to%2520PARP%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D6414%26epage%3D6424%26doi%3D10.1158%2F0008-5472.CAN-12-1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Curtis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turashvili, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueda, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunning, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speed, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samarajiwa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gräf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haffari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bashashati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">METABRIC Group</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langerød, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provenzano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markowetz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purushotham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Børresen-Dale, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenton, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavaré, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, S.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1038/nature10983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnature10983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22522925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslSnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=346-352&author=C.+Curtisauthor=S.+P.+Shahauthor=S.+F.+Chinauthor=G.+Turashviliauthor=O.+M.+Ruedaauthor=M.+J.+Dunningauthor=D.+Speedauthor=A.+G.+Lynchauthor=S.+Samarajiwaauthor=Y.+Yuanauthor=S.+Gr%C3%A4fauthor=G.+Haauthor=G.+Haffariauthor=A.+Bashashatiauthor=R.+Russellauthor=S.+McKinneyauthor=METABRIC+Groupauthor=A.+Langer%C3%B8dauthor=A.+Greenauthor=E.+Provenzanoauthor=G.+Wishartauthor=S.+Pinderauthor=P.+Watsonauthor=F.+Markowetzauthor=L.+Murphyauthor=I.+Ellisauthor=A.+Purushothamauthor=A.+L.+B%C3%B8rresen-Daleauthor=J.+D.+Brentonauthor=S.+Tavar%C3%A9author=C.+Caldasauthor=S.+Aparicio&title=The+genomic+and+transcriptomic+architecture+of+2%2C000+breast+tumours+reveals+novel+subgroups&doi=10.1038%2Fnature10983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">The genomic and transcriptomic architecture of 2,000 breast tumors reveals novel subgroups</span></div><div class="casAuthors">Curtis, Christina; Shah, Sohrab P.; Chin, Suet-Feung; Turashvili, Gulisa; Rueda, Oscar M.; Dunning, Mark J.; Speed, Doug; Lynch, Andy G.; Samarajiwa, Shamith; Yuan, Yinyin; Graef, Stefan; Ha, Gavin; Haffari, Gholamreza; Bashashati, Ali; Russell, Roslin; McKinney, Steven; Caldas, Carlos; Aparicio, Samuel; Curtis, Christina; Caldas, Carlos; Aparicio, Samuel; Brenton, James D.; Ellis, Ian; Huntsman, David; Pinder, Sarah; Purushotham, Arnie; Murphy, Leigh; Caldas, Carlos; Aparicio, Samuel; Caldas, Carlos; Bardwell, Helen; Chin, Suet-Feung; Curtis, Christina; Ding, Zhihao; Graef, Stefan; Jones, Linda; Liu, Bin; Papatheodorou, Irene; Sammut, Stephen J.; Wishart, Gordon; Aparicio, Samuel; Chia, Steven; Gelmon, Karen; Speers, Caroline; Watson, Peter; Ellis, Ian; Blamey, Roger; Green, Andrew; MacMillan, Douglas; Rakha, Emad; Gillett, Cheryl; Grigoriadis, Anita; Pinder, Sarah; di Rinaldis, Emanuele; Tutt, Andy; Parisien, Michelle; Troup, Sandra; Caldas, Carlos; Chin, Suet-Feung; Chan, Derek; Fielding, Claire; Maia, Ana-Teresa; McGuire, Sarah; Osborne, Michelle; Sayalero, Sara M.; Spiteri, Inmaculada; Hadfield, James; Aparicio, Samuel; Bell, Lynda; Chow, Katie; Gale, Nadia; Kovalik, Maria; Ng, Ying; Prentice, Leah; Caldas, Carlos; Tavare, Simon; Curtis, Christina; Dunning, Mark J.; Graef, Stefan; Rueda, Oscar M.; Speed, Doug; Markowetz, Florian; Yuan, Yinyin; Brenton, James D.; Aparicio, Samuel; Bashashati, Ali; Ha, Gavin; Langerod, Anita; Green, Andrew; Provenzano, Elena; Pinder, Sarah; Watson, Peter; Ellis, Ian; Borresen-Dale, Anne-Lise; Brenton, James D.; Caldas, Carlos; Aparicio, Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7403</span>),
    <span class="NLM_cas:pages">346-352</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The elucidation of breast cancer subgroups and their mol. drivers requires integrated views of the genome and transcriptome from representative nos. of patients.  We present an integrated anal. of copy no. and gene expression in a discovery and validation set of 997 and 995 primary breast tumors, resp., with long-term clin. follow-up.  Inherited variants (copy no. variants and single nucleotide polymorphisms) and acquired somatic copy no. aberrations (CNAs) were assocd. with expression in ∼40% of genes, with the landscape dominated by cis- and trans-acting CNAs.  By delineating expression outlier genes driven in cis by CNAs, we identified putative cancer genes, including deletions in PPP2R2A, MTAP and MAP2K4.  Unsupervised anal. of paired DNA-RNA profiles revealed novel subgroups with distinct clin. outcomes, which reproduced in the validation cohort.  These include a high-risk, estrogen-receptor-pos. 11q13/14 cis-acting subgroup and a favorable prognosis subgroup devoid of CNAs.  Trans-acting aberration hotspots were found to modulate subgroup-specific gene networks, including a TCR deletion-mediated adaptive immune response in the CNA-devoid' subgroup and a basal-specific chromosome 5 deletion-assocd. mitotic network.  Our results provide a novel mol. stratification of the breast cancer population, derived from the impact of somatic CNAs on the transcriptome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGU8faP0OgmbVg90H21EOLACvtfcHk0ljO7t1qg2_8mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslSnsL8%253D&md5=7208505099b57dd63c339352935bf60a</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fnature10983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10983%26sid%3Dliteratum%253Aachs%26aulast%3DCurtis%26aufirst%3DC.%26aulast%3DShah%26aufirst%3DS.%2BP.%26aulast%3DChin%26aufirst%3DS.%2BF.%26aulast%3DTurashvili%26aufirst%3DG.%26aulast%3DRueda%26aufirst%3DO.%2BM.%26aulast%3DDunning%26aufirst%3DM.%2BJ.%26aulast%3DSpeed%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DA.%2BG.%26aulast%3DSamarajiwa%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DGr%25C3%25A4f%26aufirst%3DS.%26aulast%3DHa%26aufirst%3DG.%26aulast%3DHaffari%26aufirst%3DG.%26aulast%3DBashashati%26aufirst%3DA.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DMcKinney%26aufirst%3DS.%26aulast%3D%26aulast%3DLanger%25C3%25B8d%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DProvenzano%26aufirst%3DE.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DPinder%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DP.%26aulast%3DMarkowetz%26aufirst%3DF.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DEllis%26aufirst%3DI.%26aulast%3DPurushotham%26aufirst%3DA.%26aulast%3DB%25C3%25B8rresen-Dale%26aufirst%3DA.%2BL.%26aulast%3DBrenton%26aufirst%3DJ.%2BD.%26aulast%3DTavar%25C3%25A9%26aufirst%3DS.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DAparicio%26aufirst%3DS.%26atitle%3DThe%2520genomic%2520and%2520transcriptomic%2520architecture%2520of%25202%252C000%2520breast%2520tumours%2520reveals%2520novel%2520subgroups%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D346%26epage%3D352%26doi%3D10.1038%2Fnature10983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Mao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yáñez-Muñoz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berney, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y. J.</span><span> </span><span class="NLM_article-title">Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer</span> <span class="citation_source-journal">Am. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">604</span><span class="NLM_x">–</span> <span class="NLM_lpage">617</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21994901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC3Mbgsl2jsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=604-617&author=X.+Maoauthor=L.+K.+Boydauthor=R.+J.+Y%C3%A1%C3%B1ez-Mu%C3%B1ozauthor=T.+Chaplinauthor=L.+Xueauthor=D.+Linauthor=L.+Shanauthor=D.+M.+Berneyauthor=B.+D.+Youngauthor=Y.+J.+Lu&title=Chromosome+rearrangement+associated+inactivation+of+tumour+suppressor+genes+in+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer</span></div><div class="casAuthors">Mao Xueying; Boyd Lara K; Yanez-Munoz Rafael J; Chaplin Tracy; Xue Liyan; Lin Dongmei; Shan Ling; Berney Daniel M; Young Bryan D; Lu Yong-Jie</div><div class="citationInfo"><span class="NLM_cas:title">American journal of cancer research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">604-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Prostate cancer, the most common male cancer in Western countries, is commonly detected with complex chromosomal rearrangements.  Following the discovery of the recurrent TMPRSS2:ETS fusions in prostate cancer and EML4:ALK in non-small-cell lung cancer, it is now accepted that fusion genes not only are the hallmark of haematological malignancies and sarcomas, but also play an important role in epithelial cell carcinogenesis.  However, previous studies aiming to identify fusion genes in prostate cancer were mainly focused on expression changes and fusion transcripts.  To investigate the genes recurrently affected by the chromosome breakpoints in prostate cancer, we analysed Affymetrix array 6.0 and 500K SNP microarray data from 77 prostate cancer samples.  While the two genes most frequently affected by genomic breakpoints were, as expected, ERG and TMPRSS2, surprisingly more known tumour suppressor genes (TSGs) than known oncogenes were identified at recurrent chromosome breakpoints.  Certain well-characterised TSGs, including p53, PTEN, BRCA1 and BRCA2 are recurrently truncated as a result of chromosome rearrangements in prostate cancer.  Interestingly, many of the genes residing at recurrent breakpoint sites have not yet been implicated in prostate carcinogenesis such as HOOK3, PPP2R2A and TCBA1.  We have confirmed the generally reduced expression of selected genes in clinical samples using quantitative RT-PCR analysis.  Subsequently, we further investigated the genes associated with the t(4:6) translocation in LNCaP cells and reveal the genomic fusion of SNX9 and putative TSG UNC5C, which led to the reduced expression of both genes.  This study reveals another common mechanism that leads to the inactivation of TSGs in prostate cancer and the identification of multiple TSGs inactivated by chromosome rearrangements will lead to new direction of research for the molecular basis of prostate carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqlQDJ948WETjk2McQZ6XmfW6udTcc2eYsyIjUd5T0rLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mbgsl2jsA%253D%253D&md5=7a3e133f116b5bb166835902ef51eb1f</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DX.%26aulast%3DBoyd%26aufirst%3DL.%2BK.%26aulast%3DY%25C3%25A1%25C3%25B1ez-Mu%25C3%25B1oz%26aufirst%3DR.%2BJ.%26aulast%3DChaplin%26aufirst%3DT.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DL.%26aulast%3DBerney%26aufirst%3DD.%2BM.%26aulast%3DYoung%26aufirst%3DB.%2BD.%26aulast%3DLu%26aufirst%3DY.%2BJ.%26atitle%3DChromosome%2520rearrangement%2520associated%2520inactivation%2520of%2520tumour%2520suppressor%2520genes%2520in%2520prostate%2520cancer%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2011%26volume%3D1%26spage%3D604%26epage%3D617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Cousineau, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmaaza, A.</span><span> </span><span class="NLM_article-title">EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases</span> <span class="citation_source-journal">Mol. Genet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1007/s00438-011-0612-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1007%2Fs00438-011-0612-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21409565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVSksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2011&pages=325-340&author=I.+Cousineauauthor=A.+Belmaaza&title=EMSY+overexpression+disrupts+the+BRCA2%2FRAD51+pathway+in+the+DNA-damage+response%3A+implications+for+chromosomal+instability%2Frecombination+syndromes+as+checkpoint+diseases&doi=10.1007%2Fs00438-011-0612-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases</span></div><div class="casAuthors">Cousineau, Isabelle; Belmaaza, Abdellah</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Genetics and Genomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">325-340</span>CODEN:
                <span class="NLM_cas:coden">MGGOAA</span>;
        ISSN:<span class="NLM_cas:issn">1617-4615</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">EMSY links the BRCA2 pathway to sporadic breast/ovarian cancer.  It encodes a nuclear protein that binds to the BRCA2 N-terminal domain implicated in chromatin/transcription regulation, but when sporadically amplified/overexpressed, increased EMSY level represses BRCA2 transactivation potential and induces chromosomal instability, mimicking the activity of BRCA2 mutations in the development of hereditary breast/ovarian cancer.  In addn. to chromatin/transcription regulation, EMSY may also play a role in the DNA-damage response, suggested by its ability to localize at chromatin sites of DNA damage/repair.  This implies that EMSY overexpression may also repress BRCA2 in DNA-damage replication/checkpoint and recombination/repair, coordinated processes that also require its interacting proteins: PALB2, the partner and localizer of BRCA2; RPA, replication/checkpoint protein A; and RAD51, the inseparable recombination/repair enzyme.  Here, using a well-characterized recombination/repair assay system, we demonstrate that a slight increase in EMSY level can indeed repress these two processes independently of transcriptional interference/repression.  Since EMSY, RPA and PALB2 all bind to the same BRCA2 region, these findings further support a scenario wherein: (a) EMSY amplification may mimic BRCA2 deficiency, at least by overriding RPA and PALB2, crippling the BRCA2/RAD51 complex at DNA-damage and replication/transcription sites; and (b) BRCA2/RAD51 may coordinate these processes by employing at least EMSY, PALB2 and RPA.  We extensively discuss the mol. details of how this can happen to ascertain its implications for a novel recombination mechanism apparently conceived as checkpoint rather than a DNA repair system for cell division, survival, death, and human diseases, including the tissue specificity of cancer predisposition, which may renew our thinking about targeted therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrajDnZET1akbVg90H21EOLACvtfcHk0lis8WEQn7VODQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVSksL4%253D&md5=784f1daa7512496d432a30c272940ce8</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1007%2Fs00438-011-0612-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00438-011-0612-5%26sid%3Dliteratum%253Aachs%26aulast%3DCousineau%26aufirst%3DI.%26aulast%3DBelmaaza%26aufirst%3DA.%26atitle%3DEMSY%2520overexpression%2520disrupts%2520the%2520BRCA2%252FRAD51%2520pathway%2520in%2520the%2520DNA-damage%2520response%253A%2520implications%2520for%2520chromosomal%2520instability%252Frecombination%2520syndromes%2520as%2520checkpoint%2520diseases%26jtitle%3DMol.%2520Genet.%2520Genomics%26date%3D2011%26volume%3D285%26spage%3D325%26epage%3D340%26doi%3D10.1007%2Fs00438-011-0612-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Lee, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ann, D. K.</span><span> </span><span class="NLM_article-title">HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">5784</span><span class="NLM_x">–</span> <span class="NLM_lpage">5798</span><span class="refDoi"> DOI: 10.1093/nar/gkt231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fnar%2Fgkt231" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=5784-5798&author=Y.+H.+Leeauthor=C.+Y.+Kuoauthor=J.+M.+Starkauthor=H.+M.+Shihauthor=D.+K.+Ann&title=HP1+promotes+tumor+suppressor+BRCA1+functions+during+the+DNA+damage+response&doi=10.1093%2Fnar%2Fgkt231"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkt231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkt231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BH.%26aulast%3DKuo%26aufirst%3DC.%2BY.%26aulast%3DStark%26aufirst%3DJ.%2BM.%26aulast%3DShih%26aufirst%3DH.%2BM.%26aulast%3DAnn%26aufirst%3DD.%2BK.%26atitle%3DHP1%2520promotes%2520tumor%2520suppressor%2520BRCA1%2520functions%2520during%2520the%2520DNA%2520damage%2520response%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2013%26volume%3D41%26spage%3D5784%26epage%3D5798%26doi%3D10.1093%2Fnar%2Fgkt231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Lee, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ann, D. K.</span><span> </span><span class="NLM_article-title">HP1beta is a biomarker for breast cancer prognosis and PARP inhibitor therapy</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0121207</span><span class="refDoi"> DOI: 10.1371/journal.pone.0121207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1371%2Fjournal.pone.0121207" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0121207&author=Y.+H.+Leeauthor=X.+Liuauthor=F.+Qiuauthor=T.+R.+O%E2%80%99Connorauthor=Y.+Yenauthor=D.+K.+Ann&title=HP1beta+is+a+biomarker+for+breast+cancer+prognosis+and+PARP+inhibitor+therapy&doi=10.1371%2Fjournal.pone.0121207"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0121207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0121207%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DT.%2BR.%26aulast%3DYen%26aufirst%3DY.%26aulast%3DAnn%26aufirst%3DD.%2BK.%26atitle%3DHP1beta%2520is%2520a%2520biomarker%2520for%2520breast%2520cancer%2520prognosis%2520and%2520PARP%2520inhibitor%2520therapy%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0121207%26doi%3D10.1371%2Fjournal.pone.0121207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Sourisseau, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniotis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span> </span><span class="NLM_article-title">Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition</span> <span class="citation_source-journal">EMBO Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1002/emmm.201000068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1002%2Femmm.201000068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20373286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksleltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=130-142&author=T.+Sourisseauauthor=D.+Maniotisauthor=A.+McCarthyauthor=C.+Tangauthor=C.+J.+Lordauthor=A.+Ashworthauthor=S.+Linardopoulos&title=Aurora-A+expressing+tumour+cells+are+deficient+for+homology-directed+DNA+double+strand-break+repair+and+sensitive+to+PARP+inhibition&doi=10.1002%2Femmm.201000068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition</span></div><div class="casAuthors">Sourisseau, Tony; Maniotis, Despina; McCarthy, Afshan; Tang, Chan; Lord, Christopher J.; Ashworth, Alan; Linardopoulos, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">130-142</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The protein kinase Aurora-A is a major regulator of the cell cycle that orchestrates mitotic entry and is required for the assembly of a functional mitotic spindle.  Overexpression of Aurora-A has been strongly linked with oncogenesis and this has led to considerable efforts at therapeutic targeting of the kinase activity of this protein.  However, the exact mechanism by which Aurora-A promotes oncogenesis remains unclear.  Here, we show that Aurora-A modulates the repair of DNA double-strand breaks (DSBs).  Aurora-A expression inhibits RAD51 recruitment to DNA DSBs, decreases DSB repair by homologous recombination and sensitizes cancer cells to PARP inhibition.  This impairment of RAD51 function requires inhibition of CHK1 by Polo-like kinase 1 (PLK1).  These results identify a novel function of Aurora-A in modulating the response to DNA DSB that likely contributes to carcinogenesis and suggest a novel therapeutic approach to the treatment of cancers overexpressing this protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWpJRvQOJvJbVg90H21EOLACvtfcHk0lis8WEQn7VODQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksleltbc%253D&md5=964227ea8a8dbe74d43ae9a1fa1c5ecf</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Femmm.201000068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201000068%26sid%3Dliteratum%253Aachs%26aulast%3DSourisseau%26aufirst%3DT.%26aulast%3DManiotis%26aufirst%3DD.%26aulast%3DMcCarthy%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DLinardopoulos%26aufirst%3DS.%26atitle%3DAurora-A%2520expressing%2520tumour%2520cells%2520are%2520deficient%2520for%2520homology-directed%2520DNA%2520double%2520strand-break%2520repair%2520and%2520sensitive%2520to%2520PARP%2520inhibition%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D130%26epage%3D142%26doi%3D10.1002%2Femmm.201000068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to therapies targeting BRCA-mutant cancers</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1381</span><span class="NLM_x">–</span> <span class="NLM_lpage">1388</span><span class="refDoi"> DOI: 10.1038/nm.3369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnm.3369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24202391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCnu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1381-1388&author=C.+J.+Lordauthor=A.+Ashworth&title=Mechanisms+of+resistance+to+therapies+targeting+BRCA-mutant+cancers&doi=10.1038%2Fnm.3369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to therapies targeting BRCA-mutant cancers</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1381-1388</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Synthetic lethality provides a potential mechanistic framework for the therapeutic targeting of genetic and functional deficiencies in cancers and is now being explored widely.  The first clin. exemplification of synthetic lethality in cancer has been the exploitation of inhibitors of poly-(ADP-ribose) polymerase (PARP) for the treatment of cancers with defects in the BRCA1 or BRCA2 tumor suppressor proteins, which are involved in the repair of DNA damage.  Although this approach has shown promise, multiple potential resistance mechanisms have been identified.  In this Perspective, we discuss these mechanisms and their relevance to the development of selective therapies for BRCA-deficient cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFkqSnv4Qj47Vg90H21EOLACvtfcHk0liZJhDFm8EiMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCnu73O&md5=40a356f8df2f32143f1ff22aff1ce536</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fnm.3369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3369%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520therapies%2520targeting%2520BRCA-mutant%2520cancers%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1381%26epage%3D1388%26doi%3D10.1038%2Fnm.3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Feng, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, A. M.</span><span> </span><span class="NLM_article-title">Molecular pathways: targeting ETS gene fusions in cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4442</span><span class="NLM_x">–</span> <span class="NLM_lpage">4448</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-13-0275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24958807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=4442-4448&author=F.+Y.+Fengauthor=J.+C.+Brennerauthor=M.+Hussainauthor=A.+M.+Chinnaiyan&title=Molecular+pathways%3A+targeting+ETS+gene+fusions+in+cancer&doi=10.1158%2F1078-0432.CCR-13-0275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting ETS Gene Fusions in Cancer</span></div><div class="casAuthors">Feng, Felix Y.; Brenner, J. Chad; Hussain, Maha; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4442-4448</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Rearrangements, or gene fusions, involving the ETS family of transcription factors are common driving events in both prostate cancer and Ewing sarcoma.  These rearrangements result in pathogenic expression of the ETS genes and trigger activation of transcriptional programs enriched for invasion and other oncogenic features.  Although ETS gene fusions represent intriguing therapeutic targets, transcription factors, such as those comprising the ETS family, have been notoriously difficult to target.  Recently, preclin. studies have demonstrated an assocn. between ETS gene fusions and components of the DNA damage response pathway, such as PARP1, the catalytic subunit of DNA protein kinase (DNAPK), and histone deactylase 1 (HDAC1), and have suggested that ETS fusions may confer sensitivity to inhibitors of these DNA repair proteins.  In this review, we discuss the role of ETS fusions in cancer, the preclin. rationale for targeting ETS fusions with inhibitors of PARP1, DNAPK, and HDAC1, as well as ongoing clin. trials targeting ETS gene fusions.  Clin Cancer Res; 20(17); 4442-8. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGazkuDaafoLVg90H21EOLACvtfcHk0liZJhDFm8EiMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykurbK&md5=2d11cdc166b255590012124d91c720a7</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0275%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DBrenner%26aufirst%3DJ.%2BC.%26aulast%3DHussain%26aufirst%3DM.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DMolecular%2520pathways%253A%2520targeting%2520ETS%2520gene%2520fusions%2520in%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D4442%26epage%3D4448%26doi%3D10.1158%2F1078-0432.CCR-13-0275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Brenner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bou-Maroun, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonigro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prensner, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlins, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, A. M.</span><span> </span><span class="NLM_article-title">PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1608</span><span class="NLM_x">–</span> <span class="NLM_lpage">1613</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-11-3648" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1608-1613&author=J.+C.+Brennerauthor=F.+Y.+Fengauthor=S.+Hanauthor=S.+Patelauthor=S.+V.+Goyalauthor=L.+M.+Bou-Marounauthor=M.+Liuauthor=R.+Lonigroauthor=J.+R.+Prensnerauthor=S.+A.+Tomlinsauthor=A.+M.+Chinnaiyan&title=PARP-1+inhibition+as+a+targeted+strategy+to+treat+Ewing%E2%80%99s+sarcoma&doi=10.1158%2F0008-5472.CAN-11-3648"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3648%26sid%3Dliteratum%253Aachs%26aulast%3DBrenner%26aufirst%3DJ.%2BC.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DGoyal%26aufirst%3DS.%2BV.%26aulast%3DBou-Maroun%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLonigro%26aufirst%3DR.%26aulast%3DPrensner%26aufirst%3DJ.%2BR.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DPARP-1%2520inhibition%2520as%2520a%2520targeted%2520strategy%2520to%2520treat%2520Ewing%25E2%2580%2599s%2520sarcoma%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1608%26epage%3D1613%26doi%3D10.1158%2F0008-5472.CAN-11-3648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Tang, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sousa, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajapakse, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing sarcoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4184</span><span class="NLM_x">–</span> <span class="NLM_lpage">4193</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-14-2112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25779942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFejtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4184-4193&author=S.+W.+Tangauthor=S.+Bilkeauthor=L.+Caoauthor=J.+Muraiauthor=F.+G.+Sousaauthor=M.+Yamadeauthor=V.+Rajapakseauthor=S.+Varmaauthor=L.+J.+Helmanauthor=J.+Khanauthor=P.+S.+Meltzerauthor=Y.+Pommier&title=SLFN11+is+a+transcriptional+target+of+EWS-FLI1+and+a+determinant+of+drug+response+in+Ewing+sarcoma&doi=10.1158%2F1078-0432.CCR-14-2112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma</span></div><div class="casAuthors">Tang, Sai-Wen; Bilke, Sven; Cao, Liang; Murai, Junko; Sousa, Fabricio G.; Yamade, Mihoko; Rajapakse, Vinodh; Varma, Sudhir; Helman, Lee J.; Khan, Javed; Meltzer, Paul S.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4184-4193</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: SLFN11 was identified as a crit. determinant of response to DNA-targeted therapies by analyzing gene expression and drug sensitivity of NCI-60 and CCLE datasets.  However, how SLFN11 is regulated in cancer cells remained unknown.  Ewing sarcoma, which is characterized by the chimeric transcription factor EWS-FLI1, has notably high SLFN11 expression, leading us to investigate whether EWS-FLI1 drives SLFN11 expression and the role of SLFN11 in the drug response of Ewing sarcoma cells.  Exptl. Design: Binding sites of EWS-FLI1 on the SLFN11 promoter were analyzed by chromatin immunopptn. sequencing and promoter-luciferase reporter analyses.  The relationship between SLFN11 and EWS-FLI1 were further examd. in EWS-FLI1-knockdown or -overexpressing cells and in clin. tumor samples.  Results: EWS-FLI1 binds near the transcription start site of SLFN11 promoter and acts as a pos. regulator of SLFN11 expression in Ewing sarcoma cells.  EWS-FLI1-mediated SLFN11 expression is responsible for high sensitivity of Ewing sarcoma to camptothecin and combinations of PARP inhibitors with temozolomide.  Importantly, Ewing sarcoma patients with higher SLFN11 expression showed better tumor-free survival rate.  The correlated expression between SLFN11 and FLI1 extends to leukemia, pediatric, colon, breast, and prostate cancers.  In addn., expression of other ETS members correlates with SLFN11 in NCI-60 and CCLE datasets, and mol. expts. demonstrate that ETS1 acts as a pos. regulator for SLFN11 expression in breast cancer cells.  Conclusions: Our results imply the emerging relevance of SLFN11 as an ETS transcription factor response gene and for therapeutic response to topoisomerase I inhibitors and temozolomide-PARP inhibitor combinations in ETS-activated cancers.  Clin Cancer Res; 21(18); 4184-93. cpr2015 AACR.  See related commentary by Kovar, p.  4033.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIQ7RMcCPdarVg90H21EOLACvtfcHk0liZJhDFm8EiMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFejtrfF&md5=3b9b84116df3793da7de2a0cd27b0f07</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2112%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DS.%2BW.%26aulast%3DBilke%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DSousa%26aufirst%3DF.%2BG.%26aulast%3DYamade%26aufirst%3DM.%26aulast%3DRajapakse%26aufirst%3DV.%26aulast%3DVarma%26aufirst%3DS.%26aulast%3DHelman%26aufirst%3DL.%2BJ.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DMeltzer%26aufirst%3DP.%2BS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DSLFN11%2520is%2520a%2520transcriptional%2520target%2520of%2520EWS-FLI1%2520and%2520a%2520determinant%2520of%2520drug%2520response%2520in%2520Ewing%2520sarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D4184%26epage%3D4193%26doi%3D10.1158%2F1078-0432.CCR-14-2112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Sandhu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelman, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hylands, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riisnaes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forster, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreischer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thway, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gevensleben, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iannone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenham, R. M.</span><span> </span><span class="NLM_article-title">The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span><span class="refDoi"> DOI: 10.1016/S1470-2045(13)70240-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS1470-2045%2813%2970240-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23810788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=882-892&author=S.+K.+Sandhuauthor=W.+R.+Schelmanauthor=G.+Wildingauthor=V.+Morenoauthor=R.+D.+Bairdauthor=S.+Mirandaauthor=L.+Hylandsauthor=R.+Riisnaesauthor=M.+Forsterauthor=A.+Omlinauthor=N.+Kreischerauthor=K.+Thwayauthor=H.+Gevenslebenauthor=L.+Sunauthor=J.+Loughneyauthor=M.+Chatterjeeauthor=C.+Toniattiauthor=C.+L.+Carpenterauthor=R.+Iannoneauthor=S.+B.+Kayeauthor=J.+S.+de+Bonoauthor=R.+M.+Wenham&title=The+poly%28ADP-ribose%29+polymerase+inhibitor+niraparib+%28MK4827%29+in+BRCA+mutation+carriers+and+patients+with+sporadic+cancer%3A+a+phase+1+dose-escalation+trial&doi=10.1016%2FS1470-2045%2813%2970240-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial</span></div><div class="casAuthors">Sandhu, Shahneen K.; Schelman, William R.; Wilding, George; Moreno, Victor; Baird, Richard D.; Miranda, Susana; Hylands, Lucy; Riisnaes, Ruth; Forster, Martin; Omlin, Aurelius; Kreischer, Nathan; Thway, Khin; Gevensleben, Heidrun; Sun, Linda; Loughney, John; Chatterjee, Manash; Toniatti, Carlo; Carpenter, Christopher L.; Iannone, Robert; Kaye, Stan B.; de Bono, Johann S.; Wenham, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">882-892</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation.  Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclin. tumor models with loss of BRCA and PTEN function.  We investigated the safety, tolerability, max. tolerated dose, pharmacokinetic and pharmacodynamic profiles, and preliminary antitumor activity of niraparib.In a phase 1 dose-escalation study, we enrolled patients with advanced solid tumors at one site in the UK and two sites in the USA.  Eligible patients were aged at least 18 years; had a life expectancy of at least 12 wk; had an Eastern Cooperative Oncol. Group performance status of 2 or less; had assessable disease; were not suitable to receive any established treatments; had adequate organ function; and had discontinued any previous anticancer treatments at least 4 wk previously.  In part A, cohorts of three to six patients, enriched for BRCA1 and BRCA2 mutation carriers, received niraparib daily at ten escalating doses from 30 mg to 400 mg in a 21-day cycle to establish the max. tolerated dose.  Dose expansion at the max. tolerated dose was pursued in 15 patients to confirm tolerability.  In part B, we further investigated the max. tolerated dose in patients with sporadic platinum-resistant high-grade serous ovarian cancer and sporadic prostate cancer.  We obtained blood, circulating tumor cells, and optional paired tumor biopsies for pharmacokinetic and pharmacodynamic assessments.  Toxic effects were assessed by common toxicity criteria and tumor responses ascribed by Response Evaluation Criteria in Solid Tumors (RECIST).  Circulating tumor cells and archival tumor tissue in prostate patients were analyzed for exploratory putative predictive biomarkers, such as loss of PTEN expression and ETS rearrangements.  This trial is registered with ClinicalTrials.gov, NCT00749502.Between Sept 15, 2008, and Jan 14, 2011, we enrolled 100 patients: 60 in part A and 40 in part B. 300 mg/day was established as the max. tolerated dose.  Dose-limiting toxic effects reported in the first cycle were grade 3 fatigue (one patient given 30 mg/day), grade 3 pneumonitis (one given 60 mg/day), and grade 4 thrombocytopenia (two given 400 mg/day).  Common treatment-related toxic effects were anemia (48 patients [48%]), nausea (42 [42%]), fatigue (42 [42%]), thrombocytopenia (35 [35%]), anorexia (26 [26%]), neutropenia (24 [24%]), constipation (23 [23%]), and vomiting (20 [20%]), and were predominantly grade 1 or 2.  Pharmacokinetics were dose proportional and the mean terminal elimination half-life was 36·4 h (range 32·8-46·0).  Pharmacodynamic analyses confirmed PARP inhibition exceeded 50% at doses greater than 80 mg/day and antitumor activity was documented beyond doses of 60 mg/day.  Eight (40% [95% CI 19-64]) of 20 BRCA1 or BRCA2 mutation carriers with ovarian cancer had RECIST partial responses, as did two (50% [7-93]) of four mutation carriers with breast cancer.  Antitumor activity was also reported in sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer.  We recorded no correlation between loss of PTEN expression or ETS rearrangements and measures of antitumor activity in patients with prostate cancer.A recommended phase 2 dose of 300 mg/day niraparib is well tolerated.  Niraparib should be further assessed in inherited and sporadic cancers with homologous recombination DNA repair defects and to target PARP-mediated transcription in cancer.Merck Sharp and Dohme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGQBD4DZcJn7Vg90H21EOLACvtfcHk0liWcLGoo6sHCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtLnF&md5=b6f27019bb7887156d1abcf05db2bca3</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970240-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970240-7%26sid%3Dliteratum%253Aachs%26aulast%3DSandhu%26aufirst%3DS.%2BK.%26aulast%3DSchelman%26aufirst%3DW.%2BR.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DBaird%26aufirst%3DR.%2BD.%26aulast%3DMiranda%26aufirst%3DS.%26aulast%3DHylands%26aufirst%3DL.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DForster%26aufirst%3DM.%26aulast%3DOmlin%26aufirst%3DA.%26aulast%3DKreischer%26aufirst%3DN.%26aulast%3DThway%26aufirst%3DK.%26aulast%3DGevensleben%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLoughney%26aufirst%3DJ.%26aulast%3DChatterjee%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DCarpenter%26aufirst%3DC.%2BL.%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DWenham%26aufirst%3DR.%2BM.%26atitle%3DThe%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520niraparib%2520%2528MK4827%2529%2520in%2520BRCA%2520mutation%2520carriers%2520and%2520patients%2520with%2520sporadic%2520cancer%253A%2520a%2520phase%25201%2520dose-escalation%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D882%26epage%3D892%26doi%3D10.1016%2FS1470-2045%2813%2970240-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, L.</span><span> </span><span class="NLM_article-title">Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">958</span><span class="refDoi"> DOI: 10.1186/s12885-015-1965-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2Fs12885-015-1965-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=958&author=C.+H.+Linauthor=C.+Y.+Changauthor=K.+R.+Leeauthor=H.+J.+Linauthor=T.+H.+Chenauthor=L.+Wan&title=Flavones+inhibit+breast+cancer+proliferation+through+the+Akt%2FFOXO3a+signaling+pathway&doi=10.1186%2Fs12885-015-1965-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1965-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1965-7%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BR.%26aulast%3DLin%26aufirst%3DH.%2BJ.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DWan%26aufirst%3DL.%26atitle%3DFlavones%2520inhibit%2520breast%2520cancer%2520proliferation%2520through%2520the%2520Akt%252FFOXO3a%2520signaling%2520pathway%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D958%26doi%3D10.1186%2Fs12885-015-1965-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Park, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, H. G.</span><span> </span><span class="NLM_article-title">Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">42</span><span class="NLM_x">) </span> <span class="NLM_fpage">44819</span><span class="NLM_x">–</span> <span class="NLM_lpage">44831</span><span class="refDoi"> DOI: 10.18632/oncotarget.6264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.6264" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=44819-44831&issue=42&author=S.+H.+Parkauthor=K.+Y.+Jangauthor=M.+J.+Kimauthor=S.+Yoonauthor=Y.+Joauthor=S.+M.+Kwonauthor=K.+M.+Kimauthor=K.+S.+Kwonauthor=C.+Y.+Kimauthor=H.+G.+Woo&title=Tumor+suppressive+effect+of+PARP1+and+FOXO3A+in+gastric+cancers+and+its+clinical+implications&doi=10.18632%2Foncotarget.6264"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6264%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BH.%26aulast%3DJang%26aufirst%3DK.%2BY.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DJo%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DS.%2BM.%26aulast%3DKim%26aufirst%3DK.%2BM.%26aulast%3DKwon%26aufirst%3DK.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BY.%26aulast%3DWoo%26aufirst%3DH.%2BG.%26atitle%3DTumor%2520suppressive%2520effect%2520of%2520PARP1%2520and%2520FOXO3A%2520in%2520gastric%2520cancers%2520and%2520its%2520clinical%2520implications%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D42%26spage%3D44819%26epage%3D44831%26doi%3D10.18632%2Foncotarget.6264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Bunting, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callén, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polato, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bothmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldhahn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Capetillo, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussenzweig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussenzweig, A.</span><span> </span><span class="NLM_article-title">53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">254</span><span class="refDoi"> DOI: 10.1016/j.cell.2010.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.cell.2010.03.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=243-254&author=S.+F.+Buntingauthor=E.+Call%C3%A9nauthor=N.+Wongauthor=H.+T.+Chenauthor=F.+Polatoauthor=A.+Gunnauthor=A.+Bothmerauthor=N.+Feldhahnauthor=O.+Fernandez-Capetilloauthor=L.+Caoauthor=X.+Xuauthor=C.+X.+Dengauthor=T.+Finkelauthor=M.+Nussenzweigauthor=J.+M.+Starkauthor=A.+Nussenzweig&title=53BP1+inhibits+homologous+recombination+in+Brca1-deficient+cells+by+blocking+resection+of+DNA+breaks&doi=10.1016%2Fj.cell.2010.03.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DBunting%26aufirst%3DS.%2BF.%26aulast%3DCall%25C3%25A9n%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DH.%2BT.%26aulast%3DPolato%26aufirst%3DF.%26aulast%3DGunn%26aufirst%3DA.%26aulast%3DBothmer%26aufirst%3DA.%26aulast%3DFeldhahn%26aufirst%3DN.%26aulast%3DFernandez-Capetillo%26aufirst%3DO.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DC.%2BX.%26aulast%3DFinkel%26aufirst%3DT.%26aulast%3DNussenzweig%26aufirst%3DM.%26aulast%3DStark%26aufirst%3DJ.%2BM.%26aulast%3DNussenzweig%26aufirst%3DA.%26atitle%3D53BP1%2520inhibits%2520homologous%2520recombination%2520in%2520Brca1-deficient%2520cells%2520by%2520blocking%2520resection%2520of%2520DNA%2520breaks%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D243%26epage%3D254%26doi%3D10.1016%2Fj.cell.2010.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersbergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boon, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sol, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Deemter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drost, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wientjens, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, S.</span><span> </span><span class="NLM_article-title">Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F2159-8290.CD-12-0049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=68-81&author=J.+E.+Jaspersauthor=A.+Kersbergenauthor=U.+Boonauthor=W.+Solauthor=L.+van+Deemterauthor=S.+A.+Zanderauthor=R.+Drostauthor=E.+Wientjensauthor=J.+Jiauthor=A.+Alyauthor=J.+H.+Doroshowauthor=A.+Cranstonauthor=N.+M.+Martinauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=S.+Ganesanauthor=P.+Borstauthor=J.+Jonkersauthor=S.+Rottenberg&title=Loss+of+53BP1+causes+PARP+inhibitor+resistance+in+Brca1-mutated+mouse+mammary+tumors&doi=10.1158%2F2159-8290.CD-12-0049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0049%26sid%3Dliteratum%253Aachs%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3DBoon%26aufirst%3DU.%26aulast%3DSol%26aufirst%3DW.%26aulast%3Dvan%2BDeemter%26aufirst%3DL.%26aulast%3DZander%26aufirst%3DS.%2BA.%26aulast%3DDrost%26aufirst%3DR.%26aulast%3DWientjens%26aufirst%3DE.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DAly%26aufirst%3DA.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DGanesan%26aufirst%3DS.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DRottenberg%26aufirst%3DS.%26atitle%3DLoss%2520of%252053BP1%2520causes%2520PARP%2520inhibitor%2520resistance%2520in%2520Brca1-mutated%2520mouse%2520mammary%2520tumors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D68%26epage%3D81%26doi%3D10.1158%2F2159-8290.CD-12-0049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Xu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandsma, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistrik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouwman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartkova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogola, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmerdam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barazas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieterse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersbergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sol, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celie, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schouten, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Broek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieuwland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Rink, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Ronde, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalink, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gent, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, S.</span><span> </span><span class="NLM_article-title">REV7 counteracts DNA double-strand break resection and affects PARP inhibition</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">521</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span><span class="refDoi"> DOI: 10.1038/nature14328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnature14328" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=521&publication_year=2015&pages=541-544&author=G.+Xuauthor=J.+R.+Chapmanauthor=I.+Brandsmaauthor=J.+Yuanauthor=M.+Mistrikauthor=P.+Bouwmanauthor=J.+Bartkovaauthor=E.+Gogolaauthor=D.+Warmerdamauthor=M.+Barazasauthor=J.+E.+Jaspersauthor=K.+Watanabeauthor=M.+Pieterseauthor=A.+Kersbergenauthor=W.+Solauthor=P.+H.+Celieauthor=P.+C.+Schoutenauthor=B.+van+den+Broekauthor=A.+Salmanauthor=M.+Nieuwlandauthor=I.+de+Rinkauthor=J.+de+Rondeauthor=K.+Jalinkauthor=S.+J.+Boultonauthor=J.+Chenauthor=D.+C.+van+Gentauthor=J.+Bartekauthor=J.+Jonkersauthor=P.+Borstauthor=S.+Rottenberg&title=REV7+counteracts+DNA+double-strand+break+resection+and+affects+PARP+inhibition&doi=10.1038%2Fnature14328"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fnature14328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14328%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DG.%26aulast%3DChapman%26aufirst%3DJ.%2BR.%26aulast%3DBrandsma%26aufirst%3DI.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DMistrik%26aufirst%3DM.%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DBartkova%26aufirst%3DJ.%26aulast%3DGogola%26aufirst%3DE.%26aulast%3DWarmerdam%26aufirst%3DD.%26aulast%3DBarazas%26aufirst%3DM.%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DPieterse%26aufirst%3DM.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3DSol%26aufirst%3DW.%26aulast%3DCelie%26aufirst%3DP.%2BH.%26aulast%3DSchouten%26aufirst%3DP.%2BC.%26aulast%3Dvan%2Bden%2BBroek%26aufirst%3DB.%26aulast%3DSalman%26aufirst%3DA.%26aulast%3DNieuwland%26aufirst%3DM.%26aulast%3Dde%2BRink%26aufirst%3DI.%26aulast%3Dde%2BRonde%26aufirst%3DJ.%26aulast%3DJalink%26aufirst%3DK.%26aulast%3DBoulton%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3Dvan%2BGent%26aufirst%3DD.%2BC.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DRottenberg%26aufirst%3DS.%26atitle%3DREV7%2520counteracts%2520DNA%2520double-strand%2520break%2520resection%2520and%2520affects%2520PARP%2520inhibition%26jtitle%3DNature%26date%3D2015%26volume%3D521%26spage%3D541%26epage%3D544%26doi%3D10.1038%2Fnature14328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iorns, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swift, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rayter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1368</span><span class="NLM_x">–</span> <span class="NLM_lpage">1377</span><span class="refDoi"> DOI: 10.1038/emboj.2008.61</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Femboj.2008.61" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1368-1377&author=N.+C.+Turnerauthor=C.+J.+Lordauthor=E.+Iornsauthor=R.+Broughauthor=S.+Swiftauthor=R.+Elliottauthor=S.+Rayterauthor=A.+N.+Tuttauthor=A.+Ashworth&title=A+synthetic+lethal+siRNA+screen+identifying+genes+mediating+sensitivity+to+a+PARP+inhibitor&doi=10.1038%2Femboj.2008.61"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Femboj.2008.61&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2008.61%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DIorns%26aufirst%3DE.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DSwift%26aufirst%3DS.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DRayter%26aufirst%3DS.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DA%2520synthetic%2520lethal%2520siRNA%2520screen%2520identifying%2520genes%2520mediating%2520sensitivity%2520to%2520a%2520PARP%2520inhibitor%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D1368%26epage%3D1377%26doi%3D10.1038%2Femboj.2008.61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Bolin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boudra, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaslin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennaneach, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaremba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordelières, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favaudon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mégnin-Chanet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J.</span><span> </span><span class="NLM_article-title">The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">951</span><span class="NLM_x">–</span> <span class="NLM_lpage">962</span><span class="refDoi"> DOI: 10.1007/s00018-011-0811-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1007%2Fs00018-011-0811-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21922195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38Xisl2rtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=951-962&author=C.+Bolinauthor=M.+T.+Boudraauthor=M.+Fernetauthor=L.+Vaslinauthor=V.+Pennaneachauthor=T.+Zarembaauthor=D.+Biardauthor=F.+P.+Cordeli%C3%A8resauthor=V.+Favaudonauthor=F.+M%C3%A9gnin-Chanetauthor=J.+Hall&title=The+impact+of+cyclin-dependent+kinase+5+depletion+on+poly%28ADP-ribose%29+polymerase+activity+and+responses+to+radiation&doi=10.1007%2Fs00018-011-0811-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation</span></div><div class="casAuthors">Bolin, Celeste; Boudra, Mohammed-Tayyib; Fernet, Marie; Vaslin, Laurence; Pennaneach, Vincent; Zaremba, Tomasz; Biard, Denis; Cordelieres, Fabrice P.; Favaudon, Vincent; Megnin-Chanet, Frederique; Hall, Janet</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">951-962</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 5 (Cdk5) has been identified as a determinant of sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors.  Here, the consequences of its depletion on cell survival, PARP activity, the recruitment of base excision repair (BER) proteins to DNA damage sites, and overall DNA single-strand break (SSB) repair were investigated using isogenic HeLa stably depleted (KD) and Control cell lines.  Synthetic lethality achieved by disrupting PARP activity in Cdk5-deficient cells was confirmed, and the Cdk5KD cells were also found to be sensitive to the killing effects of ionizing radiation (IR) but not Me methanesulfonate or neocarzinostatin.  The recruitment profiles of GFP-PARP-1 and XRCC1-YFP to sites of micro-irradiated Cdk5KD cells were slower and reached lower max. values, while the profile of GFP-PCNA recruitment was faster and attained higher max. values compared to Control cells.  Higher basal, IR, and hydrogen peroxide-induced polymer levels were obsd. in Cdk5KD compared to Control cells.  Recruitment of GFP-PARP-1 in which serines 782, 785, and 786, potential Cdk5 phosphorylation targets, were mutated to alanines in micro-irradiated Control cells was also reduced.  We hypothesize that Cdk5-dependent PARP-1 phosphorylation on one or more of these serines results in an attenuation of its ribosylating activity facilitating persistence at DNA damage sites.  Despite these deficiencies, Cdk5KD cells are able to effectively repair SSBs probably via the long patch BER pathway, suggesting that the enhanced radiation sensitivity of Cdk5KD cells is due to a role of Cdk5 in other pathways or the altered polymer levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXsx-zTa5XX7Vg90H21EOLACvtfcHk0lgVxde5qEAchQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xisl2rtrk%253D&md5=6fc9630ae70b46c7f55c56d8d60638a1</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1007%2Fs00018-011-0811-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-011-0811-6%26sid%3Dliteratum%253Aachs%26aulast%3DBolin%26aufirst%3DC.%26aulast%3DBoudra%26aufirst%3DM.%2BT.%26aulast%3DFernet%26aufirst%3DM.%26aulast%3DVaslin%26aufirst%3DL.%26aulast%3DPennaneach%26aufirst%3DV.%26aulast%3DZaremba%26aufirst%3DT.%26aulast%3DBiard%26aufirst%3DD.%26aulast%3DCordeli%25C3%25A8res%26aufirst%3DF.%2BP.%26aulast%3DFavaudon%26aufirst%3DV.%26aulast%3DM%25C3%25A9gnin-Chanet%26aufirst%3DF.%26aulast%3DHall%26aufirst%3DJ.%26atitle%3DThe%2520impact%2520of%2520cyclin-dependent%2520kinase%25205%2520depletion%2520on%2520poly%2528ADP-ribose%2529%2520polymerase%2520activity%2520and%2520responses%2520to%2520radiation%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2012%26volume%3D69%26spage%3D951%26epage%3D962%26doi%3D10.1007%2Fs00018-011-0811-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Chiker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennaneach, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loew, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordelières, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemble, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieche, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernet, M.</span><span> </span><span class="NLM_article-title">Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3066</span><span class="NLM_x">–</span> <span class="NLM_lpage">3078</span><span class="refDoi"> DOI: 10.1080/15384101.2015.1078020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1080%2F15384101.2015.1078020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=3066-3078&author=S.+Chikerauthor=V.+Pennaneachauthor=D.+Loewauthor=F.+Dingliauthor=D.+Biardauthor=F.+P.+Cordeli%C3%A8resauthor=S.+Gembleauthor=S.+Vacherauthor=I.+Biecheauthor=J.+Hallauthor=M.+Fernet&title=Cdk5+promotes+DNA+replication+stress+checkpoint+activation+through+RPA-32+phosphorylation%2C+and+impacts+on+metastasis+free+survival+in+breast+cancer+patients&doi=10.1080%2F15384101.2015.1078020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1078020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1078020%26sid%3Dliteratum%253Aachs%26aulast%3DChiker%26aufirst%3DS.%26aulast%3DPennaneach%26aufirst%3DV.%26aulast%3DLoew%26aufirst%3DD.%26aulast%3DDingli%26aufirst%3DF.%26aulast%3DBiard%26aufirst%3DD.%26aulast%3DCordeli%25C3%25A8res%26aufirst%3DF.%2BP.%26aulast%3DGemble%26aufirst%3DS.%26aulast%3DVacher%26aufirst%3DS.%26aulast%3DBieche%26aufirst%3DI.%26aulast%3DHall%26aufirst%3DJ.%26aulast%3DFernet%26aufirst%3DM.%26atitle%3DCdk5%2520promotes%2520DNA%2520replication%2520stress%2520checkpoint%2520activation%2520through%2520RPA-32%2520phosphorylation%252C%2520and%2520impacts%2520on%2520metastasis%2520free%2520survival%2520in%2520breast%2520cancer%2520patients%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26spage%3D3066%26epage%3D3078%26doi%3D10.1080%2F15384101.2015.1078020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Chin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVries, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridlyand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spellman, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roydasgupta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapuk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feiler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokuyasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingsley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairkee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chew, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ljung, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esserman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertson, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. W.</span><span> </span><span class="NLM_article-title">Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">541</span><span class="refDoi"> DOI: 10.1016/j.ccr.2006.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.ccr.2006.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=17157792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCnsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=529-541&author=K.+Chinauthor=S.+DeVriesauthor=J.+Fridlyandauthor=P.+T.+Spellmanauthor=R.+Roydasguptaauthor=W.+L.+Kuoauthor=A.+Lapukauthor=R.+M.+Neveauthor=Z.+Qianauthor=T.+Ryderauthor=F.+Chenauthor=H.+Feilerauthor=T.+Tokuyasuauthor=C.+Kingsleyauthor=S.+Dairkeeauthor=Z.+Mengauthor=K.+Chewauthor=D.+Pinkelauthor=A.+Jainauthor=B.+M.+Ljungauthor=L.+Essermanauthor=D.+G.+Albertsonauthor=F.+M.+Waldmanauthor=J.+W.+Gray&title=Genomic+and+transcriptional+aberrations+linked+to+breast+cancer+pathophysiologies&doi=10.1016%2Fj.ccr.2006.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</span></div><div class="casAuthors">Chin, Koei; DeVries, Sandy; Fridlyand, Jane; Spellman, Paul T.; Roydasgupta, Ritu; Kuo, Wen-Lin; Lapuk, Anna; Neve, Richard M.; Qian, Zuwei; Ryder, Tom; Chen, Fanqing; Feiler, Heidi; Tokuyasu, Taku; Kingsley, Chris; Dairkee, Shanaz; Meng, Zhenhang; Chew, Karen; Pinkel, Daniel; Jain, Ajay; Ljung, Britt Marie; Esserman, Laura; Albertson, Donna G.; Waldman, Frederic M.; Gray, Joe W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">529-541</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">This study explores the roles of genome copy no. abnormalities (CNAs) in breast cancer pathophysiol. by identifying assocns. between recurrent CNAs, gene expression, and clin. outcome in a set of aggressively treated early-stage breast tumors.  It shows that the recurrent CNAs differ between tumor subtypes defined by expression pattern and that stratification of patients according to outcome can be improved by measuring both expression and copy no., esp. high-level amplification.  Sixty-six genes deregulated by the high-level amplifications are potential therapeutic targets.  Nine of these (FGFR1, IKBKB, ERBB2, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1) are considered as therapeutic targets.  Low-level CNAs appear to contribute to cancer progression by altering RNA and cellular metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHiq8I1mqFn7Vg90H21EOLACvtfcHk0lhQDl3Ybpdafw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCnsrbF&md5=8848be946221c3d3236bf9bc3154b77e</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DK.%26aulast%3DDeVries%26aufirst%3DS.%26aulast%3DFridlyand%26aufirst%3DJ.%26aulast%3DSpellman%26aufirst%3DP.%2BT.%26aulast%3DRoydasgupta%26aufirst%3DR.%26aulast%3DKuo%26aufirst%3DW.%2BL.%26aulast%3DLapuk%26aufirst%3DA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DFeiler%26aufirst%3DH.%26aulast%3DTokuyasu%26aufirst%3DT.%26aulast%3DKingsley%26aufirst%3DC.%26aulast%3DDairkee%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DChew%26aufirst%3DK.%26aulast%3DPinkel%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DA.%26aulast%3DLjung%26aufirst%3DB.%2BM.%26aulast%3DEsserman%26aufirst%3DL.%26aulast%3DAlbertson%26aufirst%3DD.%2BG.%26aulast%3DWaldman%26aufirst%3DF.%2BM.%26aulast%3DGray%26aufirst%3DJ.%2BW.%26atitle%3DGenomic%2520and%2520transcriptional%2520aberrations%2520linked%2520to%2520breast%2520cancer%2520pathophysiologies%26jtitle%3DCancer%2520Cell%26date%3D2006%26volume%3D10%26spage%3D529%26epage%3D541%26doi%3D10.1016%2Fj.ccr.2006.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Ehrlich, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardelt, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehr, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Toni, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerbes, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollmar, A. M.</span><span> </span><span class="NLM_article-title">Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.01.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.jhep.2015.01.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25660209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1Srtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=102-113&author=S.+M.+Ehrlichauthor=J.+Lieblauthor=M.+A.+Ardeltauthor=T.+Lehrauthor=E.+N.+De+Toniauthor=D.+Mayrauthor=L.+Brandlauthor=T.+Kirchnerauthor=S.+Zahlerauthor=A.+L.+Gerbesauthor=A.+M.+Vollmar&title=Targeting+cyclin+dependent+kinase+5+in+hepatocellular+carcinoma%2D%2DA+novel+therapeutic+approach&doi=10.1016%2Fj.jhep.2015.01.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cyclin dependent kinase 5 in hepatocellular carcinoma - A novel therapeutic approach</span></div><div class="casAuthors">Ehrlich, Sandra M.; Liebl, Johanna; Ardelt, Maximilian A.; Lehr, Thorsten; De Toni, Enrico N.; Mayr, Doris; Brandl, Lydia; Kirchner, Thomas; Zahler, Stefan; Gerbes, Alexander L.; Vollmar, Angelika M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-113</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">For a long time cyclin dependent kinase 5 (Cdk5) was thought to be exclusively important in neuronal cells.  However, increasing evidence recently suggests a function of Cdk5 in cancer progression.  In this study, we examd. the role of Cdk5 and its therapeutic accessibility in hepatocellular carcinoma (HCC), a highly chemoresistant cancer with poor prognosis and paramount clin. importance in order to develop novel targeted therapies for systemic treatment.  Expression and activity of Cdk5 was analyzed in a human HCC tissue microarray, human patient samples and HCC cell lines.  To characterize Cdk5 functions and signaling pathways in HCC, we applied genetic downregulation and pharmacol. inhibition in various approaches including cell based assays and mouse xenograft models.  Expression and activity of Cdk5 was increased in human HCC tissues as compared to normal liver tissues.  Functional ablation of Cdk5 significantly decreased HCC cell proliferation and clonogenic survival.  Moreover, genetic and pharmacol. inhibition of Cdk5 showed in vivo efficacy in HCC xenograft mouse models.  Investigating the mechanisms behind these functional effects revealed that Cdk5 is most active in the nucleus of cells in G2/M phase.  Cdk5 regulates DNA damage response by phosphorylating ataxia telangiectasia mutated (ATM) kinase and thereby influencing its downstream cascade.  Consequently, combination of Cdk5 inhibition with DNA-damage-inducing chemotherapeutics synergistically inhibited HCC tumor progression in vitro and in vivo.  In summary, we introduce Cdk5 as a novel drugable target for HCC treatment and suggest the combination of Cdk5 inhibition and DNA damaging agents as a novel therapeutic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDSzPpX1jOhbVg90H21EOLACvtfcHk0lhQDl3Ybpdafw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1Srtbc%253D&md5=948af74199cce8a02a0d4cd7f52f1d12</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.01.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.01.031%26sid%3Dliteratum%253Aachs%26aulast%3DEhrlich%26aufirst%3DS.%2BM.%26aulast%3DLiebl%26aufirst%3DJ.%26aulast%3DArdelt%26aufirst%3DM.%2BA.%26aulast%3DLehr%26aufirst%3DT.%26aulast%3DDe%2BToni%26aufirst%3DE.%2BN.%26aulast%3DMayr%26aufirst%3DD.%26aulast%3DBrandl%26aufirst%3DL.%26aulast%3DKirchner%26aufirst%3DT.%26aulast%3DZahler%26aufirst%3DS.%26aulast%3DGerbes%26aufirst%3DA.%2BL.%26aulast%3DVollmar%26aufirst%3DA.%2BM.%26atitle%3DTargeting%2520cyclin%2520dependent%2520kinase%25205%2520in%2520hepatocellular%2520carcinoma--A%2520novel%2520therapeutic%2520approach%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D63%26spage%3D102%26epage%3D113%26doi%3D10.1016%2Fj.jhep.2015.01.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Huang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, D. S.</span><span> </span><span class="NLM_article-title">Cdk5: Links to DNA damage</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3142</span><span class="NLM_x">–</span> <span class="NLM_lpage">3143</span><span class="refDoi"> DOI: 10.4161/cc.9.16.12955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.4161%2Fcc.9.16.12955" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=3142-3143&author=E.+Huangauthor=D.+Quauthor=D.+S.+Park&title=Cdk5%3A+Links+to+DNA+damage&doi=10.4161%2Fcc.9.16.12955"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.16.12955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.16.12955%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DQu%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DD.%2BS.%26atitle%3DCdk5%253A%2520Links%2520to%2520DNA%2520damage%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26spage%3D3142%26epage%3D3143%26doi%3D10.4161%2Fcc.9.16.12955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span><span class="refDoi"> DOI: 10.1146/annurev-med-050913-022545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1146%2Fannurev-med-050913-022545" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=455-470&author=C.+J.+Lordauthor=A.+N.+Tuttauthor=A.+Ashworth&title=Synthetic+lethality+and+cancer+therapy%3A+lessons+learned+from+the+development+of+PARP+inhibitors&doi=10.1146%2Fannurev-med-050913-022545"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-050913-022545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-050913-022545%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DSynthetic%2520lethality%2520and%2520cancer%2520therapy%253A%2520lessons%2520learned%2520from%2520the%2520development%2520of%2520PARP%2520inhibitors%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D455%26epage%3D470%26doi%3D10.1146%2Fannurev-med-050913-022545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Livraghi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garber, J. E.</span><span> </span><span class="NLM_article-title">PARP inhibitors in the management of breast cancer: current data and future prospects</span> <span class="citation_source-journal">BMC Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="refDoi"> DOI: 10.1186/s12916-015-0425-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2Fs12916-015-0425-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26268938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC287is1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=188&author=L.+Livraghiauthor=J.+E.+Garber&title=PARP+inhibitors+in+the+management+of+breast+cancer%3A+current+data+and+future+prospects&doi=10.1186%2Fs12916-015-0425-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors in the management of breast cancer: current data and future prospects</span></div><div class="casAuthors">Livraghi Luca; Garber Judy E</div><div class="citationInfo"><span class="NLM_cas:title">BMC medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">188</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair.  Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers.  Several PARP inhibitors are currently in trials in the adjuvant, neoadjuvant, and metastatic settings for the treatment of ovarian, BRCA-mutated breast, and other cancers.  We herein review the development of PARP inhibitors and the basis for the excitement surrounding these agents, their use as single agents and in combinations, as well as their toxicities, mechanisms of acquired resistance, and companion diagnostics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTN9YoyeMbnGkH3Rlp_k91zfW6udTcc2eas2wph8HzT17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287is1Kktg%253D%253D&md5=9be050964d88c81526f7bbb7873ee2b4</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1186%2Fs12916-015-0425-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12916-015-0425-1%26sid%3Dliteratum%253Aachs%26aulast%3DLivraghi%26aufirst%3DL.%26aulast%3DGarber%26aufirst%3DJ.%2BE.%26atitle%3DPARP%2520inhibitors%2520in%2520the%2520management%2520of%2520breast%2520cancer%253A%2520current%2520data%2520and%2520future%2520prospects%26jtitle%3DBMC%2520Med.%26date%3D2015%26volume%3D13%26spage%3D188%26doi%3D10.1186%2Fs12916-015-0425-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Bouwman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">540</span><span class="NLM_x">–</span> <span class="NLM_lpage">547</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-13-0225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24270682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=540-547&author=P.+Bouwmanauthor=J.+Jonkers&title=Molecular+pathways%3A+how+can+BRCA-mutated+tumors+become+resistant+to+PARP+inhibitors%3F&doi=10.1158%2F1078-0432.CCR-13-0225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?</span></div><div class="casAuthors">Bouwman, Peter; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">540-547</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  PARP inhibition is synthetic lethal with defective DNA repair via homologous recombination.  Phase I and II clin. trials show that PARP inhibitors are effective at well-tolerated doses and have antitumor activity for BRCA1- and BRCA2-assocd. cancers.  However, not all patients respond equally well and tumors may eventually become resistant.  Thus far, the only resistance mechanism that has been found in human tumors is genetic reversion that corrects or bypasses the original BRCA1- or BRCA2-inactivating mutation.  However, data from fundamental and preclin. research suggest that resistance to PARP inhibitors may be induced by addnl. mechanisms involving hypomorphic activity of mutant BRCA1 alleles, upregulation of drug efflux pumps, and rewiring of the DNA damage response.  Preclin. models will be instrumental to develop methods for adequate patient stratification, as well as treatment strategies that prevent or counteract resistance to PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK8cSjdD2_ObVg90H21EOLACvtfcHk0lgFQ3DeyKVMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWjsrs%253D&md5=8d670ec3b09fe26963087de8c533f77a</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0225%26sid%3Dliteratum%253Aachs%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DMolecular%2520pathways%253A%2520how%2520can%2520BRCA-mutated%2520tumors%2520become%2520resistant%2520to%2520PARP%2520inhibitors%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D540%26epage%3D547%26doi%3D10.1158%2F1078-0432.CCR-13-0225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Drost, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouwman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boon, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schut, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klarenbeek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klijn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heijden, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Gulden, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wientjens, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieterse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catteau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">809</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.ccr.2011.11.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=797-809&author=R.+Drostauthor=P.+Bouwmanauthor=S.+Rottenbergauthor=U.+Boonauthor=E.+Schutauthor=S.+Klarenbeekauthor=C.+Klijnauthor=I.+van+der+Heijdenauthor=H.+van+der+Guldenauthor=E.+Wientjensauthor=M.+Pieterseauthor=A.+Catteauauthor=P.+Greenauthor=E.+Solomonauthor=J.+R.+Morrisauthor=J.+Jonkers&title=BRCA1+RING+function+is+essential+for+tumor+suppression+but+dispensable+for+therapy+resistance&doi=10.1016%2Fj.ccr.2011.11.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DDrost%26aufirst%3DR.%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DBoon%26aufirst%3DU.%26aulast%3DSchut%26aufirst%3DE.%26aulast%3DKlarenbeek%26aufirst%3DS.%26aulast%3DKlijn%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DI.%26aulast%3Dvan%2Bder%2BGulden%26aufirst%3DH.%26aulast%3DWientjens%26aufirst%3DE.%26aulast%3DPieterse%26aufirst%3DM.%26aulast%3DCatteau%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DE.%26aulast%3DMorris%26aufirst%3DJ.%2BR.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DBRCA1%2520RING%2520function%2520is%2520essential%2520for%2520tumor%2520suppression%2520but%2520dispensable%2520for%2520therapy%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D20%26spage%3D797%26epage%3D809%26doi%3D10.1016%2Fj.ccr.2011.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Moskwa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buffa, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panchakshari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottipati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muschel, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beech, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulshrestha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdelmohsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorospe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdhury, D.</span><span> </span><span class="NLM_article-title">miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span><span class="refDoi"> DOI: 10.1016/j.molcel.2010.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.molcel.2010.12.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=210-220&author=P.+Moskwaauthor=F.+M.+Buffaauthor=Y.+Panauthor=R.+Panchakshariauthor=P.+Gottipatiauthor=R.+J.+Muschelauthor=J.+Beechauthor=R.+Kulshresthaauthor=K.+Abdelmohsenauthor=D.+M.+Weinstockauthor=M.+Gorospeauthor=A.+L.+Harrisauthor=T.+Helledayauthor=D.+Chowdhury&title=miR-182-mediated+downregulation+of+BRCA1+impacts+DNA+repair+and+sensitivity+to+PARP+inhibitors&doi=10.1016%2Fj.molcel.2010.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2010.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2010.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DMoskwa%26aufirst%3DP.%26aulast%3DBuffa%26aufirst%3DF.%2BM.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DPanchakshari%26aufirst%3DR.%26aulast%3DGottipati%26aufirst%3DP.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DBeech%26aufirst%3DJ.%26aulast%3DKulshrestha%26aufirst%3DR.%26aulast%3DAbdelmohsen%26aufirst%3DK.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26aulast%3DGorospe%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DChowdhury%26aufirst%3DD.%26atitle%3DmiR-182-mediated%2520downregulation%2520of%2520BRCA1%2520impacts%2520DNA%2520repair%2520and%2520sensitivity%2520to%2520PARP%2520inhibitors%26jtitle%3DMol.%2520Cell%26date%3D2011%26volume%3D41%26spage%3D210%26epage%3D220%26doi%3D10.1016%2Fj.molcel.2010.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span> </span><span class="NLM_article-title">miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">1750</span><span class="NLM_x">–</span> <span class="NLM_lpage">1758</span><span class="refDoi"> DOI: 10.1093/jnci/djt302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fjnci%2Fdjt302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24168967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKgu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2013&pages=1750-1758&author=C.+Sunauthor=N.+Liauthor=Z.+Yangauthor=B.+Zhouauthor=Y.+Heauthor=D.+Wengauthor=Y.+Fangauthor=P.+Wuauthor=P.+Chenauthor=X.+Yangauthor=D.+Maauthor=J.+Zhouauthor=G.+Chen&title=miR-9+regulation+of+BRCA1+and+ovarian+cancer+sensitivity+to+cisplatin+and+PARP+inhibition&doi=10.1093%2Fjnci%2Fdjt302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition</span></div><div class="casAuthors">Sun, Chaoyang; Li, Na; Yang, Zongyuan; Zhou, Bo; He, Yang; Weng, Danhui; Fang, Yong; Wu, Peng; Chen, Pingbo; Yang, Xiaokui; Ma, Ding; Zhou, Jianfeng; Chen, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1750-1758</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Expression of BRCA1 is commonly decreased in sporadic ovarian cancer, and this is assocd. with platinum sensitivity and favorable prognosis.  However, multiple mechanisms underlying low BRCA1 expression are not fully understood.  Methods A bioinformatics-driven microRNA (miR) library screening was used to identify miRs that regulate BRCA1 expression.  The effects of miR-9 on cisplatin (cDDP) and PARP inhibitor sensitivity were measured in ovarian cancer cells and C13* xenograft mice (n = 6 per group).  The roles of miR-9 on prognosis were assessed in a cohort of ovarian cancer patients (n = 113) with Kaplan-Meier and Cox proportional hazards analyses.  All statistical tests were two-sided.  Reverse miR library screening revealed that miR-9 reduced the normalized luciferase activity to 60.3% (95% confidence interval [CI] = 52.0% to 68.5%; P < .001). miR-9 bound directly to the 3'-UTR of BRCA1 and downregulated BRCA1 expression in ovarian cancer cells.  Treatment with miR-9 agomiR sensitized BRCA1-proficient C13* xenograft tumors to cisplatin and AG014699.  In serous ovarian cancer, higher levels of miR-9 were inversely correlated with BRCA1 expression (Spearman rank correlation: R2 = 0.379; P = .003).  Patients with higher levels of miR-9 had better chemotherapy response, platinum sensitivity, and longer progression-free survival (PFS) (high vs low miR-9 expression: median PFS = 26.4 mo, 95% CI = 13.8 to 39.0 mo vs median PFS = 15.4 mo, 95% CI = 6.8 to 23.9 mo, P = .01).  MiR-9 mediates the downregulation of BRCA1 and impedes DNA damage repair in ovarian cancer. miR-9 may improve chemotherapeutic efficacy by increasing the sensitivity of cancer cells to DNA damage and may impact ovarian cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraG3mmr2R12rVg90H21EOLACvtfcHk0lgC6d676U2WPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKgu7rF&md5=321ea02b70e81db1a5010c493f100ff0</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjt302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjt302%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DWeng%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26atitle%3DmiR-9%2520regulation%2520of%2520BRCA1%2520and%2520ovarian%2520cancer%2520sensitivity%2520to%2520cisplatin%2520and%2520PARP%2520inhibition%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2013%26volume%3D105%26spage%3D1750%26epage%3D1758%26doi%3D10.1093%2Fjnci%2Fdjt302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Esposito, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, C. W. E.</span><span> </span><span class="NLM_article-title">Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1481</span><span class="NLM_x">–</span> <span class="NLM_lpage">1490</span><span class="refDoi"> DOI: 10.1038/nm.3993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnm.3993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26594843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1481-1490&author=M.+T.+Espositoauthor=L.+Zhaoauthor=T.+K.+Fungauthor=J.+K.+Raneauthor=A.+Wilsonauthor=N.+Martinauthor=J.+Gilauthor=A.+Y.+Leungauthor=A.+Ashworthauthor=C.+W.+E.+So&title=Synthetic+lethal+targeting+of+oncogenic+transcription+factors+in+acute+leukemia+by+PARP+inhibitors&doi=10.1038%2Fnm.3993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors</span></div><div class="casAuthors">Esposito, Maria Teresa; Zhao, Lu; Fung, Tsz Kan; Rane, Jayant K.; Wilson, Amanda; Martin, Nadine; Gil, Jesus; Leung, Anskar Y.; Ashworth, Alan; Eric So, Chi Wai</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1481-1490</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is mostly driven by oncogenic transcription factors, which have been classically viewed as intractable targets using small-mol. inhibitor approaches.  Here we demonstrate that AML driven by repressive transcription factors, including AML1-ETO (encoded by the fusion oncogene RUNX1-RUNX1T1) and PML-RARα fusion oncoproteins (encoded by PML-RARA) are extremely sensitive to poly (ADP-ribose) polymerase (PARP) inhibition, in part owing to their suppressed expression of key homologous recombination (HR)-assocd. genes and their compromised DNA-damage response (DDR).  In contrast, leukemia driven by mixed-lineage leukemia (MLL, encoded by KMT2A) fusions with dominant transactivation ability is proficient in DDR and insensitive to PARP inhibition.  Intriguingly, genetic or pharmacol. inhibition of an MLL downstream target, HOXA9, which activates expression of various HR-assocd. genes, impairs DDR and sensitizes MLL leukemia to PARP inhibitors (PARPis).  Conversely, HOXA9 overexpression confers PARPi resistance to AML1-ETO and PML-RARα transformed cells.  Together, these studies describe a potential utility of PARPi-induced synthetic lethality for leukemia treatment and reveal a novel mol. mechanism governing PARPi sensitivity in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolE-gRQ6jVb7Vg90H21EOLACvtfcHk0lgC6d676U2WPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtLbM&md5=3e69876e4110e9006d97673fb09e8e6d</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fnm.3993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3993%26sid%3Dliteratum%253Aachs%26aulast%3DEsposito%26aufirst%3DM.%2BT.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DFung%26aufirst%3DT.%2BK.%26aulast%3DRane%26aufirst%3DJ.%2BK.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DGil%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DA.%2BY.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DSo%26aufirst%3DC.%2BW.%2BE.%26atitle%3DSynthetic%2520lethal%2520targeting%2520of%2520oncogenic%2520transcription%2520factors%2520in%2520acute%2520leukemia%2520by%2520PARP%2520inhibitors%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D1481%26epage%3D1490%26doi%3D10.1038%2Fnm.3993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Sun, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Q.</span><span> </span><span class="NLM_article-title">Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3375</span><span class="NLM_x">–</span> <span class="NLM_lpage">3385</span><span class="refDoi"> DOI: 10.18632/oncotarget.1952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.1952" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3375-3385&author=C.+K.+Sunauthor=F.+Zhangauthor=T.+Xiangauthor=Q.+Chenauthor=T.+K.+Panditaauthor=Y.+Huangauthor=M.+C.+Huauthor=Q.+Yang&title=Phosphorylation+of+ribosomal+protein+S6+confers+PARP+inhibitor+resistance+in+BRCA1-deficient+cancers&doi=10.18632%2Foncotarget.1952"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1952%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%2BK.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DXiang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DPandita%26aufirst%3DT.%2BK.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DM.%2BC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DPhosphorylation%2520of%2520ribosomal%2520protein%2520S6%2520confers%2520PARP%2520inhibitor%2520resistance%2520in%2520BRCA1-deficient%2520cancers%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D3375%26epage%3D3385%26doi%3D10.18632%2Foncotarget.1952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Volinia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sana, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palatini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huebner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croce, C. M.</span><span> </span><span class="NLM_article-title">Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">3024</span><span class="NLM_x">–</span> <span class="NLM_lpage">3029</span><span class="refDoi"> DOI: 10.1073/pnas.1200010109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1073%2Fpnas.1200010109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22315424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=3024-3029&author=S.+Voliniaauthor=M.+Galassoauthor=M.+E.+Sanaauthor=T.+F.+Wiseauthor=J.+Palatiniauthor=K.+Huebnerauthor=C.+M.+Croce&title=Breast+cancer+signatures+for+invasiveness+and+prognosis+defined+by+deep+sequencing+of+microRNA&doi=10.1073%2Fpnas.1200010109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA</span></div><div class="casAuthors">Volinia, Stefano; Galasso, Marco; Sana, Maria Elena; Wise, Timothy F.; Palatini, Jeff; Huebner, Kay; Croce, Carlo M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3024-3029, S3024/1-S3024/12</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The transition from ductal carcinoma in situ to invasive ductal carcinoma is a key event in breast cancer progression that is still not well understood.  To discover the microRNAs regulating this crit. transition, we used 80 biopsies from invasive ductal carcinoma, 8 from ductal carcinoma in situ, and 6 from normal breast.  We selected them from a recently published deep-sequencing dataset.  The microRNA profile established for the normal breast to ductal carcinoma in situ transition was largely maintained in the in situ to invasive ductal carcinoma transition.  Nevertheless, a nine-micro-RNA signature was identified that differentiated invasive from in situ carcinoma.  Specifically, let-7d, miR-210, and -221 were down-regulated in the in situ and up-regulated in the invasive transition, thus featuring an expression reversal along the cancer progression path.  Addnl., we identified microRNAs for overall survival and time to metastasis.  Five noncoding genes were assocd. with both prognostic signatures - miR-210, -21, -106b*, -197, and let-7i, with miR-210 the only one also involved in the invasive transition.  To pinpoint crit. cellular functions affected in the invasive transition, we identified the protein coding genes with inversely related profiles to miR-210: BRCA1, FANCD, FANCF, PARP1, E-cadherin, and Rb1 were all activated in the in situ and down-regulated in the invasive carcinoma.  Addnl., we detected differential splicing isoforms with special features, including a truncated EGFR lacking the kinase domain and overexpressed only in ductal carcinoma in situ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdk7DF5YMwyLVg90H21EOLACvtfcHk0lj0DlG-y90cEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wmt7s%253D&md5=d25f1754fe2c3f5ab2da6337cd452c3e</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1200010109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1200010109%26sid%3Dliteratum%253Aachs%26aulast%3DVolinia%26aufirst%3DS.%26aulast%3DGalasso%26aufirst%3DM.%26aulast%3DSana%26aufirst%3DM.%2BE.%26aulast%3DWise%26aufirst%3DT.%2BF.%26aulast%3DPalatini%26aufirst%3DJ.%26aulast%3DHuebner%26aufirst%3DK.%26aulast%3DCroce%26aufirst%3DC.%2BM.%26atitle%3DBreast%2520cancer%2520signatures%2520for%2520invasiveness%2520and%2520prognosis%2520defined%2520by%2520deep%2520sequencing%2520of%2520microRNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D3024%26epage%3D3029%26doi%3D10.1073%2Fpnas.1200010109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Pettitt, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehman, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajrami, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarewa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenwick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assiotis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">A genetic screen using the PiggyBac transposon in haploid cells identifies PARP1 as a mediator of olaparib toxicity</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e61520</span><span class="refDoi"> DOI: 10.1371/journal.pone.0061520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1371%2Fjournal.pone.0061520" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e61520&author=S.+J.+Pettittauthor=F.+L.+Rehmanauthor=I.+Bajramiauthor=R.+Broughauthor=F.+Wallbergauthor=I.+Kozarewaauthor=K.+Fenwickauthor=I.+Assiotisauthor=L.+Chenauthor=J.+Campbellauthor=C.+J.+Lordauthor=A.+Ashworth&title=A+genetic+screen+using+the+PiggyBac+transposon+in+haploid+cells+identifies+PARP1+as+a+mediator+of+olaparib+toxicity&doi=10.1371%2Fjournal.pone.0061520"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0061520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0061520%26sid%3Dliteratum%253Aachs%26aulast%3DPettitt%26aufirst%3DS.%2BJ.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DWallberg%26aufirst%3DF.%26aulast%3DKozarewa%26aufirst%3DI.%26aulast%3DFenwick%26aufirst%3DK.%26aulast%3DAssiotis%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DA%2520genetic%2520screen%2520using%2520the%2520PiggyBac%2520transposon%2520in%2520haploid%2520cells%2520identifies%2520PARP1%2520as%2520a%2520mediator%2520of%2520olaparib%2520toxicity%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De61520%26doi%3D10.1371%2Fjournal.pone.0061520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Lawlor, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busschots, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Leary, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennessy, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stordal, B.</span><span> </span><span class="NLM_article-title">PARP inhibitors as P-glyoprotein substrates</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">1913</span><span class="NLM_x">–</span> <span class="NLM_lpage">1920</span><span class="refDoi"> DOI: 10.1002/jps.23952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1002%2Fjps.23952" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2014&pages=1913-1920&author=D.+Lawlorauthor=P.+Martinauthor=S.+Busschotsauthor=J.+Theryauthor=J.+J.+O%E2%80%99Learyauthor=B.+T.+Hennessyauthor=B.+Stordal&title=PARP+inhibitors+as+P-glyoprotein+substrates&doi=10.1002%2Fjps.23952"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fjps.23952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23952%26sid%3Dliteratum%253Aachs%26aulast%3DLawlor%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DBusschots%26aufirst%3DS.%26aulast%3DThery%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DJ.%2BJ.%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DStordal%26aufirst%3DB.%26atitle%3DPARP%2520inhibitors%2520as%2520P-glyoprotein%2520substrates%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D103%26spage%3D1913%26epage%3D1920%26doi%3D10.1002%2Fjps.23952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Henneman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Miltenburg, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braumuller, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drenth, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Korte-Grimmerink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogola, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szuhai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlicker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bin Ali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huijbers, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berns, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">8409</span><span class="NLM_x">–</span> <span class="NLM_lpage">8414</span><span class="refDoi"> DOI: 10.1073/pnas.1500223112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1073%2Fpnas.1500223112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=8409-8414&author=L.+Hennemanauthor=M.+H.+van+Miltenburgauthor=E.+M.+Michalakauthor=T.+M.+Braumullerauthor=J.+E.+Jaspersauthor=A.+P.+Drenthauthor=R.+de+Korte-Grimmerinkauthor=E.+Gogolaauthor=K.+Szuhaiauthor=A.+Schlickerauthor=R.+Bin+Aliauthor=C.+Pritchardauthor=I.+J.+Huijbersauthor=A.+Bernsauthor=S.+Rottenbergauthor=J.+Jonkers&title=Selective+resistance+to+the+PARP+inhibitor+olaparib+in+a+mouse+model+for+BRCA1-deficient+metaplastic+breast+cancer&doi=10.1073%2Fpnas.1500223112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1500223112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1500223112%26sid%3Dliteratum%253Aachs%26aulast%3DHenneman%26aufirst%3DL.%26aulast%3Dvan%2BMiltenburg%26aufirst%3DM.%2BH.%26aulast%3DMichalak%26aufirst%3DE.%2BM.%26aulast%3DBraumuller%26aufirst%3DT.%2BM.%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DDrenth%26aufirst%3DA.%2BP.%26aulast%3Dde%2BKorte-Grimmerink%26aufirst%3DR.%26aulast%3DGogola%26aufirst%3DE.%26aulast%3DSzuhai%26aufirst%3DK.%26aulast%3DSchlicker%26aufirst%3DA.%26aulast%3DBin%2BAli%26aufirst%3DR.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DHuijbers%26aufirst%3DI.%2BJ.%26aulast%3DBerns%26aufirst%3DA.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DSelective%2520resistance%2520to%2520the%2520PARP%2520inhibitor%2520olaparib%2520in%2520a%2520mouse%2520model%2520for%2520BRCA1-deficient%2520metaplastic%2520breast%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D8409%26epage%3D8414%26doi%3D10.1073%2Fpnas.1500223112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sol, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersbergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlicker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guyader, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessels, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, S.</span><span> </span><span class="NLM_article-title">BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">732</span><span class="NLM_x">–</span> <span class="NLM_lpage">741</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-14-0839" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=732-741&author=J.+E.+Jaspersauthor=W.+Solauthor=A.+Kersbergenauthor=A.+Schlickerauthor=C.+Guyaderauthor=G.+Xuauthor=L.+Wesselsauthor=P.+Borstauthor=J.+Jonkersauthor=S.+Rottenberg&title=BRCA2-deficient+sarcomatoid+mammary+tumors+exhibit+multidrug+resistance&doi=10.1158%2F0008-5472.CAN-14-0839"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0839%26sid%3Dliteratum%253Aachs%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DSol%26aufirst%3DW.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3DSchlicker%26aufirst%3DA.%26aulast%3DGuyader%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DWessels%26aufirst%3DL.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DRottenberg%26aufirst%3DS.%26atitle%3DBRCA2-deficient%2520sarcomatoid%2520mammary%2520tumors%2520exhibit%2520multidrug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D732%26epage%3D741%26doi%3D10.1158%2F0008-5472.CAN-14-0839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Dufour, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daumar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mounetou, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwiatkowski, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrial, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vatoux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penault-Llorca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamdad, M.</span><span> </span><span class="NLM_article-title">BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">12670</span><span class="refDoi"> DOI: 10.1038/srep12670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fsrep12670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26234720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKiurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=12670&author=R.+Dufourauthor=P.+Daumarauthor=E.+Mounetouauthor=C.+Aubelauthor=F.+Kwiatkowskiauthor=C.+Abrialauthor=C.+Vatouxauthor=F.+Penault-Llorcaauthor=M.+Bamdad&title=BCRP+and+P-gp+relay+overexpression+in+triple+negative+basal-like+breast+cancer+cell+line%3A+a+prospective+role+in+resistance+to+Olaparib&doi=10.1038%2Fsrep12670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib</span></div><div class="casAuthors">Dufour, Robin; Daumar, Pierre; Mounetou, Emmanuelle; Aubel, Corinne; Kwiatkowski, Fabrice; Abrial, Catherine; Vatoux, Catherine; Penault-Llorca, Frederique; Bamdad, Mahchid</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12670</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The triple neg. basal-like (TNBL) breast carcinoma is an aggressive and unfavorable prognosis disease.  Inhibitors of poly(ADP-ribose) polymerase such as Olaparib could represent a promising targeted therapy but their sensitivity against Multidrug Resistance proteins (MDR), which causes resistance, is not well defined.  Thus, our work focused on the anal. of P-gp and BCRP coexpression in the SUM1315 TNBL human cell line, in correlation with Olaparib intracellular concn.  Western blot analyses showed a clear coexpression of P-gp and BCRP in SUM1315 cells.  A low cytotoxic Olaparib treatment clearly led to an increased expression of both BCRP and P-gp in these cells.  Indeed, after 1.5 h of treatment, BCRP expression was increased with a 1.8 fold increase rate.  Then, P-gp took over from 3 h to 15 h with an av. increase rate of 1.8 fold, and finally returned to control value at 24 h.  HPLC-UV analyses showed that, in the same treatment conditions, the intracellular Olaparib concn. increased from 1 h to 3 h and remained relatively stable until 24 h.  Results suggest that the resistance mechanism induced by Olaparib in TNBL SUM1315 cell line may be overpassed if a cytotoxic and stable intracellular level of the drug can be maintained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX2PmpeqODKrVg90H21EOLACvtfcHk0lj0LqYHN7BeDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKiurzI&md5=0b52863324c3544a33964b8bd2edc634</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1038%2Fsrep12670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep12670%26sid%3Dliteratum%253Aachs%26aulast%3DDufour%26aufirst%3DR.%26aulast%3DDaumar%26aufirst%3DP.%26aulast%3DMounetou%26aufirst%3DE.%26aulast%3DAubel%26aufirst%3DC.%26aulast%3DKwiatkowski%26aufirst%3DF.%26aulast%3DAbrial%26aufirst%3DC.%26aulast%3DVatoux%26aufirst%3DC.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DBamdad%26aufirst%3DM.%26atitle%3DBCRP%2520and%2520P-gp%2520relay%2520overexpression%2520in%2520triple%2520negative%2520basal-like%2520breast%2520cancer%2520cell%2520line%253A%2520a%2520prospective%2520role%2520in%2520resistance%2520to%2520Olaparib%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D12670%26doi%3D10.1038%2Fsrep12670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Nakagawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sedukhina, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche-Molina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narváez, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyasekharan, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernal, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span> </span><span class="NLM_article-title">NF-κB signaling mediates acquired resistance after PARP inhibition</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3825</span><span class="NLM_x">–</span> <span class="NLM_lpage">3839</span><span class="refDoi"> DOI: 10.18632/oncotarget.2868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.2868" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=3825-3839&author=Y.+Nakagawaauthor=A.+S.+Sedukhinaauthor=N.+Okamotoauthor=S.+Nagasawaauthor=N.+Suzukiauthor=T.+Ohtaauthor=H.+Hattoriauthor=M.+Roche-Molinaauthor=A.+J.+Narv%C3%A1ezauthor=A.+D.+Jeyasekharanauthor=J.+A.+Bernalauthor=K.+Sato&title=NF-%CE%BAB+signaling+mediates+acquired+resistance+after+PARP+inhibition&doi=10.18632%2Foncotarget.2868"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2868%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DY.%26aulast%3DSedukhina%26aufirst%3DA.%2BS.%26aulast%3DOkamoto%26aufirst%3DN.%26aulast%3DNagasawa%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DOhta%26aufirst%3DT.%26aulast%3DHattori%26aufirst%3DH.%26aulast%3DRoche-Molina%26aufirst%3DM.%26aulast%3DNarv%25C3%25A1ez%26aufirst%3DA.%2BJ.%26aulast%3DJeyasekharan%26aufirst%3DA.%2BD.%26aulast%3DBernal%26aufirst%3DJ.%2BA.%26aulast%3DSato%26aufirst%3DK.%26atitle%3DNF-%25CE%25BAB%2520signaling%2520mediates%2520acquired%2520resistance%2520after%2520PARP%2520inhibition%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D3825%26epage%3D3839%26doi%3D10.18632%2Foncotarget.2868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Ruf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, G. E.</span><span> </span><span class="NLM_article-title">Inhibitor and NAD<sup>+</sup> binding to poly (ADP-ribose) polymerase as derived from crystal structures and homology modeling</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">3893</span><span class="NLM_x">–</span> <span class="NLM_lpage">3900</span><span class="refDoi"> DOI: 10.1021/bi972383s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi972383s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=3893-3900&author=A.+Rufauthor=G.+de+Murciaauthor=G.+E.+Schulz&title=Inhibitor+and+NAD%2B+binding+to+poly+%28ADP-ribose%29+polymerase+as+derived+from+crystal+structures+and+homology+modeling&doi=10.1021%2Fbi972383s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fbi972383s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi972383s%26sid%3Dliteratum%253Aachs%26aulast%3DRuf%26aufirst%3DA.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26aulast%3DSchulz%26aufirst%3DG.%2BE.%26atitle%3DInhibitor%2520and%2520NAD%252B%2520binding%2520to%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520as%2520derived%2520from%2520crystal%2520structures%2520and%2520homology%2520modeling%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D3893%26epage%3D3900%26doi%3D10.1021%2Fbi972383s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Banasik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span> </span><span class="NLM_article-title">Specific inhibitors of poly (ADP-ribose) synthetase and mono (ADP-ribosyl) transferase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">1569</span><span class="NLM_x">–</span> <span class="NLM_lpage">1575</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=1569-1575&author=M.+Banasikauthor=H.+Komuraauthor=M.+Shimoyamaauthor=K.+Ueda&title=Specific+inhibitors+of+poly+%28ADP-ribose%29+synthetase+and+mono+%28ADP-ribosyl%29+transferase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBanasik%26aufirst%3DM.%26aulast%3DKomura%26aufirst%3DH.%26aulast%3DShimoyama%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DK.%26atitle%3DSpecific%2520inhibitors%2520of%2520poly%2520%2528ADP-ribose%2529%2520synthetase%2520and%2520mono%2520%2528ADP-ribosyl%2529%2520transferase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D1569%26epage%3D1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">5-Aminoisoquinolin-1-one (5-AIQ), a water-soluble inhibitor of the poly(ADP-ribose)polymerases (PARPs)</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3807</span><span class="NLM_x">–</span> <span class="NLM_lpage">3829</span><span class="refDoi"> DOI: 10.2174/0929867322666151002110602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.2174%2F0929867322666151002110602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26429070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=3807-3829&author=M.+D.+Threadgill&title=5-Aminoisoquinolin-1-one+%285-AIQ%29%2C+a+water-soluble+inhibitor+of+the+poly%28ADP-ribose%29polymerases+%28PARPs%29&doi=10.2174%2F0929867322666151002110602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)</span></div><div class="casAuthors">Threadgill, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3807-3829</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  5-Aminoisoquinolin-1-one (5-AIQ) is a water-sol. inhibitor of the poly(ADPribose) polymerases (PARPs), lacking isoform-selectivity.  Although of only moderate potency in vitro against PARP-1, it is highly active in many assays in cells and in models in vivo, indicating excellent uptake.  Optimization of the several synthetic sequences to 5-AIQ has led to development of a short and efficient route from 1-chloroisoquinoline.  It has been used widely as a biochem. and pharmacol. tool to study the effects of inhibition of the PARPs.  It ameliorates the damage to cells and tissues following reperfusion of ischemic tissue, showing significant protective activity in a rodent model of haemorrhagic shock at the remarkably low dose of 30 μg Kg-1.  Protection is also seen in models of myocardial infarction, ischemic kidney and liver disorders, stroke and organ transplantation.  Inhibition of PARP-1 by 5-AIQ causes down-regulation of the activity of NF-κB, which then down-regulates the expression of several gene products.  Thus 5-AIQ has anti-inflammatory activity in vivo, through modulating the expression of cytokines and adhesion mols.  This indirect inhibition of expression is relevant in the activity of 5-AIQ in models of arthritis, Parkinson's disease, multiple sclerosis, spinal cord injury, periodontitis and inflammatory conditions of the lung.  Inhibition of expression of matrix metalloproteinases and other factors gives rise to anti-angiogenic activity and to remarkable anti-metastatic activity in a mouse model.  Thus, although it has been overtaken by other PARP-inhibiting drugs in the oncol. clinic, 5-AIQ remains a valuable tool to study the roles of PARPs in health and in diverse diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Pd2dtXXqI7Vg90H21EOLACvtfcHk0lj0LqYHN7BeDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsbnP&md5=bcc39758198f7944fb6707f5d0e68291</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.2174%2F0929867322666151002110602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666151002110602%26sid%3Dliteratum%253Aachs%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3D5-Aminoisoquinolin-1-one%2520%25285-AIQ%2529%252C%2520a%2520water-soluble%2520inhibitor%2520of%2520the%2520poly%2528ADP-ribose%2529polymerases%2520%2528PARPs%2529%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D3807%26epage%3D3829%26doi%3D10.2174%2F0929867322666151002110602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Rottenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersbergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Burg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nygren, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derksen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bruin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zevenhoven, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">17079</span><span class="NLM_x">–</span> <span class="NLM_lpage">17084</span><span class="refDoi"> DOI: 10.1073/pnas.0806092105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1073%2Fpnas.0806092105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=18971340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=17079-17084&author=S.+Rottenbergauthor=J.+E.+Jaspersauthor=A.+Kersbergenauthor=E.+van+der+Burgauthor=A.+O.+Nygrenauthor=S.+A.+Zanderauthor=P.+W.+Derksenauthor=M.+de+Bruinauthor=J.+Zevenhovenauthor=A.+Lauauthor=R.+Boulterauthor=A.+Cranstonauthor=M.+J.+O%E2%80%99Connorauthor=N.+M.+Martinauthor=P.+Borstauthor=J.+Jonkers&title=High+sensitivity+of+BRCA1-deficient+mammary+tumors+to+the+PARP+inhibitor+AZD2281+alone+and+in+combination+with+platinum+drugs&doi=10.1073%2Fpnas.0806092105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span></div><div class="casAuthors">Rottenberg, Sven; Jaspers, Janneke E.; Kersbergen, Ariena; van der Burg, Eline; Nygren, Anders O. H.; Zander, Serge A. L.; Derksen, Patrick W. B.; de Bruin, Michiel; Zevenhoven, John; Lau, Alan; Boulter, Robert; Cranston, Aaron; O'Connor, Mark J.; Martin, Niall M. B.; Borst, Piet; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17079-17084</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone receptor-pos. breast cancers, no tailored therapy exists for hormone receptor- and ERBB2-neg. ("triple-neg.") mammary carcinomas.  Triple-neg. tumors account for 15% of all breast cancers and frequently harbor defects in DNA double-strand break repair through homologous recombination (HR), such as BRCA1 dysfunction.  The DNA-repair defects characteristic of BRCA1-deficient cells confer sensitivity to poly(ADP-ribose) polymerase 1 (PARP1) inhibition, which could be relevant to treatment of triple-neg. tumors.  To evaluate PARP1 inhibition in a realistic in vivo setting, we tested the PARP inhibitor AZD2281 in a genetically engineered mouse model (GEMM) for BRCA1-assocd. breast cancer.  Treatment of tumor-bearing mice with AZD2281 inhibited tumor growth without signs of toxicity, resulting in strongly increased survival.  Long-term treatment with AZD2281 in this model did result in the development of drug resistance, caused by up-regulation of Abcb1a/b genes encoding P-glycoprotein efflux pumps.  This resistance to AZD2281 could be reversed by coadministration of the P-glycoprotein inhibitor tariquidar.  Combination of AZD2281 with cisplatin or carboplatin increased the recurrence-free and overall survival, suggesting that AZD2281 potentiates the effect of these DNA-damaging agents.  Our results demonstrate in vivo efficacy of AZD2281 against BRCA1-deficient breast cancer and illustrate how GEMMs of cancer can be used for preclin. evaluation of novel therapeutics and for testing ways to overcome or circumvent therapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr95zB9OKZ4ObVg90H21EOLACvtfcHk0ljPkKhMmlbbuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F&md5=788a7d8b5341b731d007753d5a234dec</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0806092105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0806092105%26sid%3Dliteratum%253Aachs%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BBurg%26aufirst%3DE.%26aulast%3DNygren%26aufirst%3DA.%2BO.%26aulast%3DZander%26aufirst%3DS.%2BA.%26aulast%3DDerksen%26aufirst%3DP.%2BW.%26aulast%3Dde%2BBruin%26aufirst%3DM.%26aulast%3DZevenhoven%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DHigh%2520sensitivity%2520of%2520BRCA1-deficient%2520mammary%2520tumors%2520to%2520the%2520PARP%2520inhibitor%2520AZD2281%2520alone%2520and%2520in%2520combination%2520with%2520platinum%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D17079%26epage%3D17084%26doi%3D10.1073%2Fpnas.0806092105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Johannes, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almeida, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosskurth, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmirski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikule, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogoe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petteruti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylvester, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Throner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. A.</span><span> </span><span class="NLM_article-title">Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5743</span><span class="NLM_x">–</span> <span class="NLM_lpage">5747</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2015.10.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26546219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyhsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5743-5747&author=J.+W.+Johannesauthor=L.+Almeidaauthor=K.+Dalyauthor=A.+D.+Fergusonauthor=S.+E.+Grosskurthauthor=H.+Guanauthor=T.+Howardauthor=S.+Ioannidisauthor=S.+Kazmirskiauthor=M.+L.+Lambauthor=N.+A.+Larsenauthor=P.+D.+Lyneauthor=K.+Mikuleauthor=C.+Ogoeauthor=B.+Pengauthor=P.+Petterutiauthor=J.+A.+Readauthor=N.+Suauthor=M.+Sylvesterauthor=S.+Thronerauthor=W.+Wangauthor=X.+Wangauthor=J.+Wuauthor=Q.+Yeauthor=Y.+Yuauthor=X.+Zhengauthor=D.+A.+Scott&title=Discovery+of+AZ0108%2C+an+orally+bioavailable+phthalazinone+PARP+inhibitor+that+blocks+centrosome+clustering&doi=10.1016%2Fj.bmcl.2015.10.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering</span></div><div class="casAuthors">Johannes, Jeffrey W.; Almeida, Lynsie; Daly, Kevin; Ferguson, Andrew D.; Grosskurth, Shaun E.; Guan, Huiping; Howard, Tina; Ioannidis, Stephanos; Kazmirski, Steven; Lamb, Michelle L.; Larsen, Nicholas A.; Lyne, Paul D.; Mikule, Keith; Ogoe, Claude; Peng, Bo; Petteruti, Philip; Read, Jon A.; Su, Nancy; Sylvester, Mark; Throner, Scott; Wang, Wenxian; Wang, Xin; Wu, Jiaquan; Ye, Qing; Yu, Yan; Zheng, Xiaolan; Scott, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5743-5747</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The propensity for cancer cells to accumulate addnl. centrosomes relative to normal cells could be exploited for therapeutic benefit in oncol.  Following literature reports that suggested TNKS1 (tankyrase 1) and PARP16 may be involved with spindle structure and function and may play a role in suppressing multipolar spindle formation in cells with supernumerary centrosomes, the authors initiated a phenotypic screen to look for small mol. poly (ADP-ribose) polymerase (PARP) enzyme family inhibitors that could produce a multipolar spindle phenotype via declustering of centrosomes.  Screening of AstraZeneca's collection of phthalazinone PARP inhibitors in HeLa cells using high-content screening techniques identified several compds. that produced a multipolar spindle phenotype at low nanomolar concns.  Characterization of these compds. across a broad panel of PARP family enzyme assays indicated that they had activity against several PARP family enzymes, including PARP1, 2, 3, 5a, 5b, and 6.  Further optimization of these initial hits for improved declustering potency, soly., permeability, and oral bioavailability resulted in AZ0108, a PARP1, 2, 6 inhibitor that potently inhibits centrosome clustering and is suitable for in vivo efficacy and tolerability studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzV-IqZ8iBJ7Vg90H21EOLACvtfcHk0ljPkKhMmlbbuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyhsbjL&md5=68fda93959cd69be615a864248b07533</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.079%26sid%3Dliteratum%253Aachs%26aulast%3DJohannes%26aufirst%3DJ.%2BW.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DDaly%26aufirst%3DK.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGrosskurth%26aufirst%3DS.%2BE.%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DKazmirski%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DLarsen%26aufirst%3DN.%2BA.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DMikule%26aufirst%3DK.%26aulast%3DOgoe%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DPetteruti%26aufirst%3DP.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DSu%26aufirst%3DN.%26aulast%3DSylvester%26aufirst%3DM.%26aulast%3DThroner%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DScott%26aufirst%3DD.%2BA.%26atitle%3DDiscovery%2520of%2520AZ0108%252C%2520an%2520orally%2520bioavailable%2520phthalazinone%2520PARP%2520inhibitor%2520that%2520blocks%2520centrosome%2520clustering%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5743%26epage%3D5747%26doi%3D10.1016%2Fj.bmcl.2015.10.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Pescatore, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bufi, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muraglia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orvieto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span> </span><span class="NLM_article-title">Identification and SAR of novel pyrrolo [1,2-a]pyrazin-1 (2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1094</span><span class="NLM_x">–</span> <span class="NLM_lpage">1099</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2009.12.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1094-1099&author=G.+Pescatoreauthor=D.+Brancaauthor=F.+Fioreauthor=O.+Kinzelauthor=L.+L.+Bufiauthor=E.+Muragliaauthor=F.+Orvietoauthor=M.+Rowleyauthor=C.+Toniattiauthor=C.+Torrisiauthor=P.+Jones&title=Identification+and+SAR+of+novel+pyrrolo+%5B1%2C2-a%5Dpyrazin-1+%282H%29-one+derivatives+as+inhibitors+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29&doi=10.1016%2Fj.bmcl.2009.12.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DPescatore%26aufirst%3DG.%26aulast%3DBranca%26aufirst%3DD.%26aulast%3DFiore%26aufirst%3DF.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DBufi%26aufirst%3DL.%2BL.%26aulast%3DMuraglia%26aufirst%3DE.%26aulast%3DOrvieto%26aufirst%3DF.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DTorrisi%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26atitle%3DIdentification%2520and%2520SAR%2520of%2520novel%2520pyrrolo%2520%255B1%252C2-a%255Dpyrazin-1%2520%25282H%2529-one%2520derivatives%2520as%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1094%26epage%3D1099%26doi%3D10.1016%2Fj.bmcl.2009.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Ferrigno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bufi, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muraglia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span> </span><span class="NLM_article-title">Development of substituted 6-[4-fluoro-3- (piperazin-1-ylcarbonyl) benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose)polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">1105</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.11.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2009.11.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1100-1105&author=F.+Ferrignoauthor=D.+Brancaauthor=O.+Kinzelauthor=S.+Lilliniauthor=L.+L.+Bufiauthor=E.+Monteagudoauthor=E.+Muragliaauthor=M.+Rowleyauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=C.+Torrisiauthor=P.+Jones&title=Development+of+substituted+6-%5B4-fluoro-3-+%28piperazin-1-ylcarbonyl%29+benzyl%5D-4%2C5-dimethylpyridazin-3%282H%29-ones+as+potent+poly%28ADP%E2%80%93ribose%29polymerase-1+%28PARP-1%29+inhibitors+active+in+BRCA+deficient+cells&doi=10.1016%2Fj.bmcl.2009.11.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.087%26sid%3Dliteratum%253Aachs%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DBranca%26aufirst%3DD.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DLillini%26aufirst%3DS.%26aulast%3DBufi%26aufirst%3DL.%2BL.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DMuraglia%26aufirst%3DE.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DTorrisi%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520substituted%25206-%255B4-fluoro-3-%2520%2528piperazin-1-ylcarbonyl%2529%2520benzyl%255D-4%252C5-dimethylpyridazin-3%25282H%2529-ones%2520as%2520potent%2520poly%2528ADP%25E2%2580%2593ribose%2529polymerase-1%2520%2528PARP-1%2529%2520inhibitors%2520active%2520in%2520BRCA%2520deficient%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1100%26epage%3D1105%26doi%3D10.1016%2Fj.bmcl.2009.11.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span> </span><span class="NLM_article-title">Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4635</span><span class="NLM_x">–</span> <span class="NLM_lpage">4645</span><span class="refDoi"> DOI: 10.1016/j.bmc.2012.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmc.2012.06.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4635-4645&author=G.+D.+Zhuauthor=J.+Gongauthor=V.+B.+Gandhiauthor=X.+Liuauthor=Y.+Shiauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=P.+A.+Ellisauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=C.+Parkauthor=Y.+Luoauthor=A.+Shoemakerauthor=V.+L.+Girandaauthor=T.+D.+Penning&title=Discovery+and+SAR+of+orally+efficacious+tetrahydropyridopyridazinone+PARP+inhibitors+for+the+treatment+of+cancer&doi=10.1016%2Fj.bmc.2012.06.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DShoemaker%26aufirst%3DA.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520orally%2520efficacious%2520tetrahydropyridopyridazinone%2520PARP%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D4635%26epage%3D4645%26doi%3D10.1016%2Fj.bmc.2012.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Wang, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1- ones as potent PARP-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3739</span><span class="NLM_x">–</span> <span class="NLM_lpage">3743</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2014.07.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3739-3743&author=L.+X.+Wangauthor=X.+B.+Zhouauthor=M.+L.+Xiaoauthor=N.+Jiangauthor=F.+Liuauthor=W.+X.+Zhouauthor=X.+K.+Wangauthor=Z.+B.+Zhengauthor=S.+Li&title=Synthesis+and+biological+evaluation+of+substituted+4-%28thiophen-2-ylmethyl%29-2H-phthalazin-1-+ones+as+potent+PARP-1+inhibitors&doi=10.1016%2Fj.bmcl.2014.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%2BX.%26aulast%3DZhou%26aufirst%3DX.%2BB.%26aulast%3DXiao%26aufirst%3DM.%2BL.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DW.%2BX.%26aulast%3DWang%26aufirst%3DX.%2BK.%26aulast%3DZheng%26aufirst%3DZ.%2BB.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520substituted%25204-%2528thiophen-2-ylmethyl%2529-2H-phthalazin-1-%2520ones%2520as%2520potent%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3739%26epage%3D3743%26doi%3D10.1016%2Fj.bmcl.2014.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Lapidus, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoover, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">PARP inhibitors enhance the effect of cisplatin against tumors and ameliorate cisplatin-induced neuropathy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=2141&author=R.+G.+Lapidusauthor=W.+Xuauthor=E.+Spicerauthor=R.+Hooverauthor=J.+Zhang&title=PARP+inhibitors+enhance+the+effect+of+cisplatin+against+tumors+and+ameliorate+cisplatin-induced+neuropathy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DSpicer%26aufirst%3DE.%26aulast%3DHoover%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPARP%2520inhibitors%2520enhance%2520the%2520effect%2520of%2520cisplatin%2520against%2520tumors%2520and%2520ameliorate%2520cisplatin-induced%2520neuropathy%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D2141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Mita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarantopoulos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kueber, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGonigle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrada, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachdev, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, J. J.,  Jr</span><span> </span><span class="NLM_article-title">Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly (ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with Temozolomide (TMZ) in patients with advanced solid tumors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">11 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">B185</span><span class="refDoi"> DOI: 10.1158/1535-7163.TARG-11-B185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.TARG-11-B185" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=B185&issue=11+suppl&author=A.+Mitaauthor=M.+Mitaauthor=J.+Sarantopoulosauthor=J.+C.+Martinauthor=J.+D.+Kueberauthor=S.+McGonigleauthor=M.+Matijevicauthor=B.+Mistryauthor=J.+L.+Ferradaauthor=P.+Sachdevauthor=J.+J.+Stephenson&title=Phase+I+study+of+the+safety%2C+pharmacokinetics+%28PK%29%2C+and+pharmacodynamics+%28PD%29+of+the+poly+%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+E7016+in+combination+with+Temozolomide+%28TMZ%29+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1535-7163.TARG-11-B185"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-11-B185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-11-B185%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DA.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DSarantopoulos%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DJ.%2BC.%26aulast%3DKueber%26aufirst%3DJ.%2BD.%26aulast%3DMcGonigle%26aufirst%3DS.%26aulast%3DMatijevic%26aufirst%3DM.%26aulast%3DMistry%26aufirst%3DB.%26aulast%3DFerrada%26aufirst%3DJ.%2BL.%26aulast%3DSachdev%26aufirst%3DP.%26aulast%3DStephenson%26aufirst%3DJ.%2BJ.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520safety%252C%2520pharmacokinetics%2520%2528PK%2529%252C%2520and%2520pharmacodynamics%2520%2528PD%2529%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520E7016%2520in%2520combination%2520with%2520Temozolomide%2520%2528TMZ%2529%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26issue%3D11%2520suppl%26spage%3DB185%26doi%3D10.1158%2F1535-7163.TARG-11-B185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of pyridazino [3, 4, 5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2340</span><span class="NLM_x">–</span> <span class="NLM_lpage">2344</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2015.04.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2340-2344&author=J.+Wangauthor=H.+Tanauthor=Q.+Sunauthor=Z.+Geauthor=X.+Wangauthor=Y.+Wangauthor=R.+Li&title=Design%2C+synthesis+and+biological+evaluation+of+pyridazino+%5B3%2C+4%2C+5-de%5Dquinazolin-3%282H%29-one+as+a+new+class+of+PARP-1+inhibitors&doi=10.1016%2Fj.bmcl.2015.04.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DGe%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520pyridazino%2520%255B3%252C%25204%252C%25205-de%255Dquinazolin-3%25282H%2529-one%2520as%2520a%2520new%2520class%2520of%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2340%26epage%3D2344%26doi%3D10.1016%2Fj.bmcl.2015.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardberg, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yip, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzpatrick, P. A.</span><span> </span><span class="NLM_article-title">Structural basis for the inhibition of poly (ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone</span> <span class="citation_source-journal">Acta Crystallogr., Sect. F: Struct. Biol. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1143</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span><span class="refDoi"> DOI: 10.1107/S2053230X14015088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1107%2FS2053230X14015088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25195882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2qt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=1143-1149&author=M.+Aoyagi-Scharberauthor=A.+S.+Gardbergauthor=B.+K.+Yipauthor=B.+Wangauthor=Y.+Shenauthor=P.+A.+Fitzpatrick&title=Structural+basis+for+the+inhibition+of+poly+%28ADP-ribose%29+polymerases+1+and+2+by+BMN+673%2C+a+potent+inhibitor+derived+from+dihydropyridophthalazinone&doi=10.1107%2FS2053230X14015088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone</span></div><div class="casAuthors">Aoyagi-Scharber, Mika; Gardberg, Anna S.; Yip, Bryan K.; Wang, Bing; Shen, Yuqiao; Fitzpatrick, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1143-1149</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerases 1 and 2 (PARP1 and PARP2), which are involved in DNA damage response, are targets of anticancer therapeutics.  BMN 673 is a novel PARP1/2 inhibitor with substantially increased PARP-mediated tumor cytotoxicity and is now in later-stage clin. development for BRCA-deficient breast cancers.  Here, in co-crystal structures, BMN 673 was anchored to the nicotinamide-binding pocket via an extensive network of H-bonding and π-stacking interactions, including those mediated by active site water mols.  The novel di-branched scaffold of BMN 673 extended the binding interactions toward the outer edges of the pocket, which exhibited the least sequence homol. among PARP enzymes.  The crystallog. structural analyses reported here therefore not only provide crit. insights into the mol. basis for the exceptionally high potency of the clin. development candidate BMN 673, but also new opportunities for increasing inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3neiOqbsUprVg90H21EOLACvtfcHk0lih5ZbEFA6dGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2qt77I&md5=6d75628ad833fa618eac02e72f326666</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1107%2FS2053230X14015088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X14015088%26sid%3Dliteratum%253Aachs%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DGardberg%26aufirst%3DA.%2BS.%26aulast%3DYip%26aufirst%3DB.%2BK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DFitzpatrick%26aufirst%3DP.%2BA.%26atitle%3DStructural%2520basis%2520for%2520the%2520inhibition%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerases%25201%2520and%25202%2520by%2520BMN%2520673%252C%2520a%2520potent%2520inhibitor%2520derived%2520from%2520dihydropyridophthalazinone%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2014%26volume%3D70%26spage%3D1143%26epage%3D1149%26doi%3D10.1107%2FS2053230X14015088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span> </span><span class="NLM_article-title">Abstract B64: Structure and preclinical characterization of BMN 673, a potent and orally active PARP inhibitor as an anticancer agent</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">11 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">B64</span><span class="refDoi"> DOI: 10.1158/1535-7163.TARG-11-B64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.TARG-11-B64" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=B64&issue=11+suppl&author=Y.+Shenauthor=Y.+Fengauthor=B.+Wangauthor=P.+Myersauthor=D.+Chuauthor=L.+E.+Post&title=Abstract+B64%3A+Structure+and+preclinical+characterization+of+BMN+673%2C+a+potent+and+orally+active+PARP+inhibitor+as+an+anticancer+agent&doi=10.1158%2F1535-7163.TARG-11-B64"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-11-B64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-11-B64%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DP.%26aulast%3DChu%26aufirst%3DD.%26aulast%3DPost%26aufirst%3DL.%2BE.%26atitle%3DAbstract%2520B64%253A%2520Structure%2520and%2520preclinical%2520characterization%2520of%2520BMN%2520673%252C%2520a%2520potent%2520and%2520orally%2520active%2520PARP%2520inhibitor%2520as%2520an%2520anticancer%2520agent%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26issue%3D11%2520suppl%26spage%3DB64%26doi%3D10.1158%2F1535-7163.TARG-11-B64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mina, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henshaw, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadha, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachdev, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jameson, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainberg, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R. K.</span><span> </span><span class="NLM_article-title">First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">2580</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23733753" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=2580&issue=15+suppl&author=J.+S.+de+Bonoauthor=L.+A.+Minaauthor=M.+Gonzalezauthor=N.+J.+Curtinauthor=E.+Wangauthor=J.+W.+Henshawauthor=M.+Chadhaauthor=J.+C.+Sachdevauthor=D.+Mateiauthor=G.+S.+Jamesonauthor=M.+Ongauthor=B.+Basuauthor=Z.+A.+Wainbergauthor=L.+A.+Byersauthor=R.+Chughauthor=A.+Dorrauthor=S.+B.+Kayeauthor=R.+K.+Ramanathan&title=First-in-human+trial+of+novel+oral+PARP+inhibitor+BMN+673+in+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DMina%26aufirst%3DL.%2BA.%26aulast%3DGonzalez%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DHenshaw%26aufirst%3DJ.%2BW.%26aulast%3DChadha%26aufirst%3DM.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DJameson%26aufirst%3DG.%2BS.%26aulast%3DOng%26aufirst%3DM.%26aulast%3DBasu%26aufirst%3DB.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DDorr%26aufirst%3DA.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26atitle%3DFirst-in-human%2520trial%2520of%2520novel%2520oral%2520PARP%2520inhibitor%2520BMN%2520673%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D15%2520suppl%26spage%3D2580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Wainberg, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mina, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachsev, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheler, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henshaw, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">7522</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=7522&issue=15+suppl&author=Z.+Wainbergauthor=S.+Rafiiauthor=R.+Ramanathanauthor=L.+Minaauthor=L.+Byersauthor=R.+Chughauthor=J.+W.+Goldmanauthor=J.+C.+Sachsevauthor=D.+E.+Mateiauthor=J.+J.+Whelerauthor=J.+W.+Henshawauthor=C.+Zhangauthor=G.+Gallantauthor=J.+S.+de+Bono&title=Safety+and+antitumor+activity+of+the+PARP+inhibitor+BMN673+in+a+phase+1+trial+recruiting+metastatic+small-cell+lung+cancer+%28SCLC%29+and+germline+BRCA-mutation+carrier+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWainberg%26aufirst%3DZ.%26aulast%3DRafii%26aufirst%3DS.%26aulast%3DRamanathan%26aufirst%3DR.%26aulast%3DMina%26aufirst%3DL.%26aulast%3DByers%26aufirst%3DL.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DSachsev%26aufirst%3DJ.%2BC.%26aulast%3DMatei%26aufirst%3DD.%2BE.%26aulast%3DWheler%26aufirst%3DJ.%2BJ.%26aulast%3DHenshaw%26aufirst%3DJ.%2BW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGallant%26aufirst%3DG.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DSafety%2520and%2520antitumor%2520activity%2520of%2520the%2520PARP%2520inhibitor%2520BMN673%2520in%2520a%2520phase%25201%2520trial%2520recruiting%2520metastatic%2520small-cell%2520lung%2520cancer%2520%2528SCLC%2529%2520and%2520germline%2520BRCA-mutation%2520carrier%2520cancer%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15%2520suppl%26spage%3D7522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. H.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of tricyclic derivatives containing a non-aromatic amide as inhibitors of poly (ADP-ribose) polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2250</span><span class="NLM_x">–</span> <span class="NLM_lpage">2253</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2010.02.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2250-2253&author=C.+H.+Parkauthor=K.+Chunauthor=B.+Y.+Joeauthor=J.+S.+Parkauthor=Y.+C.+Kimauthor=J.+S.+Choiauthor=D.+K.+Ryuauthor=S.+H.+Kohauthor=G.+W.+Choauthor=S.+H.+Kimauthor=M.+H.+Kim&title=Synthesis+and+evaluation+of+tricyclic+derivatives+containing+a+non-aromatic+amide+as+inhibitors+of+poly+%28ADP-ribose%29+polymerase-1+%28PARP-1%29&doi=10.1016%2Fj.bmcl.2010.02.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DChun%26aufirst%3DK.%26aulast%3DJoe%26aufirst%3DB.%2BY.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DY.%2BC.%26aulast%3DChoi%26aufirst%3DJ.%2BS.%26aulast%3DRyu%26aufirst%3DD.%2BK.%26aulast%3DKoh%26aufirst%3DS.%2BH.%26aulast%3DCho%26aufirst%3DG.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DM.%2BH.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520tricyclic%2520derivatives%2520containing%2520a%2520non-aromatic%2520amide%2520as%2520inhibitors%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2250%26epage%3D2253%26doi%3D10.1016%2Fj.bmcl.2010.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Gangloff, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimshaw, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hixon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiryanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, P.</span><span> </span><span class="NLM_article-title">Discovery of novel benzo [b][1, 4] oxazin-3 (4H)-ones as poly (ADP-ribose) polymerase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4501</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2013.06.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4501-4505&author=A.+R.+Gangloffauthor=J.+Brownauthor=R.+de+Jongauthor=D.+R.+Douganauthor=C.+E.+Grimshawauthor=M.+Hixonauthor=A.+Jenningsauthor=R.+Kamranauthor=A.+Kiryanovauthor=S.+O%E2%80%99Connellauthor=E.+Taylorauthor=P.+Vu&title=Discovery+of+novel+benzo+%5Bb%5D%5B1%2C+4%5D+oxazin-3+%284H%29-ones+as+poly+%28ADP-ribose%29+polymerase+inhibitors&doi=10.1016%2Fj.bmcl.2013.06.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.055%26sid%3Dliteratum%253Aachs%26aulast%3DGangloff%26aufirst%3DA.%2BR.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3Dde%2BJong%26aufirst%3DR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DHixon%26aufirst%3DM.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DKamran%26aufirst%3DR.%26aulast%3DKiryanov%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DE.%26aulast%3DVu%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520novel%2520benzo%2520%255Bb%255D%255B1%252C%25204%255D%2520oxazin-3%2520%25284H%2529-ones%2520as%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4501%26epage%3D4505%26doi%3D10.1016%2Fj.bmcl.2013.06.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span> </span><span class="NLM_article-title">Synthesis of isoquinolinone-based tricycles as novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2669</span><span class="NLM_x">–</span> <span class="NLM_lpage">2673</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2014.04.061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2669-2673&author=J.+Chenauthor=H.+Pengauthor=J.+Heauthor=X.+Huanauthor=Z.+Miaoauthor=C.+Yang&title=Synthesis+of+isoquinolinone-based+tricycles+as+novel+poly+%28ADP-ribose%29+polymerase-1+%28PARP-1%29+inhibitors&doi=10.1016%2Fj.bmcl.2014.04.061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.061%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHuan%26aufirst%3DX.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520isoquinolinone-based%2520tricycles%2520as%2520novel%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2669%26epage%3D2673%26doi%3D10.1016%2Fj.bmcl.2014.04.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Ye, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huan, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of a series of benzo [de][1, 7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2885</span><span class="NLM_x">–</span> <span class="NLM_lpage">2903</span><span class="refDoi"> DOI: 10.1021/jm301825t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301825t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2885-2903&author=N.+Yeauthor=C.+H.+Chenauthor=T.+Chenauthor=Z.+Songauthor=J.+X.+Heauthor=X.+J.+Huanauthor=S.+S.+Songauthor=Q.+Liuauthor=Y.+Chenauthor=J.+Dingauthor=Y.+Xuauthor=Z.+H.+Miaoauthor=A.+Zhang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+a+series+of+benzo+%5Bde%5D%5B1%2C+7%5Dnaphthyridin-7%288H%29-ones+bearing+a+functionalized+longer+chain+appendage+as+novel+PARP1+inhibitors&doi=10.1021%2Fjm301825t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Fjm301825t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301825t%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DJ.%2BX.%26aulast%3DHuan%26aufirst%3DX.%2BJ.%26aulast%3DSong%26aufirst%3DS.%2BS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520benzo%2520%255Bde%255D%255B1%252C%25207%255Dnaphthyridin-7%25288H%2529-ones%2520bearing%2520a%2520functionalized%2520longer%2520chain%2520appendage%2520as%2520novel%2520PARP1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2885%26epage%3D2903%26doi%3D10.1021%2Fjm301825t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Giannini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battistuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milazzo, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Paolis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbarino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guglielmi, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carollo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallavalle, S.</span><span> </span><span class="NLM_article-title">Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2013.12.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24388690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1Knsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=462-466&author=G.+Gianniniauthor=G.+Battistuzziauthor=L.+Vesciauthor=F.+M.+Milazzoauthor=F.+De+Paolisauthor=M.+Barbarinoauthor=M.+B.+Guglielmiauthor=V.+Carolloauthor=G.+Galloauthor=R.+Artaliauthor=S.+Dallavalle&title=Novel+PARP-1+inhibitors+based+on+a+2-propanoyl-3H-quinazolin-4-one+scaffold&doi=10.1016%2Fj.bmcl.2013.12.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold</span></div><div class="casAuthors">Giannini, Giuseppe; Battistuzzi, Gianfranco; Vesci, Loredana; Milazzo, Ferdinando M.; De Paolis, Francesca; Barbarino, Marcella; Guglielmi, Mario Berardino; Carollo, Valeria; Gallo, Grazia; Artali, Roberto; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-466</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Poly(ADP-ribose)polymerase-I (PARP-1) enzyme is involved in maintaining DNA integrity and programmed cell death.  A virtual screening of com. libraries led to the identification of five novel scaffolds with inhibitory profile in the low nanomolar range.  A hit-to-lead optimization led to the identification of a group of new potent PARP-1 inhibitors, acyl-piperazinylamides of 3-(4-oxo-3,4-dihydro-quinazolin-2-yl)-propionic acid.  Mol. modeling studies highlighted the preponderant role of the propanoyl side chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsOEzNP5GTqLVg90H21EOLACvtfcHk0lhMpchK7hd02A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1Knsg%253D%253D&md5=df8b3d8367a78fbcfa15bb107f3e6e05</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.048%26sid%3Dliteratum%253Aachs%26aulast%3DGiannini%26aufirst%3DG.%26aulast%3DBattistuzzi%26aufirst%3DG.%26aulast%3DVesci%26aufirst%3DL.%26aulast%3DMilazzo%26aufirst%3DF.%2BM.%26aulast%3DDe%2BPaolis%26aufirst%3DF.%26aulast%3DBarbarino%26aufirst%3DM.%26aulast%3DGuglielmi%26aufirst%3DM.%2BB.%26aulast%3DCarollo%26aufirst%3DV.%26aulast%3DGallo%26aufirst%3DG.%26aulast%3DArtali%26aufirst%3DR.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3DNovel%2520PARP-1%2520inhibitors%2520based%2520on%2520a%25202-propanoyl-3H-quinazolin-4-one%2520scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D462%26epage%3D466%26doi%3D10.1016%2Fj.bmcl.2013.12.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Yao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, B.</span><span> </span><span class="NLM_article-title">Discovery of 1-substituted benzyl-quinazoline-2, 4(1H,3H)-dione derivatives as novel poly (ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">693</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.12.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmc.2014.12.071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=681-693&author=H.+Yaoauthor=M.+Jiauthor=Z.+Zhuauthor=J.+Zhouauthor=R.+Caoauthor=X.+Chenauthor=B.+Xu&title=Discovery+of+1-substituted+benzyl-quinazoline-2%2C+4%281H%2C3H%29-dione+derivatives+as+novel+poly+%28ADP-ribose%29+polymerase-1+inhibitors&doi=10.1016%2Fj.bmc.2014.12.071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.071%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DB.%26atitle%3DDiscovery%2520of%25201-substituted%2520benzyl-quinazoline-2%252C%25204%25281H%252C3H%2529-dione%2520derivatives%2520as%2520novel%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D681%26epage%3D693%26doi%3D10.1016%2Fj.bmc.2014.12.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Zhou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1016/j.bcp.2016.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bcp.2016.02.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=29-40&author=Q.+Zhouauthor=M.+Jiauthor=J.+Zhouauthor=J.+Jinauthor=N.+Xueauthor=J.+Chenauthor=B.+Xuauthor=X.+Chen&title=Poly+%28ADP-ribose%29+polymerases+inhibitor%2C+Zj6413%2C+as+a+potential+therapeutic+agent+against+breast+cancer&doi=10.1016%2Fj.bcp.2016.02.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DXue%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DPoly%2520%2528ADP-ribose%2529%2520polymerases%2520inhibitor%252C%2520Zj6413%252C%2520as%2520a%2520potential%2520therapeutic%2520agent%2520against%2520breast%2520cancer%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D107%26spage%3D29%26epage%3D40%26doi%3D10.1016%2Fj.bcp.2016.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel imidazo[4, 5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1996</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2013.02.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1993-1996&author=Q.+Zhuauthor=X.+Wangauthor=Z.+Chuauthor=G.+Heauthor=G.+Dongauthor=Y.+Xu&title=Design%2C+synthesis+and+biological+evaluation+of+novel+imidazo%5B4%2C+5-c%5Dpyridinecarboxamide+derivatives+as+PARP-1+inhibitors&doi=10.1016%2Fj.bmcl.2013.02.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.032%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChu%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520imidazo%255B4%252C%25205-c%255Dpyridinecarboxamide%2520derivatives%2520as%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1993%26epage%3D1996%26doi%3D10.1016%2Fj.bmcl.2013.02.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Patel, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffen, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chergui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trombetta, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fronczek, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talele, T. T.</span><span> </span><span class="NLM_article-title">Discovery and structure–activity relationship of novel 2, 3-dihydrobenzofuran-7-carboxamide and 2, 3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly (ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5579</span><span class="NLM_x">–</span> <span class="NLM_lpage">5601</span><span class="refDoi"> DOI: 10.1021/jm5002502</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5002502" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5579-5601&author=M.+R.+Patelauthor=A.+Bhattauthor=J.+D.+Steffenauthor=A.+Cherguiauthor=J.+Muraiauthor=Y.+Pommierauthor=J.+M.+Pascalauthor=L.+D.+Trombettaauthor=F.+R.+Fronczekauthor=T.+T.+Talele&title=Discovery+and+structure%E2%80%93activity+relationship+of+novel+2%2C+3-dihydrobenzofuran-7-carboxamide+and+2%2C+3-dihydrobenzofuran-3%282H%29-one-7-carboxamide+derivatives+as+poly+%28ADP-ribose%29+polymerase-1+inhibitors&doi=10.1021%2Fjm5002502"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fjm5002502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5002502%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DBhatt%26aufirst%3DA.%26aulast%3DSteffen%26aufirst%3DJ.%2BD.%26aulast%3DChergui%26aufirst%3DA.%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DPascal%26aufirst%3DJ.%2BM.%26aulast%3DTrombetta%26aufirst%3DL.%2BD.%26aulast%3DFronczek%26aufirst%3DF.%2BR.%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DDiscovery%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520of%2520novel%25202%252C%25203-dihydrobenzofuran-7-carboxamide%2520and%25202%252C%25203-dihydrobenzofuran-3%25282H%2529-one-7-carboxamide%2520derivatives%2520as%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5579%26epage%3D5601%26doi%3D10.1021%2Fjm5002502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Cincinelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musso, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milazzo, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carenini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunino, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallavalle, S.</span><span> </span><span class="NLM_article-title">7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1103</span><span class="refDoi"> DOI: 10.1016/j.bmc.2013.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmc.2013.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24398383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFyltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=1089-1103&author=R.+Cincinelliauthor=L.+Mussoauthor=L.+Merliniauthor=G.+Gianniniauthor=L.+Vesciauthor=F.+M.+Milazzoauthor=N.+Careniniauthor=P.+Peregoauthor=S.+Pencoauthor=R.+Artaliauthor=F.+Zuninoauthor=C.+Pisanoauthor=S.+Dallavalle&title=7-Azaindole-1-carboxamides+as+a+new+class+of+PARP-1+inhibitors&doi=10.1016%2Fj.bmc.2013.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors</span></div><div class="casAuthors">Cincinelli, Raffaella; Musso, Loana; Merlini, Lucio; Giannini, Giuseppe; Vesci, Loredana; Milazzo, Ferdinando M.; Carenini, Nives; Perego, Paola; Penco, Sergio; Artali, Roberto; Zunino, Franco; Pisano, Claudio; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1089-1103</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">7-Azaindole-1-carboxamides were designed as a new class of PARP-1 inhibitors.  The compds. displayed a variable pattern of target inhibition profile that, in part, paralleled the antiproliferative activity in cell lines characterized by homologous recombination defects.  A selected compd. I (ST7710AA1) showed significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp.  In antitumor activity studies against the MX1 human breast carcinoma growth in nude mice, the compd. exhibited an effect similar to that of Olaparib in terms of tumor vol. inhibition when used at a lower dose than the ref. compd.  Treatment was well tolerated, as no deaths or significant wt. losses were obsd. among the treated animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGousYJ49CeoYrVg90H21EOLACvtfcHk0lgpov0Vjv_8pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFyltg%253D%253D&md5=bd205428bf023358f6f388013648d8fa</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DMerlini%26aufirst%3DL.%26aulast%3DGiannini%26aufirst%3DG.%26aulast%3DVesci%26aufirst%3DL.%26aulast%3DMilazzo%26aufirst%3DF.%2BM.%26aulast%3DCarenini%26aufirst%3DN.%26aulast%3DPerego%26aufirst%3DP.%26aulast%3DPenco%26aufirst%3DS.%26aulast%3DArtali%26aufirst%3DR.%26aulast%3DZunino%26aufirst%3DF.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3D7-Azaindole-1-carboxamides%2520as%2520a%2520new%2520class%2520of%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D1089%26epage%3D1103%26doi%3D10.1016%2Fj.bmc.2013.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamijo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkubo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1378</span><span class="NLM_x">–</span> <span class="NLM_lpage">1390</span><span class="refDoi"> DOI: 10.1016/j.bmc.2005.09.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmc.2005.09.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=16288880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1378-1390&author=J.+Ishidaauthor=H.+Yamamotoauthor=Y.+Kidoauthor=K.+Kamijoauthor=K.+Muranoauthor=H.+Miyakeauthor=M.+Ohkuboauthor=T.+Kinoshitaauthor=M.+Warizayaauthor=A.+Iwashitaauthor=K.+Miharaauthor=N.+Matsuokaauthor=K.+Hattori&title=Discovery+of+potent+and+selective+PARP-1+and+PARP-2+inhibitors%3A+SBDD+analysis+via+a+combination+of+X-ray+structural+study+and+homology+modeling&doi=10.1016%2Fj.bmc.2005.09.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span></div><div class="casAuthors">Ishida, Junya; Yamamoto, Hirofumi; Kido, Yoshiyuki; Kamijo, Kazunori; Murano, Kenji; Miyake, Hiroshi; Ohkubo, Mitsuru; Kinoshita, Takayoshi; Warizaya, Masaichi; Iwashita, Akinori; Mihara, Kayoko; Matsuoka, Nobuya; Hattori, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1378-1390</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We disclose herein our efforts aimed at discovery of selective PARP-1 and PARP-2 inhibitors.  We have recently discovered several novel classes of quinazolinones, quinazolidinones, and quinoxalines as potent PARP-1 inhibitors, which may represent attractive therapeutic candidates.  In PARP enzyme assays using recombinant PARP-1 and PARP-2, the quinazolinone derivs. displayed relatively high selectivity for PARP-1 and quinoxaline derivs. showed superior selectivity for PARP-2, and the quinazolidinone derivs. did not have selectivity for PARP-1/2.  Structure-based drug design anal. via a combination of X-ray structural study utilizing the complexes of inhibitors and human PARP-1 catalytic domain, and homol. modeling using murine PARP-2 suggested distinct interactions of inhibitors with PARP-1 and PARP-2.  These findings provide a new structural framework for the design of selective inhibitors for PARP-1 and PARP-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrukfYFsnRIEbVg90H21EOLACvtfcHk0lhIsoEg9sxYDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D&md5=9f72cd79428d0c006e2995c19a345c0f</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.09.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.09.061%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DMurano%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520PARP-1%2520and%2520PARP-2%2520inhibitors%253A%2520SBDD%2520analysis%2520via%2520a%2520combination%2520of%2520X-ray%2520structural%2520study%2520and%2520homology%2520modeling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D1378%26epage%3D1390%26doi%3D10.1016%2Fj.bmc.2005.09.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Eltze, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinbrenner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiemermann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bürkle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T.</span><span> </span><span class="NLM_article-title">Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly (ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors</span> <span class="citation_source-journal">Mol. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1587</span><span class="NLM_x">–</span> <span class="NLM_lpage">1598</span><span class="refDoi"> DOI: 10.1124/mol.108.048751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1124%2Fmol.108.048751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=18809672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGls73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1587-1598&author=T.+Eltzeauthor=R.+Boerauthor=T.+Wagnerauthor=S.+Weinbrennerauthor=M.+C.+McDonaldauthor=C.+Thiemermannauthor=A.+B%C3%BCrkleauthor=T.+Klein&title=Imidazoquinolinone%2C+imidazopyridine%2C+and+isoquinolindione+derivatives+as+novel+and+potent+inhibitors+of+the+poly+%28ADP-ribose%29+polymerase+%28PARP%29%3A+a+comparison+with+standard+PARP+inhibitors&doi=10.1124%2Fmol.108.048751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors</span></div><div class="casAuthors">Eltze, Tobias; Boer, Rainer; Wagner, Thomas; Weinbrenner, Steffen; McDonald, Michelle C.; Thiemermann, Christoph; Buerkle, Alexander; Klein, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1587-1598</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We have identified three novel structures for inhibitors of the poly(ADP-ribose) polymerase (PARP), a nuclear enzyme activated by strand breaks in DNA and implicated in DNA repair, apoptosis, organ dysfunction or necrosis.  2-[4-(5-Methyl-1H-imidazol-4-yl)-piperidin-1-yl]-4,5-dihydro-imidazo[4,5,1-i,j]quinolin-6-one (BYK49187), 2-(4-pyridin-2-yl-phenyl)-4,5-dihydro-imidazo[4,5,1-i,j]quinolin-6-one (BYK236864), 6-chloro-8-hydroxy-2,3-dimethyl-imidazo-[1,2-α]-pyridine (BYK20370), and 4-(1-methyl-1H-pyrrol-2-ylmethylene)-4H-isoquinolin-1,3-dione (BYK204165) inhibited cell-free recombinant human PARP-1 with pIC50 values of 8.36, 7.81, 6.40, and 7.35 (pKi 7.97, 7.43, 5.90, and 7.05), and murine PARP-2 with pIC50 values of 7.50, 7.55, 5.71, and 5.38, resp.  BYK49187, BYK236864, and BYK20370 displayed no selectivity for PARP-1/2, whereas BYK204165 displayed 100-fold selectivity for PARP-1.  The IC50 values for inhibition of poly(ADP-ribose) synthesis in human lung epithelial A549 and cervical carcinoma C4I cells as well in rat cardiac myoblast H9c2 cells after PARP activation by H2O2 were highly significantly correlated with those at cell-free PARP-1 (r2 = 0.89-0.96, P < 0.001) but less with those at PARP-2 (r2 = 0.78-0.84, P < 0.01).  The infarct size caused by coronary artery occlusion and reperfusion in the anesthetized rat was reduced by 22% (P < 0.05) by treatment with BYK49187 (3 mg/kg i.v. bolus and 3 mg/kg/h i.v. during 2-h reperfusion), whereas the weaker PARP inhibitors, BYK236864 and BYK20370, were not cardioprotective.  In conclusion, the imidazoquinolinone BYK49187 is a potent inhibitor of human PARP-1 activity in cell-free and cellular assays in vitro and reduces myocardial infarct size in vivo.  The isoquinolindione BYK204165 was 100-fold more selective for PARP-1.  Thus, both compds. might be novel and valuable tools for investigating PARP-1-mediated effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomLykJcmtd4bVg90H21EOLACvtfcHk0lhIsoEg9sxYDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGls73K&md5=df104e66303dc8a885859a49c07424e7</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.048751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.048751%26sid%3Dliteratum%253Aachs%26aulast%3DEltze%26aufirst%3DT.%26aulast%3DBoer%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWeinbrenner%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DM.%2BC.%26aulast%3DThiemermann%26aufirst%3DC.%26aulast%3DB%25C3%25BCrkle%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DT.%26atitle%3DImidazoquinolinone%252C%2520imidazopyridine%252C%2520and%2520isoquinolindione%2520derivatives%2520as%2520novel%2520and%2520potent%2520inhibitors%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%253A%2520a%2520comparison%2520with%2520standard%2520PARP%2520inhibitors%26jtitle%3DMol.%2520Pharm.%26date%3D2008%26volume%3D74%26spage%3D1587%26epage%3D1598%26doi%3D10.1124%2Fmol.108.048751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Pellicciari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camaioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costantino, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Formentini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbatini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venturoni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eren, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellocchi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarugi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moroni, F.</span><span> </span><span class="NLM_article-title">On the way to selective PARP - 2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">914</span><span class="NLM_x">–</span> <span class="NLM_lpage">923</span><span class="refDoi"> DOI: 10.1002/cmdc.200800010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1002%2Fcmdc.200800010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=914-923&author=R.+Pellicciariauthor=E.+Camaioniauthor=G.+Costantinoauthor=L.+Formentiniauthor=P.+Sabbatiniauthor=F.+Venturoniauthor=G.+Erenauthor=D.+Bellocchiauthor=A.+Chiarugiauthor=F.+Moroni&title=On+the+way+to+selective+PARP+-+2+inhibitors.+Design%2C+synthesis%2C+and+preliminary+evaluation+of+a+series+of+isoquinolinone+derivatives&doi=10.1002%2Fcmdc.200800010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800010%26sid%3Dliteratum%253Aachs%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DFormentini%26aufirst%3DL.%26aulast%3DSabbatini%26aufirst%3DP.%26aulast%3DVenturoni%26aufirst%3DF.%26aulast%3DEren%26aufirst%3DG.%26aulast%3DBellocchi%26aufirst%3DD.%26aulast%3DChiarugi%26aufirst%3DA.%26aulast%3DMoroni%26aufirst%3DF.%26atitle%3DOn%2520the%2520way%2520to%2520selective%2520PARP%2520-%25202%2520inhibitors.%2520Design%252C%2520synthesis%252C%2520and%2520preliminary%2520evaluation%2520of%2520a%2520series%2520of%2520isoquinolinone%2520derivatives%26jtitle%3DChemMedChem%26date%3D2008%26volume%3D3%26spage%3D914%26epage%3D923%26doi%3D10.1002%2Fcmdc.200800010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Sunderland, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woon, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergin, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahon, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tully, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl) isoquinolin-1-ones as isoform-selective inhibitors of poly (ADP-ribose) polymerase 2 (PARP-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2049</span><span class="NLM_x">–</span> <span class="NLM_lpage">2059</span><span class="refDoi"> DOI: 10.1021/jm1010918</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1010918" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2049-2059&author=P.+T.+Sunderlandauthor=E.+C.+Woonauthor=A.+Dhamiauthor=A.+B.+Berginauthor=M.+F.+Mahonauthor=P.+J.+Woodauthor=L.+A.+Jonesauthor=S.+R.+Tullyauthor=M.+D.+Lloydauthor=A.+S.+Thompsonauthor=H.+Javaidauthor=N.+M.+Martinauthor=M.+D.+Threadgill&title=5-Benzamidoisoquinolin-1-ones+and+5-%28%CF%89-carboxyalkyl%29+isoquinolin-1-ones+as+isoform-selective+inhibitors+of+poly+%28ADP-ribose%29+polymerase+2+%28PARP-2%29&doi=10.1021%2Fjm1010918"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Fjm1010918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1010918%26sid%3Dliteratum%253Aachs%26aulast%3DSunderland%26aufirst%3DP.%2BT.%26aulast%3DWoon%26aufirst%3DE.%2BC.%26aulast%3DDhami%26aufirst%3DA.%26aulast%3DBergin%26aufirst%3DA.%2BB.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DWood%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DTully%26aufirst%3DS.%2BR.%26aulast%3DLloyd%26aufirst%3DM.%2BD.%26aulast%3DThompson%26aufirst%3DA.%2BS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3D5-Benzamidoisoquinolin-1-ones%2520and%25205-%2528%25CF%2589-carboxyalkyl%2529%2520isoquinolin-1-ones%2520as%2520isoform-selective%2520inhibitors%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerase%25202%2520%2528PARP-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2049%26epage%3D2059%26doi%3D10.1021%2Fjm1010918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Papeo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posteri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busel, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caprera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Anello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khvat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasavin, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzetta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainoldi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi-Sirtori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sola, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span> </span><span class="NLM_article-title">Discovery of 2-[1-(4,4-difluorocyclohexyl) piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4- carboxamide (NMS-P118): A potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6875</span><span class="NLM_x">–</span> <span class="NLM_lpage">6898</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00680</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00680" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6875-6898&author=G.+Papeoauthor=H.+Posteriauthor=D.+Borghiauthor=A.+A.+Buselauthor=F.+Capreraauthor=E.+Casaleauthor=M.+Ciomeiauthor=A.+Cirlaauthor=E.+Cortiauthor=M.+D%E2%80%99Anelloauthor=M.+Fasoliniauthor=B.+Forteauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+Khvatauthor=M.+Y.+Krasavinauthor=R.+Lupiauthor=P.+Orsiniauthor=R.+Peregoauthor=E.+Pesentiauthor=D.+Pezzettaauthor=S.+Rainoldiauthor=F.+Riccardi-Sirtoriauthor=A.+Scolaroauthor=F.+Solaauthor=F.+Zuccottoauthor=E.+R.+Felderauthor=D.+Donatiauthor=A.+Montagnoli&title=Discovery+of+2-%5B1-%284%2C4-difluorocyclohexyl%29+piperidin-4-yl%5D-6-fluoro-3-oxo-2%2C3-dihydro-1H-isoindole-4-+carboxamide+%28NMS-P118%29%3A+A+potent%2C+orally+available%2C+and+highly+selective+PARP-1+inhibitor+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.5b00680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00680%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DBorghi%26aufirst%3DD.%26aulast%3DBusel%26aufirst%3DA.%2BA.%26aulast%3DCaprera%26aufirst%3DF.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DCirla%26aufirst%3DA.%26aulast%3DCorti%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Anello%26aufirst%3DM.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DKhvat%26aufirst%3DA.%26aulast%3DKrasavin%26aufirst%3DM.%2BY.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPezzetta%26aufirst%3DD.%26aulast%3DRainoldi%26aufirst%3DS.%26aulast%3DRiccardi-Sirtori%26aufirst%3DF.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DSola%26aufirst%3DF.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DFelder%26aufirst%3DE.%2BR.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DMontagnoli%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25202-%255B1-%25284%252C4-difluorocyclohexyl%2529%2520piperidin-4-yl%255D-6-fluoro-3-oxo-2%252C3-dihydro-1H-isoindole-4-%2520carboxamide%2520%2528NMS-P118%2529%253A%2520A%2520potent%252C%2520orally%2520available%252C%2520and%2520highly%2520selective%2520PARP-1%2520inhibitor%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6875%26epage%3D6898%26doi%3D10.1021%2Facs.jmedchem.5b00680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schierz, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, F. M.</span><span> </span><span class="NLM_article-title">Therapeutic opportunities within the DNA damage response</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">166</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1038/nrc3891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnrc3891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25709118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Snt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=166-180&author=L.+H.+Pearlauthor=A.+C.+Schierzauthor=S.+E.+Wardauthor=B.+Al-Lazikaniauthor=F.+M.+Pearl&title=Therapeutic+opportunities+within+the+DNA+damage+response&doi=10.1038%2Fnrc3891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic opportunities within the DNA damage response</span></div><div class="casAuthors">Pearl, Laurence H.; Schierz, Amanda C.; Ward, Simon E.; Al-Lazikani, Bissan; Pearl, Frances M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">166-180</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The DNA damage response (DDR) is essential for maintaining the genomic integrity of the cell, and its disruption is one of the hallmarks of cancer.  Classically, defects in the DDR have been exploited therapeutically in the treatment of cancer with radiation therapies or genotoxic chemotherapies.  More recently, protein components of the DDR systems have been identified as promising avenues for targeted cancer therapeutics.  Here, we present an in-depth anal. of the function, role in cancer and therapeutic potential of 450 expert-curated human DDR genes.  We discuss the DDR drugs that have been approved by the US Food and Drug Administration (FDA) or that are under clin. investigation.  We examine large-scale genomic and expression data for 15 cancers to identify deregulated components of the DDR, and we apply systematic computational anal. to identify DDR proteins that are amenable to modulation by small mols., highlighting potential novel therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosptr9Y-2e6LVg90H21EOLACvtfcHk0lgJ1JP7BUE68w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Snt74%253D&md5=47ceba5c42cc7ebb59e18f3aa53e0f60</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1038%2Fnrc3891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3891%26sid%3Dliteratum%253Aachs%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DSchierz%26aufirst%3DA.%2BC.%26aulast%3DWard%26aufirst%3DS.%2BE.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DPearl%26aufirst%3DF.%2BM.%26atitle%3DTherapeutic%2520opportunities%2520within%2520the%2520DNA%2520damage%2520response%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D166%26epage%3D180%26doi%3D10.1038%2Fnrc3891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Wahlberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouznetsova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsell, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frostell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Öncü, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicciari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigelt, J.</span><span> </span><span class="NLM_article-title">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span><span class="refDoi"> DOI: 10.1038/nbt.2121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnbt.2121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22343925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=283-288&author=E.+Wahlbergauthor=T.+Karlbergauthor=E.+Kouznetsovaauthor=N.+Markovaauthor=A.+Macchiaruloauthor=A.+G.+Thorsellauthor=E.+Polauthor=A.+Frostellauthor=T.+Ekbladauthor=D.+%C3%96nc%C3%BCauthor=B.+Kullauthor=G.+M.+Robertsonauthor=R.+Pellicciariauthor=H.+Sch%C3%BClerauthor=J.+Weigelt&title=Family-wide+chemical+profiling+and+structural+analysis+of+PARP+and+tankyrase+inhibitors&doi=10.1038%2Fnbt.2121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span></div><div class="casAuthors">Wahlberg, Elisabet; Karlberg, Tobias; Kouznetsova, Ekaterina; Markova, Natalia; Macchiarulo, Antonio; Thorsell, Ann-Gerd; Pol, Ewa; Frostell, Aasa; Ekblad, Torun; Oencue, Delal; Kull, Bjoern; Robertson, Graeme Michael; Pellicciari, Roberto; Schueler, Herwig; Weigelt, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-288</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibitors of poly-ADP-ribose polymerase (PARP) family proteins are currently in clin. trials as cancer therapeutics, yet the specificity of many of these compds. is unknown.  Here we evaluated a series of 185 small-mol. inhibitors, including research reagents and compds. being tested clin., for the ability to bind to the catalytic domains of 13 of the 17 human PARP family members including the tankyrases, TNKS1 and TNKS2.  Many of the best-known inhibitors, including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bound to several PARP family members, suggesting that these mols. lack specificity and have promiscuous inhibitory activity.  We also detd. X-ray crystal structures for five TNKS2 ligand complexes and four PARP14 ligand complexes.  In addn. to showing that the majority of PARP inhibitors bind multiple targets, these results provide insight into the design of new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYSebsCVufibVg90H21EOLACvtfcHk0lhcrrOwSVrJTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D&md5=71f17fd5b6bb602dd70c8fcc17df95f9</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2121%26sid%3Dliteratum%253Aachs%26aulast%3DWahlberg%26aufirst%3DE.%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DKouznetsova%26aufirst%3DE.%26aulast%3DMarkova%26aufirst%3DN.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DThorsell%26aufirst%3DA.%2BG.%26aulast%3DPol%26aufirst%3DE.%26aulast%3DFrostell%26aufirst%3DA.%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3D%25C3%2596nc%25C3%25BC%26aufirst%3DD.%26aulast%3DKull%26aufirst%3DB.%26aulast%3DRobertson%26aufirst%3DG.%2BM.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DWeigelt%26aufirst%3DJ.%26atitle%3DFamily-wide%2520chemical%2520profiling%2520and%2520structural%2520analysis%2520of%2520PARP%2520and%2520tankyrase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D283%26epage%3D288%26doi%3D10.1038%2Fnbt.2121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Boehler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yelamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noll, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantzer, F.</span><span> </span><span class="NLM_article-title">Phenotypic characterization of Parp-1 and Parp-2 deficient mice and cells</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">780</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1007/978-1-61779-270-0_19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1007%2F978-1-61779-270-0_19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21870269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvV2nsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=780&publication_year=2011&pages=313-336&author=C.+Boehlerauthor=L.+Gauthierauthor=J.+Yelamosauthor=A.+Nollauthor=V.+Schreiberauthor=F.+Dantzer&title=Phenotypic+characterization+of+Parp-1+and+Parp-2+deficient+mice+and+cells&doi=10.1007%2F978-1-61779-270-0_19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic characterization of Parp-1 and Parp-2 deficient mice and cells</span></div><div class="casAuthors">Boehler, Christian; Gauthier, Laurent; Yelamos, Jose; Noll, Aurelia; Schreiber, Valerie; Dantzer, Francoise</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">780</span>
        (<span class="NLM_cas:issue">Poly(ADP-ribose) Polymerase</span>),
    <span class="NLM_cas:pages">313-336</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Poly(ADP-ribosyl)ation is a post-translational modification of proteins mediated by Poly(ADP-ribose) polymerases (Parps), a family of 17 members.  Among them, Poly(ADP-ribose) polymerase-1 (Parp-1)and Parp-2 are so far the sole enzymes whose catalytic activity has been shown to be induced by DNA strand breaks.  The generation and characterization of Parp-1 and Parp-2 deficient cellular and animal models have largely contributed to describe both proteins as active players of the base excision repair/single-strand break repair (BER/SSBR) process with both redundant and more specific functions.  Double Parp-1-/-Parp-2-/- embryos die at gastrulation demonstrating the crucial role of poly(ADP-ribosyl)ation during embryonic development, whereas a specific female lethality related to X chromosome instability is assocd. with the Parp-1+/-Parp-2-/- genotype.  Finally, recent research discovered emerging unique functions of Parp-2 in physiol. processes including spermatogenesis, T-cell maturation, and adipogenesis although with distinct mechanisms.  In this chapter, we describe std. operating procedures used to genotype and phenotype both mouse lines and the derived mouse embryonic fibroblasts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_HNE1f3RQrbVg90H21EOLACvtfcHk0lhcrrOwSVrJTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvV2nsbY%253D&md5=bd260e619dde6116515a30139e9b4ff5</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-270-0_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-270-0_19%26sid%3Dliteratum%253Aachs%26aulast%3DBoehler%26aufirst%3DC.%26aulast%3DGauthier%26aufirst%3DL.%26aulast%3DYelamos%26aufirst%3DJ.%26aulast%3DNoll%26aufirst%3DA.%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DDantzer%26aufirst%3DF.%26atitle%3DPhenotypic%2520characterization%2520of%2520Parp-1%2520and%2520Parp-2%2520deficient%2520mice%2520and%2520cells%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D780%26spage%3D313%26epage%3D336%26doi%3D10.1007%2F978-1-61779-270-0_19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Poruchynsky, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komlodi-Pasztor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trostel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkerson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regairaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar Maity, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burotto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sackett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guha, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, A. T.</span><span> </span><span class="NLM_article-title">Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">1571</span><span class="NLM_x">–</span> <span class="NLM_lpage">1576</span><span class="refDoi"> DOI: 10.1073/pnas.1416418112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1073%2Fpnas.1416418112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25605897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=1571-1576&author=M.+S.+Poruchynskyauthor=E.+Komlodi-Pasztorauthor=S.+Trostelauthor=J.+Wilkersonauthor=M.+Regairazauthor=Y.+Pommierauthor=X.+Zhangauthor=T.+Kumar+Maityauthor=R.+Robeyauthor=M.+Burottoauthor=D.+Sackettauthor=U.+Guhaauthor=A.+T.+Fojo&title=Microtubule-targeting+agents+augment+the+toxicity+of+DNA-damaging+agents+by+disrupting+intracellular+trafficking+of+DNA+repair+proteins&doi=10.1073%2Fpnas.1416418112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins</span></div><div class="casAuthors">Poruchynsky, Marianne S.; Komlodi-Pasztor, Edina; Trostel, Shana; Wilkerson, Julia; Regairaz, Marie; Pommier, Yves; Zhang, Xu; Maity, Tapan Kumar; Robey, Robert; Burotto, Mauricio; Sackett, Dan; Guha, Udayan; Fojo, Antonio Tito</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1571-1576</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The paradigm that microtubule-targeting agents (MTAs) cause cell death via mitotic arrest applies to rapidly dividing cells but cannot explain MTA activity in slowly growing human cancers.  Many preferred cancer regimens combine a MTA with a DNA-damaging agent (DDA).  We hypothesized that MTAs synergize with DDAs by interfering with trafficking of DNA repair proteins on interphase microtubules.  We investigated nine proteins involved in DNA repair: ATM, ATR, DNA-PK, Rad50, Mre11, p95/NBS1, p53, 53BP1, and p63.  The proteins were sequestered in the cytoplasm by vincristine and paclitaxel but not by an aurora kinase inhibitor, colocalized with tubulin by confocal microscopy and coimmunopptd. with the microtubule motor dynein.  Furthermore, adding MTAs to radiation, doxorubicin, or etoposide led to more sustained γ-H2AX levels.  We conclude DNA damage-repair proteins traffic on microtubules and addn. of MTAs sequesters them in the cytoplasm, explaining why MTA/DDA combinations are common anticancer regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RzUulWoZyLVg90H21EOLACvtfcHk0lhc2mL25K5yXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOhu74%253D&md5=f7f94679f54bf5859c18437a40076aae</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1416418112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1416418112%26sid%3Dliteratum%253Aachs%26aulast%3DPoruchynsky%26aufirst%3DM.%2BS.%26aulast%3DKomlodi-Pasztor%26aufirst%3DE.%26aulast%3DTrostel%26aufirst%3DS.%26aulast%3DWilkerson%26aufirst%3DJ.%26aulast%3DRegairaz%26aufirst%3DM.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKumar%2BMaity%26aufirst%3DT.%26aulast%3DRobey%26aufirst%3DR.%26aulast%3DBurotto%26aufirst%3DM.%26aulast%3DSackett%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DU.%26aulast%3DFojo%26aufirst%3DA.%2BT.%26atitle%3DMicrotubule-targeting%2520agents%2520augment%2520the%2520toxicity%2520of%2520DNA-damaging%2520agents%2520by%2520disrupting%2520intracellular%2520trafficking%2520of%2520DNA%2520repair%2520proteins%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D1571%26epage%3D1576%26doi%3D10.1073%2Fpnas.1416418112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Chan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, R. G.</span><span> </span><span class="NLM_article-title">″Contextual″ synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4553</span><span class="NLM_x">–</span> <span class="NLM_lpage">4560</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-0527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-10-0527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20823145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4553-4560&author=N.+Chanauthor=R.+G.+Bristow&title=%E2%80%B3Contextual%E2%80%B3+synthetic+lethality+and%2For+loss+of+heterozygosity%3A+tumor+hypoxia+and+modification+of+DNA+repair&doi=10.1158%2F1078-0432.CCR-10-0527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">"Contextual" Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair</span></div><div class="casAuthors">Chan, Norman; Bristow, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4553-4560</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Hypoxia exists in every solid tumor and is assocd. with poor prognosis because of both local and systemic therapeutic resistance.  Recent studies have focused on the interaction between tumor cell genetics and the dynamic state of oxygenation and metab.  Hypoxia generates aggressive tumor cell phenotypes in part owing to ongoing genetic instability and a "mutator" phenotype.  The latter may be due to suppression of DNA mismatch repair (MMR), nucleotide excision repair (NER), and double-strand break (DSB) repair.  We propose a theor. model in which hypoxia-mediated defects in DNA repair can lead to "contextual loss of heterozygosity" and drive oncogenesis.  Addnl., hypoxia-mediated repair defects can be specifically targeted by DNA damaging agents and/or "contextual synthetic lethality" to kill repair-deficient cells and preserve the therapeutic ratio.  These proposed concepts support the interrogation of solid tumors to document repair defects in both oxic and hypoxic tumor subregions as a conduit to novel clin. trials within the context of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqELUzR5x4-57Vg90H21EOLACvtfcHk0lhc2mL25K5yXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bK&md5=8bf6ea26a620138d35e515bafd753af7</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0527%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DN.%26aulast%3DBristow%26aufirst%3DR.%2BG.%26atitle%3D%25E2%2580%25B3Contextual%25E2%2580%25B3%2520synthetic%2520lethality%2520and%252For%2520loss%2520of%2520heterozygosity%253A%2520tumor%2520hypoxia%2520and%2520modification%2520of%2520DNA%2520repair%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D4553%26epage%3D4560%26doi%3D10.1158%2F1078-0432.CCR-10-0527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimenez-Capitan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertran-Alamillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provencio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Campelo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reguart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viteri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcereny, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queralt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Aguirre, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez-Ronco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mate, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benlloch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span> </span><span class="NLM_article-title">Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1160</span><span class="NLM_x">–</span> <span class="NLM_lpage">1168</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-2158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-10-2158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21233402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXis1eitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1160-1168&author=R.+Rosellauthor=M.+A.+Molinaauthor=C.+Costaauthor=S.+Simonettiauthor=A.+Gimenez-Capitanauthor=J.+Bertran-Alamilloauthor=C.+Mayoauthor=T.+Moranauthor=P.+Mendezauthor=F.+Cardenalauthor=D.+Islaauthor=M.+Provencioauthor=M.+Coboauthor=A.+Insaauthor=R.+Garcia-Campeloauthor=N.+Reguartauthor=M.+Majemauthor=S.+Viteriauthor=E.+Carcerenyauthor=R.+Portaauthor=B.+Massutiauthor=C.+Queraltauthor=I.+de+Aguirreauthor=J.+M.+Sanchezauthor=M.+Sanchez-Roncoauthor=J.+L.+Mateauthor=A.+Arizaauthor=S.+Benllochauthor=J.+J.+Sanchezauthor=T.+G.+Bivonaauthor=C.+L.+Sawyersauthor=M.+Taron&title=Pretreatment+EGFR+T790M+mutation+and+BRCA1+mRNA+expression+in+erlotinib-treated+advanced+non-small-cell+lung+cancer+patients+with+EGFR+mutations&doi=10.1158%2F1078-0432.CCR-10-2158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations</span></div><div class="casAuthors">Rosell, Rafael; Molina, Miguel Angel; Costa, Carlota; Simonetti, Sara; Gimenez-Capitan, Ana; Bertran-Alamillo, Jordi; Mayo, Clara; Moran, Teresa; Mendez, Pedro; Cardenal, Felipe; Isla, Dolores; Provencio, Mariano; Cobo, Manuel; Insa, Amelia; Garcia-Campelo, Rosario; Reguart, Noemi; Majem, Margarita; Viteri, Santiago; Carcereny, Enric; Porta, Ruth; Massuti, Bartomeu; Queralt, Cristina; de Aguirre, Itziar; Sanchez, Jose Miguel; Sanchez-Ronco, Maria; Mate, Jose Luis; Ariza, Aurelio; Benlloch, Susana; Sanchez, Jose Javier; Bivona, Trever G.; Sawyers, Charles L.; Taron, Miquel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1160-1168</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 mo when treated with erlotinib.  However, the presence of EGFR mutations can only imperfectly predict outcome.  We hypothesized that progression-free survival could be influenced both by the pretreatment EGFR T790M mutation and by components of DNA repair pathways.  Exptl. Design: We assessed the T790M mutation in pretreatment diagnostic specimens from 129 erlotinib-treated advanced NSCLC patients with EGFR mutations.  The expression of eight genes and two proteins involved in DNA repair and four receptor tyrosine kinases was also examd.  Results: The EGFR T790M mutation was obsd. in 45 of 129 patients (35%).  Progression-free survival was 12 mo in patients with and 18 mo in patients without the T790M mutation (P = 0.05).  Progression-free survival was 27 mo in patients with low BRCA1 mRNA levels, 18 mo in those with intermediate levels, and 10 mo in those with high levels (P = 0.02).  In the multivariate anal., the presence of the T790M mutation (HR, 4.35; P = 0.001), intermediate BRCA1 levels (HR, 8.19; P < 0.0001), and high BRCA1 levels (HR, 8.46; P < 0.0001) emerged as markers of shorter progression-free survival.  Conclusions: Low BRCA1 levels neutralized the neg. effect of the T790M mutation and were assocd. with longer progression-free survival to erlotinib.  We advocate baseline assessment of the T790M mutation and BRCA1 expression to predict outcome and provide alternative individualized treatment to patients based on T790M mutations and BRCA1 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZpYMrHRqQLVg90H21EOLACvtfcHk0lhc2mL25K5yXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXis1eitrY%253D&md5=ade8984309e69171fc187bfeeae745c7</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2158%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DSimonetti%26aufirst%3DS.%26aulast%3DGimenez-Capitan%26aufirst%3DA.%26aulast%3DBertran-Alamillo%26aufirst%3DJ.%26aulast%3DMayo%26aufirst%3DC.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DMendez%26aufirst%3DP.%26aulast%3DCardenal%26aufirst%3DF.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DCobo%26aufirst%3DM.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DViteri%26aufirst%3DS.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3Dde%2BAguirre%26aufirst%3DI.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DSanchez-Ronco%26aufirst%3DM.%26aulast%3DMate%26aufirst%3DJ.%2BL.%26aulast%3DAriza%26aufirst%3DA.%26aulast%3DBenlloch%26aufirst%3DS.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DTaron%26aufirst%3DM.%26atitle%3DPretreatment%2520EGFR%2520T790M%2520mutation%2520and%2520BRCA1%2520mRNA%2520expression%2520in%2520erlotinib-treated%2520advanced%2520non-small-cell%2520lung%2520cancer%2520patients%2520with%2520EGFR%2520mutations%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D1160%26epage%3D1168%26doi%3D10.1158%2F1078-0432.CCR-10-2158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Hegan, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stachelek, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bindra, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazer, P. M.</span><span> </span><span class="NLM_article-title">Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">2201</span><span class="NLM_x">–</span> <span class="NLM_lpage">2206</span><span class="refDoi"> DOI: 10.1073/pnas.0904783107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1073%2Fpnas.0904783107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=2201-2206&author=D.+C.+Heganauthor=Y.+Luauthor=G.+C.+Stachelekauthor=M.+E.+Crosbyauthor=R.+S.+Bindraauthor=P.+M.+Glazer&title=Inhibition+of+poly%28ADP-ribose%29+polymerase+down-regulates+BRCA1+and+RAD51+in+a+pathway+mediated+by+E2F4+and+p130&doi=10.1073%2Fpnas.0904783107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904783107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904783107%26sid%3Dliteratum%253Aachs%26aulast%3DHegan%26aufirst%3DD.%2BC.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DStachelek%26aufirst%3DG.%2BC.%26aulast%3DCrosby%26aufirst%3DM.%2BE.%26aulast%3DBindra%26aufirst%3DR.%2BS.%26aulast%3DGlazer%26aufirst%3DP.%2BM.%26atitle%3DInhibition%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520down-regulates%2520BRCA1%2520and%2520RAD51%2520in%2520a%2520pathway%2520mediated%2520by%2520E2F4%2520and%2520p130%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D2201%26epage%3D2206%26doi%3D10.1073%2Fpnas.0904783107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 88 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Junwei Wang, Hui Li, Guangchao He, Zhaoxing Chu, Kewen Peng, Yiran Ge, Qihua Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Yungen Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 122-139. <a href="https://doi.org/10.1021/acs.jmedchem.9b00622" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00622</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00622%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BDual%252BPoly%252528ADP-ribose%252529polymerase%252Band%252BPhosphoinositide%252B3-Kinase%252BInhibitors%252Bas%252Ba%252BPromising%252BStrategy%252Bfor%252BCancer%252BTherapy%26aulast%3DWang%26aufirst%3DJunwei%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D11042019%26date%3D27122019%26date%3D17122019%26volume%3D63%26issue%3D1%26spage%3D122%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zoufeng Xu, Cai Li, Qiyuan Zhou, Zhiqin Deng, Zixuan Tong, Man-Kit Tse, <span class="NLM_string-name hlFld-ContribAuthor">Guangyu Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (23)
                                     , 16279-16291. <a href="https://doi.org/10.1021/acs.inorgchem.9b02839" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.9b02839</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.9b02839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.9b02839%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DSynthesis%25252C%252BCytotoxicity%25252C%252Band%252BMechanistic%252BInvestigation%252Bof%252BPlatinum%252528IV%252529%252BAnticancer%252BComplexes%252BConjugated%252Bwith%252BPoly%252528ADP-ribose%252529%252BPolymerase%252BInhibitors%26aulast%3DXu%26aufirst%3DZoufeng%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23092019%26date%3D18112019%26volume%3D58%26issue%3D23%26spage%3D16279%26epage%3D16291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Haitang Yang, Peng Li, Dingzhong Wang, Yong Liu, Wei Wei, Yuanjian Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Songqin Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Quartz Crystal Microbalance Detection of Poly(ADP-ribose) Polymerase-1 Based on Gold Nanorods Signal Amplification. </span><span class="cited-content_cbyCitation_journal-name">Analytical Chemistry</span><span> <strong>2019,</strong> <em>91 </em>
                                    (17)
                                     , 11038-11044. <a href="https://doi.org/10.1021/acs.analchem.9b01366" title="DOI URL">https://doi.org/10.1021/acs.analchem.9b01366</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.analchem.9b01366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.analchem.9b01366%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Chemistry%26atitle%3DQuartz%252BCrystal%252BMicrobalance%252BDetection%252Bof%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%252BBased%252Bon%252BGold%252BNanorods%252BSignal%252BAmplification%26aulast%3DYang%26aufirst%3DHaitang%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17032019%26date%3D01072019%26date%3D11072019%26date%3D01072019%26volume%3D91%26issue%3D17%26spage%3D11038%26epage%3D11044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gianluca Papeo, Paolo Orsini, Nilla R. Avanzi, Daniela Borghi, Elena Casale, Marina Ciomei, Alessandra Cirla, Viviana Desperati, Daniele Donati, Eduard R. Felder, Arturo Galvani, Marco Guanci, Antonella Isacchi, Helena Posteri, Sonia Rainoldi, Federico Riccardi-Sirtori, Alessandra Scolaro, <span class="NLM_string-name hlFld-ContribAuthor">Alessia Montagnoli</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (4)
                                     , 534-538. <a href="https://doi.org/10.1021/acsmedchemlett.8b00569" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00569%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BStereospecific%252BPARP-1%252BInhibitor%252BIsoindolinone%252BNMS-P515%26aulast%3DPapeo%26aufirst%3DGianluca%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D22112018%26date%3D13032019%26date%3D15032019%26date%3D13032019%26volume%3D10%26issue%3D4%26spage%3D534%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lik Hang Yuen, Srikanta Dana, Yu Liu, Samuel I. Bloom, Ann-Gerd Thorsell, Dario Neri, Anthony J. Donato, Dmitri Kireev, Herwig Schüler, <span class="NLM_string-name hlFld-ContribAuthor">Raphael M. Franzini</span>. </span><span class="cited-content_cbyCitation_article-title">A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD+-Dependent Enzymes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (13)
                                     , 5169-5181. <a href="https://doi.org/10.1021/jacs.8b08039" title="DOI URL">https://doi.org/10.1021/jacs.8b08039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b08039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b08039%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DA%252BFocused%252BDNA-Encoded%252BChemical%252BLibrary%252Bfor%252Bthe%252BDiscovery%252Bof%252BInhibitors%252Bof%252BNAD%25252B-Dependent%252BEnzymes%26aulast%3DYuen%26aufirst%3DLik%2BHang%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D28072018%26date%3D19032019%26date%3D11032019%26volume%3D141%26issue%3D13%26spage%3D5169%26epage%3D5181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chuanlong Guo, Lijun Wang, Xiuxue Li, Shuaiyu Wang, Xuemin Yu, Kuo Xu, Yue Zhao, Jiao Luo, Xiangqian Li, Bo Jiang, <span class="NLM_string-name hlFld-ContribAuthor">Dayong Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Bromophenol–Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (6)
                                     , 3051-3067. <a href="https://doi.org/10.1021/acs.jmedchem.8b01946" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01946%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BBromophenol%2525E2%252580%252593Thiosemicarbazone%252BHybrids%252Bas%252BPotent%252BSelective%252BInhibitors%252Bof%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%252B%252528PARP-1%252529%252Bfor%252BUse%252Bin%252BCancer%26aulast%3DGuo%26aufirst%3DChuanlong%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D13122018%26date%3D19032019%26date%3D07032019%26volume%3D62%26issue%3D6%26spage%3D3051%26epage%3D3067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tanja Krainz, Andrew M. Lamade, Lina Du, Taber S. Maskrey, Michael J. Calderon, Simon C. Watkins, Michael W. Epperly, Joel S. Greenberger, Hülya Bayır, Peter Wipf, <span class="NLM_string-name hlFld-ContribAuthor">Robert S. B. Clark</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (10)
                                     , 2868-2879. <a href="https://doi.org/10.1021/acschembio.8b00423" title="DOI URL">https://doi.org/10.1021/acschembio.8b00423</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.8b00423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.8b00423%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252Ba%252BMitochondria-Targeting%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%252BInhibitor%26aulast%3DKrainz%26aufirst%3DTanja%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D07052018%26date%3D05092018%26date%3D14092018%26date%3D05092018%26volume%3D13%26issue%3D10%26spage%3D2868%26epage%3D2879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sean W. Reilly, Laura N. Puentes, Chia-Ju Hsieh, Mehran Makvandi, <span class="NLM_string-name hlFld-ContribAuthor">Robert H. Mach</span>. </span><span class="cited-content_cbyCitation_article-title">Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein Interactions. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (8)
                                     , 9997-10001. <a href="https://doi.org/10.1021/acsomega.8b00896" title="DOI URL">https://doi.org/10.1021/acsomega.8b00896</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b00896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b00896%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DAltering%252BNitrogen%252BHeterocycles%252Bof%252BAZD2461%252BAffords%252BHigh%252BAffinity%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%252BInhibitors%252Bwith%252BDecreased%252BP-Glycoprotein%252BInteractions%26aulast%3DReilly%26aufirst%3DSean%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04052018%26date%3D02082018%26volume%3D3%26issue%3D8%26spage%3D9997%26epage%3D10001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sean W. Reilly, Laura N. Puentes, Khadija Wilson, Chia-Ju Hsieh, Chi-Chang Weng, Mehran Makvandi, <span class="NLM_string-name hlFld-ContribAuthor">Robert H. Mach</span>. </span><span class="cited-content_cbyCitation_article-title">Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5367-5379. <a href="https://doi.org/10.1021/acs.jmedchem.8b00576" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00576</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00576%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExamination%252Bof%252BDiazaspiro%252BCores%252Bas%252BPiperazine%252BBioisosteres%252Bin%252Bthe%252BOlaparib%252BFramework%252BShows%252BReduced%252BDNA%252BDamage%252Band%252BCytotoxicity%26aulast%3DReilly%26aufirst%3DSean%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12042018%26date%3D14062018%26date%3D01062018%26volume%3D61%26issue%3D12%26spage%3D5367%26epage%3D5379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sean W. Reilly, Mehran Makvandi, Kuiying Xu, <span class="NLM_string-name hlFld-ContribAuthor">Robert H. Mach</span>. </span><span class="cited-content_cbyCitation_article-title">Rapid Cu-Catalyzed [211At]Astatination and [125I]Iodination of Boronic Esters at Room Temperature. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (7)
                                     , 1752-1755. <a href="https://doi.org/10.1021/acs.orglett.8b00232" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b00232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b00232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b00232%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRapid%252BCu-Catalyzed%252B%25255B211At%25255DAstatination%252Band%252B%25255B125I%25255DIodination%252Bof%252BBoronic%252BEsters%252Bat%252BRoom%252BTemperature%26aulast%3DReilly%26aufirst%3DSean%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D22012018%26date%3D21032018%26volume%3D20%26issue%3D7%26spage%3D1752%26epage%3D1755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Navnath S.  Gavande</span>, <span class="hlFld-ContribAuthor ">Pamela  VanderVere-Carozza</span>, <span class="hlFld-ContribAuthor ">Akaash K.  Mishra</span>, <span class="hlFld-ContribAuthor ">Tyler L.  Vernon</span>, <span class="hlFld-ContribAuthor ">Katherine S.  Pawelczak</span>, and <span class="hlFld-ContribAuthor ">John J.  Turchi</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein–DNA Interaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (19)
                                     , 8055-8070. <a href="https://doi.org/10.1021/acs.jmedchem.7b00780" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00780</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00780%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BStructure-Guided%252BDevelopment%252Bof%252BNovel%252BInhibitors%252Bof%252Bthe%252BXeroderma%252BPigmentosum%252BGroup%252BA%252B%252528XPA%252529%252BProtein%2525E2%252580%252593DNA%252BInteraction%26aulast%3DGavande%26aufirst%3DNavnath%2BS.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D31052017%26date%3D21092017%26date%3D12102017%26volume%3D60%26issue%3D19%26spage%3D8055%26epage%3D8070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Georges Abi  Tayeh</span>, <span class="hlFld-ContribAuthor ">Marwan  Alkassis</span>, <span class="hlFld-ContribAuthor ">Albert  Semaan</span>, <span class="hlFld-ContribAuthor ">Nour  Khalil</span>, <span class="hlFld-ContribAuthor ">Elie  Nemr</span>, <span class="hlFld-ContribAuthor ">Chady  Waked</span>. </span><span class="cited-content_cbyCitation_article-title">Neoadjuvant PARPi for urothelial carcinoma: between lifeline and desperation. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.2217/fon-2021-0443" title="DOI URL">https://doi.org/10.2217/fon-2021-0443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2021-0443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2021-0443%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DNeoadjuvant%252BPARPi%252Bfor%252Burothelial%252Bcarcinoma%25253A%252Bbetween%252Blifeline%252Band%252Bdesperation%26aulast%3DTayeh%26aufirst%3DGeorges%2BAbi%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Uday Kiran  Velagapudi</span>, <span class="hlFld-ContribAuthor ">Bhargav A.  Patel</span>, <span class="hlFld-ContribAuthor ">Xuwei  Shao</span>, <span class="hlFld-ContribAuthor ">Sanjai Kumar  Pathak</span>, <span class="hlFld-ContribAuthor ">Dana V.  Ferraris</span>, <span class="hlFld-ContribAuthor ">Tanaji T.  Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (7)
                                     , 609-623. <a href="https://doi.org/10.1080/13543776.2021.1886275" title="DOI URL">https://doi.org/10.1080/13543776.2021.1886275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1886275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1886275%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DRecent%252Bdevelopment%252Bin%252Bthe%252Bdiscovery%252Bof%252BPARP%252Binhibitors%252Bas%252Banticancer%252Bagents%25253A%252Ba%252Bpatent%252Bupdate%252B%2525282016-2020%252529%26aulast%3DVelagapudi%26aufirst%3DUday%2BKiran%26date%3D2021%26date%3D2021%26volume%3D31%26issue%3D7%26spage%3D609%26epage%3D623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Li</span>, <span class="hlFld-ContribAuthor ">Xin-yang  Li</span>, <span class="hlFld-ContribAuthor ">Ting-jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Ju  Zhu</span>, <span class="hlFld-ContribAuthor ">Kai-li  Liu</span>, <span class="hlFld-ContribAuthor ">De-pu  Wang</span>, <span class="hlFld-ContribAuthor ">Fan-hao  Meng</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 4,5-dihydrospiro[benzo[c]azepine-1,1′-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>111 </em>, 104840. <a href="https://doi.org/10.1016/j.bioorg.2021.104840" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104840%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252B4%25252C5-dihydrospiro%25255Bbenzo%25255Bc%25255Dazepine-1%25252C1%2525E2%252580%2525B2-cyclohexan%25255D-3%2525282H%252529-one%252Bderivatives%252Bas%252BPARP-1%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DLi%26aufirst%3DShuai%26date%3D2021%26volume%3D111%26spage%3D104840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Wu</span>, <span class="hlFld-ContribAuthor ">Xiaojiao  Li</span>, <span class="hlFld-ContribAuthor ">Jixuan  Sun</span>, <span class="hlFld-ContribAuthor ">Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Yanhua  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2021,</strong> <em>17 </em>
                                    (4)
                                     , 503-508. <a href="https://doi.org/10.1080/17425255.2021.1881480" title="DOI URL">https://doi.org/10.1080/17425255.2021.1881480</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2021.1881480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2021.1881480%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DA%252Bphase%252BI%252Bstudy%252Bof%252Bfluzoparib%252Btablet%252Bformulation%25252C%252Ban%252Boral%252BPARP%252Binhibitor%25253A%252Beffect%252Bof%252Bfood%252Bon%252Bthe%252Bpharmacokinetics%252Band%252Bmetabolism%252Bafter%252Boral%252Bdosing%252Bin%252Bhealthy%252BChinese%252Bvolunteers%26aulast%3DWu%26aufirst%3DMin%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D4%26spage%3D503%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Federica  Guarra</span>, <span class="hlFld-ContribAuthor ">Alessandro  Pratesi</span>, <span class="hlFld-ContribAuthor ">Chiara  Gabbiani</span>, <span class="hlFld-ContribAuthor ">Tarita  Biver</span>. </span><span class="cited-content_cbyCitation_article-title">A focus on the biological targets for coinage metal-NHCs as potential anticancer complexes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2021,</strong> <em>217 </em>, 111355. <a href="https://doi.org/10.1016/j.jinorgbio.2021.111355" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2021.111355</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2021.111355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2021.111355%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DA%252Bfocus%252Bon%252Bthe%252Bbiological%252Btargets%252Bfor%252Bcoinage%252Bmetal-NHCs%252Bas%252Bpotential%252Banticancer%252Bcomplexes%26aulast%3DGuarra%26aufirst%3DFederica%26date%3D2021%26volume%3D217%26spage%3D111355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng-Zhu  Li</span>, <span class="hlFld-ContribAuthor ">Tao  Meng</span>, <span class="hlFld-ContribAuthor ">Shan-Shan  Song</span>, <span class="hlFld-ContribAuthor ">Xu-Bin  Bao</span>, <span class="hlFld-ContribAuthor ">Lan-Ping  Ma</span>, <span class="hlFld-ContribAuthor ">Ning  Zhang</span>, <span class="hlFld-ContribAuthor ">Ting  Yu</span>, <span class="hlFld-ContribAuthor ">Yong-Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Bing  Xiong</span>, <span class="hlFld-ContribAuthor ">Jing-Kang  Shen</span>, <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>, <span class="hlFld-ContribAuthor ">Jin-Xue  He</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2021,</strong> <em>32 </em><a href="https://doi.org/10.1007/s10637-021-01096-4" title="DOI URL">https://doi.org/10.1007/s10637-021-01096-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-021-01096-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-021-01096-4%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DDiscovery%252Bof%252BMTR-106%252Bas%252Ba%252Bhighly%252Bpotent%252BG-quadruplex%252Bstabilizer%252Bfor%252Btreating%252BBRCA-deficient%252Bcancers%26aulast%3DLi%26aufirst%3DMeng-Zhu%26date%3D2021%26date%3D2021%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zi-Yi  Yang</span>, <span class="hlFld-ContribAuthor ">Zhi-Jiang  Yang</span>, <span class="hlFld-ContribAuthor ">Yue  Zhao</span>, <span class="hlFld-ContribAuthor ">Ming-Zhu  Yin</span>, <span class="hlFld-ContribAuthor ">Ai-Ping  Lu</span>, <span class="hlFld-ContribAuthor ">Xiang  Chen</span>, <span class="hlFld-ContribAuthor ">Shao  Liu</span>, <span class="hlFld-ContribAuthor ">Ting-Jun  Hou</span>, <span class="hlFld-ContribAuthor ">Dong-Sheng  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">PySmash: Python package and individual executable program for representative substructure generation and application. </span><span class="cited-content_cbyCitation_journal-name">Briefings in Bioinformatics</span><span> <strong>2021,</strong> <em>19 </em><a href="https://doi.org/10.1093/bib/bbab017" title="DOI URL">https://doi.org/10.1093/bib/bbab017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/bib/bbab017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbib%2Fbbab017%26sid%3Dliteratum%253Aachs%26jtitle%3DBriefings%2520in%2520Bioinformatics%26atitle%3DPySmash%25253A%252BPython%252Bpackage%252Band%252Bindividual%252Bexecutable%252Bprogram%252Bfor%252Brepresentative%252Bsubstructure%252Bgeneration%252Band%252Bapplication%26aulast%3DYang%26aufirst%3DZi-Yi%26date%3D2021%26date%3D2021%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Garri  Manasaryan</span>, <span class="hlFld-ContribAuthor ">Dmitry  Suplatov</span>, <span class="hlFld-ContribAuthor ">Sergey  Pushkarev</span>, <span class="hlFld-ContribAuthor ">Viktor  Drobot</span>, <span class="hlFld-ContribAuthor ">Alexander  Kuimov</span>, <span class="hlFld-ContribAuthor ">Vytas  Švedas</span>, <span class="hlFld-ContribAuthor ">Dmitry  Nilov</span>. </span><span class="cited-content_cbyCitation_article-title">Bioinformatic Analysis of the Nicotinamide Binding Site in Poly(ADP-Ribose) Polymerase Family Proteins. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (6)
                                     , 1201. <a href="https://doi.org/10.3390/cancers13061201" title="DOI URL">https://doi.org/10.3390/cancers13061201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13061201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13061201%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DBioinformatic%252BAnalysis%252Bof%252Bthe%252BNicotinamide%252BBinding%252BSite%252Bin%252BPoly%252528ADP-Ribose%252529%252BPolymerase%252BFamily%252BProteins%26aulast%3DManasaryan%26aufirst%3DGarri%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D6%26spage%3D1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ning  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu-Nan  Tian</span>, <span class="hlFld-ContribAuthor ">Li-Na  Zhou</span>, <span class="hlFld-ContribAuthor ">Meng-Zhu  Li</span>, <span class="hlFld-ContribAuthor ">Hua-Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Shan-Shan  Song</span>, <span class="hlFld-ContribAuthor ">Xia-Juan  Huan</span>, <span class="hlFld-ContribAuthor ">Xu-Bin  Bao</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>, <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>, <span class="hlFld-ContribAuthor ">Jin-Xue  He</span>. </span><span class="cited-content_cbyCitation_article-title">Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2021,</strong> <em>12 </em>
                                    (2)
                                     <a href="https://doi.org/10.1038/s41419-021-03475-4" title="DOI URL">https://doi.org/10.1038/s41419-021-03475-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-021-03475-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-021-03475-4%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DGlycogen%252Bsynthase%252Bkinase%252B3%2525CE%2525B2%252Binhibition%252Bsynergizes%252Bwith%252BPARP%252Binhibitors%252Bthrough%252Bthe%252Binduction%252Bof%252Bhomologous%252Brecombination%252Bdeficiency%252Bin%252Bcolorectal%252Bcancer%26aulast%3DZhang%26aufirst%3DNing%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheling  Chen</span>, <span class="hlFld-ContribAuthor ">Xiao  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao  Li</span>, <span class="hlFld-ContribAuthor ">Yucheng  Zhou</span>, <span class="hlFld-ContribAuthor ">Ke  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of International Medical Research</span><span> <strong>2021,</strong> <em>49 </em>
                                    (2)
                                     , 030006052199101. <a href="https://doi.org/10.1177/0300060521991019" title="DOI URL">https://doi.org/10.1177/0300060521991019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/0300060521991019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F0300060521991019%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520International%2520Medical%2520Research%26atitle%3DDeep%252Bexploration%252Bof%252BPARP%252Binhibitors%252Bin%252Bbreast%252Bcancer%25253A%252Bmonotherapy%252Band%252Bcombination%252Btherapy%26aulast%3DChen%26aufirst%3DZheling%26date%3D2021%26date%3D2021%26volume%3D49%26issue%3D2%26spage%3D030006052199101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nour E. A.  Abd El-sattar</span>, <span class="hlFld-ContribAuthor ">Eman H. K.  Badawy</span>, <span class="hlFld-ContribAuthor ">Eman Z.  Elrazaz</span>, <span class="hlFld-ContribAuthor ">Nasser S. M.  Ismail</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrano[2,3-
              d
              ]pyrimidine-2,4-dione derivatives as novel PARP-1 inhibitors: design, synthesis and antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (8)
                                     , 4454-4464. <a href="https://doi.org/10.1039/D0RA10321G" title="DOI URL">https://doi.org/10.1039/D0RA10321G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA10321G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA10321G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDiscovery%252Bof%252Bpyrano%25255B2%25252C3-%252Bd%252B%25255Dpyrimidine-2%25252C4-dione%252Bderivatives%252Bas%252Bnovel%252BPARP-1%252Binhibitors%25253A%252Bdesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%26aulast%3DAbd%2BEl-sattar%26aufirst%3DNour%2BE.%2BA.%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D8%26spage%3D4454%26epage%3D4464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao-Yue  Xiang</span>, <span class="hlFld-ContribAuthor ">Jian-Yang  Chen</span>, <span class="hlFld-ContribAuthor ">Xia-Juan  Huan</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Zhao-bing  Gao</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>, <span class="hlFld-ContribAuthor ">Chun-Hao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127710. <a href="https://doi.org/10.1016/j.bmcl.2020.127710" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127710%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252B2-substituted%252Bpyrrolo%25255B1%25252C2-b%25255Dpyridazine%252Bderivatives%252Bas%252Bnew%252BPARP-1%252Binhibitors%26aulast%3DXiang%26aufirst%3DHao-Yue%26date%3D2021%26volume%3D31%26spage%3D127710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gargi Nikhil  Vaidya</span>, <span class="hlFld-ContribAuthor ">Pooja  Rana</span>, <span class="hlFld-ContribAuthor ">Ashwini  Venkatesh</span>, <span class="hlFld-ContribAuthor ">Deep Rohan  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Darshan  Contractor</span>, <span class="hlFld-ContribAuthor ">Dinesh Parshuram  Satpute</span>, <span class="hlFld-ContribAuthor ">Mithilesh  Nagpure</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>, <span class="hlFld-ContribAuthor ">Dinesh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Paradigm shift of “classical” HDAC inhibitors to “hybrid” HDAC inhibitors in therapeutic interventions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112844. <a href="https://doi.org/10.1016/j.ejmech.2020.112844" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112844%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DParadigm%252Bshift%252Bof%252B%2525E2%252580%25259Cclassical%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bto%252B%2525E2%252580%25259Chybrid%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bin%252Btherapeutic%252Binterventions%26aulast%3DVaidya%26aufirst%3DGargi%2BNikhil%26date%3D2021%26volume%3D209%26spage%3D112844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaochen  Wu</span>, <span class="hlFld-ContribAuthor ">Qiqi  Li</span>, <span class="hlFld-ContribAuthor ">Fan  Zhang</span>, <span class="hlFld-ContribAuthor ">Lijun  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Junting  Fan</span>, <span class="hlFld-ContribAuthor ">Guohu  Di</span>, <span class="hlFld-ContribAuthor ">Chuanlong  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Food and Chemical Toxicology</span><span> <strong>2021,</strong> <em>147 </em>, 111892. <a href="https://doi.org/10.1016/j.fct.2020.111892" title="DOI URL">https://doi.org/10.1016/j.fct.2020.111892</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.fct.2020.111892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.fct.2020.111892%26sid%3Dliteratum%253Aachs%26jtitle%3DFood%2520and%2520Chemical%2520Toxicology%26atitle%3DNovel%252Bpoly%252B%252528ADP-ribose%252529%252Bpolymerases%252Binhibitor%252BDHC-1%252Bexhibits%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Banticancer%252Bactivity%252Bon%252BBRCA-deficient%252Bpancreatic%252Bcancer%252Bcells%26aulast%3DWu%26aufirst%3DXiaochen%26date%3D2021%26volume%3D147%26spage%3D111892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenchao  Li</span>, <span class="hlFld-ContribAuthor ">Bowen  Pan</span>, <span class="hlFld-ContribAuthor ">Yang  Shi</span>, <span class="hlFld-ContribAuthor ">Meiying  Wang</span>, <span class="hlFld-ContribAuthor ">Tianjiao  Han</span>, <span class="hlFld-ContribAuthor ">Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Guifang  Duan</span>, <span class="hlFld-ContribAuthor ">Hongzheng  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of poly(ADP-ribose)polymerase 1 and 2 (PARP1/2) as targets of andrographolide using an integrated chemical biology approach. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>29 </em><a href="https://doi.org/10.1039/D1CC02272E" title="DOI URL">https://doi.org/10.1039/D1CC02272E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CC02272E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CC02272E%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DIdentification%252Bof%252Bpoly%252528ADP-ribose%252529polymerase%252B1%252Band%252B2%252B%252528PARP1%25252F2%252529%252Bas%252Btargets%252Bof%252Bandrographolide%252Busing%252Ban%252Bintegrated%252Bchemical%252Bbiology%252Bapproach%26aulast%3DLi%26aufirst%3DWenchao%26date%3D2021%26date%3D2021%26volume%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean W.  Reilly</span>, <span class="hlFld-ContribAuthor ">Robert H.  Mach</span>. </span><span class="cited-content_cbyCitation_article-title">Cu
              ‐Mediated Radiohalogenation of Organoboranes. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 325-341. <a href="https://doi.org/10.1002/9781119500575.ch10" title="DOI URL">https://doi.org/10.1002/9781119500575.ch10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119500575.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119500575.ch10%26sid%3Dliteratum%253Aachs%26atitle%3DCu%252B%2525E2%252580%252590Mediated%252BRadiohalogenation%252Bof%252BOrganoboranes%26aulast%3DReilly%26aufirst%3DSean%2BW.%26date%3D2020%26date%3D2021%26spage%3D325%26epage%3D341%26pub%3DWiley%26atitle%3DHandbook%252Bof%252BRadiopharmaceuticals%26aulast%3DScott%26aufirst%3DPeter%26date%3D2020%26date%3D2021%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wan-Qiong  Huang</span>, <span class="hlFld-ContribAuthor ">Chuan-Xian  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Zi-Xin  Li</span>, <span class="hlFld-ContribAuthor ">Chen  Pan</span>, <span class="hlFld-ContribAuthor ">Yun-Zhou  Chen</span>, <span class="hlFld-ContribAuthor ">Xin  Lian</span>, <span class="hlFld-ContribAuthor ">Wai-Lun  Man</span>, <span class="hlFld-ContribAuthor ">Wen-Xiu  Ni</span>. </span><span class="cited-content_cbyCitation_article-title">A cytotoxic nitrido-osmium(
              vi
              ) complex induces caspase-mediated apoptosis in HepG2 cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2020,</strong> <em>49 </em>
                                    (47)
                                     , 17173-17182. <a href="https://doi.org/10.1039/D0DT02715D" title="DOI URL">https://doi.org/10.1039/D0DT02715D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0DT02715D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0DT02715D%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DA%252Bcytotoxic%252Bnitrido-osmium%252528%252Bvi%252B%252529%252Bcomplex%252Binduces%252Bcaspase-mediated%252Bapoptosis%252Bin%252BHepG2%252Bcancer%252Bcells%26aulast%3DHuang%26aufirst%3DWan-Qiong%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D47%26spage%3D17173%26epage%3D17182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sabry M.  Attia</span>, <span class="hlFld-ContribAuthor ">Sheikh F.  Ahmad</span>, <span class="hlFld-ContribAuthor ">Ahmed  Nadeem</span>, <span class="hlFld-ContribAuthor ">Mohamed S.M.  Attia</span>, <span class="hlFld-ContribAuthor ">Mushtaq A.  Ansari</span>, <span class="hlFld-ContribAuthor ">Homood M.  As Sobeai</span>, <span class="hlFld-ContribAuthor ">Haneen A.  Al-Mazroua</span>, <span class="hlFld-ContribAuthor ">Abdullah F.  Alasmari</span>, <span class="hlFld-ContribAuthor ">Saleh A.  Bakheet</span>. </span><span class="cited-content_cbyCitation_article-title">3-Aminobenzamide alleviates elevated DNA damage and DNA methylation in a BTBR T+Itpr3/J mouse model of autism by enhancing repair gene expression. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology Biochemistry and Behavior</span><span> <strong>2020,</strong> <em>199 </em>, 173057. <a href="https://doi.org/10.1016/j.pbb.2020.173057" title="DOI URL">https://doi.org/10.1016/j.pbb.2020.173057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pbb.2020.173057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pbb.2020.173057%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520Biochemistry%2520and%2520Behavior%26atitle%3D3-Aminobenzamide%252Balleviates%252Belevated%252BDNA%252Bdamage%252Band%252BDNA%252Bmethylation%252Bin%252Ba%252BBTBR%252BT%25252BItpr3%25252FJ%252Bmouse%252Bmodel%252Bof%252Bautism%252Bby%252Benhancing%252Brepair%252Bgene%252Bexpression%26aulast%3DAttia%26aufirst%3DSabry%2BM.%26date%3D2020%26volume%3D199%26spage%3D173057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nur Aininie  Yusoh</span>, <span class="hlFld-ContribAuthor ">Haslina  Ahmad</span>, <span class="hlFld-ContribAuthor ">Martin R.  Gill</span>. </span><span class="cited-content_cbyCitation_article-title">Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (22)
                                     , 2121-2135. <a href="https://doi.org/10.1002/cmdc.202000391" title="DOI URL">https://doi.org/10.1002/cmdc.202000391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000391%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DCombining%252BPARP%252BInhibition%252Bwith%252BPlatinum%25252C%252BRuthenium%252Bor%252BGold%252BComplexes%252Bfor%252BCancer%252BTherapy%26aulast%3DYusoh%26aufirst%3DNur%2BAininie%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D22%26spage%3D2121%26epage%3D2135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gulisa  Turashvili</span>, <span class="hlFld-ContribAuthor ">Conxi  Lazaro</span>, <span class="hlFld-ContribAuthor ">Shengjie  Ying</span>, <span class="hlFld-ContribAuthor ">George  Charames</span>, <span class="hlFld-ContribAuthor ">Andrew  Wong</span>, <span class="hlFld-ContribAuthor ">Krista  Hamilton</span>, <span class="hlFld-ContribAuthor ">Denise  Yee</span>, <span class="hlFld-ContribAuthor ">Evangeline  Agro</span>, <span class="hlFld-ContribAuthor ">Martin  Chang</span>, <span class="hlFld-ContribAuthor ">Aaron  Pollett</span>, <span class="hlFld-ContribAuthor ">Jordan  Lerner-Ellis</span>. </span><span class="cited-content_cbyCitation_article-title">Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (11)
                                     , 3468. <a href="https://doi.org/10.3390/cancers12113468" title="DOI URL">https://doi.org/10.3390/cancers12113468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12113468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12113468%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTumor%252BBRCA%252BTesting%252Bin%252BHigh%252BGrade%252BSerous%252BCarcinoma%25253A%252BMutation%252BRates%252Band%252BOptimal%252BTissue%252BRequirements%26aulast%3DTurashvili%26aufirst%3DGulisa%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D11%26spage%3D3468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">, <span class="hlFld-ContribAuthor ">Gabrielle J.  Grundy</span>, <span class="hlFld-ContribAuthor ">Jason L.  Parsons</span>. </span><span class="cited-content_cbyCitation_article-title">Base excision repair and its implications to cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Essays in Biochemistry</span><span> <strong>2020,</strong> <em>64 </em>
                                    (5)
                                     , 831-843. <a href="https://doi.org/10.1042/EBC20200013" title="DOI URL">https://doi.org/10.1042/EBC20200013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/EBC20200013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FEBC20200013%26sid%3Dliteratum%253Aachs%26jtitle%3DEssays%2520in%2520Biochemistry%26atitle%3DBase%252Bexcision%252Brepair%252Band%252Bits%252Bimplications%252Bto%252Bcancer%252Btherapy%26aulast%3DWu%26aufirst%3DQian%26date%3D2020%26date%3D2020%26volume%3D64%26issue%3D5%26spage%3D831%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria Grazia  Perrone</span>, <span class="hlFld-ContribAuthor ">Oreste  Luisi</span>, <span class="hlFld-ContribAuthor ">Anna  De Grassi</span>, <span class="hlFld-ContribAuthor ">Savina  Ferorelli</span>, <span class="hlFld-ContribAuthor ">Gennaro  Cormio</span>, <span class="hlFld-ContribAuthor ">Antonio  Scilimati</span>. </span><span class="cited-content_cbyCitation_article-title">Translational Theragnosis of Ovarian Cancer: where do we stand?. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (34)
                                     , 5675-5715. <a href="https://doi.org/10.2174/0929867326666190816232330" title="DOI URL">https://doi.org/10.2174/0929867326666190816232330</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867326666190816232330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867326666190816232330%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DTranslational%252BTheragnosis%252Bof%252BOvarian%252BCancer%25253A%252Bwhere%252Bdo%252Bwe%252Bstand%25253F%26aulast%3DPerrone%26aufirst%3DMaria%2BGrazia%26date%3D2020%26volume%3D27%26issue%3D34%26spage%3D5675%26epage%3D5715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicola J.  Curtin</span>, <span class="hlFld-ContribAuthor ">Csaba  Szabo</span>. </span><span class="cited-content_cbyCitation_article-title">Poly(ADP-ribose) polymerase inhibition: past, present and future. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2020,</strong> <em>19 </em>
                                    (10)
                                     , 711-736. <a href="https://doi.org/10.1038/s41573-020-0076-6" title="DOI URL">https://doi.org/10.1038/s41573-020-0076-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-020-0076-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-020-0076-6%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DPoly%252528ADP-ribose%252529%252Bpolymerase%252Binhibition%25253A%252Bpast%25252C%252Bpresent%252Band%252Bfuture%26aulast%3DCurtin%26aufirst%3DNicola%2BJ.%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D10%26spage%3D711%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Jiajia  Sun</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Feng  Tang</span>, <span class="hlFld-ContribAuthor ">Zhaoyu  Liu</span>, <span class="hlFld-ContribAuthor ">Qiu  Jin</span>, <span class="hlFld-ContribAuthor ">Jia  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (19)
                                     , 1691-1707. <a href="https://doi.org/10.4155/fmc-2020-0009" title="DOI URL">https://doi.org/10.4155/fmc-2020-0009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0009%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252Bphthalazinone%252Bderivatives%252Bas%252Bpotent%252Bpoly%252528ADP-ribose%252529polymerase%252B1%252Binhibitors%26aulast%3DXin%26aufirst%3DMinhang%26date%3D2020%26volume%3D12%26issue%3D19%26spage%3D1691%26epage%3D1707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shu-Yuan  Ni</span>, <span class="hlFld-ContribAuthor ">Xing-Long  Zhong</span>, <span class="hlFld-ContribAuthor ">Ze-Hua  Li</span>, <span class="hlFld-ContribAuthor ">Dong-Jian  Huang</span>, <span class="hlFld-ContribAuthor ">Wen-Ting  Xu</span>, <span class="hlFld-ContribAuthor ">Yan  Zhou</span>, <span class="hlFld-ContribAuthor ">Cai-Wen  Ou</span>, <span class="hlFld-ContribAuthor ">Min-Sheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Puerarin Alleviates Lipopolysaccharide-Induced Myocardial Fibrosis by Inhibiting PARP-1 to Prevent HMGB1-Mediated TLR4-NF-κB Signaling Pathway. </span><span class="cited-content_cbyCitation_journal-name">Cardiovascular Toxicology</span><span> <strong>2020,</strong> <em>20 </em>
                                    (5)
                                     , 482-491. <a href="https://doi.org/10.1007/s12012-020-09571-9" title="DOI URL">https://doi.org/10.1007/s12012-020-09571-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12012-020-09571-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12012-020-09571-9%26sid%3Dliteratum%253Aachs%26jtitle%3DCardiovascular%2520Toxicology%26atitle%3DPuerarin%252BAlleviates%252BLipopolysaccharide-Induced%252BMyocardial%252BFibrosis%252Bby%252BInhibiting%252BPARP-1%252Bto%252BPrevent%252BHMGB1-Mediated%252BTLR4-NF-%2525CE%2525BAB%252BSignaling%252BPathway%26aulast%3DNi%26aufirst%3DShu-Yuan%26date%3D2020%26date%3D2020%26volume%3D20%26issue%3D5%26spage%3D482%26epage%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sayed K.  Ramadan</span>, <span class="hlFld-ContribAuthor ">Eman Z.  Elrazaz</span>, <span class="hlFld-ContribAuthor ">Khaled A. M.  Abouzid</span>, <span class="hlFld-ContribAuthor ">Abeer M.  El-Naggar</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and
              in silico
              studies of new quinazolinone derivatives as antitumor PARP-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (49)
                                     , 29475-29492. <a href="https://doi.org/10.1039/D0RA05943A" title="DOI URL">https://doi.org/10.1039/D0RA05943A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA05943A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA05943A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bin%252Bsilico%252Bstudies%252Bof%252Bnew%252Bquinazolinone%252Bderivatives%252Bas%252Bantitumor%252BPARP-1%252Binhibitors%26aulast%3DRamadan%26aufirst%3DSayed%2BK.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D49%26spage%3D29475%26epage%3D29492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuele  Maramai</span>, <span class="hlFld-ContribAuthor ">Mohamed  Benchekroun</span>, <span class="hlFld-ContribAuthor ">Moustafa T.  Gabr</span>, <span class="hlFld-ContribAuthor ">Samir  Yahiaoui</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations. </span><span class="cited-content_cbyCitation_journal-name">BioMed Research International</span><span> <strong>2020,</strong> <em>2020 </em>, 1-27. <a href="https://doi.org/10.1155/2020/5120230" title="DOI URL">https://doi.org/10.1155/2020/5120230</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2020/5120230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2020%2F5120230%26sid%3Dliteratum%253Aachs%26jtitle%3DBioMed%2520Research%2520International%26atitle%3DMultitarget%252BTherapeutic%252BStrategies%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%25253A%252BReview%252Bon%252BEmerging%252BTarget%252BCombinations%26aulast%3DMaramai%26aufirst%3DSamuele%26date%3D2020%26volume%3D2020%26spage%3D1%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heike J.  Wobst</span>, <span class="hlFld-ContribAuthor ">Korrie L.  Mack</span>, <span class="hlFld-ContribAuthor ">Dean G.  Brown</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Brandon</span>, <span class="hlFld-ContribAuthor ">James  Shorter</span>. </span><span class="cited-content_cbyCitation_article-title">The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (4)
                                     , 1352-1384. <a href="https://doi.org/10.1002/med.21661" title="DOI URL">https://doi.org/10.1002/med.21661</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21661%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DThe%252Bclinical%252Btrial%252Blandscape%252Bin%252Bamyotrophic%252Blateral%252Bsclerosis%2525E2%252580%252594Past%25252C%252Bpresent%25252C%252Band%252Bfuture%26aulast%3DWobst%26aufirst%3DHeike%2BJ.%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D4%26spage%3D1352%26epage%3D1384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaviarasan  Lakshmanan</span>, <span class="hlFld-ContribAuthor ">Gowramma  Byran</span>, <span class="hlFld-ContribAuthor ">Manal  Mohammed</span>. </span><span class="cited-content_cbyCitation_article-title">A Brief Review on Dual Target of PARP1 and STAT3 for Cancer Therapy: A Novel Perception. </span><span class="cited-content_cbyCitation_journal-name">Current Enzyme Inhibition</span><span> <strong>2020,</strong> <em>16 </em>
                                    (2)
                                     , 115-134. <a href="https://doi.org/10.2174/1573408016666200316114209" title="DOI URL">https://doi.org/10.2174/1573408016666200316114209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573408016666200316114209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573408016666200316114209%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Enzyme%2520Inhibition%26atitle%3DA%252BBrief%252BReview%252Bon%252BDual%252BTarget%252Bof%252BPARP1%252Band%252BSTAT3%252Bfor%252BCancer%252BTherapy%25253A%252BA%252BNovel%252BPerception%26aulast%3DLakshmanan%26aufirst%3DKaviarasan%26date%3D2020%26volume%3D16%26issue%3D2%26spage%3D115%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florent  Peyraud</span>, <span class="hlFld-ContribAuthor ">Antoine  Italiano</span>. </span><span class="cited-content_cbyCitation_article-title">Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (6)
                                     , 1502. <a href="https://doi.org/10.3390/cancers12061502" title="DOI URL">https://doi.org/10.3390/cancers12061502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12061502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12061502%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DCombined%252BPARP%252BInhibition%252Band%252BImmune%252BCheckpoint%252BTherapy%252Bin%252BSolid%252BTumors%26aulast%3DPeyraud%26aufirst%3DFlorent%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D6%26spage%3D1502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chuanlong  Guo</span>, <span class="hlFld-ContribAuthor ">Fan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaochen  Wu</span>, <span class="hlFld-ContribAuthor ">Xuemin  Yu</span>, <span class="hlFld-ContribAuthor ">Xianggen  Wu</span>, <span class="hlFld-ContribAuthor ">Dayong  Shi</span>, <span class="hlFld-ContribAuthor ">Lijun  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2020,</strong> <em>150 </em>, 238-245. <a href="https://doi.org/10.1016/j.ijbiomac.2020.02.069" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2020.02.069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2020.02.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2020.02.069%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DBTH-8%25252C%252Ba%252Bnovel%252Bpoly%252B%252528ADP-ribose%252529%252Bpolymerase-1%252B%252528PARP-1%252529%252Binhibitor%25252C%252Bcauses%252BDNA%252Bdouble-strand%252Bbreaks%252Band%252Bexhibits%252Banticancer%252Bactivities%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DGuo%26aufirst%3DChuanlong%26date%3D2020%26volume%3D150%26spage%3D238%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoxi  Li</span>, <span class="hlFld-ContribAuthor ">Siyi  Xu</span>, <span class="hlFld-ContribAuthor ">Meijuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhengzheng  Wu</span>, <span class="hlFld-ContribAuthor ">Xi  Zhang</span>, <span class="hlFld-ContribAuthor ">Yun  Xu</span>, <span class="hlFld-ContribAuthor ">Yanting  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Delayed PARP-1 Inhibition Alleviates Post-stroke Inflammation in Male Versus Female Mice: Differences and Similarities. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cellular Neuroscience</span><span> <strong>2020,</strong> <em>14 </em><a href="https://doi.org/10.3389/fncel.2020.00077" title="DOI URL">https://doi.org/10.3389/fncel.2020.00077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fncel.2020.00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffncel.2020.00077%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cellular%2520Neuroscience%26atitle%3DDelayed%252BPARP-1%252BInhibition%252BAlleviates%252BPost-stroke%252BInflammation%252Bin%252BMale%252BVersus%252BFemale%252BMice%25253A%252BDifferences%252Band%252BSimilarities%26aulast%3DChen%26aufirst%3DJian%26date%3D2020%26date%3D2020%26volume%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongbin  Tian</span>, <span class="hlFld-ContribAuthor ">Zhouling  Xie</span>, <span class="hlFld-ContribAuthor ">Chenzhong  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (8)
                                     , 127036. <a href="https://doi.org/10.1016/j.bmcl.2020.127036" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127036%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Banticancer%252Bactivities%252Bof%252Bnovel%252Bdual%252Bpoly%252528ADP-ribose%252529%252Bpolymerase-1%25252Fhistone%252Bdeacetylase-1%252Binhibitors%26aulast%3DTian%26aufirst%3DYongbin%26date%3D2020%26volume%3D30%26issue%3D8%26spage%3D127036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Luo</span>, <span class="hlFld-ContribAuthor ">Xinchi  Dai</span>, <span class="hlFld-ContribAuthor ">Hua  Hu</span>, <span class="hlFld-ContribAuthor ">Jie  Chen</span>, <span class="hlFld-ContribAuthor ">Lujun  Zhao</span>, <span class="hlFld-ContribAuthor ">Changyong  Yang</span>, <span class="hlFld-ContribAuthor ">Jifeng  Sun</span>, <span class="hlFld-ContribAuthor ">Lianmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Qian  Wang</span>, <span class="hlFld-ContribAuthor ">Shilei  Xu</span>, <span class="hlFld-ContribAuthor ">Yue  Xu</span>, <span class="hlFld-ContribAuthor ">Ningbo  Liu</span>, <span class="hlFld-ContribAuthor ">Guoguang  Ying</span>, <span class="hlFld-ContribAuthor ">Ping  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cancer Research and Clinical Oncology</span><span> <strong>2020,</strong> <em>146 </em>
                                    (3)
                                     , 721-737. <a href="https://doi.org/10.1007/s00432-019-03097-6" title="DOI URL">https://doi.org/10.1007/s00432-019-03097-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00432-019-03097-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00432-019-03097-6%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cancer%2520Research%2520and%2520Clinical%2520Oncology%26atitle%3DFluzoparib%252Bincreases%252Bradiation%252Bsensitivity%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528NSCLC%252529%252Bcells%252Bwithout%252BBRCA1%25252F2%252Bmutation%25252C%252Ba%252Bnovel%252BPARP1%252Binhibitor%252Bundergoing%252Bclinical%252Btrials%26aulast%3DLuo%26aufirst%3DJing%26date%3D2020%26date%3D2019%26volume%3D146%26issue%3D3%26spage%3D721%26epage%3D737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dmitry  Nilov</span>, <span class="hlFld-ContribAuthor ">Natalya  Maluchenko</span>, <span class="hlFld-ContribAuthor ">Tatyana  Kurgina</span>, <span class="hlFld-ContribAuthor ">Sergey  Pushkarev</span>, <span class="hlFld-ContribAuthor ">Alexandra  Lys</span>, <span class="hlFld-ContribAuthor ">Mikhail  Kutuzov</span>, <span class="hlFld-ContribAuthor ">Nadezhda  Gerasimova</span>, <span class="hlFld-ContribAuthor ">Alexey  Feofanov</span>, <span class="hlFld-ContribAuthor ">Vytas  Švedas</span>, <span class="hlFld-ContribAuthor ">Olga  Lavrik</span>, <span class="hlFld-ContribAuthor ">Vasily M.  Studitsky</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (6)
                                     , 2159. <a href="https://doi.org/10.3390/ijms21062159" title="DOI URL">https://doi.org/10.3390/ijms21062159</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21062159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21062159%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMolecular%252BMechanisms%252Bof%252BPARP-1%252BInhibitor%252B7-Methylguanine%26aulast%3DNilov%26aufirst%3DDmitry%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D6%26spage%3D2159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. F.  Sagitova</span>, <span class="hlFld-ContribAuthor ">L. N.  Sobenina</span>, <span class="hlFld-ContribAuthor ">B. A.  Trofimov</span>. </span><span class="cited-content_cbyCitation_article-title">From Acylethynylpyrroles to Pyrrolo[1,2-a]pyrazines in One Step. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>56 </em>
                                    (2)
                                     , 225-233. <a href="https://doi.org/10.1134/S1070428020020082" title="DOI URL">https://doi.org/10.1134/S1070428020020082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428020020082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428020020082%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DFrom%252BAcylethynylpyrroles%252Bto%252BPyrrolo%25255B1%25252C2-a%25255Dpyrazines%252Bin%252BOne%252BStep%26aulast%3DSagitova%26aufirst%3DE.%2BF.%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D2%26spage%3D225%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Nan  Tian</span>, <span class="hlFld-ContribAuthor ">Hua-Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Chang-Qing  Tian</span>, <span class="hlFld-ContribAuthor ">Ying-Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41419-020-2265-y" title="DOI URL">https://doi.org/10.1038/s41419-020-2265-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-020-2265-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-020-2265-y%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DPolymerase%252Bindependent%252Brepression%252Bof%252BFoxO1%252Btranscription%252Bby%252Bsequence-specific%252BPARP1%252Bbinding%252Bto%252BFoxO1%252Bpromoter%26aulast%3DTian%26aufirst%3DYu-Nan%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicolas C.  Hoch</span>, <span class="hlFld-ContribAuthor ">Luis M.  Polo</span>. </span><span class="cited-content_cbyCitation_article-title">ADP-ribosylation: from molecular mechanisms to human disease. </span><span class="cited-content_cbyCitation_journal-name">Genetics and Molecular Biology</span><span> <strong>2020,</strong> <em>43 </em>
                                    (1 suppl 1)
                                     <a href="https://doi.org/10.1590/1678-4685-gmb-2019-0075" title="DOI URL">https://doi.org/10.1590/1678-4685-gmb-2019-0075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1590/1678-4685-gmb-2019-0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1590%2F1678-4685-gmb-2019-0075%26sid%3Dliteratum%253Aachs%26jtitle%3DGenetics%2520and%2520Molecular%2520Biology%26atitle%3DADP-ribosylation%25253A%252Bfrom%252Bmolecular%252Bmechanisms%252Bto%252Bhuman%252Bdisease%26aulast%3DHoch%26aufirst%3DNicolas%2BC.%26date%3D2020%26date%3D2020%26volume%3D43%26issue%3D1%2520suppl%25201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xinyue  Chang</span>, <span class="hlFld-ContribAuthor ">Chixiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Shenxin  Zeng</span>, <span class="hlFld-ContribAuthor ">Meihao  Liang</span>, <span class="hlFld-ContribAuthor ">Zhen  Ma</span>, <span class="hlFld-ContribAuthor ">Zunyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Wenhai  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengrong  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1). </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 1606-1615. <a href="https://doi.org/10.1080/14756366.2020.1804382" title="DOI URL">https://doi.org/10.1080/14756366.2020.1804382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2020.1804382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2020.1804382%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bprobe-quality%252Bdegraders%252Bfor%252BPoly%252528ADP-ribose%252529%252Bpolymerase-1%252B%252528PARP-1%252529%26aulast%3DZhang%26aufirst%3DZhimin%26date%3D2020%26date%3D2020%26volume%3D35%26issue%3D1%26spage%3D1606%26epage%3D1615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hubert  Fleury</span>, <span class="hlFld-ContribAuthor ">Nicolas  Malaquin</span>, <span class="hlFld-ContribAuthor ">Véronique  Tu</span>, <span class="hlFld-ContribAuthor ">Sophie  Gilbert</span>, <span class="hlFld-ContribAuthor ">Aurélie  Martinez</span>, <span class="hlFld-ContribAuthor ">Marc-Alexandre  Olivier</span>, <span class="hlFld-ContribAuthor ">Alexandre  Sauriol</span>, <span class="hlFld-ContribAuthor ">Laudine  Communal</span>, <span class="hlFld-ContribAuthor ">Kim  Leclerc-Desaulniers</span>, <span class="hlFld-ContribAuthor ">Euridice  Carmona</span>, <span class="hlFld-ContribAuthor ">Diane  Provencher</span>, <span class="hlFld-ContribAuthor ">Anne-Marie  Mes-Masson</span>, <span class="hlFld-ContribAuthor ">Francis  Rodier</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-019-10460-1" title="DOI URL">https://doi.org/10.1038/s41467-019-10460-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-019-10460-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-019-10460-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DExploiting%252Binterconnected%252Bsynthetic%252Blethal%252Binteractions%252Bbetween%252BPARP%252Binhibition%252Band%252Bcancer%252Bcell%252Breversible%252Bsenescence%26aulast%3DFleury%26aufirst%3DHubert%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anping  Li</span>, <span class="hlFld-ContribAuthor ">Ming  Yi</span>, <span class="hlFld-ContribAuthor ">Shuang  Qin</span>, <span class="hlFld-ContribAuthor ">Qian  Chu</span>, <span class="hlFld-ContribAuthor ">Suxia  Luo</span>, <span class="hlFld-ContribAuthor ">Kongming  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Prospects for combining immune checkpoint blockade with PARP inhibition. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2019,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-019-0784-8" title="DOI URL">https://doi.org/10.1186/s13045-019-0784-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-019-0784-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-019-0784-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DProspects%252Bfor%252Bcombining%252Bimmune%252Bcheckpoint%252Bblockade%252Bwith%252BPARP%252Binhibition%26aulast%3DLi%26aufirst%3DAnping%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed T.A.  Boraei</span>, <span class="hlFld-ContribAuthor ">Pankaj K.  Singh</span>, <span class="hlFld-ContribAuthor ">Mario  Sechi</span>, <span class="hlFld-ContribAuthor ">Sandro  Satta</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111621. <a href="https://doi.org/10.1016/j.ejmech.2019.111621" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111621</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111621%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bfunctionalized%252B1%25252C2%25252C4-triazoles%252Bas%252BPARP-1%252Binhibitors%252Bin%252Bbreast%252Bcancer%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%252Bevaluation%26aulast%3DBoraei%26aufirst%3DAhmed%2BT.A.%26date%3D2019%26volume%3D182%26spage%3D111621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernard T.  Golding</span>. </span><span class="cited-content_cbyCitation_article-title">The Story of Rucaparib (Rubraca). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 201-223. <a href="https://doi.org/10.1002/9783527814695.ch8" title="DOI URL">https://doi.org/10.1002/9783527814695.ch8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527814695.ch8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527814695.ch8%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BStory%252Bof%252BRucaparib%252B%252528Rubraca%252529%26aulast%3DGolding%26aufirst%3DBernard%2BT.%26date%3D2019%26date%3D2019%26spage%3D201%26epage%3D223%26pub%3DWiley%26atitle%3DSuccessful%252BDrug%252BDiscovery%26aulast%3DFischer%26aufirst%3DJ%25C3%25A1nos%26date%3D2019%26date%3D2019%26volume%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erhu  Fang</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Wang</span>, <span class="hlFld-ContribAuthor ">Feng  Yang</span>, <span class="hlFld-ContribAuthor ">Anpei  Hu</span>, <span class="hlFld-ContribAuthor ">Jianqun  Wang</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Huajie  Song</span>, <span class="hlFld-ContribAuthor ">Mei  Hong</span>, <span class="hlFld-ContribAuthor ">Yanhua  Guo</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Hongjun  Li</span>, <span class="hlFld-ContribAuthor ">Kai  Huang</span>, <span class="hlFld-ContribAuthor ">Liduan  Zheng</span>, <span class="hlFld-ContribAuthor ">Qiangsong  Tong</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Targeting of
              MZF1‐AS1
              /PARP1/E2F1 Axis Inhibits Proline Synthesis and Neuroblastoma Progression. </span><span class="cited-content_cbyCitation_journal-name">Advanced Science</span><span> <strong>2019,</strong> <em>6 </em>
                                    (19)
                                     , 1900581. <a href="https://doi.org/10.1002/advs.201900581" title="DOI URL">https://doi.org/10.1002/advs.201900581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/advs.201900581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadvs.201900581%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Science%26atitle%3DTherapeutic%252BTargeting%252Bof%252BMZF1%2525E2%252580%252590AS1%252B%25252FPARP1%25252FE2F1%252BAxis%252BInhibits%252BProline%252BSynthesis%252Band%252BNeuroblastoma%252BProgression%26aulast%3DFang%26aufirst%3DErhu%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D19%26spage%3D1900581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hua-Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Chuan-Huizi  Chen</span>, <span class="hlFld-ContribAuthor ">Yu-Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Ne  Guo</span>, <span class="hlFld-ContribAuthor ">Yu-Nan  Tian</span>, <span class="hlFld-ContribAuthor ">Xia-Juan  Huan</span>, <span class="hlFld-ContribAuthor ">Shan-Shan  Song</span>, <span class="hlFld-ContribAuthor ">Jin-Xue  He</span>, <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Cancer</span><span> <strong>2019,</strong> <em>145 </em>
                                    (3)
                                     , 714-727. <a href="https://doi.org/10.1002/ijc.32131" title="DOI URL">https://doi.org/10.1002/ijc.32131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ijc.32131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fijc.32131%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Cancer%26atitle%3DIncreased%252BPARP1-DNA%252Bbinding%252Bdue%252Bto%252BautoPARylation%252Binhibition%252Bof%252BPARP1%252Bon%252BDNA%252Brather%252Bthan%252BPARP1-DNA%252Btrapping%252Bis%252Bcorrelated%252Bwith%252BPARP1%252Binhibitor%252527s%252Bcytotoxicity%26aulast%3DChen%26aufirst%3DHua-Dong%26date%3D2019%26date%3D2019%26volume%3D145%26issue%3D3%26spage%3D714%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenbin  Shen</span>, <span class="hlFld-ContribAuthor ">Xinhua  Lu</span>, <span class="hlFld-ContribAuthor ">Jingtong  Zhu</span>, <span class="hlFld-ContribAuthor ">Yunlong  Mu</span>, <span class="hlFld-ContribAuthor ">Yan  Xu</span>, <span class="hlFld-ContribAuthor ">Jian  Gao</span>, <span class="hlFld-ContribAuthor ">Xuexia  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of naphthacemycins as a novel class of PARP1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (15)
                                     , 1904-1908. <a href="https://doi.org/10.1016/j.bmcl.2019.05.055" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.05.055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.05.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.05.055%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnaphthacemycins%252Bas%252Ba%252Bnovel%252Bclass%252Bof%252BPARP1%252Binhibitors%26aulast%3DShen%26aufirst%3DWenbin%26date%3D2019%26volume%3D29%26issue%3D15%26spage%3D1904%26epage%3D1908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammad  Mirza-Aghazadeh-Attari</span>, <span class="hlFld-ContribAuthor ">Caspian  Ostadian</span>, <span class="hlFld-ContribAuthor ">Amir Ata  Saei</span>, <span class="hlFld-ContribAuthor ">Ainaz  Mihanfar</span>, <span class="hlFld-ContribAuthor ">Saber Ghazizadeh  Darband</span>, <span class="hlFld-ContribAuthor ">Shirin  Sadighparvar</span>, <span class="hlFld-ContribAuthor ">Mojtaba  Kaviani</span>, <span class="hlFld-ContribAuthor ">Hossein  Samadi Kafil</span>, <span class="hlFld-ContribAuthor ">Bahman  Yousefi</span>, <span class="hlFld-ContribAuthor ">Maryam  Majidinia</span>. </span><span class="cited-content_cbyCitation_article-title">DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies. </span><span class="cited-content_cbyCitation_journal-name">DNA Repair</span><span> <strong>2019,</strong> <em>80 </em>, 59-84. <a href="https://doi.org/10.1016/j.dnarep.2019.06.005" title="DOI URL">https://doi.org/10.1016/j.dnarep.2019.06.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.dnarep.2019.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.dnarep.2019.06.005%26sid%3Dliteratum%253Aachs%26jtitle%3DDNA%2520Repair%26atitle%3DDNA%252Bdamage%252Bresponse%252Band%252Brepair%252Bin%252Bovarian%252Bcancer%25253A%252BPotential%252Btargets%252Bfor%252Btherapeutic%252Bstrategies%26aulast%3DMirza-Aghazadeh-Attari%26aufirst%3DMohammad%26date%3D2019%26volume%3D80%26spage%3D59%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanhua  Wu</span>, <span class="hlFld-ContribAuthor ">Shoumin  Bai</span>, <span class="hlFld-ContribAuthor ">Dingjun  Zhu</span>, <span class="hlFld-ContribAuthor ">Kaiwen  Li</span>, <span class="hlFld-ContribAuthor ">Wen  Dong</span>, <span class="hlFld-ContribAuthor ">Wang  He</span>, <span class="hlFld-ContribAuthor ">Shengmeng  Peng</span>, <span class="hlFld-ContribAuthor ">Yiming  Lai</span>, <span class="hlFld-ContribAuthor ">Qiong  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenghui  Guo</span>, <span class="hlFld-ContribAuthor ">Leyuan  Liu</span>, <span class="hlFld-ContribAuthor ">Hai  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Overexpression of malignant brain tumor domain containing protein 1 predicts a poor prognosis of prostate cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncology Letters</span><span> <strong>2019,</strong> <em> </em><a href="https://doi.org/10.3892/ol.2019.10109" title="DOI URL">https://doi.org/10.3892/ol.2019.10109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ol.2019.10109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fol.2019.10109%26sid%3Dliteratum%253Aachs%26jtitle%3DOncology%2520Letters%26atitle%3DOverexpression%252Bof%252Bmalignant%252Bbrain%252Btumor%252Bdomain%252Bcontaining%252Bprotein%252B1%252Bpredicts%252Ba%252Bpoor%252Bprognosis%252Bof%252Bprostate%252Bcancer%26aulast%3DWu%26aufirst%3DWanhua%26date%3D2019%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean W.  Reilly</span>, <span class="hlFld-ContribAuthor ">Laura N.  Puentes</span>, <span class="hlFld-ContribAuthor ">Alexander  Schmitz</span>, <span class="hlFld-ContribAuthor ">Chia-Ju  Hsieh</span>, <span class="hlFld-ContribAuthor ">Chi-Chang  Weng</span>, <span class="hlFld-ContribAuthor ">Catherine  Hou</span>, <span class="hlFld-ContribAuthor ">Shihong  Li</span>, <span class="hlFld-ContribAuthor ">Yin-Ming  Kuo</span>, <span class="hlFld-ContribAuthor ">Prashanth  Padakanti</span>, <span class="hlFld-ContribAuthor ">Hsiaoju  Lee</span>, <span class="hlFld-ContribAuthor ">Aladdin A.  Riad</span>, <span class="hlFld-ContribAuthor ">Mehran  Makvandi</span>, <span class="hlFld-ContribAuthor ">Robert H.  Mach</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of an AZD2461 [18F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>83 </em>, 242-249. <a href="https://doi.org/10.1016/j.bioorg.2018.10.015" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.10.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.10.015%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Ban%252BAZD2461%252B%25255B18F%25255DPET%252Bprobe%252Bin%252Bnon-human%252Bprimates%252Breveals%252Bthe%252BPARP-1%252Binhibitor%252Bto%252Bbe%252Bnon-blood-brain%252Bbarrier%252Bpenetrant%26aulast%3DReilly%26aufirst%3DSean%2BW.%26date%3D2019%26volume%3D83%26spage%3D242%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priyancy G.  Jain</span>, <span class="hlFld-ContribAuthor ">Bhumika D.  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>165 </em>, 198-215. <a href="https://doi.org/10.1016/j.ejmech.2019.01.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.01.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.01.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252Bchemistry%252Bapproaches%252Bof%252Bpoly%252BADP-Ribose%252Bpolymerase%252B1%252B%252528PARP1%252529%252Binhibitors%252Bas%252Banticancer%252Bagents%252B-%252BA%252Brecent%252Bupdate%26aulast%3DJain%26aufirst%3DPriyancy%2BG.%26date%3D2019%26volume%3D165%26spage%3D198%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng-Zhi  Gao</span>, <span class="hlFld-ContribAuthor ">Wei  Dong</span>, <span class="hlFld-ContribAuthor ">Zhi-Wen  Cui</span>, <span class="hlFld-ContribAuthor ">Qiong  Yuan</span>, <span class="hlFld-ContribAuthor ">Xia-Min  Hu</span>, <span class="hlFld-ContribAuthor ">Qing-Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Xianlin  Han</span>, <span class="hlFld-ContribAuthor ">Yao  Xu</span>, <span class="hlFld-ContribAuthor ">Zhen-Li  Min</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 150-162. <a href="https://doi.org/10.1080/14756366.2018.1530224" title="DOI URL">https://doi.org/10.1080/14756366.2018.1530224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2018.1530224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2018.1530224%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bpreliminarily%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bdocking%252Bstudy%252Bof%252Bnew%252BOlaparib%252Banalogues%252Bas%252Bmultifunctional%252BPARP-1%252Band%252Bcholinesterase%252Binhibitors%26aulast%3DGao%26aufirst%3DCheng-Zhi%26date%3D2019%26date%3D2018%26volume%3D34%26issue%3D1%26spage%3D150%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng  Zheng</span>, <span class="hlFld-ContribAuthor ">Martin  Mex</span>, <span class="hlFld-ContribAuthor ">Kathrin H.  Götz</span>, <span class="hlFld-ContribAuthor ">Andreas  Marx</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (46)
                                     , 8904-8907. <a href="https://doi.org/10.1039/C8OB01894D" title="DOI URL">https://doi.org/10.1039/C8OB01894D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB01894D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB01894D%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bdisaccharide%252Bnucleoside%252Banalogues%252Bas%252Bpotential%252Bpoly%252528ADP-ribose%252529%252Bpolymerase-1%252Binhibitors%26aulast%3DZheng%26aufirst%3DMeng%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D46%26spage%3D8904%26epage%3D8907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Wu</span>, <span class="hlFld-ContribAuthor ">Sheng  Xiao</span>, <span class="hlFld-ContribAuthor ">Miaomiao  Yuan</span>, <span class="hlFld-ContribAuthor ">Qianyuan  Li</span>, <span class="hlFld-ContribAuthor ">Guangfen  Xiao</span>, <span class="hlFld-ContribAuthor ">Wei  Wu</span>, <span class="hlFld-ContribAuthor ">Yuexian  Ouyang</span>, <span class="hlFld-ContribAuthor ">Lihua  Huang</span>, <span class="hlFld-ContribAuthor ">Chenjiao  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis. </span><span class="cited-content_cbyCitation_journal-name">Molecular Medicine Reports</span><span> <strong>2018,</strong> <em> </em><a href="https://doi.org/10.3892/mmr.2018.9628" title="DOI URL">https://doi.org/10.3892/mmr.2018.9628</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/mmr.2018.9628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fmmr.2018.9628%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Medicine%2520Reports%26atitle%3DPARP%252Binhibitor%252Bre%2525E2%252580%252591sensitizes%252BAdriamycin%252Bresistant%252Bleukemia%252Bcells%252Bthrough%252BDNA%252Bdamage%252Band%252Bapoptosis%26aulast%3DWu%26aufirst%3DJie%26date%3D2018%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuangshuang  Wu</span>, <span class="hlFld-ContribAuthor ">Changhui  Chen</span>, <span class="hlFld-ContribAuthor ">Haitang  Yang</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Min  Wei</span>, <span class="hlFld-ContribAuthor ">Yuanjian  Zhang</span>, <span class="hlFld-ContribAuthor ">Songqin  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">A sensitive fluorescence “turn-off-on” biosensor for poly(ADP-ribose) polymerase-1 detection based on cationic conjugated polymer-MnO2 nanosheets. </span><span class="cited-content_cbyCitation_journal-name">Sensors and Actuators B: Chemical</span><span> <strong>2018,</strong> <em>273 </em>, 1047-1053. <a href="https://doi.org/10.1016/j.snb.2018.07.013" title="DOI URL">https://doi.org/10.1016/j.snb.2018.07.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.snb.2018.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.snb.2018.07.013%26sid%3Dliteratum%253Aachs%26jtitle%3DSensors%2520and%2520Actuators%2520B%253A%2520Chemical%26atitle%3DA%252Bsensitive%252Bfluorescence%252B%2525E2%252580%25259Cturn-off-on%2525E2%252580%25259D%252Bbiosensor%252Bfor%252Bpoly%252528ADP-ribose%252529%252Bpolymerase-1%252Bdetection%252Bbased%252Bon%252Bcationic%252Bconjugated%252Bpolymer-MnO2%252Bnanosheets%26aulast%3DWu%26aufirst%3DShuangshuang%26date%3D2018%26volume%3D273%26spage%3D1047%26epage%3D1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Bo  Yuan</span>, <span class="hlFld-ContribAuthor ">Hua-Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Lin  Xu</span>, <span class="hlFld-ContribAuthor ">Yu-Nan  Tian</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin-Xue  He</span>, <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2018,</strong> <em>109 </em>
                                    (3)
                                     , 821-831. <a href="https://doi.org/10.1111/cas.13477" title="DOI URL">https://doi.org/10.1111/cas.13477</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.13477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.13477%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3DAcquired%252Bresistance%252Bof%252Bphosphatase%252Band%252Btensin%252Bhomolog-deficient%252Bcells%252Bto%252Bpoly%252528ADP-ribose%252529%252Bpolymerase%252Binhibitor%252Band%252BAra-C%252Bmediated%252Bby%252B53BP1%252Bloss%252Band%252BSAMHD1%252Boverexpression%26aulast%3DWang%26aufirst%3DYu-Ting%26date%3D2018%26date%3D2018%26volume%3D109%26issue%3D3%26spage%3D821%26epage%3D831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuxing  Chen</span>, <span class="hlFld-ContribAuthor ">Xiajuan  Huan</span>, <span class="hlFld-ContribAuthor ">Qiufeng  Liu</span>, <span class="hlFld-ContribAuthor ">Yuqin  Wang</span>, <span class="hlFld-ContribAuthor ">Qian  He</span>, <span class="hlFld-ContribAuthor ">Cun  Tan</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Yechun  Xu</span>, <span class="hlFld-ContribAuthor ">Zehong  Miao</span>, <span class="hlFld-ContribAuthor ">Chunhao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>145 </em>, 389-403. <a href="https://doi.org/10.1016/j.ejmech.2018.01.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B2-%2525284%25252C5%25252C6%25252C7-tetrahydrothienopyridin-2-yl%252529-benzoimidazole%252Bcarboxamides%252Bas%252Bnovel%252Borally%252Befficacious%252BPoly%252528ADP-ribose%252529polymerase%252B%252528PARP%252529%252Binhibitors%26aulast%3DChen%26aufirst%3DXuxing%26date%3D2018%26volume%3D145%26spage%3D389%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. K.  Nilov</span>, <span class="hlFld-ContribAuthor ">K. I.  Yashina</span>, <span class="hlFld-ContribAuthor ">I. V.  Gushchina</span>, <span class="hlFld-ContribAuthor ">A. L.  Zakharenko</span>, <span class="hlFld-ContribAuthor ">M. V.  Sukhanova</span>, <span class="hlFld-ContribAuthor ">O. I.  Lavrik</span>, <span class="hlFld-ContribAuthor ">V. K.  Švedas</span>. </span><span class="cited-content_cbyCitation_article-title">2,5-Diketopiperazines: A New Class of Poly(ADP-ribose)polymerase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry (Moscow)</span><span> <strong>2018,</strong> <em>83 </em>
                                    (2)
                                     , 152-158. <a href="https://doi.org/10.1134/S0006297918020074" title="DOI URL">https://doi.org/10.1134/S0006297918020074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S0006297918020074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS0006297918020074%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%2520%2528Moscow%2529%26atitle%3D2%25252C5-Diketopiperazines%25253A%252BA%252BNew%252BClass%252Bof%252BPoly%252528ADP-ribose%252529polymerase%252BInhibitors%26aulast%3DNilov%26aufirst%3DD.%2BK.%26date%3D2018%26date%3D2018%26volume%3D83%26issue%3D2%26spage%3D152%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christos  Fountzilas</span>, <span class="hlFld-ContribAuthor ">Virginia G.  Kaklamani</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-gene Panel Testing in Breast Cancer Management. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 121-140. <a href="https://doi.org/10.1007/978-3-319-70197-4_8" title="DOI URL">https://doi.org/10.1007/978-3-319-70197-4_8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-70197-4_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-70197-4_8%26sid%3Dliteratum%253Aachs%26atitle%3DMulti-gene%252BPanel%252BTesting%252Bin%252BBreast%252BCancer%252BManagement%26aulast%3DFountzilas%26aufirst%3DChristos%26date%3D2018%26date%3D2018%26spage%3D121%26epage%3D140%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DOptimizing%252BBreast%252BCancer%252BManagement%26aulast%3DGradishar%26aufirst%3DWilliam%2BJ.%26date%3D2018%26volume%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid I.  Belen’kii</span>, <span class="hlFld-ContribAuthor ">Yulia B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The Literature of Heterocyclic Chemistry, Part XVI, 2016. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 173-254. <a href="https://doi.org/10.1016/bs.aihch.2018.02.003" title="DOI URL">https://doi.org/10.1016/bs.aihch.2018.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2018.02.003%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BLiterature%252Bof%252BHeterocyclic%252BChemistry%25252C%252BPart%252BXVI%25252C%252B2016%26aulast%3DBelen%25E2%2580%2599kii%26aufirst%3DLeonid%2BI.%26date%3D2018%26spage%3D173%26epage%3D254%26pub%3DElsevier%26date%3D2018%26volume%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chilaluck C.  Konkankit</span>, <span class="hlFld-ContribAuthor ">Sierra C.  Marker</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Knopf</span>, <span class="hlFld-ContribAuthor ">Justin J.  Wilson</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2018,</strong> <em>47 </em>
                                    (30)
                                     , 9934-9974. <a href="https://doi.org/10.1039/C8DT01858H" title="DOI URL">https://doi.org/10.1039/C8DT01858H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8DT01858H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8DT01858H%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DAnticancer%252Bactivity%252Bof%252Bcomplexes%252Bof%252Bthe%252Bthird%252Brow%252Btransition%252Bmetals%25252C%252Brhenium%25252C%252Bosmium%25252C%252Band%252Biridium%26aulast%3DKonkankit%26aufirst%3DChilaluck%2BC.%26date%3D2018%26date%3D2018%26volume%3D47%26issue%3D30%26spage%3D9934%26epage%3D9974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Ming  Ji</span>, <span class="hlFld-ContribAuthor ">Haiping  Yao</span>, <span class="hlFld-ContribAuthor ">Ran  Cao</span>, <span class="hlFld-ContribAuthor ">Hailong  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Chen</span>, <span class="hlFld-ContribAuthor ">Bailing  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of quinazoline-2,4(1
              H
              ,3
              H
              )-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (17)
                                     , 3189-3202. <a href="https://doi.org/10.1039/C8OB00286J" title="DOI URL">https://doi.org/10.1039/C8OB00286J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB00286J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB00286J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bquinazoline-2%25252C4%2525281%252BH%252B%25252C3%252BH%252B%252529-dione%252Bderivatives%252Bas%252Bnovel%252BPARP-1%25252F2%252Binhibitors%25253A%252Bdesign%25252C%252Bsynthesis%252Band%252Btheir%252Bantitumor%252Bactivity%26aulast%3DZhou%26aufirst%3DJie%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D17%26spage%3D3189%26epage%3D3202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-hua  Chen</span>, <span class="hlFld-ContribAuthor ">Shan-shan  Song</span>, <span class="hlFld-ContribAuthor ">Ming-hui  Qi</span>, <span class="hlFld-ContribAuthor ">Xia-juan  Huan</span>, <span class="hlFld-ContribAuthor ">Ying-qing  Wang</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Guo-bin  Ren</span>, <span class="hlFld-ContribAuthor ">Ze-hong  Miao</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2017,</strong> <em>38 </em>
                                    (11)
                                     , 1521-1532. <a href="https://doi.org/10.1038/aps.2017.104" title="DOI URL">https://doi.org/10.1038/aps.2017.104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/aps.2017.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Faps.2017.104%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DDiscovery%252Bof%252Bpotent%252B2%25252C4-difluoro-linker%252Bpoly%252528ADP-ribose%252529%252Bpolymerase%252B1%252Binhibitors%252Bwith%252Benhanced%252Bwater%252Bsolubility%252Band%252Bin%252Bvivo%252Banticancer%252Befficacy%26aulast%3DChen%26aufirst%3DWen-hua%26date%3D2017%26date%3D2017%26volume%3D38%26issue%3D11%26spage%3D1521%26epage%3D1532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Katsyuba</span>, <span class="hlFld-ContribAuthor ">Johan  Auwerx</span>. </span><span class="cited-content_cbyCitation_article-title">Modulating
              NAD
              +
              metabolism, from bench to bedside. </span><span class="cited-content_cbyCitation_journal-name">The EMBO Journal</span><span> <strong>2017,</strong> <em>36 </em>
                                    (18)
                                     , 2670-2683. <a href="https://doi.org/10.15252/embj.201797135" title="DOI URL">https://doi.org/10.15252/embj.201797135</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.15252/embj.201797135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.15252%2Fembj.201797135%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520EMBO%2520Journal%26atitle%3DModulating%252BNAD%252B%25252B%252Bmetabolism%25252C%252Bfrom%252Bbench%252Bto%2525C2%2525A0bedside%26aulast%3DKatsyuba%26aufirst%3DElena%26date%3D2017%26date%3D2017%26volume%3D36%26issue%3D18%26spage%3D2670%26epage%3D2683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Qin</span>, <span class="hlFld-ContribAuthor ">Lei  Fang</span>, <span class="hlFld-ContribAuthor ">Feihong  Chen</span>, <span class="hlFld-ContribAuthor ">Shaohua  Gou</span>. </span><span class="cited-content_cbyCitation_article-title">Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a “joint action” mode toward DNA. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>137 </em>, 167-175. <a href="https://doi.org/10.1016/j.ejmech.2017.05.056" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.056%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DConjugation%252Bof%252Bplatinum%252528IV%252529%252Bcomplexes%252Bwith%252Bchlorambucil%252Bto%252Bovercome%252Bcisplatin%252Bresistance%252Bvia%252Ba%252B%2525E2%252580%25259Cjoint%252Baction%2525E2%252580%25259D%252Bmode%252Btoward%252BDNA%26aulast%3DQin%26aufirst%3DXiaodong%26date%3D2017%26volume%3D137%26spage%3D167%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhua  Chen</span>, <span class="hlFld-ContribAuthor ">Ne  Guo</span>, <span class="hlFld-ContribAuthor ">Minghui  Qi</span>, <span class="hlFld-ContribAuthor ">Haiying  Dai</span>, <span class="hlFld-ContribAuthor ">Minghuang  Hong</span>, <span class="hlFld-ContribAuthor ">Longfei  Guan</span>, <span class="hlFld-ContribAuthor ">Xiajuan  Huan</span>, <span class="hlFld-ContribAuthor ">Shanshan  Song</span>, <span class="hlFld-ContribAuthor ">Jinxue  He</span>, <span class="hlFld-ContribAuthor ">Yingqing  Wang</span>, <span class="hlFld-ContribAuthor ">Yong  Xi</span>, <span class="hlFld-ContribAuthor ">Xinying  Yang</span>, <span class="hlFld-ContribAuthor ">Yanyan  Shen</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Yiming  Sun</span>, <span class="hlFld-ContribAuthor ">Yinglei  Gao</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Yun  Tang</span>, <span class="hlFld-ContribAuthor ">Guobin  Ren</span>, <span class="hlFld-ContribAuthor ">Zehong  Miao</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>138 </em>, 514-531. <a href="https://doi.org/10.1016/j.ejmech.2017.06.053" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.06.053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.06.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.06.053%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252Bmechanism%252Band%252Bmetabolism%252Bstudies%252Bof%252B2%25252C3-difluorophenyl-linker-containing%252BPARP1%252Binhibitors%252Bwith%252Benhanced%252Bin%2525C2%2525A0vivo%252Befficacy%252Bfor%252Bcancer%252Btherapy%26aulast%3DChen%26aufirst%3DWenhua%26date%3D2017%26volume%3D138%26spage%3D514%26epage%3D531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Shaopeng  Chen</span>, <span class="hlFld-ContribAuthor ">Changjun  Chen</span>, <span class="hlFld-ContribAuthor ">Jiwei  Chen</span>, <span class="hlFld-ContribAuthor ">Chengken  Chen</span>, <span class="hlFld-ContribAuthor ">Qiuzi  Dai</span>, <span class="hlFld-ContribAuthor ">Chunmei  Gao</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>138 </em>, 1135-1146. <a href="https://doi.org/10.1016/j.ejmech.2017.07.050" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.07.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.07.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.07.050%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B4-amidobenzimidazole%252Bacridine%252Bderivatives%252Bas%252Bdual%252BPARP%252Band%252BTopo%252Binhibitors%252Bfor%252Bcancer%252Btherapy%26aulast%3DYuan%26aufirst%3DZigao%26date%3D2017%26volume%3D138%26spage%3D1135%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Shaopeng  Chen</span>, <span class="hlFld-ContribAuthor ">Qinsheng  Sun</span>, <span class="hlFld-ContribAuthor ">Ning  Wang</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Shuangshuang  Miao</span>, <span class="hlFld-ContribAuthor ">Chunmei  Gao</span>, <span class="hlFld-ContribAuthor ">Yuzong  Chen</span>, <span class="hlFld-ContribAuthor ">Chunyan  Tan</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (15)
                                     , 4100-4109. <a href="https://doi.org/10.1016/j.bmc.2017.05.058" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.05.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.05.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.05.058%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOlaparib%252Bhydroxamic%252Bacid%252Bderivatives%252Bas%252Bdual%252BPARP%252Band%252BHDAC%252Binhibitors%252Bfor%252Bcancer%252Btherapy%26aulast%3DYuan%26aufirst%3DZigao%26date%3D2017%26volume%3D25%26issue%3D15%26spage%3D4100%26epage%3D4109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yajun  Zheng</span>, <span class="hlFld-ContribAuthor ">Colin M.  Tice</span>, <span class="hlFld-ContribAuthor ">Suresh B.  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Conformational control in structure-based drug design. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (13)
                                     , 2825-2837. <a href="https://doi.org/10.1016/j.bmcl.2017.04.079" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.04.079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.04.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.04.079%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DConformational%252Bcontrol%252Bin%252Bstructure-based%252Bdrug%252Bdesign%26aulast%3DZheng%26aufirst%3DYajun%26date%3D2017%26volume%3D27%26issue%3D13%26spage%3D2825%26epage%3D2837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhong-min  Yang</span>, <span class="hlFld-ContribAuthor ">Xue-mei  Liao</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Yan-yan  Shen</span>, <span class="hlFld-ContribAuthor ">Xin-ying  Yang</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Yi-ming  Sun</span>, <span class="hlFld-ContribAuthor ">Ying-lei  Gao</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin-xue  He</span>, <span class="hlFld-ContribAuthor ">Ze-hong  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2017,</strong> <em>38 </em>
                                    (7)
                                     , 1038-1047. <a href="https://doi.org/10.1038/aps.2017.8" title="DOI URL">https://doi.org/10.1038/aps.2017.8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/aps.2017.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Faps.2017.8%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DCombining%252B53BP1%252Bwith%252BBRCA1%252Bas%252Ba%252Bbiomarker%252Bto%252Bpredict%252Bthe%252Bsensitivity%252Bof%252Bpoly%252528ADP-ribose%252529%252Bpolymerase%252B%252528PARP%252529%252Binhibitors%26aulast%3DYang%26aufirst%3DZhong-min%26date%3D2017%26date%3D2017%26volume%3D38%26issue%3D7%26spage%3D1038%26epage%3D1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kalen J.  Rimar</span>, <span class="hlFld-ContribAuthor ">Phuoc T.  Tran</span>, <span class="hlFld-ContribAuthor ">Richard S.  Matulewicz</span>, <span class="hlFld-ContribAuthor ">Maha  Hussain</span>, <span class="hlFld-ContribAuthor ">Joshua J.  Meeks</span>. </span><span class="cited-content_cbyCitation_article-title">The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. </span><span class="cited-content_cbyCitation_journal-name">Cancer</span><span> <strong>2017,</strong> <em>123 </em>
                                    (11)
                                     , 1912-1924. <a href="https://doi.org/10.1002/cncr.30631" title="DOI URL">https://doi.org/10.1002/cncr.30631</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cncr.30631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcncr.30631%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%26atitle%3DThe%252Bemerging%252Brole%252Bof%252Bhomologous%252Brecombination%252Brepair%252Band%252BPARP%252Binhibitors%252Bin%252Bgenitourinary%252Bmalignancies%26aulast%3DRimar%26aufirst%3DKalen%2BJ.%26date%3D2017%26date%3D2017%26volume%3D123%26issue%3D11%26spage%3D1912%26epage%3D1924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ettore  Capoluongo</span>, <span class="hlFld-ContribAuthor ">Gillian  Ellison</span>, <span class="hlFld-ContribAuthor ">José Antonio  López-Guerrero</span>, <span class="hlFld-ContribAuthor ">Frederique  Penault-Llorca</span>, <span class="hlFld-ContribAuthor ">Marjolijn J.L.  Ligtenberg</span>, <span class="hlFld-ContribAuthor ">Susana  Banerjee</span>, <span class="hlFld-ContribAuthor ">Christian  Singer</span>, <span class="hlFld-ContribAuthor ">Eitan  Friedman</span>, <span class="hlFld-ContribAuthor ">Birgid  Markiefka</span>, <span class="hlFld-ContribAuthor ">Peter  Schirmacher</span>, <span class="hlFld-ContribAuthor ">Reinhard  Büttner</span>, <span class="hlFld-ContribAuthor ">Christi J.  van Asperen</span>, <span class="hlFld-ContribAuthor ">Isabelle  Ray-Coquard</span>, <span class="hlFld-ContribAuthor ">Volker  Endris</span>, <span class="hlFld-ContribAuthor ">Suzanne  Kamel-Reid</span>, <span class="hlFld-ContribAuthor ">Natalie  Percival</span>, <span class="hlFld-ContribAuthor ">Jane  Bryce</span>, <span class="hlFld-ContribAuthor ">Benno  Röthlisberger</span>, <span class="hlFld-ContribAuthor ">Richie  Soong</span>, <span class="hlFld-ContribAuthor ">David Gonzalez  de Castro</span>. </span><span class="cited-content_cbyCitation_article-title">Guidance Statement On  BRCA1/2  Tumor Testing in Ovarian Cancer Patients. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Oncology</span><span> <strong>2017,</strong> <em>44 </em>
                                    (3)
                                     , 187-197. <a href="https://doi.org/10.1053/j.seminoncol.2017.08.004" title="DOI URL">https://doi.org/10.1053/j.seminoncol.2017.08.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1053/j.seminoncol.2017.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1053%2Fj.seminoncol.2017.08.004%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Oncology%26atitle%3DGuidance%252BStatement%252BOn%252BBRCA1%25252F2%252BTumor%252BTesting%252Bin%252BOvarian%252BCancer%252BPatients%26aulast%3DCapoluongo%26aufirst%3DEttore%26date%3D2017%26volume%3D44%26issue%3D3%26spage%3D187%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Ming  Ji</span>, <span class="hlFld-ContribAuthor ">Zhixiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Ran  Cao</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Chen</span>, <span class="hlFld-ContribAuthor ">Bailing  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-substituted 1 H -benzo[ d ]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>132 </em>, 26-41. <a href="https://doi.org/10.1016/j.ejmech.2017.03.013" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.03.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.03.013%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-substituted%252B1%252BH%252B-benzo%25255B%252Bd%252B%25255Dimmidazole-4-carboxamide%252Bderivatives%252Bas%252Bnovel%252Bpoly%252528ADP-ribose%252529polymerase-1%252Binhibitors%252Bwith%252Bin%2525C2%2525A0vivo%252Banti-tumor%252Bactivity%26aulast%3DZhou%26aufirst%3DJie%26date%3D2017%26volume%3D132%26spage%3D26%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sreekanth A.  Ramachandran</span>, <span class="hlFld-ContribAuthor ">Pradeep S.  Jadhavar</span>, <span class="hlFld-ContribAuthor ">Manvendra P.  Singh</span>, <span class="hlFld-ContribAuthor ">Ankesh  Sharma</span>, <span class="hlFld-ContribAuthor ">Gaurav N.  Bagle</span>, <span class="hlFld-ContribAuthor ">Kevin P.  Quinn</span>, <span class="hlFld-ContribAuthor ">Po-yin  Wong</span>, <span class="hlFld-ContribAuthor ">Andrew A.  Protter</span>, <span class="hlFld-ContribAuthor ">Roopa  Rai</span>, <span class="hlFld-ContribAuthor ">Son M.  Pham</span>, <span class="hlFld-ContribAuthor ">Jeffrey N.  Lindquist</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (4)
                                     , 750-754. <a href="https://doi.org/10.1016/j.bmcl.2017.01.045" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.01.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.01.045%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bpyrazolopyrimidine%252Bderivatives%252Bas%252Bnovel%252Binhibitors%252Bof%252Bataxia%252Btelangiectasia%252Band%252Brad3%252Brelated%252Bprotein%252B%252528ATR%252529%26aulast%3DRamachandran%26aufirst%3DSreekanth%2BA.%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D750%26epage%3D754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Yuan</span>, <span class="hlFld-ContribAuthor ">Na  Ye</span>, <span class="hlFld-ContribAuthor ">Shan-Shan  Song</span>, <span class="hlFld-ContribAuthor ">Yu-Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Hua-Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Chuan-Huizi  Chen</span>, <span class="hlFld-ContribAuthor ">Xia-Juan  Huan</span>, <span class="hlFld-ContribAuthor ">Ying-Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Yan-Yan  Shen</span>, <span class="hlFld-ContribAuthor ">Yi-Ming  Sun</span>, <span class="hlFld-ContribAuthor ">Xin-Ying  Yang</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Shi-Yan  Guo</span>, <span class="hlFld-ContribAuthor ">Yong  Gan</span>, <span class="hlFld-ContribAuthor ">Zhi-Wei  Gao</span>, <span class="hlFld-ContribAuthor ">Xiao-Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Jin-Xue  He</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>, <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2017,</strong> <em>386 </em>, 47-56. <a href="https://doi.org/10.1016/j.canlet.2016.11.010" title="DOI URL">https://doi.org/10.1016/j.canlet.2016.11.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2016.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2016.11.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DPoly%252528ADP-ribose%252529polymerase%252B%252528PARP%252529%252Binhibition%252Band%252Banticancer%252Bactivity%252Bof%252Bsimmiparib%25252C%252Ba%252Bnew%252Binhibitor%252Bundergoing%252Bclinical%252Btrials%26aulast%3DYuan%26aufirst%3DBo%26date%3D2017%26volume%3D386%26spage%3D47%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Subhash C.  Lakhotia</span>. </span><span class="cited-content_cbyCitation_article-title">From Heterochromatin to Long Noncoding RNAs in Drosophila: Expanding the Arena of Gene Function and Regulation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 75-118. <a href="https://doi.org/10.1007/978-981-10-5203-3_3" title="DOI URL">https://doi.org/10.1007/978-981-10-5203-3_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-10-5203-3_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-10-5203-3_3%26sid%3Dliteratum%253Aachs%26atitle%3DFrom%252BHeterochromatin%252Bto%252BLong%252BNoncoding%252BRNAs%252Bin%252BDrosophila%25253A%252BExpanding%252Bthe%252BArena%252Bof%252BGene%252BFunction%252Band%252BRegulation%26aulast%3DLakhotia%26aufirst%3DSubhash%2BC.%26date%3D2017%26date%3D2017%26spage%3D75%26epage%3D118%26pub%3DSpringer%2520Singapore%26atitle%3DLong%252BNon%252BCoding%252BRNA%252BBiology%26aulast%3DRao%26aufirst%3DM.R.S.%26date%3D2017%26volume%3D1008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Clare M.  Crean</span>, <span class="hlFld-ContribAuthor ">Ken I.  Mills</span>, <span class="hlFld-ContribAuthor ">Kienan I.  Savage</span>. </span><span class="cited-content_cbyCitation_article-title">The Potential of Targeting DNA Repair Deficiency in Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cancer Therapy</span><span> <strong>2017,</strong> <em>08 </em>
                                    (08)
                                     , 691-698. <a href="https://doi.org/10.4236/jct.2017.88060" title="DOI URL">https://doi.org/10.4236/jct.2017.88060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4236/jct.2017.88060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4236%2Fjct.2017.88060%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cancer%2520Therapy%26atitle%3DThe%252BPotential%252Bof%252BTargeting%252BDNA%252BRepair%252BDeficiency%252Bin%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DCrean%26aufirst%3DClare%2BM.%26date%3D2017%26volume%3D08%26issue%3D08%26spage%3D691%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.T.  Baines</span>, <span class="hlFld-ContribAuthor ">P.M.  Martin</span>, <span class="hlFld-ContribAuthor ">C.J.  Rorie</span>. </span><span class="cited-content_cbyCitation_article-title">Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 277-320. <a href="https://doi.org/10.1016/bs.pmbts.2016.09.006" title="DOI URL">https://doi.org/10.1016/bs.pmbts.2016.09.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.pmbts.2016.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.pmbts.2016.09.006%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252Band%252BEmerging%252BTargeting%252BStrategies%252Bfor%252BTreatment%252Bof%252BPancreatic%252BCancer%26aulast%3DBaines%26aufirst%3DA.T.%26date%3D2016%26spage%3D277%26epage%3D320%26pub%3DElsevier%26atitle%3DMolecular%252Band%252BCellular%252BChanges%252Bin%252Bthe%252BCancer%252BCell%26date%3D2016%26volume%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of some PARP-1 inhibitors that are currently being or have been (gray structures) evaluated clinically for cancer therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Simplified schematic representation of the repair pathways for SSBs and DSBs and the forms of synthetic lethality caused by PARP-1 inhibitors. The cyan rectangles represent different repair pathways. In the text, red represents the target (PARP-1) or the most important HRR defects (BRCA1/2); blue, green, orange, and purple represent the potential biomarkers, i.e., HRR factors and their downstream-regulated factors, factors that regulate HRR factors, the target PARP-1 and its related factors, and other molecules, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of <b>14</b> and <b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding modes of PARP-1 inhibitors in nicotinamide binding sites. (A) NAD<sup>+</sup> binding domain and subdomains of PARP-1/2 proteins. (B) Binding mode of PARP-1 inhibitors bearing a lactam bicyclic pharmacophore or a pseudobicyclic pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. New PARP-1 inhibitors bearing a phthalazinone scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PARP-1 inhibitors bearing the pyrrolo[1,2-<i>a</i>]pyrazinone or dimethylpyridazin-3-one scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PARP-1 inhibitors by modification of the phthalazinone scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. PARP-1 inhibitors by modification of the tetracyclic isoquinolones scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Discovery of the highly potent clinical PARP-1 inhibitor <b>6</b> and its cocrystal structure with the catalytic domain of PARP-1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PJT">4PJT</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. PARP-1 inhibitors bearing a dihydroquinolin-2(1<i>H</i>)-one core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. PARP-1 inhibitors bearing a tetrahydroisoquinolin-1-one core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. PARP-1 inhibitors bearing a quinazolinone or quinazolinedione core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. PARP-1 inhibitors bearing a pseudobicyclic lactam core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Selective PARP-1 or PARP-2 inhibitors bearing a quinazolinone or isoquinolinone core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/medium/jm-2016-000559_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Selective PARP-1 inhibitors bearing anisoindolinone core and cocrystal structure of <b>60</b> with PARP-1 (left) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A00">5A00</a>) and PARP-2 (right) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZY">4ZZY</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00055/20161104/images/large/jm-2016-000559_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00055&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 178 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Ferraris, D. V.</span><span> </span><span class="NLM_article-title">Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4561</span><span class="NLM_x">–</span> <span class="NLM_lpage">4584</span><span class="refDoi"> DOI: 10.1021/jm100012m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100012m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4561-4584&author=D.+V.+Ferraris&title=Evolution+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29+inhibitors.+From+concept+to+clinic&doi=10.1021%2Fjm100012m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic</span></div><div class="casAuthors">Ferraris, Dana V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4561-4584</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1) has been an actively pursued drug discovery target for almost 3 decades.  Often referred to as the "guardian angel of DNA", this abundant nuclear enzyme has been the focus of over 20 medicinal chem. programs in a wide range of therapeutic areas encompassing stroke, cardiac ischemia, cancer, inflammation, and diabetes.  Despite the great therapeutic potential for this target and the tremendous academic and industrial efforts dedicated to it, only recently have PARP-1 inhibitors made headway in clin. trials.  Recent results from several PARP-1 inhibitors in phase II clin. trials for cancer therapy have attracted the attention of national media.  Of the several potential therapeutic indications for PARP-1 inhibitors, the two major areas that hold the most promise are ischemia and cancer.  This review is structured to provide the readers with a brief summary of the rationale for PARP-1 as a therapeutic target, to explain the PARP-1 inhibitor pharmacophore, and to provide an update on the progress of the PARP-1 drug discovery programs.  This Perspective will offer a historical account of the crit. PARP-1 publications that instilled the interest of the biopharmaceutical industry in the late 1980s and early 1990s.  Furthermore, I will discuss why PARP- 1 received so much attention in the late 1990s and early 2000s followed by the slight decline in the medicinal chem. efforts today.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPhFTTs4raarVg90H21EOLACvtfcHk0ljAybKzFFnhKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D&md5=6c093238562c908d45dfcd2f3055457d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm100012m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100012m%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26atitle%3DEvolution%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%2520inhibitors.%2520From%2520concept%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4561%26epage%3D4584%26doi%3D10.1021%2Fjm100012m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M. Y.</span><span> </span><span class="NLM_article-title">Emerging cancer therapeutic opportunities target DNA-repair systems</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">338</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span><span class="refDoi"> DOI: 10.1016/j.tips.2006.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.tips.2006.04.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=338-344&author=J.+Dingauthor=Z.+H.+Miaoauthor=L.+H.+Mengauthor=M.+Y.+Geng&title=Emerging+cancer+therapeutic+opportunities+target+DNA-repair+systems&doi=10.1016%2Fj.tips.2006.04.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2006.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2006.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26aulast%3DMeng%26aufirst%3DL.%2BH.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26atitle%3DEmerging%2520cancer%2520therapeutic%2520opportunities%2520target%2520DNA-repair%2520systems%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D338%26epage%3D344%26doi%3D10.1016%2Fj.tips.2006.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">He, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z. H.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1172</span><span class="NLM_x">–</span> <span class="NLM_lpage">1180</span><span class="refDoi"> DOI: 10.1038/aps.2010.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Faps.2010.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20676117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSntr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=1172-1180&author=J.+X.+Heauthor=C.+H.+Yangauthor=Z.+H.+Miao&title=Poly%28ADP-ribose%29+polymerase+inhibitors+as+promising+cancer+therapeutics&doi=10.1038%2Faps.2010.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics</span></div><div class="casAuthors">He, Jin-xue; Yang, Chun-hao; Miao, Ze-hong</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1172-1180</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The year of 2005 was a watershed in the history of poly(ADP-ribose) polymerase (PARP) inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition.  The findings made PARP inhibition one of the most promising new therapeutic approaches to cancers, esp. to those with specific defects.  With AZD2281 and BSI-201 entering phase III clin. trials, the final application of PARP inhibitors in clinic would come true soon.  This current paper will review the major advances in targeting PARP for cancer therapy and discuss the existing questions, the answers to which may influence the future of PARP inhibitors as cancer therapeutics.  Acta Pharmacologica Sinica (2010) 31: 1172-1180; doi: 10.1038/aps.2010.103; published online 2 Aug 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzohhmJ-aZLVg90H21EOLACvtfcHk0lilaQzvEMTaCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSntr3P&md5=618e92fd637cf51f1979928527df9ae7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Faps.2010.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2010.103%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%2BX.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%2520as%2520promising%2520cancer%2520therapeutics%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2010%26volume%3D31%26spage%3D1172%26epage%3D1180%26doi%3D10.1038%2Faps.2010.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Vyas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, P.</span><span> </span><span class="NLM_article-title">New PARP targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span><span class="refDoi"> DOI: 10.1038/nrc3748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnrc3748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24898058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlKqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=502-509&author=S.+Vyasauthor=P.+Chang&title=New+PARP+targets+for+cancer+therapy&doi=10.1038%2Fnrc3748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">New PARP targets for cancer therapy</span></div><div class="casAuthors">Vyas, Sejal; Chang, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-509</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARPs) modify target proteins post-translationally with poly(ADP-ribose) (PAR) or mono(ADP-ribose) (MAR) using NAD+ as substrate.  The best-studied PARPs generate PAR modifications and include PARP1 and the tankyrase PARP5A, both of which are targets for cancer therapy with inhibitors in either clin. trials or preclin. development.  There are 15 addnl. PARPs, most of which modify proteins with MAR, and their biol. is less well understood.  Recent data identify potentially cancer-relevant functions for these PARPs, which indicates that we need to understand more about these PARPs to effectively target them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouf6CtI5GhsrVg90H21EOLACvtfcHk0ljCz9n4WwPCuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlKqsb0%253D&md5=24a3b64d2d0518e13c9540ee012e29ca</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc3748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3748%26sid%3Dliteratum%253Aachs%26aulast%3DVyas%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DP.%26atitle%3DNew%2520PARP%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D502%26epage%3D509%26doi%3D10.1038%2Fnrc3748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Morales, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattah, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bey, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boothman, D. A.</span><span> </span><span class="NLM_article-title">Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases</span> <span class="citation_source-journal">Crit. Rev. Eukaryotic Gene Expression</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.1615/CritRevEukaryotGeneExpr.2013006875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1615%2FCritRevEukaryotGeneExpr.2013006875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24579667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2cvpsVSrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=15-28&author=J.+Moralesauthor=L.+Liauthor=F.+J.+Fattahauthor=Y.+Dongauthor=E.+A.+Beyauthor=M.+Patelauthor=J.+Gaoauthor=D.+A.+Boothman&title=Review+of+poly+%28ADP-ribose%29+polymerase+%28PARP%29+mechanisms+of+action+and+rationale+for+targeting+in+cancer+and+other+diseases&doi=10.1615%2FCritRevEukaryotGeneExpr.2013006875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases</span></div><div class="casAuthors">Morales Julio; Li Longshan; Fattah Farjana J; Dong Ying; Patel Malina; Gao Jinming; Boothman David A; Bey Erik A</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in eukaryotic gene expression</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-28</span>
        ISSN:<span class="NLM_cas:issn">1045-4403</span>.
    </div><div class="casAbstract">Poly (ADP-ribose) polymerases (PARPs) are a family of related enzymes that share the ability to catalyze the transfer of ADP-ribose to target proteins.  PARPs play an important role in various cellular processes, including modulation of chromatin structure, transcription, replication, recombination, and DNA repair.  The role of PARP proteins in DNA repair is of particular interest, in view of the finding that certain tumors defective in homologous recombination mechanisms, may rely on PARP-mediated DNA repair for survival, and are sensitive to its inhibition.  PARP inhibitors may also increase tumor sensitivity to DNA-damaging agents.  Clinical trials of PARP inhibitors are investigating the utility of these approaches in cancer.  The hyperactivation of PARP has also been shown to result in a specific programmed cell death pathway involving NAD+/ATP depletion, mu-calpain activation, loss of mitochondrial membrane potential, and the release of apoptosis inducing factor.  Hyperactivation of the PARP pathway may be exploited to selectively kill cancer cells.  Other PARP forms, including tankyrase 1 (PARP 5a), which plays an important role in enhancing telomere elongation by telomerase, have been found to be potential targets in cancer therapy.  The PARP pathway and its inhibition thus offers a number of opportunities for therapeutic intervention in both cancer and other disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQO6ujQ1G1GLwaK-_ZudimnfW6udTcc2eaQDZH-V56f0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvpsVSrsw%253D%253D&md5=3590812f36c4075309ad19923d2e2852</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1615%2FCritRevEukaryotGeneExpr.2013006875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevEukaryotGeneExpr.2013006875%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DFattah%26aufirst%3DF.%2BJ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DBey%26aufirst%3DE.%2BA.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DBoothman%26aufirst%3DD.%2BA.%26atitle%3DReview%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520mechanisms%2520of%2520action%2520and%2520rationale%2520for%2520targeting%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DCrit.%2520Rev.%2520Eukaryotic%2520Gene%2520Expression%26date%3D2014%26volume%3D24%26spage%3D15%26epage%3D28%26doi%3D10.1615%2FCritRevEukaryotGeneExpr.2013006875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Benafif, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M.</span><span> </span><span class="NLM_article-title">An update on PARP inhibitors for the treatment of cancer</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.2147/OTT.S30793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.2147%2FOTT.S30793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25750544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1WntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=519-528&author=S.+Benafifauthor=M.+Hall&title=An+update+on+PARP+inhibitors+for+the+treatment+of+cancer&doi=10.2147%2FOTT.S30793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">An update on PARP inhibitors for the treatment of cancer</span></div><div class="casAuthors">Benafif, Sarah; Hall, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519-528</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The development of poly (ADP [ADP]) ribose polymerase (PARP) inhibitors (PARPi) has progressed greatly over the last few years and has shown encouraging results in the BRCA1/2 mutation-related cancers.  This article attempts to summarize the rationale and theory behind PARPi, the clin. trials already reported, as well as ongoing studies designed to det. the role of PARPi in patients with and without germline mutations of BRCA genes.  Future plans for PARPi both as monotherapy and in combination with std. cytotoxics, other biol. agents, and as radiosensitizers are also covered.  The widening scope of PARPi adds another important targeted agent to the growing list of mol. inhibitors; future and ongoing trials will identify the most effective role for PARPi, including for patients other than BRCA germline mutation carriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG5uVLd7Fi37Vg90H21EOLACvtfcHk0ljCz9n4WwPCuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1WntLg%253D&md5=3256f24adfac3e4f006314db8fd3ab48</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2147%2FOTT.S30793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S30793%26sid%3Dliteratum%253Aachs%26aulast%3DBenafif%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DM.%26atitle%3DAn%2520update%2520on%2520PARP%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2015%26volume%3D8%26spage%3D519%26epage%3D528%26doi%3D10.2147%2FOTT.S30793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">O’Shaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippen, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocha, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C.</span><span> </span><span class="NLM_article-title">Iniparib plus chemotherapy in metastatic triple-negative breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span><span class="refDoi"> DOI: 10.1056/NEJMoa1011418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1056%2FNEJMoa1011418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21208101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=205-214&author=J.+O%E2%80%99Shaughnessyauthor=C.+Osborneauthor=J.+E.+Pippenauthor=M.+Yoffeauthor=D.+Pattauthor=C.+Rochaauthor=I.+C.+Kooauthor=B.+M.+Shermanauthor=C.+Bradley&title=Iniparib+plus+chemotherapy+in+metastatic+triple-negative+breast+cancer&doi=10.1056%2FNEJMoa1011418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Iniparib plus chemotherapy in metastatic triple-negative breast cancer</span></div><div class="casAuthors">O'Shaughnessy, Joyce; Osborne, Cynthia; Pippen, John E.; Yoffe, Mark; Patt, Debra; Rocha, Christine; Koo, Ingrid Chou; Sherman, Barry M.; Bradley, Charles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-214</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(ADP-ribose) polymerase (PARP) inhibition.  We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small mol. with PARP-inhibitory activity, in patients with metastatic triple-neg. breast cancer.  A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equiv. to an area under the concn.-time curve of 2) on days 1 and 8 - with or without iniparib (at a dose of 5.6 mg per kg of body wt.) on days 1, 4, 8, and 11 - every 21 days.  Primary end points were the rate of clin. benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 mo) and safety.  Addnl. end points included the rate of objective response, progression-free survival, and overall survival.  The addn. of iniparib to gemcitabine and carboplatin improved the rate of clin. benefit from 34 to 56% and the rate of overall response from 32 to 52%.  The addn. of iniparib also prolonged the median progression-free survival from 3.6 mo to 5.9 mo (hazard ratio for progression, 0.59) and the median overall survival from 7.7 mo to 12.3 mo (hazard ratio for death, 0.57).  The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level.  No significant difference was seen between the 2 groups in the rate of adverse events.  The addn. of iniparib to chemotherapy improved the clin. benefit and survival of patients with metastatic triple-neg. breast cancer without, significantly increased toxic effects.  On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7tn6oRjsja7Vg90H21EOLACvtfcHk0lh69uutqnYZcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGis7c%253D&md5=d50866c03ab6a61f780f14e13fdbae28</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1011418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1011418%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DPippen%26aufirst%3DJ.%2BE.%26aulast%3DYoffe%26aufirst%3DM.%26aulast%3DPatt%26aufirst%3DD.%26aulast%3DRocha%26aufirst%3DC.%26aulast%3DKoo%26aufirst%3DI.%2BC.%26aulast%3DSherman%26aufirst%3DB.%2BM.%26aulast%3DBradley%26aufirst%3DC.%26atitle%3DIniparib%2520plus%2520chemotherapy%2520in%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D205%26epage%3D214%26doi%3D10.1056%2FNEJMoa1011418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span> </span><span class="NLM_article-title">4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4- fluorobenzyl]-2 H-phthalazin- 1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">–</span> <span class="NLM_lpage">6591</span><span class="refDoi"> DOI: 10.1021/jm8001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.+L.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+M.+Smithauthor=N.+M.+Martin&title=4-%5B3-%284-cyclopropanecarbonylpiperazine-1-carbonyl%29-4-+fluorobenzyl%5D-2+H-phthalazin-+1-one%3A+a+novel+bioavailable+inhibitor+of+poly+%28ADP-ribose%29+polymerase-1&doi=10.1021%2Fjm8001263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26atitle%3D4-%255B3-%25284-cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-%2520fluorobenzyl%255D-2%2520H-phthalazin-%25201-one%253A%2520a%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591%26doi%3D10.1021%2Fjm8001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">O’Shaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartzberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danso, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellerstedt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specht, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yardley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charpentier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Ribas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span> </span><span class="NLM_article-title">Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">3840</span><span class="NLM_x">–</span> <span class="NLM_lpage">3847</span><span class="refDoi"> DOI: 10.1200/JCO.2014.55.2984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2014.55.2984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25349301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslCnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=3840-3847&author=J.+O%E2%80%99Shaughnessyauthor=L.+Schwartzbergauthor=M.+A.+Dansoauthor=K.+D.+Millerauthor=H.+S.+Rugoauthor=M.+Neubauerauthor=N.+Robertauthor=B.+Hellerstedtauthor=M.+Salehauthor=P.+Richardsauthor=J.+M.+Spechtauthor=D.+A.+Yardleyauthor=R.+W.+Carlsonauthor=R.+S.+Finnauthor=E.+Charpentierauthor=I.+Garcia-Ribasauthor=E.+P.+Winer&title=Phase+III+study+of+iniparib+plus+gemcitabine+and+carboplatin+versus+gemcitabine+and+carboplatin+in+patients+with+metastatic+triple-negative+breast+cancer&doi=10.1200%2FJCO.2014.55.2984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer</span></div><div class="casAuthors">O'Shaughnessy, Joyce; Schwartzberg, Lee; Danso, Michael A.; Miller, Kathy D.; Rugo, Hope S.; Neubauer, Marcus; Robert, Nicholas; Hellerstedt, Beth; Saleh, Mansoor; Richards, Paul; Specht, Jennifer M.; Yardley, Denise A.; Carlson, Robert W.; Finn, Richard S.; Charpentier, Eric; Garcia-Ribas, Ignacio; Winer, Eric P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3840-3847</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: There is a lack of treatments providing survival benefit for patients with metastatic triple-neg. breast cancer (mTNBC), with no std. of care.  A randomized phase II trial showed significant benefit for gemcitabine, carboplatin, and iniparib (GCI) over gemcitabine and carboplatin (GC) in clin. benefit rate, response rate, progression-free survival (PFS), and overall survival (OS).  Here, we formally compare the efficacy of these regimens in a phase III trial.  Patients and Methods: Patients with stage IV/locally recurrent TNBC who had received no more than two previous chemotherapy regimens for mTNBC were randomly allocated to gemcitabine 1,000 mg/m2 and carboplatin area under the curve 2 (days 1 and 8) alone or GC plus iniparib 5.6 mg/kg (days 1, 4, 8, and 11) every 3 wk.  Random assignment was stratified by the no. of prior chemotherapies.  The coprimary end points were OS and PFS.  Patients receiving GC could cross over to iniparib on progression.  Results: Five hundred nineteen patients were randomly assigned (261 GCI; 258 GC).  In the primary anal., no statistically significant difference was obsd. for OS (hazard ratio [HR] = 0.88; 95% CI, 0.69 to 1.12; P = .28) nor PFS (HR = 0.79; 95% CI, 0.65 to 0.98; P = .027).  An exploratory anal. showed that patients in the second-/third-line had improved OS (HR = 0.65; 95% CI, 0.46 to 0.91) and PFS (HR = 0.68; 95% CI, 0.50 to 0.92) with GCI.  The safety profile for GCI was similar to GC.  Conclusion: The trial did not meet the prespecified criteria for the coprimary end points of PFS and OS in the ITT population.  The potential benefit with iniparib obsd. in second-/third-line subgroup warrants further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAG23pXvdehrVg90H21EOLACvtfcHk0lhk7Ab_fCKd5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslCnsQ%253D%253D&md5=04c056c1d2e0d61729d3c9917c7ce08e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.55.2984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.55.2984%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DSchwartzberg%26aufirst%3DL.%26aulast%3DDanso%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DNeubauer%26aufirst%3DM.%26aulast%3DRobert%26aufirst%3DN.%26aulast%3DHellerstedt%26aufirst%3DB.%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DRichards%26aufirst%3DP.%26aulast%3DSpecht%26aufirst%3DJ.%2BM.%26aulast%3DYardley%26aufirst%3DD.%2BA.%26aulast%3DCarlson%26aufirst%3DR.%2BW.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DCharpentier%26aufirst%3DE.%26aulast%3DGarcia-Ribas%26aufirst%3DI.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26atitle%3DPhase%2520III%2520study%2520of%2520iniparib%2520plus%2520gemcitabine%2520and%2520carboplatin%2520versus%2520gemcitabine%2520and%2520carboplatin%2520in%2520patients%2520with%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D3840%26epage%3D3847%26doi%3D10.1200%2FJCO.2014.55.2984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Novello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlesi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazieres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcereny, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Ribas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scagliotti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2156</span><span class="NLM_x">–</span> <span class="NLM_lpage">2162</span><span class="refDoi"> DOI: 10.1093/annonc/mdu384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fannonc%2Fmdu384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25139550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FjtlaisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=2156-2162&author=S.+Novelloauthor=B.+Besseauthor=E.+Felipauthor=F.+Barlesiauthor=J.+Mazieresauthor=G.+Zalcmanauthor=J.+von+Pawelauthor=M.+Reckauthor=F.+Cappuzzoauthor=D.+Ferryauthor=E.+Carcerenyauthor=A.+Santoroauthor=I.+Garcia-Ribasauthor=G.+Scagliottiauthor=J.+C.+Soria&title=A+phase+II+randomized+study+evaluating+the+addition+of+iniparib+to+gemcitabine+plus+cisplatin+as+first-line+therapy+for+metastatic+non-small-cell+lung+cancer&doi=10.1093%2Fannonc%2Fmdu384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer</span></div><div class="casAuthors">Novello S; Scagliotti G; Besse B; Soria J-C; Felip E; Barlesi F; Mazieres J; Zalcman G; von Pawel J; Reck M; Cappuzzo F; Ferry D; Carcereny E; Santoro A; Garcia-Ribas I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2156-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Iniparib is a novel anticancer agent initially considered a poly (ADP-ribose) polymerase (PARP) inhibitor, but subsequently shown to act via non-selective protein modification through cysteine adducts.  This randomized phase II study investigated the addition of iniparib to gemcitabine-cisplatin in metastatic non-small-cell lung cancer (NSCLC) patients.  PATIENTS AND METHODS:  Patients with histologically confirmed stage IV NSCLC were randomized 2 : 1 to receive gemcitabine (1250 mg/m(2), days 1/8) and cisplatin (75 mg/m(2), day 1) with [gemcitabine/cisplatin/iniparib (GCI)] or without [gemcitabine/cisplatin (GC)] iniparib (5.6 mg/kg, days 1/4/8/11) every 3 weeks for six cycles.  The primary end point was the overall response rate (ORR).  Secondary objectives included progression-free survival (PFS), overall survival (OS), and safety.  The study was not designed for formal efficacy comparison, the control arm being to benchmark results against the literature.  RESULTS:  One hundred and nineteen patients were randomized (39 GC and 80 GCI).  More GCI patients were male (80% GCI and 67% GC) and had PS 0 (61% GCI and 49% GC).  The ORR was 25.6% [95% confidence interval (CI) 13.0%-42.1%] with GC versus 20.0% (95% CI 11.9%-30.4%) with GCI, which did not allow rejection of the null hypothesis (ORR with GCI ≤20%; P = 0.545).  Median PFS was 4.3 (95% CI 2.8-5.6) months with GC and 5.7 (95% CI 4.6-6.6) months with GCI (hazard ratio 0.89, 95% CI 0.56-1.40).  Median OS was 8.5 (95% CI 5.5 to not reached) months with GC, and 12.0 (95% CI 8.9-17.1) months with GCI (hazard ratio 0.78, 95% CI 0.48-1.27).  More GCI patients received second-line treatment (51% GC and 68% GCI).  Toxicity was similar in the two arms.  Grade 3-4 toxicities included asthenia (28% GC and 8% GCI), nausea (3% GC and 14% GCI), and decreased appetite (10% in each).  CONCLUSIONS:  Addition of iniparib to GC did not improve ORR over GC alone.  The GCI safety profile was comparable to GC alone.  Imbalances in PS and gender distribution may have impacted study results regarding PFS and OS.  TRIAL REGISTRATION:  ClinicalTrial.gov Identifier NCT01086254.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJ5_69URqBZmgRQsDqrjW_fW6udTcc2ebx8L5efhyxE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FjtlaisQ%253D%253D&md5=076aa5b16ee2dfb8ba124168a9c3c64d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu384%26sid%3Dliteratum%253Aachs%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DZalcman%26aufirst%3DG.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DFerry%26aufirst%3DD.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DGarcia-Ribas%26aufirst%3DI.%26aulast%3DScagliotti%26aufirst%3DG.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DA%2520phase%2520II%2520randomized%2520study%2520evaluating%2520the%2520addition%2520of%2520iniparib%2520to%2520gemcitabine%2520plus%2520cisplatin%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520non-small-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D2156%26epage%3D2162%26doi%3D10.1093%2Fannonc%2Fmdu384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Mendeleyev, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsten, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buki, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kun, E.</span><span> </span><span class="NLM_article-title">Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span><span class="refDoi"> DOI: 10.1016/0006-2952(95)00189-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2F0006-2952%2895%2900189-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1995&pages=705-714&author=J.+Mendeleyevauthor=E.+Kirstenauthor=A.+Hakamauthor=K.+G.+Bukiauthor=E.+Kun&title=Potential+chemotherapeutic+activity+of+4-iodo-3-nitrobenzamide.+Metabolic+reduction+to+the+3-nitroso+derivative+and+induction+of+cell+death+in+tumor+cells+in+culture&doi=10.1016%2F0006-2952%2895%2900189-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2895%2900189-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252895%252900189-7%26sid%3Dliteratum%253Aachs%26aulast%3DMendeleyev%26aufirst%3DJ.%26aulast%3DKirsten%26aufirst%3DE.%26aulast%3DHakam%26aufirst%3DA.%26aulast%3DBuki%26aufirst%3DK.%2BG.%26aulast%3DKun%26aufirst%3DE.%26atitle%3DPotential%2520chemotherapeutic%2520activity%2520of%25204-iodo-3-nitrobenzamide.%2520Metabolic%2520reduction%2520to%2520the%25203-nitroso%2520derivative%2520and%2520induction%2520of%2520cell%2520death%2520in%2520tumor%2520cells%2520in%2520culture%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D50%26spage%3D705%26epage%3D714%26doi%3D10.1016%2F0006-2952%2895%2900189-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Patel, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lorenzo, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatten, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1662</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-11-2890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22291137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVynu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1655-1662&author=A.+G.+Patelauthor=S.+B.+De+Lorenzoauthor=K.+S.+Flattenauthor=G.+G.+Poirierauthor=S.+H.+Kaufmann&title=Failure+of+iniparib+to+inhibit+poly%28ADP-Ribose%29+polymerase+in+vitro&doi=10.1158%2F1078-0432.CCR-11-2890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro</span></div><div class="casAuthors">Patel, Anand G.; De Lorenzo, Silvana B.; Flatten, Karen S.; Poirier, Guy G.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1655-1662</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Poly(ADP-ribose) polymerase (PARP) inhibitors are undergoing extensive clin. testing for their single-agent activity in homologous recombination (HR)-deficient tumors and ability to enhance the action of certain DNA-damaging agents.  Compared with other PARP inhibitors in development, iniparib (4-iodo-3-nitrobenzamide) is notable for its simple structure and the reported ability of its intracellular metabolite 4-iodo-3-nitrosobenzamide to covalently inhibit PARP1 under cell-free conditions.  The present preclin. studies were conducted to compare the actions iniparib with the more extensively characterized PARP inhibitors olaparib and veliparib.  Exptl. Design: The abilities of iniparib, olaparib, and veliparib to (i) selectively induce apoptosis or inhibit colony formation in HR-deficient cell lines, (ii) selectively sensitize HR-proficient cells to topoisomerase I poisons, and (iii) inhibit formation of poly(ADP-ribose) polymer (pADPr) in intact cells were compared.  RESULTS: Consistent with earlier reports, olaparib and veliparib selectively induced apoptosis and inhibited colony formation in cells lacking BRCA2 or ATM.  Moreover, like earlier generation PARP inhibitors, olaparib and veliparib sensitized cells to the topoisomerase I poisons camptothecin and topotecan.  Finally, olaparib and veliparib inhibited formation of pADPr in intact cells.  In contrast, iniparib exhibited little or no ability to selectively kill HR-deficient cells, sensitize cells to topoisomerase I poisons, or inhibit pADPr formation in situ.  In further expts., iniparib also failed to sensitize cells to cisplatin, gemcitabine, or paclitaxel.  CONCLUSIONS: While iniparib kills normal and neoplastic cells at high (>40 μmol/L) concns., its effects are unlikely to reflect PARP inhibition and should not be used to guide decisions about other PARP inhibitors.  Clin Cancer Res; 18(6); 1655-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6PlliVCr5ErVg90H21EOLACvtfcHk0lgknVwvWaKPCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVynu7k%253D&md5=82cb650b8bb7114cfc6afdc68fc5c3d9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2890%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DA.%2BG.%26aulast%3DDe%2BLorenzo%26aufirst%3DS.%2BB.%26aulast%3DFlatten%26aufirst%3DK.%2BS.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DFailure%2520of%2520iniparib%2520to%2520inhibit%2520poly%2528ADP-Ribose%2529%2520polymerase%2520in%2520vitro%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1655%26epage%3D1662%26doi%3D10.1158%2F1078-0432.CCR-11-2890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira-Frommer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span> </span><span class="NLM_article-title">Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">1382</span><span class="NLM_x">–</span> <span class="NLM_lpage">1392</span><span class="refDoi"> DOI: 10.1056/NEJMoa1105535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1056%2FNEJMoa1105535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22452356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=1382-1392&author=J.+Ledermannauthor=P.+Harterauthor=C.+Gourleyauthor=M.+Friedlanderauthor=I.+Vergoteauthor=G.+Rustinauthor=C.+Scottauthor=W.+Meierauthor=R.+Shapira-Frommerauthor=T.+Safraauthor=D.+Mateiauthor=E.+Macphersonauthor=C.+Watkinsauthor=J.+Carmichaelauthor=U.+Matulonis&title=Olaparib+maintenance+therapy+in+platinum-sensitive+relapsed+ovarian+cancer&doi=10.1056%2FNEJMoa1105535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer</span></div><div class="casAuthors">Ledermann, Jonathan; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; MacPherson, Euan; Watkins, Claire; Carmichael, James; Matulonis, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1382-1392</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Olaparib (AZD2281) is an oral poly(ADP [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations.  METHODS We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen.  Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo.  The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines.  RESULTS Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group.  Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 mo vs. 4.8 mo from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001).  Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression.  Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2.  An interim anal. of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P = 0.75).  CONCLUSIONS Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer.  Interim anal. showed no overall survival benefit.  The toxicity profile of olaparib in this population was consistent with that in previous studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroGMJNLsHGObVg90H21EOLACvtfcHk0lgknVwvWaKPCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOrsLw%253D&md5=1612aa24cd17a29f03599a7c2acf5f0f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105535%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DHarter%26aufirst%3DP.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DScott%26aufirst%3DC.%26aulast%3DMeier%26aufirst%3DW.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DMatulonis%26aufirst%3DU.%26atitle%3DOlaparib%2520maintenance%2520therapy%2520in%2520platinum-sensitive%2520relapsed%2520ovarian%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D1382%26epage%3D1392%26doi%3D10.1056%2FNEJMoa1105535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira-Frommer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span> </span><span class="NLM_article-title">Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">861</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70228-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS1470-2045%2814%2970228-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24882434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWrsrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=852-861&author=J.+Ledermannauthor=P.+Harterauthor=C.+Gourleyauthor=M.+Friedlanderauthor=I.+Vergoteauthor=G.+Rustinauthor=C.+L.+Scottauthor=W.+Meierauthor=R.+Shapira-Frommerauthor=T.+Safraauthor=D.+Mateiauthor=A.+Fieldingauthor=S.+Spencerauthor=B.+Doughertyauthor=M.+Orrauthor=D.+Hodgsonauthor=J.+C.+Barrettauthor=U.+Matulonis&title=Olaparib+maintenance+therapy+in+patients+with+platinum-sensitive+relapsed+serous+ovarian+cancer%3A+a+preplanned+retrospective+analysis+of+outcomes+by+BRCA+status+in+a+randomised+phase+2+trial&doi=10.1016%2FS1470-2045%2814%2970228-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial</span></div><div class="casAuthors">Ledermann, Jonathan; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare L.; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; Fielding, Anitra; Spencer, Stuart; Dougherty, Brian; Orr, Maria; Hodgson, Darren; Barrett, J. Carl; Matulonis, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-861</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Maintenance monotherapy with the PARP inhibitor olaparib significantly prolonged progression-free survival (PFS) vs. placebo in patients with platinum-sensitive recurrent serous ovarian cancer.  We aimed to explore the hypothesis that olaparib is most likely to benefit patients with a BRCA mutation.We present data from the second interim anal. of overall survival and a retrospective, preplanned anal. of data by BRCA mutation status from our randomised, double-blind, phase 2 study that assessed maintenance treatment with olaparib 400 mg twice daily (capsules) vs. placebo in patients with platinum-sensitive recurrent serous ovarian cancer who had received two or more platinum-based regimens and who had a partial or complete response to their most recent platinum-based regimen.  Randomisation was by an interactive voice response system, stratified by time to progression on penultimate platinum-based regimen, response to the most recent platinum-based regimen before randomisation, and ethnic descent.  The primary endpoint was PFS, analyzed for the overall population and by BRCA status.  This study is registered with ClinicalTrials.gov, no. NCT00753545.Between Aug 28, 2008, and Feb 9, 2010, 136 patients were assigned to olaparib and 129 to placebo.  BRCA status was known for 131 (96%) patients in the olaparib group vs. 123 (95%) in the placebo group, of whom 74 (56%) vs. 62 (50%) had a deleterious or suspected deleterious germline or tumor BRCA mutation.  Of patients with a BRCA mutation, median PFS was significantly longer in the olaparib group than in the placebo group (11·2 mo [95% CI 8·3-not calculable] vs 4·3 mo [3·0-5·4]; HR 0·18 [0·10-0·31]; p<0·0001); similar findings were noted for patients with wild-type BRCA, although the difference between groups was lower (7·4 mo [5·5-10·3] vs 5·5 mo [3·7-5·6]; HR 0·54 [0·34-0·85]; p=0·0075).  At the second interim anal. of overall survival (58% maturity), overall survival did not significantly differ between the groups (HR 0·88 [95% CI 0·64-1·21]; p=0·44); similar findings were noted for patients with mutated BRCA (HR 0·73 [0·45-1·17]; p=0·19) and wild-type BRCA (HR 0·99 [0·63-1·55]; p=0·96).  The most common grade 3 or worse adverse events in the olaparib group were fatigue (in ten [7%] patients in the olaparib group vs four [3%] in the placebo group) and anemia (seven [5%] vs one [<1%]).  Serious adverse events were reported in 25 (18%) patients who received olaparib and 11 (9%) who received placebo.  Tolerability was similar in patients with mutated BRCA and the overall population.These results support the hypothesis that patients with platinum-sensitive recurrent serous ovarian cancer with a BRCA mutation have the greatest likelihood of benefiting from olaparib treatment.AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozZjZdcu1e4rVg90H21EOLACvtfcHk0lgiVyXJnmawIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWrsrrK&md5=bfc15e933746672148dd7237e3f67f01</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970228-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970228-1%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DHarter%26aufirst%3DP.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DScott%26aufirst%3DC.%2BL.%26aulast%3DMeier%26aufirst%3DW.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DFielding%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DOrr%26aufirst%3DM.%26aulast%3DHodgson%26aufirst%3DD.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DMatulonis%26aufirst%3DU.%26atitle%3DOlaparib%2520maintenance%2520therapy%2520in%2520patients%2520with%2520platinum-sensitive%2520relapsed%2520serous%2520ovarian%2520cancer%253A%2520a%2520preplanned%2520retrospective%2520analysis%2520of%2520outcomes%2520by%2520BRCA%2520status%2520in%2520a%2520randomised%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D852%26epage%3D861%26doi%3D10.1016%2FS1470-2045%2814%2970228-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Gelmon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischkowitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenerton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robidoux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonkin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirte, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntsman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemons, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilks, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yerushalmi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, A.</span><span> </span><span class="NLM_article-title">Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">861</span><span class="refDoi"> DOI: 10.1016/S1470-2045(11)70214-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS1470-2045%2811%2970214-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21862407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSqs7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=852-861&author=K.+A.+Gelmonauthor=M.+Tischkowitzauthor=H.+Mackayauthor=K.+Swenertonauthor=A.+Robidouxauthor=K.+Tonkinauthor=H.+Hirteauthor=D.+Huntsmanauthor=M.+Clemonsauthor=B.+Gilksauthor=R.+Yerushalmiauthor=E.+Macphersonauthor=J.+Carmichaelauthor=A.+Oza&title=Olaparib+in+patients+with+recurrent+high-grade+serous+or+poorly+differentiated+ovarian+carcinoma+or+triple-negative+breast+cancer%3A+a+phase+2%2C+multicentre%2C+open-label%2C+non-randomised+study&doi=10.1016%2FS1470-2045%2811%2970214-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study</span></div><div class="casAuthors">Gelmon, Karen A.; Tischkowitz, Marc; MacKay, Helen; Swenerton, Kenneth; Robidoux, Andre; Tonkin, Katia; Hirte, Hal; Huntsman, David; Clemons, Mark; Gilks, Blake; Yerushalmi, Rinat; MacPherson, Euan; Carmichael, James; Oza, Amit</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">852-861</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Olaparib (AZD2281) is a small-mol., potent oral poly(ADP-ribose) polymerase (PARP) inhibitor.  We aimed to assess the safety and tolerability of this drug in patients without BRCA1 or BRCA2 mutations with advanced triple-neg. breast cancer or high-grade serous and/or undifferentiated ovarian cancer.  Methods: In this phase 2, multicenter open-label, non-randomized study, women with advanced high-grade serous and/or undifferentiated ovarian carcinoma or triple-neg. breast cancer were enrolled and received olaparib 400 mg twice a day.  Patients were stratified according to whether they had a BRCA1 or BRCA2 mutation or not.  The primary endpoint was objective response rate by Response Evaluation Criteria In Solid Tumors (RECIST).  All patients who received treatment were included in the anal. of toxic effects, and patients who had measurable lesions at baseline were included in the primary efficacy anal.  This trial is registered at ClinicalTrials.gov, no. NCT00679783.  Findings: 91 patients were enrolled (65 with ovarian cancer and 26 breast cancer) and 90 were treated between July 8, 2008, and Sept 24, 2009.  In the ovarian cancer cohorts, 64 patients received treatment. 63 patients had target lesions and therefore were evaluable for objective response as per RECIST.  In these patients, confirmed objective responses were seen in seven (41%; 95% CI 22-64) of 17 patients with BRCA1 or BRCA2 mutations and 11 (24%; 14-38) of 46 without mutations.  No confirmed objective responses were reported in patients with breast cancer.  The most common adverse events were fatigue (45 [70%] of patients with ovarian cancer, 13 [50%] of patients with breast cancer), nausea (42 [66%] and 16 [62%]), vomiting (25 [39%] and nine [35%]), and decreased appetite (23 [36%] and seven [27%]).  Interpretation: Our study suggests that olaparib is a promising treatment for women with ovarian cancer and further assessment of the drug in clin. trials is needed.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRwn4h9db66rVg90H21EOLACvtfcHk0lgiVyXJnmawIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSqs7%252FE&md5=6b05f51741618757c4ef7a9b74d8041a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970214-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970214-5%26sid%3Dliteratum%253Aachs%26aulast%3DGelmon%26aufirst%3DK.%2BA.%26aulast%3DTischkowitz%26aufirst%3DM.%26aulast%3DMackay%26aufirst%3DH.%26aulast%3DSwenerton%26aufirst%3DK.%26aulast%3DRobidoux%26aufirst%3DA.%26aulast%3DTonkin%26aufirst%3DK.%26aulast%3DHirte%26aufirst%3DH.%26aulast%3DHuntsman%26aufirst%3DD.%26aulast%3DClemons%26aufirst%3DM.%26aulast%3DGilks%26aufirst%3DB.%26aulast%3DYerushalmi%26aufirst%3DR.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DOza%26aufirst%3DA.%26atitle%3DOlaparib%2520in%2520patients%2520with%2520recurrent%2520high-grade%2520serous%2520or%2520poorly%2520differentiated%2520ovarian%2520carcinoma%2520or%2520triple-negative%2520breast%2520cancer%253A%2520a%2520phase%25202%252C%2520multicentre%252C%2520open-label%252C%2520non-randomised%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D852%26epage%3D861%26doi%3D10.1016%2FS1470-2045%2811%2970214-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Kaufman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapira-Frommer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmutzler, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audeh, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balmana, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemmer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosengarten, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domchek, S. M.</span><span> </span><span class="NLM_article-title">Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1200/JCO.2014.56.2728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2014.56.2728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25366685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVWrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=244-250&author=B.+Kaufmanauthor=R.+Shapira-Frommerauthor=R.+K.+Schmutzlerauthor=M.+W.+Audehauthor=M.+Friedlanderauthor=J.+Balmanaauthor=G.+Mitchellauthor=G.+Friedauthor=S.+M.+Stemmerauthor=A.+Hubertauthor=O.+Rosengartenauthor=M.+Steinerauthor=N.+Lomanauthor=K.+Bowenauthor=A.+Fieldingauthor=S.+M.+Domchek&title=Olaparib+monotherapy+in+patients+with+advanced+cancer+and+a+germline+BRCA1%2F2+mutation&doi=10.1200%2FJCO.2014.56.2728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation</span></div><div class="casAuthors">Kaufman, Bella; Shapira-Frommer, Ronnie; Schmutzler, Rita K.; Audeh, M. William; Friedlander, Michael; Balmana, Judith; Mitchell, Gillian; Fried, Georgeta; Stemmer, Salomon M.; Hubert, Ayala; Rosengarten, Ora; Steiner, Mariana; Loman, Niklas; Bowen, Karin; Fielding, Anitra; Domchek, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-250</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) -assocd. breast and ovarian cancers.  We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-assocd. cancers.  This multicenter phase II study enrolled individuals with a germline BRCA1/2 mutation and recurrent cancer.  Eligibility included ovarian cancer resistant to prior platinum; breast cancer with ≥ three chemotherapy regimens for metastatic disease; pancreatic cancer with prior gemcitabine treatment; or prostate cancer with progression on hormonal and one systemic therapy.  Olaparib was administered at 400 mg twice per day.  The primary efficacy end point was tumor response rate.  A total of 298 patients received treatment and were evaluable.  The tumor response rate was 26.2% (78 of 298; 95% CI, 21.3 to 31.6) overall and 31.1% (60 of 193; 95% CI, 24.6 to 38.1), 12.9% (eight of 62; 95% CI, 5.7 to 23.9), 21.7% (five of 23; 95% CI, 7.5 to 43.7), and 50.0% (four of eight; 95% CI, 15.7 to 84.3) in ovarian, breast, pancreatic, and prostate cancers, resp.  Stable disease ≥ 8 wk was obsd. in 42% of patients (95% CI, 36.0 to 47.4), including 40% (95% CI, 33.4 to 47.7), 47% (95% CI, 34.0 to 59.9), 35% (95% CI, 16.4 to 57.3), and 25% (95% CI, 3.2 to 65.1) of those with ovarian, breast, pancreatic, or prostate cancer, resp.  The most common adverse events (AEs) were fatigue, nausea, and vomiting.  Grade ≥ 3 AEs were reported for 54% of patients; anemia was the most common (17%).  Responses to olaparib were obsd. across different tumor types assocd. with germline BRCA1/2 mutations.  Olaparib warrants further investigation in confirmatory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooKvduc8Sx3bVg90H21EOLACvtfcHk0litQtug0MUQTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVWrsLY%253D&md5=8ba52a3fa98d1137e6c134245ea42b87</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.56.2728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.56.2728%26sid%3Dliteratum%253Aachs%26aulast%3DKaufman%26aufirst%3DB.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DBalmana%26aufirst%3DJ.%26aulast%3DMitchell%26aufirst%3DG.%26aulast%3DFried%26aufirst%3DG.%26aulast%3DStemmer%26aufirst%3DS.%2BM.%26aulast%3DHubert%26aufirst%3DA.%26aulast%3DRosengarten%26aufirst%3DO.%26aulast%3DSteiner%26aufirst%3DM.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DBowen%26aufirst%3DK.%26aulast%3DFielding%26aufirst%3DA.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26atitle%3DOlaparib%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520cancer%2520and%2520a%2520germline%2520BRCA1%252F2%2520mutation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D244%26epage%3D250%26doi%3D10.1200%2FJCO.2014.56.2728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span>Lynparza Approved in the European Union As First-in-Class Treatment for Advanced BRCA-Mutated Ovarian Cancer; <span class="NLM_publisher-name">AstraZeneca Global</span>, 18 Dec<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span><a href="http://astrazeneca.com" class="extLink">http://astrazeneca.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lynparza+Approved+in+the+European+Union+As+First-in-Class+Treatment+for+Advanced+BRCA-Mutated+Ovarian+Cancer%3B+AstraZeneca+Global%2C+18+Dec+2014%3B+http%3A%2F%2Fastrazeneca.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DLynparza%2520Approved%2520in%2520the%2520European%2520Union%2520As%2520First-in-Class%2520Treatment%2520for%2520Advanced%2520BRCA-Mutated%2520Ovarian%2520Cancer%26pub%3DAstraZeneca%2520Global%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span>LYNPARZA Approved by the US Food and Drug Administration for the Treatment of Advanced Ovarian Cancer in Patients with Germline BRCA Mutations; <span class="NLM_publisher-name">AstraZeneca Global</span>, 19 Dec<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span><a href="http://astrazeneca.com" class="extLink">http://astrazeneca.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LYNPARZA+Approved+by+the+US+Food+and+Drug+Administration+for+the+Treatment+of+Advanced+Ovarian+Cancer+in+Patients+with+Germline+BRCA+Mutations%3B+AstraZeneca+Global%2C+19+Dec+2014%3B+http%3A%2F%2Fastrazeneca.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DLYNPARZA%2520Approved%2520by%2520the%2520US%2520Food%2520and%2520Drug%2520Administration%2520for%2520the%2520Treatment%2520of%2520Advanced%2520Ovarian%2520Cancer%2520in%2520Patients%2520with%2520Germline%2520BRCA%2520Mutations%26pub%3DAstraZeneca%2520Global%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span>Lynparza (Olaparib) Granted Breakthrough Therapy Designation by US FDA for Treatment of BRCA1/2 or ATM Gene Mutated Metastatic Castration Resistant Prostate Cancer; <span class="NLM_publisher-name">AstraZeneca</span>, 28 Jan<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://astrazeneca.com" class="extLink">http://astrazeneca.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lynparza+%28Olaparib%29+Granted+Breakthrough+Therapy+Designation+by+US+FDA+for+Treatment+of+BRCA1%2F2+or+ATM+Gene+Mutated+Metastatic+Castration+Resistant+Prostate+Cancer%3B+AstraZeneca%2C+28+Jan+2016%3B+http%3A%2F%2Fastrazeneca.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DLynparza%2520%2528Olaparib%2529%2520Granted%2520Breakthrough%2520Therapy%2520Designation%2520by%2520US%2520FDA%2520for%2520Treatment%2520of%2520BRCA1%252F2%2520or%2520ATM%2520Gene%2520Mutated%2520Metastatic%2520Castration%2520Resistant%2520Prostate%2520Cancer%26pub%3DAstraZeneca%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Miknyoczki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worrell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deibold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parchment, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span> </span><span class="NLM_article-title">The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to Temozolomide and irinotecan but does not potentiate myelotoxicity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2290</span><span class="NLM_x">–</span> <span class="NLM_lpage">2302</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.MCT-07-0062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=17699724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2290-2302&author=S.+Miknyoczkiauthor=H.+Changauthor=J.+Grobelnyauthor=S.+Pritchardauthor=C.+Worrellauthor=N.+McGannauthor=M.+Atorauthor=J.+Hustenauthor=J.+Deiboldauthor=R.+Hudkinsauthor=A.+Zulliauthor=R.+Parchmentauthor=B.+Ruggeri&title=The+selective+poly%28ADP-ribose%29+polymerase-1%282%29+inhibitor%2C+CEP-8983%2C+increases+the+sensitivity+of+chemoresistant+tumor+cells+to+Temozolomide+and+irinotecan+but+does+not+potentiate+myelotoxicity&doi=10.1158%2F1535-7163.MCT-07-0062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity</span></div><div class="casAuthors">Miknyoczki, Sheila; Chang, Hong; Grobelny, Jennifer; Pritchard, Sonya; Worrell, Candace; McGann, Natalie; Ator, Mark; Husten, Jean; Deibold, James; Hudkins, Robert; Zulli, Allison; Parchment, Ralph; Ruggeri, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2290-2302</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The effect of the potent and selective poly(ADP-ribose) (PAR) polymerase-1 [and PAR polymerase-2] inhibitor CEP-8983 on the ability to sensitize chemoresistant glioblastoma (RG2), rhabdomyosarcoma (RH18), neuroblastoma (NB1691), and colon carcinoma (HT29) tumor cells to temozolomide- and camptothecin-induced cytotoxicity, DNA damage, and G2-M arrest and on the potentiation of chemotherapy-induced myelotoxicity was evaluated using in vitro assays.  In addn., the effect of the prodrug CEP-9722 in combination with temozolomide and/or irinotecan on PAR accumulation and tumor growth was also detd. using glioblastoma and/or colon carcinoma xenografts relative to chemotherapy alone.  CEP-8983 sensitized carcinoma cells to the growth-inhibitory effects of temozolomide and/or SN38 increased the fraction of and/or lengthened duration of time tumor cells accumulated in chemotherapy-induced G2-M arrest and sensitized tumor cells to chemotherapy-induced DNA damage and apoptosis.  A granulocyte-macrophage colony-forming unit colony formation assay showed that coincubation of CEP-8983 with temozolomide or topotecan did not potentiate chemotherapy-assocd. myelotoxicity.  CEP-9722 (136 mg/kg) administered with temozolomide (68 mg/kg for 5 days) or irinotecan (10 mg/kg for 5 days) inhibited significantly the growth of RG2 tumors (60%) or HT29 tumors (80%) compared with temozolomide or irinotecan monotherapy, resp.  In addn., CEP-9722 showed "stand alone" antitumor efficacy in these preclin. xenografts.  In vivo biochem. efficacy studies showed that CEP-9722 attenuated PAR accumulation in glioma xenografts in a dose- and time-related manner.  These data indicate that CEP-8983 and its prodrug are effective chemosensitizing agents when administered in combination with select chemotherapeutic agents against chemoresistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr870nJ_ojOQbVg90H21EOLACvtfcHk0liP_aLMkZ6HUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltbc%253D&md5=eef1600ec2ce56e71ca6045dca135bf4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0062%26sid%3Dliteratum%253Aachs%26aulast%3DMiknyoczki%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DGrobelny%26aufirst%3DJ.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWorrell%26aufirst%3DC.%26aulast%3DMcGann%26aufirst%3DN.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DDeibold%26aufirst%3DJ.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DZulli%26aufirst%3DA.%26aulast%3DParchment%26aufirst%3DR.%26aulast%3DRuggeri%26aufirst%3DB.%26atitle%3DThe%2520selective%2520poly%2528ADP-ribose%2529%2520polymerase-1%25282%2529%2520inhibitor%252C%2520CEP-8983%252C%2520increases%2520the%2520sensitivity%2520of%2520chemoresistant%2520tumor%2520cells%2520to%2520Temozolomide%2520and%2520irinotecan%2520but%2520does%2520not%2520potentiate%2520myelotoxicity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2290%26epage%3D2302%26doi%3D10.1158%2F1535-7163.MCT-07-0062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Lechaftois, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margaill, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchand-Leroux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachelot-Loza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerouet, D.</span><span> </span><span class="NLM_article-title">Another ″string to the bow″ of PJ34, a potent poly(ADP-Ribose)polymerase inhibitor: an antiplatelet effect through P2Y12 antagonism?</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e110776</span><span class="refDoi"> DOI: 10.1371/journal.pone.0110776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1371%2Fjournal.pone.0110776" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e110776&author=M.+Lechaftoisauthor=E.+Dreanoauthor=B.+Palmierauthor=I.+Margaillauthor=C.+Marchand-Lerouxauthor=C.+Bachelot-Lozaauthor=D.+Lerouet&title=Another+%E2%80%B3string+to+the+bow%E2%80%B3+of+PJ34%2C+a+potent+poly%28ADP-Ribose%29polymerase+inhibitor%3A+an+antiplatelet+effect+through+P2Y12+antagonism%3F&doi=10.1371%2Fjournal.pone.0110776"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0110776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0110776%26sid%3Dliteratum%253Aachs%26aulast%3DLechaftois%26aufirst%3DM.%26aulast%3DDreano%26aufirst%3DE.%26aulast%3DPalmier%26aufirst%3DB.%26aulast%3DMargaill%26aufirst%3DI.%26aulast%3DMarchand-Leroux%26aufirst%3DC.%26aulast%3DBachelot-Loza%26aufirst%3DC.%26aulast%3DLerouet%26aufirst%3DD.%26atitle%3DAnother%2520%25E2%2580%25B3string%2520to%2520the%2520bow%25E2%2580%25B3%2520of%2520PJ34%252C%2520a%2520potent%2520poly%2528ADP-Ribose%2529polymerase%2520inhibitor%253A%2520an%2520antiplatelet%2520effect%2520through%2520P2Y12%2520antagonism%253F%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De110776%26doi%3D10.1371%2Fjournal.pone.0110776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Menear, K. A.; Hummersone, M. G.; Gomez, S.; Javaid, M. H.; Martin, N. M. B.; Kerrigan, F.</span><span> </span><span class="NLM_article-title">Phthalazinone derivatives</span>. WO 2009093032,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+A.+Menear&author=M.+G.+Hummersone&author=S.+Gomez&author=M.+H.+Javaid&author=N.+M.+B.+Martin&author=F.+Kerrigan&title=Phthalazinone+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26atitle%3DPhthalazinone%2520derivatives%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Awada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aftimos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenel, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahleda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gombos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourbouloux, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1097%2FCAD.0000000000000336" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=342-348&author=A.+Awadaauthor=M.+Camponeauthor=A.+Vargaauthor=P.+Aftimosauthor=J.+S.+Frenelauthor=R.+Bahledaauthor=A.+Gombosauthor=E.+Bourboulouxauthor=J.+C.+Soria&title=An+open-label%2C+dose-escalation+study+to+evaluate+the+safety+and+pharmacokinetics+of+CEP-9722+%28a+PARP-1+and+PARP-2+inhibitor%29+in+combination+with+gemcitabine+and+cisplatin+in+patients+with+advanced+solid+tumors&doi=10.1097%2FCAD.0000000000000336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000336%26sid%3Dliteratum%253Aachs%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DAftimos%26aufirst%3DP.%26aulast%3DFrenel%26aufirst%3DJ.%2BS.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DGombos%26aufirst%3DA.%26aulast%3DBourbouloux%26aufirst%3DE.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DAn%2520open-label%252C%2520dose-escalation%2520study%2520to%2520evaluate%2520the%2520safety%2520and%2520pharmacokinetics%2520of%2520CEP-9722%2520%2528a%2520PARP-1%2520and%2520PARP-2%2520inhibitor%2529%2520in%2520combination%2520with%2520gemcitabine%2520and%2520cisplatin%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2016%26volume%3D27%26spage%3D342%26epage%3D348%26doi%3D10.1097%2FCAD.0000000000000336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Bedikian, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwu, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homsi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudewicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernillet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwu, P.</span><span> </span><span class="NLM_article-title">A phase IB trial of intravenous INO-1001 plus oral Temozolomide in subjects with unresectable stage-III or IV melanoma</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span><span class="refDoi"> DOI: 10.1080/07357900802709159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1080%2F07357900802709159" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=756-763&author=A.+Y.+Bedikianauthor=N.+E.+Papadopoulosauthor=K.+B.+Kimauthor=W.+J.+Hwuauthor=J.+Homsiauthor=M.+R.+Glassauthor=S.+Cainauthor=P.+Rudewiczauthor=L.+Vernilletauthor=P.+Hwu&title=A+phase+IB+trial+of+intravenous+INO-1001+plus+oral+Temozolomide+in+subjects+with+unresectable+stage-III+or+IV+melanoma&doi=10.1080%2F07357900802709159"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F07357900802709159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07357900802709159%26sid%3Dliteratum%253Aachs%26aulast%3DBedikian%26aufirst%3DA.%2BY.%26aulast%3DPapadopoulos%26aufirst%3DN.%2BE.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DHomsi%26aufirst%3DJ.%26aulast%3DGlass%26aufirst%3DM.%2BR.%26aulast%3DCain%26aufirst%3DS.%26aulast%3DRudewicz%26aufirst%3DP.%26aulast%3DVernillet%26aufirst%3DL.%26aulast%3DHwu%26aufirst%3DP.%26atitle%3DA%2520phase%2520IB%2520trial%2520of%2520intravenous%2520INO-1001%2520plus%2520oral%2520Temozolomide%2520in%2520subjects%2520with%2520unresectable%2520stage-III%2520or%2520IV%2520melanoma%26jtitle%3DCancer%2520Invest.%26date%3D2009%26volume%3D27%26spage%3D756%26epage%3D763%26doi%3D10.1080%2F07357900802709159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">945</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.MCT-06-0552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=17363489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=945-956&author=H.+D.+Thomasauthor=C.+R.+Calabreseauthor=M.+A.+Bateyauthor=S.+Cananauthor=Z.+Hostomskyauthor=S.+Kyleauthor=K.+A.+Maegleyauthor=D.+R.+Newellauthor=D.+Skalitzkyauthor=L.+Z.+Wangauthor=S.+E.+Webberauthor=N.+J.+Curtin&title=Preclinical+selection+of+a+novel+poly%28ADP-ribose%29+polymerase+inhibitor+for+clinical+trial&doi=10.1158%2F1535-7163.MCT-06-0552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span></div><div class="casAuthors">Thomas, Huw D.; Calabrese, Christopher R.; Batey, Michael A.; Canan, Stacie; Hostomsky, Zdenek; Kyle, Suzanne; Maegley, Karen A.; Newell, David R.; Skalitzky, Donald; Wang, Lan-Zhen; Webber, Stephen E.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks.  Inhibition of PARP-1 enhances the efficacy of DNA alkylating agents, topoisomerase I poisons, and ionizing radiation.  Our aim was to identify a PARP inhibitor for clin. trial from a panel of 42 potent PARP inhibitors (Ki, 1.4-15.1 nmol/L) based on the quinazolinone, benzimidazole, tricyclic benzimidazole, tricyclic indole, and tricyclic indole-1-one core structures.  We evaluated chemosensitization of temozolomide and topotecan using LoVo and SW620 human colorectal cells; in vitro radiosensitization was measured using LoVo cells, and the enhancement of antitumor activity of temozolomide was evaluated in mice bearing SW620 xenografts.  Excellent chemopotentiation and radiopotentiation were obsd. in vitro, with 17 of the compds. causing a greater temozolomide and topotecan sensitization than the benchmark inhibitor AG14361 and 10 compds. were more potent radiosensitizers than AG14361.  In tumor-bearing mice, none of the compds. were toxic when given alone, and the antitumor activity of the PARP inhibitor-temozolomide combinations was unrelated to toxicity.  Compds. that were more potent chemosensitizers in vivo than AG14361 were also more potent in vitro, validating in vitro assays as a prescreen.  These studies have identified a compd., AG14447, as a PARP inhibitor with outstanding in vivo chemosensitization potency at tolerable doses, which is at least 10 times more potent than the initial lead, AG14361.  The phosphate salt of AG14447 (AG014699), which has improved aq. soly., has been selected for clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-3D2oL2giLVg90H21EOLACvtfcHk0liJq-OSLnpuDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D&md5=b451bf2c1fc836cc5a800c2799e5d211</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0552%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCanan%26aufirst%3DS.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPreclinical%2520selection%2520of%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520for%2520clinical%2520trial%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D945%26epage%3D956%26doi%3D10.1158%2F1535-7163.MCT-06-0552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcoxen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span> </span><span class="NLM_article-title">Niraparib: A Poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3302</span><span class="NLM_x">–</span> <span class="NLM_lpage">3314</span><span class="refDoi"> DOI: 10.1021/jm5018237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5018237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFams7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3302-3314&author=P.+Jonesauthor=K.+Wilcoxenauthor=M.+Rowleyauthor=C.+Toniatti&title=Niraparib%3A+A+Poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+for+the+treatment+of+tumors+with+defective+homologous+recombination&doi=10.1021%2Fjm5018237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination</span></div><div class="casAuthors">Jones, Philip; Wilcoxen, Keith; Rowley, Michael; Toniatti, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3302-3314</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repair following damage by endogenous or exogenous processes.  It has become clear over the past decade that inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells.  We describe the rationale for this approach and the design and discovery of niraparib, a potent PARP-1/2 inhibitor with good cell based activity, selectivity for cancer over normal cells, and oral bioavailability.  Niraparib was characterized in a no. of preclin. models before moving to phase I clin. trials, where it showed excellent human pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had promising activity in cancer patients.  It is currently being tested in phase 3 clin. trials as maintenance therapy in ovarian cancer and as a treatment for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsaJDnhFDPhbVg90H21EOLACvtfcHk0liJq-OSLnpuDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFams7s%253D&md5=ffb7cb2503acde0a1e3452448d98693f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm5018237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5018237%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26atitle%3DNiraparib%253A%2520A%2520Poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520tumors%2520with%2520defective%2520homologous%2520recombination%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3302%26epage%3D3314%26doi%3D10.1021%2Fjm5018237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery of the poly (ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1 H-benzimidazole-4- carboxamide (ABT-888) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">523</span><span class="refDoi"> DOI: 10.1021/jm801171j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly+%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1+H-benzimidazole-4-+carboxamide+%28ABT-888%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm801171j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1%2520H-benzimidazole-4-%2520carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523%26doi%3D10.1021%2Fjm801171j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span> </span><span class="NLM_article-title">Discovery and characterization of (8S, 9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1, 2, 4-triazol-5-yl)-2, 7, 8, 9-tetrahydro-3H-pyrido [4, 3, 2-de] phthalazin-3-one (BMN 673, talazoparib), a novel, highly potent, and orally efficacious poly (ADP-ribose) polymerase-1/2 inhibitor as an anticancer agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">357</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01498</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01498" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=335-357&author=B.+Wangauthor=D.+Chuauthor=Y.+Fengauthor=Y.+Shenauthor=M.+Aoyagi-Scharberauthor=L.+E.+Post&title=Discovery+and+characterization+of+%288S%2C+9R%29-5-fluoro-8-%284-fluorophenyl%29-9-%281-methyl-1H-1%2C+2%2C+4-triazol-5-yl%29-2%2C+7%2C+8%2C+9-tetrahydro-3H-pyrido+%5B4%2C+3%2C+2-de%5D+phthalazin-3-one+%28BMN+673%2C+talazoparib%29%2C+a+novel%2C+highly+potent%2C+and+orally+efficacious+poly+%28ADP-ribose%29+polymerase-1%2F2+inhibitor+as+an+anticancer+agent&doi=10.1021%2Facs.jmedchem.5b01498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent</span></div><div class="casAuthors">Wang, Bing; Chu, Daniel; Feng, Ying; Shen, Yuqiao; Aoyagi-Scharber, Mika; Post, Leonard E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">335-357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors discovered and developed a novel series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors.  Lead optimization led to the identification of (I) (talazoparib; BMN 673; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one).  The novel stereospecific dual chiral-center-embedded structure of this compd. has enabled extensive and unique binding interactions with PARP1/2 proteins. I demonstrates excellent potency, inhibiting PARP1 and PARP2 enzyme activity with Ki = 1.2 and 0.87 nM, resp.  It inhibits PARP-mediated PARylation in a whole-cell assay with an EC50 of 2.51 nM and prevents proliferation of cancer cells carrying mutant BRCA1/2, with EC50 = 0.3 nM (MX-1) and 5 nM (Capan-1), resp. I is orally available, displaying favorable pharmacokinetic (PK) properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following oral administration as a single-agent or in combination with chemotherapy agents such as temozolomide and cisplatin. I has completed phase 1 clin. trial and is currently being studied in phase 2 and 3 clin. trials for the treatment of locally advanced and/or metastatic breast cancer with germline BRCA1/2 deleterious mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBpTb90_rQhLVg90H21EOLACvtfcHk0li5bYzJeaAAEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN&md5=443bfeb7aeda6c6522d41ab52793931a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01498%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DPost%26aufirst%3DL.%2BE.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520%25288S%252C%25209R%2529-5-fluoro-8-%25284-fluorophenyl%2529-9-%25281-methyl-1H-1%252C%25202%252C%25204-triazol-5-yl%2529-2%252C%25207%252C%25208%252C%25209-tetrahydro-3H-pyrido%2520%255B4%252C%25203%252C%25202-de%255D%2520phthalazin-3-one%2520%2528BMN%2520673%252C%2520talazoparib%2529%252C%2520a%2520novel%252C%2520highly%2520potent%252C%2520and%2520orally%2520efficacious%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%252F2%2520inhibitor%2520as%2520an%2520anticancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D335%26epage%3D357%26doi%3D10.1021%2Facs.jmedchem.5b01498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Plummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dua, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cresti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prathapan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de las Heras, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarker, D.</span><span> </span><span class="NLM_article-title">Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">e19531</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=e19531&issue=15+suppl&author=R.+Plummerauthor=D.+Duaauthor=N.+Crestiauthor=A.+Suderauthor=Y.+Drewauthor=V.+Prathapanauthor=P.+Stephensauthor=J.+K.+Thorntonauthor=B.+de+las+Herasauthor=B.+Inkauthor=L.+Leeauthor=M.+Matijevicauthor=S.+McGrathauthor=D.+Sarker&title=Phase+1+study+of+the+PARP+inhibitor+E7449+as+a+single+agent+in+patients+with+advanced+solid+tumors+or+B-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DDua%26aufirst%3DD.%26aulast%3DCresti%26aufirst%3DN.%26aulast%3DSuder%26aufirst%3DA.%26aulast%3DDrew%26aufirst%3DY.%26aulast%3DPrathapan%26aufirst%3DV.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DThornton%26aufirst%3DJ.%2BK.%26aulast%3Dde%2Blas%2BHeras%26aufirst%3DB.%26aulast%3DInk%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DMatijevic%26aufirst%3DM.%26aulast%3DMcGrath%26aufirst%3DS.%26aulast%3DSarker%26aufirst%3DD.%26atitle%3DPhase%25201%2520study%2520of%2520the%2520PARP%2520inhibitor%2520E7449%2520as%2520a%2520single%2520agent%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%2520or%2520B-cell%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15%2520suppl%26spage%3De19531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">McGonigle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolber-Simonds, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackermann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twine, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shie, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moniz, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomoto, K.</span><span> </span><span class="NLM_article-title">E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">41307</span><span class="NLM_x">–</span> <span class="NLM_lpage">41323</span><span class="refDoi"> DOI: 10.18632/oncotarget.5846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.5846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26513298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC28zmsFajsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=41307-41323&author=S.+McGonigleauthor=Z.+Chenauthor=J.+Wuauthor=P.+Changauthor=D.+Kolber-Simondsauthor=K.+Ackermannauthor=N.+C.+Twineauthor=J.+L.+Shieauthor=J.+T.+Miuauthor=K.+C.+Huangauthor=G.+A.+Monizauthor=K.+Nomoto&title=E7449%3A+A+dual+inhibitor+of+PARP1%2F2+and+tankyrase1%2F2+inhibits+growth+of+DNA+repair+deficient+tumors+and+antagonizes+Wnt+signaling&doi=10.18632%2Foncotarget.5846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling</span></div><div class="casAuthors">McGonigle Sharon; Chen Zhihong; Wu Jiayi; Kolber-Simonds Donna; Ackermann Karen; Twine Natalie C; Shie Jue-Lon; Miu Jingzang Tao; Huang Kuan-Chun; Nomoto Kenichi; Chang Paul; Chang Paul; Miu Jingzang Tao; Moniz George A; Moniz George A</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">41307-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have demonstrated clinical proof of concept for cancer treatment.  Here, we describe the development of the novel PARP inhibitor E7449, a potent PARP1/2 inhibitor that also inhibits PARP5a/5b, otherwise known as tankyrase1 and 2 (TNKS1 and 2), important regulators of canonical Wnt/β-catenin signaling.  E7449 inhibits PARP enzymatic activity and additionally traps PARP1 onto damaged DNA; a mechanism previously shown to augment cytotoxicity.  Cells deficient in DNA repair pathways beyond homologous recombination were sensitive to E7449 treatment.  Chemotherapy was potentiated by E7449 and single agent had significant antitumor activity in BRCA-deficient xenografts.  Additionally, E7449 inhibited Wnt/β-catenin signaling in colon cancer cell lines, likely through TNKS inhibition.  Consistent with this possibility, E7449 stabilized axin and TNKS proteins resulting in β-catenin de-stabilization and significantly altered expression of Wnt target genes.  Notably, hair growth mediated by Wnt signaling was inhibited by E7449.  A pharmacodynamic effect of E7449 on Wnt target genes was observed in tumors, although E7449 lacked single agent antitumor activity in vivo, a finding typical for selective TNKS inhibitors.  E7449 antitumor activity was increased through combination with MEK inhibition.  Particularly noteworthy was the lack of toxicity, most significantly the lack of intestinal toxicity reported for other TNKS inhibitors.  E7449 represents a novel dual PARP1/2 and TNKS1/2 inhibitor which has the advantage of targeting Wnt/β-catenin signaling addicted tumors.  E7449 is currently in early clinical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScNmr1n8UDWbrIbt-tGZmxfW6udTcc2eYU_AXEyf85Drntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zmsFajsA%253D%253D&md5=8e0ce94993305253e4b5d76355583498</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5846%26sid%3Dliteratum%253Aachs%26aulast%3DMcGonigle%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DP.%26aulast%3DKolber-Simonds%26aufirst%3DD.%26aulast%3DAckermann%26aufirst%3DK.%26aulast%3DTwine%26aufirst%3DN.%2BC.%26aulast%3DShie%26aufirst%3DJ.%2BL.%26aulast%3DMiu%26aufirst%3DJ.%2BT.%26aulast%3DHuang%26aufirst%3DK.%2BC.%26aulast%3DMoniz%26aufirst%3DG.%2BA.%26aulast%3DNomoto%26aufirst%3DK.%26atitle%3DE7449%253A%2520A%2520dual%2520inhibitor%2520of%2520PARP1%252F2%2520and%2520tankyrase1%252F2%2520inhibits%2520growth%2520of%2520DNA%2520repair%2520deficient%2520tumors%2520and%2520antagonizes%2520Wnt%2520signaling%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D41307%26epage%3D41323%26doi%3D10.18632%2Foncotarget.5846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span>BGB-290: PARP1 and PARP2 Inhibitor with Unique Properties; <span class="NLM_publisher-name">BeiGene</span>: <span class="NLM_publisher-loc">Beijing</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.beigene.com/pipeline/clinical-candidates/bgb-290/" class="extLink">http://www.beigene.com/pipeline/clinical-candidates/bgb-290/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BGB-290%3A+PARP1+and+PARP2+Inhibitor+with+Unique+Properties%3B+BeiGene%3A+Beijing%2C+2016%3B+http%3A%2F%2Fwww.beigene.com%2Fpipeline%2Fclinical-candidates%2Fbgb-290%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DBGB-290%253A%2520PARP1%2520and%2520PARP2%2520Inhibitor%2520with%2520Unique%2520Properties%26pub%3DBeiGene%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">de Jonge, M. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Herpen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koornstra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jager, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Den Hollander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serpenti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">452P A study of ABT-767 in advanced solid tumors with BRCA 1 and BRCA 2 mutations and high grade serous ovarian, fallopian tube, or primary peritoneal cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">suppl 4</span><span class="NLM_x">) </span> <span class="NLM_fpage">iv150</span><span class="refDoi"> DOI: 10.1093/annonc/mdu331.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fannonc%2Fmdu331.12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=iv150&issue=suppl+4&author=M.+J.+A.+de+Jongeauthor=C.+van+Herpenauthor=J.+Gietemaauthor=S.+Shepherdauthor=R.+Koornstraauthor=A.+Jagerauthor=M.+Den+Hollanderauthor=M.+Dunbarauthor=R.+Hetmanauthor=C.+Serpentiauthor=H.+Xiongauthor=M.+Zhuauthor=V.+L.+Giranda&title=452P+A+study+of+ABT-767+in+advanced+solid+tumors+with+BRCA+1+and+BRCA+2+mutations+and+high+grade+serous+ovarian%2C+fallopian+tube%2C+or+primary+peritoneal+cancer&doi=10.1093%2Fannonc%2Fmdu331.12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu331.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu331.12%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BJ.%2BA.%26aulast%3Dvan%2BHerpen%26aufirst%3DC.%26aulast%3DGietema%26aufirst%3DJ.%26aulast%3DShepherd%26aufirst%3DS.%26aulast%3DKoornstra%26aufirst%3DR.%26aulast%3DJager%26aufirst%3DA.%26aulast%3DDen%2BHollander%26aufirst%3DM.%26aulast%3DDunbar%26aufirst%3DM.%26aulast%3DHetman%26aufirst%3DR.%26aulast%3DSerpenti%26aufirst%3DC.%26aulast%3DXiong%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3D452P%2520A%2520study%2520of%2520ABT-767%2520in%2520advanced%2520solid%2520tumors%2520with%2520BRCA%25201%2520and%2520BRCA%25202%2520mutations%2520and%2520high%2520grade%2520serous%2520ovarian%252C%2520fallopian%2520tube%252C%2520or%2520primary%2520peritoneal%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26issue%3Dsuppl%25204%26spage%3Div150%26doi%3D10.1093%2Fannonc%2Fmdu331.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Fong, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mergui-Roelvink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.1056/NEJMoa0900212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1056%2FNEJMoa0900212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=19553641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=123-134&author=P.+C.+Fongauthor=D.+S.+Bossauthor=T.+A.+Yapauthor=A.+Tuttauthor=P.+Wuauthor=M.+Mergui-Roelvinkauthor=P.+Mortimerauthor=H.+Swaislandauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=A.+Ashworthauthor=J.+Carmichaelauthor=S.+B.+Kayeauthor=J.+H.+Schellensauthor=J.+S.+de+Bono&title=Inhibition+of+poly%28ADP-Ribose%29+polymerase+in+tumors+from+BRCA+mutation+carriers&doi=10.1056%2FNEJMoa0900212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</span></div><div class="casAuthors">Fong, Peter C.; Boss, David S.; Yap, Timothy A.; Tutt, Andrew; Wu, Peijun; Mergui-Roelvink, Marja; Mortimer, Peter; Swaisland, Helen; Lau, Alan; O'Connor, Mark J.; Ashworth, Alan; Carmichael, James; Kaye, Stan B.; Schellens, Jan H. M.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The inhibition of poly(ADP-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation.  We conducted a clin. evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor.  This was a phase 1 trial that included the anal. of pharmacokinetic and pharmacodynamic characteristics of olaparib.  Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation.  We enrolled and treated 60 patients; 22 were carriers of a BRCA1 or BRCA2 mutation and 1 had a strong family history of BRCA-assocd. cancer but declined to undergo mutational testing.  The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 wk to 600 mg twice daily continuously.  Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily (grade 3 mood alteration and fatigue) and two of five patients receiving 600 mg twice daily (grade 4 thrombocytopenia and grade 3 somnolence).  This led us to enroll another cohort, consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olaparib at a dose of 200 mg twice daily.  Other adverse effects included mild gastrointestinal symptoms.  There was no obvious increase in adverse effects seen in the mutation carriers.  Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic studies confirmed PARP inhibition in surrogate samples (of peripheral-blood mononuclear cells and plucked eyebrow-hair follicles) and tumor tissue.  Objective antitumor activity was reported only in mutation carriers, all of whom had ovarian, breast, or prostate cancer and had received multiple treatment regimens.  Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer assocd. with the BRCA1 or BRCA2 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCT49Hz0HbW7Vg90H21EOLACvtfcHk0lj6-otlwfbWJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D&md5=aec7dcffe3d3cf614362a4f38bbb369a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0900212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0900212%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DMergui-Roelvink%26aufirst%3DM.%26aulast%3DMortimer%26aufirst%3DP.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520poly%2528ADP-Ribose%2529%2520polymerase%2520in%2520tumors%2520from%2520BRCA%2520mutation%2520carriers%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D123%26epage%3D134%26doi%3D10.1056%2FNEJMoa0900212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nokihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahina, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T. A.</span><span> </span><span class="NLM_article-title">A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">504</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span><span class="refDoi"> DOI: 10.1111/j.1349-7006.2011.02179.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1111%2Fj.1349-7006.2011.02179.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22145984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1eru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2012&pages=504-509&author=N.+Yamamotoauthor=H.+Nokiharaauthor=Y.+Yamadaauthor=Y.+Gotoauthor=M.+Taniokaauthor=T.+Shibataauthor=K.+Yamadaauthor=H.+Asahinaauthor=T.+Kawataauthor=X.+Shiauthor=T.+A.+Tamura&title=A+phase+I%2C+dose-finding+and+pharmacokinetic+study+of+olaparib+%28AZD2281%29+in+Japanese+patients+with+advanced+solid+tumors&doi=10.1111%2Fj.1349-7006.2011.02179.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors</span></div><div class="casAuthors">Yamamoto, Noboru; Nokihara, Hiroshi; Yamada, Yasuhide; Goto, Yasushi; Tanioka, Maki; Shibata, Takashi; Yamada, Kazuhiko; Asahina, Hajime; Kawata, Toshio; Shi, Xiaojin; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">504-509</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Olaparib (AZD2281) is an orally active Poly(ADP-ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers with BRCA1/2 mutations in Western (USA and European) studies.  This Phase I dose-finding study evaluated the tolerability, pharmacokinetics, PARP inhibitory activity, and antitumor activity of olaparib in Japanese patients with solid tumors.  Olaparib was administered as a single-dose on day 1, followed by twice-daily dosing for 28 days from 48 h after a single dose.  Doses were escalated from 100 mg b.i.d. in successive cohorts, up to a max. of 400 mg b.i.d.  The present study enrolled 12 patients (n = 3, 3, and 6 in 100, 200 and 400-mg b.i.d. levels, resp.).  The most common adverse events were nausea, increased blood creatinine, decreased hematocrit, leukopenia and lymphopenia; dose-limiting toxicities were not obsd. up to and including the 400-mg b.i.d. dose level.  Following twice-daily dosing, olaparib showed no marked increase in exposure at steady state over that expected from the single-dose pharmacokinetics.  PARP-1 inhibition was obsd. from the 100-mg b.i.d. dose level in peripheral blood mononuclear cells from 6 h post-dose on day 1 during the multiple-dosing period.  A patient with metastatic breast cancer (100 mg b.i.d.) had a partial response for 13 mo and four patients (two each in the 200 and 400-mg b.i.d. levels) had stable disease >8 wk.  Olaparib was well tolerated up to the 400-mg b.i.d. dose in Japanese patients with solid tumors.  Preliminary evidence of antitumor activity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfnA3Dxz9hnbVg90H21EOLACvtfcHk0liit_MqMSY8OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1eru7k%253D&md5=56706a86e4388164e010ea363bd1524c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2011.02179.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2011.02179.x%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DTanioka%26aufirst%3DM.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DAsahina%26aufirst%3DH.%26aulast%3DKawata%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTamura%26aufirst%3DT.%2BA.%26atitle%3DA%2520phase%2520I%252C%2520dose-finding%2520and%2520pharmacokinetic%2520study%2520of%2520olaparib%2520%2528AZD2281%2529%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Sci.%26date%3D2012%26volume%3D103%26spage%3D504%26epage%3D509%26doi%3D10.1111%2Fj.1349-7006.2011.02179.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Molife, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forster, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pwint, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">2599</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2599&issue=15+suppl&author=L.+R.+Molifeauthor=M.+D.+Forsterauthor=M.+Krebsauthor=T.+Pwintauthor=M.+R.+Middletonauthor=S.+B.+Kayeauthor=P.+McCormackauthor=H.+Swaislandauthor=J.+Carmichaelauthor=M.+Ranson&title=A+phase+I+study+to+determine+the+comparative+bioavailability+of+two+different+oral+formulations+of+the+PARP+inhibitor%2C+olaparib+%28AZD2281%29%2C+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DForster%26aufirst%3DM.%2BD.%26aulast%3DKrebs%26aufirst%3DM.%26aulast%3DPwint%26aufirst%3DT.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DMcCormack%26aufirst%3DP.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DA%2520phase%2520I%2520study%2520to%2520determine%2520the%2520comparative%2520bioavailability%2520of%2520two%2520different%2520oral%2520formulations%2520of%2520the%2520PARP%2520inhibitor%252C%2520olaparib%2520%2528AZD2281%2529%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D15%2520suppl%26spage%3D2599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Bundred, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardovskis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaskiewicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eglitis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paramonov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavallin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, J. M.</span><span> </span><span class="NLM_article-title">Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">958</span><span class="refDoi"> DOI: 10.1007/s10637-012-9922-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1007%2Fs10637-012-9922-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=949-958&author=N.+Bundredauthor=J.+Gardovskisauthor=J.+Jaskiewiczauthor=J.+Eglitisauthor=V.+Paramonovauthor=P.+McCormackauthor=H.+Swaislandauthor=M.+Cavallinauthor=T.+Parryauthor=J.+Carmichaelauthor=J.+M.+Dixon&title=Evaluation+of+the+pharmacodynamics+and+pharmacokinetics+of+the+PARP+inhibitor+olaparib%3A+a+Phase+I+multicentre+trial+in+patients+scheduled+for+elective+breast+cancer+surgery&doi=10.1007%2Fs10637-012-9922-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9922-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9922-7%26sid%3Dliteratum%253Aachs%26aulast%3DBundred%26aufirst%3DN.%26aulast%3DGardovskis%26aufirst%3DJ.%26aulast%3DJaskiewicz%26aufirst%3DJ.%26aulast%3DEglitis%26aufirst%3DJ.%26aulast%3DParamonov%26aufirst%3DV.%26aulast%3DMcCormack%26aufirst%3DP.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DCavallin%26aufirst%3DM.%26aulast%3DParry%26aufirst%3DT.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DDixon%26aufirst%3DJ.%2BM.%26atitle%3DEvaluation%2520of%2520the%2520pharmacodynamics%2520and%2520pharmacokinetics%2520of%2520the%2520PARP%2520inhibitor%2520olaparib%253A%2520a%2520Phase%2520I%2520multicentre%2520trial%2520in%2520patients%2520scheduled%2520for%2520elective%2520breast%2520cancer%2520surgery%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D949%26epage%3D958%26doi%3D10.1007%2Fs10637-012-9922-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Fong, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carden, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mergui-Roelvink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Greve, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messiou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">A’Hern, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span> </span><span class="NLM_article-title">Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2512</span><span class="NLM_x">–</span> <span class="NLM_lpage">2519</span><span class="refDoi"> DOI: 10.1200/JCO.2009.26.9589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2009.26.9589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20406929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVyjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2512-2519&author=P.+C.+Fongauthor=T.+A.+Yapauthor=D.+S.+Bossauthor=C.+P.+Cardenauthor=M.+Mergui-Roelvinkauthor=C.+Gourleyauthor=J.+De+Greveauthor=J.+Lubinskiauthor=S.+Shanleyauthor=C.+Messiouauthor=R.+A%E2%80%99Hernauthor=A.+Tuttauthor=A.+Ashworthauthor=J.+Stoneauthor=J.+Carmichaelauthor=J.+H.+Schellensauthor=J.+S.+de+Bonoauthor=S.+B.+Kaye&title=Poly%28ADP%29-ribose+polymerase+inhibition%3A+frequent+durable+responses+in+BRCA+carrier+ovarian+cancer+correlating+with+platinum-free+interval&doi=10.1200%2FJCO.2009.26.9589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval</span></div><div class="casAuthors">Fong, Peter C.; Yap, Timothy A.; Boss, David S.; Carden, Craig P.; Mergui-Roelvink, Maria; Gourley, Charlie; De Greve, Jacques; Lubinski, Jan; Shanley, Susan; Messiou, Christina; A'Hern, Roger; Tutt, Andrew; Ashworth, Alan; Stone, John; Carmichael, James; Schellens, Jan H. M.; de Bono, Johann S.; Kaye, Stan B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2512-2519</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair.  Platinum-based chemotherapy responses correlate with HR DNA repair capacity.  Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers.  Patients and Methods: Patients with BRCA1/2-mutated ovarian cancer were treated with olaparib within a dose-escalation and single-stage expansion of a phase I trial.  Antitumor activity was subsequently correlated with platinum sensitivity.  Results: Fifty patients were treated: 48 had germline BRCA1/2 mutations; one had a BRCA2 germline sequence change of unknown significance, and another had a strong family history of BRCA1/2-assocd. cancers who declined mutation testing.  Of the 50 patients, 13 had platinum-sensitive disease, 24 had platinum-resistant disease, and 13 had platinum-refractory disease (according to platinum-free interval).  Twenty (40%; 95% CI, 26% to 55%) achieved Response Evaluation Criteria in Solid Tumors (RECIST) complete or partial responses and/or tumor marker (CA125) responses, and three (6.0%) maintained RECIST disease stabilization for more than 4 mo, giving an overall clin. benefit rate of 46% (95% CI, 32% to 61 %).  Median response duration was 28 wk.  There was a significant assocn. between the clin. benefit rate and platinum-free interval across the platinum-sensitive, resistant, and refractory subgroups (69%, 45%, and 23%, resp.).  Post hoc analyses indicated assocns. between platinum sensitivity and extent of olaparib response (radiol. change, P = .001; CA125 change, P = .002).  Conclusion: Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is assocd. with platinum sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvj9Ym5yY27Vg90H21EOLACvtfcHk0liit_MqMSY8OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVyjtr4%253D&md5=4198806c2b9d41e7068d26049fd0cd3f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.26.9589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.26.9589%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DCarden%26aufirst%3DC.%2BP.%26aulast%3DMergui-Roelvink%26aufirst%3DM.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DDe%2BGreve%26aufirst%3DJ.%26aulast%3DLubinski%26aufirst%3DJ.%26aulast%3DShanley%26aufirst%3DS.%26aulast%3DMessiou%26aufirst%3DC.%26aulast%3DA%25E2%2580%2599Hern%26aufirst%3DR.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DPoly%2528ADP%2529-ribose%2520polymerase%2520inhibition%253A%2520frequent%2520durable%2520responses%2520in%2520BRCA%2520carrier%2520ovarian%2520cancer%2520correlating%2520with%2520platinum-free%2520interval%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D2512%26epage%3D2519%26doi%3D10.1200%2FJCO.2009.26.9589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Audeh, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penson, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell-McGuinn, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitzel, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oaknin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmutzler, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span> </span><span class="NLM_article-title">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">251</span><span class="refDoi"> DOI: 10.1016/S0140-6736(10)60893-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS0140-6736%2810%2960893-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20609468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=245-251&author=M.+W.+Audehauthor=J.+Carmichaelauthor=R.+T.+Pensonauthor=M.+Friedlanderauthor=B.+Powellauthor=K.+M.+Bell-McGuinnauthor=C.+Scottauthor=J.+N.+Weitzelauthor=A.+Oakninauthor=N.+Lomanauthor=K.+Luauthor=R.+K.+Schmutzlerauthor=U.+Matulonisauthor=M.+Wickensauthor=A.+Tutt&title=Oral+poly%28ADP-ribose%29+polymerase+inhibitor+olaparib+in+patients+with+BRCA1+or+BRCA2+mutations+and+recurrent+ovarian+cancer%3A+a+proof-of-concept+trial&doi=10.1016%2FS0140-6736%2810%2960893-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span></div><div class="casAuthors">Audeh, M. William; Carmichael, James; Penson, Richard T.; Friedlander, Michael; Powell, Bethan; Bell-McGuinn, Katherine M.; Scott, Clare; Weitzel, Jeffrey N.; Oaknin, Ana; Loman, Niklas; Lu, Karen; Schmutzler, Rita K.; Matulonis, Ursula; Wickens, Mark; Tutt, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9737</span>),
    <span class="NLM_cas:pages">245-251</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells.  We aimed to assess the efficacy and safety of olaparib for treatment of advanced ovarian cancer in patients with BRCA1 or BRCA2 mutations.  In this international, multicentre, phase 2 study, we enrolled two sequential cohorts of women (aged ≥18 years) with confirmed genetic BRCA1 or BRCA2 mutations, and recurrent, measurable disease.  The study was undertaken in 12 centers in Australia, Germany, Spain, Sweden, and the USA.  The first cohort (n=33) was given continuous oral olaparib at the max. tolerated dose of 400 mg twice daily, and the second cohort (n=24) was given continuous oral olaparib at 100 mg twice daily.  The primary efficacy endpoint was objective response rate (ORR).  This study is registered with ClinicalTrials.gov, no. NCT00494442.  Patients had been given a median of three (range 1-16) previous chemotherapy regimens.  ORR was 11 (33%) of 33 patients (95% CI 20-51) in the cohort assigned to olaparib 400 mg twice daily, and three (13%) of 24 (4-31) in the cohort assigned to 100 mg twice daily.  In patients given olaparib 400 mg twice daily, the most frequent causally related adverse events were nausea (grade 1 or 2, 14 [42%]; grade 3 or 4, 2 [6%]), fatigue (grade 1 or 2, 10 [30%]; grade 3 or 4, one [3%]), and anemia (grade 1 or 2, 5 [15%]; grade 3 or 4, 1 [3%]).  The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea (grade 1 or 2, 7 [29%]; grade 3 or 4, 2 [8%]) and fatigue (grade 1 or 2, 9 [38%]; none grade 3 or 4).  Findings from this phase 2 study provide pos. proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfC3epcFKsLrVg90H21EOLACvtfcHk0ljcnBA9Ll_Rrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D&md5=e74985d2c7ae53462d48277fbc36bb6a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960893-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960893-8%26sid%3Dliteratum%253Aachs%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DPenson%26aufirst%3DR.%2BT.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DScott%26aufirst%3DC.%26aulast%3DWeitzel%26aufirst%3DJ.%2BN.%26aulast%3DOaknin%26aufirst%3DA.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DMatulonis%26aufirst%3DU.%26aulast%3DWickens%26aufirst%3DM.%26aulast%3DTutt%26aufirst%3DA.%26atitle%3DOral%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520olaparib%2520in%2520patients%2520with%2520BRCA1%2520or%2520BRCA2%2520mutations%2520and%2520recurrent%2520ovarian%2520cancer%253A%2520a%2520proof-of-concept%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D245%26epage%3D251%26doi%3D10.1016%2FS0140-6736%2810%2960893-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlan, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amnon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell-McGuinn, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, B.</span><span> </span><span class="NLM_article-title">Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">372</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span><span class="refDoi"> DOI: 10.1200/JCO.2011.36.9215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2011.36.9215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22203755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=372-379&author=S.+B.+Kayeauthor=J.+Lubinskiauthor=U.+Matulonisauthor=J.+E.+Angauthor=C.+Gourleyauthor=B.+Y.+Karlanauthor=A.+Amnonauthor=K.+M.+Bell-McGuinnauthor=L.+M.+Chenauthor=M.+Friedlanderauthor=T.+Safraauthor=I.+Vergoteauthor=M.+Wickensauthor=E.+S.+Loweauthor=J.+Carmichaelauthor=B.+Kaufman&title=Phase+II%2C+open-label%2C+randomized%2C+multicenter+study+comparing+the+efficacy+and+safety+of+olaparib%2C+a+poly+%28ADP-ribose%29+polymerase+inhibitor%2C+and+pegylated+liposomal+doxorubicin+in+patients+with+BRCA1+or+BRCA2+mutations+and+recurrent+ovarian+cancer&doi=10.1200%2FJCO.2011.36.9215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II, open-label, randomized, multicenter study comparing the efficacy of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 and BRCA2 mutations and recurrent ovarian cancer</span></div><div class="casAuthors">Kaye, Stan B.; Lubinski, Jan; Matulonis, Ursula; Ang, Joo Ern; Gourley, Charlie; Karlan, Beth V.; Amnon, Amit; Bell-McGuinn, Katherine M.; Chen, Lee-May; Friedlander, Michael; Safra, Tamar; Vergote, Ignace; Wickens, Mark; Lowe, Elizabeth S.; Carmichael, James; Kaufman, Bella</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">372-379</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or BRCA2-deficient cells, has shown promising clin. efficacy in nonrandomized phase II trials in patients with ovarian cancer with BRCA1 or BRCA2 deficiency.  We assessed the comparative efficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population.  Patients and Methods In this multicenter, open-label, randomized, phase II study, patients with ovarian cancer that recurred within 12 mo of prior platinum therapy and with confirmed germline BRCA1 or BRCA2 mutations were enrolled.  Patients were assigned in a 1:1:1 ratio to olaparib 200 mg twice per day or 400 mg twice per day continuously or PLD 50 mg/m2 i.v. every 28 days.  The primary efficacy end point was Response Evaluation Criteria in Solid Tumors (RECIST) -assessed progression-free survival (PFS).  Secondary end points included objective response rate (ORR) and safety.  Results Ninety-seven patients were randomly assigned.  Median PFS was 6.5 mo (95% CI, 5.5 to 10.1 mo), 8.8 mo (95% CI, 5.4 to 9.2 mo), and 7.1 mo (95% CI, 3.7 to 10.7 mo) for the olaparib 200 mg, olaparib 400 mg, and PLD groups, resp.  There was no statistically significant difference in PFS (hazard ratio, 0.88; 95% CI, 0.51 to 1.56; P = .66) for combined olaparib doses vs. PLD.  RECIST-assessed ORRs were 25%, 31 %, and 18% for olaparib 200 mg, olaparib 400 mg, and PLD, resp.; differences were not statistically significant.  Tolerability of both treatments was as expected based on previous trials.  Conclusion The efficacy of olaparib was consistent with previous studies.  However, the efficacy of PLD was greater than expected.  Olaparib 400 mg twice per day is a suitable dose to explore in further studies in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMk-rXAQhaM7Vg90H21EOLACvtfcHk0ljcnBA9Ll_Rrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKgsr8%253D&md5=4f32a5c28cb1e568687f2d58c19ef885</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.36.9215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.36.9215%26sid%3Dliteratum%253Aachs%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DLubinski%26aufirst%3DJ.%26aulast%3DMatulonis%26aufirst%3DU.%26aulast%3DAng%26aufirst%3DJ.%2BE.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DKarlan%26aufirst%3DB.%2BY.%26aulast%3DAmnon%26aufirst%3DA.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DChen%26aufirst%3DL.%2BM.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DWickens%26aufirst%3DM.%26aulast%3DLowe%26aufirst%3DE.%2BS.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DB.%26atitle%3DPhase%2520II%252C%2520open-label%252C%2520randomized%252C%2520multicenter%2520study%2520comparing%2520the%2520efficacy%2520and%2520safety%2520of%2520olaparib%252C%2520a%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitor%252C%2520and%2520pegylated%2520liposomal%2520doxorubicin%2520in%2520patients%2520with%2520BRCA1%2520or%2520BRCA2%2520mutations%2520and%2520recurrent%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D372%26epage%3D379%26doi%3D10.1200%2FJCO.2011.36.9215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garber, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domchek, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audeh, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitzel, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arun, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmutzler, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span> </span><span class="NLM_article-title">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.1016/S0140-6736(10)60892-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS0140-6736%2810%2960892-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20609467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1KktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=235-244&author=A.+Tuttauthor=M.+Robsonauthor=J.+E.+Garberauthor=S.+M.+Domchekauthor=M.+W.+Audehauthor=J.+N.+Weitzelauthor=M.+Friedlanderauthor=B.+Arunauthor=N.+Lomanauthor=R.+K.+Schmutzlerauthor=A.+Wardleyauthor=G.+Mitchellauthor=H.+Earlauthor=M.+Wickensauthor=J.+Carmichael&title=Oral+poly%28ADP-ribose%29+polymerase+inhibitor+olaparib+in+patients+with+BRCA1+or+BRCA2+mutations+and+advanced+breast+cancer%3A+a+proof-of-concept+trial&doi=10.1016%2FS0140-6736%2810%2960892-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial</span></div><div class="casAuthors">Tutt, Andrew; Robson, Mark; Garber, Judy E.; Domchek, Susan M.; Audeh, M. William; Weitzel, Jeffrey N.; Friedlander, Michael; Arun, Banu; Loman, Niklas; Schmutzler, Rita K.; Wardley, Andrew; Mitchell, Gillian; Earl, Helena; Wickens, Mark; Carmichael, James</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9737</span>),
    <span class="NLM_cas:pages">235-244</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced synthetic lethality in BRCA-deficient cells.  A max. tolerated dose and initial signal of efficacy in BRCA-deficient ovarian cancers have been reported.  We therefore assessed the efficacy, safety, and tolerability of olaparib alone in women with BRCA1 or BRCA2 mutations and advanced breast cancer.  Women (aged ≥18 years) with confirmed BRCA1 or BRCA2 mutations and recurrent, advanced breast cancer were assigned to two sequential cohorts in a phase 2 study undertaken in 16 centers in Australia, Germany, Spain, Sweden, the UK, and the USA.  The first cohort (n=27) was given continuous oral olaparib at the max. tolerated dose (400 mg twice daily), and the second (n=27) was given a lower dose (100 mg twice daily).  The primary efficacy endpoint was objective response rate (ORR).  This study is registered with ClinicalTrials.gov, no. NCT00494234.  Patients had been given a median of three previous chemotherapy regimens (range 1-5 in cohort 1, and 2-4 in cohort 2).  ORR was 11 (41%) of 27 patients (95% CI 25-59) in the cohort assigned to 400 mg twice daily, and 6 (22%) of 27 (11-41) in the cohort assigned to 100 mg twice daily.  Toxicities were mainly at low grades.  The most frequent causally related adverse events in the cohort given 400 mg twice daily were fatigue (grade 1 or 2, 11 [41%]; grade 3 or 4, 4 [15%]), nausea (grade 1 or 2, 11 [41%]; grade 3 or 4, 4 [15%]), vomiting (grade 1 or 2, 3 [11%]; grade 3 or 4, 3 [11%]), and anemia (grade 1 or 2, 1 [4%]; grade 3 or 4, 3 [11%]).  The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea (grade 1 or 2, 11 [41%]; none grade 3 or 4) and fatigue (grade 1 or 2, 7 [26%]; grade 3 or 4, 1 [4%]).  The results of this study provide pos. proof of concept for PARP inhibition in BRCA-deficient breast cancers and shows a favorable therapeutic index for a novel targeted treatment strategy in patients with tumors that have genetic loss of function of BRCA1-assocd. or BRCA2-assocd. DNA repair.  Toxicity in women with BRCA1 and BRCA2 mutations was similar to that reported previously in those without such mutations.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonjJjcPScaZbVg90H21EOLACvtfcHk0lgad7Q17q8ZXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1KktLc%253D&md5=a797f2aef3dd530bc74e57f2050fa7d7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960892-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960892-6%26sid%3Dliteratum%253Aachs%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DGarber%26aufirst%3DJ.%2BE.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DWeitzel%26aufirst%3DJ.%2BN.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DArun%26aufirst%3DB.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DWardley%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DG.%26aulast%3DEarl%26aufirst%3DH.%26aulast%3DWickens%26aufirst%3DM.%26aulast%3DCarmichael%26aufirst%3DJ.%26atitle%3DOral%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520olaparib%2520in%2520patients%2520with%2520BRCA1%2520or%2520BRCA2%2520mutations%2520and%2520advanced%2520breast%2520cancer%253A%2520a%2520proof-of-concept%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D235%26epage%3D244%26doi%3D10.1016%2FS0140-6736%2810%2960892-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Mateo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mossop, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Lopez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nava Rodrigues, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunariu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boysen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figueiredo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulding, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seed, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralph, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protheroe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGovern, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zafeiriou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraldeschi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riisnaes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebbs, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">A’Hern, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunju, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eeles, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">DNA-repair defects and olaparib in metastatic prostate cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">1697</span><span class="NLM_x">–</span> <span class="NLM_lpage">1708</span><span class="refDoi"> DOI: 10.1056/NEJMoa1506859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1056%2FNEJMoa1506859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26510020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVemuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1697-1708&author=J.+Mateoauthor=S.+Carreiraauthor=S.+Sandhuauthor=S.+Mirandaauthor=H.+Mossopauthor=R.+Perez-Lopezauthor=D.+Nava+Rodriguesauthor=D.+Robinsonauthor=A.+Omlinauthor=N.+Tunariuauthor=G.+Boysenauthor=N.+Portaauthor=P.+Flohrauthor=A.+Gillmanauthor=I.+Figueiredoauthor=C.+Pauldingauthor=G.+Seedauthor=S.+Jainauthor=C.+Ralphauthor=A.+Protheroeauthor=S.+Hussainauthor=R.+Jonesauthor=T.+Elliottauthor=U.+McGovernauthor=D.+Bianchiniauthor=J.+Goodallauthor=Z.+Zafeiriouauthor=C.+T.+Williamsonauthor=R.+Ferraldeschiauthor=R.+Riisnaesauthor=B.+Ebbsauthor=G.+Fowlerauthor=D.+Rodaauthor=W.+Yuanauthor=Y.+M.+Wuauthor=X.+Caoauthor=R.+Broughauthor=H.+Pembertonauthor=R.+A%E2%80%99Hernauthor=A.+Swainauthor=L.+P.+Kunjuauthor=R.+Eelesauthor=G.+Attardauthor=C.+J.+Lordauthor=A.+Ashworthauthor=M.+A.+Rubinauthor=K.+E.+Knudsenauthor=F.+Y.+Fengauthor=A.+M.+Chinnaiyanauthor=E.+Hallauthor=J.+S.+de+Bono&title=DNA-repair+defects+and+olaparib+in+metastatic+prostate+cancer&doi=10.1056%2FNEJMoa1506859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-repair defects and olaparib in metastatic prostate cancer</span></div><div class="casAuthors">Mateo, J.; Carreira, S.; Sandhu, S.; Miranda, S.; Mossop, H.; Perez-Lopez, R.; Rodrigues, D. Nava; Robinson, D.; Omlin, A.; Tunariu, N.; Boysen, G.; Porta, N.; Flohr, P.; Gillman, A.; Figueiredo, I.; Paulding, C.; Seed, G.; Jain, S.; Ralph, C.; Protheroe, A.; Hussain, S.; Jones, R.; Elliott, T.; McGovern, U.; Bianchini, D.; Goodall, J.; Zafeiriou, Z.; Williamson, C. T.; Ferraldeschi, R.; Riisnaes, R.; Ebbs, B.; Fowler, G.; Roda, D.; Yuan, W.; Wu, Y.-M.; Cao, X.; Brough, R.; Pemberton, H.; A'Hern, R.; Swain, A.; Kunju, L. P.; Eeles, R.; Attard, G.; Lord, C. J.; Ashworth, A.; Rubin, M. A.; Knudsen, K. E.; Feng, F. Y.; Chinnaiyan, A. M.; Hall, E.; de Bono, J. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1697-1708</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Prostate cancer is a heterogeneous disease, but current treatments are not based on mol. stratification.  We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(ADP [ADP]-ribose) polymerase (PARP) inhibition with olaparib.  We conducted a phase 2 trial in which patients with metastatic, castration-resistant prostate cancer were treated with olaparib tablets at a dose of 400 mg twice a day.  The primary end point was the response rate, defined either as an objective response according to Response Evaluation Criteria in Solid Tumors, version 1.1, or as a redn. of at least 50% in the prostate-specific antigen level or a confirmed redn. in the circulating tumor-cell count from 5 or more cells per 7.5 mL of blood to less than 5 cells per 7.5 mL.  Targeted next-generation sequencing, exome and transcriptome anal., and digital polymerase-chain-reaction testing were performed on samples from mandated tumor biopsies.  Overall, 50 patients were enrolled; all had received prior treatment with docetaxel, 49 (98%) had received abiraterone or enzalutamide, and 29 (58%) had received cabazitaxel.  Sixteen of 49 patients who could be evaluated had a response (33%; 95% confidence interval, 20 to 48), with 12 patients receiving the study treatment for more than 6 mo.  Next-generation sequencing identified homozygous deletions, deleterious mutations, or both in DNA-repair genes - including BRCA1/2, ATM, Fanconi's anemia genes, and CHEK2 - in 16 of 49 patients who could be evaluated (33%).  Of these 16 patients, 14 (88%) had a response to olaparib, including all 7 patients with BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations) and 4 of 5 with ATM aberrations.  The specificity of the biomarker suite was 94%.  Anemia (in 10 of the 50 patients [20%]) and fatigue (in 6 [12%]) were the most common grade 3 or 4 adverse events, findings that are consistent with previous studies of olaparib.  Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to std. treatments and who had defects in DNA-repair genes led to a high response rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6UTScmDZ6SLVg90H21EOLACvtfcHk0lgad7Q17q8ZXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVemuro%253D&md5=8a54b17a8d5b7dd8d35afae907c00fe8</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1506859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1506859%26sid%3Dliteratum%253Aachs%26aulast%3DMateo%26aufirst%3DJ.%26aulast%3DCarreira%26aufirst%3DS.%26aulast%3DSandhu%26aufirst%3DS.%26aulast%3DMiranda%26aufirst%3DS.%26aulast%3DMossop%26aufirst%3DH.%26aulast%3DPerez-Lopez%26aufirst%3DR.%26aulast%3DNava%2BRodrigues%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DOmlin%26aufirst%3DA.%26aulast%3DTunariu%26aufirst%3DN.%26aulast%3DBoysen%26aufirst%3DG.%26aulast%3DPorta%26aufirst%3DN.%26aulast%3DFlohr%26aufirst%3DP.%26aulast%3DGillman%26aufirst%3DA.%26aulast%3DFigueiredo%26aufirst%3DI.%26aulast%3DPaulding%26aufirst%3DC.%26aulast%3DSeed%26aufirst%3DG.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DRalph%26aufirst%3DC.%26aulast%3DProtheroe%26aufirst%3DA.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DElliott%26aufirst%3DT.%26aulast%3DMcGovern%26aufirst%3DU.%26aulast%3DBianchini%26aufirst%3DD.%26aulast%3DGoodall%26aufirst%3DJ.%26aulast%3DZafeiriou%26aufirst%3DZ.%26aulast%3DWilliamson%26aufirst%3DC.%2BT.%26aulast%3DFerraldeschi%26aufirst%3DR.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DEbbs%26aufirst%3DB.%26aulast%3DFowler%26aufirst%3DG.%26aulast%3DRoda%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DY.%2BM.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DPemberton%26aufirst%3DH.%26aulast%3DA%25E2%2580%2599Hern%26aufirst%3DR.%26aulast%3DSwain%26aufirst%3DA.%26aulast%3DKunju%26aufirst%3DL.%2BP.%26aulast%3DEeles%26aufirst%3DR.%26aulast%3DAttard%26aufirst%3DG.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DKnudsen%26aufirst%3DK.%2BE.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26aulast%3DHall%26aufirst%3DE.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DDNA-repair%2520defects%2520and%2520olaparib%2520in%2520metastatic%2520prostate%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1697%26epage%3D1708%26doi%3D10.1056%2FNEJMoa1506859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Choy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmon, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Adamo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamand, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="refDoi"> DOI: 10.1186/1471-2407-14-813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2F1471-2407-14-813" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=813&author=E.+Choyauthor=J.+E.+Butrynskiauthor=D.+C.+Harmonauthor=J.+A.+Morganauthor=S.+Georgeauthor=A.+J.+Wagnerauthor=D.+D%E2%80%99Adamoauthor=G.+M.+Coteauthor=Y.+Flamandauthor=C.+H.+Benesauthor=D.+A.+Haberauthor=J.+M.+Baselgaauthor=G.+D.+Demetri&title=Phase+II+study+of+olaparib+in+patients+with+refractory+Ewing+sarcoma+following+failure+of+standard+chemotherapy&doi=10.1186%2F1471-2407-14-813"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-14-813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-14-813%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DE.%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DHarmon%26aufirst%3DD.%2BC.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%26aulast%3DCote%26aufirst%3DG.%2BM.%26aulast%3DFlamand%26aufirst%3DY.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DBaselga%26aufirst%3DJ.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DPhase%2520II%2520study%2520of%2520olaparib%2520in%2520patients%2520with%2520refractory%2520Ewing%2520sarcoma%2520following%2520failure%2520of%2520standard%2520chemotherapy%26jtitle%3DBMC%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D813%26doi%3D10.1186%2F1471-2407-14-813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hays, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annunziata, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noonan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minasian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zujewski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sissung, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azad, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, E. C.</span><span> </span><span class="NLM_article-title">Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">dju089</span><span class="refDoi"> DOI: 10.1093/jnci/dju089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fjnci%2Fdju089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24842883" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=dju089&author=J.+M.+Leeauthor=J.+L.+Haysauthor=C.+M.+Annunziataauthor=A.+M.+Noonanauthor=L.+Minasianauthor=J.+A.+Zujewskiauthor=M.+Yuauthor=N.+Gordonauthor=J.+Jiauthor=T.+M.+Sissungauthor=W.+D.+Figgauthor=N.+Azadauthor=B.+J.+Woodauthor=J.+Doroshowauthor=E.+C.+Kohn&title=Phase+I%2FIb+study+of+olaparib+and+carboplatin+in+BRCA1+or+BRCA2+mutation-associated+breast+or+ovarian+cancer+with+biomarker+analyses&doi=10.1093%2Fjnci%2Fdju089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdju089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdju089%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DHays%26aufirst%3DJ.%2BL.%26aulast%3DAnnunziata%26aufirst%3DC.%2BM.%26aulast%3DNoonan%26aufirst%3DA.%2BM.%26aulast%3DMinasian%26aufirst%3DL.%26aulast%3DZujewski%26aufirst%3DJ.%2BA.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DN.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DSissung%26aufirst%3DT.%2BM.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DAzad%26aufirst%3DN.%26aulast%3DWood%26aufirst%3DB.%2BJ.%26aulast%3DDoroshow%26aufirst%3DJ.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26atitle%3DPhase%2520I%252FIb%2520study%2520of%2520olaparib%2520and%2520carboplatin%2520in%2520BRCA1%2520or%2520BRCA2%2520mutation-associated%2520breast%2520or%2520ovarian%2520cancer%2520with%2520biomarker%2520analyses%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2014%26volume%3D106%26spage%3Ddju089%26doi%3D10.1093%2Fjnci%2Fdju089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Balmaña, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakoff, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graña, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frewer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garber, J. E.</span><span> </span><span class="NLM_article-title">Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1656</span><span class="NLM_x">–</span> <span class="NLM_lpage">1663</span><span class="refDoi"> DOI: 10.1093/annonc/mdu187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fannonc%2Fmdu187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24827126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2cjislyjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1656-1663&author=J.+Balma%C3%B1aauthor=N.+M.+Tungauthor=S.+J.+Isakoffauthor=B.+Gra%C3%B1aauthor=P.+D.+Ryanauthor=C.+Sauraauthor=E.+S.+Loweauthor=P.+Frewerauthor=E.+Winerauthor=J.+Baselgaauthor=J.+E.+Garber&title=Phase+I+trial+of+olaparib+in+combination+with+cisplatin+for+the+treatment+of+patients+with+advanced+breast%2C+ovarian+and+other+solid+tumors&doi=10.1093%2Fannonc%2Fmdu187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors</span></div><div class="casAuthors">Balmana J; Grana B; Saura C; Tung N M; Isakoff S J; Ryan P D; Lowe E S; Frewer P; Winer E; Garber J E; Baselga J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1656-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  To establish the maximum tolerated dose, determine safety/tolerability and evaluate the pharmacokinetics and preliminary efficacy of olaparib in combination with cisplatin in patients with advanced solid tumors.  PATIENTS AND METHODS:  Patients aged ≥ 18 years with advanced solid tumors, who had progressed on standard treatment, were assigned to a treatment cohort and received oral olaparib [50-200 mg twice daily (bid); 21-day cycle] continuously or intermittently (days 1-5 or 1-10) in combination with cisplatin (60-75 mg/m(2) intravenously) on day 1 of each cycle.  RESULTS:  Dose-limiting toxicities (DLTs) of grade 3 neutropenia (cisplatin 75 mg/m(2) with continuous olaparib 100 mg bid or 200 mg bid; n = 1 each) and grade 3 lipase elevation (cisplatin 75 mg/m(2) with olaparib 100 mg bid days 1-10 or 50 mg bid days 1-5; n = 1 each) were reported.  Olaparib and cisplatin doses were subsequently reduced to 50 mg bid days 1-5 and 60 mg/m(2), respectively; no DLTs were reported for patients receiving this regimen.  The most frequent grade ≥ 3 adverse events were neutropenia (16.7%), anemia (9.3%) and leucopenia (9.3%).  Thirty patients (55.6%) received colony-stimulating factors for hematologic support.  The overall objective response rate was 41% for patients with measurable disease, and 43% and 71% among patients with a BRCA1/2 mutation who had ovarian and breast cancer, respectively.  CONCLUSIONS:  Olaparib in combination with cisplatin 75 mg/m(2) was not considered tolerable; intermittent olaparib (50 mg bid, days 1-5) with cisplatin 60 mg/m(2) improved tolerability.  Promising antitumor activity in patients with germline BRCA1/2 mutations was observed and warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsk4Vjqyl9wRpyrDyM_m9cfW6udTcc2eZSnlmuWoWPILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjislyjug%253D%253D&md5=10beab5b7a4eec0000a7a8e687f88d3e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu187%26sid%3Dliteratum%253Aachs%26aulast%3DBalma%25C3%25B1a%26aufirst%3DJ.%26aulast%3DTung%26aufirst%3DN.%2BM.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DGra%25C3%25B1a%26aufirst%3DB.%26aulast%3DRyan%26aufirst%3DP.%2BD.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DLowe%26aufirst%3DE.%2BS.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DWiner%26aufirst%3DE.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DGarber%26aufirst%3DJ.%2BE.%26atitle%3DPhase%2520I%2520trial%2520of%2520olaparib%2520in%2520combination%2520with%2520cisplatin%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520advanced%2520breast%252C%2520ovarian%2520and%2520other%2520solid%2520tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D1656%26epage%3D1663%26doi%3D10.1093%2Fannonc%2Fmdu187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Del Conte, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sessa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Moos, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viganò, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Digena, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locatelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallerani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasolo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tessari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cathomas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span> </span><span class="NLM_article-title">Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span><span class="refDoi"> DOI: 10.1038/bjc.2014.345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fbjc.2014.345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25025963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyhsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=651-659&author=G.+Del+Conteauthor=C.+Sessaauthor=R.+von+Moosauthor=L.+Vigan%C3%B2author=T.+Digenaauthor=A.+Locatelliauthor=E.+Galleraniauthor=A.+Fasoloauthor=A.+Tessariauthor=R.+Cathomasauthor=L.+Gianni&title=Phase+I+study+of+olaparib+in+combination+with+liposomal+doxorubicin+in+patients+with+advanced+solid+tumours&doi=10.1038%2Fbjc.2014.345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours</span></div><div class="casAuthors">Del Conte, G.; Sessa, C.; von Moos, R.; Vigano, L.; Digena, T.; Locatelli, A.; Gallerani, E.; Fasolo, A.; Tessari, A.; Cathomas, R.; Gianni, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">651-659</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Olaparib, an oral PARP inhibitor, has shown antitumor activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer.  This study evaluated olaparib capsules in combination with liposomal doxorubicin (PLD) in patients with advanced solid tumors (NCT00819221).  Methods: Patients received 28-day cycles of olaparib, continuously (days 1-28) or intermittently (days 1-7), plus PLD (40 mg m-2, day 1); seven olaparib dose cohorts (50-400 mg bid) were explored to det. the recommended dose.  Assessments included safety, pharmacokinetics, pharmacodynamics and preliminary efficacy (objective response rate (ORR)).  Results: Of 44 patients treated (ovarian, n=28; breast, n=13; other/unknown, n=3), two experienced dose-limiting toxicities (grade 3 stomatitis and fatal pneumonia/pneumonitis (200 mg per 28-day cycle); grade 4 thrombocytopenia (400 mg per 7-day cycle)).  The max. tolerated dose was not reached using continuous olaparib 400 mg bid plus PLD.  Grade ≥3 and serious AEs were reported for 27 (61%) and 12 (27%) patients, resp.  No major pharmacokinetic interference was obsd. between olaparib and PLD.  The ORR was 33% (n=14 out of 42; complete response, n=3).  A total of 13 responders had ovarian cancer: 10 were platinum-sensitive, 11 had a gBRCA mutation.  Conclusions: Continuous/intermittent olaparib (up to 400 mg bid) combined with PLD (40 mg m-2) was generally tolerated and showed evidence of antitumor activity in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-rSh3-J1BVbVg90H21EOLACvtfcHk0liOWWK7qERMqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyhsbzP&md5=02f946362148381e15a25e527a4117f5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2014.345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2014.345%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BConte%26aufirst%3DG.%26aulast%3DSessa%26aufirst%3DC.%26aulast%3Dvon%2BMoos%26aufirst%3DR.%26aulast%3DVigan%25C3%25B2%26aufirst%3DL.%26aulast%3DDigena%26aufirst%3DT.%26aulast%3DLocatelli%26aufirst%3DA.%26aulast%3DGallerani%26aufirst%3DE.%26aulast%3DFasolo%26aufirst%3DA.%26aulast%3DTessari%26aufirst%3DA.%26aulast%3DCathomas%26aufirst%3DR.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DPhase%2520I%2520study%2520of%2520olaparib%2520in%2520combination%2520with%2520liposomal%2520doxorubicin%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2014%26volume%3D111%26spage%3D651%26epage%3D659%26doi%3D10.1038%2Fbjc.2014.345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Rajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kummar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannargudi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span> </span><span class="NLM_article-title">A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2344</span><span class="NLM_x">–</span> <span class="NLM_lpage">2351</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-11-2425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22371451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFOnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2344-2351&author=A.+Rajanauthor=C.+A.+Carterauthor=R.+J.+Kellyauthor=M.+Gutierrezauthor=S.+Kummarauthor=E.+Szaboauthor=M.+A.+Yanceyauthor=J.+Jiauthor=B.+Mannargudiauthor=S.+Wooauthor=S.+Spencerauthor=W.+D.+Figgauthor=G.+Giaccone&title=A+phase+I+combination+study+of+olaparib+with+cisplatin+and+gemcitabine+in+adults+with+solid+tumors&doi=10.1158%2F1078-0432.CCR-11-2425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors</span></div><div class="casAuthors">Rajan, Arun; Carter, Corey A.; Kelly, Ronan J.; Gutierrez, Martin; Kummar, Shivaani; Szabo, Eva; Yancey, Mary Ann; Ji, Jiuping; Mannargudi, Baskar; Woo, Sukyung; Spencer, Shawn; Figg, William Douglas; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2344-2351</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To det. the safety and tolerability of olaparib with cisplatin and gemcitabine, establish the max. tolerated dose (MTD), and evaluate the pharmacodynamic and pharmacokinetic profile of the combination.  Exptl. Design: We conducted a phase I study of olaparib with cisplatin and gemcitabine in patients with advanced solid tumors.  Treatment at dose level 1 (DL1) consisted of olaparib 100 mg orally every 12 h on days 1 to 4, gemcitabine 500 mg/m2 on days 3 and 10, and cisplatin 60 mg/m2 on day 3.  PAR levels were measured in peripheral blood mononuclear cells (PBMC).  RESULTS: Dose-limiting toxicities (DLT) in two of three patients at DL1 included thrombocytopenia and febrile neutropenia.  The protocol was amended to enroll patients treated with ≤2 prior severely myelosuppressive chemotherapy regimens and treated with olaparib 100 mg once daily on days 1 to 4 (DL-1).  No DLTs were seen in six patients at DL-1.  Because of persistent thrombocytopenia and neutropenia following a return to DL1, patients received 100 mg olaparib every 12 h on day 1 only.  No hematol. DLTs were obsd.; nonhematol. DLTs included gastrointestinal bleed, syncope, and hypoxia.  Of 21 patients evaluable for response, two had partial response.  Olaparib inhibited PARP in PBMCs and tumor tissue, although PAR levels were less effectively inhibited when olaparib was used for a short duration.  CONCLUSIONS: Olaparib in combination with cisplatin and gemcitabine is assocd. with myelosuppression even at relatively low doses.  Modified schedules of olaparib in chemotherapy naive patients will have to be explored with std. doses of chemotherapy.  Clin Cancer Res; 18(8); 2344-51.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI7TqGiAg307Vg90H21EOLACvtfcHk0lg8UqApZyffUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFOnu7o%253D&md5=c1b311dfb8abb03ba06b7d5b5a9739b6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2425%26sid%3Dliteratum%253Aachs%26aulast%3DRajan%26aufirst%3DA.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DKelly%26aufirst%3DR.%2BJ.%26aulast%3DGutierrez%26aufirst%3DM.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DYancey%26aufirst%3DM.%2BA.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DMannargudi%26aufirst%3DB.%26aulast%3DWoo%26aufirst%3DS.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DA%2520phase%2520I%2520combination%2520study%2520of%2520olaparib%2520with%2520cisplatin%2520and%2520gemcitabine%2520in%2520adults%2520with%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2344%26epage%3D2351%26doi%3D10.1158%2F1078-0432.CCR-11-2425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Samol, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassidy, J.</span><span> </span><span class="NLM_article-title">Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span><span class="refDoi"> DOI: 10.1007/s10637-011-9682-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1007%2Fs10637-011-9682-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21590367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVyksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1493-1500&author=J.+Samolauthor=M.+Ransonauthor=E.+Scottauthor=E.+Macphersonauthor=J.+Carmichaelauthor=A.+Thomasauthor=J.+Cassidy&title=Safety+and+tolerability+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor%2C+olaparib+%28AZD2281%29+in+combination+with+topotecan+for+the+treatment+of+patients+with+advanced+solid+tumors%3A+a+phase+I+study&doi=10.1007%2Fs10637-011-9682-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study</span></div><div class="casAuthors">Samol, Jens; Ranson, Malcolm; Scott, Edwina; MacPherson, Euan; Carmichael, James; Thomas, Anne; Cassidy, James</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1493-1500</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: The aim of this phase I study was to det. the safety and tolerability and to establish the max. tolerated dose (MTD) of orally administered olaparib (AZD2281) in combination with topotecan in patients with advanced solid tumors.  Patients and methods: Patients aged ≥18 years with histol. or cytol. diagnosed advanced solid tumors for whom no suitable effective therapy exists were included.  Patients in four cohorts received topotecan (0.5 mg/m2/day × 3 days or 1.0 mg/m2/day × 3 days) i.v. in combination with oral olaparib 50, 100 or 200 mg bid for six cycles.  The primary objectives were to det. the safety and tolerability and to establish the MTD of olaparib in combination with topotecan.  Results: Twenty-one patients were enrolled and 19 received treatment.  Dose-limiting toxicities were neutropenia and thrombocytopenia.  The MTD was established as topotecan 1.0 mg/m2/day × 3 days plus olaparib 100 mg bid.  The most common adverse events (AEs) included fatigue and gastrointestinal events.  There was an olaparib and topotecan dose-related increase in neutropenia which was dose limiting.  Conclusions: Further development of olaparib and topotecan in combination was not explored due to dose-limiting hematol. AEs and the resulting sub-therapeutic MTD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpxE-e7YyctbVg90H21EOLACvtfcHk0lg8UqApZyffUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVyksrg%253D&md5=4c51e093fa061c437d15e29add6f7fb0</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs10637-011-9682-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-011-9682-9%26sid%3Dliteratum%253Aachs%26aulast%3DSamol%26aufirst%3DJ.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DE.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DCassidy%26aufirst%3DJ.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%252C%2520olaparib%2520%2528AZD2281%2529%2520in%2520combination%2520with%2520topotecan%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520advanced%2520solid%2520tumors%253A%2520a%2520phase%2520I%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D1493%26epage%3D1500%26doi%3D10.1007%2Fs10637-011-9682-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Khan, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greystoke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGown, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorncroft, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margison, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Califano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span> </span><span class="NLM_article-title">A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">750</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span><span class="refDoi"> DOI: 10.1038/bjc.2011.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fbjc.2011.8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21326243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXis1eit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2011&pages=750-755&author=O.+A.+Khanauthor=M.+Goreauthor=P.+Loriganauthor=J.+Stoneauthor=A.+Greystokeauthor=W.+Burkeauthor=J.+Carmichaelauthor=A.+J.+Watsonauthor=G.+McGownauthor=M.+Thorncroftauthor=G.+P.+Margisonauthor=R.+Califanoauthor=J.+Larkinauthor=S.+Wellmanauthor=M.+R.+Middleton&title=A+phase+I+study+of+the+safety+and+tolerability+of+olaparib+%28AZD2281%2C+KU0059436%29+and+dacarbazine+in+patients+with+advanced+solid+tumours&doi=10.1038%2Fbjc.2011.8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours</span></div><div class="casAuthors">Khan, O. A.; Gore, M.; Lorigan, P.; Stone, J.; Greystoke, A.; Burke, W.; Carmichael, J.; Watson, A. J.; McGown, G.; Thorncroft, M.; Margison, G. P.; Califano, R.; Larkin, J.; Wellman, S.; Middleton, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">750-755</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Poly ADP-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the base excision repair pathway (BER).  The PARP inhibition can be directly cytotoxic to tumor cells and augments the anti-tumor effects of DNA-damaging agents.  This study evaluated the optimally tolerated dose of olaparib (4-(3--4-fluorophenyl) methyl-1(2H)-one; AZD2281, KU0059436), a potent PARP inhibitor, with dacarbazine and assessed safety, toxicity, clin. pharmacokinetics and efficacy of combination treatment.  Patients and methods: Patients with advanced cancer received olaparib (20-200 mg PO) on days 1-7 with dacarbazine (600-800 mg m-2 IV) on day 1 (cycle 2, day 2) of a 21-day cycle.  An expansion cohort of chemonaive melanoma patients was treated at an optimally tolerated dose.  The BER enzyme, methylpurine-DNA glycosylase and its substrate 7-methylguanine were quantified in peripheral blood mononuclear cells.  Results: The optimal combination to proceed to phase II was defined as 100 mg bd olaparib with 600 mg m-2 dacarbazine.  Dose-limiting toxicities were neutropaenia and thrombocytopaenia.  There were two partial responses, both in patients with melanoma.  Conclusion: This study defined a tolerable dose of olaparib in combination with dacarbazine, but there were no responses in chemonaive melanoma patients, demonstrating no clin. advantage over single-agent dacarbazine at these doses.  British Journal of Cancer (2011) 104, 750-755; doi:10.1038/bjc.2011.8 www.bjcancer.com. Published online 15 Feb. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVFcr3GWBYlrVg90H21EOLACvtfcHk0liroo3I0U6Row"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXis1eit7Y%253D&md5=0fb6c9543b41feafac4821e5c55c5d30</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.8%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DO.%2BA.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DGreystoke%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DW.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DA.%2BJ.%26aulast%3DMcGown%26aufirst%3DG.%26aulast%3DThorncroft%26aufirst%3DM.%26aulast%3DMargison%26aufirst%3DG.%2BP.%26aulast%3DCalifano%26aufirst%3DR.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DWellman%26aufirst%3DS.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520the%2520safety%2520and%2520tolerability%2520of%2520olaparib%2520%2528AZD2281%252C%2520KU0059436%2529%2520and%2520dacarbazine%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D104%26spage%3D750%26epage%3D755%26doi%3D10.1038%2Fbjc.2011.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Dent, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemons, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildiers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span> </span><span class="NLM_article-title">Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">R88</span><span class="refDoi"> DOI: 10.1186/bcr3484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2Fbcr3484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24063698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=R88&author=R.+A.+Dentauthor=G.+J.+Lindemanauthor=M.+Clemonsauthor=H.+Wildiersauthor=A.+Chanauthor=N.+J.+McCarthyauthor=C.+F.+Singerauthor=E.+S.+Loweauthor=C.+L.+Watkinsauthor=J.+Carmichael&title=Phase+I+trial+of+the+oral+PARP+inhibitor+olaparib+in+combination+with+paclitaxel+for+first-+or+second-line+treatment+of+patients+with+metastatic+triple-negative+breast+cancer&doi=10.1186%2Fbcr3484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer</span></div><div class="casAuthors">Dent, Rebecca A.; Lindeman, Geoffrey J.; Clemons, Mark; Wildiers, Hans; Chan, Arlene; McCarthy, Nicole J.; Singer, Christian F.; Lowe, Elizabeth S.; Watkins, Claire L.; Carmichael, James</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">R88/1-R88/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-neg. breast cancer (mTNBC).  Methods: Eligible patients who had received ≤1 prior cytotoxic regimen for mTNBC were treated with olaparib 200 mg bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle.  Dose modifications in a large proportion of patients due to neutropenia resulted in enrollment of a second cohort of patients who, if they experienced grade ≥2 neutropenia in cycle 1, received granulocyte-colony stimulating factor, which was continued prophylactically in subsequent cycles.  All patients had measurable disease; tumor responses were evaluated according to RECIST (version 1.0).  Results: Nineteen patients (cohort 1, n = 9; cohort 2, n = 10) received treatment; 15 had received prior taxane chemotherapy.  The most frequent adverse events were diarrhea (n = 12, 63%), nausea (n = 11, 58%) and neutropenia (n = 11, 58%).  Seven neutropenia events were reported in cohort 1 (four grade ≥3) and four in cohort 2 (two grade ≥3, including one event of febrile neutropenia).  The median (range) dose intensity of paclitaxel was 57% (26 to 100%) in cohort 1 and 73% (29 to 100%) in cohort 2.  Seven patients (37%) had a confirmed partial response; one patient remains on olaparib monotherapy without progression.  Conclusions: The combination of olaparib and weekly paclitaxel was complicated by a significant clin. interaction, with higher-than-expected rates of neutropenia despite secondary prophylaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFe81cPlJPr7Vg90H21EOLACvtfcHk0liroo3I0U6Row"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb8%253D&md5=1da261cd68c4d2cd5b8eb222dc61db9c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1186%2Fbcr3484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr3484%26sid%3Dliteratum%253Aachs%26aulast%3DDent%26aufirst%3DR.%2BA.%26aulast%3DLindeman%26aufirst%3DG.%2BJ.%26aulast%3DClemons%26aufirst%3DM.%26aulast%3DWildiers%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DMcCarthy%26aufirst%3DN.%2BJ.%26aulast%3DSinger%26aufirst%3DC.%2BF.%26aulast%3DLowe%26aufirst%3DE.%2BS.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DCarmichael%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520oral%2520PARP%2520inhibitor%2520olaparib%2520in%2520combination%2520with%2520paclitaxel%2520for%2520first-%2520or%2520second-line%2520treatment%2520of%2520patients%2520with%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2013%26volume%3D15%26spage%3DR88%26doi%3D10.1186%2Fbcr3484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Rivkin, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iriarte, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiseman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, J.</span><span> </span><span class="NLM_article-title">Phase Ib/II with expansion of patients at the MTD study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">5527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=5527&issue=15+suppl&author=S.+E.+Rivkinauthor=D.+Iriarteauthor=H.+Sloanauthor=C.+Wisemanauthor=J.+Moon&title=Phase+Ib%2FII+with+expansion+of+patients+at+the+MTD+study+of+olaparib+plus+weekly+%28metronomic%29+carboplatin+and+paclitaxel+in+relapsed+ovarian+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRivkin%26aufirst%3DS.%2BE.%26aulast%3DIriarte%26aufirst%3DD.%26aulast%3DSloan%26aufirst%3DH.%26aulast%3DWiseman%26aufirst%3DC.%26aulast%3DMoon%26aufirst%3DJ.%26atitle%3DPhase%2520Ib%252FII%2520with%2520expansion%2520of%2520patients%2520at%2520the%2520MTD%2520study%2520of%2520olaparib%2520plus%2520weekly%2520%2528metronomic%2529%2520carboplatin%2520and%2520paclitaxel%2520in%2520relapsed%2520ovarian%2520cancer%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15%2520suppl%26spage%3D5527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Oza, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cibula, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benzaquen, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathijssen, R. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonke, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spacek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vuylsteke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirte, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plante, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmalfeldt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowbottom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchakov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlander, M.</span><span> </span><span class="NLM_article-title">Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">5001</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=5001&issue=15+suppl&author=A.+M.+Ozaauthor=D.+Cibulaauthor=A.+O.+Benzaquenauthor=C.+J.+Pooleauthor=R.+H.+J.+Mathijssenauthor=G.+S.+Sonkeauthor=N.+Colomboauthor=J.+Spacekauthor=P.+Vuylstekeauthor=H.+W.+Hirteauthor=S.+Mahnerauthor=M.+Planteauthor=B.+Schmalfeldtauthor=H.+Mackayauthor=J.+Rowbottomauthor=I.+Tchakovauthor=M.+Friedlander&title=Olaparib+plus+paclitaxel+plus+carboplatin+%28P%2FC%29+followed+by+olaparib+maintenance+treatment+in+patients+%28pts%29+with+platinum-sensitive+recurrent+serous+ovarian+cancer+%28PSR+SOC%29%3A+A+randomized%2C+open-label+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOza%26aufirst%3DA.%2BM.%26aulast%3DCibula%26aufirst%3DD.%26aulast%3DBenzaquen%26aufirst%3DA.%2BO.%26aulast%3DPoole%26aufirst%3DC.%2BJ.%26aulast%3DMathijssen%26aufirst%3DR.%2BH.%2BJ.%26aulast%3DSonke%26aufirst%3DG.%2BS.%26aulast%3DColombo%26aufirst%3DN.%26aulast%3DSpacek%26aufirst%3DJ.%26aulast%3DVuylsteke%26aufirst%3DP.%26aulast%3DHirte%26aufirst%3DH.%2BW.%26aulast%3DMahner%26aufirst%3DS.%26aulast%3DPlante%26aufirst%3DM.%26aulast%3DSchmalfeldt%26aufirst%3DB.%26aulast%3DMackay%26aufirst%3DH.%26aulast%3DRowbottom%26aufirst%3DJ.%26aulast%3DTchakov%26aufirst%3DI.%26aulast%3DFriedlander%26aufirst%3DM.%26atitle%3DOlaparib%2520plus%2520paclitaxel%2520plus%2520carboplatin%2520%2528P%252FC%2529%2520followed%2520by%2520olaparib%2520maintenance%2520treatment%2520in%2520patients%2520%2528pts%2529%2520with%2520platinum-sensitive%2520recurrent%2520serous%2520ovarian%2520cancer%2520%2528PSR%2520SOC%2529%253A%2520A%2520randomized%252C%2520open-label%2520phase%2520II%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26issue%3D15%2520suppl%26spage%3D5001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zang, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowbottom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. H.</span><span> </span><span class="NLM_article-title">Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">3858</span><span class="NLM_x">–</span> <span class="NLM_lpage">3865</span><span class="refDoi"> DOI: 10.1200/JCO.2014.60.0320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2014.60.0320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26282658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVylsbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3858-3865&author=Y.+J.+Bangauthor=S.+A.+Imauthor=K.+W.+Leeauthor=J.+Y.+Choauthor=E.+K.+Songauthor=K.+H.+Leeauthor=Y.+H.+Kimauthor=J.+O.+Parkauthor=H.+G.+Chunauthor=D.+Y.+Zangauthor=A.+Fieldingauthor=J.+Rowbottomauthor=D.+Hodgsonauthor=M.+J.+O%E2%80%99Connorauthor=X.+Yinauthor=W.+H.+Kim&title=Randomized%2C+double-blind+phase+II+trial+with+prospective+classification+by+ATM+protein+level+to+evaluate+the+efficacy+and+tolerability+of+olaparib+plus+paclitaxel+in+patients+with+recurrent+or+metastatic+gastric+cancer&doi=10.1200%2FJCO.2014.60.0320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, double-blind phase II trial with prospective classification by ATM Protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer</span></div><div class="casAuthors">Bang, Yung-Jue; Im, Seock-Ah; Lee, Keun-Wook; Cho, Jae Yong; Song, Eun-Kee; Lee, Kyung Hee; Kim, Yeul Hong; Park, Joon Oh; Chun, Hoo Geun; Zang, Dae Young; Fielding, Anitra; Rowbottom, Jacqui; Hodgson, Darren; O'Connor, Mark J.; Yin, Xiaolu; Kim, Woo Ho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3858-3865</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Gastric cancer cell lines, particularly those with low levels of ataxia telangiectasia mutated (ATM), a key activator of DNA damage response, are sensitive to the poly (ADP-ribose) polymerase inhibitor olaparib.  We compared the efficacy of olaparib plus paclitaxel (olaparib/paclitaxel) with paclitaxel alone in patients with recurrent or metastatic gastric cancer and assessed whether low ATM expression is predictive of improved clin. outcome for olaparib/paclitaxel.  Patients and Methods In this phase II, double-blind study (Study 39;NCT01063517), patients were randomly assigned to oral olaparib 100 mg twice per day (tablets) plus paclitaxel (80 mg/m2 per day i.v. on days 1, 8, and 15 of every 28-day cycle) or placebo plus paclitaxel (placebo/paclitaxel), followed by maintenance monotherapy with olaparib (200 mg twice per day) or placebo.  The study population was enriched to 50% for patients with low or undetectable ATM levels (ATMlow).  Primary end point was progression-free survival (PFS).  Results One hundred twenty-three of 124 randomly assigned patients received treatment (olaparib/paclitaxel, n = 61; placebo/paclitaxel, n = 62).  The screening prevalence of ATMlow patients was 14%.  Olaparib/paclitaxel did not lead to a significant improvement in PFS vs. placebo/paclitaxel (overall population: hazard ratio [HR], 0.80; median PFS, 3.91 v 3.55 mo, resp.; ATMlow population: HR, 0.74; median PFS, 5.29 v 3.68 mo, resp.).  However, olaparib/paclitaxel significantly improved overall survival (OS) vs. placebo/paclitaxel in both the overall population (HR, 0.56; 80% CI, 0.41 to 0.75; P =.005; median OS, 13.1 v 8.3 mo, resp.) and the ATMlow population (HR, 0.35; 80% CI, 0.22 to 0.56; P =.002; median OS, not reached v 8.2 mo, resp.).  Olaparib/paclitaxel was generally well tolerated, with no unexpected safety findings.  Conclusion Olaparib/paclitaxel is active in the treatment of patients with metastatic gastric cancer, with a greater OS benefit in ATMlow patients.  A phase III trial in this setting is under way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZFw6yUXmfdbVg90H21EOLACvtfcHk0li0VKzeEFc_3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVylsbbI&md5=366f633d5c7e010d6037289029879c7b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.60.0320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.60.0320%26sid%3Dliteratum%253Aachs%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DCho%26aufirst%3DJ.%2BY.%26aulast%3DSong%26aufirst%3DE.%2BK.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DChun%26aufirst%3DH.%2BG.%26aulast%3DZang%26aufirst%3DD.%2BY.%26aulast%3DFielding%26aufirst%3DA.%26aulast%3DRowbottom%26aufirst%3DJ.%26aulast%3DHodgson%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DW.%2BH.%26atitle%3DRandomized%252C%2520double-blind%2520phase%2520II%2520trial%2520with%2520prospective%2520classification%2520by%2520ATM%2520protein%2520level%2520to%2520evaluate%2520the%2520efficacy%2520and%2520tolerability%2520of%2520olaparib%2520plus%2520paclitaxel%2520in%2520patients%2520with%2520recurrent%2520or%2520metastatic%2520gastric%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D3858%26epage%3D3865%26doi%3D10.1200%2FJCO.2014.60.0320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Dean, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pwint, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmichael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodege-Kunwar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">468</span><span class="NLM_x">–</span> <span class="NLM_lpage">474</span><span class="refDoi"> DOI: 10.1038/bjc.2011.555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fbjc.2011.555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22223088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslGgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=468-474&author=E.+Deanauthor=M.+R.+Middletonauthor=T.+Pwintauthor=H.+Swaislandauthor=J.+Carmichaelauthor=P.+Goodege-Kunwarauthor=M.+Ranson&title=Phase+I+study+to+assess+the+safety+and+tolerability+of+olaparib+in+combination+with+bevacizumab+in+patients+with+advanced+solid+tumours&doi=10.1038%2Fbjc.2011.555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours</span></div><div class="casAuthors">Dean, E.; Middleton, M. R.; Pwint, T.; Swaisland, H.; Carmichael, J.; Goodege-Kunwar, P.; Ranson, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">468-474</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Olaparib (AZD2281) is a potent oral poly(ADP-ribose) polymerase inhibitor with anti-tumor activity and acceptable toxicity as monotherapy in patients with BRCA-deficient cancers.  The vascular endothelial growth factor receptor inhibitor bevacizumab has been incorporated into std. of care with chemotherapy in various tumors.  This phase I study established the safety, tolerability and clin. pharmacokinetics of olaparib alone and in combination with bevacizumab.  Methods: Patients with advanced solid tumors received increasing doses of continuous oral olaparib (100, 200 and 400 mg b.i.d. capsule formulation) in combination with bevacizumab (10 mg kg-1 i.v. q2w).  Results: In all, 12 patients enrolled and received treatment.  The most common adverse events (AEs) related to olaparib were grade 1/2 nausea and fatigue.  No haematol. parameters were reported as AEs.  No serious AEs related to olaparib or dose-limiting toxicities (DLTs) were reported.  Three patients discontinued due to AEs, two patients discontinued both olaparib and bevacizumab and one patient discontinued olaparib.  Five patients received combination treatment for over 6 mo.  There was no evidence that bevacizumab affected olaparib.  Conclusion: The combination of olaparib 400 mg b.i.d. with bevacizumab 10 mg kg-1 q2w was generally well tolerated with no DLTs.  This combination could be considered for future clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-ENSDqg38vLVg90H21EOLACvtfcHk0li0VKzeEFc_3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslGgu7c%253D&md5=fdfa3b274b116623c067c1fbe52f8cc8</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.555%26sid%3Dliteratum%253Aachs%26aulast%3DDean%26aufirst%3DE.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DPwint%26aufirst%3DT.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DGoodege-Kunwar%26aufirst%3DP.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DPhase%2520I%2520study%2520to%2520assess%2520the%2520safety%2520and%2520tolerability%2520of%2520olaparib%2520in%2520combination%2520with%2520bevacizumab%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D106%26spage%3D468%26epage%3D474%26doi%3D10.1038%2Fbjc.2011.555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Liu, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buss, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyburski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U. A.</span><span> </span><span class="NLM_article-title">A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2972</span><span class="NLM_x">–</span> <span class="NLM_lpage">2978</span><span class="refDoi"> DOI: 10.1016/j.ejca.2013.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.ejca.2013.05.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=2972-2978&author=J.+F.+Liuauthor=S.+M.+Tolaneyauthor=M.+Birrerauthor=G.+F.+Flemingauthor=M.+K.+Bussauthor=S.+E.+Dahlbergauthor=H.+Leeauthor=C.+Whalenauthor=K.+Tyburskiauthor=E.+Winerauthor=P.+Ivyauthor=U.+A.+Matulonis&title=A+Phase+1+trial+of+the+poly%28ADP-ribose%29+polymerase+inhibitor+olaparib+%28AZD2281%29+in+combination+with+the+anti-angiogenic+cediranib+%28AZD2171%29+in+recurrent+epithelial+ovarian+or+triple-negative+breast+cancer&doi=10.1016%2Fj.ejca.2013.05.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2013.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2013.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DBirrer%26aufirst%3DM.%26aulast%3DFleming%26aufirst%3DG.%2BF.%26aulast%3DBuss%26aufirst%3DM.%2BK.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DWhalen%26aufirst%3DC.%26aulast%3DTyburski%26aufirst%3DK.%26aulast%3DWiner%26aufirst%3DE.%26aulast%3DIvy%26aufirst%3DP.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26atitle%3DA%2520Phase%25201%2520trial%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520olaparib%2520%2528AZD2281%2529%2520in%2520combination%2520with%2520the%2520anti-angiogenic%2520cediranib%2520%2528AZD2171%2529%2520in%2520recurrent%2520epithelial%2520ovarian%2520or%2520triple-negative%2520breast%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3D2972%26epage%3D2978%26doi%3D10.1016%2Fj.ejca.2013.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Liu, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckanovich, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buss, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nattam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurteau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obermayer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulonis, U. A.</span><span> </span><span class="NLM_article-title">Combination of cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1207</span><span class="NLM_x">–</span> <span class="NLM_lpage">1214</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70391-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS1470-2045%2814%2970391-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25218906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KltbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1207-1214&author=J.+F.+Liuauthor=W.+T.+Barryauthor=M.+Birrerauthor=J.+M.+Leeauthor=R.+J.+Buckanovichauthor=G.+F.+Flemingauthor=B.+Rimelauthor=M.+K.+Bussauthor=S.+Nattamauthor=J.+Hurteauauthor=W.+Luoauthor=P.+Quyauthor=C.+Whalenauthor=L.+Obermayerauthor=H.+Leeauthor=E.+P.+Winerauthor=E.+C.+Kohnauthor=S.+P.+Ivyauthor=U.+A.+Matulonis&title=Combination+of+cediranib+and+olaparib+versus+olaparib+alone+for+women+with+recurrent+platinum-sensitive+ovarian+cancer%3A+a+randomised+phase+2+study&doi=10.1016%2FS1470-2045%2814%2970391-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study</span></div><div class="casAuthors">Liu, Joyce F.; Barry, William T.; Birrer, Michael; Lee, Jung-Min; Buckanovich, Ronald J.; Fleming, Gini F.; Rimel, B. J.; Buss, Mary K.; Nattam, Sreenivasa; Hurteau, Jean; Luo, Weixiu; Quy, Philippa; Whalen, Christin; Obermayer, Lisa; Lee, Hang; Winer, Eric P.; Kohn, Elise C.; Ivy, S. Percy; Matulonis, Ursula A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1207-1214</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3.  Both oral agents have antitumor activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial.  We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer.  In our randomized, open-label, phase 2 study, we recruited women (aged ≥18 years) who had measurable platinum-sensitive, relapsed, high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer, or those with deleterious germline BRCA1/2 mutations from nine participating US academic medical centers.  We randomly allocated participants (1:1) according to permuted blocks, stratified by germline BRCA status and previous anti-angiogenic therapy, to receive olaparib capsules 400 mg twice daily or the combination at the recommended phase 2 dose of cediranib 30 mg daily and olaparib capsules 200 mg twice daily.  The primary endpoint was progression-free survival analyzed in the intention-to-treat population.  The phase 2 trial is no longer accruing patients.  An interim anal. was conducted in Nov., 2013, after 50% of expected events had occurred and efficacy results were unmasked.  The primary anal. was performed on March 31, 2014, after 47 events (66% of those expected).  The trial is registered with ClinicalTrials.gov, no. NCT01116648.  Between Oct 26, 2011, and June 3, 2013, we randomly allocated 46 women to receive olaparib alone and 44 to receive the combination of olaparib and cediranib.  Median PFS was 17·7 mo (95% CI 14·7-not reached) for the women treated with cediranib plus olaparib compared with 9·0 mo (95% CI 5·7-16·5) for those treated with olaparib monotherapy (hazard ratio 0·42, 95% CI 0·23-0·76; p=0·005).  Grade 3 and 4 adverse events were more common with combination therapy than with monotherapy, including fatigue (12 patients in the cediranib plus olaparib group vs five patients in the olaparib monotherapy group), diarrhea (ten vs none), and hypertension (18 vs none).  Cediranib plus olaparib seems to improve PFS in women with recurrent platinum-sensitive high-grade serous or endometrioid ovarian cancer, and warrants study in a phase 3 trial.  The side-effect profile suggests such investigations should include assessments of quality of life and patient-reported outcomes to understand the effects of a continuing oral regimen with that of intermittent chemotherapy.  American Recovery and Reinvestment Act grant from the National Institutes of Health (NIH) (3 U01 CA062490-16S2); Intramural Program of the Center for Cancer Research; and the Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBLud-6qAoe7Vg90H21EOLACvtfcHk0lj0hYdZQTOJuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KltbfP&md5=4ee05408050567ae01591fe319beaebd</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970391-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970391-2%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DBarry%26aufirst%3DW.%2BT.%26aulast%3DBirrer%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DBuckanovich%26aufirst%3DR.%2BJ.%26aulast%3DFleming%26aufirst%3DG.%2BF.%26aulast%3DRimel%26aufirst%3DB.%26aulast%3DBuss%26aufirst%3DM.%2BK.%26aulast%3DNattam%26aufirst%3DS.%26aulast%3DHurteau%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DQuy%26aufirst%3DP.%26aulast%3DWhalen%26aufirst%3DC.%26aulast%3DObermayer%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26atitle%3DCombination%2520of%2520cediranib%2520and%2520olaparib%2520versus%2520olaparib%2520alone%2520for%2520women%2520with%2520recurrent%2520platinum-sensitive%2520ovarian%2520cancer%253A%2520a%2520randomised%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1207%26epage%3D1214%26doi%3D10.1016%2FS1470-2045%2814%2970391-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Matulonis, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulf, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birrer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westin, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell-McGuinn, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasonde, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aghajanian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span> </span><span class="NLM_article-title">Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">2510</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=2510&issue=15+suppl&author=U.+Matulonisauthor=G.+M.+Wulfauthor=M.+J.+Birrerauthor=S.+N.+Westinauthor=P.+Quyauthor=K.+M.+Bell-McGuinnauthor=B.+Lasondeauthor=C.+Whalenauthor=C.+Aghajanianauthor=D.+B.+Solitauthor=G.+B.+Millsauthor=L.+Cantleyauthor=E.+P.+Winer&title=Phase+I+study+of+oral+BKM120+and+oral+olaparib+for+high-grade+serous+ovarian+cancer+%28HGSC%29+or+triple-negative+breast+cancer+%28TNBC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatulonis%26aufirst%3DU.%26aulast%3DWulf%26aufirst%3DG.%2BM.%26aulast%3DBirrer%26aufirst%3DM.%2BJ.%26aulast%3DWestin%26aufirst%3DS.%2BN.%26aulast%3DQuy%26aufirst%3DP.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DLasonde%26aufirst%3DB.%26aulast%3DWhalen%26aufirst%3DC.%26aulast%3DAghajanian%26aufirst%3DC.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DCantley%26aufirst%3DL.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26atitle%3DPhase%2520I%2520study%2520of%2520oral%2520BKM120%2520and%2520oral%2520olaparib%2520for%2520high-grade%2520serous%2520ovarian%2520cancer%2520%2528HGSC%2529%2520or%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15%2520suppl%26spage%3D2510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Campelo, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcereny, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina-Vila, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cajal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez-Ronco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span> </span><span class="NLM_article-title">Phase Ib study to evaluate the efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) patients</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">8079</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8079&issue=15+suppl&author=R.+G.+Campeloauthor=E.+Felipauthor=B.+Massutiauthor=M.+Majemauthor=E.+Carcerenyauthor=R.+Palmeroauthor=M.+A.+Molina-Vilaauthor=R.+Cajalauthor=M.+Sanchez-Roncoauthor=R.+Rosell&title=Phase+Ib+study+to+evaluate+the+efficacy+and+tolerability+of+olaparib+%28AZD2281%29+plus+gefitinib+in+patients+%28P%29+with+epidermal+growth+factor+receptor+%28EGFR%29+mutation+positive+advanced+non-small+cell+lung+cancer+%28NSCLC%29+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampelo%26aufirst%3DR.%2BG.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DMolina-Vila%26aufirst%3DM.%2BA.%26aulast%3DCajal%26aufirst%3DR.%26aulast%3DSanchez-Ronco%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26atitle%3DPhase%2520Ib%2520study%2520to%2520evaluate%2520the%2520efficacy%2520and%2520tolerability%2520of%2520olaparib%2520%2528AZD2281%2529%2520plus%2520gefitinib%2520in%2520patients%2520%2528P%2529%2520with%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520mutation%2520positive%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15%2520suppl%26spage%3D8079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Tang, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, We. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span> </span><span class="NLM_article-title">BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1653</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-1653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1538-7445.AM2015-1653" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1653&author=Z.+Y.+Tangauthor=Y.+Liuauthor=Q.+Zhenauthor=B.+Renauthor=H.+X.+Wangauthor=Z.+Y.+Shiauthor=We.+F.+Gongauthor=Y.+Liuauthor=X.+Wangauthor=Y.+J.+Gaoauthor=F.+L.+Yuauthor=Y.+Y.+Wuauthor=B.+Jiangauthor=X.+B.+Sunauthor=M.+Weiauthor=C.+Y.+Zhouauthor=L.+S.+Luoauthor=Z.+X.+Liauthor=J.+Y.+Yuauthor=J.+Zhaoauthor=J.+Wangauthor=L.+Wang&title=BGB-290%3A+A+highly+potent+and+specific+PARP1%2F2+inhibitor+potentiates+anti-tumor+activity+of+chemotherapeutics+in+patient+biopsy+derived+SCLC+models&doi=10.1158%2F1538-7445.AM2015-1653"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-1653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-1653%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.%2BY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhen%26aufirst%3DQ.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%2BX.%26aulast%3DShi%26aufirst%3DZ.%2BY.%26aulast%3DGong%26aufirst%3DWe.%2BF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DY.%2BJ.%26aulast%3DYu%26aufirst%3DF.%2BL.%26aulast%3DWu%26aufirst%3DY.%2BY.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DX.%2BB.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DC.%2BY.%26aulast%3DLuo%26aufirst%3DL.%2BS.%26aulast%3DLi%26aufirst%3DZ.%2BX.%26aulast%3DYu%26aufirst%3DJ.%2BY.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DBGB-290%253A%2520A%2520highly%2520potent%2520and%2520specific%2520PARP1%252F2%2520inhibitor%2520potentiates%2520anti-tumor%2520activity%2520of%2520chemotherapeutics%2520in%2520patient%2520biopsy%2520derived%2520SCLC%2520models%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D1653%26doi%3D10.1158%2F1538-7445.AM2015-1653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Russo, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgan, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slusher, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tofilon, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camphausen, K.</span><span> </span><span class="NLM_article-title">In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">607</span><span class="NLM_x">–</span> <span class="NLM_lpage">612</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-08-2079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=19147766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFeqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=607-612&author=A.+L.+Russoauthor=H.+C.+Kwonauthor=W.+E.+Burganauthor=D.+Carterauthor=K.+Beamauthor=X.+Weizhengauthor=J.+Zhangauthor=B.+S.+Slusherauthor=A.+Chakravartiauthor=P.+J.+Tofilonauthor=K.+Camphausen&title=In+vitro+and+in+vivo+radiosensitization+of+glioblastoma+cells+by+the+poly+%28ADP-ribose%29+polymerase+inhibitor+E7016&doi=10.1158%2F1078-0432.CCR-08-2079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016</span></div><div class="casAuthors">Russo, Andrea L.; Kwon, Hyuk-Chan; Burgan, William E.; Carter, Donna; Beam, Katie; Weizheng, Xu; Zhang, Jie; Slusher, Barbara S.; Chakravarti, Arnab; Tofilon, Philip J.; Camphausen, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">607-612</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Poly (ADP-ribose) polymerase (PARP) inhibitors are undergoing clin. evaluation for cancer therapy.  Because PARP inhibition has been shown to enhance tumor cell sensitivity to radiation, we investigated the in vitro and in vivo effects of the novel PARP inhibitor E7016.  Exptl. Design: The effect of E7016 on the in vitro radiosensitivity of tumor cell lines was evaluated using clonogenic survival.  DNA damage and repair were measured using γH2AX foci and neutral comet assay.  Mitotic catastrophe was detd. by immunostaining. Tumor growth delay was evaluated in mice for the effect of E7016 on in vivo (U251) tumor radiosensitivity.  Results: Cell lines exposed to E7016 preirradn. yielded an increase in radiosensitivity with dose enhancement factors at a surviving fraction of 0.1 from 1.4 to 1.7.  To assess DNA double-strand breaks repair, γH2AX measured at 24 h postirradn. had significantly more foci per cell in the E7016/irradn. group vs. irradn. alone.  Neutral comet assay further suggested unrepaired double-strand breaks with significantly greater DNA damage at 6 h postirradn. in the combination group vs. irradn. alone.  Mitotic catastrophe staining revealed a significantly greater no. of cells staining pos. at 24 h postirradn. in the combination group.  In vivo, mice treated with E7016/irradn./temozolomide had an addnl. growth delay of six days compared with the combination of temozolomide and irradn.  Conclusions: These results indicate that E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair.  Moreover, enhanced growth delay with the addn. of E7016 to temozolomide and radiotherapy in a glioma mouse model suggests a potential role for this drug in the treatment of glioblastoma multiforme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwKbKGkXjVd7Vg90H21EOLACvtfcHk0lgily7tvtasig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFeqsg%253D%253D&md5=6b7d2b4cc62ff752d8402788fae07d71</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2079%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DA.%2BL.%26aulast%3DKwon%26aufirst%3DH.%2BC.%26aulast%3DBurgan%26aufirst%3DW.%2BE.%26aulast%3DCarter%26aufirst%3DD.%26aulast%3DBeam%26aufirst%3DK.%26aulast%3DWeizheng%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DChakravarti%26aufirst%3DA.%26aulast%3DTofilon%26aufirst%3DP.%2BJ.%26aulast%3DCamphausen%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520radiosensitization%2520of%2520glioblastoma%2520cells%2520by%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520E7016%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D607%26epage%3D612%26doi%3D10.1158%2F1078-0432.CCR-08-2079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span> </span><span class="NLM_article-title">Trapping poly(ADP-Ribose) polymerase</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span><span class="refDoi"> DOI: 10.1124/jpet.114.222448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1124%2Fjpet.114.222448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25758918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=446-457&author=Y.+Shenauthor=M.+Aoyagi-Scharberauthor=B.+Wang&title=Trapping+poly%28ADP-Ribose%29+polymerase&doi=10.1124%2Fjpet.114.222448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Shen, Yuqiao; Aoyagi-Scharber, Mika; Wang, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">446-457</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the sites of DNA damage.  The PARP enzyme-inhibitor complex "locks" onto damaged DNA and prevents DNA repair, replication, and transcription, leading to cell death.  Several clin.-stage PARP inhibitors, including veliparib, rucaparib, olaparib, niraparib, and talazoparib, have been evaluated for their PARP-trapping activity.  Although they display similar capacity to inhibit PARP catalytic activity, their relative abilities to trap PARP differ by several orders of magnitude, with the ability to trap PARP closely correlating with each drug's ability to kill cancer cells.  In this article, we review the available data on mol. interactions between these clin.-stage PARP inhibitors and PARP proteins, and discuss how their biol. differences might be explained by the trapping mechanism.  We also discuss how to use the PARP-trapping mechanism to guide the development of PARP inhibitors as a new class of cancer therapy, both for single-agent and combination treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf7H8kc8UmXLVg90H21EOLACvtfcHk0lgily7tvtasig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D&md5=36ceb95db0a63ab9ce002906df555482</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.222448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.222448%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DTrapping%2520poly%2528ADP-Ribose%2529%2520polymerase%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D446%26epage%3D457%26doi%3D10.1124%2Fjpet.114.222448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Scott, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swisher, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">Poly (ADP-ribose) polymerase inhibitors: recent advances and future development</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1397</span><span class="NLM_x">–</span> <span class="NLM_lpage">1406</span><span class="refDoi"> DOI: 10.1200/JCO.2014.58.8848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1200%2FJCO.2014.58.8848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25779564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVaqtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1397-1406&author=C.+L.+Scottauthor=E.+M.+Swisherauthor=S.+H.+Kaufmann&title=Poly+%28ADP-ribose%29+polymerase+inhibitors%3A+recent+advances+and+future+development&doi=10.1200%2FJCO.2014.58.8848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Poly (ADP-Ribose) polymerase inhibitors: recent advances and future development</span></div><div class="casAuthors">Scott, Clare L.; Swisher, Elizabeth M.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1397-1406</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, esp. relapsed platinum-sensitive high-grade serous disease.  Consistent with preclin. studies, ovarian cancers and a no. of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive.  However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors.  We provide an update on PARP inhibitor clin. development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowf5pO-7WPjrVg90H21EOLACvtfcHk0lgily7tvtasig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVaqtL%252FM&md5=a9a1668a322c4a2e099a1fd9891a15da</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.58.8848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.58.8848%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DC.%2BL.%26aulast%3DSwisher%26aufirst%3DE.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DPoly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitors%253A%2520recent%2520advances%2520and%2520future%2520development%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1397%26epage%3D1406%26doi%3D10.1200%2FJCO.2014.58.8848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Trapping of PARP1 and PARP-2 by clinical PARP inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5588</span><span class="NLM_x">–</span> <span class="NLM_lpage">5599</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-2753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-12-2753" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=5588-5599&author=J.+Muraiauthor=S.+Y.+Huangauthor=B.+B.+Dasauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+H.+Doroshowauthor=J.+Jiauthor=S.+Takedaauthor=Y.+Pommier&title=Trapping+of+PARP1+and+PARP-2+by+clinical+PARP+inhibitors&doi=10.1158%2F0008-5472.CAN-12-2753"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-2753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-2753%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DDas%26aufirst%3DB.%2BB.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DTrapping%2520of%2520PARP1%2520and%2520PARP-2%2520by%2520clinical%2520PARP%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D5588%26epage%3D5599%26doi%3D10.1158%2F0008-5472.CAN-12-2753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.MCT-13-0803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24356813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=433-443&author=J.+Muraiauthor=S.+Y.+Huangauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+Jiauthor=S.+Takedaauthor=J.+Morrisauthor=B.+Teicherauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Stereospecific+PARP+trapping+by+BMN+673+and+comparison+with+olaparib+and+rucaparib&doi=10.1158%2F1535-7163.MCT-13-0803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-Yin N.; Renaud, Amelie; Zhang, Yiping; Ji, Jiuping; Takeda, Shunichi; Morris, Joel; Teicher, Beverly; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks.  We recently reported that several PARP inhibitors have an addnl. cytotoxic mechanism by trapping PARP-DNA complexes, and that both olaparib and niraparib act as PARP poisons at pharmacol. concns.  Therefore, we have proposed that PARP inhibitors should be evaluated based both on catalytic PARP inhibition and PARP-DNA trapping.  Here, we evaluated the novel PARP inhibitor, BMN 673, and compared its effects on PARP1 and PARP2 with two other clin. PARP inhibitors, olaparib and rucaparib, using biochem. and cellular assays in genetically modified chicken DT40 and human cancer cell lines.  Although BMN 673, olaparib, and rucaparib are comparable at inhibiting PARP catalytic activity, BMN 673 is ∼100-fold more potent at trapping PARP-DNA complexes and more cytotoxic as single agent than olaparib, whereas olaparib and rucaparib show similar potencies in trapping PARP-DNA complexes.  The high level of resistance of PARP1/2 knockout cells to BMN 673 demonstrates the selectivity of BMN 673 for PARP1/2.  Moreover, we show that BMN 673 acts by stereospecific binding to PARP1 as its enantiomer, LT674, is several orders of magnitude less efficient.  BMN 673 is also approx. 100-fold more cytotoxic than olaparib and rucaparib in combination with the DNA alkylating agents Me methane sulfonate (MMS) and temozolomide.  Our study demonstrates that BMN 673 is the most potent clin. PARP inhibitor tested to date with the highest efficiency at trapping PARP-DNA complexes.  Mol Cancer Ther; 13(2); 433-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8p5YTwAneh7Vg90H21EOLACvtfcHk0ljl9HfNsknyzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D&md5=513c544d1cb5c2203e7696af76201afd</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0803%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DStereospecific%2520PARP%2520trapping%2520by%2520BMN%2520673%2520and%2520comparison%2520with%2520olaparib%2520and%2520rucaparib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D433%26epage%3D443%26doi%3D10.1158%2F1535-7163.MCT-13-0803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or Temozolomide based on PARP trapping versus catalytic inhibition</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">408</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span><span class="refDoi"> DOI: 10.1124/jpet.113.210146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1124%2Fjpet.113.210146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24650937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2crlslWjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2014&pages=408-416&author=J.+Muraiauthor=Y.+Zhangauthor=J.+Morrisauthor=J.+Jiauthor=S.+Takedaauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Rationale+for+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitors+in+combination+therapy+with+camptothecins+or+Temozolomide+based+on+PARP+trapping+versus+catalytic+inhibition&doi=10.1124%2Fjpet.113.210146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition</span></div><div class="casAuthors">Murai Junko; Zhang Yiping; Morris Joel; Ji Jiuping; Takeda Shunichi; Doroshow James H; Pommier Yves</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">408-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We recently showed that poly(ADP-ribose) polymerase (PARP) inhibitors exert their cytotoxicity primarily by trapping PARP-DNA complexes in addition to their NAD(+)-competitive catalytic inhibitory mechanism.  PARP trapping is drug-specific, with olaparib exhibiting a greater ability than veliparib, whereas both compounds are potent catalytic PARP inhibitors.  Here, we evaluated the combination of olaparib or veliparib with therapeutically relevant DNA-targeted drugs, including the topoisomerase I inhibitor camptothecin, the alkylating agent temozolomide, the cross-linking agent cisplatin, and the topoisomerase II inhibitor etoposide at the cellular and molecular levels.  We determined PARP-DNA trapping and catalytic PARP inhibition in genetically modified chicken lymphoma DT40, human prostate DU145, and glioblastoma SF295 cancer cells.  For camptothecin, both PARP inhibitors showed highly synergistic effects due to catalytic PARP inhibition, indicating the value of combining either veliparib or olaparib with topoisomerase I inhibitors.  On the other hand, for temozolomide, PARP trapping was critical in addition to catalytic inhibition, consistent with the fact that olaparib was more effective than veliparib in combination with temozolomide.  For cisplatin and etoposide, olaparib only showed no or a weak combination effect, which is consistent with the lack of involvement of PARP in the repair of cisplatin- and etoposide-induced lesions.  Hence, we conclude that catalytic PARP inhibitors are highly effective in combination with camptothecins, whereas PARP inhibitors capable of PARP trapping are more effective with temozolomide.  Our study provides insights in combination treatment rationales for different PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxMGPopCndgkbxh97K6Vt6fW6udTcc2eZwBrzCYFhKW7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crlslWjtQ%253D%253D&md5=c3614636b019d2543975a5d677535c18</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.210146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.210146%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DRationale%2520for%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitors%2520in%2520combination%2520therapy%2520with%2520camptothecins%2520or%2520Temozolomide%2520based%2520on%2520PARP%2520trapping%2520versus%2520catalytic%2520inhibition%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D349%26spage%3D408%26epage%3D416%26doi%3D10.1124%2Fjpet.113.210146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Hopkins, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiGiammarino, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panchal, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilsbacher, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolarik, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maag, D.</span><span> </span><span class="NLM_article-title">Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1477</span><span class="refDoi"> DOI: 10.1158/1541-7786.MCR-15-0191-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1541-7786.MCR-15-0191-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26217019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVajsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=1465-1477&author=T.+A.+Hopkinsauthor=Y.+Shiauthor=L.+E.+Rodriguezauthor=L.+R.+Solomonauthor=C.+K.+Donawhoauthor=E.+L.+DiGiammarinoauthor=S.+C.+Panchalauthor=J.+L.+Wilsbacherauthor=W.+Gaoauthor=A.+M.+Olsonauthor=D.+F.+Stolarikauthor=D.+J.+Osterlingauthor=E.+F.+Johnsonauthor=D.+Maag&title=Mechanistic+dissection+of+PARP1+trapping+and+the+impact+on+in+vivo+tolerability+and+efficacy+of+PARP+inhibitors&doi=10.1158%2F1541-7786.MCR-15-0191-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors</span></div><div class="casAuthors">Hopkins, Todd A.; Shi, Yan; Rodriguez, Luis E.; Solomon, Larry R.; Donawho, Cherrie K.; DiGiammarino, Enrico L.; Panchal, Sanjay C.; Wilsbacher, Julie L.; Gao, Wenqing; Olson, Amanda M.; Stolarik, DeAnne F.; Osterling, Donald J.; Johnson, Eric F.; Maag, David</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1465-1477</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerases (PARP1, -2, and -3) play important roles in DNA damage repair.  As such, a no. of PARP inhibitors are undergoing clin. development as anticancer therapies, particularly in tumors with DNA repair deficits and in combination with DNA-damaging agents.  Preclin. evidence indicates that PARP inhibitors potentiate the cytotoxicity of DNA alkylating agents.  It has been proposed that a major mechanism underlying this activity is the allosteric trapping of PARP1 at DNA single-strand breaks during base excision repair; however, direct evidence of allostery has not been reported.  Here the data reveal that veliparib, olaparib, niraparib, and talazoparib (BMN-673) potentiate the cytotoxicity of alkylating agents.  Consistent with this, all four drugs possess PARP1 trapping activity.  Using biochem. and cellular approaches, we directly probe the trapping mechanism for an allosteric component.  These studies indicate that trapping is due to catalytic inhibition and not allostery.  The potency of PARP inhibitors with respect to trapping and catalytic inhibition is linearly correlated in biochem. systems but is nonlinear in cells.  High-content imaging of γH2Ax levels suggests that this is attributable to differential potentiation of DNA damage in cells.  Trapping potency is inversely correlated with tolerability when PARP inhibitors are combined with temozolomide in mouse xenograft studies.  As a result, PARP inhibitors with dramatically different trapping potencies elicit comparable in vivo efficacy at max. tolerated doses.  Finally, the impact of trapping on tolerability and efficacy is likely to be context specific.  Implications: Understanding the context-specific relationships of trapping and catalytic inhibition with both tolerability and efficacy will aid in detg. the suitability of a PARP inhibitor for inclusion in a particular clin. regimen.  Mol Cancer Res; 13(11); 1465-77. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ITvwLl2ImbVg90H21EOLACvtfcHk0libYQPMvM-TwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVajsbbK&md5=3a7f11c925a3d51a6a87ca5f01ff5e5c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-15-0191-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-15-0191-T%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DT.%2BA.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DRodriguez%26aufirst%3DL.%2BE.%26aulast%3DSolomon%26aufirst%3DL.%2BR.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DDiGiammarino%26aufirst%3DE.%2BL.%26aulast%3DPanchal%26aufirst%3DS.%2BC.%26aulast%3DWilsbacher%26aufirst%3DJ.%2BL.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DStolarik%26aufirst%3DD.%2BF.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMaag%26aufirst%3DD.%26atitle%3DMechanistic%2520dissection%2520of%2520PARP1%2520trapping%2520and%2520the%2520impact%2520on%2520in%2520vivo%2520tolerability%2520and%2520efficacy%2520of%2520PARP%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2015%26volume%3D13%26spage%3D1465%26epage%3D1477%26doi%3D10.1158%2F1541-7786.MCR-15-0191-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Montoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouliot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, G. M.</span><span> </span><span class="NLM_article-title">Resistance to PARP-inhibitors in cancer therapy</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="refDoi"> DOI: 10.3389/fphar.2013.00018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.3389%2Ffphar.2013.00018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23450678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC3svitlKjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=18&author=A.+Montoniauthor=M.+Robuauthor=E.+Pouliotauthor=G.+M.+Shah&title=Resistance+to+PARP-inhibitors+in+cancer+therapy&doi=10.3389%2Ffphar.2013.00018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to PARP-Inhibitors in Cancer Therapy</span></div><div class="casAuthors">Montoni Alicia; Robu Mihaela; Pouliot Emilie; Shah Girish M</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) family of proteins have shown promising results in preclinical studies and clinical trials as a monotherapy or in combination therapy for some cancers.  Thus, usage of PARP-inhibitors (PARPi) in cancer therapy is bound to increase with time, but resistance of cancer cells to PARPi is also beginning to be observed.  Here we review different known and potential mechanisms by which: (i) PARPi kill cancer cells; and (ii) cancer cells develop resistance to PARPi.  Understanding the lethality caused by PARPi and the countermeasures deployed by cancers cells to survive PARPi will help us rationalize the use of this new class of drugs in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR47jIB3kLCzdK0qsdY6Nc1fW6udTcc2eY8k4PaLMs6DLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svitlKjug%253D%253D&md5=b76a0ac9d0cbb311bc2429f231fb2d14</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2013.00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2013.00018%26sid%3Dliteratum%253Aachs%26aulast%3DMontoni%26aufirst%3DA.%26aulast%3DRobu%26aufirst%3DM.%26aulast%3DPouliot%26aufirst%3DE.%26aulast%3DShah%26aufirst%3DG.%2BM.%26atitle%3DResistance%2520to%2520PARP-inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DFront.%2520Pharmacol.%26date%3D2013%26volume%3D4%26spage%3D18%26doi%3D10.3389%2Ffphar.2013.00018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Ceccaldi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amunugama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Primack, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petalcorin, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstantinopoulos, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elledge, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusufzai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, A. D.</span><span> </span><span class="NLM_article-title">Homologous-recombination-deficient tumours are dependent on Polθ -mediated repair</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">518</span><span class="NLM_x">, </span> <span class="NLM_fpage">258</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1038/nature14184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnature14184" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=518&publication_year=2015&pages=258-262&author=R.+Ceccaldiauthor=J.+C.+Liuauthor=R.+Amunugamaauthor=I.+Hajduauthor=B.+Primackauthor=M.+I.+Petalcorinauthor=K.+W.+O%E2%80%99Connorauthor=P.+A.+Konstantinopoulosauthor=S.+J.+Elledgeauthor=S.+J.+Boultonauthor=T.+Yusufzaiauthor=A.+D.+D%E2%80%99Andrea&title=Homologous-recombination-deficient+tumours+are+dependent+on+Pol%CE%B8+-mediated+repair&doi=10.1038%2Fnature14184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnature14184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14184%26sid%3Dliteratum%253Aachs%26aulast%3DCeccaldi%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%2BC.%26aulast%3DAmunugama%26aufirst%3DR.%26aulast%3DHajdu%26aufirst%3DI.%26aulast%3DPrimack%26aufirst%3DB.%26aulast%3DPetalcorin%26aufirst%3DM.%2BI.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DK.%2BW.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26aulast%3DBoulton%26aufirst%3DS.%2BJ.%26aulast%3DYusufzai%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26atitle%3DHomologous-recombination-deficient%2520tumours%2520are%2520dependent%2520on%2520Pol%25CE%25B8%2520-mediated%2520repair%26jtitle%3DNature%26date%3D2015%26volume%3D518%26spage%3D258%26epage%3D262%26doi%3D10.1038%2Fnature14184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Mateos-Gomez, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazzerini-Denchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sfeir, A.</span><span> </span><span class="NLM_article-title">Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">518</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span><span class="refDoi"> DOI: 10.1038/nature14157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnature14157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25642960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=518&publication_year=2015&pages=254-257&author=P.+A.+Mateos-Gomezauthor=F.+Gongauthor=N.+Nairauthor=K.+M.+Millerauthor=E.+Lazzerini-Denchiauthor=A.+Sfeir&title=Mammalian+polymerase+%CE%B8+promotes+alternative+NHEJ+and+suppresses+recombination&doi=10.1038%2Fnature14157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination</span></div><div class="casAuthors">Mateos-Gomez, Pedro A.; Gong, Fade; Nair, Nidhi; Miller, Kyle M.; Lazzerini-Denchi, Eros; Sfeir, Agnel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">518</span>
        (<span class="NLM_cas:issue">7538</span>),
    <span class="NLM_cas:pages">254-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The alternative non-homologous end-joining (NHEJ) machinery facilitates several genomic rearrangements, some of which can lead to cellular transformation.  This error-prone repair pathway is triggered upon telomere de-protection to promote the formation of deleterious chromosome end-to-end fusions.  Using next-generation sequencing technol., here we show that repair by alternative NHEJ yields non-TTAGGG nucleotide insertions at fusion breakpoints of dysfunctional telomeres.  Investigating the enzymic activity responsible for the random insertions enabled us to identify polymerase theta (Polθ; encoded by Polq in mice) as a crucial alternative NHEJ factor in mammalian cells.  Polq inhibition suppresses alternative NHEJ at dysfunctional telomeres, and hinders chromosomal translocations at non-telomeric loci.  In addn., we found that loss of Polq in mice results in increased rates of homol.-directed repair, evident by recombination of dysfunctional telomeres and accumulation of RAD51 at double-stranded breaks.  Lastly, we show that depletion of Polθ has a synergistic effect on cell survival in the absence of BRCA genes, suggesting that the inhibition of this mutagenic polymerase represents a valid therapeutic avenue for tumors carrying mutations in homol.-directed repair genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjmeOnljJKrVg90H21EOLACvtfcHk0ljMAVDOWkAoYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGisbs%253D&md5=253d05f40b619712fbe7be371a7e64ea</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnature14157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14157%26sid%3Dliteratum%253Aachs%26aulast%3DMateos-Gomez%26aufirst%3DP.%2BA.%26aulast%3DGong%26aufirst%3DF.%26aulast%3DNair%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26aulast%3DLazzerini-Denchi%26aufirst%3DE.%26aulast%3DSfeir%26aufirst%3DA.%26atitle%3DMammalian%2520polymerase%2520%25CE%25B8%2520promotes%2520alternative%2520NHEJ%2520and%2520suppresses%2520recombination%26jtitle%3DNature%26date%3D2015%26volume%3D518%26spage%3D254%26epage%3D257%26doi%3D10.1038%2Fnature14157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Rodriguez, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majuelos-Melguizo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martí Martín-Consuegra, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz de Almodovar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López-Rivas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javier Oliver, F.</span><span> </span><span class="NLM_article-title">Deciphering the insights of poly(ADP-ribosylation) in tumor progression</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">697</span><span class="refDoi"> DOI: 10.1002/med.21339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1002%2Fmed.21339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25604534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWgs7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=678-697&author=M.+I.+Rodriguezauthor=J.+Majuelos-Melguizoauthor=J.+M.+Mart%C3%AD+Mart%C3%ADn-Consuegraauthor=M.+Ruiz+de+Almodovarauthor=A.+L%C3%B3pez-Rivasauthor=F.+Javier+Oliver&title=Deciphering+the+insights+of+poly%28ADP-ribosylation%29+in+tumor+progression&doi=10.1002%2Fmed.21339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Deciphering the Insights of Poly(ADP-Ribosylation) in Tumor Progression</span></div><div class="casAuthors">Rodriguez, Maria Isabel; Majuelos-Melguizo, Jara; Marti Martin-Consuegra, Juan Manuel; Ruiz de Almodovar, Mariano; Lopez-Rivas, Abelardo; Javier Oliver, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">678-697</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Poly (ADP-ribose) polymerase (PARP) inhibitors are particularly efficient against tumors with defects in the homologous recombination repair pathway.  Nonetheless poly(ADP-ribosylation) (PARylation) modulates prometastasic activities and adaptation of tumor to a hostile microenvironment.  Modulation of metastasis-promoting traits is possible through the alteration of key transcription factors involved in the regulation of the hypoxic response, the recruitment of new vessels (or angiogenesis), and the stimulation of epithelial to mesenchymal transition (EMT).  In this review, we summarized some of the findings that focalize on PARP-1's action on tumor aggressiveness, suggesting new therapeutic opportunities against an assembly of tumors not necessarily bearing DNA repair defects.  Metastasis accounts for the vast majority of mortality derived from solid cancer.  PARP-1 is an active player in tumor adaptation to metastasis and PARP inhibitors, recognized as promising therapeutic agents against homologous recombination deficient tumors, has novel properties responsible for the antimetastatic actions in different tumor settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8fqnWODbvJbVg90H21EOLACvtfcHk0ljMAVDOWkAoYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWgs7nI&md5=58436604c3b03d5741f15fd65d1bd541</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fmed.21339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21339%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DM.%2BI.%26aulast%3DMajuelos-Melguizo%26aufirst%3DJ.%26aulast%3DMart%25C3%25AD%2BMart%25C3%25ADn-Consuegra%26aufirst%3DJ.%2BM.%26aulast%3DRuiz%2Bde%2BAlmodovar%26aufirst%3DM.%26aulast%3DL%25C3%25B3pez-Rivas%26aufirst%3DA.%26aulast%3DJavier%2BOliver%26aufirst%3DF.%26atitle%3DDeciphering%2520the%2520insights%2520of%2520poly%2528ADP-ribosylation%2529%2520in%2520tumor%2520progression%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2015%26volume%3D35%26spage%3D678%26epage%3D697%26doi%3D10.1002%2Fmed.21339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Ryu, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, W. L.</span><span> </span><span class="NLM_article-title">New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2453</span><span class="NLM_x">–</span> <span class="NLM_lpage">2481</span><span class="refDoi"> DOI: 10.1021/cr5004248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr5004248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1yrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=2453-2481&author=K.+W.+Ryuauthor=D.+S.+Kimauthor=W.+L.+Kraus&title=New+facets+in+the+regulation+of+gene+expression+by+ADP-ribosylation+and+poly%28ADP-ribose%29+polymerases&doi=10.1021%2Fcr5004248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases</span></div><div class="casAuthors">Ryu, Keun Woo; Kim, Dae-Seok; Kraus, W. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2453-2481</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the role of poly(ADP-ribose) polymerases (PARPs) and ADP-ribosylation in gene regulation, with a particular emphasis on the role of PARPs in RNA biol.  Topics include: the PARP family; NAD+ metab. and PARP-1; PARP-1 in gene regulation including chromatin modulation, transcription regulation, and non-coding RNA regulation; and PARP-1 in ribosome biogenesis, stress response, circadian rhythm, and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF0xfFz6hkG7Vg90H21EOLACvtfcHk0ljMAVDOWkAoYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1yrsg%253D%253D&md5=496f79e7a373d08dd7c116fe9d74eb1a</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fcr5004248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr5004248%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DK.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DNew%2520facets%2520in%2520the%2520regulation%2520of%2520gene%2520expression%2520by%2520ADP-ribosylation%2520and%2520poly%2528ADP-ribose%2529%2520polymerases%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26spage%3D2453%26epage%3D2481%26doi%3D10.1021%2Fcr5004248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Rodríguez, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peralta-Leal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Valle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Vargas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Flores, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majuelos-Melguizo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Herreros, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodríguez-Manzaneque, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Moral, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Almodóvar, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, F. J.</span><span> </span><span class="NLM_article-title">PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation</span> <span class="citation_source-journal">PLoS Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1003531</span><span class="refDoi"> DOI: 10.1371/journal.pgen.1003531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1371%2Fjournal.pgen.1003531" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=e1003531&author=M.+I.+Rodr%C3%ADguezauthor=A.+Peralta-Lealauthor=F.+O%E2%80%99Valleauthor=J.+M.+Rodriguez-Vargasauthor=A.+Gonzalez-Floresauthor=J.+Majuelos-Melguizoauthor=L.+L%C3%B3pezauthor=S.+Serranoauthor=A.+G.+de+Herrerosauthor=J.+C.+Rodr%C3%ADguez-Manzanequeauthor=R.+Fern%C3%A1ndezauthor=R.+G.+Del+Moralauthor=J.+M.+de+Almod%C3%B3varauthor=F.+J.+Oliver&title=PARP-1+regulates+metastatic+melanoma+through+modulation+of+vimentin-induced+malignant+transformation&doi=10.1371%2Fjournal.pgen.1003531"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1003531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1003531%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DM.%2BI.%26aulast%3DPeralta-Leal%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Valle%26aufirst%3DF.%26aulast%3DRodriguez-Vargas%26aufirst%3DJ.%2BM.%26aulast%3DGonzalez-Flores%26aufirst%3DA.%26aulast%3DMajuelos-Melguizo%26aufirst%3DJ.%26aulast%3DL%25C3%25B3pez%26aufirst%3DL.%26aulast%3DSerrano%26aufirst%3DS.%26aulast%3Dde%2BHerreros%26aufirst%3DA.%2BG.%26aulast%3DRodr%25C3%25ADguez-Manzaneque%26aufirst%3DJ.%2BC.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DR.%26aulast%3DDel%2BMoral%26aufirst%3DR.%2BG.%26aulast%3Dde%2BAlmod%25C3%25B3var%26aufirst%3DJ.%2BM.%26aulast%3DOliver%26aufirst%3DF.%2BJ.%26atitle%3DPARP-1%2520regulates%2520metastatic%2520melanoma%2520through%2520modulation%2520of%2520vimentin-induced%2520malignant%2520transformation%26jtitle%3DPLoS%2520Genet.%26date%3D2013%26volume%3D9%26spage%3De1003531%26doi%3D10.1371%2Fjournal.pgen.1003531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Kraus, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hottiger, M. O.</span><span> </span><span class="NLM_article-title">PARP-1 and gene regulation: progress and puzzles</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1109</span><span class="NLM_x">–</span> <span class="NLM_lpage">1123</span><span class="refDoi"> DOI: 10.1016/j.mam.2013.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.mam.2013.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23357755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisVygsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=1109-1123&author=W.+L.+Krausauthor=M.+O.+Hottiger&title=PARP-1+and+gene+regulation%3A+progress+and+puzzles&doi=10.1016%2Fj.mam.2013.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-1 and gene regulation: Progress and puzzles</span></div><div class="casAuthors">Kraus, W. Lee; Hottiger, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1109-1123</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1), also referred to as ADP-ribosyltransferase Diphtheria toxin-like 1 (ARTD1), is an abundant nuclear protein that plays key roles in a variety of nuclear processes, including the regulation of transcription.  PARP-1 possesses an intrinsic enzymic activity that catalyzes the transfer of ADP-ribose (ADPR) units from NAD (NAD+) onto target gene regulatory proteins, thereby modulating their activities.  Although great strides have been made in the past decade in deciphering the seemingly opposing and varied roles of PARP-1 in gene regulation, many puzzles remain.  In this review, the authors discuss the current state of understanding in this area, esp. how PARP-1 interfaces with various components of gene regulatory pathways (e.g., the basal transcription machinery, DNA-binding transcription factors, coregulators, chromatin remodeling, histone modifications, and DNA methylation).  In addn., the authors discuss some gene-specific, cell type-specific, and cell state-specific effects of PARP-1 on gene regulation, which might contribute to its biol. functions.  Finally, the authors review some of the recent progress targeting PARPs using chem. inhibitors, some of which may alter PARP-1-dependent gene regulatory programs to promote therapeutic outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCLrQy2hgJJ7Vg90H21EOLACvtfcHk0ljszp5nltnNQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisVygsL8%253D&md5=96d89c9df4cd49011e55d3a9e6407747</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2013.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2013.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DW.%2BL.%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26atitle%3DPARP-1%2520and%2520gene%2520regulation%253A%2520progress%2520and%2520puzzles%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26spage%3D1109%26epage%3D1123%26doi%3D10.1016%2Fj.mam.2013.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Gunderson, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, K. N.</span><span> </span><span class="NLM_article-title">BRACAnalysis CDx as a companion diagnostic tool for Lynparza</span> <span class="citation_source-journal">Expert Rev. Mol. Diagn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">–</span> <span class="NLM_lpage">1116</span><span class="refDoi"> DOI: 10.1586/14737159.2015.1078238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1586%2F14737159.2015.1078238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26292709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCms7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=1111-1116&author=C.+C.+Gundersonauthor=K.+N.+Moore&title=BRACAnalysis+CDx+as+a+companion+diagnostic+tool+for+Lynparza&doi=10.1586%2F14737159.2015.1078238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">BRACAnalysis CDx as a companion diagnostic tool for Lynparza</span></div><div class="casAuthors">Gunderson, Camille C.; Moore, Kathleen N.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Molecular Diagnostics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1111-1116</span>CODEN:
                <span class="NLM_cas:coden">ERMDCW</span>;
        ISSN:<span class="NLM_cas:issn">1473-7159</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Lynparza and its companion diagnostic test, BRACAnal. were approved by the US FDA in Dec. 2014 for recurrent ovarian cancer in women with a germline BRCA mutation.  Women with a deleterious BRCA mutation are predisposed to ovarian cancer due to deficient homologous recombination repair.  Inhibition of the PARP enzyme forces use of an alternate error-prone pathway for repair; PARP trapping is another mechanism utilized that blocks cellular replication by trapping inactivated PARP onto single-stranded DNA breaks.  Although many companion diagnostic kits are already in use in oncol., BRACAnaylsis is unique in several ways including comprehensive BRCA gene germline profiling, availability to all women with ovarian cancer and implications for family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRE8_moU7kr7Vg90H21EOLACvtfcHk0ljszp5nltnNQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCms7vO&md5=a83b033abe4fc9f9e10e56989869abae</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1586%2F14737159.2015.1078238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737159.2015.1078238%26sid%3Dliteratum%253Aachs%26aulast%3DGunderson%26aufirst%3DC.%2BC.%26aulast%3DMoore%26aufirst%3DK.%2BN.%26atitle%3DBRACAnalysis%2520CDx%2520as%2520a%2520companion%2520diagnostic%2520tool%2520for%2520Lynparza%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Diagn.%26date%3D2015%26volume%3D15%26spage%3D1111%26epage%3D1116%26doi%3D10.1586%2F14737159.2015.1078238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">The Cancer Genome Atlas Research Network</span>. <span> </span><span class="NLM_article-title">Integrated genomic analyses of ovarian carcinoma</span>.  <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">474</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span>.<span class="refDoi"> DOI: 10.1038/nature10166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnature10166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21720365" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=474&publication_year=2011&pages=609-615&author=The+Cancer+Genome+Atlas+Research+Network&title=Integrated+genomic+analyses+of+ovarian+carcinoma&doi=10.1038%2Fnature10166"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnature10166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10166%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DIntegrated%2520genomic%2520analyses%2520of%2520ovarian%2520carcinoma%26jtitle%3DNature%26date%3D2011%26volume%3D474%26spage%3D609%26epage%3D615%26doi%3D10.1038%2Fnature10166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Ihnen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">zu Eulenburg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolarova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manivong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalukya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winterhoff, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velculescu, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Udar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänicke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konecny, G. E.</span><span> </span><span class="NLM_article-title">Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1002</span><span class="NLM_x">–</span> <span class="NLM_lpage">1015</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.MCT-12-0813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23729402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1002-1015&author=M.+Ihnenauthor=C.+zu+Eulenburgauthor=T.+Kolarovaauthor=J.+Qiauthor=K.+Manivongauthor=M.+Chalukyaauthor=J.+Deringauthor=L.+Andersonauthor=C.+Gintherauthor=A.+Meuterauthor=B.+Winterhoffauthor=S.+Jonesauthor=V.+E.+Velculescuauthor=N.+Venkatesanauthor=H.+M.+Rongauthor=S.+Dandekarauthor=N.+Udarauthor=F.+J%C3%A4nickeauthor=G.+Losauthor=D.+J.+Slamonauthor=G.+E.+Konecny&title=Therapeutic+potential+of+the+poly%28ADP-ribose%29+polymerase+inhibitor+rucaparib+for+the+treatment+of+sporadic+human+ovarian+cancer&doi=10.1158%2F1535-7163.MCT-12-0813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer</span></div><div class="casAuthors">Ihnen, Maike; zu Eulenburg, Christine; Kolarova, Teodora; Qi, Jing Wei; Manivong, Kanthinh; Chalukya, Meenal; Dering, Judy; Anderson, Lee; Ginther, Charles; Meuter, Alexandra; Winterhoff, Boris; Jones, Sian; Velculescu, Victor E.; Venkatesan, Natarajan; Rong, Hong-Mei; Dandekar, Sugandha; Udar, Nitin; Jaenicke, Fritz; Los, Gerrit; Slamon, Dennis J.; Konecny, Gottfried E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1002-1015</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer.  We studied the growth inhibitory effects of rucaparib in a panel of 39 ovarian cancer cell lines that were each characterized for mutation and methylation status of BRCA1/2, baseline gene expression signatures, copy no. variations of selected genes, PTEN status, and sensitivity to platinum-based chemotherapy.  To study interactions with chemotherapy, we used multiple drug effect analyses and assessed apoptosis, DNA fragmentation, and γH2AX formation.  Concn.-dependent antiproliferative effects of rucaparib were seen in 26 of 39 (67%) cell lines and were not restricted to cell lines with BRCA1/2 mutations.  Low expression of other genes involved in homologous repair (e.g., BCCIP, BRCC3, ATM, RAD51L1), amplification of AURKA or EMSY, and response to platinum-based chemotherapy was assocd. with sensitivity to rucaparib.  Drug interactions with rucaparib were synergistic for topotecan, synergistic, or additive for carboplatin, doxorubicin or paclitaxel, and additive for gemcitabine.  Synergy was most pronounced when rucaparib was combined with topotecan, which resulted in enhanced apoptosis, DNA fragmentation, and γH2AX formation.  Importantly, rucaparib potentiated chemotherapy independent of its activity as a single agent.  PARP inhibition may be a useful therapeutic strategy for a wider range of ovarian cancers bearing deficiencies in the homologous recombination pathway other than just BRCA1/2 mutations.  These results support further clin. evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe7ZBqJCdQobVg90H21EOLACvtfcHk0ljszp5nltnNQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOltLw%253D&md5=4eaf35f1dd521263a63ee6cb5a8c8ad6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0813%26sid%3Dliteratum%253Aachs%26aulast%3DIhnen%26aufirst%3DM.%26aulast%3Dzu%2BEulenburg%26aufirst%3DC.%26aulast%3DKolarova%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DManivong%26aufirst%3DK.%26aulast%3DChalukya%26aufirst%3DM.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DMeuter%26aufirst%3DA.%26aulast%3DWinterhoff%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DVenkatesan%26aufirst%3DN.%26aulast%3DRong%26aufirst%3DH.%2BM.%26aulast%3DDandekar%26aufirst%3DS.%26aulast%3DUdar%26aufirst%3DN.%26aulast%3DJ%25C3%25A4nicke%26aufirst%3DF.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26atitle%3DTherapeutic%2520potential%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520rucaparib%2520for%2520the%2520treatment%2520of%2520sporadic%2520human%2520ovarian%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1002%26epage%3D1015%26doi%3D10.1158%2F1535-7163.MCT-12-0813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Hartlerode, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D. O.</span><span> </span><span class="NLM_article-title">Recruitment and activation of the ATM kinase in the absence of DNA-damage sensors</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">736</span><span class="NLM_x">–</span> <span class="NLM_lpage">743</span><span class="refDoi"> DOI: 10.1038/nsmb.3072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnsmb.3072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26280532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSnt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=736-743&author=A.+J.+Hartlerodeauthor=M.+J.+Morganauthor=Y.+Wuauthor=J.+Buisauthor=D.+O.+Ferguson&title=Recruitment+and+activation+of+the+ATM+kinase+in+the+absence+of+DNA-damage+sensors&doi=10.1038%2Fnsmb.3072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Recruitment and activation of the ATM kinase in the absence of DNA-damage sensors</span></div><div class="casAuthors">Hartlerode, Andrea J.; Morgan, Mary J.; Wu, Yipin; Buis, Jeffrey; Ferguson, David O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">736-743</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Two kinases, ATM and DNA-PKcs, control rapid responses to DNA double-strand breaks (DSBs).  The paradigm for ATM control is recruitment and activation by the Mre11-Rad50-NBS1 (MRN) sensor complex, whereas DNA-PKcs requires the sensor Ku (Ku70-Ku80).  Using mouse cells contg. targeted mutant alleles of Mre11 (Mre11a) and/or Ku70 (Xrcc6), together with pharmacol. kinase inhibition, we demonstrate that ATM can be activated by DSBs in the absence of MRN.  When MRN is deficient, DNA-PKcs efficiently substitutes for ATM in facilitating local chromatin responses.  In the absence of both MRN and Ku, ATM is recruited to chromatin, where it phosphorylates H2AX and triggers the G2-M cell-cycle checkpoint, but the DNA-repair functions of MRN are not restored.  These results suggest that, in contrast to straightforward recruitment and activation by MRN, a complex interplay between sensors has a substantial role in ATM control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8KcjWkVKNabVg90H21EOLACvtfcHk0ljcQIR0RYE3hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSnt7%252FP&md5=bafce12c6277489b19437f07684ebc71</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3072%26sid%3Dliteratum%253Aachs%26aulast%3DHartlerode%26aufirst%3DA.%2BJ.%26aulast%3DMorgan%26aufirst%3DM.%2BJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBuis%26aufirst%3DJ.%26aulast%3DFerguson%26aufirst%3DD.%2BO.%26atitle%3DRecruitment%2520and%2520activation%2520of%2520the%2520ATM%2520kinase%2520in%2520the%2520absence%2520of%2520DNA-damage%2520sensors%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D736%26epage%3D743%26doi%3D10.1038%2Fnsmb.3072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Stracker, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrini, J. H.</span><span> </span><span class="NLM_article-title">The MRE11 complex: starting from the ends</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1038/nrm3047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnrm3047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21252998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlSgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=90-103&author=T.+H.+Strackerauthor=J.+H.+Petrini&title=The+MRE11+complex%3A+starting+from+the+ends&doi=10.1038%2Fnrm3047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">The MRE11 complex: Starting from the ends</span></div><div class="casAuthors">Stracker, Travis H.; Petrini, John H. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The maintenance of genome stability depends on the DNA damage response (DDR), which is a functional network comprising signal transduction, cell cycle regulation and DNA repair.  The metab. of DNA double-strand breaks governed by the DDR is important for preventing genomic alterations and sporadic cancers, and hereditary defects in this response cause debilitating human pathologies, including developmental defects and cancer.  The MRE11 complex, composed of the meiotic recombination 11 (MRE11), RAD50 and Nijmegen breakage syndrome 1 (NBS1; also known as nibrin) proteins is central to the DDR, and recent insights into its structure and function were gained from in vitro structural anal. and studies of animal models in which the DDR response is deficient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosXAZgukwJ-7Vg90H21EOLACvtfcHk0ljcQIR0RYE3hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlSgsA%253D%253D&md5=bbdf62041cb087a33f1c3d023282a11b</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnrm3047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3047%26sid%3Dliteratum%253Aachs%26aulast%3DStracker%26aufirst%3DT.%2BH.%26aulast%3DPetrini%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520MRE11%2520complex%253A%2520starting%2520from%2520the%2520ends%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2011%26volume%3D12%26spage%3D90%26epage%3D103%26doi%3D10.1038%2Fnrm3047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Oplustilova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolanin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistrik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korinkova, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simkova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouchal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenobel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartkova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span> </span><span class="NLM_article-title">Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3837</span><span class="NLM_x">–</span> <span class="NLM_lpage">3850</span><span class="refDoi"> DOI: 10.4161/cc.22026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.4161%2Fcc.22026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=3837-3850&author=L.+Oplustilovaauthor=K.+Wolaninauthor=M.+Mistrikauthor=G.+Korinkovaauthor=D.+Simkovaauthor=J.+Bouchalauthor=R.+Lenobelauthor=J.+Bartkovaauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=J.+Lukasauthor=J.+Bartek&title=Evaluation+of+candidate+biomarkers+to+predict+cancer+cell+sensitivity+or+resistance+to+PARP-1+inhibitor+treatment&doi=10.4161%2Fcc.22026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.4161%2Fcc.22026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.22026%26sid%3Dliteratum%253Aachs%26aulast%3DOplustilova%26aufirst%3DL.%26aulast%3DWolanin%26aufirst%3DK.%26aulast%3DMistrik%26aufirst%3DM.%26aulast%3DKorinkova%26aufirst%3DG.%26aulast%3DSimkova%26aufirst%3DD.%26aulast%3DBouchal%26aufirst%3DJ.%26aulast%3DLenobel%26aufirst%3DR.%26aulast%3DBartkova%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DLukas%26aufirst%3DJ.%26aulast%3DBartek%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520candidate%2520biomarkers%2520to%2520predict%2520cancer%2520cell%2520sensitivity%2520or%2520resistance%2520to%2520PARP-1%2520inhibitor%2520treatment%26jtitle%3DCell%2520Cycle%26date%3D2012%26volume%3D11%26spage%3D3837%26epage%3D3850%26doi%3D10.4161%2Fcc.22026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Koppensteiner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samartzis, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noske, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Teichman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dedes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwerder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imesch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikenberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stucki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dedes, K. J.</span><span> </span><span class="NLM_article-title">Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e100041</span><span class="refDoi"> DOI: 10.1371/journal.pone.0100041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1371%2Fjournal.pone.0100041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e100041&author=R.+Koppensteinerauthor=E.+P.+Samartzisauthor=A.+Noskeauthor=A.+von+Teichmanauthor=I.+Dedesauthor=M.+Gwerderauthor=P.+Imeschauthor=K.+Ikenbergauthor=H.+Mochauthor=D.+Finkauthor=M.+Stuckiauthor=K.+J.+Dedes&title=Effect+of+MRE11+loss+on+PARP-inhibitor+sensitivity+in+endometrial+cancer+in+vitro&doi=10.1371%2Fjournal.pone.0100041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0100041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0100041%26sid%3Dliteratum%253Aachs%26aulast%3DKoppensteiner%26aufirst%3DR.%26aulast%3DSamartzis%26aufirst%3DE.%2BP.%26aulast%3DNoske%26aufirst%3DA.%26aulast%3Dvon%2BTeichman%26aufirst%3DA.%26aulast%3DDedes%26aufirst%3DI.%26aulast%3DGwerder%26aufirst%3DM.%26aulast%3DImesch%26aufirst%3DP.%26aulast%3DIkenberg%26aufirst%3DK.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DD.%26aulast%3DStucki%26aufirst%3DM.%26aulast%3DDedes%26aufirst%3DK.%2BJ.%26atitle%3DEffect%2520of%2520MRE11%2520loss%2520on%2520PARP-inhibitor%2520sensitivity%2520in%2520endometrial%2520cancer%2520in%2520vitro%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De100041%26doi%3D10.1371%2Fjournal.pone.0100041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Vilar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartnik, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenzel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raskin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iniesta, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennert, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, S. B.</span><span> </span><span class="NLM_article-title">MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">2632</span><span class="NLM_x">–</span> <span class="NLM_lpage">2642</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-10-1120" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2632-2642&author=E.+Vilarauthor=C.+M.+Bartnikauthor=S.+L.+Stenzelauthor=L.+Raskinauthor=J.+Ahnauthor=V.+Morenoauthor=B.+Mukherjeeauthor=M.+D.+Iniestaauthor=M.+A.+Morganauthor=G.+Rennertauthor=S.+B.+Gruber&title=MRE11+deficiency+increases+sensitivity+to+poly%28ADP-ribose%29+polymerase+inhibition+in+microsatellite+unstable+colorectal+cancers&doi=10.1158%2F0008-5472.CAN-10-1120"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1120%26sid%3Dliteratum%253Aachs%26aulast%3DVilar%26aufirst%3DE.%26aulast%3DBartnik%26aufirst%3DC.%2BM.%26aulast%3DStenzel%26aufirst%3DS.%2BL.%26aulast%3DRaskin%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DJ.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DMukherjee%26aufirst%3DB.%26aulast%3DIniesta%26aufirst%3DM.%2BD.%26aulast%3DMorgan%26aufirst%3DM.%2BA.%26aulast%3DRennert%26aufirst%3DG.%26aulast%3DGruber%26aufirst%3DS.%2BB.%26atitle%3DMRE11%2520deficiency%2520increases%2520sensitivity%2520to%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibition%2520in%2520microsatellite%2520unstable%2520colorectal%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2632%26epage%3D2642%26doi%3D10.1158%2F0008-5472.CAN-10-1120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Faraoni, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Compagnone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavorgna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelini, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cencioni, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piras, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panetta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venditti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo-Coco, F.</span><span> </span><span class="NLM_article-title">BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Basis Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1852</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span><span class="refDoi"> DOI: 10.1016/j.bbadis.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bbadis.2014.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25483710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyksbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1852&publication_year=2015&pages=462-472&author=I.+Faraoniauthor=M.+Compagnoneauthor=S.+Lavorgnaauthor=D.+F.+Angeliniauthor=M.+T.+Cencioniauthor=E.+Pirasauthor=P.+Panettaauthor=T.+Ottoneauthor=S.+Dolciauthor=A.+Vendittiauthor=G.+Grazianiauthor=F.+Lo-Coco&title=BRCA1%2C+PARP1+and+gammaH2AX+in+acute+myeloid+leukemia%3A+Role+as+biomarkers+of+response+to+the+PARP+inhibitor+olaparib&doi=10.1016%2Fj.bbadis.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib</span></div><div class="casAuthors">Faraoni, Isabella; Compagnone, Mirco; Lavorgna, Serena; Angelini, Daniela Francesca; Cencioni, Maria Teresa; Piras, Eleonora; Panetta, Paola; Ottone, Tiziana; Dolci, Susanna; Venditti, Adriano; Graziani, Grazia; Lo-Coco, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1852</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">462-472</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase (PARP) inhibitor currently under investigation in patients with solid tumors.  To study the clin. potential of olaparib as a single-agent for the treatment of acute myeloid leukemia (AML) patients, we analyzed the in vitro sensitivity of AML cell lines and primary blasts.  Clin. achievable concns. of olaparib were able to induce cell death in the majority of primary AML case samples (88%) and tested cell lines.  At these concns., olaparib preferentially killed leukemic blasts sparing normal lymphocytes derived from the same patient and did not substantially affect the viability of normal bone marrow and CD34-enriched peripheral blood cells obtained from healthy donors.  Most primary AML analyzed were characterized by low BRCA1 mRNA level and undetectable protein expression that likely contributed to explain their sensitivity to olaparib.  Noteworthy, while PARP1 over-expression was detected in blasts not responsive to olaparib, phosphorylation of the histone H2AFX (γH2AX) was assocd. with drug sensitivity.  As to genetic features of tested cases the highest sensitivity was shown by a patient carrying a 11q23 deletion.  The high sensitivity of AML blasts and the identification of biomarkers potentially able to predict response and/or resistance may foster further investigation of olaparib monotherapy for AML patients unfit to conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUBo2_k6iHarVg90H21EOLACvtfcHk0lj_W8QtH0gbSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyksbvK&md5=2d7a28d00a293fa716fbb960c78b9638</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DFaraoni%26aufirst%3DI.%26aulast%3DCompagnone%26aufirst%3DM.%26aulast%3DLavorgna%26aufirst%3DS.%26aulast%3DAngelini%26aufirst%3DD.%2BF.%26aulast%3DCencioni%26aufirst%3DM.%2BT.%26aulast%3DPiras%26aufirst%3DE.%26aulast%3DPanetta%26aufirst%3DP.%26aulast%3DOttone%26aufirst%3DT.%26aulast%3DDolci%26aufirst%3DS.%26aulast%3DVenditti%26aufirst%3DA.%26aulast%3DGraziani%26aufirst%3DG.%26aulast%3DLo-Coco%26aufirst%3DF.%26atitle%3DBRCA1%252C%2520PARP1%2520and%2520gammaH2AX%2520in%2520acute%2520myeloid%2520leukemia%253A%2520Role%2520as%2520biomarkers%2520of%2520response%2520to%2520the%2520PARP%2520inhibitor%2520olaparib%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2015%26volume%3D1852%26spage%3D462%26epage%3D472%26doi%3D10.1016%2Fj.bbadis.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Weber, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span> </span><span class="NLM_article-title">ATM and ATR as therapeutic targets in cancer</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">124</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.pharmthera.2014.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25512053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtV2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2015&pages=124-138&author=A.+M.+Weberauthor=A.+J.+Ryan&title=ATM+and+ATR+as+therapeutic+targets+in+cancer&doi=10.1016%2Fj.pharmthera.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">ATM and ATR as therapeutic targets in cancer</span></div><div class="casAuthors">Weber, Anika Maria; Ryan, Anderson Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">124-138</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  In order to maintain genomic stability, cells have developed sophisticated signalling pathways to enable DNA damage or DNA replication stress to be resolved.  Key mediators of this DNA damage response (DDR) are the ATM and ATR kinases, which induce cell cycle arrest and facilitate DNA repair via their downstream targets.  Inhibiting the DDR has become an attractive therapeutic concept in cancer therapy, since (i) resistance to genotoxic therapies has been assocd. with increased DDR signalling, and (ii) many cancers have defects in certain components of the DDR rendering them highly dependent on the remaining DDR pathways for survival.  ATM and ATR act as the apical regulators of the response to DNA double strand breaks and replication stress, resp., with overlapping but non-redundant activities.  Highly selective small mol. inhibitors of ATM and ATR are currently in preclin. and clin. development, resp.  Preclin. data have provided a strong rationale for clin. testing of these compds. both in combination with radio- or chemotherapy, and in synthetic lethal approaches to treat tumors with deficiencies in certain DDR components.  Whole genome sequencing studies have reported that mutations in DDR genes occur with a high frequency in many common tumor types, suggesting that a synthetic lethal approach with ATM or ATR inhibitors could have widespread utility, providing that appropriate biomarkers are developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXNTHNVGQUGbVg90H21EOLACvtfcHk0lj_W8QtH0gbSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtV2msA%253D%253D&md5=204198bfeef4fc9cdf3d0e8968334363</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DA.%2BM.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26atitle%3DATM%2520and%2520ATR%2520as%2520therapeutic%2520targets%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D149%26spage%3D124%26epage%3D138%26doi%3D10.1016%2Fj.pharmthera.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Hoglund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stromvall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forshell, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, J. A.</span><span> </span><span class="NLM_article-title">Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">3598</span><span class="NLM_x">–</span> <span class="NLM_lpage">3607</span><span class="refDoi"> DOI: 10.4161/cc.10.20.17887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.4161%2Fcc.10.20.17887" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=3598-3607&author=A.+Hoglundauthor=K.+Stromvallauthor=Y.+Liauthor=L.+P.+Forshellauthor=J.+A.+Nilsson&title=Chk2+deficiency+in+Myc+overexpressing+lymphoma+cells+elicits+a+synergistic+lethal+response+in+combination+with+PARP+inhibition&doi=10.4161%2Fcc.10.20.17887"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.4161%2Fcc.10.20.17887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.10.20.17887%26sid%3Dliteratum%253Aachs%26aulast%3DHoglund%26aufirst%3DA.%26aulast%3DStromvall%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DForshell%26aufirst%3DL.%2BP.%26aulast%3DNilsson%26aufirst%3DJ.%2BA.%26atitle%3DChk2%2520deficiency%2520in%2520Myc%2520overexpressing%2520lymphoma%2520cells%2520elicits%2520a%2520synergistic%2520lethal%2520response%2520in%2520combination%2520with%2520PARP%2520inhibition%26jtitle%3DCell%2520Cycle%26date%3D2011%26volume%3D10%26spage%3D3598%26epage%3D3607%26doi%3D10.4161%2Fcc.10.20.17887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Gilardini Montani, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodosmo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stagni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteonofrio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentileschi, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barila, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soddu, S.</span><span> </span><span class="NLM_article-title">ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition</span> <span class="citation_source-journal">J. Exp. Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="refDoi"> DOI: 10.1186/1756-9966-32-95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2F1756-9966-32-95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24252502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2c7os1Glsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=95&author=M.+S.+Gilardini+Montaniauthor=A.+Prodosmoauthor=V.+Stagniauthor=D.+Merliauthor=L.+Monteonofrioauthor=V.+Gattiauthor=M.+P.+Gentileschiauthor=D.+Barilaauthor=S.+Soddu&title=ATM-depletion+in+breast+cancer+cells+confers+sensitivity+to+PARP+inhibition&doi=10.1186%2F1756-9966-32-95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition</span></div><div class="casAuthors">Gilardini Montani Maria Saveria; Prodosmo Andrea; Stagni Venturina; Merli Dania; Monteonofrio Laura; Gatti Veronica; Gentileschi Maria Pia; Barila Daniela; Soddu Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mutations in the DNA damage response (DDR) factors, breast cancer 1 (BRCA1) and BRCA2, sensitize tumor cells to poly(ADP-ribose) polymerase (PARP) inhibitors.  The ataxia telangiectasia mutated (ATM) kinase is a key DDR protein whose heterozygous germline mutation is a moderate-risk factor for developing breast cancer.  In this study, we examined whether ATM inactivation in breast cancer cell lines confers sensitivity to PARP inhibitors.  METHODS:  Wild-type BRCA1/2 breast cancer cells (i.e., MCF-7 and ZR-75-1 lines) were genetically manipulated to downregulate ATM expression then assayed for cytostaticity/cytotoxicity upon treatment with PARP inhibitors, olaparib and iniparib.  RESULTS:  When ATM-depleted cells and their relative controls were treated with olaparib (a competitive PARP-1/2 inhibitor) and iniparib (a molecule originally described as a covalent PARP-1 inhibitor) a different response to the two compounds was observed.  ATM-depletion sensitized both MCF-7 and ZR-75-1 cells to olaparib-treatment, as assessed by short and long survival assays and cell cycle profiles.  In contrast, iniparib induced only a mild, ATM-dependent cytostatic effect in MCF-7 cells whereas ZR-75-1 cells were sensitive to this drug, independently of ATM inactivation.  These latest results might be explained by recent observations indicating that iniparib acts with mechanisms other than PARP inhibition.  CONCLUSIONS:  These data indicate that ATM-depletion can sensitize breast cancer cells to PARP inhibition, suggesting a potential in the treatment of breast cancers low in ATM protein expression/activity, such as those arising in mutant ATM heterozygous carriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRve4U0u-sYhbmQt-ICR3qNfW6udTcc2eao5eepbMJMCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7os1Glsw%253D%253D&md5=00fee550e2b9a4d7ad30171b228f235a</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1186%2F1756-9966-32-95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-9966-32-95%26sid%3Dliteratum%253Aachs%26aulast%3DGilardini%2BMontani%26aufirst%3DM.%2BS.%26aulast%3DProdosmo%26aufirst%3DA.%26aulast%3DStagni%26aufirst%3DV.%26aulast%3DMerli%26aufirst%3DD.%26aulast%3DMonteonofrio%26aufirst%3DL.%26aulast%3DGatti%26aufirst%3DV.%26aulast%3DGentileschi%26aufirst%3DM.%2BP.%26aulast%3DBarila%26aufirst%3DD.%26aulast%3DSoddu%26aufirst%3DS.%26atitle%3DATM-depletion%2520in%2520breast%2520cancer%2520cells%2520confers%2520sensitivity%2520to%2520PARP%2520inhibition%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D32%26spage%3D95%26doi%3D10.1186%2F1756-9966-32-95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Kubota, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elegbede, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lees-Miller, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebb, D. G.</span><span> </span><span class="NLM_article-title">Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2137</span><span class="refDoi"> DOI: 10.4161/cc.29212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.4161%2Fcc.29212" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2129-2137&author=E.+Kubotaauthor=C.+T.+Williamsonauthor=R.+Yeauthor=A.+Elegbedeauthor=L.+Petersonauthor=S.+P.+Lees-Millerauthor=D.+G.+Bebb&title=Low+ATM+protein+expression+and+depletion+of+p53+correlates+with+olaparib+sensitivity+in+gastric+cancer+cell+lines&doi=10.4161%2Fcc.29212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.4161%2Fcc.29212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.29212%26sid%3Dliteratum%253Aachs%26aulast%3DKubota%26aufirst%3DE.%26aulast%3DWilliamson%26aufirst%3DC.%2BT.%26aulast%3DYe%26aufirst%3DR.%26aulast%3DElegbede%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DL.%26aulast%3DLees-Miller%26aufirst%3DS.%2BP.%26aulast%3DBebb%26aufirst%3DD.%2BG.%26atitle%3DLow%2520ATM%2520protein%2520expression%2520and%2520depletion%2520of%2520p53%2520correlates%2520with%2520olaparib%2520sensitivity%2520in%2520gastric%2520cancer%2520cell%2520lines%26jtitle%3DCell%2520Cycle%26date%3D2014%26volume%3D13%26spage%3D2129%26epage%3D2137%26doi%3D10.4161%2Fcc.29212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Weston, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldreive, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skowronska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oscier, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudzki, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearns, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stankovic, T.</span><span> </span><span class="NLM_article-title">The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">4578</span><span class="NLM_x">–</span> <span class="NLM_lpage">4587</span><span class="refDoi"> DOI: 10.1182/blood-2010-01-265769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1182%2Fblood-2010-01-265769" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=4578-4587&author=V.+J.+Westonauthor=C.+E.+Oldreiveauthor=A.+Skowronskaauthor=D.+G.+Oscierauthor=G.+Prattauthor=M.+J.+Dyerauthor=G.+Smithauthor=J.+E.+Powellauthor=Z.+Rudzkiauthor=P.+Kearnsauthor=P.+A.+Mossauthor=A.+M.+Taylorauthor=T.+Stankovic&title=The+PARP+inhibitor+olaparib+induces+significant+killing+of+ATM-deficient+lymphoid+tumor+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2010-01-265769"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-01-265769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-01-265769%26sid%3Dliteratum%253Aachs%26aulast%3DWeston%26aufirst%3DV.%2BJ.%26aulast%3DOldreive%26aufirst%3DC.%2BE.%26aulast%3DSkowronska%26aufirst%3DA.%26aulast%3DOscier%26aufirst%3DD.%2BG.%26aulast%3DPratt%26aufirst%3DG.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DPowell%26aufirst%3DJ.%2BE.%26aulast%3DRudzki%26aufirst%3DZ.%26aulast%3DKearns%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DP.%2BA.%26aulast%3DTaylor%26aufirst%3DA.%2BM.%26aulast%3DStankovic%26aufirst%3DT.%26atitle%3DThe%2520PARP%2520inhibitor%2520olaparib%2520induces%2520significant%2520killing%2520of%2520ATM-deficient%2520lymphoid%2520tumor%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D4578%26epage%3D4587%26doi%3D10.1182%2Fblood-2010-01-265769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Williamson, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzik, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turhan, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamò, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebb, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lees-Miller, S. P.</span><span> </span><span class="NLM_article-title">ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">357</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.MCT-09-0872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20124459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslektb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=347-357&author=C.+T.+Williamsonauthor=H.+Muzikauthor=A.+G.+Turhanauthor=A.+Zam%C3%B2author=M.+J.+O%E2%80%99Connorauthor=D.+G.+Bebbauthor=S.+P.+Lees-Miller&title=ATM+deficiency+sensitizes+mantle+cell+lymphoma+cells+to+poly%28ADP-ribose%29+polymerase-1+inhibitors&doi=10.1158%2F1535-7163.MCT-09-0872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors</span></div><div class="casAuthors">Williamson, Chris T.; Muzik, Huong; Turhan, Ali G.; Zamo, Alberto; O'Connor, Mark J.; Bebb, D. Gwyn; Lees-Miller, Susan P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase-1 (PARP-1) inhibition is toxic to cells with mutations in the breast and ovarian cancer susceptibility genes BRCA1 or BRCA2, a concept termed synthetic lethality.  However, whether this approach is applicable to other human cancers with defects in other DNA repair genes has yet to be detd.  The ataxia telangiectasia mutated (ATM) gene is altered in several human cancers including mantle cell lymphoma (MCL).  Here, the authors characterize a panel of MCL cell lines for ATM status and function and investigate the potential for synthetic lethality in MCL in the presence of small-mol. inhibitors of PARP-1.  The authors show that Granta-519 and UPN2 cells have low levels of ATM protein, are defective in DNA damage-induced ATM-dependent signaling, are radiation sensitive, and have cell cycle checkpoint defects: all characteristics of defective ATM function.  Significantly, Granta-519 and UPN2 cells were more sensitive to PARP-1 inhibition than were the ATM-proficient MCL cell lines examd.  Furthermore, the PARP-1 inhibitor olaparib (known previously as AZD2281/KU-0059436) significantly decreased tumor growth and increased overall survival in mice bearing s.c. xenografts of ATM-deficient Granta-519 cells while producing only a modest effect on overall survival of mice bearing xenografts of the ATM-proficient cell line, Z138.  Thus, PARP inhibitors have therapeutic potential in the treatment of MCL, and the concept of synthetic lethality extends to human cancers with ATM alterations.  Mol Cancer Ther; 9(2); 347-57.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQmQjsqIbdVrVg90H21EOLACvtfcHk0lhq1OwM06nksA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslektb8%253D&md5=6243397aa39febdd9bd613b413a1f9ad</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0872%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DC.%2BT.%26aulast%3DMuzik%26aufirst%3DH.%26aulast%3DTurhan%26aufirst%3DA.%2BG.%26aulast%3DZam%25C3%25B2%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DBebb%26aufirst%3DD.%2BG.%26aulast%3DLees-Miller%26aufirst%3DS.%2BP.%26atitle%3DATM%2520deficiency%2520sensitizes%2520mantle%2520cell%2520lymphoma%2520cells%2520to%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D347%26epage%3D357%26doi%3D10.1158%2F1535-7163.MCT-09-0872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Herriott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudhope, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junge, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhouse, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allinson, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willmore, E.</span><span> </span><span class="NLM_article-title">PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">43978</span><span class="NLM_x">–</span> <span class="NLM_lpage">43991</span><span class="refDoi"> DOI: 10.18632/oncotarget.6287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.6287" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=43978-43991&author=A.+Herriottauthor=S.+J.+Tudhopeauthor=G.+Jungeauthor=N.+Rodriguesauthor=M.+J.+Pattersonauthor=L.+Woodhouseauthor=J.+Lunecauthor=J.+E.+Hunterauthor=E.+A.+Mulliganauthor=M.+Coleauthor=L.+M.+Allinsonauthor=J.+P.+Wallisauthor=S.+Marshallauthor=E.+Wangauthor=N.+J.+Curtinauthor=E.+Willmore&title=PARP1+expression%2C+activity+and+ex+vivo+sensitivity+to+the+PARP+inhibitor%2C+talazoparib+%28BMN+673%29%2C+in+chronic+lymphocytic+leukaemia&doi=10.18632%2Foncotarget.6287"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6287%26sid%3Dliteratum%253Aachs%26aulast%3DHerriott%26aufirst%3DA.%26aulast%3DTudhope%26aufirst%3DS.%2BJ.%26aulast%3DJunge%26aufirst%3DG.%26aulast%3DRodrigues%26aufirst%3DN.%26aulast%3DPatterson%26aufirst%3DM.%2BJ.%26aulast%3DWoodhouse%26aufirst%3DL.%26aulast%3DLunec%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DJ.%2BE.%26aulast%3DMulligan%26aufirst%3DE.%2BA.%26aulast%3DCole%26aufirst%3DM.%26aulast%3DAllinson%26aufirst%3DL.%2BM.%26aulast%3DWallis%26aufirst%3DJ.%2BP.%26aulast%3DMarshall%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DWillmore%26aufirst%3DE.%26atitle%3DPARP1%2520expression%252C%2520activity%2520and%2520ex%2520vivo%2520sensitivity%2520to%2520the%2520PARP%2520inhibitor%252C%2520talazoparib%2520%2528BMN%2520673%2529%252C%2520in%2520chronic%2520lymphocytic%2520leukaemia%26jtitle%3DOncotarget%26date%3D2015%26volume%3D22%26spage%3D43978%26epage%3D43991%26doi%3D10.18632%2Foncotarget.6287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Wang, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, X. P.</span><span> </span><span class="NLM_article-title">Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression</span> <span class="citation_source-journal">J. Obstet. Gynaecol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">554</span><span class="refDoi"> DOI: 10.1111/j.1447-0756.2012.01979.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1111%2Fj.1447-0756.2012.01979.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23006047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisVCisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=549-554&author=Y.+Q.+Wangauthor=Q.+Yanauthor=J.+R.+Zhangauthor=S.+D.+Liauthor=Y.+X.+Yangauthor=X.+P.+Wan&title=Epigenetic+inactivation+of+BRCA1+through+promoter+hypermethylation+in+ovarian+cancer+progression&doi=10.1111%2Fj.1447-0756.2012.01979.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression</span></div><div class="casAuthors">Wang, Yan-Qiu; Yan, Qin; Zhang, Jia-Rong; Li, Shuang-Di; Yang, Yi-Xia; Wan, Xiao-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Obstetrics and Gynaecology Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">549-554, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOGRFD</span>;
        ISSN:<span class="NLM_cas:issn">1447-0756</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim: The BRCA1 promoter is hypermethylated in ovarian cancer patients.  We postulated that this hypermethylation might be involved in ovarian cancer progression.  Methods: To confirm our hypothesis, tissue and serum samples were collected from ovarian carcinoma patients and categorized according to tumor stage.  Healthy or benign ovarian disease tissue samples and corresponding serum samples were used as controls.  Breast and ovarian cancer susceptibility gene 1 (BRCA1) promoter methylation levels were detected by real-time polymerase chain reaction (PCR).  Real-time PCR was also used to evaluate BRCA1 gene expression and Western blot was performed to assay the expression of BRCA1 protein.  Results: BRCA1 showed hypomethylation in 30 normal ovarian and 30 benign ovarian tumors, but showed hypermethylation or methylation in ovarian cancer patients.  There was also a significant difference in the BRCA1 promoter methylation levels between different ovarian cancer stages.  Compared to stage I and the control groups, there were higher BRCA1 promoter methylation frequencies in stage II and III ovarian cancers.  BRCA1 methylation correlated with the loss of BRCA1 expression.  BRCA1 promoter in stage I tumors showed hypomethylated.  Conclusion: Promoter hypermethylation may act as a biomarker for sporadic ovarian cancer progression, but is unlikely to be helpful in the early diagnosis of ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5RYjc-u-FWbVg90H21EOLACvtfcHk0lhq1OwM06nksA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisVCisrY%253D&md5=ad27a54a34e8de0e62358226edc36815</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1111%2Fj.1447-0756.2012.01979.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1447-0756.2012.01979.x%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BQ.%26aulast%3DYan%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DS.%2BD.%26aulast%3DYang%26aufirst%3DY.%2BX.%26aulast%3DWan%26aufirst%3DX.%2BP.%26atitle%3DEpigenetic%2520inactivation%2520of%2520BRCA1%2520through%2520promoter%2520hypermethylation%2520in%2520ovarian%2520cancer%2520progression%26jtitle%3DJ.%2520Obstet.%2520Gynaecol.%2520Res.%26date%3D2013%26volume%3D39%26spage%3D549%26epage%3D554%26doi%3D10.1111%2Fj.1447-0756.2012.01979.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Yamashita, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokunaga, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hisamatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taketani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyoshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maehara, Y.</span><span> </span><span class="NLM_article-title">Epigenetic inactivation of BRCA1 through promoter hypermethylation and its clinical importance in triple-negative breast cancer</span> <span class="citation_source-journal">Clin. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span><span class="refDoi"> DOI: 10.1016/j.clbc.2015.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.clbc.2015.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26195437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2is7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=498-504&author=N.+Yamashitaauthor=E.+Tokunagaauthor=H.+Kitaoauthor=M.+Hitchinsauthor=Y.+Inoueauthor=K.+Tanakaauthor=Y.+Hisamatsuauthor=K.+Taketaniauthor=S.+Akiyoshiauthor=S.+Okadaauthor=Y.+Odaauthor=H.+Saekiauthor=E.+Okiauthor=Y.+Maehara&title=Epigenetic+inactivation+of+BRCA1+through+promoter+hypermethylation+and+its+clinical+importance+in+triple-negative+breast+cancer&doi=10.1016%2Fj.clbc.2015.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Yamashita, Nami; Tokunaga, Eriko; Kitao, Hiroyuki; Hitchins, Megan; Inoue, Yuka; Tanaka, Kimihiro; Hisamatsu, Yuichi; Taketani, Kenji; Akiyoshi, Sayuri; Okada, Satoko; Oda, Yoshinao; Saeki, Hiroshi; Oki, Eiji; Maehara, Yoshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">498-504</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) has many similarities with basal-like breast cancer.  Addnl., TNBCs are assocd. with Breast cancer susceptibility gene I (BRCA1) functional loss, which leads to impaired homologous recombination-mediated DNA repair.  Although somatic mutations in BRCA1 rarely occur in sporadic breast cancer, lower than normal rates of expression of BRCA1 is reported to be an important factor that contributes to tumorigenesis in sporadic tumors.  The epigenetic inactivation of BRCA1 expression might thus play an important role in sporadic breast cancer cases.  Breast cancer specimens were obtained from 69 TNBC and 161 non-TNBC patients who underwent surgery without neoadjuvant systemic therapy.  BRCA1 promoter methylation status was investigated using combined bisulfite and restriction anal.  BRCA1 mRNA expression was evaluated using quant. reverse transcriptase polymerase chain reaction and BRCA1 protein expression was assessed using immunohistochem.  BRCA1 promoter methylation was found in 11 tumors and all of these were in TNBC cases (P < .0001).  BRCA1 promoter methylation was significantly assocd. with lymphovessel invasion (P = .02), high nuclear grade (P = .05), low BRCA1 mRNA expression (P < .0001), and loss of BRCA1 protein expression (P = .0015).  BRCA1 promoter methylation was significantly assocd. with shorter overall survival (P = .038).BRCA1 promotor methylation was found only in TNBC cases and the methylated cases account for 16% of TNBC.  BRCA1 promoter methylation was significantly assocd. with reduced BRCA1 expression, aggressive phenotype, and poor prognosis.  BRCA1 promoter methylation is an important mechanism that leads to functional loss of BRCA1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreIh-usNCN-bVg90H21EOLACvtfcHk0lhq1OwM06nksA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2is7%252FP&md5=1e4e736cf744ff5d1b2ed1e06fffc26f</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2015.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2015.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DN.%26aulast%3DTokunaga%26aufirst%3DE.%26aulast%3DKitao%26aufirst%3DH.%26aulast%3DHitchins%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DHisamatsu%26aufirst%3DY.%26aulast%3DTaketani%26aufirst%3DK.%26aulast%3DAkiyoshi%26aufirst%3DS.%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DOda%26aufirst%3DY.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DOki%26aufirst%3DE.%26aulast%3DMaehara%26aufirst%3DY.%26atitle%3DEpigenetic%2520inactivation%2520of%2520BRCA1%2520through%2520promoter%2520hypermethylation%2520and%2520its%2520clinical%2520importance%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D498%26epage%3D504%26doi%3D10.1016%2Fj.clbc.2015.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Ruscito, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasconcelos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellhaus, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwachula, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeillinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti-Panici, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergote, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cacsire-Tong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darb-Esfahani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambrechts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sehouli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braicu, E. I.</span><span> </span><span class="NLM_article-title">BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2090</span><span class="NLM_x">–</span> <span class="NLM_lpage">2098</span><span class="refDoi"> DOI: 10.1016/j.ejca.2014.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.ejca.2014.05.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=2090-2098&author=I.+Ruscitoauthor=D.+Dimitrovaauthor=I.+Vasconcelosauthor=K.+Gellhausauthor=T.+Schwachulaauthor=F.+Bellatiauthor=R.+Zeillingerauthor=P.+Benedetti-Paniciauthor=I.+Vergoteauthor=S.+Mahnerauthor=D.+Cacsire-Tongauthor=N.+Concinauthor=S.+Darb-Esfahaniauthor=S.+Lambrechtsauthor=J.+Sehouliauthor=S.+Olekauthor=E.+I.+Braicu&title=BRCA1+gene+promoter+methylation+status+in+high-grade+serous+ovarian+cancer+patients%2D%2Da+study+of+the+tumour+Bank+ovarian+cancer+%28TOC%29+and+ovarian+cancer+diagnosis+consortium+%28OVCAD%29&doi=10.1016%2Fj.ejca.2014.05.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2014.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2014.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DRuscito%26aufirst%3DI.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DVasconcelos%26aufirst%3DI.%26aulast%3DGellhaus%26aufirst%3DK.%26aulast%3DSchwachula%26aufirst%3DT.%26aulast%3DBellati%26aufirst%3DF.%26aulast%3DZeillinger%26aufirst%3DR.%26aulast%3DBenedetti-Panici%26aufirst%3DP.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DMahner%26aufirst%3DS.%26aulast%3DCacsire-Tong%26aufirst%3DD.%26aulast%3DConcin%26aufirst%3DN.%26aulast%3DDarb-Esfahani%26aufirst%3DS.%26aulast%3DLambrechts%26aufirst%3DS.%26aulast%3DSehouli%26aufirst%3DJ.%26aulast%3DOlek%26aufirst%3DS.%26aulast%3DBraicu%26aufirst%3DE.%2BI.%26atitle%3DBRCA1%2520gene%2520promoter%2520methylation%2520status%2520in%2520high-grade%2520serous%2520ovarian%2520cancer%2520patients--a%2520study%2520of%2520the%2520tumour%2520Bank%2520ovarian%2520cancer%2520%2528TOC%2529%2520and%2520ovarian%2520cancer%2520diagnosis%2520consortium%2520%2528OVCAD%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2014%26volume%3D50%26spage%3D2090%26epage%3D2098%26doi%3D10.1016%2Fj.ejca.2014.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Jacot, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thezenas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viglianti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laberenne, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Crapez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibeau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleuse, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romieu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamy, P. J.</span><span> </span><span class="NLM_article-title">BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="refDoi"> DOI: 10.1186/1471-2407-13-523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2F1471-2407-13-523" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=523&author=W.+Jacotauthor=S.+Thezenasauthor=R.+Senalauthor=C.+Vigliantiauthor=A.+C.+Laberenneauthor=E.+Lopez-Crapezauthor=F.+Bibeauauthor=J.+P.+Bleuseauthor=G.+Romieuauthor=P.+J.+Lamy&title=BRCA1+promoter+hypermethylation%2C+53BP1+protein+expression+and+PARP-1+activity+as+biomarkers+of+DNA+repair+deficit+in+breast+cancer&doi=10.1186%2F1471-2407-13-523"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-523%26sid%3Dliteratum%253Aachs%26aulast%3DJacot%26aufirst%3DW.%26aulast%3DThezenas%26aufirst%3DS.%26aulast%3DSenal%26aufirst%3DR.%26aulast%3DViglianti%26aufirst%3DC.%26aulast%3DLaberenne%26aufirst%3DA.%2BC.%26aulast%3DLopez-Crapez%26aufirst%3DE.%26aulast%3DBibeau%26aufirst%3DF.%26aulast%3DBleuse%26aufirst%3DJ.%2BP.%26aulast%3DRomieu%26aufirst%3DG.%26aulast%3DLamy%26aufirst%3DP.%2BJ.%26atitle%3DBRCA1%2520promoter%2520hypermethylation%252C%252053BP1%2520protein%2520expression%2520and%2520PARP-1%2520activity%2520as%2520biomarkers%2520of%2520DNA%2520repair%2520deficit%2520in%2520breast%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D523%26doi%3D10.1186%2F1471-2407-13-523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Lombardi, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoskins, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foglesong, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wikenheiser-Brokamp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmüller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanenberg, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreassen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeble, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hays, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S. I.</span><span> </span><span class="NLM_article-title">Acquisition of relative interstrand crosslinker resistance and PARP inhibitor sensitivity in fanconi anemia head and neck cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1962</span><span class="NLM_x">–</span> <span class="NLM_lpage">1972</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-14-2616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25609062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsl2gtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1962-1972&author=A.+J.+Lombardiauthor=E.+E.+Hoskinsauthor=G.+D.+Foglesongauthor=K.+A.+Wikenheiser-Brokampauthor=L.+Wiesm%C3%BCllerauthor=H.+Hanenbergauthor=P.+R.+Andreassenauthor=A.+J.+Jacobsauthor=S.+B.+Olsonauthor=W.+W.+Keebleauthor=L.+E.+Haysauthor=S.+I.+Wells&title=Acquisition+of+relative+interstrand+crosslinker+resistance+and+PARP+inhibitor+sensitivity+in+fanconi+anemia+head+and+neck+cancers&doi=10.1158%2F1078-0432.CCR-14-2616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers</span></div><div class="casAuthors">Lombardi, Anne J.; Hoskins, Elizabeth E.; Foglesong, Grant D.; Wikenheiser-Brokamp, Kathryn A.; Wiesmueller, Lisa; Hanenberg, Helmut; Andreassen, Paul R.; Jacobs, Allison J.; Olson, Susan B.; Keeble, Winifred W.; Hays, Laura E.; Wells, Susanne I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1962-1972</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Fanconi anemia is an inherited disorder assocd. with a constitutional defect in the Fanconi anemia DNA repair machinery that is essential for resoln. of DNA interstrand crosslinks.  Individuals with Fanconi anemia are predisposed to formation of head and neck squamous cell carcinomas (HNSCC) at a young age.  Prognosis is poor, partly due to patient intolerance of chemotherapy and radiation requiring dose redn., which may lead to early recurrence of disease.  Exptl. Design: Using HNSCC cell lines derived from the tumors of patients with Fanconi anemia, and murine HNSCC cell lines derived from the tumors of wild-type and Fancc-/- mice, we sought to define Fanconi anemia-dependent chemosensitivity and DNA repair characteristics.  We utilized DNA repair reporter assays to explore the preference of Fanconi anemia HNSCC cells for non-homologous end joining (NHEJ).  Results: Surprisingly, interstrand crosslinker (ICL) sensitivity was not necessarily Fanconi anemia-dependent in human or murine cell systems.  Our results suggest that the increased Ku-dependent NHEJ that is expected in Fanconi anemia cells did not mediate relative ICL resistance.  ICL exposure resulted in increased DNA damage sensing and repair by PARP in Fanconi anemia-deficient cells.  Moreover, human and murine Fanconi anemia HNSCC cells were sensitive to PARP inhibition, and sensitivity of human cells was attenuated by Fanconi anemia gene complementation.  Conclusions: The obsd. reliance upon PARP-mediated mechanisms reveals a means by which Fanconi anemia HNSCCs can acquire relative resistance to the ICL-based chemotherapy that is a foundation of HNSCC treatment, as well as a potential target for overcoming chemoresistance in the chemosensitive individual.  Clin Cancer Res; 21(8); 1962-72. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcw9nBMGFl9rVg90H21EOLACvtfcHk0lj-Cv1ZXERXZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsl2gtbo%253D&md5=b0b40c1229cf1808b30551418a5ba770</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2616%26sid%3Dliteratum%253Aachs%26aulast%3DLombardi%26aufirst%3DA.%2BJ.%26aulast%3DHoskins%26aufirst%3DE.%2BE.%26aulast%3DFoglesong%26aufirst%3DG.%2BD.%26aulast%3DWikenheiser-Brokamp%26aufirst%3DK.%2BA.%26aulast%3DWiesm%25C3%25BCller%26aufirst%3DL.%26aulast%3DHanenberg%26aufirst%3DH.%26aulast%3DAndreassen%26aufirst%3DP.%2BR.%26aulast%3DJacobs%26aufirst%3DA.%2BJ.%26aulast%3DOlson%26aufirst%3DS.%2BB.%26aulast%3DKeeble%26aufirst%3DW.%2BW.%26aulast%3DHays%26aufirst%3DL.%2BE.%26aulast%3DWells%26aufirst%3DS.%2BI.%26atitle%3DAcquisition%2520of%2520relative%2520interstrand%2520crosslinker%2520resistance%2520and%2520PARP%2520inhibitor%2520sensitivity%2520in%2520fanconi%2520anemia%2520head%2520and%2520neck%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1962%26epage%3D1972%26doi%3D10.1158%2F1078-0432.CCR-14-2616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Duan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguila, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalvala, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterson, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalona-Calero, M. A.</span><span> </span><span class="NLM_article-title">Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">368</span><span class="refDoi"> DOI: 10.3389/fonc.2014.00368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.3389%2Ffonc.2014.00368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25566506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC2MvksFaitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=368&author=W.+Duanauthor=L.+Gaoauthor=B.+Aguilaauthor=A.+Kalvalaauthor=G.+A.+Ottersonauthor=M.+A.+Villalona-Calero&title=Fanconi+anemia+repair+pathway+dysfunction%2C+a+potential+therapeutic+target+in+lung+cancer&doi=10.3389%2Ffonc.2014.00368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer</span></div><div class="casAuthors">Duan Wenrui; Otterson Gregory A; Gao Li; Aguila Brittany; Kalvala Arjun; Villalona-Calero Miguel A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">368</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Fanconi anemia (FA) pathway is a major mechanism of homologous recombination DNA repair.  The functional readout of the pathway is activation through mono-ubiquitination of FANCD2 leading to nuclear foci of repair.  We have recently developed an FA triple-staining immunofluorescence based method (FATSI) to evaluate FANCD2 foci formation in formalin fixed paraffin-embedded (FFPE) tumor samples.  DNA-repair deficiencies have been considered of interest in lung cancer prevention, given the persistence of damage produced by cigarette smoke in this setting, as well as in treatment, given potential increased efficacy of DNA-damaging drugs.  We screened 139 non-small cell lung cancer (NSCLC) FFPE tumors for FANCD2 foci formation by FATSI analysis.  Among 104 evaluable tumors, 23 (22%) were FANCD2 foci negative, thus repair deficient.  To evaluate and compare novel-targeted agents in the background of FA deficiency, we utilized RNAi technology to render several lung cancer cell lines FANCD2 deficient.  Successful FANCD2 knockdown was confirmed by reduction in the FANCD2 protein.  Subsequently, we treated the FA defective H1299D2-down and A549D2-down NSCLC cells and their FA competent counterparts (empty vector controls) with the PARP inhibitors veliparib (ABT-888) (5 μM) and BMN673 (0.5 μM), as well as the CHK1 inhibitor Arry-575 at a dose of 0.5 μM.  We also treated the FA defective small cell lung cancer cell lines H719D2-down and H792D2-down and their controls with the BCL-2/XL inhibitor ABT-263 at a dose of 2 μM.  The treated cells were harvested at 24, 48, and 72 h post treatment.  MTT cell viability analysis showed that each agent was more cytotoxic to the FANCD2 knock-down cells.  In all tests, the FA defective lung cancer cells had less viable cells as comparing to controls 72 h post treatment.  Both MTT and clonogenic analyses comparing the two PARP inhibitors, showed that BMN673 was more potent compared to veliparib.  Given that FA pathway plays essential roles in response to DNA damage, our results suggest that a subset of lung cancer patients are likely to be more susceptible to DNA cross-link based therapy, or to treatments in which additional repair mechanisms are targeted.  These subjects can be identified through FATSI analysis.  Clinical trials to evaluate this therapeutic concept are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3SpAGegTY3HthwrmtH4OBfW6udTcc2ebEC4XubV_OAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvksFaitw%253D%253D&md5=e96d223c4459e2749129c71cd8d4ceb1</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2014.00368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2014.00368%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DAguila%26aufirst%3DB.%26aulast%3DKalvala%26aufirst%3DA.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DVillalona-Calero%26aufirst%3DM.%2BA.%26atitle%3DFanconi%2520anemia%2520repair%2520pathway%2520dysfunction%252C%2520a%2520potential%2520therapeutic%2520target%2520in%2520lung%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2014%26volume%3D4%26spage%3D368%26doi%3D10.3389%2Ffonc.2014.00368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Stoepker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faramarz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooimans, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Mil, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balk, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velleuer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ameziane, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Te Riele, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Winter, J. P.</span><span> </span><span class="NLM_article-title">DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity</span> <span class="citation_source-journal">DNA Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1016/j.dnarep.2014.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.dnarep.2014.12.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=54-64&author=C.+Stoepkerauthor=A.+Faramarzauthor=M.+A.+Rooimansauthor=S.+E.+van+Milauthor=J.+A.+Balkauthor=E.+Velleuerauthor=N.+Amezianeauthor=H.+Te+Rieleauthor=J.+P.+de+Winter&title=DNA+helicases+FANCM+and+DDX11+are+determinants+of+PARP+inhibitor+sensitivity&doi=10.1016%2Fj.dnarep.2014.12.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.dnarep.2014.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dnarep.2014.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DStoepker%26aufirst%3DC.%26aulast%3DFaramarz%26aufirst%3DA.%26aulast%3DRooimans%26aufirst%3DM.%2BA.%26aulast%3Dvan%2BMil%26aufirst%3DS.%2BE.%26aulast%3DBalk%26aufirst%3DJ.%2BA.%26aulast%3DVelleuer%26aufirst%3DE.%26aulast%3DAmeziane%26aufirst%3DN.%26aulast%3DTe%2BRiele%26aufirst%3DH.%26aulast%3Dde%2BWinter%26aufirst%3DJ.%2BP.%26atitle%3DDNA%2520helicases%2520FANCM%2520and%2520DDX11%2520are%2520determinants%2520of%2520PARP%2520inhibitor%2520sensitivity%26jtitle%3DDNA%2520Repair%26date%3D2015%26volume%3D26%26spage%3D54%26epage%3D64%26doi%3D10.1016%2Fj.dnarep.2014.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Bajrami, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankum, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehman, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafiq, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarewa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assiotis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenwick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natrajan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-2541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-13-2541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24240700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=287-297&author=I.+Bajramiauthor=J.+R.+Frankumauthor=A.+Kondeauthor=R.+E.+Millerauthor=F.+L.+Rehmanauthor=R.+Broughauthor=J.+Campbellauthor=D.+Simsauthor=R.+Rafiqauthor=S.+Hooperauthor=L.+N.+Chenauthor=I.+Kozarewaauthor=I.+Assiotisauthor=K.+Fenwickauthor=R.+Natrajanauthor=C.+J.+Lordauthor=A.+Ashworth&title=Genome-wide+profiling+of+genetic+synthetic+lethality+identifies+CDK12+as+a+novel+determinant+of+PARP1%2F2+inhibitor+sensitivity&doi=10.1158%2F0008-5472.CAN-13-2541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity</span></div><div class="casAuthors">Bajrami, Ilirjana; Frankum, Jessica R.; Konde, Asha; Miller, Rowan E.; Rehman, Farah L.; Brough, Rachel; Campbell, James; Sims, David; Rafiq, Rumana; Hooper, Sean; Chen, Lina; Kozarewa, Iwanka; Assiotis, Ioannis; Fenwick, Kerry; Natrajan, Rachael; Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">287-297</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of PARP1/2, such as olaparib, have been proposed to serve as a synthetic lethal therapy for cancers that harbor BRCA1 or BRCA2 mutations.  Indeed, in clin. trials, PARP1/2 inhibitors elicit sustained antitumor responses in patients with germline BRCA gene mutations.  In hypothesizing that addnl. genetic determinants might direct use of these drugs, we conducted a genome-wide synthetic lethal screen for candidate olaparib sensitivity genes.  In support of this hypothesis, the set of identified genes included known determinants of olaparib sensitivity, such as BRCA1, RAD51, and Fanconi's anemia susceptibility genes.  In addn., the set included genes implicated in established networks of DNA repair, DNA cohesion, and chromatin remodeling, none of which were known previously to confer sensitivity to PARP1/2 inhibition.  Notably, integration of the list of candidate sensitivity genes with data from tumor DNA sequencing studies identified CDK12 deficiency as a clin. relevant biomarker of PARP1/2 inhibitor sensitivity.  In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1.  As one of only nine genes known to be significantly mutated in HGS-OVCa, CDK12 has properties that should confirm interest in its use as a biomarker, particularly in ongoing clin. trials of PARP1/2 inhibitors and other agents that trigger replication fork arrest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNCJR_Nh_WjbVg90H21EOLACvtfcHk0libxPF6rfdBTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjuw%253D%253D&md5=9e07aa538aed0fb3a5ac6be21659d051</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-2541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-2541%26sid%3Dliteratum%253Aachs%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DFrankum%26aufirst%3DJ.%2BR.%26aulast%3DKonde%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DR.%2BE.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DSims%26aufirst%3DD.%26aulast%3DRafiq%26aufirst%3DR.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DL.%2BN.%26aulast%3DKozarewa%26aufirst%3DI.%26aulast%3DAssiotis%26aufirst%3DI.%26aulast%3DFenwick%26aufirst%3DK.%26aulast%3DNatrajan%26aufirst%3DR.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DGenome-wide%2520profiling%2520of%2520genetic%2520synthetic%2520lethality%2520identifies%2520CDK12%2520as%2520a%2520novel%2520determinant%2520of%2520PARP1%252F2%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D287%26epage%3D297%26doi%3D10.1158%2F0008-5472.CAN-13-2541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Joshi, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntoon, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnitz, L. M.</span><span> </span><span class="NLM_article-title">Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">9247</span><span class="NLM_x">–</span> <span class="NLM_lpage">9253</span><span class="refDoi"> DOI: 10.1074/jbc.M114.551143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1074%2Fjbc.M114.551143" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=9247-9253&author=P.+M.+Joshiauthor=S.+L.+Sutorauthor=C.+J.+Huntoonauthor=L.+M.+Karnitz&title=Ovarian+cancer-associated+mutations+disable+catalytic+activity+of+CDK12%2C+a+kinase+that+promotes+homologous+recombination+repair+and+resistance+to+cisplatin+and+poly%28ADP-ribose%29+polymerase+inhibitors&doi=10.1074%2Fjbc.M114.551143"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.551143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.551143%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DP.%2BM.%26aulast%3DSutor%26aufirst%3DS.%2BL.%26aulast%3DHuntoon%26aufirst%3DC.%2BJ.%26aulast%3DKarnitz%26aufirst%3DL.%2BM.%26atitle%3DOvarian%2520cancer-associated%2520mutations%2520disable%2520catalytic%2520activity%2520of%2520CDK12%252C%2520a%2520kinase%2520that%2520promotes%2520homologous%2520recombination%2520repair%2520and%2520resistance%2520to%2520cisplatin%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D9247%26epage%3D9253%26doi%3D10.1074%2Fjbc.M114.551143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Ip, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulogiannis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viciano, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kofuji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spanswick, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhauser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewinner, C. A.</span><span> </span><span class="NLM_article-title">Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">10548</span><span class="NLM_x">–</span> <span class="NLM_lpage">10562</span><span class="refDoi"> DOI: 10.18632/oncotarget.3307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.3307" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10548-10562&author=L.+R.+Ipauthor=G.+Poulogiannisauthor=F.+C.+Vicianoauthor=J.+Sasakiauthor=S.+Kofujiauthor=V.+J.+Spanswickauthor=D.+Hochhauserauthor=J.+A.+Hartleyauthor=T.+Sasakiauthor=C.+A.+Gewinner&title=Loss+of+INPP4B+causes+a+DNA+repair+defect+through+loss+of+BRCA1%2C+ATM+and+ATR+and+can+be+targeted+with+PARP+inhibitor+treatment&doi=10.18632%2Foncotarget.3307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3307%26sid%3Dliteratum%253Aachs%26aulast%3DIp%26aufirst%3DL.%2BR.%26aulast%3DPoulogiannis%26aufirst%3DG.%26aulast%3DViciano%26aufirst%3DF.%2BC.%26aulast%3DSasaki%26aufirst%3DJ.%26aulast%3DKofuji%26aufirst%3DS.%26aulast%3DSpanswick%26aufirst%3DV.%2BJ.%26aulast%3DHochhauser%26aufirst%3DD.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DGewinner%26aufirst%3DC.%2BA.%26atitle%3DLoss%2520of%2520INPP4B%2520causes%2520a%2520DNA%2520repair%2520defect%2520through%2520loss%2520of%2520BRCA1%252C%2520ATM%2520and%2520ATR%2520and%2520can%2520be%2520targeted%2520with%2520PARP%2520inhibitor%2520treatment%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D10548%26epage%3D10562%26doi%3D10.18632%2Foncotarget.3307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Salmena, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fans, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narod, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotsopoulos, J.</span><span> </span><span class="NLM_article-title">Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer</span> <span class="citation_source-journal">Eur. J. Gynaecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26189250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FkslajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=260-267&author=L.+Salmenaauthor=P.+Shawauthor=I.+Fansauthor=+McLaughlinauthor=B.+Rosenauthor=H.+Rischauthor=C.+Mitchellauthor=P.+Sunauthor=S.+A.+Narodauthor=J.+Kotsopoulos&title=Prognostic+value+of+INPP4B+protein+immunohistochemistry+in+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer</span></div><div class="casAuthors">Salmena L; Shaw P; Fans I; McLaughlin; Rosen B; Risch H; Mitchell C; Sun P; Narod S A; Kotsopoulos J</div><div class="citationInfo"><span class="NLM_cas:title">European journal of gynaecological oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">260-7</span>
        ISSN:<span class="NLM_cas:issn">0392-2936</span>.
    </div><div class="casAbstract">PURPOSE OF INVESTIGATION:  Ovarian cancer is associated with poor prognosis and altered protein expression patterns may be useful for identifying patients likely to have poor disease outcomes.  The impact of altered INPP4B protein expression on prognosis is unclear.  The aim of this study was to evaluate the implication of INPP4B expression changes in a large series of ovarian cancer tissue samples.  MATERIALS AND METHODS:  Tissue microarrays were constructed from 599 epithelial ovarian tumors and stained with antibodies for INPP4B, p53, and PTEN.  Proportional hazard models were used to estimate survival hazard ratios (HRs) associated with altered protein expression.  RESULTS:  Seventy-nine percent of the ovarian cancers demonstrated loss of INPP4B, whereas 53% showed aberrant p53 expression (i.e., complete loss of p53 or over-expression of p53) and 8% showed loss of PTEN.  INPP4B was frequently lost in serous and endometrioid cancer subtypes, aberrant p53 expression was most common among serous subtype, and loss of PTEN was most common among endometrioid tumors (p for all three proteins across histologic subtypes ≤ 0.0001).  INPP4B loss or aberrant p53 expression were both associated with increased mortality (HR = 1.84; 95% CI 1.27 - 2.68 and HR = 3.10; 95% CI 2.33 - 4.11, respectively); however, in multivariate models, only the relationship with p53 achieved statistical significance (HR = 1.20; 95% CI 0.82 - 1.76 for INPP4B and HR = 1.73; 95% CI 1.28 - 2.34 for p53).  Conclusion: The INPP4B protein is frequently lost in serous and endometrioid subtypes of ovarian cancer.  A possible prognostic role of INPP4B for endometrioid ovarian tumors requires further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTH_GNAkXtkK-IHSmpohpd0fW6udTcc2eZH9Q2QReyETLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FkslajsQ%253D%253D&md5=be6ee65120d07c350f3c7748f4183191</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalmena%26aufirst%3DL.%26aulast%3DShaw%26aufirst%3DP.%26aulast%3DFans%26aufirst%3DI.%26aulast%3DMcLaughlin%26aulast%3DRosen%26aufirst%3DB.%26aulast%3DRisch%26aufirst%3DH.%26aulast%3DMitchell%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DNarod%26aufirst%3DS.%2BA.%26aulast%3DKotsopoulos%26aufirst%3DJ.%26atitle%3DPrognostic%2520value%2520of%2520INPP4B%2520protein%2520immunohistochemistry%2520in%2520ovarian%2520cancer%26jtitle%3DEur.%2520J.%2520Gynaecol.%2520Oncol.%26date%3D2015%26volume%3D36%26spage%3D260%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Fraser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luoto, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coackley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshua, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bismar, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, R. G.</span><span> </span><span class="NLM_article-title">PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1027</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-11-2189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22114138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGhu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1015-1027&author=M.+Fraserauthor=H.+Zhaoauthor=K.+R.+Luotoauthor=C.+Lundinauthor=C.+Coackleyauthor=N.+Chanauthor=A.+M.+Joshuaauthor=T.+A.+Bismarauthor=A.+Evansauthor=T.+Helledayauthor=R.+G.+Bristow&title=PTEN+deletion+in+prostate+cancer+cells+does+not+associate+with+loss+of+RAD51+function%3A+implications+for+radiotherapy+and+chemotherapy&doi=10.1158%2F1078-0432.CCR-11-2189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy</span></div><div class="casAuthors">Fraser, Michael; Zhao, Helen; Luoto, Kaisa R.; Lundin, Cecilia; Coackley, Carla; Chan, Norman; Joshua, Anthony M.; Bismar, Tarek A.; Evans, Andrew; Helleday, Thomas; Bristow, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1015-1027</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE:PTEN deletions in prostate cancer are assocd. with tumor aggression and poor outcome.  Recent studies have implicated PTEN as a determinant of homologous recombination (HR) through defective RAD51 function.  Similar to BRCA1/2-defective tumor cells, PTEN-null prostate and other cancer cells have been reported to be sensitive to PARP inhibitors (PARPi).  To date, no direct comparison between PTEN and RAD51 expression in primary prostate tumors has been reported.  Exptl. Design: Prostate cancer cell lines and xenografts with known PTEN status (22RV1-PTEN+/+, DU145-PTEN+/-, PC3-PTEN-/-) and H1299 and HCT116 cancer cells were used to evaluate how PTEN loss affects RAD51 expression and PARPi sensitivity.  Primary prostate cancers with known PTEN status were analyzed for RAD51 expression.  RESULTS:PTEN status is not assocd. with reduced RAD51 mRNA or protein expression in primary prostate cancers.  Decreased PTEN expression did not reduce RAD51 expression or clonogenic survival following PARPi among prostate cancer cells that vary in TP53 and PTEN.  PARPi sensitivity instead assocd. with a defect in MRE11 expression.  PTEN-deficient cells had only mild PARPi sensitivity and no loss of HR or RAD51 recruitment.  Clonogenic cell survival following a series of DNA damaging agents was variable: PTEN-deficient cells were sensitive to ionizing radiation, mitomycin-C, UV, H2O2, and Me methanesulfonate but not to cisplatin, camptothecin, or paclitaxel.  CONCLUSIONS: These data suggest that the relationship between PTEN status and survival following DNA damage is indirect and complex.  It is unlikely that PTEN status will be a direct biomarker for HR status or PARPi response in prostate cancer clin. trials.  Clin Cancer Res; 18(4); 1015-27.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdSEknO1ii17Vg90H21EOLACvtfcHk0li_V1RccPXasA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGhu78%253D&md5=4587c3be1a7b7930edab02d67d45ac54</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2189%26sid%3Dliteratum%253Aachs%26aulast%3DFraser%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLuoto%26aufirst%3DK.%2BR.%26aulast%3DLundin%26aufirst%3DC.%26aulast%3DCoackley%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DN.%26aulast%3DJoshua%26aufirst%3DA.%2BM.%26aulast%3DBismar%26aufirst%3DT.%2BA.%26aulast%3DEvans%26aufirst%3DA.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DBristow%26aufirst%3DR.%2BG.%26atitle%3DPTEN%2520deletion%2520in%2520prostate%2520cancer%2520cells%2520does%2520not%2520associate%2520with%2520loss%2520of%2520RAD51%2520function%253A%2520implications%2520for%2520radiotherapy%2520and%2520chemotherapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1015%26epage%3D1027%26doi%3D10.1158%2F1078-0432.CCR-11-2189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Hunt, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horikoshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, T. K.</span><span> </span><span class="NLM_article-title">Does PTEN loss impair DNA double-strand break repair by homologous recombination?</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">920</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-11-3131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22179663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGgsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=920-922&author=C.+R.+Huntauthor=A.+Guptaauthor=N.+Horikoshiauthor=T.+K.+Pandita&title=Does+PTEN+loss+impair+DNA+double-strand+break+repair+by+homologous+recombination%3F&doi=10.1158%2F1078-0432.CCR-11-3131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Does PTEN Loss Impair DNA Double-Strand Break Repair by Homologous Recombination?</span></div><div class="casAuthors">Hunt, Clayton R.; Gupta, Arun; Horikoshi, Nobuo; Pandita, Tej K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">920-922</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The tumor suppressor PTEN is frequently lost in cancer cells, resulting in altered radiation and drug sensitivity.  However, the role of PTEN in DNA repair is controversial.  Detailed studies in prostate cancer cells now indicate PTEN does not regulate RAD51 expression or homologous recombination and is not a biomarker for PARP inhibitor sensitivity.  Clin Cancer Res; 18(4); 920-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaJF1ZTOF0wrVg90H21EOLACvtfcHk0lj_GTuwRngIuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGgsrc%253D&md5=376c7ca945c950f2c2ae55bf30b0882b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3131%26sid%3Dliteratum%253Aachs%26aulast%3DHunt%26aufirst%3DC.%2BR.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHorikoshi%26aufirst%3DN.%26aulast%3DPandita%26aufirst%3DT.%2BK.%26atitle%3DDoes%2520PTEN%2520loss%2520impair%2520DNA%2520double-strand%2520break%2520repair%2520by%2520homologous%2520recombination%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D920%26epage%3D922%26doi%3D10.1158%2F1078-0432.CCR-11-3131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Freeman, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteiro, A. N.</span><span> </span><span class="NLM_article-title">Phosphatases in the cellular response to DNA damage</span> <span class="citation_source-journal">Cell Commun. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="refDoi"> DOI: 10.1186/1478-811X-8-27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2F1478-811X-8-27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20860841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC3cfosFOitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=27&author=A.+K.+Freemanauthor=A.+N.+Monteiro&title=Phosphatases+in+the+cellular+response+to+DNA+damage&doi=10.1186%2F1478-811X-8-27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatases in the cellular response to DNA damage</span></div><div class="casAuthors">Freeman Alyson K; Monteiro Alvaro Na</div><div class="citationInfo"><span class="NLM_cas:title">Cell communication and signaling : CCS</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract"> In the last fifteen years, rapid progress has been made in delineating the cellular response to DNA damage.  The DNA damage response network is composed of a large number of proteins with different functions that detect and signal the presence of DNA damage in order to coordinate DNA repair with a variety of cellular processes, notably cell cycle progression.  This signal, which radiates from the chromatin template, is driven primarily by phosphorylation events, mainly on serine and threonine residues.  While we have accumulated detailed information about kinases and their substrates our understanding of the role of phosphatases in the DNA damage response is still preliminary.  Identifying the phosphatases and their regulation will be instrumental to obtain a complete picture of the dynamics of the DNA damage response.  Here we give an overview of the DNA damage response in mammalian cells and then review the data on the role of different phosphatases and discuss their biological relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhDrrK_lAT3jQLBVDQn4bCfW6udTcc2ebCFUrMPZMUPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfosFOitA%253D%253D&md5=66d2062f064ff876f379964fc2028283</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1186%2F1478-811X-8-27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1478-811X-8-27%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DA.%2BK.%26aulast%3DMonteiro%26aufirst%3DA.%2BN.%26atitle%3DPhosphatases%2520in%2520the%2520cellular%2520response%2520to%2520DNA%2520damage%26jtitle%3DCell%2520Commun.%2520Signaling%26date%3D2010%26volume%3D8%26spage%3D27%26doi%3D10.1186%2F1478-811X-8-27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Kalev, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simicek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sablina, A.</span><span> </span><span class="NLM_article-title">Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">6414</span><span class="NLM_x">–</span> <span class="NLM_lpage">6424</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-1667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-12-1667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23087057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyns7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=6414-6424&author=P.+Kalevauthor=M.+Simicekauthor=I.+Vazquezauthor=S.+Munckauthor=L.+Chenauthor=T.+Soinauthor=N.+Dandaauthor=W.+Chenauthor=A.+Sablina&title=Loss+of+PPP2R2A+inhibits+homologous+recombination+DNA+repair+and+predicts+tumor+sensitivity+to+PARP+inhibition&doi=10.1158%2F0008-5472.CAN-12-1667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition</span></div><div class="casAuthors">Kalev, Peter; Simicek, Michal; Vazquez, Iria; Munck, Sebastian; Chen, Liping; Soin, Thomas; Danda, Natasha; Chen, Wen; Sablina, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6414-6424</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings suggest that downregulation of a PP2A family phosphatase in tumors may predict therapeutic responses to a promising new class of anticancer agents currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3mqXzgrVh4LVg90H21EOLACvtfcHk0lj_GTuwRngIuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyns7rK&md5=b93954d366c436b42e61d924466bc717</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-1667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-1667%26sid%3Dliteratum%253Aachs%26aulast%3DKalev%26aufirst%3DP.%26aulast%3DSimicek%26aufirst%3DM.%26aulast%3DVazquez%26aufirst%3DI.%26aulast%3DMunck%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSoin%26aufirst%3DT.%26aulast%3DDanda%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSablina%26aufirst%3DA.%26atitle%3DLoss%2520of%2520PPP2R2A%2520inhibits%2520homologous%2520recombination%2520DNA%2520repair%2520and%2520predicts%2520tumor%2520sensitivity%2520to%2520PARP%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D6414%26epage%3D6424%26doi%3D10.1158%2F0008-5472.CAN-12-1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Curtis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turashvili, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueda, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunning, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speed, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samarajiwa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gräf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haffari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bashashati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">METABRIC Group</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langerød, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provenzano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markowetz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purushotham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Børresen-Dale, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenton, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavaré, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, S.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1038/nature10983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnature10983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22522925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslSnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=346-352&author=C.+Curtisauthor=S.+P.+Shahauthor=S.+F.+Chinauthor=G.+Turashviliauthor=O.+M.+Ruedaauthor=M.+J.+Dunningauthor=D.+Speedauthor=A.+G.+Lynchauthor=S.+Samarajiwaauthor=Y.+Yuanauthor=S.+Gr%C3%A4fauthor=G.+Haauthor=G.+Haffariauthor=A.+Bashashatiauthor=R.+Russellauthor=S.+McKinneyauthor=METABRIC+Groupauthor=A.+Langer%C3%B8dauthor=A.+Greenauthor=E.+Provenzanoauthor=G.+Wishartauthor=S.+Pinderauthor=P.+Watsonauthor=F.+Markowetzauthor=L.+Murphyauthor=I.+Ellisauthor=A.+Purushothamauthor=A.+L.+B%C3%B8rresen-Daleauthor=J.+D.+Brentonauthor=S.+Tavar%C3%A9author=C.+Caldasauthor=S.+Aparicio&title=The+genomic+and+transcriptomic+architecture+of+2%2C000+breast+tumours+reveals+novel+subgroups&doi=10.1038%2Fnature10983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">The genomic and transcriptomic architecture of 2,000 breast tumors reveals novel subgroups</span></div><div class="casAuthors">Curtis, Christina; Shah, Sohrab P.; Chin, Suet-Feung; Turashvili, Gulisa; Rueda, Oscar M.; Dunning, Mark J.; Speed, Doug; Lynch, Andy G.; Samarajiwa, Shamith; Yuan, Yinyin; Graef, Stefan; Ha, Gavin; Haffari, Gholamreza; Bashashati, Ali; Russell, Roslin; McKinney, Steven; Caldas, Carlos; Aparicio, Samuel; Curtis, Christina; Caldas, Carlos; Aparicio, Samuel; Brenton, James D.; Ellis, Ian; Huntsman, David; Pinder, Sarah; Purushotham, Arnie; Murphy, Leigh; Caldas, Carlos; Aparicio, Samuel; Caldas, Carlos; Bardwell, Helen; Chin, Suet-Feung; Curtis, Christina; Ding, Zhihao; Graef, Stefan; Jones, Linda; Liu, Bin; Papatheodorou, Irene; Sammut, Stephen J.; Wishart, Gordon; Aparicio, Samuel; Chia, Steven; Gelmon, Karen; Speers, Caroline; Watson, Peter; Ellis, Ian; Blamey, Roger; Green, Andrew; MacMillan, Douglas; Rakha, Emad; Gillett, Cheryl; Grigoriadis, Anita; Pinder, Sarah; di Rinaldis, Emanuele; Tutt, Andy; Parisien, Michelle; Troup, Sandra; Caldas, Carlos; Chin, Suet-Feung; Chan, Derek; Fielding, Claire; Maia, Ana-Teresa; McGuire, Sarah; Osborne, Michelle; Sayalero, Sara M.; Spiteri, Inmaculada; Hadfield, James; Aparicio, Samuel; Bell, Lynda; Chow, Katie; Gale, Nadia; Kovalik, Maria; Ng, Ying; Prentice, Leah; Caldas, Carlos; Tavare, Simon; Curtis, Christina; Dunning, Mark J.; Graef, Stefan; Rueda, Oscar M.; Speed, Doug; Markowetz, Florian; Yuan, Yinyin; Brenton, James D.; Aparicio, Samuel; Bashashati, Ali; Ha, Gavin; Langerod, Anita; Green, Andrew; Provenzano, Elena; Pinder, Sarah; Watson, Peter; Ellis, Ian; Borresen-Dale, Anne-Lise; Brenton, James D.; Caldas, Carlos; Aparicio, Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7403</span>),
    <span class="NLM_cas:pages">346-352</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The elucidation of breast cancer subgroups and their mol. drivers requires integrated views of the genome and transcriptome from representative nos. of patients.  We present an integrated anal. of copy no. and gene expression in a discovery and validation set of 997 and 995 primary breast tumors, resp., with long-term clin. follow-up.  Inherited variants (copy no. variants and single nucleotide polymorphisms) and acquired somatic copy no. aberrations (CNAs) were assocd. with expression in ∼40% of genes, with the landscape dominated by cis- and trans-acting CNAs.  By delineating expression outlier genes driven in cis by CNAs, we identified putative cancer genes, including deletions in PPP2R2A, MTAP and MAP2K4.  Unsupervised anal. of paired DNA-RNA profiles revealed novel subgroups with distinct clin. outcomes, which reproduced in the validation cohort.  These include a high-risk, estrogen-receptor-pos. 11q13/14 cis-acting subgroup and a favorable prognosis subgroup devoid of CNAs.  Trans-acting aberration hotspots were found to modulate subgroup-specific gene networks, including a TCR deletion-mediated adaptive immune response in the CNA-devoid' subgroup and a basal-specific chromosome 5 deletion-assocd. mitotic network.  Our results provide a novel mol. stratification of the breast cancer population, derived from the impact of somatic CNAs on the transcriptome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGU8faP0OgmbVg90H21EOLACvtfcHk0livAaKmHRe7DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslSnsL8%253D&md5=7208505099b57dd63c339352935bf60a</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fnature10983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10983%26sid%3Dliteratum%253Aachs%26aulast%3DCurtis%26aufirst%3DC.%26aulast%3DShah%26aufirst%3DS.%2BP.%26aulast%3DChin%26aufirst%3DS.%2BF.%26aulast%3DTurashvili%26aufirst%3DG.%26aulast%3DRueda%26aufirst%3DO.%2BM.%26aulast%3DDunning%26aufirst%3DM.%2BJ.%26aulast%3DSpeed%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DA.%2BG.%26aulast%3DSamarajiwa%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DGr%25C3%25A4f%26aufirst%3DS.%26aulast%3DHa%26aufirst%3DG.%26aulast%3DHaffari%26aufirst%3DG.%26aulast%3DBashashati%26aufirst%3DA.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DMcKinney%26aufirst%3DS.%26aulast%3D%26aulast%3DLanger%25C3%25B8d%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DProvenzano%26aufirst%3DE.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DPinder%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DP.%26aulast%3DMarkowetz%26aufirst%3DF.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DEllis%26aufirst%3DI.%26aulast%3DPurushotham%26aufirst%3DA.%26aulast%3DB%25C3%25B8rresen-Dale%26aufirst%3DA.%2BL.%26aulast%3DBrenton%26aufirst%3DJ.%2BD.%26aulast%3DTavar%25C3%25A9%26aufirst%3DS.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DAparicio%26aufirst%3DS.%26atitle%3DThe%2520genomic%2520and%2520transcriptomic%2520architecture%2520of%25202%252C000%2520breast%2520tumours%2520reveals%2520novel%2520subgroups%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D346%26epage%3D352%26doi%3D10.1038%2Fnature10983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Mao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yáñez-Muñoz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berney, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y. J.</span><span> </span><span class="NLM_article-title">Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer</span> <span class="citation_source-journal">Am. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">604</span><span class="NLM_x">–</span> <span class="NLM_lpage">617</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21994901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC3Mbgsl2jsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=604-617&author=X.+Maoauthor=L.+K.+Boydauthor=R.+J.+Y%C3%A1%C3%B1ez-Mu%C3%B1ozauthor=T.+Chaplinauthor=L.+Xueauthor=D.+Linauthor=L.+Shanauthor=D.+M.+Berneyauthor=B.+D.+Youngauthor=Y.+J.+Lu&title=Chromosome+rearrangement+associated+inactivation+of+tumour+suppressor+genes+in+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer</span></div><div class="casAuthors">Mao Xueying; Boyd Lara K; Yanez-Munoz Rafael J; Chaplin Tracy; Xue Liyan; Lin Dongmei; Shan Ling; Berney Daniel M; Young Bryan D; Lu Yong-Jie</div><div class="citationInfo"><span class="NLM_cas:title">American journal of cancer research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">604-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Prostate cancer, the most common male cancer in Western countries, is commonly detected with complex chromosomal rearrangements.  Following the discovery of the recurrent TMPRSS2:ETS fusions in prostate cancer and EML4:ALK in non-small-cell lung cancer, it is now accepted that fusion genes not only are the hallmark of haematological malignancies and sarcomas, but also play an important role in epithelial cell carcinogenesis.  However, previous studies aiming to identify fusion genes in prostate cancer were mainly focused on expression changes and fusion transcripts.  To investigate the genes recurrently affected by the chromosome breakpoints in prostate cancer, we analysed Affymetrix array 6.0 and 500K SNP microarray data from 77 prostate cancer samples.  While the two genes most frequently affected by genomic breakpoints were, as expected, ERG and TMPRSS2, surprisingly more known tumour suppressor genes (TSGs) than known oncogenes were identified at recurrent chromosome breakpoints.  Certain well-characterised TSGs, including p53, PTEN, BRCA1 and BRCA2 are recurrently truncated as a result of chromosome rearrangements in prostate cancer.  Interestingly, many of the genes residing at recurrent breakpoint sites have not yet been implicated in prostate carcinogenesis such as HOOK3, PPP2R2A and TCBA1.  We have confirmed the generally reduced expression of selected genes in clinical samples using quantitative RT-PCR analysis.  Subsequently, we further investigated the genes associated with the t(4:6) translocation in LNCaP cells and reveal the genomic fusion of SNX9 and putative TSG UNC5C, which led to the reduced expression of both genes.  This study reveals another common mechanism that leads to the inactivation of TSGs in prostate cancer and the identification of multiple TSGs inactivated by chromosome rearrangements will lead to new direction of research for the molecular basis of prostate carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqlQDJ948WETjk2McQZ6XmfW6udTcc2eZJ8b8kvapuqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mbgsl2jsA%253D%253D&md5=7a3e133f116b5bb166835902ef51eb1f</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DX.%26aulast%3DBoyd%26aufirst%3DL.%2BK.%26aulast%3DY%25C3%25A1%25C3%25B1ez-Mu%25C3%25B1oz%26aufirst%3DR.%2BJ.%26aulast%3DChaplin%26aufirst%3DT.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DL.%26aulast%3DBerney%26aufirst%3DD.%2BM.%26aulast%3DYoung%26aufirst%3DB.%2BD.%26aulast%3DLu%26aufirst%3DY.%2BJ.%26atitle%3DChromosome%2520rearrangement%2520associated%2520inactivation%2520of%2520tumour%2520suppressor%2520genes%2520in%2520prostate%2520cancer%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2011%26volume%3D1%26spage%3D604%26epage%3D617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Cousineau, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmaaza, A.</span><span> </span><span class="NLM_article-title">EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases</span> <span class="citation_source-journal">Mol. Genet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1007/s00438-011-0612-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1007%2Fs00438-011-0612-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21409565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVSksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2011&pages=325-340&author=I.+Cousineauauthor=A.+Belmaaza&title=EMSY+overexpression+disrupts+the+BRCA2%2FRAD51+pathway+in+the+DNA-damage+response%3A+implications+for+chromosomal+instability%2Frecombination+syndromes+as+checkpoint+diseases&doi=10.1007%2Fs00438-011-0612-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases</span></div><div class="casAuthors">Cousineau, Isabelle; Belmaaza, Abdellah</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Genetics and Genomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">325-340</span>CODEN:
                <span class="NLM_cas:coden">MGGOAA</span>;
        ISSN:<span class="NLM_cas:issn">1617-4615</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">EMSY links the BRCA2 pathway to sporadic breast/ovarian cancer.  It encodes a nuclear protein that binds to the BRCA2 N-terminal domain implicated in chromatin/transcription regulation, but when sporadically amplified/overexpressed, increased EMSY level represses BRCA2 transactivation potential and induces chromosomal instability, mimicking the activity of BRCA2 mutations in the development of hereditary breast/ovarian cancer.  In addn. to chromatin/transcription regulation, EMSY may also play a role in the DNA-damage response, suggested by its ability to localize at chromatin sites of DNA damage/repair.  This implies that EMSY overexpression may also repress BRCA2 in DNA-damage replication/checkpoint and recombination/repair, coordinated processes that also require its interacting proteins: PALB2, the partner and localizer of BRCA2; RPA, replication/checkpoint protein A; and RAD51, the inseparable recombination/repair enzyme.  Here, using a well-characterized recombination/repair assay system, we demonstrate that a slight increase in EMSY level can indeed repress these two processes independently of transcriptional interference/repression.  Since EMSY, RPA and PALB2 all bind to the same BRCA2 region, these findings further support a scenario wherein: (a) EMSY amplification may mimic BRCA2 deficiency, at least by overriding RPA and PALB2, crippling the BRCA2/RAD51 complex at DNA-damage and replication/transcription sites; and (b) BRCA2/RAD51 may coordinate these processes by employing at least EMSY, PALB2 and RPA.  We extensively discuss the mol. details of how this can happen to ascertain its implications for a novel recombination mechanism apparently conceived as checkpoint rather than a DNA repair system for cell division, survival, death, and human diseases, including the tissue specificity of cancer predisposition, which may renew our thinking about targeted therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrajDnZET1akbVg90H21EOLACvtfcHk0livAaKmHRe7DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVSksL4%253D&md5=784f1daa7512496d432a30c272940ce8</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1007%2Fs00438-011-0612-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00438-011-0612-5%26sid%3Dliteratum%253Aachs%26aulast%3DCousineau%26aufirst%3DI.%26aulast%3DBelmaaza%26aufirst%3DA.%26atitle%3DEMSY%2520overexpression%2520disrupts%2520the%2520BRCA2%252FRAD51%2520pathway%2520in%2520the%2520DNA-damage%2520response%253A%2520implications%2520for%2520chromosomal%2520instability%252Frecombination%2520syndromes%2520as%2520checkpoint%2520diseases%26jtitle%3DMol.%2520Genet.%2520Genomics%26date%3D2011%26volume%3D285%26spage%3D325%26epage%3D340%26doi%3D10.1007%2Fs00438-011-0612-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Lee, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ann, D. K.</span><span> </span><span class="NLM_article-title">HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">5784</span><span class="NLM_x">–</span> <span class="NLM_lpage">5798</span><span class="refDoi"> DOI: 10.1093/nar/gkt231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fnar%2Fgkt231" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=5784-5798&author=Y.+H.+Leeauthor=C.+Y.+Kuoauthor=J.+M.+Starkauthor=H.+M.+Shihauthor=D.+K.+Ann&title=HP1+promotes+tumor+suppressor+BRCA1+functions+during+the+DNA+damage+response&doi=10.1093%2Fnar%2Fgkt231"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkt231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkt231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BH.%26aulast%3DKuo%26aufirst%3DC.%2BY.%26aulast%3DStark%26aufirst%3DJ.%2BM.%26aulast%3DShih%26aufirst%3DH.%2BM.%26aulast%3DAnn%26aufirst%3DD.%2BK.%26atitle%3DHP1%2520promotes%2520tumor%2520suppressor%2520BRCA1%2520functions%2520during%2520the%2520DNA%2520damage%2520response%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2013%26volume%3D41%26spage%3D5784%26epage%3D5798%26doi%3D10.1093%2Fnar%2Fgkt231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Lee, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ann, D. K.</span><span> </span><span class="NLM_article-title">HP1beta is a biomarker for breast cancer prognosis and PARP inhibitor therapy</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0121207</span><span class="refDoi"> DOI: 10.1371/journal.pone.0121207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1371%2Fjournal.pone.0121207" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0121207&author=Y.+H.+Leeauthor=X.+Liuauthor=F.+Qiuauthor=T.+R.+O%E2%80%99Connorauthor=Y.+Yenauthor=D.+K.+Ann&title=HP1beta+is+a+biomarker+for+breast+cancer+prognosis+and+PARP+inhibitor+therapy&doi=10.1371%2Fjournal.pone.0121207"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0121207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0121207%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DT.%2BR.%26aulast%3DYen%26aufirst%3DY.%26aulast%3DAnn%26aufirst%3DD.%2BK.%26atitle%3DHP1beta%2520is%2520a%2520biomarker%2520for%2520breast%2520cancer%2520prognosis%2520and%2520PARP%2520inhibitor%2520therapy%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0121207%26doi%3D10.1371%2Fjournal.pone.0121207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Sourisseau, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniotis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span> </span><span class="NLM_article-title">Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition</span> <span class="citation_source-journal">EMBO Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1002/emmm.201000068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1002%2Femmm.201000068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20373286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksleltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=130-142&author=T.+Sourisseauauthor=D.+Maniotisauthor=A.+McCarthyauthor=C.+Tangauthor=C.+J.+Lordauthor=A.+Ashworthauthor=S.+Linardopoulos&title=Aurora-A+expressing+tumour+cells+are+deficient+for+homology-directed+DNA+double+strand-break+repair+and+sensitive+to+PARP+inhibition&doi=10.1002%2Femmm.201000068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition</span></div><div class="casAuthors">Sourisseau, Tony; Maniotis, Despina; McCarthy, Afshan; Tang, Chan; Lord, Christopher J.; Ashworth, Alan; Linardopoulos, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">130-142</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The protein kinase Aurora-A is a major regulator of the cell cycle that orchestrates mitotic entry and is required for the assembly of a functional mitotic spindle.  Overexpression of Aurora-A has been strongly linked with oncogenesis and this has led to considerable efforts at therapeutic targeting of the kinase activity of this protein.  However, the exact mechanism by which Aurora-A promotes oncogenesis remains unclear.  Here, we show that Aurora-A modulates the repair of DNA double-strand breaks (DSBs).  Aurora-A expression inhibits RAD51 recruitment to DNA DSBs, decreases DSB repair by homologous recombination and sensitizes cancer cells to PARP inhibition.  This impairment of RAD51 function requires inhibition of CHK1 by Polo-like kinase 1 (PLK1).  These results identify a novel function of Aurora-A in modulating the response to DNA DSB that likely contributes to carcinogenesis and suggest a novel therapeutic approach to the treatment of cancers overexpressing this protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWpJRvQOJvJbVg90H21EOLACvtfcHk0liO9DmQx81AuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksleltbc%253D&md5=964227ea8a8dbe74d43ae9a1fa1c5ecf</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Femmm.201000068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201000068%26sid%3Dliteratum%253Aachs%26aulast%3DSourisseau%26aufirst%3DT.%26aulast%3DManiotis%26aufirst%3DD.%26aulast%3DMcCarthy%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DLinardopoulos%26aufirst%3DS.%26atitle%3DAurora-A%2520expressing%2520tumour%2520cells%2520are%2520deficient%2520for%2520homology-directed%2520DNA%2520double%2520strand-break%2520repair%2520and%2520sensitive%2520to%2520PARP%2520inhibition%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D130%26epage%3D142%26doi%3D10.1002%2Femmm.201000068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to therapies targeting BRCA-mutant cancers</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1381</span><span class="NLM_x">–</span> <span class="NLM_lpage">1388</span><span class="refDoi"> DOI: 10.1038/nm.3369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnm.3369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24202391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCnu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1381-1388&author=C.+J.+Lordauthor=A.+Ashworth&title=Mechanisms+of+resistance+to+therapies+targeting+BRCA-mutant+cancers&doi=10.1038%2Fnm.3369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to therapies targeting BRCA-mutant cancers</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1381-1388</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Synthetic lethality provides a potential mechanistic framework for the therapeutic targeting of genetic and functional deficiencies in cancers and is now being explored widely.  The first clin. exemplification of synthetic lethality in cancer has been the exploitation of inhibitors of poly-(ADP-ribose) polymerase (PARP) for the treatment of cancers with defects in the BRCA1 or BRCA2 tumor suppressor proteins, which are involved in the repair of DNA damage.  Although this approach has shown promise, multiple potential resistance mechanisms have been identified.  In this Perspective, we discuss these mechanisms and their relevance to the development of selective therapies for BRCA-deficient cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFkqSnv4Qj47Vg90H21EOLACvtfcHk0liO9DmQx81AuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCnu73O&md5=40a356f8df2f32143f1ff22aff1ce536</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fnm.3369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3369%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520therapies%2520targeting%2520BRCA-mutant%2520cancers%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1381%26epage%3D1388%26doi%3D10.1038%2Fnm.3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Feng, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, A. M.</span><span> </span><span class="NLM_article-title">Molecular pathways: targeting ETS gene fusions in cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4442</span><span class="NLM_x">–</span> <span class="NLM_lpage">4448</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-13-0275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24958807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=4442-4448&author=F.+Y.+Fengauthor=J.+C.+Brennerauthor=M.+Hussainauthor=A.+M.+Chinnaiyan&title=Molecular+pathways%3A+targeting+ETS+gene+fusions+in+cancer&doi=10.1158%2F1078-0432.CCR-13-0275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting ETS Gene Fusions in Cancer</span></div><div class="casAuthors">Feng, Felix Y.; Brenner, J. Chad; Hussain, Maha; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4442-4448</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Rearrangements, or gene fusions, involving the ETS family of transcription factors are common driving events in both prostate cancer and Ewing sarcoma.  These rearrangements result in pathogenic expression of the ETS genes and trigger activation of transcriptional programs enriched for invasion and other oncogenic features.  Although ETS gene fusions represent intriguing therapeutic targets, transcription factors, such as those comprising the ETS family, have been notoriously difficult to target.  Recently, preclin. studies have demonstrated an assocn. between ETS gene fusions and components of the DNA damage response pathway, such as PARP1, the catalytic subunit of DNA protein kinase (DNAPK), and histone deactylase 1 (HDAC1), and have suggested that ETS fusions may confer sensitivity to inhibitors of these DNA repair proteins.  In this review, we discuss the role of ETS fusions in cancer, the preclin. rationale for targeting ETS fusions with inhibitors of PARP1, DNAPK, and HDAC1, as well as ongoing clin. trials targeting ETS gene fusions.  Clin Cancer Res; 20(17); 4442-8. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGazkuDaafoLVg90H21EOLACvtfcHk0lgnMGo5EbrTJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykurbK&md5=2d11cdc166b255590012124d91c720a7</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0275%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DBrenner%26aufirst%3DJ.%2BC.%26aulast%3DHussain%26aufirst%3DM.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DMolecular%2520pathways%253A%2520targeting%2520ETS%2520gene%2520fusions%2520in%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D4442%26epage%3D4448%26doi%3D10.1158%2F1078-0432.CCR-13-0275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Brenner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bou-Maroun, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonigro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prensner, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlins, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, A. M.</span><span> </span><span class="NLM_article-title">PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1608</span><span class="NLM_x">–</span> <span class="NLM_lpage">1613</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-11-3648" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1608-1613&author=J.+C.+Brennerauthor=F.+Y.+Fengauthor=S.+Hanauthor=S.+Patelauthor=S.+V.+Goyalauthor=L.+M.+Bou-Marounauthor=M.+Liuauthor=R.+Lonigroauthor=J.+R.+Prensnerauthor=S.+A.+Tomlinsauthor=A.+M.+Chinnaiyan&title=PARP-1+inhibition+as+a+targeted+strategy+to+treat+Ewing%E2%80%99s+sarcoma&doi=10.1158%2F0008-5472.CAN-11-3648"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3648%26sid%3Dliteratum%253Aachs%26aulast%3DBrenner%26aufirst%3DJ.%2BC.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DGoyal%26aufirst%3DS.%2BV.%26aulast%3DBou-Maroun%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLonigro%26aufirst%3DR.%26aulast%3DPrensner%26aufirst%3DJ.%2BR.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DPARP-1%2520inhibition%2520as%2520a%2520targeted%2520strategy%2520to%2520treat%2520Ewing%25E2%2580%2599s%2520sarcoma%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1608%26epage%3D1613%26doi%3D10.1158%2F0008-5472.CAN-11-3648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Tang, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sousa, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajapakse, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing sarcoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4184</span><span class="NLM_x">–</span> <span class="NLM_lpage">4193</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-14-2112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25779942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFejtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4184-4193&author=S.+W.+Tangauthor=S.+Bilkeauthor=L.+Caoauthor=J.+Muraiauthor=F.+G.+Sousaauthor=M.+Yamadeauthor=V.+Rajapakseauthor=S.+Varmaauthor=L.+J.+Helmanauthor=J.+Khanauthor=P.+S.+Meltzerauthor=Y.+Pommier&title=SLFN11+is+a+transcriptional+target+of+EWS-FLI1+and+a+determinant+of+drug+response+in+Ewing+sarcoma&doi=10.1158%2F1078-0432.CCR-14-2112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma</span></div><div class="casAuthors">Tang, Sai-Wen; Bilke, Sven; Cao, Liang; Murai, Junko; Sousa, Fabricio G.; Yamade, Mihoko; Rajapakse, Vinodh; Varma, Sudhir; Helman, Lee J.; Khan, Javed; Meltzer, Paul S.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4184-4193</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: SLFN11 was identified as a crit. determinant of response to DNA-targeted therapies by analyzing gene expression and drug sensitivity of NCI-60 and CCLE datasets.  However, how SLFN11 is regulated in cancer cells remained unknown.  Ewing sarcoma, which is characterized by the chimeric transcription factor EWS-FLI1, has notably high SLFN11 expression, leading us to investigate whether EWS-FLI1 drives SLFN11 expression and the role of SLFN11 in the drug response of Ewing sarcoma cells.  Exptl. Design: Binding sites of EWS-FLI1 on the SLFN11 promoter were analyzed by chromatin immunopptn. sequencing and promoter-luciferase reporter analyses.  The relationship between SLFN11 and EWS-FLI1 were further examd. in EWS-FLI1-knockdown or -overexpressing cells and in clin. tumor samples.  Results: EWS-FLI1 binds near the transcription start site of SLFN11 promoter and acts as a pos. regulator of SLFN11 expression in Ewing sarcoma cells.  EWS-FLI1-mediated SLFN11 expression is responsible for high sensitivity of Ewing sarcoma to camptothecin and combinations of PARP inhibitors with temozolomide.  Importantly, Ewing sarcoma patients with higher SLFN11 expression showed better tumor-free survival rate.  The correlated expression between SLFN11 and FLI1 extends to leukemia, pediatric, colon, breast, and prostate cancers.  In addn., expression of other ETS members correlates with SLFN11 in NCI-60 and CCLE datasets, and mol. expts. demonstrate that ETS1 acts as a pos. regulator for SLFN11 expression in breast cancer cells.  Conclusions: Our results imply the emerging relevance of SLFN11 as an ETS transcription factor response gene and for therapeutic response to topoisomerase I inhibitors and temozolomide-PARP inhibitor combinations in ETS-activated cancers.  Clin Cancer Res; 21(18); 4184-93. cpr2015 AACR.  See related commentary by Kovar, p.  4033.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIQ7RMcCPdarVg90H21EOLACvtfcHk0lgnMGo5EbrTJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFejtrfF&md5=3b9b84116df3793da7de2a0cd27b0f07</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2112%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DS.%2BW.%26aulast%3DBilke%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DSousa%26aufirst%3DF.%2BG.%26aulast%3DYamade%26aufirst%3DM.%26aulast%3DRajapakse%26aufirst%3DV.%26aulast%3DVarma%26aufirst%3DS.%26aulast%3DHelman%26aufirst%3DL.%2BJ.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DMeltzer%26aufirst%3DP.%2BS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DSLFN11%2520is%2520a%2520transcriptional%2520target%2520of%2520EWS-FLI1%2520and%2520a%2520determinant%2520of%2520drug%2520response%2520in%2520Ewing%2520sarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D4184%26epage%3D4193%26doi%3D10.1158%2F1078-0432.CCR-14-2112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Sandhu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelman, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hylands, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riisnaes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forster, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreischer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thway, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gevensleben, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iannone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenham, R. M.</span><span> </span><span class="NLM_article-title">The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span><span class="refDoi"> DOI: 10.1016/S1470-2045(13)70240-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2FS1470-2045%2813%2970240-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23810788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=882-892&author=S.+K.+Sandhuauthor=W.+R.+Schelmanauthor=G.+Wildingauthor=V.+Morenoauthor=R.+D.+Bairdauthor=S.+Mirandaauthor=L.+Hylandsauthor=R.+Riisnaesauthor=M.+Forsterauthor=A.+Omlinauthor=N.+Kreischerauthor=K.+Thwayauthor=H.+Gevenslebenauthor=L.+Sunauthor=J.+Loughneyauthor=M.+Chatterjeeauthor=C.+Toniattiauthor=C.+L.+Carpenterauthor=R.+Iannoneauthor=S.+B.+Kayeauthor=J.+S.+de+Bonoauthor=R.+M.+Wenham&title=The+poly%28ADP-ribose%29+polymerase+inhibitor+niraparib+%28MK4827%29+in+BRCA+mutation+carriers+and+patients+with+sporadic+cancer%3A+a+phase+1+dose-escalation+trial&doi=10.1016%2FS1470-2045%2813%2970240-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial</span></div><div class="casAuthors">Sandhu, Shahneen K.; Schelman, William R.; Wilding, George; Moreno, Victor; Baird, Richard D.; Miranda, Susana; Hylands, Lucy; Riisnaes, Ruth; Forster, Martin; Omlin, Aurelius; Kreischer, Nathan; Thway, Khin; Gevensleben, Heidrun; Sun, Linda; Loughney, John; Chatterjee, Manash; Toniatti, Carlo; Carpenter, Christopher L.; Iannone, Robert; Kaye, Stan B.; de Bono, Johann S.; Wenham, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">882-892</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation.  Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclin. tumor models with loss of BRCA and PTEN function.  We investigated the safety, tolerability, max. tolerated dose, pharmacokinetic and pharmacodynamic profiles, and preliminary antitumor activity of niraparib.In a phase 1 dose-escalation study, we enrolled patients with advanced solid tumors at one site in the UK and two sites in the USA.  Eligible patients were aged at least 18 years; had a life expectancy of at least 12 wk; had an Eastern Cooperative Oncol. Group performance status of 2 or less; had assessable disease; were not suitable to receive any established treatments; had adequate organ function; and had discontinued any previous anticancer treatments at least 4 wk previously.  In part A, cohorts of three to six patients, enriched for BRCA1 and BRCA2 mutation carriers, received niraparib daily at ten escalating doses from 30 mg to 400 mg in a 21-day cycle to establish the max. tolerated dose.  Dose expansion at the max. tolerated dose was pursued in 15 patients to confirm tolerability.  In part B, we further investigated the max. tolerated dose in patients with sporadic platinum-resistant high-grade serous ovarian cancer and sporadic prostate cancer.  We obtained blood, circulating tumor cells, and optional paired tumor biopsies for pharmacokinetic and pharmacodynamic assessments.  Toxic effects were assessed by common toxicity criteria and tumor responses ascribed by Response Evaluation Criteria in Solid Tumors (RECIST).  Circulating tumor cells and archival tumor tissue in prostate patients were analyzed for exploratory putative predictive biomarkers, such as loss of PTEN expression and ETS rearrangements.  This trial is registered with ClinicalTrials.gov, NCT00749502.Between Sept 15, 2008, and Jan 14, 2011, we enrolled 100 patients: 60 in part A and 40 in part B. 300 mg/day was established as the max. tolerated dose.  Dose-limiting toxic effects reported in the first cycle were grade 3 fatigue (one patient given 30 mg/day), grade 3 pneumonitis (one given 60 mg/day), and grade 4 thrombocytopenia (two given 400 mg/day).  Common treatment-related toxic effects were anemia (48 patients [48%]), nausea (42 [42%]), fatigue (42 [42%]), thrombocytopenia (35 [35%]), anorexia (26 [26%]), neutropenia (24 [24%]), constipation (23 [23%]), and vomiting (20 [20%]), and were predominantly grade 1 or 2.  Pharmacokinetics were dose proportional and the mean terminal elimination half-life was 36·4 h (range 32·8-46·0).  Pharmacodynamic analyses confirmed PARP inhibition exceeded 50% at doses greater than 80 mg/day and antitumor activity was documented beyond doses of 60 mg/day.  Eight (40% [95% CI 19-64]) of 20 BRCA1 or BRCA2 mutation carriers with ovarian cancer had RECIST partial responses, as did two (50% [7-93]) of four mutation carriers with breast cancer.  Antitumor activity was also reported in sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer.  We recorded no correlation between loss of PTEN expression or ETS rearrangements and measures of antitumor activity in patients with prostate cancer.A recommended phase 2 dose of 300 mg/day niraparib is well tolerated.  Niraparib should be further assessed in inherited and sporadic cancers with homologous recombination DNA repair defects and to target PARP-mediated transcription in cancer.Merck Sharp and Dohme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGQBD4DZcJn7Vg90H21EOLACvtfcHk0lgnMGo5EbrTJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtLnF&md5=b6f27019bb7887156d1abcf05db2bca3</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970240-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970240-7%26sid%3Dliteratum%253Aachs%26aulast%3DSandhu%26aufirst%3DS.%2BK.%26aulast%3DSchelman%26aufirst%3DW.%2BR.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DBaird%26aufirst%3DR.%2BD.%26aulast%3DMiranda%26aufirst%3DS.%26aulast%3DHylands%26aufirst%3DL.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DForster%26aufirst%3DM.%26aulast%3DOmlin%26aufirst%3DA.%26aulast%3DKreischer%26aufirst%3DN.%26aulast%3DThway%26aufirst%3DK.%26aulast%3DGevensleben%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLoughney%26aufirst%3DJ.%26aulast%3DChatterjee%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DCarpenter%26aufirst%3DC.%2BL.%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DWenham%26aufirst%3DR.%2BM.%26atitle%3DThe%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520niraparib%2520%2528MK4827%2529%2520in%2520BRCA%2520mutation%2520carriers%2520and%2520patients%2520with%2520sporadic%2520cancer%253A%2520a%2520phase%25201%2520dose-escalation%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D882%26epage%3D892%26doi%3D10.1016%2FS1470-2045%2813%2970240-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, L.</span><span> </span><span class="NLM_article-title">Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">958</span><span class="refDoi"> DOI: 10.1186/s12885-015-1965-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2Fs12885-015-1965-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=958&author=C.+H.+Linauthor=C.+Y.+Changauthor=K.+R.+Leeauthor=H.+J.+Linauthor=T.+H.+Chenauthor=L.+Wan&title=Flavones+inhibit+breast+cancer+proliferation+through+the+Akt%2FFOXO3a+signaling+pathway&doi=10.1186%2Fs12885-015-1965-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1965-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1965-7%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BR.%26aulast%3DLin%26aufirst%3DH.%2BJ.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DWan%26aufirst%3DL.%26atitle%3DFlavones%2520inhibit%2520breast%2520cancer%2520proliferation%2520through%2520the%2520Akt%252FFOXO3a%2520signaling%2520pathway%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D958%26doi%3D10.1186%2Fs12885-015-1965-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Park, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, H. G.</span><span> </span><span class="NLM_article-title">Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">42</span><span class="NLM_x">) </span> <span class="NLM_fpage">44819</span><span class="NLM_x">–</span> <span class="NLM_lpage">44831</span><span class="refDoi"> DOI: 10.18632/oncotarget.6264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.6264" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=44819-44831&issue=42&author=S.+H.+Parkauthor=K.+Y.+Jangauthor=M.+J.+Kimauthor=S.+Yoonauthor=Y.+Joauthor=S.+M.+Kwonauthor=K.+M.+Kimauthor=K.+S.+Kwonauthor=C.+Y.+Kimauthor=H.+G.+Woo&title=Tumor+suppressive+effect+of+PARP1+and+FOXO3A+in+gastric+cancers+and+its+clinical+implications&doi=10.18632%2Foncotarget.6264"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6264%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BH.%26aulast%3DJang%26aufirst%3DK.%2BY.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DJo%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DS.%2BM.%26aulast%3DKim%26aufirst%3DK.%2BM.%26aulast%3DKwon%26aufirst%3DK.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BY.%26aulast%3DWoo%26aufirst%3DH.%2BG.%26atitle%3DTumor%2520suppressive%2520effect%2520of%2520PARP1%2520and%2520FOXO3A%2520in%2520gastric%2520cancers%2520and%2520its%2520clinical%2520implications%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D42%26spage%3D44819%26epage%3D44831%26doi%3D10.18632%2Foncotarget.6264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Bunting, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callén, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polato, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bothmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldhahn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Capetillo, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussenzweig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussenzweig, A.</span><span> </span><span class="NLM_article-title">53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">254</span><span class="refDoi"> DOI: 10.1016/j.cell.2010.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.cell.2010.03.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=243-254&author=S.+F.+Buntingauthor=E.+Call%C3%A9nauthor=N.+Wongauthor=H.+T.+Chenauthor=F.+Polatoauthor=A.+Gunnauthor=A.+Bothmerauthor=N.+Feldhahnauthor=O.+Fernandez-Capetilloauthor=L.+Caoauthor=X.+Xuauthor=C.+X.+Dengauthor=T.+Finkelauthor=M.+Nussenzweigauthor=J.+M.+Starkauthor=A.+Nussenzweig&title=53BP1+inhibits+homologous+recombination+in+Brca1-deficient+cells+by+blocking+resection+of+DNA+breaks&doi=10.1016%2Fj.cell.2010.03.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DBunting%26aufirst%3DS.%2BF.%26aulast%3DCall%25C3%25A9n%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DH.%2BT.%26aulast%3DPolato%26aufirst%3DF.%26aulast%3DGunn%26aufirst%3DA.%26aulast%3DBothmer%26aufirst%3DA.%26aulast%3DFeldhahn%26aufirst%3DN.%26aulast%3DFernandez-Capetillo%26aufirst%3DO.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DC.%2BX.%26aulast%3DFinkel%26aufirst%3DT.%26aulast%3DNussenzweig%26aufirst%3DM.%26aulast%3DStark%26aufirst%3DJ.%2BM.%26aulast%3DNussenzweig%26aufirst%3DA.%26atitle%3D53BP1%2520inhibits%2520homologous%2520recombination%2520in%2520Brca1-deficient%2520cells%2520by%2520blocking%2520resection%2520of%2520DNA%2520breaks%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D243%26epage%3D254%26doi%3D10.1016%2Fj.cell.2010.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersbergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boon, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sol, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Deemter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drost, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wientjens, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, S.</span><span> </span><span class="NLM_article-title">Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F2159-8290.CD-12-0049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=68-81&author=J.+E.+Jaspersauthor=A.+Kersbergenauthor=U.+Boonauthor=W.+Solauthor=L.+van+Deemterauthor=S.+A.+Zanderauthor=R.+Drostauthor=E.+Wientjensauthor=J.+Jiauthor=A.+Alyauthor=J.+H.+Doroshowauthor=A.+Cranstonauthor=N.+M.+Martinauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=S.+Ganesanauthor=P.+Borstauthor=J.+Jonkersauthor=S.+Rottenberg&title=Loss+of+53BP1+causes+PARP+inhibitor+resistance+in+Brca1-mutated+mouse+mammary+tumors&doi=10.1158%2F2159-8290.CD-12-0049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0049%26sid%3Dliteratum%253Aachs%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3DBoon%26aufirst%3DU.%26aulast%3DSol%26aufirst%3DW.%26aulast%3Dvan%2BDeemter%26aufirst%3DL.%26aulast%3DZander%26aufirst%3DS.%2BA.%26aulast%3DDrost%26aufirst%3DR.%26aulast%3DWientjens%26aufirst%3DE.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DAly%26aufirst%3DA.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DGanesan%26aufirst%3DS.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DRottenberg%26aufirst%3DS.%26atitle%3DLoss%2520of%252053BP1%2520causes%2520PARP%2520inhibitor%2520resistance%2520in%2520Brca1-mutated%2520mouse%2520mammary%2520tumors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D68%26epage%3D81%26doi%3D10.1158%2F2159-8290.CD-12-0049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Xu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandsma, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistrik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouwman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartkova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogola, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmerdam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barazas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieterse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersbergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sol, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celie, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schouten, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Broek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieuwland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Rink, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Ronde, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalink, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gent, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, S.</span><span> </span><span class="NLM_article-title">REV7 counteracts DNA double-strand break resection and affects PARP inhibition</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">521</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span><span class="refDoi"> DOI: 10.1038/nature14328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnature14328" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=521&publication_year=2015&pages=541-544&author=G.+Xuauthor=J.+R.+Chapmanauthor=I.+Brandsmaauthor=J.+Yuanauthor=M.+Mistrikauthor=P.+Bouwmanauthor=J.+Bartkovaauthor=E.+Gogolaauthor=D.+Warmerdamauthor=M.+Barazasauthor=J.+E.+Jaspersauthor=K.+Watanabeauthor=M.+Pieterseauthor=A.+Kersbergenauthor=W.+Solauthor=P.+H.+Celieauthor=P.+C.+Schoutenauthor=B.+van+den+Broekauthor=A.+Salmanauthor=M.+Nieuwlandauthor=I.+de+Rinkauthor=J.+de+Rondeauthor=K.+Jalinkauthor=S.+J.+Boultonauthor=J.+Chenauthor=D.+C.+van+Gentauthor=J.+Bartekauthor=J.+Jonkersauthor=P.+Borstauthor=S.+Rottenberg&title=REV7+counteracts+DNA+double-strand+break+resection+and+affects+PARP+inhibition&doi=10.1038%2Fnature14328"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fnature14328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14328%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DG.%26aulast%3DChapman%26aufirst%3DJ.%2BR.%26aulast%3DBrandsma%26aufirst%3DI.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DMistrik%26aufirst%3DM.%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DBartkova%26aufirst%3DJ.%26aulast%3DGogola%26aufirst%3DE.%26aulast%3DWarmerdam%26aufirst%3DD.%26aulast%3DBarazas%26aufirst%3DM.%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DPieterse%26aufirst%3DM.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3DSol%26aufirst%3DW.%26aulast%3DCelie%26aufirst%3DP.%2BH.%26aulast%3DSchouten%26aufirst%3DP.%2BC.%26aulast%3Dvan%2Bden%2BBroek%26aufirst%3DB.%26aulast%3DSalman%26aufirst%3DA.%26aulast%3DNieuwland%26aufirst%3DM.%26aulast%3Dde%2BRink%26aufirst%3DI.%26aulast%3Dde%2BRonde%26aufirst%3DJ.%26aulast%3DJalink%26aufirst%3DK.%26aulast%3DBoulton%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3Dvan%2BGent%26aufirst%3DD.%2BC.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DRottenberg%26aufirst%3DS.%26atitle%3DREV7%2520counteracts%2520DNA%2520double-strand%2520break%2520resection%2520and%2520affects%2520PARP%2520inhibition%26jtitle%3DNature%26date%3D2015%26volume%3D521%26spage%3D541%26epage%3D544%26doi%3D10.1038%2Fnature14328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iorns, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swift, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rayter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1368</span><span class="NLM_x">–</span> <span class="NLM_lpage">1377</span><span class="refDoi"> DOI: 10.1038/emboj.2008.61</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Femboj.2008.61" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1368-1377&author=N.+C.+Turnerauthor=C.+J.+Lordauthor=E.+Iornsauthor=R.+Broughauthor=S.+Swiftauthor=R.+Elliottauthor=S.+Rayterauthor=A.+N.+Tuttauthor=A.+Ashworth&title=A+synthetic+lethal+siRNA+screen+identifying+genes+mediating+sensitivity+to+a+PARP+inhibitor&doi=10.1038%2Femboj.2008.61"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Femboj.2008.61&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2008.61%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DIorns%26aufirst%3DE.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DSwift%26aufirst%3DS.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DRayter%26aufirst%3DS.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DA%2520synthetic%2520lethal%2520siRNA%2520screen%2520identifying%2520genes%2520mediating%2520sensitivity%2520to%2520a%2520PARP%2520inhibitor%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D1368%26epage%3D1377%26doi%3D10.1038%2Femboj.2008.61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Bolin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boudra, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaslin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennaneach, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaremba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordelières, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favaudon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mégnin-Chanet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J.</span><span> </span><span class="NLM_article-title">The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">951</span><span class="NLM_x">–</span> <span class="NLM_lpage">962</span><span class="refDoi"> DOI: 10.1007/s00018-011-0811-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1007%2Fs00018-011-0811-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21922195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38Xisl2rtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=951-962&author=C.+Bolinauthor=M.+T.+Boudraauthor=M.+Fernetauthor=L.+Vaslinauthor=V.+Pennaneachauthor=T.+Zarembaauthor=D.+Biardauthor=F.+P.+Cordeli%C3%A8resauthor=V.+Favaudonauthor=F.+M%C3%A9gnin-Chanetauthor=J.+Hall&title=The+impact+of+cyclin-dependent+kinase+5+depletion+on+poly%28ADP-ribose%29+polymerase+activity+and+responses+to+radiation&doi=10.1007%2Fs00018-011-0811-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation</span></div><div class="casAuthors">Bolin, Celeste; Boudra, Mohammed-Tayyib; Fernet, Marie; Vaslin, Laurence; Pennaneach, Vincent; Zaremba, Tomasz; Biard, Denis; Cordelieres, Fabrice P.; Favaudon, Vincent; Megnin-Chanet, Frederique; Hall, Janet</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">951-962</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 5 (Cdk5) has been identified as a determinant of sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors.  Here, the consequences of its depletion on cell survival, PARP activity, the recruitment of base excision repair (BER) proteins to DNA damage sites, and overall DNA single-strand break (SSB) repair were investigated using isogenic HeLa stably depleted (KD) and Control cell lines.  Synthetic lethality achieved by disrupting PARP activity in Cdk5-deficient cells was confirmed, and the Cdk5KD cells were also found to be sensitive to the killing effects of ionizing radiation (IR) but not Me methanesulfonate or neocarzinostatin.  The recruitment profiles of GFP-PARP-1 and XRCC1-YFP to sites of micro-irradiated Cdk5KD cells were slower and reached lower max. values, while the profile of GFP-PCNA recruitment was faster and attained higher max. values compared to Control cells.  Higher basal, IR, and hydrogen peroxide-induced polymer levels were obsd. in Cdk5KD compared to Control cells.  Recruitment of GFP-PARP-1 in which serines 782, 785, and 786, potential Cdk5 phosphorylation targets, were mutated to alanines in micro-irradiated Control cells was also reduced.  We hypothesize that Cdk5-dependent PARP-1 phosphorylation on one or more of these serines results in an attenuation of its ribosylating activity facilitating persistence at DNA damage sites.  Despite these deficiencies, Cdk5KD cells are able to effectively repair SSBs probably via the long patch BER pathway, suggesting that the enhanced radiation sensitivity of Cdk5KD cells is due to a role of Cdk5 in other pathways or the altered polymer levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXsx-zTa5XX7Vg90H21EOLACvtfcHk0lgjYm4zOdBPYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xisl2rtrk%253D&md5=6fc9630ae70b46c7f55c56d8d60638a1</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1007%2Fs00018-011-0811-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-011-0811-6%26sid%3Dliteratum%253Aachs%26aulast%3DBolin%26aufirst%3DC.%26aulast%3DBoudra%26aufirst%3DM.%2BT.%26aulast%3DFernet%26aufirst%3DM.%26aulast%3DVaslin%26aufirst%3DL.%26aulast%3DPennaneach%26aufirst%3DV.%26aulast%3DZaremba%26aufirst%3DT.%26aulast%3DBiard%26aufirst%3DD.%26aulast%3DCordeli%25C3%25A8res%26aufirst%3DF.%2BP.%26aulast%3DFavaudon%26aufirst%3DV.%26aulast%3DM%25C3%25A9gnin-Chanet%26aufirst%3DF.%26aulast%3DHall%26aufirst%3DJ.%26atitle%3DThe%2520impact%2520of%2520cyclin-dependent%2520kinase%25205%2520depletion%2520on%2520poly%2528ADP-ribose%2529%2520polymerase%2520activity%2520and%2520responses%2520to%2520radiation%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2012%26volume%3D69%26spage%3D951%26epage%3D962%26doi%3D10.1007%2Fs00018-011-0811-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Chiker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennaneach, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loew, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordelières, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemble, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieche, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernet, M.</span><span> </span><span class="NLM_article-title">Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3066</span><span class="NLM_x">–</span> <span class="NLM_lpage">3078</span><span class="refDoi"> DOI: 10.1080/15384101.2015.1078020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1080%2F15384101.2015.1078020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=3066-3078&author=S.+Chikerauthor=V.+Pennaneachauthor=D.+Loewauthor=F.+Dingliauthor=D.+Biardauthor=F.+P.+Cordeli%C3%A8resauthor=S.+Gembleauthor=S.+Vacherauthor=I.+Biecheauthor=J.+Hallauthor=M.+Fernet&title=Cdk5+promotes+DNA+replication+stress+checkpoint+activation+through+RPA-32+phosphorylation%2C+and+impacts+on+metastasis+free+survival+in+breast+cancer+patients&doi=10.1080%2F15384101.2015.1078020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1078020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1078020%26sid%3Dliteratum%253Aachs%26aulast%3DChiker%26aufirst%3DS.%26aulast%3DPennaneach%26aufirst%3DV.%26aulast%3DLoew%26aufirst%3DD.%26aulast%3DDingli%26aufirst%3DF.%26aulast%3DBiard%26aufirst%3DD.%26aulast%3DCordeli%25C3%25A8res%26aufirst%3DF.%2BP.%26aulast%3DGemble%26aufirst%3DS.%26aulast%3DVacher%26aufirst%3DS.%26aulast%3DBieche%26aufirst%3DI.%26aulast%3DHall%26aufirst%3DJ.%26aulast%3DFernet%26aufirst%3DM.%26atitle%3DCdk5%2520promotes%2520DNA%2520replication%2520stress%2520checkpoint%2520activation%2520through%2520RPA-32%2520phosphorylation%252C%2520and%2520impacts%2520on%2520metastasis%2520free%2520survival%2520in%2520breast%2520cancer%2520patients%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26spage%3D3066%26epage%3D3078%26doi%3D10.1080%2F15384101.2015.1078020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Chin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVries, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridlyand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spellman, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roydasgupta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapuk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feiler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokuyasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingsley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairkee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chew, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ljung, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esserman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertson, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. W.</span><span> </span><span class="NLM_article-title">Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">541</span><span class="refDoi"> DOI: 10.1016/j.ccr.2006.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.ccr.2006.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=17157792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCnsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=529-541&author=K.+Chinauthor=S.+DeVriesauthor=J.+Fridlyandauthor=P.+T.+Spellmanauthor=R.+Roydasguptaauthor=W.+L.+Kuoauthor=A.+Lapukauthor=R.+M.+Neveauthor=Z.+Qianauthor=T.+Ryderauthor=F.+Chenauthor=H.+Feilerauthor=T.+Tokuyasuauthor=C.+Kingsleyauthor=S.+Dairkeeauthor=Z.+Mengauthor=K.+Chewauthor=D.+Pinkelauthor=A.+Jainauthor=B.+M.+Ljungauthor=L.+Essermanauthor=D.+G.+Albertsonauthor=F.+M.+Waldmanauthor=J.+W.+Gray&title=Genomic+and+transcriptional+aberrations+linked+to+breast+cancer+pathophysiologies&doi=10.1016%2Fj.ccr.2006.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</span></div><div class="casAuthors">Chin, Koei; DeVries, Sandy; Fridlyand, Jane; Spellman, Paul T.; Roydasgupta, Ritu; Kuo, Wen-Lin; Lapuk, Anna; Neve, Richard M.; Qian, Zuwei; Ryder, Tom; Chen, Fanqing; Feiler, Heidi; Tokuyasu, Taku; Kingsley, Chris; Dairkee, Shanaz; Meng, Zhenhang; Chew, Karen; Pinkel, Daniel; Jain, Ajay; Ljung, Britt Marie; Esserman, Laura; Albertson, Donna G.; Waldman, Frederic M.; Gray, Joe W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">529-541</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">This study explores the roles of genome copy no. abnormalities (CNAs) in breast cancer pathophysiol. by identifying assocns. between recurrent CNAs, gene expression, and clin. outcome in a set of aggressively treated early-stage breast tumors.  It shows that the recurrent CNAs differ between tumor subtypes defined by expression pattern and that stratification of patients according to outcome can be improved by measuring both expression and copy no., esp. high-level amplification.  Sixty-six genes deregulated by the high-level amplifications are potential therapeutic targets.  Nine of these (FGFR1, IKBKB, ERBB2, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1) are considered as therapeutic targets.  Low-level CNAs appear to contribute to cancer progression by altering RNA and cellular metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHiq8I1mqFn7Vg90H21EOLACvtfcHk0lh4P5WTT4RYOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCnsrbF&md5=8848be946221c3d3236bf9bc3154b77e</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DK.%26aulast%3DDeVries%26aufirst%3DS.%26aulast%3DFridlyand%26aufirst%3DJ.%26aulast%3DSpellman%26aufirst%3DP.%2BT.%26aulast%3DRoydasgupta%26aufirst%3DR.%26aulast%3DKuo%26aufirst%3DW.%2BL.%26aulast%3DLapuk%26aufirst%3DA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DFeiler%26aufirst%3DH.%26aulast%3DTokuyasu%26aufirst%3DT.%26aulast%3DKingsley%26aufirst%3DC.%26aulast%3DDairkee%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DChew%26aufirst%3DK.%26aulast%3DPinkel%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DA.%26aulast%3DLjung%26aufirst%3DB.%2BM.%26aulast%3DEsserman%26aufirst%3DL.%26aulast%3DAlbertson%26aufirst%3DD.%2BG.%26aulast%3DWaldman%26aufirst%3DF.%2BM.%26aulast%3DGray%26aufirst%3DJ.%2BW.%26atitle%3DGenomic%2520and%2520transcriptional%2520aberrations%2520linked%2520to%2520breast%2520cancer%2520pathophysiologies%26jtitle%3DCancer%2520Cell%26date%3D2006%26volume%3D10%26spage%3D529%26epage%3D541%26doi%3D10.1016%2Fj.ccr.2006.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Ehrlich, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardelt, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehr, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Toni, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerbes, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollmar, A. M.</span><span> </span><span class="NLM_article-title">Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.01.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.jhep.2015.01.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25660209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1Srtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=102-113&author=S.+M.+Ehrlichauthor=J.+Lieblauthor=M.+A.+Ardeltauthor=T.+Lehrauthor=E.+N.+De+Toniauthor=D.+Mayrauthor=L.+Brandlauthor=T.+Kirchnerauthor=S.+Zahlerauthor=A.+L.+Gerbesauthor=A.+M.+Vollmar&title=Targeting+cyclin+dependent+kinase+5+in+hepatocellular+carcinoma%2D%2DA+novel+therapeutic+approach&doi=10.1016%2Fj.jhep.2015.01.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cyclin dependent kinase 5 in hepatocellular carcinoma - A novel therapeutic approach</span></div><div class="casAuthors">Ehrlich, Sandra M.; Liebl, Johanna; Ardelt, Maximilian A.; Lehr, Thorsten; De Toni, Enrico N.; Mayr, Doris; Brandl, Lydia; Kirchner, Thomas; Zahler, Stefan; Gerbes, Alexander L.; Vollmar, Angelika M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-113</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">For a long time cyclin dependent kinase 5 (Cdk5) was thought to be exclusively important in neuronal cells.  However, increasing evidence recently suggests a function of Cdk5 in cancer progression.  In this study, we examd. the role of Cdk5 and its therapeutic accessibility in hepatocellular carcinoma (HCC), a highly chemoresistant cancer with poor prognosis and paramount clin. importance in order to develop novel targeted therapies for systemic treatment.  Expression and activity of Cdk5 was analyzed in a human HCC tissue microarray, human patient samples and HCC cell lines.  To characterize Cdk5 functions and signaling pathways in HCC, we applied genetic downregulation and pharmacol. inhibition in various approaches including cell based assays and mouse xenograft models.  Expression and activity of Cdk5 was increased in human HCC tissues as compared to normal liver tissues.  Functional ablation of Cdk5 significantly decreased HCC cell proliferation and clonogenic survival.  Moreover, genetic and pharmacol. inhibition of Cdk5 showed in vivo efficacy in HCC xenograft mouse models.  Investigating the mechanisms behind these functional effects revealed that Cdk5 is most active in the nucleus of cells in G2/M phase.  Cdk5 regulates DNA damage response by phosphorylating ataxia telangiectasia mutated (ATM) kinase and thereby influencing its downstream cascade.  Consequently, combination of Cdk5 inhibition with DNA-damage-inducing chemotherapeutics synergistically inhibited HCC tumor progression in vitro and in vivo.  In summary, we introduce Cdk5 as a novel drugable target for HCC treatment and suggest the combination of Cdk5 inhibition and DNA damaging agents as a novel therapeutic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDSzPpX1jOhbVg90H21EOLACvtfcHk0lh4P5WTT4RYOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1Srtbc%253D&md5=948af74199cce8a02a0d4cd7f52f1d12</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.01.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.01.031%26sid%3Dliteratum%253Aachs%26aulast%3DEhrlich%26aufirst%3DS.%2BM.%26aulast%3DLiebl%26aufirst%3DJ.%26aulast%3DArdelt%26aufirst%3DM.%2BA.%26aulast%3DLehr%26aufirst%3DT.%26aulast%3DDe%2BToni%26aufirst%3DE.%2BN.%26aulast%3DMayr%26aufirst%3DD.%26aulast%3DBrandl%26aufirst%3DL.%26aulast%3DKirchner%26aufirst%3DT.%26aulast%3DZahler%26aufirst%3DS.%26aulast%3DGerbes%26aufirst%3DA.%2BL.%26aulast%3DVollmar%26aufirst%3DA.%2BM.%26atitle%3DTargeting%2520cyclin%2520dependent%2520kinase%25205%2520in%2520hepatocellular%2520carcinoma--A%2520novel%2520therapeutic%2520approach%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D63%26spage%3D102%26epage%3D113%26doi%3D10.1016%2Fj.jhep.2015.01.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Huang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, D. S.</span><span> </span><span class="NLM_article-title">Cdk5: Links to DNA damage</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3142</span><span class="NLM_x">–</span> <span class="NLM_lpage">3143</span><span class="refDoi"> DOI: 10.4161/cc.9.16.12955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.4161%2Fcc.9.16.12955" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=3142-3143&author=E.+Huangauthor=D.+Quauthor=D.+S.+Park&title=Cdk5%3A+Links+to+DNA+damage&doi=10.4161%2Fcc.9.16.12955"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.16.12955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.16.12955%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DQu%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DD.%2BS.%26atitle%3DCdk5%253A%2520Links%2520to%2520DNA%2520damage%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26spage%3D3142%26epage%3D3143%26doi%3D10.4161%2Fcc.9.16.12955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span><span class="refDoi"> DOI: 10.1146/annurev-med-050913-022545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1146%2Fannurev-med-050913-022545" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=455-470&author=C.+J.+Lordauthor=A.+N.+Tuttauthor=A.+Ashworth&title=Synthetic+lethality+and+cancer+therapy%3A+lessons+learned+from+the+development+of+PARP+inhibitors&doi=10.1146%2Fannurev-med-050913-022545"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-050913-022545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-050913-022545%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DSynthetic%2520lethality%2520and%2520cancer%2520therapy%253A%2520lessons%2520learned%2520from%2520the%2520development%2520of%2520PARP%2520inhibitors%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D455%26epage%3D470%26doi%3D10.1146%2Fannurev-med-050913-022545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Livraghi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garber, J. E.</span><span> </span><span class="NLM_article-title">PARP inhibitors in the management of breast cancer: current data and future prospects</span> <span class="citation_source-journal">BMC Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="refDoi"> DOI: 10.1186/s12916-015-0425-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1186%2Fs12916-015-0425-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26268938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A280%3ADC%252BC287is1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=188&author=L.+Livraghiauthor=J.+E.+Garber&title=PARP+inhibitors+in+the+management+of+breast+cancer%3A+current+data+and+future+prospects&doi=10.1186%2Fs12916-015-0425-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors in the management of breast cancer: current data and future prospects</span></div><div class="casAuthors">Livraghi Luca; Garber Judy E</div><div class="citationInfo"><span class="NLM_cas:title">BMC medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">188</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair.  Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers.  Several PARP inhibitors are currently in trials in the adjuvant, neoadjuvant, and metastatic settings for the treatment of ovarian, BRCA-mutated breast, and other cancers.  We herein review the development of PARP inhibitors and the basis for the excitement surrounding these agents, their use as single agents and in combinations, as well as their toxicities, mechanisms of acquired resistance, and companion diagnostics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTN9YoyeMbnGkH3Rlp_k91zfW6udTcc2eayMrg4dkoFOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287is1Kktg%253D%253D&md5=9be050964d88c81526f7bbb7873ee2b4</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1186%2Fs12916-015-0425-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12916-015-0425-1%26sid%3Dliteratum%253Aachs%26aulast%3DLivraghi%26aufirst%3DL.%26aulast%3DGarber%26aufirst%3DJ.%2BE.%26atitle%3DPARP%2520inhibitors%2520in%2520the%2520management%2520of%2520breast%2520cancer%253A%2520current%2520data%2520and%2520future%2520prospects%26jtitle%3DBMC%2520Med.%26date%3D2015%26volume%3D13%26spage%3D188%26doi%3D10.1186%2Fs12916-015-0425-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Bouwman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">540</span><span class="NLM_x">–</span> <span class="NLM_lpage">547</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-13-0225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24270682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=540-547&author=P.+Bouwmanauthor=J.+Jonkers&title=Molecular+pathways%3A+how+can+BRCA-mutated+tumors+become+resistant+to+PARP+inhibitors%3F&doi=10.1158%2F1078-0432.CCR-13-0225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?</span></div><div class="casAuthors">Bouwman, Peter; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">540-547</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  PARP inhibition is synthetic lethal with defective DNA repair via homologous recombination.  Phase I and II clin. trials show that PARP inhibitors are effective at well-tolerated doses and have antitumor activity for BRCA1- and BRCA2-assocd. cancers.  However, not all patients respond equally well and tumors may eventually become resistant.  Thus far, the only resistance mechanism that has been found in human tumors is genetic reversion that corrects or bypasses the original BRCA1- or BRCA2-inactivating mutation.  However, data from fundamental and preclin. research suggest that resistance to PARP inhibitors may be induced by addnl. mechanisms involving hypomorphic activity of mutant BRCA1 alleles, upregulation of drug efflux pumps, and rewiring of the DNA damage response.  Preclin. models will be instrumental to develop methods for adequate patient stratification, as well as treatment strategies that prevent or counteract resistance to PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK8cSjdD2_ObVg90H21EOLACvtfcHk0lh9pw5FvWkeHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWjsrs%253D&md5=8d670ec3b09fe26963087de8c533f77a</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0225%26sid%3Dliteratum%253Aachs%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DMolecular%2520pathways%253A%2520how%2520can%2520BRCA-mutated%2520tumors%2520become%2520resistant%2520to%2520PARP%2520inhibitors%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D540%26epage%3D547%26doi%3D10.1158%2F1078-0432.CCR-13-0225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Drost, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouwman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boon, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schut, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klarenbeek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klijn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heijden, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Gulden, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wientjens, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieterse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catteau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">809</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.ccr.2011.11.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=797-809&author=R.+Drostauthor=P.+Bouwmanauthor=S.+Rottenbergauthor=U.+Boonauthor=E.+Schutauthor=S.+Klarenbeekauthor=C.+Klijnauthor=I.+van+der+Heijdenauthor=H.+van+der+Guldenauthor=E.+Wientjensauthor=M.+Pieterseauthor=A.+Catteauauthor=P.+Greenauthor=E.+Solomonauthor=J.+R.+Morrisauthor=J.+Jonkers&title=BRCA1+RING+function+is+essential+for+tumor+suppression+but+dispensable+for+therapy+resistance&doi=10.1016%2Fj.ccr.2011.11.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DDrost%26aufirst%3DR.%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DBoon%26aufirst%3DU.%26aulast%3DSchut%26aufirst%3DE.%26aulast%3DKlarenbeek%26aufirst%3DS.%26aulast%3DKlijn%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DI.%26aulast%3Dvan%2Bder%2BGulden%26aufirst%3DH.%26aulast%3DWientjens%26aufirst%3DE.%26aulast%3DPieterse%26aufirst%3DM.%26aulast%3DCatteau%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DE.%26aulast%3DMorris%26aufirst%3DJ.%2BR.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DBRCA1%2520RING%2520function%2520is%2520essential%2520for%2520tumor%2520suppression%2520but%2520dispensable%2520for%2520therapy%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D20%26spage%3D797%26epage%3D809%26doi%3D10.1016%2Fj.ccr.2011.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Moskwa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buffa, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panchakshari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottipati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muschel, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beech, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulshrestha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdelmohsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorospe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdhury, D.</span><span> </span><span class="NLM_article-title">miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span><span class="refDoi"> DOI: 10.1016/j.molcel.2010.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.molcel.2010.12.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=210-220&author=P.+Moskwaauthor=F.+M.+Buffaauthor=Y.+Panauthor=R.+Panchakshariauthor=P.+Gottipatiauthor=R.+J.+Muschelauthor=J.+Beechauthor=R.+Kulshresthaauthor=K.+Abdelmohsenauthor=D.+M.+Weinstockauthor=M.+Gorospeauthor=A.+L.+Harrisauthor=T.+Helledayauthor=D.+Chowdhury&title=miR-182-mediated+downregulation+of+BRCA1+impacts+DNA+repair+and+sensitivity+to+PARP+inhibitors&doi=10.1016%2Fj.molcel.2010.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2010.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2010.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DMoskwa%26aufirst%3DP.%26aulast%3DBuffa%26aufirst%3DF.%2BM.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DPanchakshari%26aufirst%3DR.%26aulast%3DGottipati%26aufirst%3DP.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DBeech%26aufirst%3DJ.%26aulast%3DKulshrestha%26aufirst%3DR.%26aulast%3DAbdelmohsen%26aufirst%3DK.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26aulast%3DGorospe%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DChowdhury%26aufirst%3DD.%26atitle%3DmiR-182-mediated%2520downregulation%2520of%2520BRCA1%2520impacts%2520DNA%2520repair%2520and%2520sensitivity%2520to%2520PARP%2520inhibitors%26jtitle%3DMol.%2520Cell%26date%3D2011%26volume%3D41%26spage%3D210%26epage%3D220%26doi%3D10.1016%2Fj.molcel.2010.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span> </span><span class="NLM_article-title">miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">1750</span><span class="NLM_x">–</span> <span class="NLM_lpage">1758</span><span class="refDoi"> DOI: 10.1093/jnci/djt302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1093%2Fjnci%2Fdjt302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24168967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKgu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2013&pages=1750-1758&author=C.+Sunauthor=N.+Liauthor=Z.+Yangauthor=B.+Zhouauthor=Y.+Heauthor=D.+Wengauthor=Y.+Fangauthor=P.+Wuauthor=P.+Chenauthor=X.+Yangauthor=D.+Maauthor=J.+Zhouauthor=G.+Chen&title=miR-9+regulation+of+BRCA1+and+ovarian+cancer+sensitivity+to+cisplatin+and+PARP+inhibition&doi=10.1093%2Fjnci%2Fdjt302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition</span></div><div class="casAuthors">Sun, Chaoyang; Li, Na; Yang, Zongyuan; Zhou, Bo; He, Yang; Weng, Danhui; Fang, Yong; Wu, Peng; Chen, Pingbo; Yang, Xiaokui; Ma, Ding; Zhou, Jianfeng; Chen, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1750-1758</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Expression of BRCA1 is commonly decreased in sporadic ovarian cancer, and this is assocd. with platinum sensitivity and favorable prognosis.  However, multiple mechanisms underlying low BRCA1 expression are not fully understood.  Methods A bioinformatics-driven microRNA (miR) library screening was used to identify miRs that regulate BRCA1 expression.  The effects of miR-9 on cisplatin (cDDP) and PARP inhibitor sensitivity were measured in ovarian cancer cells and C13* xenograft mice (n = 6 per group).  The roles of miR-9 on prognosis were assessed in a cohort of ovarian cancer patients (n = 113) with Kaplan-Meier and Cox proportional hazards analyses.  All statistical tests were two-sided.  Reverse miR library screening revealed that miR-9 reduced the normalized luciferase activity to 60.3% (95% confidence interval [CI] = 52.0% to 68.5%; P < .001). miR-9 bound directly to the 3'-UTR of BRCA1 and downregulated BRCA1 expression in ovarian cancer cells.  Treatment with miR-9 agomiR sensitized BRCA1-proficient C13* xenograft tumors to cisplatin and AG014699.  In serous ovarian cancer, higher levels of miR-9 were inversely correlated with BRCA1 expression (Spearman rank correlation: R2 = 0.379; P = .003).  Patients with higher levels of miR-9 had better chemotherapy response, platinum sensitivity, and longer progression-free survival (PFS) (high vs low miR-9 expression: median PFS = 26.4 mo, 95% CI = 13.8 to 39.0 mo vs median PFS = 15.4 mo, 95% CI = 6.8 to 23.9 mo, P = .01).  MiR-9 mediates the downregulation of BRCA1 and impedes DNA damage repair in ovarian cancer. miR-9 may improve chemotherapeutic efficacy by increasing the sensitivity of cancer cells to DNA damage and may impact ovarian cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraG3mmr2R12rVg90H21EOLACvtfcHk0lg5BZZzkNab3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKgu7rF&md5=321ea02b70e81db1a5010c493f100ff0</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjt302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjt302%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DWeng%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26atitle%3DmiR-9%2520regulation%2520of%2520BRCA1%2520and%2520ovarian%2520cancer%2520sensitivity%2520to%2520cisplatin%2520and%2520PARP%2520inhibition%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2013%26volume%3D105%26spage%3D1750%26epage%3D1758%26doi%3D10.1093%2Fjnci%2Fdjt302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Esposito, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, C. W. E.</span><span> </span><span class="NLM_article-title">Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1481</span><span class="NLM_x">–</span> <span class="NLM_lpage">1490</span><span class="refDoi"> DOI: 10.1038/nm.3993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnm.3993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26594843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1481-1490&author=M.+T.+Espositoauthor=L.+Zhaoauthor=T.+K.+Fungauthor=J.+K.+Raneauthor=A.+Wilsonauthor=N.+Martinauthor=J.+Gilauthor=A.+Y.+Leungauthor=A.+Ashworthauthor=C.+W.+E.+So&title=Synthetic+lethal+targeting+of+oncogenic+transcription+factors+in+acute+leukemia+by+PARP+inhibitors&doi=10.1038%2Fnm.3993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors</span></div><div class="casAuthors">Esposito, Maria Teresa; Zhao, Lu; Fung, Tsz Kan; Rane, Jayant K.; Wilson, Amanda; Martin, Nadine; Gil, Jesus; Leung, Anskar Y.; Ashworth, Alan; Eric So, Chi Wai</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1481-1490</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is mostly driven by oncogenic transcription factors, which have been classically viewed as intractable targets using small-mol. inhibitor approaches.  Here we demonstrate that AML driven by repressive transcription factors, including AML1-ETO (encoded by the fusion oncogene RUNX1-RUNX1T1) and PML-RARα fusion oncoproteins (encoded by PML-RARA) are extremely sensitive to poly (ADP-ribose) polymerase (PARP) inhibition, in part owing to their suppressed expression of key homologous recombination (HR)-assocd. genes and their compromised DNA-damage response (DDR).  In contrast, leukemia driven by mixed-lineage leukemia (MLL, encoded by KMT2A) fusions with dominant transactivation ability is proficient in DDR and insensitive to PARP inhibition.  Intriguingly, genetic or pharmacol. inhibition of an MLL downstream target, HOXA9, which activates expression of various HR-assocd. genes, impairs DDR and sensitizes MLL leukemia to PARP inhibitors (PARPis).  Conversely, HOXA9 overexpression confers PARPi resistance to AML1-ETO and PML-RARα transformed cells.  Together, these studies describe a potential utility of PARPi-induced synthetic lethality for leukemia treatment and reveal a novel mol. mechanism governing PARPi sensitivity in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolE-gRQ6jVb7Vg90H21EOLACvtfcHk0lg5BZZzkNab3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtLbM&md5=3e69876e4110e9006d97673fb09e8e6d</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fnm.3993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3993%26sid%3Dliteratum%253Aachs%26aulast%3DEsposito%26aufirst%3DM.%2BT.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DFung%26aufirst%3DT.%2BK.%26aulast%3DRane%26aufirst%3DJ.%2BK.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DGil%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DA.%2BY.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DSo%26aufirst%3DC.%2BW.%2BE.%26atitle%3DSynthetic%2520lethal%2520targeting%2520of%2520oncogenic%2520transcription%2520factors%2520in%2520acute%2520leukemia%2520by%2520PARP%2520inhibitors%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D1481%26epage%3D1490%26doi%3D10.1038%2Fnm.3993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Sun, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Q.</span><span> </span><span class="NLM_article-title">Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3375</span><span class="NLM_x">–</span> <span class="NLM_lpage">3385</span><span class="refDoi"> DOI: 10.18632/oncotarget.1952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.1952" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3375-3385&author=C.+K.+Sunauthor=F.+Zhangauthor=T.+Xiangauthor=Q.+Chenauthor=T.+K.+Panditaauthor=Y.+Huangauthor=M.+C.+Huauthor=Q.+Yang&title=Phosphorylation+of+ribosomal+protein+S6+confers+PARP+inhibitor+resistance+in+BRCA1-deficient+cancers&doi=10.18632%2Foncotarget.1952"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1952%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%2BK.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DXiang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DPandita%26aufirst%3DT.%2BK.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DM.%2BC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DPhosphorylation%2520of%2520ribosomal%2520protein%2520S6%2520confers%2520PARP%2520inhibitor%2520resistance%2520in%2520BRCA1-deficient%2520cancers%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D3375%26epage%3D3385%26doi%3D10.18632%2Foncotarget.1952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Volinia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sana, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palatini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huebner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croce, C. M.</span><span> </span><span class="NLM_article-title">Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">3024</span><span class="NLM_x">–</span> <span class="NLM_lpage">3029</span><span class="refDoi"> DOI: 10.1073/pnas.1200010109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1073%2Fpnas.1200010109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22315424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=3024-3029&author=S.+Voliniaauthor=M.+Galassoauthor=M.+E.+Sanaauthor=T.+F.+Wiseauthor=J.+Palatiniauthor=K.+Huebnerauthor=C.+M.+Croce&title=Breast+cancer+signatures+for+invasiveness+and+prognosis+defined+by+deep+sequencing+of+microRNA&doi=10.1073%2Fpnas.1200010109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA</span></div><div class="casAuthors">Volinia, Stefano; Galasso, Marco; Sana, Maria Elena; Wise, Timothy F.; Palatini, Jeff; Huebner, Kay; Croce, Carlo M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3024-3029, S3024/1-S3024/12</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The transition from ductal carcinoma in situ to invasive ductal carcinoma is a key event in breast cancer progression that is still not well understood.  To discover the microRNAs regulating this crit. transition, we used 80 biopsies from invasive ductal carcinoma, 8 from ductal carcinoma in situ, and 6 from normal breast.  We selected them from a recently published deep-sequencing dataset.  The microRNA profile established for the normal breast to ductal carcinoma in situ transition was largely maintained in the in situ to invasive ductal carcinoma transition.  Nevertheless, a nine-micro-RNA signature was identified that differentiated invasive from in situ carcinoma.  Specifically, let-7d, miR-210, and -221 were down-regulated in the in situ and up-regulated in the invasive transition, thus featuring an expression reversal along the cancer progression path.  Addnl., we identified microRNAs for overall survival and time to metastasis.  Five noncoding genes were assocd. with both prognostic signatures - miR-210, -21, -106b*, -197, and let-7i, with miR-210 the only one also involved in the invasive transition.  To pinpoint crit. cellular functions affected in the invasive transition, we identified the protein coding genes with inversely related profiles to miR-210: BRCA1, FANCD, FANCF, PARP1, E-cadherin, and Rb1 were all activated in the in situ and down-regulated in the invasive carcinoma.  Addnl., we detected differential splicing isoforms with special features, including a truncated EGFR lacking the kinase domain and overexpressed only in ductal carcinoma in situ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdk7DF5YMwyLVg90H21EOLACvtfcHk0lg5BZZzkNab3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wmt7s%253D&md5=d25f1754fe2c3f5ab2da6337cd452c3e</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1200010109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1200010109%26sid%3Dliteratum%253Aachs%26aulast%3DVolinia%26aufirst%3DS.%26aulast%3DGalasso%26aufirst%3DM.%26aulast%3DSana%26aufirst%3DM.%2BE.%26aulast%3DWise%26aufirst%3DT.%2BF.%26aulast%3DPalatini%26aufirst%3DJ.%26aulast%3DHuebner%26aufirst%3DK.%26aulast%3DCroce%26aufirst%3DC.%2BM.%26atitle%3DBreast%2520cancer%2520signatures%2520for%2520invasiveness%2520and%2520prognosis%2520defined%2520by%2520deep%2520sequencing%2520of%2520microRNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D3024%26epage%3D3029%26doi%3D10.1073%2Fpnas.1200010109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Pettitt, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehman, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajrami, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarewa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenwick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assiotis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">A genetic screen using the PiggyBac transposon in haploid cells identifies PARP1 as a mediator of olaparib toxicity</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e61520</span><span class="refDoi"> DOI: 10.1371/journal.pone.0061520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1371%2Fjournal.pone.0061520" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e61520&author=S.+J.+Pettittauthor=F.+L.+Rehmanauthor=I.+Bajramiauthor=R.+Broughauthor=F.+Wallbergauthor=I.+Kozarewaauthor=K.+Fenwickauthor=I.+Assiotisauthor=L.+Chenauthor=J.+Campbellauthor=C.+J.+Lordauthor=A.+Ashworth&title=A+genetic+screen+using+the+PiggyBac+transposon+in+haploid+cells+identifies+PARP1+as+a+mediator+of+olaparib+toxicity&doi=10.1371%2Fjournal.pone.0061520"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0061520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0061520%26sid%3Dliteratum%253Aachs%26aulast%3DPettitt%26aufirst%3DS.%2BJ.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DWallberg%26aufirst%3DF.%26aulast%3DKozarewa%26aufirst%3DI.%26aulast%3DFenwick%26aufirst%3DK.%26aulast%3DAssiotis%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DA%2520genetic%2520screen%2520using%2520the%2520PiggyBac%2520transposon%2520in%2520haploid%2520cells%2520identifies%2520PARP1%2520as%2520a%2520mediator%2520of%2520olaparib%2520toxicity%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De61520%26doi%3D10.1371%2Fjournal.pone.0061520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Lawlor, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busschots, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Leary, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennessy, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stordal, B.</span><span> </span><span class="NLM_article-title">PARP inhibitors as P-glyoprotein substrates</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">1913</span><span class="NLM_x">–</span> <span class="NLM_lpage">1920</span><span class="refDoi"> DOI: 10.1002/jps.23952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1002%2Fjps.23952" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2014&pages=1913-1920&author=D.+Lawlorauthor=P.+Martinauthor=S.+Busschotsauthor=J.+Theryauthor=J.+J.+O%E2%80%99Learyauthor=B.+T.+Hennessyauthor=B.+Stordal&title=PARP+inhibitors+as+P-glyoprotein+substrates&doi=10.1002%2Fjps.23952"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fjps.23952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23952%26sid%3Dliteratum%253Aachs%26aulast%3DLawlor%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DBusschots%26aufirst%3DS.%26aulast%3DThery%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DJ.%2BJ.%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DStordal%26aufirst%3DB.%26atitle%3DPARP%2520inhibitors%2520as%2520P-glyoprotein%2520substrates%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D103%26spage%3D1913%26epage%3D1920%26doi%3D10.1002%2Fjps.23952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Henneman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Miltenburg, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braumuller, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drenth, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Korte-Grimmerink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogola, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szuhai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlicker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bin Ali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huijbers, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berns, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">8409</span><span class="NLM_x">–</span> <span class="NLM_lpage">8414</span><span class="refDoi"> DOI: 10.1073/pnas.1500223112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1073%2Fpnas.1500223112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=8409-8414&author=L.+Hennemanauthor=M.+H.+van+Miltenburgauthor=E.+M.+Michalakauthor=T.+M.+Braumullerauthor=J.+E.+Jaspersauthor=A.+P.+Drenthauthor=R.+de+Korte-Grimmerinkauthor=E.+Gogolaauthor=K.+Szuhaiauthor=A.+Schlickerauthor=R.+Bin+Aliauthor=C.+Pritchardauthor=I.+J.+Huijbersauthor=A.+Bernsauthor=S.+Rottenbergauthor=J.+Jonkers&title=Selective+resistance+to+the+PARP+inhibitor+olaparib+in+a+mouse+model+for+BRCA1-deficient+metaplastic+breast+cancer&doi=10.1073%2Fpnas.1500223112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1500223112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1500223112%26sid%3Dliteratum%253Aachs%26aulast%3DHenneman%26aufirst%3DL.%26aulast%3Dvan%2BMiltenburg%26aufirst%3DM.%2BH.%26aulast%3DMichalak%26aufirst%3DE.%2BM.%26aulast%3DBraumuller%26aufirst%3DT.%2BM.%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DDrenth%26aufirst%3DA.%2BP.%26aulast%3Dde%2BKorte-Grimmerink%26aufirst%3DR.%26aulast%3DGogola%26aufirst%3DE.%26aulast%3DSzuhai%26aufirst%3DK.%26aulast%3DSchlicker%26aufirst%3DA.%26aulast%3DBin%2BAli%26aufirst%3DR.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DHuijbers%26aufirst%3DI.%2BJ.%26aulast%3DBerns%26aufirst%3DA.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DSelective%2520resistance%2520to%2520the%2520PARP%2520inhibitor%2520olaparib%2520in%2520a%2520mouse%2520model%2520for%2520BRCA1-deficient%2520metaplastic%2520breast%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D8409%26epage%3D8414%26doi%3D10.1073%2Fpnas.1500223112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sol, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersbergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlicker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guyader, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessels, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, S.</span><span> </span><span class="NLM_article-title">BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">732</span><span class="NLM_x">–</span> <span class="NLM_lpage">741</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F0008-5472.CAN-14-0839" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=732-741&author=J.+E.+Jaspersauthor=W.+Solauthor=A.+Kersbergenauthor=A.+Schlickerauthor=C.+Guyaderauthor=G.+Xuauthor=L.+Wesselsauthor=P.+Borstauthor=J.+Jonkersauthor=S.+Rottenberg&title=BRCA2-deficient+sarcomatoid+mammary+tumors+exhibit+multidrug+resistance&doi=10.1158%2F0008-5472.CAN-14-0839"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0839%26sid%3Dliteratum%253Aachs%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DSol%26aufirst%3DW.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3DSchlicker%26aufirst%3DA.%26aulast%3DGuyader%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DWessels%26aufirst%3DL.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DRottenberg%26aufirst%3DS.%26atitle%3DBRCA2-deficient%2520sarcomatoid%2520mammary%2520tumors%2520exhibit%2520multidrug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D732%26epage%3D741%26doi%3D10.1158%2F0008-5472.CAN-14-0839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Dufour, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daumar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mounetou, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwiatkowski, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrial, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vatoux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penault-Llorca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamdad, M.</span><span> </span><span class="NLM_article-title">BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">12670</span><span class="refDoi"> DOI: 10.1038/srep12670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fsrep12670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26234720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKiurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=12670&author=R.+Dufourauthor=P.+Daumarauthor=E.+Mounetouauthor=C.+Aubelauthor=F.+Kwiatkowskiauthor=C.+Abrialauthor=C.+Vatouxauthor=F.+Penault-Llorcaauthor=M.+Bamdad&title=BCRP+and+P-gp+relay+overexpression+in+triple+negative+basal-like+breast+cancer+cell+line%3A+a+prospective+role+in+resistance+to+Olaparib&doi=10.1038%2Fsrep12670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib</span></div><div class="casAuthors">Dufour, Robin; Daumar, Pierre; Mounetou, Emmanuelle; Aubel, Corinne; Kwiatkowski, Fabrice; Abrial, Catherine; Vatoux, Catherine; Penault-Llorca, Frederique; Bamdad, Mahchid</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12670</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The triple neg. basal-like (TNBL) breast carcinoma is an aggressive and unfavorable prognosis disease.  Inhibitors of poly(ADP-ribose) polymerase such as Olaparib could represent a promising targeted therapy but their sensitivity against Multidrug Resistance proteins (MDR), which causes resistance, is not well defined.  Thus, our work focused on the anal. of P-gp and BCRP coexpression in the SUM1315 TNBL human cell line, in correlation with Olaparib intracellular concn.  Western blot analyses showed a clear coexpression of P-gp and BCRP in SUM1315 cells.  A low cytotoxic Olaparib treatment clearly led to an increased expression of both BCRP and P-gp in these cells.  Indeed, after 1.5 h of treatment, BCRP expression was increased with a 1.8 fold increase rate.  Then, P-gp took over from 3 h to 15 h with an av. increase rate of 1.8 fold, and finally returned to control value at 24 h.  HPLC-UV analyses showed that, in the same treatment conditions, the intracellular Olaparib concn. increased from 1 h to 3 h and remained relatively stable until 24 h.  Results suggest that the resistance mechanism induced by Olaparib in TNBL SUM1315 cell line may be overpassed if a cytotoxic and stable intracellular level of the drug can be maintained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX2PmpeqODKrVg90H21EOLACvtfcHk0lhD4ec75F3JyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKiurzI&md5=0b52863324c3544a33964b8bd2edc634</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1038%2Fsrep12670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep12670%26sid%3Dliteratum%253Aachs%26aulast%3DDufour%26aufirst%3DR.%26aulast%3DDaumar%26aufirst%3DP.%26aulast%3DMounetou%26aufirst%3DE.%26aulast%3DAubel%26aufirst%3DC.%26aulast%3DKwiatkowski%26aufirst%3DF.%26aulast%3DAbrial%26aufirst%3DC.%26aulast%3DVatoux%26aufirst%3DC.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DBamdad%26aufirst%3DM.%26atitle%3DBCRP%2520and%2520P-gp%2520relay%2520overexpression%2520in%2520triple%2520negative%2520basal-like%2520breast%2520cancer%2520cell%2520line%253A%2520a%2520prospective%2520role%2520in%2520resistance%2520to%2520Olaparib%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D12670%26doi%3D10.1038%2Fsrep12670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Nakagawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sedukhina, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche-Molina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narváez, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyasekharan, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernal, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span> </span><span class="NLM_article-title">NF-κB signaling mediates acquired resistance after PARP inhibition</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3825</span><span class="NLM_x">–</span> <span class="NLM_lpage">3839</span><span class="refDoi"> DOI: 10.18632/oncotarget.2868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.18632%2Foncotarget.2868" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=3825-3839&author=Y.+Nakagawaauthor=A.+S.+Sedukhinaauthor=N.+Okamotoauthor=S.+Nagasawaauthor=N.+Suzukiauthor=T.+Ohtaauthor=H.+Hattoriauthor=M.+Roche-Molinaauthor=A.+J.+Narv%C3%A1ezauthor=A.+D.+Jeyasekharanauthor=J.+A.+Bernalauthor=K.+Sato&title=NF-%CE%BAB+signaling+mediates+acquired+resistance+after+PARP+inhibition&doi=10.18632%2Foncotarget.2868"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2868%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DY.%26aulast%3DSedukhina%26aufirst%3DA.%2BS.%26aulast%3DOkamoto%26aufirst%3DN.%26aulast%3DNagasawa%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DOhta%26aufirst%3DT.%26aulast%3DHattori%26aufirst%3DH.%26aulast%3DRoche-Molina%26aufirst%3DM.%26aulast%3DNarv%25C3%25A1ez%26aufirst%3DA.%2BJ.%26aulast%3DJeyasekharan%26aufirst%3DA.%2BD.%26aulast%3DBernal%26aufirst%3DJ.%2BA.%26aulast%3DSato%26aufirst%3DK.%26atitle%3DNF-%25CE%25BAB%2520signaling%2520mediates%2520acquired%2520resistance%2520after%2520PARP%2520inhibition%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D3825%26epage%3D3839%26doi%3D10.18632%2Foncotarget.2868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Ruf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, G. E.</span><span> </span><span class="NLM_article-title">Inhibitor and NAD<sup>+</sup> binding to poly (ADP-ribose) polymerase as derived from crystal structures and homology modeling</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">3893</span><span class="NLM_x">–</span> <span class="NLM_lpage">3900</span><span class="refDoi"> DOI: 10.1021/bi972383s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi972383s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=3893-3900&author=A.+Rufauthor=G.+de+Murciaauthor=G.+E.+Schulz&title=Inhibitor+and+NAD%2B+binding+to+poly+%28ADP-ribose%29+polymerase+as+derived+from+crystal+structures+and+homology+modeling&doi=10.1021%2Fbi972383s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fbi972383s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi972383s%26sid%3Dliteratum%253Aachs%26aulast%3DRuf%26aufirst%3DA.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26aulast%3DSchulz%26aufirst%3DG.%2BE.%26atitle%3DInhibitor%2520and%2520NAD%252B%2520binding%2520to%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520as%2520derived%2520from%2520crystal%2520structures%2520and%2520homology%2520modeling%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D3893%26epage%3D3900%26doi%3D10.1021%2Fbi972383s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Banasik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span> </span><span class="NLM_article-title">Specific inhibitors of poly (ADP-ribose) synthetase and mono (ADP-ribosyl) transferase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">1569</span><span class="NLM_x">–</span> <span class="NLM_lpage">1575</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=1569-1575&author=M.+Banasikauthor=H.+Komuraauthor=M.+Shimoyamaauthor=K.+Ueda&title=Specific+inhibitors+of+poly+%28ADP-ribose%29+synthetase+and+mono+%28ADP-ribosyl%29+transferase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBanasik%26aufirst%3DM.%26aulast%3DKomura%26aufirst%3DH.%26aulast%3DShimoyama%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DK.%26atitle%3DSpecific%2520inhibitors%2520of%2520poly%2520%2528ADP-ribose%2529%2520synthetase%2520and%2520mono%2520%2528ADP-ribosyl%2529%2520transferase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D1569%26epage%3D1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">5-Aminoisoquinolin-1-one (5-AIQ), a water-soluble inhibitor of the poly(ADP-ribose)polymerases (PARPs)</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3807</span><span class="NLM_x">–</span> <span class="NLM_lpage">3829</span><span class="refDoi"> DOI: 10.2174/0929867322666151002110602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.2174%2F0929867322666151002110602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26429070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=3807-3829&author=M.+D.+Threadgill&title=5-Aminoisoquinolin-1-one+%285-AIQ%29%2C+a+water-soluble+inhibitor+of+the+poly%28ADP-ribose%29polymerases+%28PARPs%29&doi=10.2174%2F0929867322666151002110602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)</span></div><div class="casAuthors">Threadgill, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3807-3829</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  5-Aminoisoquinolin-1-one (5-AIQ) is a water-sol. inhibitor of the poly(ADPribose) polymerases (PARPs), lacking isoform-selectivity.  Although of only moderate potency in vitro against PARP-1, it is highly active in many assays in cells and in models in vivo, indicating excellent uptake.  Optimization of the several synthetic sequences to 5-AIQ has led to development of a short and efficient route from 1-chloroisoquinoline.  It has been used widely as a biochem. and pharmacol. tool to study the effects of inhibition of the PARPs.  It ameliorates the damage to cells and tissues following reperfusion of ischemic tissue, showing significant protective activity in a rodent model of haemorrhagic shock at the remarkably low dose of 30 μg Kg-1.  Protection is also seen in models of myocardial infarction, ischemic kidney and liver disorders, stroke and organ transplantation.  Inhibition of PARP-1 by 5-AIQ causes down-regulation of the activity of NF-κB, which then down-regulates the expression of several gene products.  Thus 5-AIQ has anti-inflammatory activity in vivo, through modulating the expression of cytokines and adhesion mols.  This indirect inhibition of expression is relevant in the activity of 5-AIQ in models of arthritis, Parkinson's disease, multiple sclerosis, spinal cord injury, periodontitis and inflammatory conditions of the lung.  Inhibition of expression of matrix metalloproteinases and other factors gives rise to anti-angiogenic activity and to remarkable anti-metastatic activity in a mouse model.  Thus, although it has been overtaken by other PARP-inhibiting drugs in the oncol. clinic, 5-AIQ remains a valuable tool to study the roles of PARPs in health and in diverse diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Pd2dtXXqI7Vg90H21EOLACvtfcHk0lju2_YmjHS9Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsbnP&md5=bcc39758198f7944fb6707f5d0e68291</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.2174%2F0929867322666151002110602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666151002110602%26sid%3Dliteratum%253Aachs%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3D5-Aminoisoquinolin-1-one%2520%25285-AIQ%2529%252C%2520a%2520water-soluble%2520inhibitor%2520of%2520the%2520poly%2528ADP-ribose%2529polymerases%2520%2528PARPs%2529%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D3807%26epage%3D3829%26doi%3D10.2174%2F0929867322666151002110602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Rottenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaspers, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersbergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Burg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nygren, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derksen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bruin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zevenhoven, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">17079</span><span class="NLM_x">–</span> <span class="NLM_lpage">17084</span><span class="refDoi"> DOI: 10.1073/pnas.0806092105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1073%2Fpnas.0806092105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=18971340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=17079-17084&author=S.+Rottenbergauthor=J.+E.+Jaspersauthor=A.+Kersbergenauthor=E.+van+der+Burgauthor=A.+O.+Nygrenauthor=S.+A.+Zanderauthor=P.+W.+Derksenauthor=M.+de+Bruinauthor=J.+Zevenhovenauthor=A.+Lauauthor=R.+Boulterauthor=A.+Cranstonauthor=M.+J.+O%E2%80%99Connorauthor=N.+M.+Martinauthor=P.+Borstauthor=J.+Jonkers&title=High+sensitivity+of+BRCA1-deficient+mammary+tumors+to+the+PARP+inhibitor+AZD2281+alone+and+in+combination+with+platinum+drugs&doi=10.1073%2Fpnas.0806092105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span></div><div class="casAuthors">Rottenberg, Sven; Jaspers, Janneke E.; Kersbergen, Ariena; van der Burg, Eline; Nygren, Anders O. H.; Zander, Serge A. L.; Derksen, Patrick W. B.; de Bruin, Michiel; Zevenhoven, John; Lau, Alan; Boulter, Robert; Cranston, Aaron; O'Connor, Mark J.; Martin, Niall M. B.; Borst, Piet; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17079-17084</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone receptor-pos. breast cancers, no tailored therapy exists for hormone receptor- and ERBB2-neg. ("triple-neg.") mammary carcinomas.  Triple-neg. tumors account for 15% of all breast cancers and frequently harbor defects in DNA double-strand break repair through homologous recombination (HR), such as BRCA1 dysfunction.  The DNA-repair defects characteristic of BRCA1-deficient cells confer sensitivity to poly(ADP-ribose) polymerase 1 (PARP1) inhibition, which could be relevant to treatment of triple-neg. tumors.  To evaluate PARP1 inhibition in a realistic in vivo setting, we tested the PARP inhibitor AZD2281 in a genetically engineered mouse model (GEMM) for BRCA1-assocd. breast cancer.  Treatment of tumor-bearing mice with AZD2281 inhibited tumor growth without signs of toxicity, resulting in strongly increased survival.  Long-term treatment with AZD2281 in this model did result in the development of drug resistance, caused by up-regulation of Abcb1a/b genes encoding P-glycoprotein efflux pumps.  This resistance to AZD2281 could be reversed by coadministration of the P-glycoprotein inhibitor tariquidar.  Combination of AZD2281 with cisplatin or carboplatin increased the recurrence-free and overall survival, suggesting that AZD2281 potentiates the effect of these DNA-damaging agents.  Our results demonstrate in vivo efficacy of AZD2281 against BRCA1-deficient breast cancer and illustrate how GEMMs of cancer can be used for preclin. evaluation of novel therapeutics and for testing ways to overcome or circumvent therapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr95zB9OKZ4ObVg90H21EOLACvtfcHk0lgAi2w1SPFltg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F&md5=788a7d8b5341b731d007753d5a234dec</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0806092105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0806092105%26sid%3Dliteratum%253Aachs%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BBurg%26aufirst%3DE.%26aulast%3DNygren%26aufirst%3DA.%2BO.%26aulast%3DZander%26aufirst%3DS.%2BA.%26aulast%3DDerksen%26aufirst%3DP.%2BW.%26aulast%3Dde%2BBruin%26aufirst%3DM.%26aulast%3DZevenhoven%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DHigh%2520sensitivity%2520of%2520BRCA1-deficient%2520mammary%2520tumors%2520to%2520the%2520PARP%2520inhibitor%2520AZD2281%2520alone%2520and%2520in%2520combination%2520with%2520platinum%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D17079%26epage%3D17084%26doi%3D10.1073%2Fpnas.0806092105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Johannes, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almeida, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosskurth, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmirski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikule, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogoe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petteruti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylvester, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Throner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. A.</span><span> </span><span class="NLM_article-title">Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5743</span><span class="NLM_x">–</span> <span class="NLM_lpage">5747</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2015.10.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=26546219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyhsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5743-5747&author=J.+W.+Johannesauthor=L.+Almeidaauthor=K.+Dalyauthor=A.+D.+Fergusonauthor=S.+E.+Grosskurthauthor=H.+Guanauthor=T.+Howardauthor=S.+Ioannidisauthor=S.+Kazmirskiauthor=M.+L.+Lambauthor=N.+A.+Larsenauthor=P.+D.+Lyneauthor=K.+Mikuleauthor=C.+Ogoeauthor=B.+Pengauthor=P.+Petterutiauthor=J.+A.+Readauthor=N.+Suauthor=M.+Sylvesterauthor=S.+Thronerauthor=W.+Wangauthor=X.+Wangauthor=J.+Wuauthor=Q.+Yeauthor=Y.+Yuauthor=X.+Zhengauthor=D.+A.+Scott&title=Discovery+of+AZ0108%2C+an+orally+bioavailable+phthalazinone+PARP+inhibitor+that+blocks+centrosome+clustering&doi=10.1016%2Fj.bmcl.2015.10.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering</span></div><div class="casAuthors">Johannes, Jeffrey W.; Almeida, Lynsie; Daly, Kevin; Ferguson, Andrew D.; Grosskurth, Shaun E.; Guan, Huiping; Howard, Tina; Ioannidis, Stephanos; Kazmirski, Steven; Lamb, Michelle L.; Larsen, Nicholas A.; Lyne, Paul D.; Mikule, Keith; Ogoe, Claude; Peng, Bo; Petteruti, Philip; Read, Jon A.; Su, Nancy; Sylvester, Mark; Throner, Scott; Wang, Wenxian; Wang, Xin; Wu, Jiaquan; Ye, Qing; Yu, Yan; Zheng, Xiaolan; Scott, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5743-5747</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The propensity for cancer cells to accumulate addnl. centrosomes relative to normal cells could be exploited for therapeutic benefit in oncol.  Following literature reports that suggested TNKS1 (tankyrase 1) and PARP16 may be involved with spindle structure and function and may play a role in suppressing multipolar spindle formation in cells with supernumerary centrosomes, the authors initiated a phenotypic screen to look for small mol. poly (ADP-ribose) polymerase (PARP) enzyme family inhibitors that could produce a multipolar spindle phenotype via declustering of centrosomes.  Screening of AstraZeneca's collection of phthalazinone PARP inhibitors in HeLa cells using high-content screening techniques identified several compds. that produced a multipolar spindle phenotype at low nanomolar concns.  Characterization of these compds. across a broad panel of PARP family enzyme assays indicated that they had activity against several PARP family enzymes, including PARP1, 2, 3, 5a, 5b, and 6.  Further optimization of these initial hits for improved declustering potency, soly., permeability, and oral bioavailability resulted in AZ0108, a PARP1, 2, 6 inhibitor that potently inhibits centrosome clustering and is suitable for in vivo efficacy and tolerability studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzV-IqZ8iBJ7Vg90H21EOLACvtfcHk0lgAi2w1SPFltg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyhsbjL&md5=68fda93959cd69be615a864248b07533</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.079%26sid%3Dliteratum%253Aachs%26aulast%3DJohannes%26aufirst%3DJ.%2BW.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DDaly%26aufirst%3DK.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGrosskurth%26aufirst%3DS.%2BE.%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DKazmirski%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DLarsen%26aufirst%3DN.%2BA.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DMikule%26aufirst%3DK.%26aulast%3DOgoe%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DPetteruti%26aufirst%3DP.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DSu%26aufirst%3DN.%26aulast%3DSylvester%26aufirst%3DM.%26aulast%3DThroner%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DScott%26aufirst%3DD.%2BA.%26atitle%3DDiscovery%2520of%2520AZ0108%252C%2520an%2520orally%2520bioavailable%2520phthalazinone%2520PARP%2520inhibitor%2520that%2520blocks%2520centrosome%2520clustering%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5743%26epage%3D5747%26doi%3D10.1016%2Fj.bmcl.2015.10.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Pescatore, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bufi, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muraglia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orvieto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span> </span><span class="NLM_article-title">Identification and SAR of novel pyrrolo [1,2-a]pyrazin-1 (2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1094</span><span class="NLM_x">–</span> <span class="NLM_lpage">1099</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2009.12.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1094-1099&author=G.+Pescatoreauthor=D.+Brancaauthor=F.+Fioreauthor=O.+Kinzelauthor=L.+L.+Bufiauthor=E.+Muragliaauthor=F.+Orvietoauthor=M.+Rowleyauthor=C.+Toniattiauthor=C.+Torrisiauthor=P.+Jones&title=Identification+and+SAR+of+novel+pyrrolo+%5B1%2C2-a%5Dpyrazin-1+%282H%29-one+derivatives+as+inhibitors+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29&doi=10.1016%2Fj.bmcl.2009.12.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DPescatore%26aufirst%3DG.%26aulast%3DBranca%26aufirst%3DD.%26aulast%3DFiore%26aufirst%3DF.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DBufi%26aufirst%3DL.%2BL.%26aulast%3DMuraglia%26aufirst%3DE.%26aulast%3DOrvieto%26aufirst%3DF.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DTorrisi%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26atitle%3DIdentification%2520and%2520SAR%2520of%2520novel%2520pyrrolo%2520%255B1%252C2-a%255Dpyrazin-1%2520%25282H%2529-one%2520derivatives%2520as%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1094%26epage%3D1099%26doi%3D10.1016%2Fj.bmcl.2009.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Ferrigno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bufi, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muraglia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span> </span><span class="NLM_article-title">Development of substituted 6-[4-fluoro-3- (piperazin-1-ylcarbonyl) benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose)polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">1105</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.11.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2009.11.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1100-1105&author=F.+Ferrignoauthor=D.+Brancaauthor=O.+Kinzelauthor=S.+Lilliniauthor=L.+L.+Bufiauthor=E.+Monteagudoauthor=E.+Muragliaauthor=M.+Rowleyauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=C.+Torrisiauthor=P.+Jones&title=Development+of+substituted+6-%5B4-fluoro-3-+%28piperazin-1-ylcarbonyl%29+benzyl%5D-4%2C5-dimethylpyridazin-3%282H%29-ones+as+potent+poly%28ADP%E2%80%93ribose%29polymerase-1+%28PARP-1%29+inhibitors+active+in+BRCA+deficient+cells&doi=10.1016%2Fj.bmcl.2009.11.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.087%26sid%3Dliteratum%253Aachs%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DBranca%26aufirst%3DD.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DLillini%26aufirst%3DS.%26aulast%3DBufi%26aufirst%3DL.%2BL.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DMuraglia%26aufirst%3DE.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DTorrisi%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520substituted%25206-%255B4-fluoro-3-%2520%2528piperazin-1-ylcarbonyl%2529%2520benzyl%255D-4%252C5-dimethylpyridazin-3%25282H%2529-ones%2520as%2520potent%2520poly%2528ADP%25E2%2580%2593ribose%2529polymerase-1%2520%2528PARP-1%2529%2520inhibitors%2520active%2520in%2520BRCA%2520deficient%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1100%26epage%3D1105%26doi%3D10.1016%2Fj.bmcl.2009.11.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span> </span><span class="NLM_article-title">Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4635</span><span class="NLM_x">–</span> <span class="NLM_lpage">4645</span><span class="refDoi"> DOI: 10.1016/j.bmc.2012.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmc.2012.06.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4635-4645&author=G.+D.+Zhuauthor=J.+Gongauthor=V.+B.+Gandhiauthor=X.+Liuauthor=Y.+Shiauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=P.+A.+Ellisauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=C.+Parkauthor=Y.+Luoauthor=A.+Shoemakerauthor=V.+L.+Girandaauthor=T.+D.+Penning&title=Discovery+and+SAR+of+orally+efficacious+tetrahydropyridopyridazinone+PARP+inhibitors+for+the+treatment+of+cancer&doi=10.1016%2Fj.bmc.2012.06.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DShoemaker%26aufirst%3DA.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520orally%2520efficacious%2520tetrahydropyridopyridazinone%2520PARP%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D4635%26epage%3D4645%26doi%3D10.1016%2Fj.bmc.2012.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Wang, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1- ones as potent PARP-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3739</span><span class="NLM_x">–</span> <span class="NLM_lpage">3743</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2014.07.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3739-3743&author=L.+X.+Wangauthor=X.+B.+Zhouauthor=M.+L.+Xiaoauthor=N.+Jiangauthor=F.+Liuauthor=W.+X.+Zhouauthor=X.+K.+Wangauthor=Z.+B.+Zhengauthor=S.+Li&title=Synthesis+and+biological+evaluation+of+substituted+4-%28thiophen-2-ylmethyl%29-2H-phthalazin-1-+ones+as+potent+PARP-1+inhibitors&doi=10.1016%2Fj.bmcl.2014.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%2BX.%26aulast%3DZhou%26aufirst%3DX.%2BB.%26aulast%3DXiao%26aufirst%3DM.%2BL.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DW.%2BX.%26aulast%3DWang%26aufirst%3DX.%2BK.%26aulast%3DZheng%26aufirst%3DZ.%2BB.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520substituted%25204-%2528thiophen-2-ylmethyl%2529-2H-phthalazin-1-%2520ones%2520as%2520potent%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3739%26epage%3D3743%26doi%3D10.1016%2Fj.bmcl.2014.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Lapidus, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoover, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">PARP inhibitors enhance the effect of cisplatin against tumors and ameliorate cisplatin-induced neuropathy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=2141&author=R.+G.+Lapidusauthor=W.+Xuauthor=E.+Spicerauthor=R.+Hooverauthor=J.+Zhang&title=PARP+inhibitors+enhance+the+effect+of+cisplatin+against+tumors+and+ameliorate+cisplatin-induced+neuropathy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DSpicer%26aufirst%3DE.%26aulast%3DHoover%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPARP%2520inhibitors%2520enhance%2520the%2520effect%2520of%2520cisplatin%2520against%2520tumors%2520and%2520ameliorate%2520cisplatin-induced%2520neuropathy%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D2141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Mita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarantopoulos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kueber, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGonigle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrada, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachdev, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, J. J.,  Jr</span><span> </span><span class="NLM_article-title">Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly (ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with Temozolomide (TMZ) in patients with advanced solid tumors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">11 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">B185</span><span class="refDoi"> DOI: 10.1158/1535-7163.TARG-11-B185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.TARG-11-B185" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=B185&issue=11+suppl&author=A.+Mitaauthor=M.+Mitaauthor=J.+Sarantopoulosauthor=J.+C.+Martinauthor=J.+D.+Kueberauthor=S.+McGonigleauthor=M.+Matijevicauthor=B.+Mistryauthor=J.+L.+Ferradaauthor=P.+Sachdevauthor=J.+J.+Stephenson&title=Phase+I+study+of+the+safety%2C+pharmacokinetics+%28PK%29%2C+and+pharmacodynamics+%28PD%29+of+the+poly+%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+E7016+in+combination+with+Temozolomide+%28TMZ%29+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1535-7163.TARG-11-B185"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-11-B185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-11-B185%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DA.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DSarantopoulos%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DJ.%2BC.%26aulast%3DKueber%26aufirst%3DJ.%2BD.%26aulast%3DMcGonigle%26aufirst%3DS.%26aulast%3DMatijevic%26aufirst%3DM.%26aulast%3DMistry%26aufirst%3DB.%26aulast%3DFerrada%26aufirst%3DJ.%2BL.%26aulast%3DSachdev%26aufirst%3DP.%26aulast%3DStephenson%26aufirst%3DJ.%2BJ.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520safety%252C%2520pharmacokinetics%2520%2528PK%2529%252C%2520and%2520pharmacodynamics%2520%2528PD%2529%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520E7016%2520in%2520combination%2520with%2520Temozolomide%2520%2528TMZ%2529%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26issue%3D11%2520suppl%26spage%3DB185%26doi%3D10.1158%2F1535-7163.TARG-11-B185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of pyridazino [3, 4, 5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2340</span><span class="NLM_x">–</span> <span class="NLM_lpage">2344</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2015.04.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2340-2344&author=J.+Wangauthor=H.+Tanauthor=Q.+Sunauthor=Z.+Geauthor=X.+Wangauthor=Y.+Wangauthor=R.+Li&title=Design%2C+synthesis+and+biological+evaluation+of+pyridazino+%5B3%2C+4%2C+5-de%5Dquinazolin-3%282H%29-one+as+a+new+class+of+PARP-1+inhibitors&doi=10.1016%2Fj.bmcl.2015.04.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DGe%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520pyridazino%2520%255B3%252C%25204%252C%25205-de%255Dquinazolin-3%25282H%2529-one%2520as%2520a%2520new%2520class%2520of%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2340%26epage%3D2344%26doi%3D10.1016%2Fj.bmcl.2015.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardberg, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yip, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzpatrick, P. A.</span><span> </span><span class="NLM_article-title">Structural basis for the inhibition of poly (ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone</span> <span class="citation_source-journal">Acta Crystallogr., Sect. F: Struct. Biol. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1143</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span><span class="refDoi"> DOI: 10.1107/S2053230X14015088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1107%2FS2053230X14015088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25195882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2qt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=1143-1149&author=M.+Aoyagi-Scharberauthor=A.+S.+Gardbergauthor=B.+K.+Yipauthor=B.+Wangauthor=Y.+Shenauthor=P.+A.+Fitzpatrick&title=Structural+basis+for+the+inhibition+of+poly+%28ADP-ribose%29+polymerases+1+and+2+by+BMN+673%2C+a+potent+inhibitor+derived+from+dihydropyridophthalazinone&doi=10.1107%2FS2053230X14015088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone</span></div><div class="casAuthors">Aoyagi-Scharber, Mika; Gardberg, Anna S.; Yip, Bryan K.; Wang, Bing; Shen, Yuqiao; Fitzpatrick, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1143-1149</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerases 1 and 2 (PARP1 and PARP2), which are involved in DNA damage response, are targets of anticancer therapeutics.  BMN 673 is a novel PARP1/2 inhibitor with substantially increased PARP-mediated tumor cytotoxicity and is now in later-stage clin. development for BRCA-deficient breast cancers.  Here, in co-crystal structures, BMN 673 was anchored to the nicotinamide-binding pocket via an extensive network of H-bonding and π-stacking interactions, including those mediated by active site water mols.  The novel di-branched scaffold of BMN 673 extended the binding interactions toward the outer edges of the pocket, which exhibited the least sequence homol. among PARP enzymes.  The crystallog. structural analyses reported here therefore not only provide crit. insights into the mol. basis for the exceptionally high potency of the clin. development candidate BMN 673, but also new opportunities for increasing inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3neiOqbsUprVg90H21EOLACvtfcHk0li5tOT-d4GvoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2qt77I&md5=6d75628ad833fa618eac02e72f326666</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1107%2FS2053230X14015088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X14015088%26sid%3Dliteratum%253Aachs%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DGardberg%26aufirst%3DA.%2BS.%26aulast%3DYip%26aufirst%3DB.%2BK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DFitzpatrick%26aufirst%3DP.%2BA.%26atitle%3DStructural%2520basis%2520for%2520the%2520inhibition%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerases%25201%2520and%25202%2520by%2520BMN%2520673%252C%2520a%2520potent%2520inhibitor%2520derived%2520from%2520dihydropyridophthalazinone%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2014%26volume%3D70%26spage%3D1143%26epage%3D1149%26doi%3D10.1107%2FS2053230X14015088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span> </span><span class="NLM_article-title">Abstract B64: Structure and preclinical characterization of BMN 673, a potent and orally active PARP inhibitor as an anticancer agent</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">11 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">B64</span><span class="refDoi"> DOI: 10.1158/1535-7163.TARG-11-B64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1535-7163.TARG-11-B64" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=B64&issue=11+suppl&author=Y.+Shenauthor=Y.+Fengauthor=B.+Wangauthor=P.+Myersauthor=D.+Chuauthor=L.+E.+Post&title=Abstract+B64%3A+Structure+and+preclinical+characterization+of+BMN+673%2C+a+potent+and+orally+active+PARP+inhibitor+as+an+anticancer+agent&doi=10.1158%2F1535-7163.TARG-11-B64"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-11-B64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-11-B64%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DP.%26aulast%3DChu%26aufirst%3DD.%26aulast%3DPost%26aufirst%3DL.%2BE.%26atitle%3DAbstract%2520B64%253A%2520Structure%2520and%2520preclinical%2520characterization%2520of%2520BMN%2520673%252C%2520a%2520potent%2520and%2520orally%2520active%2520PARP%2520inhibitor%2520as%2520an%2520anticancer%2520agent%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26issue%3D11%2520suppl%26spage%3DB64%26doi%3D10.1158%2F1535-7163.TARG-11-B64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mina, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henshaw, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadha, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachdev, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jameson, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainberg, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R. K.</span><span> </span><span class="NLM_article-title">First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">2580</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=23733753" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=2580&issue=15+suppl&author=J.+S.+de+Bonoauthor=L.+A.+Minaauthor=M.+Gonzalezauthor=N.+J.+Curtinauthor=E.+Wangauthor=J.+W.+Henshawauthor=M.+Chadhaauthor=J.+C.+Sachdevauthor=D.+Mateiauthor=G.+S.+Jamesonauthor=M.+Ongauthor=B.+Basuauthor=Z.+A.+Wainbergauthor=L.+A.+Byersauthor=R.+Chughauthor=A.+Dorrauthor=S.+B.+Kayeauthor=R.+K.+Ramanathan&title=First-in-human+trial+of+novel+oral+PARP+inhibitor+BMN+673+in+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DMina%26aufirst%3DL.%2BA.%26aulast%3DGonzalez%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DHenshaw%26aufirst%3DJ.%2BW.%26aulast%3DChadha%26aufirst%3DM.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DJameson%26aufirst%3DG.%2BS.%26aulast%3DOng%26aufirst%3DM.%26aulast%3DBasu%26aufirst%3DB.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DDorr%26aufirst%3DA.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26atitle%3DFirst-in-human%2520trial%2520of%2520novel%2520oral%2520PARP%2520inhibitor%2520BMN%2520673%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D15%2520suppl%26spage%3D2580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Wainberg, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mina, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachsev, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matei, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheler, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henshaw, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">7522</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=7522&issue=15+suppl&author=Z.+Wainbergauthor=S.+Rafiiauthor=R.+Ramanathanauthor=L.+Minaauthor=L.+Byersauthor=R.+Chughauthor=J.+W.+Goldmanauthor=J.+C.+Sachsevauthor=D.+E.+Mateiauthor=J.+J.+Whelerauthor=J.+W.+Henshawauthor=C.+Zhangauthor=G.+Gallantauthor=J.+S.+de+Bono&title=Safety+and+antitumor+activity+of+the+PARP+inhibitor+BMN673+in+a+phase+1+trial+recruiting+metastatic+small-cell+lung+cancer+%28SCLC%29+and+germline+BRCA-mutation+carrier+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWainberg%26aufirst%3DZ.%26aulast%3DRafii%26aufirst%3DS.%26aulast%3DRamanathan%26aufirst%3DR.%26aulast%3DMina%26aufirst%3DL.%26aulast%3DByers%26aufirst%3DL.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DSachsev%26aufirst%3DJ.%2BC.%26aulast%3DMatei%26aufirst%3DD.%2BE.%26aulast%3DWheler%26aufirst%3DJ.%2BJ.%26aulast%3DHenshaw%26aufirst%3DJ.%2BW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGallant%26aufirst%3DG.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DSafety%2520and%2520antitumor%2520activity%2520of%2520the%2520PARP%2520inhibitor%2520BMN673%2520in%2520a%2520phase%25201%2520trial%2520recruiting%2520metastatic%2520small-cell%2520lung%2520cancer%2520%2528SCLC%2529%2520and%2520germline%2520BRCA-mutation%2520carrier%2520cancer%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3D15%2520suppl%26spage%3D7522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. H.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of tricyclic derivatives containing a non-aromatic amide as inhibitors of poly (ADP-ribose) polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2250</span><span class="NLM_x">–</span> <span class="NLM_lpage">2253</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2010.02.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2250-2253&author=C.+H.+Parkauthor=K.+Chunauthor=B.+Y.+Joeauthor=J.+S.+Parkauthor=Y.+C.+Kimauthor=J.+S.+Choiauthor=D.+K.+Ryuauthor=S.+H.+Kohauthor=G.+W.+Choauthor=S.+H.+Kimauthor=M.+H.+Kim&title=Synthesis+and+evaluation+of+tricyclic+derivatives+containing+a+non-aromatic+amide+as+inhibitors+of+poly+%28ADP-ribose%29+polymerase-1+%28PARP-1%29&doi=10.1016%2Fj.bmcl.2010.02.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DChun%26aufirst%3DK.%26aulast%3DJoe%26aufirst%3DB.%2BY.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DY.%2BC.%26aulast%3DChoi%26aufirst%3DJ.%2BS.%26aulast%3DRyu%26aufirst%3DD.%2BK.%26aulast%3DKoh%26aufirst%3DS.%2BH.%26aulast%3DCho%26aufirst%3DG.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DM.%2BH.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520tricyclic%2520derivatives%2520containing%2520a%2520non-aromatic%2520amide%2520as%2520inhibitors%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2250%26epage%3D2253%26doi%3D10.1016%2Fj.bmcl.2010.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Gangloff, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimshaw, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hixon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiryanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, P.</span><span> </span><span class="NLM_article-title">Discovery of novel benzo [b][1, 4] oxazin-3 (4H)-ones as poly (ADP-ribose) polymerase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4501</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2013.06.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4501-4505&author=A.+R.+Gangloffauthor=J.+Brownauthor=R.+de+Jongauthor=D.+R.+Douganauthor=C.+E.+Grimshawauthor=M.+Hixonauthor=A.+Jenningsauthor=R.+Kamranauthor=A.+Kiryanovauthor=S.+O%E2%80%99Connellauthor=E.+Taylorauthor=P.+Vu&title=Discovery+of+novel+benzo+%5Bb%5D%5B1%2C+4%5D+oxazin-3+%284H%29-ones+as+poly+%28ADP-ribose%29+polymerase+inhibitors&doi=10.1016%2Fj.bmcl.2013.06.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.055%26sid%3Dliteratum%253Aachs%26aulast%3DGangloff%26aufirst%3DA.%2BR.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3Dde%2BJong%26aufirst%3DR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DHixon%26aufirst%3DM.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DKamran%26aufirst%3DR.%26aulast%3DKiryanov%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DE.%26aulast%3DVu%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520novel%2520benzo%2520%255Bb%255D%255B1%252C%25204%255D%2520oxazin-3%2520%25284H%2529-ones%2520as%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4501%26epage%3D4505%26doi%3D10.1016%2Fj.bmcl.2013.06.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span> </span><span class="NLM_article-title">Synthesis of isoquinolinone-based tricycles as novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2669</span><span class="NLM_x">–</span> <span class="NLM_lpage">2673</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2014.04.061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2669-2673&author=J.+Chenauthor=H.+Pengauthor=J.+Heauthor=X.+Huanauthor=Z.+Miaoauthor=C.+Yang&title=Synthesis+of+isoquinolinone-based+tricycles+as+novel+poly+%28ADP-ribose%29+polymerase-1+%28PARP-1%29+inhibitors&doi=10.1016%2Fj.bmcl.2014.04.061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.061%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHuan%26aufirst%3DX.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520isoquinolinone-based%2520tricycles%2520as%2520novel%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2669%26epage%3D2673%26doi%3D10.1016%2Fj.bmcl.2014.04.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Ye, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huan, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of a series of benzo [de][1, 7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2885</span><span class="NLM_x">–</span> <span class="NLM_lpage">2903</span><span class="refDoi"> DOI: 10.1021/jm301825t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301825t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2885-2903&author=N.+Yeauthor=C.+H.+Chenauthor=T.+Chenauthor=Z.+Songauthor=J.+X.+Heauthor=X.+J.+Huanauthor=S.+S.+Songauthor=Q.+Liuauthor=Y.+Chenauthor=J.+Dingauthor=Y.+Xuauthor=Z.+H.+Miaoauthor=A.+Zhang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+a+series+of+benzo+%5Bde%5D%5B1%2C+7%5Dnaphthyridin-7%288H%29-ones+bearing+a+functionalized+longer+chain+appendage+as+novel+PARP1+inhibitors&doi=10.1021%2Fjm301825t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Fjm301825t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301825t%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DJ.%2BX.%26aulast%3DHuan%26aufirst%3DX.%2BJ.%26aulast%3DSong%26aufirst%3DS.%2BS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520benzo%2520%255Bde%255D%255B1%252C%25207%255Dnaphthyridin-7%25288H%2529-ones%2520bearing%2520a%2520functionalized%2520longer%2520chain%2520appendage%2520as%2520novel%2520PARP1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2885%26epage%3D2903%26doi%3D10.1021%2Fjm301825t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Giannini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battistuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milazzo, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Paolis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbarino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guglielmi, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carollo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallavalle, S.</span><span> </span><span class="NLM_article-title">Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2013.12.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24388690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1Knsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=462-466&author=G.+Gianniniauthor=G.+Battistuzziauthor=L.+Vesciauthor=F.+M.+Milazzoauthor=F.+De+Paolisauthor=M.+Barbarinoauthor=M.+B.+Guglielmiauthor=V.+Carolloauthor=G.+Galloauthor=R.+Artaliauthor=S.+Dallavalle&title=Novel+PARP-1+inhibitors+based+on+a+2-propanoyl-3H-quinazolin-4-one+scaffold&doi=10.1016%2Fj.bmcl.2013.12.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold</span></div><div class="casAuthors">Giannini, Giuseppe; Battistuzzi, Gianfranco; Vesci, Loredana; Milazzo, Ferdinando M.; De Paolis, Francesca; Barbarino, Marcella; Guglielmi, Mario Berardino; Carollo, Valeria; Gallo, Grazia; Artali, Roberto; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-466</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Poly(ADP-ribose)polymerase-I (PARP-1) enzyme is involved in maintaining DNA integrity and programmed cell death.  A virtual screening of com. libraries led to the identification of five novel scaffolds with inhibitory profile in the low nanomolar range.  A hit-to-lead optimization led to the identification of a group of new potent PARP-1 inhibitors, acyl-piperazinylamides of 3-(4-oxo-3,4-dihydro-quinazolin-2-yl)-propionic acid.  Mol. modeling studies highlighted the preponderant role of the propanoyl side chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsOEzNP5GTqLVg90H21EOLACvtfcHk0liQthCBpzjHrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1Knsg%253D%253D&md5=df8b3d8367a78fbcfa15bb107f3e6e05</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.048%26sid%3Dliteratum%253Aachs%26aulast%3DGiannini%26aufirst%3DG.%26aulast%3DBattistuzzi%26aufirst%3DG.%26aulast%3DVesci%26aufirst%3DL.%26aulast%3DMilazzo%26aufirst%3DF.%2BM.%26aulast%3DDe%2BPaolis%26aufirst%3DF.%26aulast%3DBarbarino%26aufirst%3DM.%26aulast%3DGuglielmi%26aufirst%3DM.%2BB.%26aulast%3DCarollo%26aufirst%3DV.%26aulast%3DGallo%26aufirst%3DG.%26aulast%3DArtali%26aufirst%3DR.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3DNovel%2520PARP-1%2520inhibitors%2520based%2520on%2520a%25202-propanoyl-3H-quinazolin-4-one%2520scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D462%26epage%3D466%26doi%3D10.1016%2Fj.bmcl.2013.12.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Yao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, B.</span><span> </span><span class="NLM_article-title">Discovery of 1-substituted benzyl-quinazoline-2, 4(1H,3H)-dione derivatives as novel poly (ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">693</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.12.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmc.2014.12.071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=681-693&author=H.+Yaoauthor=M.+Jiauthor=Z.+Zhuauthor=J.+Zhouauthor=R.+Caoauthor=X.+Chenauthor=B.+Xu&title=Discovery+of+1-substituted+benzyl-quinazoline-2%2C+4%281H%2C3H%29-dione+derivatives+as+novel+poly+%28ADP-ribose%29+polymerase-1+inhibitors&doi=10.1016%2Fj.bmc.2014.12.071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.071%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DB.%26atitle%3DDiscovery%2520of%25201-substituted%2520benzyl-quinazoline-2%252C%25204%25281H%252C3H%2529-dione%2520derivatives%2520as%2520novel%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D681%26epage%3D693%26doi%3D10.1016%2Fj.bmc.2014.12.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Zhou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1016/j.bcp.2016.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bcp.2016.02.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=29-40&author=Q.+Zhouauthor=M.+Jiauthor=J.+Zhouauthor=J.+Jinauthor=N.+Xueauthor=J.+Chenauthor=B.+Xuauthor=X.+Chen&title=Poly+%28ADP-ribose%29+polymerases+inhibitor%2C+Zj6413%2C+as+a+potential+therapeutic+agent+against+breast+cancer&doi=10.1016%2Fj.bcp.2016.02.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DXue%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DPoly%2520%2528ADP-ribose%2529%2520polymerases%2520inhibitor%252C%2520Zj6413%252C%2520as%2520a%2520potential%2520therapeutic%2520agent%2520against%2520breast%2520cancer%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D107%26spage%3D29%26epage%3D40%26doi%3D10.1016%2Fj.bcp.2016.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel imidazo[4, 5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1996</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmcl.2013.02.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1993-1996&author=Q.+Zhuauthor=X.+Wangauthor=Z.+Chuauthor=G.+Heauthor=G.+Dongauthor=Y.+Xu&title=Design%2C+synthesis+and+biological+evaluation+of+novel+imidazo%5B4%2C+5-c%5Dpyridinecarboxamide+derivatives+as+PARP-1+inhibitors&doi=10.1016%2Fj.bmcl.2013.02.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.032%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChu%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520imidazo%255B4%252C%25205-c%255Dpyridinecarboxamide%2520derivatives%2520as%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1993%26epage%3D1996%26doi%3D10.1016%2Fj.bmcl.2013.02.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Patel, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffen, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chergui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trombetta, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fronczek, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talele, T. T.</span><span> </span><span class="NLM_article-title">Discovery and structure–activity relationship of novel 2, 3-dihydrobenzofuran-7-carboxamide and 2, 3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly (ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5579</span><span class="NLM_x">–</span> <span class="NLM_lpage">5601</span><span class="refDoi"> DOI: 10.1021/jm5002502</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5002502" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5579-5601&author=M.+R.+Patelauthor=A.+Bhattauthor=J.+D.+Steffenauthor=A.+Cherguiauthor=J.+Muraiauthor=Y.+Pommierauthor=J.+M.+Pascalauthor=L.+D.+Trombettaauthor=F.+R.+Fronczekauthor=T.+T.+Talele&title=Discovery+and+structure%E2%80%93activity+relationship+of+novel+2%2C+3-dihydrobenzofuran-7-carboxamide+and+2%2C+3-dihydrobenzofuran-3%282H%29-one-7-carboxamide+derivatives+as+poly+%28ADP-ribose%29+polymerase-1+inhibitors&doi=10.1021%2Fjm5002502"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fjm5002502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5002502%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DBhatt%26aufirst%3DA.%26aulast%3DSteffen%26aufirst%3DJ.%2BD.%26aulast%3DChergui%26aufirst%3DA.%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DPascal%26aufirst%3DJ.%2BM.%26aulast%3DTrombetta%26aufirst%3DL.%2BD.%26aulast%3DFronczek%26aufirst%3DF.%2BR.%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DDiscovery%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520of%2520novel%25202%252C%25203-dihydrobenzofuran-7-carboxamide%2520and%25202%252C%25203-dihydrobenzofuran-3%25282H%2529-one-7-carboxamide%2520derivatives%2520as%2520poly%2520%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5579%26epage%3D5601%26doi%3D10.1021%2Fjm5002502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Cincinelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musso, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milazzo, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carenini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunino, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallavalle, S.</span><span> </span><span class="NLM_article-title">7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1103</span><span class="refDoi"> DOI: 10.1016/j.bmc.2013.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmc.2013.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=24398383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFyltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=1089-1103&author=R.+Cincinelliauthor=L.+Mussoauthor=L.+Merliniauthor=G.+Gianniniauthor=L.+Vesciauthor=F.+M.+Milazzoauthor=N.+Careniniauthor=P.+Peregoauthor=S.+Pencoauthor=R.+Artaliauthor=F.+Zuninoauthor=C.+Pisanoauthor=S.+Dallavalle&title=7-Azaindole-1-carboxamides+as+a+new+class+of+PARP-1+inhibitors&doi=10.1016%2Fj.bmc.2013.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors</span></div><div class="casAuthors">Cincinelli, Raffaella; Musso, Loana; Merlini, Lucio; Giannini, Giuseppe; Vesci, Loredana; Milazzo, Ferdinando M.; Carenini, Nives; Perego, Paola; Penco, Sergio; Artali, Roberto; Zunino, Franco; Pisano, Claudio; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1089-1103</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">7-Azaindole-1-carboxamides were designed as a new class of PARP-1 inhibitors.  The compds. displayed a variable pattern of target inhibition profile that, in part, paralleled the antiproliferative activity in cell lines characterized by homologous recombination defects.  A selected compd. I (ST7710AA1) showed significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp.  In antitumor activity studies against the MX1 human breast carcinoma growth in nude mice, the compd. exhibited an effect similar to that of Olaparib in terms of tumor vol. inhibition when used at a lower dose than the ref. compd.  Treatment was well tolerated, as no deaths or significant wt. losses were obsd. among the treated animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGousYJ49CeoYrVg90H21EOLACvtfcHk0lj00B_KehxP-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFyltg%253D%253D&md5=bd205428bf023358f6f388013648d8fa</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DMerlini%26aufirst%3DL.%26aulast%3DGiannini%26aufirst%3DG.%26aulast%3DVesci%26aufirst%3DL.%26aulast%3DMilazzo%26aufirst%3DF.%2BM.%26aulast%3DCarenini%26aufirst%3DN.%26aulast%3DPerego%26aufirst%3DP.%26aulast%3DPenco%26aufirst%3DS.%26aulast%3DArtali%26aufirst%3DR.%26aulast%3DZunino%26aufirst%3DF.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3D7-Azaindole-1-carboxamides%2520as%2520a%2520new%2520class%2520of%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D1089%26epage%3D1103%26doi%3D10.1016%2Fj.bmc.2013.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamijo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkubo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1378</span><span class="NLM_x">–</span> <span class="NLM_lpage">1390</span><span class="refDoi"> DOI: 10.1016/j.bmc.2005.09.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1016%2Fj.bmc.2005.09.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=16288880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1378-1390&author=J.+Ishidaauthor=H.+Yamamotoauthor=Y.+Kidoauthor=K.+Kamijoauthor=K.+Muranoauthor=H.+Miyakeauthor=M.+Ohkuboauthor=T.+Kinoshitaauthor=M.+Warizayaauthor=A.+Iwashitaauthor=K.+Miharaauthor=N.+Matsuokaauthor=K.+Hattori&title=Discovery+of+potent+and+selective+PARP-1+and+PARP-2+inhibitors%3A+SBDD+analysis+via+a+combination+of+X-ray+structural+study+and+homology+modeling&doi=10.1016%2Fj.bmc.2005.09.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span></div><div class="casAuthors">Ishida, Junya; Yamamoto, Hirofumi; Kido, Yoshiyuki; Kamijo, Kazunori; Murano, Kenji; Miyake, Hiroshi; Ohkubo, Mitsuru; Kinoshita, Takayoshi; Warizaya, Masaichi; Iwashita, Akinori; Mihara, Kayoko; Matsuoka, Nobuya; Hattori, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1378-1390</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We disclose herein our efforts aimed at discovery of selective PARP-1 and PARP-2 inhibitors.  We have recently discovered several novel classes of quinazolinones, quinazolidinones, and quinoxalines as potent PARP-1 inhibitors, which may represent attractive therapeutic candidates.  In PARP enzyme assays using recombinant PARP-1 and PARP-2, the quinazolinone derivs. displayed relatively high selectivity for PARP-1 and quinoxaline derivs. showed superior selectivity for PARP-2, and the quinazolidinone derivs. did not have selectivity for PARP-1/2.  Structure-based drug design anal. via a combination of X-ray structural study utilizing the complexes of inhibitors and human PARP-1 catalytic domain, and homol. modeling using murine PARP-2 suggested distinct interactions of inhibitors with PARP-1 and PARP-2.  These findings provide a new structural framework for the design of selective inhibitors for PARP-1 and PARP-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrukfYFsnRIEbVg90H21EOLACvtfcHk0lhmiNI5oy3C6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D&md5=9f72cd79428d0c006e2995c19a345c0f</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.09.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.09.061%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DMurano%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520PARP-1%2520and%2520PARP-2%2520inhibitors%253A%2520SBDD%2520analysis%2520via%2520a%2520combination%2520of%2520X-ray%2520structural%2520study%2520and%2520homology%2520modeling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D1378%26epage%3D1390%26doi%3D10.1016%2Fj.bmc.2005.09.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Eltze, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinbrenner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiemermann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bürkle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T.</span><span> </span><span class="NLM_article-title">Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly (ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors</span> <span class="citation_source-journal">Mol. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1587</span><span class="NLM_x">–</span> <span class="NLM_lpage">1598</span><span class="refDoi"> DOI: 10.1124/mol.108.048751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1124%2Fmol.108.048751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=18809672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGls73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1587-1598&author=T.+Eltzeauthor=R.+Boerauthor=T.+Wagnerauthor=S.+Weinbrennerauthor=M.+C.+McDonaldauthor=C.+Thiemermannauthor=A.+B%C3%BCrkleauthor=T.+Klein&title=Imidazoquinolinone%2C+imidazopyridine%2C+and+isoquinolindione+derivatives+as+novel+and+potent+inhibitors+of+the+poly+%28ADP-ribose%29+polymerase+%28PARP%29%3A+a+comparison+with+standard+PARP+inhibitors&doi=10.1124%2Fmol.108.048751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors</span></div><div class="casAuthors">Eltze, Tobias; Boer, Rainer; Wagner, Thomas; Weinbrenner, Steffen; McDonald, Michelle C.; Thiemermann, Christoph; Buerkle, Alexander; Klein, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1587-1598</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We have identified three novel structures for inhibitors of the poly(ADP-ribose) polymerase (PARP), a nuclear enzyme activated by strand breaks in DNA and implicated in DNA repair, apoptosis, organ dysfunction or necrosis.  2-[4-(5-Methyl-1H-imidazol-4-yl)-piperidin-1-yl]-4,5-dihydro-imidazo[4,5,1-i,j]quinolin-6-one (BYK49187), 2-(4-pyridin-2-yl-phenyl)-4,5-dihydro-imidazo[4,5,1-i,j]quinolin-6-one (BYK236864), 6-chloro-8-hydroxy-2,3-dimethyl-imidazo-[1,2-α]-pyridine (BYK20370), and 4-(1-methyl-1H-pyrrol-2-ylmethylene)-4H-isoquinolin-1,3-dione (BYK204165) inhibited cell-free recombinant human PARP-1 with pIC50 values of 8.36, 7.81, 6.40, and 7.35 (pKi 7.97, 7.43, 5.90, and 7.05), and murine PARP-2 with pIC50 values of 7.50, 7.55, 5.71, and 5.38, resp.  BYK49187, BYK236864, and BYK20370 displayed no selectivity for PARP-1/2, whereas BYK204165 displayed 100-fold selectivity for PARP-1.  The IC50 values for inhibition of poly(ADP-ribose) synthesis in human lung epithelial A549 and cervical carcinoma C4I cells as well in rat cardiac myoblast H9c2 cells after PARP activation by H2O2 were highly significantly correlated with those at cell-free PARP-1 (r2 = 0.89-0.96, P < 0.001) but less with those at PARP-2 (r2 = 0.78-0.84, P < 0.01).  The infarct size caused by coronary artery occlusion and reperfusion in the anesthetized rat was reduced by 22% (P < 0.05) by treatment with BYK49187 (3 mg/kg i.v. bolus and 3 mg/kg/h i.v. during 2-h reperfusion), whereas the weaker PARP inhibitors, BYK236864 and BYK20370, were not cardioprotective.  In conclusion, the imidazoquinolinone BYK49187 is a potent inhibitor of human PARP-1 activity in cell-free and cellular assays in vitro and reduces myocardial infarct size in vivo.  The isoquinolindione BYK204165 was 100-fold more selective for PARP-1.  Thus, both compds. might be novel and valuable tools for investigating PARP-1-mediated effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomLykJcmtd4bVg90H21EOLACvtfcHk0lhmiNI5oy3C6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGls73K&md5=df104e66303dc8a885859a49c07424e7</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.048751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.048751%26sid%3Dliteratum%253Aachs%26aulast%3DEltze%26aufirst%3DT.%26aulast%3DBoer%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWeinbrenner%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DM.%2BC.%26aulast%3DThiemermann%26aufirst%3DC.%26aulast%3DB%25C3%25BCrkle%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DT.%26atitle%3DImidazoquinolinone%252C%2520imidazopyridine%252C%2520and%2520isoquinolindione%2520derivatives%2520as%2520novel%2520and%2520potent%2520inhibitors%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%253A%2520a%2520comparison%2520with%2520standard%2520PARP%2520inhibitors%26jtitle%3DMol.%2520Pharm.%26date%3D2008%26volume%3D74%26spage%3D1587%26epage%3D1598%26doi%3D10.1124%2Fmol.108.048751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Pellicciari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camaioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costantino, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Formentini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbatini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venturoni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eren, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellocchi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarugi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moroni, F.</span><span> </span><span class="NLM_article-title">On the way to selective PARP - 2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">914</span><span class="NLM_x">–</span> <span class="NLM_lpage">923</span><span class="refDoi"> DOI: 10.1002/cmdc.200800010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1002%2Fcmdc.200800010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=914-923&author=R.+Pellicciariauthor=E.+Camaioniauthor=G.+Costantinoauthor=L.+Formentiniauthor=P.+Sabbatiniauthor=F.+Venturoniauthor=G.+Erenauthor=D.+Bellocchiauthor=A.+Chiarugiauthor=F.+Moroni&title=On+the+way+to+selective+PARP+-+2+inhibitors.+Design%2C+synthesis%2C+and+preliminary+evaluation+of+a+series+of+isoquinolinone+derivatives&doi=10.1002%2Fcmdc.200800010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800010%26sid%3Dliteratum%253Aachs%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DFormentini%26aufirst%3DL.%26aulast%3DSabbatini%26aufirst%3DP.%26aulast%3DVenturoni%26aufirst%3DF.%26aulast%3DEren%26aufirst%3DG.%26aulast%3DBellocchi%26aufirst%3DD.%26aulast%3DChiarugi%26aufirst%3DA.%26aulast%3DMoroni%26aufirst%3DF.%26atitle%3DOn%2520the%2520way%2520to%2520selective%2520PARP%2520-%25202%2520inhibitors.%2520Design%252C%2520synthesis%252C%2520and%2520preliminary%2520evaluation%2520of%2520a%2520series%2520of%2520isoquinolinone%2520derivatives%26jtitle%3DChemMedChem%26date%3D2008%26volume%3D3%26spage%3D914%26epage%3D923%26doi%3D10.1002%2Fcmdc.200800010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Sunderland, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woon, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergin, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahon, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tully, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl) isoquinolin-1-ones as isoform-selective inhibitors of poly (ADP-ribose) polymerase 2 (PARP-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2049</span><span class="NLM_x">–</span> <span class="NLM_lpage">2059</span><span class="refDoi"> DOI: 10.1021/jm1010918</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1010918" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2049-2059&author=P.+T.+Sunderlandauthor=E.+C.+Woonauthor=A.+Dhamiauthor=A.+B.+Berginauthor=M.+F.+Mahonauthor=P.+J.+Woodauthor=L.+A.+Jonesauthor=S.+R.+Tullyauthor=M.+D.+Lloydauthor=A.+S.+Thompsonauthor=H.+Javaidauthor=N.+M.+Martinauthor=M.+D.+Threadgill&title=5-Benzamidoisoquinolin-1-ones+and+5-%28%CF%89-carboxyalkyl%29+isoquinolin-1-ones+as+isoform-selective+inhibitors+of+poly+%28ADP-ribose%29+polymerase+2+%28PARP-2%29&doi=10.1021%2Fjm1010918"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Fjm1010918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1010918%26sid%3Dliteratum%253Aachs%26aulast%3DSunderland%26aufirst%3DP.%2BT.%26aulast%3DWoon%26aufirst%3DE.%2BC.%26aulast%3DDhami%26aufirst%3DA.%26aulast%3DBergin%26aufirst%3DA.%2BB.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DWood%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DTully%26aufirst%3DS.%2BR.%26aulast%3DLloyd%26aufirst%3DM.%2BD.%26aulast%3DThompson%26aufirst%3DA.%2BS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3D5-Benzamidoisoquinolin-1-ones%2520and%25205-%2528%25CF%2589-carboxyalkyl%2529%2520isoquinolin-1-ones%2520as%2520isoform-selective%2520inhibitors%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerase%25202%2520%2528PARP-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2049%26epage%3D2059%26doi%3D10.1021%2Fjm1010918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Papeo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posteri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busel, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caprera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Anello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khvat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasavin, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzetta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainoldi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi-Sirtori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sola, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span> </span><span class="NLM_article-title">Discovery of 2-[1-(4,4-difluorocyclohexyl) piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4- carboxamide (NMS-P118): A potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6875</span><span class="NLM_x">–</span> <span class="NLM_lpage">6898</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00680</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00680" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6875-6898&author=G.+Papeoauthor=H.+Posteriauthor=D.+Borghiauthor=A.+A.+Buselauthor=F.+Capreraauthor=E.+Casaleauthor=M.+Ciomeiauthor=A.+Cirlaauthor=E.+Cortiauthor=M.+D%E2%80%99Anelloauthor=M.+Fasoliniauthor=B.+Forteauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+Khvatauthor=M.+Y.+Krasavinauthor=R.+Lupiauthor=P.+Orsiniauthor=R.+Peregoauthor=E.+Pesentiauthor=D.+Pezzettaauthor=S.+Rainoldiauthor=F.+Riccardi-Sirtoriauthor=A.+Scolaroauthor=F.+Solaauthor=F.+Zuccottoauthor=E.+R.+Felderauthor=D.+Donatiauthor=A.+Montagnoli&title=Discovery+of+2-%5B1-%284%2C4-difluorocyclohexyl%29+piperidin-4-yl%5D-6-fluoro-3-oxo-2%2C3-dihydro-1H-isoindole-4-+carboxamide+%28NMS-P118%29%3A+A+potent%2C+orally+available%2C+and+highly+selective+PARP-1+inhibitor+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.5b00680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00680%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DBorghi%26aufirst%3DD.%26aulast%3DBusel%26aufirst%3DA.%2BA.%26aulast%3DCaprera%26aufirst%3DF.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DCirla%26aufirst%3DA.%26aulast%3DCorti%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Anello%26aufirst%3DM.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DKhvat%26aufirst%3DA.%26aulast%3DKrasavin%26aufirst%3DM.%2BY.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPezzetta%26aufirst%3DD.%26aulast%3DRainoldi%26aufirst%3DS.%26aulast%3DRiccardi-Sirtori%26aufirst%3DF.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DSola%26aufirst%3DF.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DFelder%26aufirst%3DE.%2BR.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DMontagnoli%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25202-%255B1-%25284%252C4-difluorocyclohexyl%2529%2520piperidin-4-yl%255D-6-fluoro-3-oxo-2%252C3-dihydro-1H-isoindole-4-%2520carboxamide%2520%2528NMS-P118%2529%253A%2520A%2520potent%252C%2520orally%2520available%252C%2520and%2520highly%2520selective%2520PARP-1%2520inhibitor%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6875%26epage%3D6898%26doi%3D10.1021%2Facs.jmedchem.5b00680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schierz, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, F. M.</span><span> </span><span class="NLM_article-title">Therapeutic opportunities within the DNA damage response</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">166</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1038/nrc3891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnrc3891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25709118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Snt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=166-180&author=L.+H.+Pearlauthor=A.+C.+Schierzauthor=S.+E.+Wardauthor=B.+Al-Lazikaniauthor=F.+M.+Pearl&title=Therapeutic+opportunities+within+the+DNA+damage+response&doi=10.1038%2Fnrc3891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic opportunities within the DNA damage response</span></div><div class="casAuthors">Pearl, Laurence H.; Schierz, Amanda C.; Ward, Simon E.; Al-Lazikani, Bissan; Pearl, Frances M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">166-180</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The DNA damage response (DDR) is essential for maintaining the genomic integrity of the cell, and its disruption is one of the hallmarks of cancer.  Classically, defects in the DDR have been exploited therapeutically in the treatment of cancer with radiation therapies or genotoxic chemotherapies.  More recently, protein components of the DDR systems have been identified as promising avenues for targeted cancer therapeutics.  Here, we present an in-depth anal. of the function, role in cancer and therapeutic potential of 450 expert-curated human DDR genes.  We discuss the DDR drugs that have been approved by the US Food and Drug Administration (FDA) or that are under clin. investigation.  We examine large-scale genomic and expression data for 15 cancers to identify deregulated components of the DDR, and we apply systematic computational anal. to identify DDR proteins that are amenable to modulation by small mols., highlighting potential novel therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosptr9Y-2e6LVg90H21EOLACvtfcHk0liTJBnWDVaqEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Snt74%253D&md5=47ceba5c42cc7ebb59e18f3aa53e0f60</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1038%2Fnrc3891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3891%26sid%3Dliteratum%253Aachs%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DSchierz%26aufirst%3DA.%2BC.%26aulast%3DWard%26aufirst%3DS.%2BE.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DPearl%26aufirst%3DF.%2BM.%26atitle%3DTherapeutic%2520opportunities%2520within%2520the%2520DNA%2520damage%2520response%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D166%26epage%3D180%26doi%3D10.1038%2Fnrc3891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Wahlberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouznetsova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsell, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frostell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Öncü, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicciari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigelt, J.</span><span> </span><span class="NLM_article-title">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span><span class="refDoi"> DOI: 10.1038/nbt.2121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1038%2Fnbt.2121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=22343925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=283-288&author=E.+Wahlbergauthor=T.+Karlbergauthor=E.+Kouznetsovaauthor=N.+Markovaauthor=A.+Macchiaruloauthor=A.+G.+Thorsellauthor=E.+Polauthor=A.+Frostellauthor=T.+Ekbladauthor=D.+%C3%96nc%C3%BCauthor=B.+Kullauthor=G.+M.+Robertsonauthor=R.+Pellicciariauthor=H.+Sch%C3%BClerauthor=J.+Weigelt&title=Family-wide+chemical+profiling+and+structural+analysis+of+PARP+and+tankyrase+inhibitors&doi=10.1038%2Fnbt.2121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span></div><div class="casAuthors">Wahlberg, Elisabet; Karlberg, Tobias; Kouznetsova, Ekaterina; Markova, Natalia; Macchiarulo, Antonio; Thorsell, Ann-Gerd; Pol, Ewa; Frostell, Aasa; Ekblad, Torun; Oencue, Delal; Kull, Bjoern; Robertson, Graeme Michael; Pellicciari, Roberto; Schueler, Herwig; Weigelt, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-288</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibitors of poly-ADP-ribose polymerase (PARP) family proteins are currently in clin. trials as cancer therapeutics, yet the specificity of many of these compds. is unknown.  Here we evaluated a series of 185 small-mol. inhibitors, including research reagents and compds. being tested clin., for the ability to bind to the catalytic domains of 13 of the 17 human PARP family members including the tankyrases, TNKS1 and TNKS2.  Many of the best-known inhibitors, including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bound to several PARP family members, suggesting that these mols. lack specificity and have promiscuous inhibitory activity.  We also detd. X-ray crystal structures for five TNKS2 ligand complexes and four PARP14 ligand complexes.  In addn. to showing that the majority of PARP inhibitors bind multiple targets, these results provide insight into the design of new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYSebsCVufibVg90H21EOLACvtfcHk0liTJBnWDVaqEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D&md5=71f17fd5b6bb602dd70c8fcc17df95f9</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2121%26sid%3Dliteratum%253Aachs%26aulast%3DWahlberg%26aufirst%3DE.%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DKouznetsova%26aufirst%3DE.%26aulast%3DMarkova%26aufirst%3DN.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DThorsell%26aufirst%3DA.%2BG.%26aulast%3DPol%26aufirst%3DE.%26aulast%3DFrostell%26aufirst%3DA.%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3D%25C3%2596nc%25C3%25BC%26aufirst%3DD.%26aulast%3DKull%26aufirst%3DB.%26aulast%3DRobertson%26aufirst%3DG.%2BM.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DWeigelt%26aufirst%3DJ.%26atitle%3DFamily-wide%2520chemical%2520profiling%2520and%2520structural%2520analysis%2520of%2520PARP%2520and%2520tankyrase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D283%26epage%3D288%26doi%3D10.1038%2Fnbt.2121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Boehler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yelamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noll, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantzer, F.</span><span> </span><span class="NLM_article-title">Phenotypic characterization of Parp-1 and Parp-2 deficient mice and cells</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">780</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1007/978-1-61779-270-0_19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1007%2F978-1-61779-270-0_19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21870269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvV2nsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=780&publication_year=2011&pages=313-336&author=C.+Boehlerauthor=L.+Gauthierauthor=J.+Yelamosauthor=A.+Nollauthor=V.+Schreiberauthor=F.+Dantzer&title=Phenotypic+characterization+of+Parp-1+and+Parp-2+deficient+mice+and+cells&doi=10.1007%2F978-1-61779-270-0_19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic characterization of Parp-1 and Parp-2 deficient mice and cells</span></div><div class="casAuthors">Boehler, Christian; Gauthier, Laurent; Yelamos, Jose; Noll, Aurelia; Schreiber, Valerie; Dantzer, Francoise</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">780</span>
        (<span class="NLM_cas:issue">Poly(ADP-ribose) Polymerase</span>),
    <span class="NLM_cas:pages">313-336</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Poly(ADP-ribosyl)ation is a post-translational modification of proteins mediated by Poly(ADP-ribose) polymerases (Parps), a family of 17 members.  Among them, Poly(ADP-ribose) polymerase-1 (Parp-1)and Parp-2 are so far the sole enzymes whose catalytic activity has been shown to be induced by DNA strand breaks.  The generation and characterization of Parp-1 and Parp-2 deficient cellular and animal models have largely contributed to describe both proteins as active players of the base excision repair/single-strand break repair (BER/SSBR) process with both redundant and more specific functions.  Double Parp-1-/-Parp-2-/- embryos die at gastrulation demonstrating the crucial role of poly(ADP-ribosyl)ation during embryonic development, whereas a specific female lethality related to X chromosome instability is assocd. with the Parp-1+/-Parp-2-/- genotype.  Finally, recent research discovered emerging unique functions of Parp-2 in physiol. processes including spermatogenesis, T-cell maturation, and adipogenesis although with distinct mechanisms.  In this chapter, we describe std. operating procedures used to genotype and phenotype both mouse lines and the derived mouse embryonic fibroblasts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_HNE1f3RQrbVg90H21EOLACvtfcHk0lj5aAZWN-5mCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvV2nsbY%253D&md5=bd260e619dde6116515a30139e9b4ff5</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-270-0_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-270-0_19%26sid%3Dliteratum%253Aachs%26aulast%3DBoehler%26aufirst%3DC.%26aulast%3DGauthier%26aufirst%3DL.%26aulast%3DYelamos%26aufirst%3DJ.%26aulast%3DNoll%26aufirst%3DA.%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DDantzer%26aufirst%3DF.%26atitle%3DPhenotypic%2520characterization%2520of%2520Parp-1%2520and%2520Parp-2%2520deficient%2520mice%2520and%2520cells%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D780%26spage%3D313%26epage%3D336%26doi%3D10.1007%2F978-1-61779-270-0_19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Poruchynsky, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komlodi-Pasztor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trostel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkerson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regairaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar Maity, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burotto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sackett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guha, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, A. T.</span><span> </span><span class="NLM_article-title">Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">1571</span><span class="NLM_x">–</span> <span class="NLM_lpage">1576</span><span class="refDoi"> DOI: 10.1073/pnas.1416418112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1073%2Fpnas.1416418112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=25605897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=1571-1576&author=M.+S.+Poruchynskyauthor=E.+Komlodi-Pasztorauthor=S.+Trostelauthor=J.+Wilkersonauthor=M.+Regairazauthor=Y.+Pommierauthor=X.+Zhangauthor=T.+Kumar+Maityauthor=R.+Robeyauthor=M.+Burottoauthor=D.+Sackettauthor=U.+Guhaauthor=A.+T.+Fojo&title=Microtubule-targeting+agents+augment+the+toxicity+of+DNA-damaging+agents+by+disrupting+intracellular+trafficking+of+DNA+repair+proteins&doi=10.1073%2Fpnas.1416418112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins</span></div><div class="casAuthors">Poruchynsky, Marianne S.; Komlodi-Pasztor, Edina; Trostel, Shana; Wilkerson, Julia; Regairaz, Marie; Pommier, Yves; Zhang, Xu; Maity, Tapan Kumar; Robey, Robert; Burotto, Mauricio; Sackett, Dan; Guha, Udayan; Fojo, Antonio Tito</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1571-1576</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The paradigm that microtubule-targeting agents (MTAs) cause cell death via mitotic arrest applies to rapidly dividing cells but cannot explain MTA activity in slowly growing human cancers.  Many preferred cancer regimens combine a MTA with a DNA-damaging agent (DDA).  We hypothesized that MTAs synergize with DDAs by interfering with trafficking of DNA repair proteins on interphase microtubules.  We investigated nine proteins involved in DNA repair: ATM, ATR, DNA-PK, Rad50, Mre11, p95/NBS1, p53, 53BP1, and p63.  The proteins were sequestered in the cytoplasm by vincristine and paclitaxel but not by an aurora kinase inhibitor, colocalized with tubulin by confocal microscopy and coimmunopptd. with the microtubule motor dynein.  Furthermore, adding MTAs to radiation, doxorubicin, or etoposide led to more sustained γ-H2AX levels.  We conclude DNA damage-repair proteins traffic on microtubules and addn. of MTAs sequesters them in the cytoplasm, explaining why MTA/DDA combinations are common anticancer regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RzUulWoZyLVg90H21EOLACvtfcHk0lj5aAZWN-5mCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOhu74%253D&md5=f7f94679f54bf5859c18437a40076aae</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1416418112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1416418112%26sid%3Dliteratum%253Aachs%26aulast%3DPoruchynsky%26aufirst%3DM.%2BS.%26aulast%3DKomlodi-Pasztor%26aufirst%3DE.%26aulast%3DTrostel%26aufirst%3DS.%26aulast%3DWilkerson%26aufirst%3DJ.%26aulast%3DRegairaz%26aufirst%3DM.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKumar%2BMaity%26aufirst%3DT.%26aulast%3DRobey%26aufirst%3DR.%26aulast%3DBurotto%26aufirst%3DM.%26aulast%3DSackett%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DU.%26aulast%3DFojo%26aufirst%3DA.%2BT.%26atitle%3DMicrotubule-targeting%2520agents%2520augment%2520the%2520toxicity%2520of%2520DNA-damaging%2520agents%2520by%2520disrupting%2520intracellular%2520trafficking%2520of%2520DNA%2520repair%2520proteins%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D1571%26epage%3D1576%26doi%3D10.1073%2Fpnas.1416418112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Chan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, R. G.</span><span> </span><span class="NLM_article-title">″Contextual″ synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4553</span><span class="NLM_x">–</span> <span class="NLM_lpage">4560</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-0527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-10-0527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=20823145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4553-4560&author=N.+Chanauthor=R.+G.+Bristow&title=%E2%80%B3Contextual%E2%80%B3+synthetic+lethality+and%2For+loss+of+heterozygosity%3A+tumor+hypoxia+and+modification+of+DNA+repair&doi=10.1158%2F1078-0432.CCR-10-0527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">"Contextual" Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair</span></div><div class="casAuthors">Chan, Norman; Bristow, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4553-4560</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Hypoxia exists in every solid tumor and is assocd. with poor prognosis because of both local and systemic therapeutic resistance.  Recent studies have focused on the interaction between tumor cell genetics and the dynamic state of oxygenation and metab.  Hypoxia generates aggressive tumor cell phenotypes in part owing to ongoing genetic instability and a "mutator" phenotype.  The latter may be due to suppression of DNA mismatch repair (MMR), nucleotide excision repair (NER), and double-strand break (DSB) repair.  We propose a theor. model in which hypoxia-mediated defects in DNA repair can lead to "contextual loss of heterozygosity" and drive oncogenesis.  Addnl., hypoxia-mediated repair defects can be specifically targeted by DNA damaging agents and/or "contextual synthetic lethality" to kill repair-deficient cells and preserve the therapeutic ratio.  These proposed concepts support the interrogation of solid tumors to document repair defects in both oxic and hypoxic tumor subregions as a conduit to novel clin. trials within the context of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqELUzR5x4-57Vg90H21EOLACvtfcHk0lj5aAZWN-5mCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bK&md5=8bf6ea26a620138d35e515bafd753af7</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0527%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DN.%26aulast%3DBristow%26aufirst%3DR.%2BG.%26atitle%3D%25E2%2580%25B3Contextual%25E2%2580%25B3%2520synthetic%2520lethality%2520and%252For%2520loss%2520of%2520heterozygosity%253A%2520tumor%2520hypoxia%2520and%2520modification%2520of%2520DNA%2520repair%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D4553%26epage%3D4560%26doi%3D10.1158%2F1078-0432.CCR-10-0527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimenez-Capitan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertran-Alamillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provencio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Campelo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reguart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viteri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcereny, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queralt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Aguirre, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez-Ronco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mate, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benlloch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span> </span><span class="NLM_article-title">Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1160</span><span class="NLM_x">–</span> <span class="NLM_lpage">1168</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-2158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1158%2F1078-0432.CCR-10-2158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=21233402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXis1eitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1160-1168&author=R.+Rosellauthor=M.+A.+Molinaauthor=C.+Costaauthor=S.+Simonettiauthor=A.+Gimenez-Capitanauthor=J.+Bertran-Alamilloauthor=C.+Mayoauthor=T.+Moranauthor=P.+Mendezauthor=F.+Cardenalauthor=D.+Islaauthor=M.+Provencioauthor=M.+Coboauthor=A.+Insaauthor=R.+Garcia-Campeloauthor=N.+Reguartauthor=M.+Majemauthor=S.+Viteriauthor=E.+Carcerenyauthor=R.+Portaauthor=B.+Massutiauthor=C.+Queraltauthor=I.+de+Aguirreauthor=J.+M.+Sanchezauthor=M.+Sanchez-Roncoauthor=J.+L.+Mateauthor=A.+Arizaauthor=S.+Benllochauthor=J.+J.+Sanchezauthor=T.+G.+Bivonaauthor=C.+L.+Sawyersauthor=M.+Taron&title=Pretreatment+EGFR+T790M+mutation+and+BRCA1+mRNA+expression+in+erlotinib-treated+advanced+non-small-cell+lung+cancer+patients+with+EGFR+mutations&doi=10.1158%2F1078-0432.CCR-10-2158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations</span></div><div class="casAuthors">Rosell, Rafael; Molina, Miguel Angel; Costa, Carlota; Simonetti, Sara; Gimenez-Capitan, Ana; Bertran-Alamillo, Jordi; Mayo, Clara; Moran, Teresa; Mendez, Pedro; Cardenal, Felipe; Isla, Dolores; Provencio, Mariano; Cobo, Manuel; Insa, Amelia; Garcia-Campelo, Rosario; Reguart, Noemi; Majem, Margarita; Viteri, Santiago; Carcereny, Enric; Porta, Ruth; Massuti, Bartomeu; Queralt, Cristina; de Aguirre, Itziar; Sanchez, Jose Miguel; Sanchez-Ronco, Maria; Mate, Jose Luis; Ariza, Aurelio; Benlloch, Susana; Sanchez, Jose Javier; Bivona, Trever G.; Sawyers, Charles L.; Taron, Miquel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1160-1168</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 mo when treated with erlotinib.  However, the presence of EGFR mutations can only imperfectly predict outcome.  We hypothesized that progression-free survival could be influenced both by the pretreatment EGFR T790M mutation and by components of DNA repair pathways.  Exptl. Design: We assessed the T790M mutation in pretreatment diagnostic specimens from 129 erlotinib-treated advanced NSCLC patients with EGFR mutations.  The expression of eight genes and two proteins involved in DNA repair and four receptor tyrosine kinases was also examd.  Results: The EGFR T790M mutation was obsd. in 45 of 129 patients (35%).  Progression-free survival was 12 mo in patients with and 18 mo in patients without the T790M mutation (P = 0.05).  Progression-free survival was 27 mo in patients with low BRCA1 mRNA levels, 18 mo in those with intermediate levels, and 10 mo in those with high levels (P = 0.02).  In the multivariate anal., the presence of the T790M mutation (HR, 4.35; P = 0.001), intermediate BRCA1 levels (HR, 8.19; P < 0.0001), and high BRCA1 levels (HR, 8.46; P < 0.0001) emerged as markers of shorter progression-free survival.  Conclusions: Low BRCA1 levels neutralized the neg. effect of the T790M mutation and were assocd. with longer progression-free survival to erlotinib.  We advocate baseline assessment of the T790M mutation and BRCA1 expression to predict outcome and provide alternative individualized treatment to patients based on T790M mutations and BRCA1 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZpYMrHRqQLVg90H21EOLACvtfcHk0liRkxcHyVDzKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXis1eitrY%253D&md5=ade8984309e69171fc187bfeeae745c7</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2158%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DSimonetti%26aufirst%3DS.%26aulast%3DGimenez-Capitan%26aufirst%3DA.%26aulast%3DBertran-Alamillo%26aufirst%3DJ.%26aulast%3DMayo%26aufirst%3DC.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DMendez%26aufirst%3DP.%26aulast%3DCardenal%26aufirst%3DF.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DCobo%26aufirst%3DM.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DViteri%26aufirst%3DS.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3Dde%2BAguirre%26aufirst%3DI.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DSanchez-Ronco%26aufirst%3DM.%26aulast%3DMate%26aufirst%3DJ.%2BL.%26aulast%3DAriza%26aufirst%3DA.%26aulast%3DBenlloch%26aufirst%3DS.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DTaron%26aufirst%3DM.%26atitle%3DPretreatment%2520EGFR%2520T790M%2520mutation%2520and%2520BRCA1%2520mRNA%2520expression%2520in%2520erlotinib-treated%2520advanced%2520non-small-cell%2520lung%2520cancer%2520patients%2520with%2520EGFR%2520mutations%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D1160%26epage%3D1168%26doi%3D10.1158%2F1078-0432.CCR-10-2158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Hegan, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stachelek, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bindra, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazer, P. M.</span><span> </span><span class="NLM_article-title">Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">2201</span><span class="NLM_x">–</span> <span class="NLM_lpage">2206</span><span class="refDoi"> DOI: 10.1073/pnas.0904783107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;key=10.1073%2Fpnas.0904783107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=2201-2206&author=D.+C.+Heganauthor=Y.+Luauthor=G.+C.+Stachelekauthor=M.+E.+Crosbyauthor=R.+S.+Bindraauthor=P.+M.+Glazer&title=Inhibition+of+poly%28ADP-ribose%29+polymerase+down-regulates+BRCA1+and+RAD51+in+a+pathway+mediated+by+E2F4+and+p130&doi=10.1073%2Fpnas.0904783107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904783107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904783107%26sid%3Dliteratum%253Aachs%26aulast%3DHegan%26aufirst%3DD.%2BC.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DStachelek%26aufirst%3DG.%2BC.%26aulast%3DCrosby%26aufirst%3DM.%2BE.%26aulast%3DBindra%26aufirst%3DR.%2BS.%26aulast%3DGlazer%26aufirst%3DP.%2BM.%26atitle%3DInhibition%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520down-regulates%2520BRCA1%2520and%2520RAD51%2520in%2520a%2520pathway%2520mediated%2520by%2520E2F4%2520and%2520p130%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D2201%26epage%3D2206%26doi%3D10.1073%2Fpnas.0904783107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PJT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PJT','PDB','4PJT'); return false;">PDB: 4PJT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A00" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A00','PDB','5A00'); return false;">PDB: 5A00</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZY','PDB','4ZZY'); return false;">PDB: 4ZZY</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i32"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00055">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_53037"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00055">10.1021/acs.jmedchem.6b00055</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Olaparib (<b>2</b>) in completed combinatorial studies (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00055/suppl_file/jm6b00055_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00055/suppl_file/jm6b00055_si_001.pdf">jm6b00055_si_001.pdf (236.1 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00055&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-21%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00055%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00055" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677af985f80322a8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
